column_name,broad_id,name,dose,screen_id,moa,target,disease.area,indication,smiles,phase
BRD-A00055058-001-01-0::2.325889319::MTS004,BRD-A00055058-001-01-0,RS-0481,2.325889319,MTS004,immunostimulant,NA,NA,NA,CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1,Phase 2
BRD-A00842753-001-01-9::2.5::MTS004,BRD-A00842753-001-01-9,oleuropein,2.5,MTS004,estrogen receptor agonist,GPER1,NA,NA,COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1,Phase 2
BRD-A02232681-001-01-8::2.5::MTS004,BRD-A02232681-001-01-8,isoleucine,2.5,MTS004,NA,"ACADSB, BCAT1, BCAT2, IARS, IARS2",NA,NA,CCC(C)C(N)C(O)=O,Launched
BRD-A04447196-001-01-8::2.5::MTS004,BRD-A04447196-001-01-8,gepefrine,2.5,MTS004,adrenergic receptor agonist,NA,cardiology,hypotension,CC(N)Cc1cccc(O)c1,Launched
BRD-A04971881-003-01-3::2.65294603::MTS004,BRD-A04971881-003-01-3,cloranolol,2.65294603,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",NA,NA,CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,Launched
BRD-A08316590-001-01-3::2.5::MTS004,BRD-A08316590-001-01-3,broxaterol,2.5,MTS004,adrenergic receptor agonist,ADRB2,NA,NA,CC(C)(C)NCC(O)c1cc(Br)no1,Phase 3
BRD-A08772153-001-02-4::2.500028879::MTS004,BRD-A08772153-001-02-4,SQ-109,2.500028879,MTS004,bacterial cell wall synthesis inhibitor,FDFT1,NA,NA,"CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2",Phase 3
BRD-A09911125-001-01-4::2.5::MTS004,BRD-A09911125-001-01-4,prolylleucylglycinamide,2.5,MTS004,melanocyte-stimulating hormone release inhibitor,NA,NA,NA,CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O,Phase 2
BRD-A10188456-001-04-9::2.5::MTS004,BRD-A10188456-001-04-9,dexamethasone,2.5,MTS004,glucocorticoid receptor agonist,"ANXA1, NOS2, NR0B1, NR3C1, NR3C2","endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-A10773072-001-03-4::2.496712929::MTS004,BRD-A10773072-001-03-4,glycerol-monolaurate,2.496712929,MTS004,beta lactamase inhibitor,NA,NA,NA,CCCCCCCCCCCC(=O)OCC(O)CO,Launched
BRD-A13116749-003-01-6::2.713967431::MTS004,BRD-A13116749-003-01-6,mabuterol,2.713967431,MTS004,adrenergic receptor agonist,ADRB2,NA,NA,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F,Launched
BRD-A14577621-001-01-5::2.5::MTS004,BRD-A14577621-001-01-5,peficitinib,2.5,MTS004,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2, NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1C2C[C@@H]3C[C@H]1C[C@@](O)(C3)C2",Phase 3
BRD-A15687940-001-05-6::2.5::MTS004,BRD-A15687940-001-05-6,clofedanol,2.5,MTS004,histamine receptor antagonist,HRH1,pulmonary,cough suppressant,CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl,Launched
BRD-A15739803-001-01-0::2.726366321::MTS004,BRD-A15739803-001-01-0,polythiazide,2.726366321,MTS004,sodium/chloride cotransporter inhibitor,SLC12A3,"cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension",CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O,Launched
BRD-A16263897-001-06-6::2.5::MTS004,BRD-A16263897-001-06-6,misonidazole,2.5,MTS004,NA,NA,NA,NA,COCC(O)Cn1ccnc1[N+]([O-])=O,Phase 3
BRD-A17009129-001-01-3::2.499993124::MTS004,BRD-A17009129-001-01-3,isavuconazole,2.499993124,MTS004,cytochrome P450 inhibitor,CYP3A4,NA,NA,C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)C(O)(Cn1cncn1)c1cc(F)ccc1F,Phase 3
BRD-A18992208-003-02-7::2.5::MTS004,BRD-A18992208-003-02-7,lercanidipine,2.5,MTS004,calcium channel blocker,"CACNA2D1, CACNG1",cardiology,hypertension,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1,Launched
BRD-A19053834-050-09-5::2.5::MTS004,BRD-A19053834-050-09-5,clorotepine,2.5,MTS004,"dopamine receptor antagonist, adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6",neurology/psychiatry,psychosis,CN1CCN(CC1)C1Cc2ccccc2Sc2ccc(Cl)cc12,Launched
BRD-A19777893-236-01-9::2.596350183::MTS004,BRD-A19777893-236-01-9,menadione-bisulfite,2.596350183,MTS004,vitamin K,"GGCX, VKORC1, VKORC1L1",NA,NA,CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O,Phase 2
BRD-A21280314-001-06-8::2.5::MTS004,BRD-A21280314-001-06-8,nifenalol,2.5,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2",NA,NA,CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-A21446384-001-01-1::2.5::MTS004,BRD-A21446384-001-01-1,xibenolol,2.5,MTS004,adrenergic receptor antagonist,NA,NA,NA,Cc1cccc(OCC(O)CNC(C)(C)C)c1C,Phase 3
BRD-A21474126-001-01-6::2.5::MTS004,BRD-A21474126-001-01-6,methoxyphenamine,2.5,MTS004,adrenergic receptor agonist,NA,pulmonary,asthma,CNC(C)Cc1ccccc1OC,Launched
BRD-A21544762-303-01-5::2.5::MTS004,BRD-A21544762-303-01-5,pipecuronium,2.5,MTS004,neuromuscular blocker,"CHRM2, CHRM3, CHRNA2",neurology/psychiatry,anesthetic,CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,Launched
BRD-A23124853-001-01-4::2.5::MTS004,BRD-A23124853-001-01-4,PF-06463922,2.5,MTS004,ALK tyrosine kinase receptor inhibitor,"ALK, FES, ROS1",NA,NA,CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,Phase 2
BRD-A23418262-001-01-5::2.519094866::MTS004,BRD-A23418262-001-01-5,floctafenine,2.519094866,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F,Launched
BRD-A24857382-001-03-4::2.488183422::MTS004,BRD-A24857382-001-03-4,N-acetyl-tyrosine,2.488183422,MTS004,NA,NA,NA,NA,CC(=O)NC(Cc1ccc(O)cc1)C(O)=O,Launched
BRD-A25492003-003-14-1::2.568211596::MTS004,BRD-A25492003-003-14-1,chlortetracycline,2.568211596,MTS004,protein synthesis inhibitor,NA,ophthalmology,conjunctivitis,"CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A27274504-001-01-6::2.400106631::MTS004,BRD-A27274504-001-01-6,butofilolol,2.400106631,MTS004,adrenergic receptor antagonist,NA,NA,NA,CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C,Phase 2
BRD-A30774155-001-01-2::2.499990706::MTS004,BRD-A30774155-001-01-2,efinaconazole,2.499990706,MTS004,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis,C[C@@H](N1CCC(=C)CC1)C(O)(Cn1cncn1)c1ccc(F)cc1F,Launched
BRD-A31362467-065-01-3::2.499984736::MTS004,BRD-A31362467-065-01-3,capreomycin,2.499984736,MTS004,protein synthesis inhibitor,NA,infectious disease,tuberculosis,"NCCCC(N)CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC1=O)=C/NC(N)=O)C1CCNC(=N)N1, CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1",Launched
BRD-A33352494-316-01-6::2.499995956::MTS004,BRD-A33352494-316-01-6,oritavancin,2.499995956,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,skin infections,CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2,Launched
BRD-A33479817-003-03-7::2.490825408::MTS004,BRD-A33479817-003-03-7,terodiline,2.490825408,MTS004,cholinergic receptor antagonist,NA,NA,NA,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,Phase 3
BRD-A33894669-065-01-9::2.312630829::MTS004,BRD-A33894669-065-01-9,hexoprenaline,2.312630829,MTS004,adrenergic receptor agonist,ADRB2,pulmonary,asthma,OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1,Launched
BRD-A34603619-001-01-9::2.427905848::MTS004,BRD-A34603619-001-01-9,tropesin,2.427905848,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1,Launched
BRD-A34788695-003-10-2::2.375699424::MTS004,BRD-A34788695-003-10-2,tetracycline,2.375699424,MTS004,bacterial 30S ribosomal subunit inhibitor,PRNP,"infectious disease, dermatology","respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis","CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A35667010-001-01-8::2.5::MTS004,BRD-A35667010-001-01-8,propylhexedrine,2.5,MTS004,adrenergic receptor agonist,"SLC18A2, TAAR1","otolaryngology, endocrinology, allergy","nasal congestion, fever, allergic rhinitis",CNC(C)CC1CCCCC1,Launched
BRD-A38706605-001-01-2::2.5::MTS004,BRD-A38706605-001-01-2,dromostanolone-propionate,2.5,MTS004,androgen receptor modulator,AR,oncology,breast cancer,CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C,Launched
BRD-A40302156-001-01-9::2.503151999::MTS004,BRD-A40302156-001-01-9,A-33903,2.503151999,MTS004,NA,NA,NA,NA,CC(=O)NC1C(=O)Nc2ccccc2C(=N1)c1ccccc1,Phase 2
BRD-A40546373-001-01-8::2.500029443::MTS004,BRD-A40546373-001-01-8,morinidazole,2.500029443,MTS004,other antibiotic,CYP51A1,NA,NA,Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O,Launched
BRD-A41698174-003-12-0::2.499982171::MTS004,BRD-A41698174-003-12-0,bacampicillin,2.499982171,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections","CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O",Launched
BRD-A42423104-001-01-4::2.495664958::MTS004,BRD-A42423104-001-01-4,benproperine,2.495664958,MTS004,antitussive,SCN5A,pulmonary,cough suppressant,CC(COc1ccccc1Cc1ccccc1)N1CCCCC1,Launched
BRD-A42881122-001-01-1::2.648380541::MTS004,BRD-A42881122-001-01-1,cyamemazine,2.648380541,MTS004,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C, HTR7",neurology/psychiatry,"schizophrenia, anxiety",CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N,Launched
BRD-A44181516-001-01-8::2.666476303::MTS004,BRD-A44181516-001-01-8,flumecinol,2.666476303,MTS004,NA,NA,NA,NA,CCC(O)(c1ccccc1)c1cccc(c1)C(F)(F)F,Launched
BRD-A44188509-001-01-2::2.639346634::MTS004,BRD-A44188509-001-01-2,AZD1446,2.639346634,MTS004,acetylcholine receptor agonist,"CHRNA4, CHRNB2",NA,NA,Clc1ccc(o1)C(=O)N1CC2CNCC2C1,Phase 2
BRD-A44511856-001-01-4::2.499987042::MTS004,BRD-A44511856-001-01-4,ginsenoside-rg3,2.499987042,MTS004,"angiogenesis inhibitor, apoptosis stimulant",KCNH2,NA,NA,CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,Launched
BRD-A44971162-001-02-7::2.5::MTS004,BRD-A44971162-001-02-7,ODM-201,2.5,MTS004,androgen receptor antagonist,AR,NA,NA,"C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O",Phase 3
BRD-A46335897-003-27-8::2.499949994::MTS004,BRD-A46335897-003-27-8,promethazine,2.499949994,MTS004,histamine receptor antagonist,"ADRA1A, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A","neurology/psychiatry, allergy","sedative, allergic rhinitis","CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C",Launched
BRD-A48376327-003-01-5::2.426818202::MTS004,BRD-A48376327-003-01-5,igmesine,2.426818202,MTS004,sigma receptor agonist,SIGMAR1,NA,NA,CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1,Phase 2
BRD-A48420483-001-02-3::2.5::MTS004,BRD-A48420483-001-02-3,bupranolol,2.5,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3","cardiology, ophthalmology","hypertension, glaucoma","Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1, Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1",Launched
BRD-A48938994-001-14-1::2.5::MTS004,BRD-A48938994-001-14-1,monoctanoin,2.5,MTS004,NA,NA,gastroenterology,gallstones,"CCCCCCCC(=O)OCC(O)CO, CCCCCCCC(=O)OCC(O)CO",Launched
BRD-A50675490-001-01-0::2.412483069::MTS004,BRD-A50675490-001-01-0,carazolol,2.412483069,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,"angina pectoris, cardiac arrythmia, hypertension, myocardial infarction",CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,Launched
BRD-A53077924-001-01-2::2.499990763::MTS004,BRD-A53077924-001-01-2,tianeptine,2.499990763,MTS004,selective serotonin reuptake enhancer (SSRE),"OPRD1, OPRK1, OPRM1","neurology/psychiatry, pulmonary, gastroenterology","depression, asthma, irritable bowel syndrome","CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O",Launched
BRD-A55416093-001-06-4::2.5::MTS004,BRD-A55416093-001-06-4,colforsin,2.5,MTS004,adenylyl cyclase activator,"ADCY2, ADCY5",NA,NA,CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C,Phase 2
BRD-A56241705-003-01-2::2.639158457::MTS004,BRD-A56241705-003-01-2,trimethoquinol,2.639158457,MTS004,adrenergic receptor antagonist,"ADRB2, ADRB3",NA,NA,COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC,Launched
BRD-A56613951-004-01-1::2.642522873::MTS004,BRD-A56613951-004-01-1,valethamate,2.642522873,MTS004,acetylcholine receptor antagonist,"CHRM1, CHRM4, CHRM5",obstetrics/gynecology,labor induction,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,Launched
BRD-A56892734-001-09-4::2.5::MTS004,BRD-A56892734-001-09-4,omeprazole-magnesium,2.5,MTS004,proton pump inhibitor,"ATP4A, ATP4B",gastroenterology,"gastroesophageal reflux disease (GERD), heartburn",COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C,Launched
BRD-A58947127-001-01-6::2.5::MTS004,BRD-A58947127-001-01-6,AMG319,2.5,MTS004,PI3K inhibitor,PIK3CD,NA,NA,CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,Phase 2
BRD-A59378440-001-01-3::2.499948202::MTS004,BRD-A59378440-001-01-3,butylphthalide,2.499948202,MTS004,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke,CCCCC1OC(=O)c2ccccc12,Launched
BRD-A59825838-326-01-4::2.499983757::MTS004,BRD-A59825838-326-01-4,netilmicin,2.499983757,MTS004,protein synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O",Launched
BRD-A59961917-001-01-0::2.5::MTS004,BRD-A59961917-001-01-0,BQ-123,2.5,MTS004,endothelin receptor antagonist,EDNRA,NA,NA,CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C,Phase 2
BRD-A60498477-001-01-2::2.508127434::MTS004,BRD-A60498477-001-01-2,tolamolol,2.508127434,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",NA,NA,Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O,Phase 3
BRD-A61633223-001-02-8::2.678394161::MTS004,BRD-A61633223-001-02-8,ulifloxacin,2.678394161,MTS004,NA,NA,NA,NA,"CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1",Launched
BRD-A62197763-001-01-1::2.532450362::MTS004,BRD-A62197763-001-01-1,enciprazine,2.532450362,MTS004,GABA receptor modulator,GABRA1,NA,NA,COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1,Phase 3
BRD-A63431791-001-01-9::2.5::MTS004,BRD-A63431791-001-01-9,sulbactam-pivoxil,2.5,MTS004,beta lactamase inhibitor,NA,infectious disease,skin infections,CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C,Launched
BRD-A64173453-015-02-3::2.500011906::MTS004,BRD-A64173453-015-02-3,octreotide,2.500011906,MTS004,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5","gastroenterology, endocrinology, oncology","diarrhea, acromegaly, carcinoid tumors","CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1, CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1, CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1",Launched
BRD-A65562236-001-01-2::2.499987842::MTS004,BRD-A65562236-001-01-2,solamargine,2.499987842,MTS004,apoptosis inhibitor,NA,NA,NA,CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1,Phase 3
BRD-A65683612-001-07-7::2.499972087::MTS004,BRD-A65683612-001-07-7,phenylpiracetam,2.499972087,MTS004,noradrenaline uptake inhibitor,NA,neurology/psychiatry,"anxiety, fatigue, depression",NC(=O)CN1CC(CC1=O)c1ccccc1,Launched
BRD-A67182178-001-01-7::2.5::MTS004,BRD-A67182178-001-01-7,toloxatone,2.5,MTS004,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,depression,Cc1cccc(c1)N1CC(CO)OC1=O,Launched
BRD-A67305656-001-01-5::2.5::MTS004,BRD-A67305656-001-01-5,spiramycin,2.5,MTS004,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,"toxoplasmosis, soft tissue infection","CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C",Launched
BRD-A71765060-001-01-4::2.5::MTS004,BRD-A71765060-001-01-4,picartamide,2.5,MTS004,H+/K+-ATPase inhibitor,ATP4A,NA,NA,CNC(=S)C1(CCCS1)c1ccccn1,Phase 2
BRD-A72297358-001-01-8::2.5::MTS004,BRD-A72297358-001-01-8,ozolinone,2.5,MTS004,diuretic,NA,NA,NA,CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1,Phase 3
BRD-A72351335-001-04-5::2.463310717::MTS004,BRD-A72351335-001-04-5,misoprostol,2.463310717,MTS004,prostanoid receptor agonist,"PTGER2, PTGER3, PTGER4, PTGIR",gastroenterology,duodenal ulcer disease,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,Launched
BRD-A72401848-001-02-2::2.551316459::MTS004,BRD-A72401848-001-02-2,gadoteridol,2.551316459,MTS004,radiopaque medium,NA,radiology,MRI contrast agent,"CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3, CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3",Launched
BRD-A72988804-001-11-1::2.5::MTS004,BRD-A72988804-001-11-1,tiaprofenic-acid,2.5,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,rheumatoid arthritis,"CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1, CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1",Launched
BRD-A73385064-001-01-5::2.603473418::MTS004,BRD-A73385064-001-01-5,beclomethasone,2.603473418,MTS004,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO,Launched
BRD-A73566563-001-01-6::2.5::MTS004,BRD-A73566563-001-01-6,tiprenolol,2.5,MTS004,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",NA,NA,CSc1ccccc1OCC(O)CNC(C)C,Phase 2
BRD-A73679382-236-01-8::2.499981367::MTS004,BRD-A73679382-236-01-8,MK-571,2.499981367,MTS004,leukotriene receptor antagonist,"ABCC2, CYSLTR1",NA,NA,CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,Phase 2
BRD-A74975734-004-09-9::2.5::MTS004,BRD-A74975734-004-09-9,homatropine,2.5,MTS004,acetylcholine receptor antagonist,"CES1, CHRM1",ophthalmology,pupil dilation,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1",Launched
BRD-A75224450-001-02-4::2.662563322::MTS004,BRD-A75224450-001-02-4,ibuprofen-piconol,2.662563322,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,"CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1, CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1",Launched
BRD-A75975749-001-01-4::2.5::MTS004,BRD-A75975749-001-01-4,bafetinib,2.5,MTS004,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A76533773-001-01-9::2.5::MTS004,BRD-A76533773-001-01-9,lisadimate,2.5,MTS004,topical sunscreen agent,NA,dermatology,sunscreen lotion,Nc1ccc(cc1)C(=O)OCC(O)CO,Launched
BRD-A78277353-001-01-9::2.492599937::MTS004,BRD-A78277353-001-01-9,metazosin,2.492599937,MTS004,adrenergic receptor antagonist,ADRA1A,NA,NA,COC(C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,Phase 2
BRD-A78965079-036-01-8::2.640168331::MTS004,BRD-A78965079-036-01-8,tafenoquine,2.640168331,MTS004,antimalarial agent,NA,NA,NA,COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1,Phase 3
BRD-A79052425-003-01-5::2.5::MTS004,BRD-A79052425-003-01-5,SIB-1553A,2.5,MTS004,acetylcholine receptor agonist,CHRNB4,NA,NA,CN1CCCC1CCSc1ccc(O)cc1,Phase 2
BRD-A80280426-001-03-8::2.43120883::MTS004,BRD-A80280426-001-03-8,AD-5467,2.43120883,MTS004,aldose reductase inhibitor,AKR1B1,NA,NA,"CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C, CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C",Phase 2
BRD-A84810646-001-01-6::2.500007302::MTS004,BRD-A84810646-001-01-6,ginsenoside-rd,2.500007302,MTS004,calcium channel blocker,NA,NA,NA,CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,Phase 3
BRD-A85295731-001-06-4::2.500008824::MTS004,BRD-A85295731-001-06-4,tiopronin,2.500008824,MTS004,"chelating agent, reducing agent",NA,urology,kidney stones,"CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O",Launched
BRD-A86665761-001-01-1::2.5::MTS004,BRD-A86665761-001-01-1,gabapentin-enacarbil,2.5,MTS004,adrenergic receptor agonist,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8",neurology/psychiatry,"restless leg syndrome, postherpetic neuralgia",CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,Launched
BRD-A88254928-001-07-9::2.5::MTS004,BRD-A88254928-001-07-9,albuterol,2.5,MTS004,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,asthma,"CC(C)(C)NCC(O)c1ccc(O)c(CO)c1, CC(C)(C)NCC(O)c1ccc(O)c(CO)c1",Launched
BRD-A88562598-001-01-7::2.500008795::MTS004,BRD-A88562598-001-01-7,degarelix,2.500008795,MTS004,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer,CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,Launched
BRD-A89082344-001-08-7::2.500026693::MTS004,BRD-A89082344-001-08-7,perifosine,2.500026693,MTS004,AKT inhibitor,AKT1,NA,NA,"CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1",Phase 3
BRD-A89207210-001-01-6::2.378054241::MTS004,BRD-A89207210-001-01-6,terguride,2.378054241,MTS004,"dopamine receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,CCN(CC)C(=O)N[C@H]1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1,Launched
BRD-A91444184-300-01-9::2.5::MTS004,BRD-A91444184-300-01-9,buclizine,2.5,MTS004,histamine receptor antagonist,"CHRM1, HRH1",neurology/psychiatry,migraine headache,CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1,Launched
BRD-A91728607-236-11-9::2.5::MTS004,BRD-A91728607-236-11-9,citicoline,2.5,MTS004,"membrane permeability enhancer, glutathione transferase stimulant","ACHE, SLC1A2","neurology/psychiatry, ophthalmology","stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma","C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O",Launched
BRD-A92177080-001-02-1::2.5::MTS004,BRD-A92177080-001-02-1,betamethasone-acetate,2.5,MTS004,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,Launched
BRD-A92262698-001-02-5::2.5::MTS004,BRD-A92262698-001-02-5,chlorphenesin,2.5,MTS004,muscle relaxant,NA,neurology/psychiatry,"muscle relaxant, sedative","OCC(O)COc1ccc(Cl)cc1, OCC(O)COc1ccc(Cl)cc1",Launched
BRD-A92341659-001-04-0::2.499993321::MTS004,BRD-A92341659-001-04-0,prulifloxacin,2.499993321,MTS004,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary, gastroenterology","urinary tract infections, bronchitis, diarrhea","CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1",Launched
BRD-A93683007-001-01-9::2.5::MTS004,BRD-A93683007-001-01-9,mabuprofen,2.5,MTS004,cyclooxygenase inhibitor,NA,neurology/psychiatry,pain relief,CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO,Launched
BRD-A96466199-001-01-4::2.442131966::MTS004,BRD-A96466199-001-01-4,nuclomedone,2.442131966,MTS004,immunosuppressant,NA,NA,NA,Clc1ccc(CC2C(=O)N=C3SCCN3C2=O)cc1,Phase 3
BRD-A99899486-004-01-9::2.293696319::MTS004,BRD-A99899486-004-01-9,cimetropium,2.293696319,MTS004,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,Launched
BRD-K00531707-001-01-3::2.608376789::MTS004,BRD-K00531707-001-01-3,cinepazet,2.608376789,MTS004,vasodilator,NA,NA,NA,CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1,Launched
BRD-K00634421-001-01-0::2.500042819::MTS004,BRD-K00634421-001-01-0,brivaracetam,2.500042819,MTS004,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00739965-001-01-9::2.675904798::MTS004,BRD-K00739965-001-01-9,guacetisal,2.675904798,MTS004,immunosuppressant,NA,NA,NA,COc1ccccc1OC(=O)c1ccccc1OC(C)=O,Launched
BRD-K01291782-001-01-1::2.50002964::MTS004,BRD-K01291782-001-01-1,molidustat,2.50002964,MTS004,hypoxia inducible factor inhibitor,EGLN2,NA,NA,"O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1",Phase 2
BRD-K01638814-011-01-4::2.587084236::MTS004,BRD-K01638814-011-01-4,rilmenidine,2.587084236,MTS004,"adrenergic receptor agonist, imidazoline receptor agonist",ADRA2A,cardiology,hypertension,"C1CC1C(NC1=NCCO1)C1CC1, C1CC1C(NC1=NCCO1)C1CC1",Launched
BRD-K01662324-001-01-8::2.618953925::MTS004,BRD-K01662324-001-01-8,priralfinamide,2.618953925,MTS004,sodium channel blocker,CACNA1B,NA,NA,"C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O",Phase 3
BRD-K01666412-001-02-0::2.5::MTS004,BRD-K01666412-001-02-0,L-proline,2.5,MTS004,glutamate receptor agonist,"EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7",NA,NA,OC(=O)[C@@H]1CCCN1,Launched
BRD-K01773083-001-01-4::2.303758671::MTS004,BRD-K01773083-001-01-4,denotivir,2.303758671,MTS004,antiviral,NA,infectious disease,"virus herpes simplex (HSV), skin infections",Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1,Launched
BRD-K02152879-414-02-1::2.500013375::MTS004,BRD-K02152879-414-02-1,sivelestat,2.500013375,MTS004,elastase inhibitor,"CELA1, ELANE",pulmonary,acute lung injury,"CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O",Launched
BRD-K02275692-300-02-6::2.499989889::MTS004,BRD-K02275692-300-02-6,cefotiam,2.499989889,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections","CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O",Launched
BRD-K02528732-001-02-4::2.425128585::MTS004,BRD-K02528732-001-02-4,fluorometholone-acetate,2.425128585,MTS004,NA,NR3C1,ophthalmology,eye inflammation,"C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K02554563-001-01-6::2.5::MTS004,BRD-K02554563-001-01-6,PF-05190457,2.5,MTS004,growth hormone secretagogue receptor inverse agonist,GHSR,NA,NA,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,Phase 2
BRD-K02729857-001-01-9::2.50244046::MTS004,BRD-K02729857-001-01-9,phenylbenzimidazole-sulfonic-acid,2.50244046,MTS004,NA,NA,dermatology,sunscreen lotion,OS(=O)(=O)c1ccc2[nH]c(nc2c1)-c1ccccc1,Launched
BRD-K02750403-001-01-4::2.499962046::MTS004,BRD-K02750403-001-01-4,piboserod,2.499962046,MTS004,serotonin receptor antagonist,"HTR2B, HTR4",NA,NA,"CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1",Phase 2
BRD-K02988401-001-01-2::2.5::MTS004,BRD-K02988401-001-01-2,UNC0737,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,Preclinical
BRD-K02995728-003-01-9::2.499993866::MTS004,BRD-K02995728-003-01-9,quinagolide,2.499993866,MTS004,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,Launched
BRD-K03165895-001-01-9::2.499970324::MTS004,BRD-K03165895-001-01-9,elafibranor,2.499970324,MTS004,PPAR receptor agonist,"PPARA, PPARD",NA,NA,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,Phase 3
BRD-K03503561-001-01-4::2.339952449::MTS004,BRD-K03503561-001-01-4,ravuconazole,2.339952449,MTS004,sterol demethylase inhibitor,NA,NA,NA,C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Phase 2
BRD-K03765900-001-01-9::2.499986292::MTS004,BRD-K03765900-001-01-9,XL-647,2.499986292,MTS004,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03894385-001-01-1::2.500025266::MTS004,BRD-K03894385-001-01-1,MK-6096,2.500025266,MTS004,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1,Phase 2
BRD-K04603573-376-01-3::2.542651982::MTS004,BRD-K04603573-376-01-3,"1,12-Besm",2.542651982,MTS004,polyamine biosynthesis inhibitor,NA,NA,NA,CCNCCCNCCCCNCCCNCC,Phase 2
BRD-K04643877-001-03-2::2.633096501::MTS004,BRD-K04643877-001-03-2,perzinfotel,2.633096501,MTS004,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B",NA,NA,OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O,Phase 2
BRD-K04701033-001-04-7::2.499987566::MTS004,BRD-K04701033-001-04-7,VE-822,2.499987566,MTS004,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04710043-001-17-8::2.5::MTS004,BRD-K04710043-001-17-8,hexamethylenebisacetamide,2.5,MTS004,"AKT inhibitor, differentiation inducer, NFKB pathway inhibitor",AKT1,NA,NA,CC(=O)NCCCCCCNC(C)=O,Phase 2
BRD-K05858796-001-01-7::2.500017956::MTS004,BRD-K05858796-001-01-7,GSK2330672,2.500017956,MTS004,bile acid transporter inhibitor,SLC10A2,NA,NA,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1,Phase 2
BRD-K06182768-001-02-3::2.5::MTS004,BRD-K06182768-001-02-3,A-366,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1",Preclinical
BRD-K06273313-001-07-9::2.5::MTS004,BRD-K06273313-001-07-9,E-64,2.5,MTS004,"cysteine protease inhibitor, calpain inhibitor",CTSS,NA,NA,"CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N, CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N",Preclinical
BRD-K06328344-015-01-7::2.500004254::MTS004,BRD-K06328344-015-01-7,bremelanotide,2.500004254,MTS004,melanocortin receptor agonist,"MC1R, MC2R, MC3R, MC4R, MC5R",NA,NA,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O,Phase 3
BRD-K06357403-001-01-4::2.49996939::MTS004,BRD-K06357403-001-01-4,velneperit,2.49996939,MTS004,neuropeptide receptor antagonist,NPY5R,NA,NA,"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F",Phase 2
BRD-K06388517-001-01-2::2.5::MTS004,BRD-K06388517-001-01-2,lofemizole,2.5,MTS004,cyclooxygenase inhibitor,NA,NA,NA,Cc1nc[nH]c1-c1ccc(Cl)cc1,Phase 3
BRD-K06455935-001-01-3::2.499992329::MTS004,BRD-K06455935-001-01-3,daprodustat,2.499992329,MTS004,hypoxia inducible factor inhibitor,EGLN1,NA,NA,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,Phase 3
BRD-K06467130-304-02-7::2.5::MTS004,BRD-K06467130-304-02-7,CL316243,2.5,MTS004,adrenergic receptor agonist,"ADRB3, UCP1, UCP2, UCP3",NA,NA,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,Phase 2
BRD-K06502269-001-02-6::2.5::MTS004,BRD-K06502269-001-02-6,L-methionine,2.5,MTS004,voltage-gated calcium channel ligand,NA,NA,NA,CSCC[C@H](N)C(O)=O,Launched
BRD-K06519765-001-01-1::2.5::MTS004,BRD-K06519765-001-01-1,vinblastine,2.5,MTS004,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06883221-001-01-9::2.686662955::MTS004,BRD-K06883221-001-01-9,apratastat,2.686662955,MTS004,"matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9",NA,NA,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1,Phase 2
BRD-K07070922-001-01-4::2.5::MTS004,BRD-K07070922-001-01-4,PF-03049423,2.5,MTS004,phosphodiesterase inhibitor,PDE5A,NA,NA,CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1,Phase 2
BRD-K07409305-001-01-1::2.391201575::MTS004,BRD-K07409305-001-01-1,Org-12962,2.391201575,MTS004,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",NA,NA,FC(F)(F)c1ccc(nc1Cl)N1CCNCC1,Phase 2
BRD-K07625016-001-01-2::2.50703254::MTS004,BRD-K07625016-001-01-2,norethisterone-enanthate,2.50703254,MTS004,contraceptive agent,NA,endocrinology,contraceptive,CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C,Launched
BRD-K07682953-001-01-8::2.499993276::MTS004,BRD-K07682953-001-01-8,palosuran,2.499993276,MTS004,urotensin receptor antagonist,UTS2R,NA,NA,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,Phase 2
BRD-K07785030-001-01-6::2.29884119::MTS004,BRD-K07785030-001-01-6,7-keto-DHEA,2.29884119,MTS004,steroid,NA,NA,NA,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1,Launched
BRD-K07790550-001-01-6::2.500001908::MTS004,BRD-K07790550-001-01-6,mavoglurant,2.500001908,MTS004,glutamate receptor antagonist,GRM5,NA,NA,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,Phase 2
BRD-K08255599-365-01-1::2.656154742::MTS004,BRD-K08255599-365-01-1,frovatriptan,2.656154742,MTS004,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D",neurology/psychiatry,migraine headache,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,Launched
BRD-K09436144-001-01-7::2.487366457::MTS004,BRD-K09436144-001-01-7,YM022,2.487366457,MTS004,CCK receptor antagonist,CCKBR,NA,NA,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,Phase 2
BRD-K09735259-001-01-3::2.500007896::MTS004,BRD-K09735259-001-01-3,elbasvir,2.500007896,MTS004,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K09821361-066-25-8::2.499990088::MTS004,BRD-K09821361-066-25-8,deferoxamine-mesylate,2.499990088,MTS004,chelating agent,NA,hematology,"acute iron intoxication, iron overload","CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN",Launched
BRD-K10415035-001-04-4::2.5::MTS004,BRD-K10415035-001-04-4,tasuldine,2.5,MTS004,mucolytic agent,NA,NA,NA,"C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1",Phase 3
BRD-K10667240-001-01-7::2.485820406::MTS004,BRD-K10667240-001-01-7,ethacizin,2.485820406,MTS004,anticonvulsant,NA,cardiology,"ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)",CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1,Launched
BRD-K10995081-001-27-9::2.316458322::MTS004,BRD-K10995081-001-27-9,perphenazine,2.316458322,MTS004,dopamine receptor antagonist,"CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7","neurology/psychiatry, gastroenterology","schizophrenia, nausea, vomiting","OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1",Launched
BRD-K11256763-001-01-5::2.5::MTS004,BRD-K11256763-001-01-5,niceritrol,2.5,MTS004,NAD precursor,NA,endocrinology,hyperlipidemia,O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1,Launched
BRD-K11443721-003-01-6::2.403980733::MTS004,BRD-K11443721-003-01-6,NE-100,2.403980733,MTS004,sigma receptor antagonist,SIGMAR1,NA,NA,"CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1",Phase 2
BRD-K11452913-001-01-9::2.5000112::MTS004,BRD-K11452913-001-01-9,evatanepag,2.5000112,MTS004,prostaglandin inhibitor,"PTGER2, PTGER4",NA,NA,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1,Phase 2
BRD-K11463116-304-03-5::2.500052374::MTS004,BRD-K11463116-304-03-5,eprodisate,2.500052374,MTS004,"antiamyloidogenic agent, amyloid protein inhibitor",SAA1,NA,NA,"OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O",Phase 3
BRD-K11792081-001-01-4::2.500009305::MTS004,BRD-K11792081-001-01-4,ABT-639,2.500009305,MTS004,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I",NA,NA,Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F,Phase 2
BRD-K11851476-003-01-7::2.499993171::MTS004,BRD-K11851476-003-01-7,pardoprunox,2.499993171,MTS004,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K12261274-001-02-4::2.499953183::MTS004,BRD-K12261274-001-02-4,zaltidine,2.499953183,MTS004,histamine receptor antagonist,HRH2,NA,NA,"Cc1ncc([nH]1)-c1csc(NC(N)=N)n1, Cc1ncc([nH]1)-c1csc(NC(N)=N)n1",Phase 3
BRD-K12742203-003-01-7::2.512196931::MTS004,BRD-K12742203-003-01-7,moxaverine,2.512196931,MTS004,phosphodiesterase inhibitor,NA,neurology/psychiatry,spasms,CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1,Launched
BRD-K12852738-001-01-2::2.584725941::MTS004,BRD-K12852738-001-01-2,veliflapon,2.584725941,MTS004,leukotriene synthesis inhibitor,ALOX5AP,NA,NA,OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1,Phase 3
BRD-K12906202-001-06-2::2.5::MTS004,BRD-K12906202-001-06-2,carbendazim,2.5,MTS004,"microtubule inhibitor, tubulin polymerization inhibitor","TP53, TUBB",infectious disease,fungicide,COC(=O)Nc1nc2ccccc2[nH]1,Launched
BRD-K13060017-001-02-1::2.499994836::MTS004,BRD-K13060017-001-02-1,UNC0631,2.499994836,MTS004,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13277760-001-01-2::2.5::MTS004,BRD-K13277760-001-01-2,rifamycin-sv,2.5,MTS004,RNA synthesis inhibitor,NA,NA,NA,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C,Phase 3
BRD-K13394247-003-01-4::2.499991328::MTS004,BRD-K13394247-003-01-4,radafaxine,2.499991328,MTS004,dopamine-norepinephrine reuptake inhibitor,SLC6A3,NA,NA,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,Phase 2
BRD-K13414800-001-01-3::2.499970601::MTS004,BRD-K13414800-001-01-3,vesnarinone,2.499970601,MTS004,phosphodiesterase inhibitor,"KCNH2, PDE3A",cardiology,congestive heart failure,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1,Launched
BRD-K13533483-001-16-2::2.5::MTS004,BRD-K13533483-001-16-2,cyclosporine,2.5,MTS004,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13664493-316-02-5::2.500014041::MTS004,BRD-K13664493-316-02-5,naphthoquine-phosphate,2.500014041,MTS004,antimalarial agent,NA,NA,NA,"CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O",Launched
BRD-K13769342-001-01-5::2.50001379::MTS004,BRD-K13769342-001-01-5,danirixin,2.50001379,MTS004,CC chemokine receptor antagonist,CXCR2,NA,NA,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,Phase 2
BRD-K14171291-001-01-4::2.499985403::MTS004,BRD-K14171291-001-01-4,omarigliptin,2.499985403,MTS004,dipeptidyl peptidase inhibitor,DPP4,NA,NA,"CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F",Launched
BRD-K14276241-001-01-2::2.49998187::MTS004,BRD-K14276241-001-01-2,daucosterol,2.49998187,MTS004,apoptosis stimulant,NA,NA,NA,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C,Phase 2
BRD-K14571191-001-01-6::2.5::MTS004,BRD-K14571191-001-01-6,zometapine,2.5,MTS004,NA,NA,NA,NA,Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1,Phase 2
BRD-K14658796-003-01-6::2.368766292::MTS004,BRD-K14658796-003-01-6,drotaverine,2.368766292,MTS004,phosphodiesterase inhibitor,"CACNA1C, PDE4A",obstetrics/gynecology,labor induction,"CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC",Launched
BRD-K14681867-001-01-6::2.5::MTS004,BRD-K14681867-001-01-6,somatostatin,2.5,MTS004,somatostatin receptor agonist,"OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5",hematology,hemorrhage,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N,Launched
BRD-K15014948-001-10-3::2.500062642::MTS004,BRD-K15014948-001-10-3,tranexamic-acid,2.500062642,MTS004,"antifibrinolytic, plasminogen activator inhibitor",PLG,hematology,hemophilia,"NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O",Launched
BRD-K15262564-001-15-0::2.500002693::MTS004,BRD-K15262564-001-15-0,mupirocin,2.500002693,MTS004,isoleucyl-tRNA synthetase inhibitor,NA,infectious disease,impetigo,"C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O",Launched
BRD-K15327298-001-05-5::2.444207768::MTS004,BRD-K15327298-001-05-5,fmoc-l-leucine,2.444207768,MTS004,PPAR receptor agonist,NA,NA,NA,CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,Phase 2
BRD-K15360631-325-01-4::2.404560312::MTS004,BRD-K15360631-325-01-4,dehydroepiandrosterone-sulfate,2.404560312,MTS004,"androgen receptor agonist, estrogen receptor agonist","AR, ESR1, ESR2",endocrinology,menopause,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O,Launched
BRD-K15691453-236-01-6::2.499981005::MTS004,BRD-K15691453-236-01-6,GSK2190915,2.499981005,MTS004,lipoxygenase inhibitor,ALOX5AP,NA,NA,CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1,Phase 2
BRD-K16180792-001-01-7::2.5::MTS004,BRD-K16180792-001-01-7,bis(maltolato)oxovanadium(IV),2.5,MTS004,tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16505263-003-02-9::2.49996754::MTS004,BRD-K16505263-003-02-9,forodesine,2.49996754,MTS004,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16546375-001-01-4::2.393310671::MTS004,BRD-K16546375-001-01-4,bicyclol,2.393310671,MTS004,NFkB pathway inhibitor,"HSPA1A, HSPB1",NA,NA,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO,Launched
BRD-K17295893-001-01-0::2.499987615::MTS004,BRD-K17295893-001-01-0,nastorazepide,2.499987615,MTS004,CCK receptor antagonist,CCKBR,NA,NA,CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1,Phase 2
BRD-K17480742-001-01-1::2.5::MTS004,BRD-K17480742-001-01-1,delamanid,2.5,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,tuberculosis,C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O,Launched
BRD-K17610631-001-03-3::2.421190843::MTS004,BRD-K17610631-001-03-3,indisulam,2.421190843,MTS004,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17641316-001-04-8::2.500015146::MTS004,BRD-K17641316-001-04-8,decoquinate,2.500015146,MTS004,antiprotozoal agent,NA,infectious disease,coccidiosis,"CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC",Launched
BRD-K17828029-001-01-5::2.536141856::MTS004,BRD-K17828029-001-01-5,cinoxate,2.536141856,MTS004,NA,NA,dermatology,sunscreen lotion,CCOCCOC(=O)\C=C\c1ccc(OC)cc1,Launched
BRD-K18135438-001-14-2::2.5::MTS004,BRD-K18135438-001-14-2,chenodeoxycholic-acid,2.5,MTS004,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K18749874-003-08-9::2.5::MTS004,BRD-K18749874-003-08-9,melevodopa,2.5,MTS004,"dopamine precursor, dopamine receptor agonist",DDC,neurology/psychiatry,Parkinson's Disease,"COC(=O)C(N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1",Launched
BRD-K18878288-001-06-4::2.457947881::MTS004,BRD-K18878288-001-06-4,schisandrol-b,2.457947881,MTS004,lipid peroxidase inhibitor,NA,NA,NA,"COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC",Phase 3
BRD-K18898553-001-01-1::2.5::MTS004,BRD-K18898553-001-01-1,salvianolic-acid-B,2.5,MTS004,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K19515365-001-02-6::2.33859482::MTS004,BRD-K19515365-001-02-6,bendazac,2.33859482,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,Launched
BRD-K20093108-001-02-3::2.5::MTS004,BRD-K20093108-001-02-3,BMS-587101,2.5,MTS004,integrin antagonist,"ITGAL, ITGB2",NA,NA,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,Phase 2
BRD-K20463415-300-01-4::2.499966791::MTS004,BRD-K20463415-300-01-4,LY2606368,2.499966791,MTS004,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20468903-001-01-6::2.49996519::MTS004,BRD-K20468903-001-01-6,BNC105,2.49996519,MTS004,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K21077415-001-01-5::2.656085278::MTS004,BRD-K21077415-001-01-5,AMG-319,2.656085278,MTS004,PI3K inhibitor,PIK3CD,NA,NA,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,Phase 2
BRD-K21152241-001-07-3::2.5082643::MTS004,BRD-K21152241-001-07-3,enoximone,2.5082643,MTS004,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21191422-001-01-5::2.499985534::MTS004,BRD-K21191422-001-01-5,selexipag,2.499985534,MTS004,"platelet aggregation inhibitor, IP1 prostacyclin receptor agonist",PTGIR,NA,NA,"CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1",Phase 3
BRD-K21237892-376-01-3::2.5::MTS004,BRD-K21237892-376-01-3,semapimod,2.5,MTS004,"cytokine production inhibitor, p38 MAPK inhibitor",MAPK14,NA,NA,NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N,Phase 2
BRD-K21586122-001-01-9::2.50000801::MTS004,BRD-K21586122-001-01-9,fimasartan,2.50000801,MTS004,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure, hypertension, congestive heart failure","CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K21612934-001-01-1::2.473727942::MTS004,BRD-K21612934-001-01-1,leteprinim,2.473727942,MTS004,nerve growth factor agonist,NA,NA,NA,OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1,Phase 2
BRD-K22064724-001-01-8::2.499989634::MTS004,BRD-K22064724-001-01-8,napabucasin,2.499989634,MTS004,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22149900-001-03-9::2.371298578::MTS004,BRD-K22149900-001-03-9,ceritinib,2.371298578,MTS004,ALK tyrosine kinase receptor inhibitor,"ALK, FLT3, IGF1R, INSR, TSSK1B",oncology,non-small cell lung cancer (NSCLC),"CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1",Launched
BRD-K22514639-001-05-7::2.500015058::MTS004,BRD-K22514639-001-05-7,EGF816,2.500015058,MTS004,EGFR inhibitor,EGFR,NA,NA,"CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12",Phase 2
BRD-K22518984-001-01-8::2.5::MTS004,BRD-K22518984-001-01-8,metacresol,2.5,MTS004,NA,INS,NA,NA,Cc1cccc(O)c1,Launched
BRD-K22525962-001-05-0::2.500010949::MTS004,BRD-K22525962-001-05-0,dihydrotestosterone,2.500010949,MTS004,androgen receptor agonist,"AR, HSD17B1","neurology/psychiatry, endocrinology","tetany, hypoparathyroidism",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,Launched
BRD-K22588750-001-07-0::2.654665484::MTS004,BRD-K22588750-001-07-0,gidazepam,2.654665484,MTS004,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K23791635-001-01-3::2.499966688::MTS004,BRD-K23791635-001-01-3,AFN-1252,2.499966688,MTS004,FABI inhibitor,NA,NA,NA,CN(Cc1oc2ccccc2c1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1,Phase 2
BRD-K23848629-401-03-7::2.5::MTS004,BRD-K23848629-401-03-7,fosaprepitant-dimeglumine,2.5,MTS004,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting","C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",Launched
BRD-K24221957-003-01-6::2.5::MTS004,BRD-K24221957-003-01-6,pralidoxime-chloride,2.5,MTS004,acetylcholinesterase inhibitor,"ACHE, BCHE",pulmonary,respiratory depression,C[n+]1ccccc1C[N+][O-],Launched
BRD-K24452555-001-01-7::2.599377769::MTS004,BRD-K24452555-001-01-7,methylprednisolone-aceponate,2.599377769,MTS004,"anti-inflammatory agent, glucocorticoid receptor agonist",NR3C1,"endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia",CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K24476327-001-01-3::2.50002878::MTS004,BRD-K24476327-001-01-3,icaritin,2.50002878,MTS004,PPAR receptor antagonist,PDE5A,NA,NA,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O",Phase 2
BRD-K24497734-001-01-6::2.499993902::MTS004,BRD-K24497734-001-01-6,setipiprant,2.499993902,MTS004,prostaglandin inhibitor,PTGDR2,NA,NA,OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12,Phase 3
BRD-K24610819-003-01-8::2.33438271::MTS004,BRD-K24610819-003-01-8,amibegron,2.33438271,MTS004,adrenergic receptor agonist,ADRB3,NA,NA,"CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1",Phase 3
BRD-K24666289-001-04-9::2.499988887::MTS004,BRD-K24666289-001-04-9,copanlisib,2.499988887,MTS004,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,follicular lymphoma,"COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12",Launched
BRD-K24864897-001-01-0::2.5::MTS004,BRD-K24864897-001-01-0,JNJ-26990990,2.5,MTS004,anticonvulsant,NA,NA,NA,NS(=O)(=O)NCc1csc2ccccc12,Phase 2
BRD-K25029121-001-05-8::2.446932239::MTS004,BRD-K25029121-001-05-8,triclocarban,2.446932239,MTS004,other antibiotic,NA,NA,NA,Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1,Launched
BRD-K25146005-001-01-0::2.5::MTS004,BRD-K25146005-001-01-0,cis-urocanic acid,2.5,MTS004,serotonin receptor agonist,HTR2A,NA,NA,OC(=O)\C=C/c1c[nH]cn1,Phase 2
BRD-K25154476-001-01-4::2.5::MTS004,BRD-K25154476-001-01-4,cinflumide,2.5,MTS004,muscle relaxant,NA,NA,NA,Fc1cccc(c1)\C=C\C(=O)NC1CC1,Phase 2
BRD-K25243230-001-01-2::2.5::MTS004,BRD-K25243230-001-01-2,oxytocin,2.5,MTS004,oxytocin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",obstetrics/gynecology,labor induction,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O",Launched
BRD-K25494650-003-01-8::2.660853131::MTS004,BRD-K25494650-003-01-8,chlorproguanil,2.660853131,MTS004,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1,Launched
BRD-K25570267-001-01-4::2.436963824::MTS004,BRD-K25570267-001-01-4,ezutromid,2.436963824,MTS004,utrophin enhancer,UTRN,NA,NA,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,Phase 2
BRD-K25970317-001-01-6::2.50000335::MTS004,BRD-K25970317-001-01-6,resibufogenin,2.50000335,MTS004,Na/K-ATPase inhibitor,NA,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1,Phase 2
BRD-K26024145-001-01-9::2.5::MTS004,BRD-K26024145-001-01-9,desoxycorticosterone-pivalate,2.5,MTS004,corticosteroid agonist,NR3C2,endocrinology,Addison's disease,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Launched
BRD-K26026438-001-01-0::2.499979456::MTS004,BRD-K26026438-001-01-0,tucatinib,2.499979456,MTS004,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26323068-001-01-8::2.5::MTS004,BRD-K26323068-001-01-8,leuprolide,2.5,MTS004,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,Launched
BRD-K26530649-001-01-6::2.568078778::MTS004,BRD-K26530649-001-01-6,carboxypyridine-disulfide,2.568078778,MTS004,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26813177-001-03-2::2.46430412::MTS004,BRD-K26813177-001-03-2,daltroban,2.46430412,MTS004,thromboxane receptor antagonist,TBXA2R,NA,NA,OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,Phase 3
BRD-K26818574-305-07-6::2.5::MTS004,BRD-K26818574-305-07-6,BIX-01294,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K27061362-001-01-6::2.499998598::MTS004,BRD-K27061362-001-01-6,AMG-337,2.499998598,MTS004,MET inhibitor,MET,NA,NA,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1,Phase 2
BRD-K27293958-001-01-5::2.450321909::MTS004,BRD-K27293958-001-01-5,tiaramide,2.450321909,MTS004,anti-inflammatory agent,NA,pulmonary,asthma,OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O,Launched
BRD-K27515606-003-01-3::2.5::MTS004,BRD-K27515606-003-01-3,cefcapene-pivoxil,2.5,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"skin infections, pneumonia, urinary tract infections","CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K27625831-001-02-9::2.499990597::MTS004,BRD-K27625831-001-02-9,pleconaril,2.499990597,MTS004,NA,NA,NA,NA,"Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1",Phase 3
BRD-K27755542-001-01-6::2.49693186::MTS004,BRD-K27755542-001-01-6,PF-04937319,2.49693186,MTS004,glucokinase activator,GCK,NA,NA,CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1,Phase 2
BRD-K27798832-001-01-5::2.350625651::MTS004,BRD-K27798832-001-01-5,cefetamet,2.350625651,MTS004,bacterial cell wall synthesis inhibitor,NA,"infectious disease, otolaryngology, pulmonary","ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections",CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1,Launched
BRD-K27885593-001-06-8::2.500027849::MTS004,BRD-K27885593-001-06-8,corosolic-acid,2.500027849,MTS004,"PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1",NA,NA,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,Phase 2
BRD-K28061410-001-06-6::2.5::MTS004,BRD-K28061410-001-06-6,beta-lapachone,2.5,MTS004,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28537285-001-01-8::2.499968715::MTS004,BRD-K28537285-001-01-8,chidamide,2.499968715,MTS004,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28687144-001-08-7::2.5::MTS004,BRD-K28687144-001-08-7,fosfosal,2.5,MTS004,phosphodiesterase inhibitor,"PTGS1, PTGS2",NA,NA,"OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O",Launched
BRD-K29570907-001-07-3::2.420672872::MTS004,BRD-K29570907-001-07-3,sulmetozine,2.420672872,MTS004,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD),COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1,Launched
BRD-K29626940-001-01-5::2.682001852::MTS004,BRD-K29626940-001-01-5,imidafenacin,2.682001852,MTS004,acetylcholine receptor antagonist,"CHRM1, CHRM3",neurology/psychiatry,"spasms, spasms","Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1",Launched
BRD-K29812331-011-01-7::2.472474424::MTS004,BRD-K29812331-011-01-7,dimemorfan,2.472474424,MTS004,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31,Launched
BRD-K30159788-001-01-9::2.49998123::MTS004,BRD-K30159788-001-01-9,RSV604,2.49998123,MTS004,RSV replication inhibitor,NA,NA,NA,Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O,Phase 2
BRD-K30485548-050-01-6::2.479775098::MTS004,BRD-K30485548-050-01-6,sumanirole,2.479775098,MTS004,dopamine receptor agonist,DRD2,NA,NA,CN[C@@H]1Cc2cccc3nc(O)n(C1)c23,Phase 3
BRD-K30764557-001-01-5::2.5::MTS004,BRD-K30764557-001-01-5,miocamycin,2.5,MTS004,other antibiotic,NA,infectious disease,"urinary tract infections, chlamydia",CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C,Launched
BRD-K30968378-001-01-9::2.500026128::MTS004,BRD-K30968378-001-01-9,INT-747,2.500026128,MTS004,FXR agonist,NA,NA,NA,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,Phase 3
BRD-K31417912-001-01-9::2.499995989::MTS004,BRD-K31417912-001-01-9,PF-3274167,2.499995989,MTS004,oxytocin receptor antagonist,"AVPR1A, OXTR",NA,NA,COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1,Phase 2
BRD-K31802667-001-01-9::2.530781625::MTS004,BRD-K31802667-001-01-9,JNJ-37822681,2.530781625,MTS004,dopamine receptor antagonist,DRD2,NA,NA,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,Phase 2
BRD-K32256160-001-01-9::2.499998021::MTS004,BRD-K32256160-001-01-9,solithromycin,2.499998021,MTS004,protein synthesis inhibitor,NA,NA,NA,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC,Phase 3
BRD-K32804101-001-01-8::2.5::MTS004,BRD-K32804101-001-01-8,valrocemide,2.5,MTS004,NA,NA,NA,NA,CCCC(CCC)C(=O)NCC(N)=O,Phase 2
BRD-K32842773-434-01-8::2.5::MTS004,BRD-K32842773-434-01-8,pemetrexed,2.5,MTS004,"dihydrofolate reductase inhibitor, thymidylate synthase inhibitor","ATIC, DHFR, GART, TYMS",oncology,"non-small cell lung cancer (NSCLC), mesothelioma","Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1",Launched
BRD-K32891457-001-15-5::2.719791572::MTS004,BRD-K32891457-001-15-5,cortodoxone,2.719791572,MTS004,androgen receptor antagonist,AR,NA,NA,"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Phase 3
BRD-K33131085-001-07-2::2.644499841::MTS004,BRD-K33131085-001-07-2,gentiopicrin,2.644499841,MTS004,glutamate receptor downregulator,GRIN2B,NA,NA,OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O,Phase 3
BRD-K33133047-001-01-8::2.5::MTS004,BRD-K33133047-001-01-8,dapiprazole,2.5,MTS004,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",ophthalmology,mydriasis,Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1,Launched
BRD-K33240821-001-06-2::2.50000539::MTS004,BRD-K33240821-001-06-2,plerixafor,2.50000539,MTS004,CC chemokine receptor antagonist,"ACKR3, CCR4, CXCR4",hematologic malignancy,"non-Hodgkin lymphoma (NHL), multiple myeloma","C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1",Launched
BRD-K33245965-001-03-4::2.50001558::MTS004,BRD-K33245965-001-03-4,BMS-833923,2.50001558,MTS004,smoothened receptor antagonist,SMO,NA,NA,"CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1",Phase 2
BRD-K33637378-001-01-7::2.500021224::MTS004,BRD-K33637378-001-01-7,flibanserin,2.500021224,MTS004,serotonin receptor agonist,"DRD4, HTR1A, HTR2A",neurology/psychiatry,hypoactive sexual desire disorder,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,Launched
BRD-K34068325-066-03-7::2.499970684::MTS004,BRD-K34068325-066-03-7,delavirdine,2.499970684,MTS004,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1",Launched
BRD-K34251960-036-01-6::2.459743274::MTS004,BRD-K34251960-036-01-6,cibenzoline,2.459743274,MTS004,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34277641-001-01-2::2.569027627::MTS004,BRD-K34277641-001-01-2,L-365260,2.569027627,MTS004,CCK receptor antagonist,"CCKAR, CCKBR, KCNQ1",NA,NA,CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1,Phase 2
BRD-K34445261-001-02-2::2.334266471::MTS004,BRD-K34445261-001-02-2,SLV-320,2.334266471,MTS004,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1",Phase 2
BRD-K34508702-001-02-4::2.499975465::MTS004,BRD-K34508702-001-02-4,CHF5074,2.499975465,MTS004,gamma secretase modulator,PSEN1,NA,NA,OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1,Phase 2
BRD-K35304636-001-01-0::2.5::MTS004,BRD-K35304636-001-01-0,examorelin,2.5,MTS004,growth hormone releasing factor agonist,"GHRHR, GHSR",NA,NA,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,Phase 2
BRD-K35367061-001-01-1::2.5::MTS004,BRD-K35367061-001-01-1,LY223982,2.5,MTS004,leukotriene receptor antagonist,LTB4R,NA,NA,COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1,Phase 2
BRD-K35626314-003-01-1::2.499986242::MTS004,BRD-K35626314-003-01-1,TRV130,2.499986242,MTS004,opioid receptor agonist,OPRM1,NA,NA,COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1,Phase 3
BRD-K35798650-001-01-4::2.5::MTS004,BRD-K35798650-001-01-4,polidocanol,2.5,MTS004,local anesthetic,NA,dermatology,varicose veins,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,Launched
BRD-K35882976-001-04-7::2.444346727::MTS004,BRD-K35882976-001-04-7,mitoflaxone,2.444346727,MTS004,antitumor agent,VWF,NA,NA,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,Phase 2
BRD-K36379990-001-01-1::2.547414282::MTS004,BRD-K36379990-001-01-1,riodipine,2.547414282,MTS004,calcium channel blocker,NA,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC,Phase 2
BRD-K36463073-001-03-9::2.499956047::MTS004,BRD-K36463073-001-03-9,OC000459,2.499956047,MTS004,CRTH receptor antagonist,PTGDR2,NA,NA,"Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O",Phase 2
BRD-K36524108-065-04-0::2.500001799::MTS004,BRD-K36524108-065-04-0,paromomycin,2.500001799,MTS004,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,amebiasis,"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K36574127-001-01-3::2.5::MTS004,BRD-K36574127-001-01-3,LOXO-101,2.5,MTS004,tropomyosin receptor kinase inhibitor,"NTRK1, NTRK2, NTRK3",NA,NA,O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,Phase 2
BRD-K36636143-001-01-0::2.518926249::MTS004,BRD-K36636143-001-01-0,nolatrexed,2.518926249,MTS004,thymidylate synthase inhibitor,TYMS,NA,NA,Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1,Phase 3
BRD-K36741660-001-01-1::2.499963039::MTS004,BRD-K36741660-001-01-1,verinurad,2.499963039,MTS004,urate transporter inhibitor,SLC22A12,NA,NA,CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O,Phase 2
BRD-K37543758-001-01-3::2.588829083::MTS004,BRD-K37543758-001-01-3,trepibutone,2.588829083,MTS004,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,irritable bowel syndrome,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,Launched
BRD-K37708699-001-01-4::2.530276706::MTS004,BRD-K37708699-001-01-4,exisulind,2.530276706,MTS004,phosphodiesterase inhibitor,PDE5A,NA,NA,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O,Phase 3
BRD-K38168441-001-03-7::2.422985058::MTS004,BRD-K38168441-001-03-7,dabigatran,2.422985058,MTS004,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1",Launched
BRD-K38398115-001-01-9::2.418470509::MTS004,BRD-K38398115-001-01-9,YM-511,2.418470509,MTS004,aromatase inhibitor,CYP19A1,NA,NA,Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1,Phase 2
BRD-K38477637-001-01-0::2.652726792::MTS004,BRD-K38477637-001-01-0,droloxifene,2.652726792,MTS004,selective estrogen receptor modulator (SERM),ESR1,NA,NA,CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,Phase 3
BRD-K38527262-300-01-0::2.300987371::MTS004,BRD-K38527262-300-01-0,atiprimod,2.300987371,MTS004,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38564664-001-01-1::2.5::MTS004,BRD-K38564664-001-01-1,rolziracetam,2.5,MTS004,NA,NA,NA,NA,O=C1CCC2CCC(=O)N12,Phase 2
BRD-K39009484-001-01-4::2.5::MTS004,BRD-K39009484-001-01-4,entrectinib,2.5,MTS004,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor","ALK, NTRK1, NTRK2, NTRK3, ROS1",NA,NA,CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1,Phase 2
BRD-K39560679-001-01-1::2.500010466::MTS004,BRD-K39560679-001-01-1,eluxadoline,2.500010466,MTS004,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,COc1ccc(CN([C@@H](C)c2ncc([nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O,Launched
BRD-K40002998-001-01-5::2.5::MTS004,BRD-K40002998-001-01-5,org-26576,2.5,MTS004,glutamate receptor modulator,NA,NA,NA,O=C1N2CCC[C@H]2COc2ncccc12,Phase 2
BRD-K41267922-001-01-4::2.5::MTS004,BRD-K41267922-001-01-4,F351,2.5,MTS004,TGF beta receptor inhibitor,TGFB1,NA,NA,Cc1ccc(=O)n(c1)-c1ccc(O)cc1,Phase 2
BRD-K41458421-034-01-6::2.500006592::MTS004,BRD-K41458421-034-01-6,naloxegol,2.500006592,MTS004,opioid receptor antagonist,OPRM1,gastroenterology,constipation,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45,Launched
BRD-K41592905-001-01-6::2.5::MTS004,BRD-K41592905-001-01-6,7-methylxanthine,2.5,MTS004,adenosine receptor antagonist,NA,NA,NA,Cn1cnc2nc(O)nc(O)c12,Phase 2
BRD-K41662846-003-01-5::2.517380705::MTS004,BRD-K41662846-003-01-5,tecalcet,2.517380705,MTS004,calcium-sensing receptor agonist,CASR,NA,NA,"COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl",Phase 2
BRD-K42066335-001-01-0::2.499995517::MTS004,BRD-K42066335-001-01-0,lorediplon,2.499995517,MTS004,GABA receptor modulator,GABRA1,NA,NA,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,Phase 2
BRD-K42140276-402-01-4::2.500009363::MTS004,BRD-K42140276-402-01-4,alarelin,2.500009363,MTS004,gonadotropin releasing factor hormone receptor antagonist,GNRH1,NA,NA,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,Launched
BRD-K42504537-001-01-6::2.500037177::MTS004,BRD-K42504537-001-01-6,norelgestromin,2.500037177,MTS004,NA,PGR,endocrinology,contraceptive,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K42673188-001-01-1::2.363355746::MTS004,BRD-K42673188-001-01-1,verubulin,2.363355746,MTS004,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42816473-001-01-0::2.38330586::MTS004,BRD-K42816473-001-01-0,zilpaterol,2.38330586,MTS004,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid,CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23,Launched
BRD-K43230258-001-01-4::2.50004725::MTS004,BRD-K43230258-001-01-4,crisaborole,2.50004725,MTS004,phosphodiesterase inhibitor,PDE4B,NA,NA,OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12,Phase 3
BRD-K43316319-001-01-8::2.356803189::MTS004,BRD-K43316319-001-01-8,MK-2295,2.356803189,MTS004,TRPV antagonist,TRPV1,NA,NA,FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1,Phase 2
BRD-K43639297-001-01-9::2.500038533::MTS004,BRD-K43639297-001-01-9,hemoglobin-modulators-1,2.500038533,MTS004,hemoglobin modulator,NA,NA,NA,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,Phase 3
BRD-K43647122-001-01-3::2.5::MTS004,BRD-K43647122-001-01-3,nerbacadol,2.5,MTS004,cyclooxygenase inhibitor,NA,NA,NA,Cc1oncc1C(=O)N1CCCCC1,Phase 3
BRD-K43837174-003-01-3::2.479237222::MTS004,BRD-K43837174-003-01-3,pruvanserin,2.479237222,MTS004,serotonin receptor antagonist,"HTR2A, HTR2C",NA,NA,"Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1",Phase 2
BRD-K43890836-001-01-6::2.5::MTS004,BRD-K43890836-001-01-6,gemcadiol,2.5,MTS004,antilipemic,NA,NA,NA,CC(C)(CO)CCCCCCC(C)(C)CO,Phase 2
BRD-K43975632-001-01-1::2.499995729::MTS004,BRD-K43975632-001-01-1,terutroban,2.499995729,MTS004,prostanoid receptor antagonist,TBXA2R,NA,NA,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,Phase 3
BRD-K44030614-001-01-6::2.500000065::MTS004,BRD-K44030614-001-01-6,ponesimod,2.500000065,MTS004,sphingosine 1 phosphate receptor agonist,S1PR1,NA,NA,CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,Phase 3
BRD-K44164034-003-01-1::2.54181785::MTS004,BRD-K44164034-003-01-1,pumosetrag,2.54181785,MTS004,serotonin receptor agonist,"HTR3A, HTR4",NA,NA,Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2,Phase 2
BRD-K44184170-001-01-7::2.5::MTS004,BRD-K44184170-001-01-7,ospemifene,2.5,MTS004,selective estrogen receptor modulator (SERM),"ESR1, ESR2","obstetrics/gynecology, endocrinology","vaginal atrophy, dyspareunia, menopause",OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1,Launched
BRD-K44471774-001-01-8::2.670187358::MTS004,BRD-K44471774-001-01-8,bay-w-9798,2.670187358,MTS004,antioxidant,NA,NA,NA,COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC,Phase 2
BRD-K45125084-001-01-4::2.5::MTS004,BRD-K45125084-001-01-4,zolimidine,2.5,MTS004,mucus protecting agent,NA,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1,Launched
BRD-K45906612-001-01-8::2.499991411::MTS004,BRD-K45906612-001-01-8,presatovir,2.499991411,MTS004,RSV fusion inhibitor,NA,NA,NA,Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O,Phase 2
BRD-K46580984-001-03-6::2.584121204::MTS004,BRD-K46580984-001-03-6,phenserine,2.584121204,MTS004,"acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor","ACHE, BCHE",NA,NA,"CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21",Phase 3
BRD-K46625559-001-01-8::2.50003993::MTS004,BRD-K46625559-001-01-8,ozanimod,2.50003993,MTS004,sphingosine 1 phosphate receptor agonist,S1PR1,NA,NA,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO,Phase 3
BRD-K46843573-001-01-9::2.5::MTS004,BRD-K46843573-001-01-9,zotarolimus,2.5,MTS004,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1,Launched
BRD-K46862739-001-14-3::2.499952208::MTS004,BRD-K46862739-001-14-3,metyrapone,2.499952208,MTS004,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K47492008-001-02-7::2.5::MTS004,BRD-K47492008-001-02-7,alclofenac,2.5,MTS004,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,Launched
BRD-K47690382-001-03-0::2.5::MTS004,BRD-K47690382-001-03-0,bipenamol,2.5,MTS004,dipeptidyl peptidase inhibitor,CTSC,NA,NA,NCc1ccccc1Sc1ccccc1CO,Phase 2
BRD-K47887731-001-01-4::2.5::MTS004,BRD-K47887731-001-01-4,nitenpyram,2.5,MTS004,NA,NA,infectious disease,flea control,CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O,Launched
BRD-K47929404-001-01-0::2.500019706::MTS004,BRD-K47929404-001-01-0,vercirnon,2.500019706,MTS004,CC chemokine receptor antagonist,CCR9,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1,Phase 3
BRD-K48429278-001-01-3::2.5::MTS004,BRD-K48429278-001-01-3,pipotiazine-palmitate,2.5,MTS004,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, DRD2, HTR1A, HTR2A",NA,NA,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,Launched
BRD-K48452630-001-01-8::2.5::MTS004,BRD-K48452630-001-01-8,SRT2104,2.5,MTS004,SIRT activator,SIRT1,NA,NA,"Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1",Phase 2
BRD-K49372556-001-04-1::2.5::MTS004,BRD-K49372556-001-04-1,mofezolac,2.5,MTS004,cyclooxygenase inhibitor,PTGS1,"rheumatology, orthopedics","rheumatoid arthritis, osteoporosis",COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,Launched
BRD-K49659468-436-01-2::2.500002467::MTS004,BRD-K49659468-436-01-2,TMC647055,2.500002467,MTS004,RNA polymerase inhibitor,NA,NA,NA,COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O,Phase 2
BRD-K49793107-402-02-6::2.5::MTS004,BRD-K49793107-402-02-6,caspofungin-acetate,2.5,MTS004,"fungal 1,3-beta-D-glucan synthase inhibitor",NA,infectious disease,"candidemia, esophageal candidiasis, aspergillosis, peritonitis","CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN, CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN",Launched
BRD-K49841478-001-01-6::2.690488579::MTS004,BRD-K49841478-001-01-6,rosoxacin,2.690488579,MTS004,topoisomerase inhibitor,NA,infectious disease,urinary tract infections,CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1,Launched
BRD-K50010139-001-02-3::2.5::MTS004,BRD-K50010139-001-02-3,poziotinib,2.5,MTS004,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50055394-001-03-6::2.701086832::MTS004,BRD-K50055394-001-03-6,halopemide,2.701086832,MTS004,phospholipase inhibitor,"PLD1, PLD2",NA,NA,Oc1nc2cc(Cl)ccc2n1C1CCN(CCNC(=O)c2ccc(F)cc2)CC1,Phase 2
BRD-K50122911-001-01-2::2.5::MTS004,BRD-K50122911-001-01-2,boronophenylalanine,2.5,MTS004,NA,NA,NA,NA,"N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O",Phase 2
BRD-K50489389-001-01-8::2.500007911::MTS004,BRD-K50489389-001-01-8,ranirestat,2.500007911,MTS004,aldose reductase inhibitor,AKR1B1,NA,NA,Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O,Phase 3
BRD-K50660797-001-05-1::2.499989832::MTS004,BRD-K50660797-001-05-1,epicatechin-gallate-(-),2.499989832,MTS004,bacterial DNA gyrase inhibitor,"BACE1, FASN",NA,NA,"Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1",Phase 2
BRD-K50813454-001-01-9::2.592830582::MTS004,BRD-K50813454-001-01-9,amflutizole,2.592830582,MTS004,xanthine oxidase inhibitor,XDH,NA,NA,Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O,Phase 2
BRD-K51730347-001-06-4::2.5::MTS004,BRD-K51730347-001-06-4,diphencyprone,2.5,MTS004,immunostimulant,NA,NA,NA,"O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1",Phase 2
BRD-K51784806-001-01-6::2.297010706::MTS004,BRD-K51784806-001-01-6,alacepril,2.297010706,MTS004,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,Launched
BRD-K51899933-001-02-6::2.500004375::MTS004,BRD-K51899933-001-02-6,azeliragon,2.500004375,MTS004,RAGE receptor antagonist,AGER,NA,NA,CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1,Phase 3
BRD-K51956333-001-03-8::2.52122192::MTS004,BRD-K51956333-001-03-8,iopodic-acid,2.52122192,MTS004,NA,NA,radiology,contrast agent,CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I,Launched
BRD-K52579889-001-01-9::2.499985811::MTS004,BRD-K52579889-001-01-9,TGR-1202,2.499985811,MTS004,PI3K inhibitor,NA,NA,NA,CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12,Phase 3
BRD-K52681925-050-01-6::2.472084005::MTS004,BRD-K52681925-050-01-6,altinicline,2.472084005,MTS004,nicotinic receptor agonist,"CHRNA4, CHRNB2",NA,NA,CN1CCC[C@H]1c1cncc(c1)C#C,Phase 2
BRD-K52914072-001-01-5::2.5::MTS004,BRD-K52914072-001-01-5,LTA,2.5,MTS004,NA,NA,NA,NA,N=C(Nc1ccccc1)c1cccs1,Phase 2
BRD-K52960356-001-15-5::2.499955314::MTS004,BRD-K52960356-001-15-5,acetohexamide,2.499955314,MTS004,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
BRD-K53156626-001-01-3::2.5::MTS004,BRD-K53156626-001-01-3,7-methoxytacrine,2.5,MTS004,acetylcholinesterase inhibitor,ACHE,NA,NA,COc1ccc2nc3CCCCc3c(N)c2c1,Phase 2
BRD-K53195974-001-01-9::2.298572309::MTS004,BRD-K53195974-001-01-9,sipatrigine,2.298572309,MTS004,voltage-gated sodium channel blocker,"CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A",NA,NA,"CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl",Phase 2
BRD-K53236343-003-03-7::2.625172304::MTS004,BRD-K53236343-003-03-7,aprindine,2.625172304,MTS004,voltage-gated sodium channel blocker,"CALM1, SCN5A",cardiology,cardiac arrythmia,CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1,Launched
BRD-K53319039-001-01-8::2.5::MTS004,BRD-K53319039-001-01-8,estradiol-acetate,2.5,MTS004,estrogen receptor agonist,ESR1,"endocrinology, obstetrics/gynecology","menopause, vaginal atrophy",CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,Launched
BRD-K53809807-304-02-4::2.7277447::MTS004,BRD-K53809807-304-02-4,fosphenytoin,2.7277447,MTS004,sodium channel blocker,SCN5A,neurology/psychiatry,"epilepsy, seizures","OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1",Launched
BRD-K54339150-001-01-8::2.5::MTS004,BRD-K54339150-001-01-8,proquazone,2.5,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1,Launched
BRD-K54519451-001-02-9::2.499971332::MTS004,BRD-K54519451-001-02-9,pexidartinib,2.499971332,MTS004,tyrosine kinase inhibitor,"CSF1R, FLT3, KIT",NA,NA,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,Phase 3
BRD-K54863166-001-01-9::2.693644572::MTS004,BRD-K54863166-001-01-9,darusentan,2.693644572,MTS004,endothelin receptor antagonist,EDNRA,NA,NA,COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1,Phase 3
BRD-K54907283-001-01-2::2.4999956::MTS004,BRD-K54907283-001-01-2,AKBA,2.4999956,MTS004,lipoxygenase inhibitor,ALOX5,NA,NA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C,Phase 3
BRD-K54955827-001-02-2::2.49997945::MTS004,BRD-K54955827-001-02-2,niraparib,2.49997945,MTS004,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K55029398-001-01-6::2.499962393::MTS004,BRD-K55029398-001-01-6,JNJ-40411813,2.499962393,MTS004,glutamate receptor positive allosteric modulator,GRM2,NA,NA,CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O,Phase 2
BRD-K55172746-001-01-3::2.5::MTS004,BRD-K55172746-001-01-3,apricitabine,2.5,MTS004,nucleoside reverse transcriptase inhibitor,NA,NA,NA,Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,Phase 3
BRD-K55696337-003-24-4::2.50001813::MTS004,BRD-K55696337-003-24-4,topotecan,2.50001813,MTS004,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55808645-001-01-4::2.500006596::MTS004,BRD-K55808645-001-01-4,elagolix,2.500006596,MTS004,gonadotropin releasing factor hormone receptor antagonist,GNRHR,NA,NA,COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O,Phase 3
BRD-K55991142-001-01-6::2.5::MTS004,BRD-K55991142-001-01-6,alcaftadine,2.5,MTS004,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis,CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12,Launched
BRD-K56107812-001-01-7::2.499996486::MTS004,BRD-K56107812-001-01-7,carbetocin,2.499996486,MTS004,oxytocin receptor agonist,OXTR,hematology,hemorrhage,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,Launched
BRD-K56155962-001-12-1::2.355251659::MTS004,BRD-K56155962-001-12-1,ergocalciferol,2.355251659,MTS004,vitamin analog,VDR,"endocrinology, orthopedics","hypoparathyroidism, rickets, hypophosphatemia","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C",Launched
BRD-K56211775-001-03-8::2.5::MTS004,BRD-K56211775-001-03-8,RTA-408,2.5,MTS004,nitric oxide production inhibitor,NFE2L2,NA,NA,"CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2",Phase 2
BRD-K56429665-001-09-6::2.500032186::MTS004,BRD-K56429665-001-09-6,calcipotriol,2.500032186,MTS004,vitamin D receptor agonist,VDR,dermatology,psoriasis,"C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K56740996-001-01-3::2.601527794::MTS004,BRD-K56740996-001-01-3,flindokalner,2.601527794,MTS004,potassium channel agonist,"KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5",NA,NA,"COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F",Phase 3
BRD-K56807945-001-01-2::2.500001454::MTS004,BRD-K56807945-001-01-2,FG-2216,2.500001454,MTS004,hypoxia inducible factor prolyl hydroxylase inhibitor,"EGLN1, EGLN2, HIF1A",NA,NA,OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O,Phase 2
BRD-K56912469-003-02-0::2.499992214::MTS004,BRD-K56912469-003-02-0,SAR407899,2.499992214,MTS004,rho associated kinase inhibitor,ROCK1,NA,NA,"O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12",Phase 2
BRD-K56981171-001-01-0::2.500008954::MTS004,BRD-K56981171-001-01-0,brigatinib,2.500008954,MTS004,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K57155378-001-01-1::2.499996307::MTS004,BRD-K57155378-001-01-1,TAK-063,2.499996307,MTS004,phosphodiesterase inhibitor,PDE10A,NA,NA,COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1,Phase 2
BRD-K57427145-001-01-6::2.5::MTS004,BRD-K57427145-001-01-6,ripazepam,2.5,MTS004,benzodiazepine receptor agonist,GABRA1,NA,NA,CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1,Phase 2
BRD-K57774929-001-01-3::2.643351543::MTS004,BRD-K57774929-001-01-3,foropafant,2.643351543,MTS004,platelet activating factor receptor antagonist,PTAFR,NA,NA,CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C,Phase 3
BRD-K57886322-001-16-6::2.5::MTS004,BRD-K57886322-001-16-6,fluocinonide,2.5,MTS004,glucocorticoid receptor agonist,"NR3C1, SERPINA6, SMO",dermatology,"seborrheic dermatitis, eczema",CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,Launched
BRD-K58277159-001-01-7::2.5::MTS004,BRD-K58277159-001-01-7,NPC-01,2.5,MTS004,steroid,NA,NA,NA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,Phase 3
BRD-K58529924-001-01-5::2.648577938::MTS004,BRD-K58529924-001-01-5,ONC201,2.648577938,MTS004,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58810291-001-16-2::2.564588683::MTS004,BRD-K58810291-001-16-2,clobetasone-butyrate,2.564588683,MTS004,corticosteroid agonist,NR3C1,dermatology,"eczema, psoriasis, dermatitis",CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl,Launched
BRD-K59256312-066-15-7::2.431061328::MTS004,BRD-K59256312-066-15-7,gabexate,2.431061328,MTS004,serine protease inhibitor,"PRSS1, TPSAB1",gastroenterology,pancreatitis,"CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1",Launched
BRD-K59391348-001-01-7::2.5::MTS004,BRD-K59391348-001-01-7,lixivaptan,2.5,MTS004,vasopressin receptor antagonist,AVPR2,NA,NA,Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1,Phase 3
BRD-K59753975-001-02-6::2.5::MTS004,BRD-K59753975-001-02-6,vindesine,2.5,MTS004,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59866480-001-07-3::2.379655165::MTS004,BRD-K59866480-001-07-3,cyclovalone,2.379655165,MTS004,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59895502-001-01-9::2.591975371::MTS004,BRD-K59895502-001-01-9,caramiphen,2.591975371,MTS004,cholinergic receptor antagonist,"CHRM1, CHRM2",neurology/psychiatry,Parkinson's Disease,CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1,Launched
BRD-K60130390-001-02-1::2.5::MTS004,BRD-K60130390-001-02-1,UNC0642,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1",Preclinical
BRD-K60241851-001-11-9::2.5::MTS004,BRD-K60241851-001-11-9,isodibut,2.5,MTS004,aldehyde reductase inhibitor,NA,NA,NA,"OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23",Phase 2
BRD-K60284353-001-01-3::2.5::MTS004,BRD-K60284353-001-01-3,titanocene-dichloride,2.5,MTS004,apoptosis stimulant,NA,NA,NA,Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1,Phase 2
BRD-K60421517-001-01-4::2.499975038::MTS004,BRD-K60421517-001-01-4,olmutinib,2.499975038,MTS004,"EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor","BTK, EGFR",NA,NA,"CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1",Launched
BRD-K60762818-003-26-0::2.467864576::MTS004,BRD-K60762818-003-26-0,desipramine,2.467864576,MTS004,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1",neurology/psychiatry,depression,"CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12",Launched
BRD-K60798049-001-03-8::2.665505334::MTS004,BRD-K60798049-001-03-8,fanetizole,2.665505334,MTS004,neutrophil superoxide production,NA,NA,NA,C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1,Phase 3
BRD-K61496577-001-19-4::2.5::MTS004,BRD-K61496577-001-19-4,flumethasone,2.5,MTS004,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61536264-001-01-3::2.499924728::MTS004,BRD-K61536264-001-01-3,fagomine,2.499924728,MTS004,glucosidase inhibitor,GLB1,NA,NA,OC[C@H]1NCC[C@@H](O)[C@@H]1O,Phase 2
BRD-K61923022-001-02-4::2.499990535::MTS004,BRD-K61923022-001-02-4,GDC-0810,2.499990535,MTS004,selective estrogen receptor destabilizer,ESR1,NA,NA,CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,Phase 2
BRD-K62040061-001-01-0::2.500015381::MTS004,BRD-K62040061-001-01-0,toceranib,2.500015381,MTS004,protein tyrosine kinase inhibitor,"FLT1, FLT3, KDR, PDGFRA, PDGFRB",oncology,"cutaneous mast cell tumors, cutaneous mast cell tumors","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1",Launched
BRD-K62050508-001-01-0::2.499980818::MTS004,BRD-K62050508-001-01-0,grapiprant,2.499980818,MTS004,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis,CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,Launched
BRD-K62240499-001-05-9::2.500058444::MTS004,BRD-K62240499-001-05-9,huperzine-a,2.500058444,MTS004,acetylcholinesterase inhibitor,ACHE,NA,NA,"C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2",Phase 2
BRD-K62309135-001-05-2::3.119534994::MTS004,BRD-K62309135-001-05-2,L-glutamic-acid,3.119534994,MTS004,glutamate receptor agonist,"AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT",NA,NA,N[C@@H](CCC(O)=O)C(O)=O,Launched
BRD-K62374002-001-01-5::2.499972663::MTS004,BRD-K62374002-001-01-5,PI3K-IN-2,2.499972663,MTS004,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62384160-001-02-0::2.499970983::MTS004,BRD-K62384160-001-02-0,siponimod,2.499970983,MTS004,sphingosine phosphate receptor modulator,S1PR1,NA,NA,"CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F",Phase 3
BRD-K62490786-001-01-1::2.495325825::MTS004,BRD-K62490786-001-01-1,ibrolipim,2.495325825,MTS004,lipoprotein lipase activator,LPL,NA,NA,CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC,Phase 2
BRD-K62971431-001-01-9::2.5::MTS004,BRD-K62971431-001-01-9,tasimelteon,2.5,MTS004,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12,Launched
BRD-K63018010-001-01-7::2.500011413::MTS004,BRD-K63018010-001-01-7,relebactam,2.500011413,MTS004,beta lactamase inhibitor,NA,NA,NA,OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O,Phase 3
BRD-K63177377-001-01-8::2.499971604::MTS004,BRD-K63177377-001-01-8,ETC-1002,2.499971604,MTS004,AMPK inhibitor,ACLY,NA,NA,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,Phase 3
BRD-K63772874-001-02-2::2.499989061::MTS004,BRD-K63772874-001-02-2,icatibant-acetate,2.499989061,MTS004,bradykinin receptor antagonist,"ANPEP, BDKRB2",cardiology,angioedema,"N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O",Launched
BRD-K64034691-001-01-9::2.499981916::MTS004,BRD-K64034691-001-01-9,acalabrutinib,2.499981916,MTS004,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12,Phase 3
BRD-K64120610-001-01-4::2.5::MTS004,BRD-K64120610-001-01-4,vinflunine,2.5,MTS004,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K65498798-001-01-7::2.5::MTS004,BRD-K65498798-001-01-7,abametapir,2.5,MTS004,metalloproteinase inhibitor,MMP9,NA,NA,Cc1ccc(nc1)-c1ccc(C)cn1,Phase 3
BRD-K65900713-003-01-0::2.686421113::MTS004,BRD-K65900713-003-01-0,caroverine,2.686421113,MTS004,"glutamate receptor antagonist, calcium channel blocker",NA,neurology/psychiatry,tinnitus,CCN(CC)CCN1C(=O)C(Nc2ccccc12)=Cc1ccc(OC)cc1,Launched
BRD-K66192203-001-02-2::2.50001534::MTS004,BRD-K66192203-001-02-2,opicapone,2.50001534,MTS004,catechol O methyltransferase inhibitor,COMT,NA,NA,"Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O",Phase 3
BRD-K66295376-001-13-1::2.5::MTS004,BRD-K66295376-001-13-1,ferulic-acid,2.5,MTS004,antioxidant,"CA1, CA12, CA14, CA2, CA4, CA6, CA9",NA,NA,"COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O",Phase 2
BRD-K66437909-001-01-0::2.49636183::MTS004,BRD-K66437909-001-01-0,KT-433,2.49636183,MTS004,uricosuric agent,NA,NA,NA,CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1,Phase 2
BRD-K66786476-001-01-3::2.500037331::MTS004,BRD-K66786476-001-01-3,pregabalin,2.500037331,MTS004,voltage-gated calcium channel ligand,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8","neurology/psychiatry, rheumatology","peripheral neuropathy, seizures, fibromyalgia, postherpetic neuralgia","CC(C)C[C@H](CN)CC(O)=O, CC(C)C[C@H](CN)CC(O)=O",Launched
BRD-K66845263-001-03-0::2.5::MTS004,BRD-K66845263-001-03-0,sophocarpine,2.5,MTS004,NA,NA,NA,NA,"O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34",Phase 3
BRD-K67117832-001-01-9::2.5::MTS004,BRD-K67117832-001-01-9,dextran,2.5,MTS004,NA,NA,"hematology, critical care","thrombosis, hypovolemia",OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Launched
BRD-K67186445-001-02-1::2.500004874::MTS004,BRD-K67186445-001-02-1,dehydrocorydaline,2.500004874,MTS004,acetylcholinesterase inhibitor,ACHE,NA,NA,"COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC",Phase 3
BRD-K67482377-001-01-8::2.500004112::MTS004,BRD-K67482377-001-01-8,itacitinib,2.500004112,MTS004,JAK inhibitor,JAK1,NA,NA,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 2
BRD-K67628093-001-01-9::2.500004949::MTS004,BRD-K67628093-001-01-9,INCB-3284,2.500004949,MTS004,CC chemokine receptor antagonist,CCR2,NA,NA,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,Phase 2
BRD-K68408772-001-05-4::2.420640995::MTS004,BRD-K68408772-001-05-4,carboxyamidotriazole,2.420640995,MTS004,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68432770-236-23-1::2.500029469::MTS004,BRD-K68432770-236-23-1,ampicillin,2.500029469,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K68544925-001-01-1::2.500014712::MTS004,BRD-K68544925-001-01-1,avatrombopag,2.500014712,MTS004,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia,OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1,Launched
BRD-K68764924-001-03-2::2.5::MTS004,BRD-K68764924-001-03-2,pantethine,2.5,MTS004,coenzyme A precursor,NA,NA,NA,"CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO",Launched
BRD-K69636617-001-01-7::2.49998713::MTS004,BRD-K69636617-001-01-7,testolactone,2.49998713,MTS004,aromatase inhibitor,CYP19A1,oncology,breast cancer,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2,Launched
BRD-K69669039-001-01-8::2.499979212::MTS004,BRD-K69669039-001-01-8,GSK163090,2.499979212,MTS004,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D",NA,NA,Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1,Phase 2
BRD-K70262971-001-01-9::2.499966077::MTS004,BRD-K70262971-001-01-9,AGN-194310,2.499966077,MTS004,retinoid receptor antagonist,"RXRA, RXRB, RXRG",NA,NA,CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O,Phase 3
BRD-K70330032-001-01-1::2.50000853::MTS004,BRD-K70330032-001-01-1,JNJ-42165279,2.50000853,MTS004,FAAH inhibitor,FAAH,NA,NA,FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1,Phase 2
BRD-K70504253-001-01-3::2.500017504::MTS004,BRD-K70504253-001-01-3,fruquintinib,2.500017504,MTS004,VEGFR inhibitor,KDR,NA,NA,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,Phase 3
BRD-K70592963-001-31-6::2.5::MTS004,BRD-K70592963-001-31-6,phenindione,2.5,MTS004,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),"O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1",Launched
BRD-K70601687-001-01-3::2.500008826::MTS004,BRD-K70601687-001-01-3,enasidenib,2.500008826,MTS004,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F,Launched
BRD-K70650177-001-01-7::2.500008535::MTS004,BRD-K70650177-001-01-7,testosterone-undecanoate,2.500008535,MTS004,androgen receptor agonist,AR,endocrinology,hypogonadism,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Launched
BRD-K71026158-304-01-0::2.397404387::MTS004,BRD-K71026158-304-01-0,carumonam,2.397404387,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, gram-negative bacterial infections",NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,Launched
BRD-K71977764-001-01-2::2.5::MTS004,BRD-K71977764-001-01-2,piroximone,2.5,MTS004,phosphodiesterase inhibitor,PDE3A,NA,NA,CCc1[nH]c(O)nc1C(=O)c1ccncc1,Phase 2
BRD-K72259270-003-25-6::2.444857586::MTS004,BRD-K72259270-003-25-6,dyclonine,2.444857586,MTS004,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,local anesthetic,"CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1",Launched
BRD-K72264770-001-03-2::2.5::MTS004,BRD-K72264770-001-03-2,BRD4770,2.5,MTS004,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1",Preclinical
BRD-K72280606-001-01-2::2.499993939::MTS004,BRD-K72280606-001-01-2,gilteritinib,2.499993939,MTS004,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72533376-001-01-2::2.5::MTS004,BRD-K72533376-001-01-2,etoposide-phosphate,2.5,MTS004,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K73027814-003-01-0::2.693425643::MTS004,BRD-K73027814-003-01-0,oxyfedrine,2.693425643,MTS004,adrenergic receptor agonist,NA,cardiology,angina pectoris,COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1,Launched
BRD-K73028949-001-02-8::2.5::MTS004,BRD-K73028949-001-02-8,vasopressin,2.5,MTS004,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",gastroenterology,abdominal distension,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,Launched
BRD-K73132780-001-01-2::2.5::MTS004,BRD-K73132780-001-01-2,pyronaridine,2.5,MTS004,antimalarial agent,NA,NA,NA,"COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1",Phase 3
BRD-K73451719-001-01-2::2.5::MTS004,BRD-K73451719-001-01-2,terlipressin,2.5,MTS004,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2",cardiology,hypotension,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Launched
BRD-K73504359-001-01-3::2.5::MTS004,BRD-K73504359-001-01-3,bivalirudin,2.5,MTS004,thrombin inhibitor,F2,cardiology,angina pectoris,"[2H]N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O",Launched
BRD-K73585091-001-02-3::2.499988098::MTS004,BRD-K73585091-001-02-3,GS-9620,2.499988098,MTS004,toll-like receptor agonist,TLR7,NA,NA,"CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1",Phase 2
BRD-K73753850-003-01-6::2.499957259::MTS004,BRD-K73753850-003-01-6,hexaminolevulinate,2.499957259,MTS004,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73881242-003-04-6::2.500023768::MTS004,BRD-K73881242-003-04-6,arbidol,2.500023768,MTS004,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection,"CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12",Launched
BRD-K74236984-001-04-8::2.5::MTS004,BRD-K74236984-001-04-8,UNC0321,2.5,MTS004,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1",Preclinical
BRD-K74671368-001-01-8::2.5::MTS004,BRD-K74671368-001-01-8,idronoxil,2.5,MTS004,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74759733-065-01-4::2.5::MTS004,BRD-K74759733-065-01-4,isepamicin,2.5,MTS004,protein synthesis inhibitor,NA,infectious disease,"pneumonia, peritonitis","CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O",Launched
BRD-K75385383-001-01-5::2.548558667::MTS004,BRD-K75385383-001-01-5,DIPT,2.548558667,MTS004,"dopamine reuptake inhibitor, serotonin reuptake inhibitor","HTR1A, HTR2A, HTR2C",NA,NA,CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,Launched
BRD-K75445017-001-01-1::2.5::MTS004,BRD-K75445017-001-01-1,estetrol,2.5,MTS004,selective estrogen receptor modulator (SERM),ESR1,NA,NA,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,Phase 3
BRD-K76204040-001-03-8::2.5::MTS004,BRD-K76204040-001-03-8,pyridoxal,2.5,MTS004,NA,PDXK,neurology/psychiatry,epilepsy,Cc1ncc(CO)c(C=O)c1O,Launched
BRD-K76315403-015-02-5::2.5::MTS004,BRD-K76315403-015-02-5,cetrorelix,2.5,MTS004,gonadotropin releasing factor hormone receptor antagonist,"GNRHR, LHCGR",endocrinology,premature luteinizing hormone surges,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Launched
BRD-K76594255-001-01-6::2.5000235::MTS004,BRD-K76594255-001-01-6,maropitant,2.5000235,MTS004,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting,COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C,Launched
BRD-K76614248-001-01-2::2.707477898::MTS004,BRD-K76614248-001-01-2,atizoram,2.707477898,MTS004,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1,Phase 2
BRD-K76634210-001-12-1::2.5::MTS004,BRD-K76634210-001-12-1,idoxuridine,2.5,MTS004,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76713213-001-02-1::2.499961706::MTS004,BRD-K76713213-001-02-1,tavaborole,2.499961706,MTS004,leucyl-tRNA synthetase inhibitor,NA,infectious disease,onychomycosis,"OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12",Launched
BRD-K76719364-001-02-5::2.466617435::MTS004,BRD-K76719364-001-02-5,GS-9973,2.466617435,MTS004,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76927775-001-11-8::2.500019441::MTS004,BRD-K76927775-001-11-8,nitrofurantoin,2.500019441,MTS004,DNA inhibitor,NA,infectious disease,"urinary tract infections, pyelonephritis","[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1",Launched
BRD-K77038618-356-01-3::2.500022896::MTS004,BRD-K77038618-356-01-3,garenoxacin,2.500022896,MTS004,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections,C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1,Launched
BRD-K77073709-435-01-2::2.5::MTS004,BRD-K77073709-435-01-2,cefminox,2.5,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,Launched
BRD-K77175907-001-08-0::2.555048691::MTS004,BRD-K77175907-001-08-0,calcifediol,2.555048691,MTS004,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C",Launched
BRD-K77320845-001-01-2::2.29566066::MTS004,BRD-K77320845-001-01-2,secoisolariciresinol-diglucoside,2.29566066,MTS004,antioxidant,NA,NA,NA,COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O,Phase 2
BRD-K77428767-001-01-7::2.5::MTS004,BRD-K77428767-001-01-7,UNC0224,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1",Preclinical
BRD-K77432251-001-01-2::2.715966218::MTS004,BRD-K77432251-001-01-2,abafungin,2.715966218,MTS004,sterol methyltransferase inhibitor,NA,NA,NA,Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1,Phase 3
BRD-K77564118-001-03-1::2.67296817::MTS004,BRD-K77564118-001-03-1,fenoverine,2.67296817,MTS004,acetylcholine receptor antagonist,NA,neurology/psychiatry,spasms,O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12,Launched
BRD-K78666663-001-01-6::2.499978008::MTS004,BRD-K78666663-001-01-6,lemborexant,2.499978008,MTS004,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1,Phase 3
BRD-K78841970-001-13-8::2.388586862::MTS004,BRD-K78841970-001-13-8,aspartame,2.388586862,MTS004,NA,"TAS1R2, TRPV1",NA,NA,"COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O",Launched
BRD-K79450420-001-01-8::2.499997604::MTS004,BRD-K79450420-001-01-8,INCB-024360,2.499997604,MTS004,"indoleamine 2,3-dioxygenase inhibitor",IDO1,NA,NA,NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O,Phase 2
BRD-K79450420-001-02-6::2.5::MTS004,BRD-K79450420-001-02-6,epacadostat,2.5,MTS004,"indoleamine 2,3-dioxygenase inhibitor",IDO1,NA,NA,"NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O, NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O",Phase 3
BRD-K79710622-001-02-9::2.5::MTS004,BRD-K79710622-001-02-9,GKT137831,2.5,MTS004,NADPH oxidase inhibitor,"NOX1, NOX4",NA,NA,"CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12",Phase 2
BRD-K79803033-300-01-3::2.5::MTS004,BRD-K79803033-300-01-3,pozanicline,2.5,MTS004,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",NA,NA,Cc1ncccc1OC[C@@H]1CCCN1,Phase 2
BRD-K79821389-001-03-5::2.562009205::MTS004,BRD-K79821389-001-03-5,rubitecan,2.562009205,MTS004,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K80076813-001-08-8::2.356620242::MTS004,BRD-K80076813-001-08-8,diftalone,2.356620242,MTS004,cyclooxygenase inhibitor,NA,endocrinology,thyroiditis,O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12,Launched
BRD-K80353807-001-25-3::2.5::MTS004,BRD-K80353807-001-25-3,khellin,2.5,MTS004,vasodilator,NA,NA,NA,"COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12",Phase 2
BRD-K80359953-001-01-3::2.500041136::MTS004,BRD-K80359953-001-01-3,talampanel,2.500041136,MTS004,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1",Phase 2
BRD-K80419150-001-02-4::2.5::MTS004,BRD-K80419150-001-02-4,debrisoquin,2.5,MTS004,adrenergic neuron blocker,SLC6A2,cardiology,hypertension,"NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1",Launched
BRD-K80607346-001-01-1::2.5::MTS004,BRD-K80607346-001-01-1,FK-962,2.5,MTS004,somatostatin receptor agonist,NA,NA,NA,CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1,Phase 2
BRD-K80738081-001-46-8::2.500037854::MTS004,BRD-K80738081-001-46-8,resveratrol,2.500037854,MTS004,"cytochrome P450 inhibitor, SIRT activator","CSNK2A1, NQO2, PTGS1, PTGS2",NA,NA,"Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1",Launched
BRD-K80762071-236-02-5::2.5::MTS004,BRD-K80762071-236-02-5,indocyanine-green,2.5,MTS004,contrast agent,SLCO1B1,NA,NA,"CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12",Launched
BRD-K80859331-001-01-5::2.5::MTS004,BRD-K80859331-001-01-5,haloperidol-decanoate,2.5,MTS004,psychoactive drug,"DRD2, DRD3, DRD4, HTR2A",neurology/psychiatry,schizophrenia,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,Launched
BRD-K81405859-300-01-4::2.5::MTS004,BRD-K81405859-300-01-4,JTE-607,2.5,MTS004,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81616657-001-01-4::2.665005855::MTS004,BRD-K81616657-001-01-4,PNU-142633,2.665005855,MTS004,serotonin receptor agonist,HTR1D,NA,NA,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,Phase 2
BRD-K81981783-236-02-9::2.570718613::MTS004,BRD-K81981783-236-02-9,gavestinel,2.570718613,MTS004,glutamate receptor antagonist,GLRB,NA,NA,"OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1",Phase 3
BRD-K82103381-003-09-4::2.500073689::MTS004,BRD-K82103381-003-09-4,hydralazine,2.500073689,MTS004,vasodilator,"AOC3, P4HA1",cardiology,hypertension,"NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12",Launched
BRD-K82118441-001-03-7::2.646883368::MTS004,BRD-K82118441-001-03-7,pyrantel,2.646883368,MTS004,nicotinic receptor agonist,NA,infectious disease,"gastrointestinal roundworms, gastrointestinal roundworms",OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O,Launched
BRD-K82687598-001-01-6::2.5::MTS004,BRD-K82687598-001-01-6,tolonidine,2.5,MTS004,adrenergic receptor antagonist,ADRA2A,NA,NA,Cc1ccc(NC2=NCCN2)c(Cl)c1,Launched
BRD-K82908348-001-01-9::2.434467427::MTS004,BRD-K82908348-001-01-9,darglitazone,2.434467427,MTS004,PPAR receptor antagonist,PPARG,NA,NA,Cc1oc(nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1)-c1ccccc1,Phase 2
BRD-K82967180-001-01-6::2.500024493::MTS004,BRD-K82967180-001-01-6,LY3023414,2.500024493,MTS004,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K83029223-001-01-3::2.500025378::MTS004,BRD-K83029223-001-01-3,litronesib,2.500025378,MTS004,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83144676-001-09-5::2.5::MTS004,BRD-K83144676-001-09-5,olmesartan,2.5,MTS004,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O",Launched
BRD-K83776863-001-08-9::2.5::MTS004,BRD-K83776863-001-08-9,tryptophan,2.5,MTS004,serotonin receptor partial agonist,"CASR, IDO1, SLC36A1, WARS, WARS2","neurology/psychiatry, gastroenterology","anxiety, bloating, constipation, fatigue, sleeplessness","N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O",Launched
BRD-K84036904-001-08-8::2.500018826::MTS004,BRD-K84036904-001-08-8,17-alpha-methyltestosterone,2.500018826,MTS004,aromatase inhibitor,AR,NA,NA,"C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K84173274-001-01-6::2.5::MTS004,BRD-K84173274-001-01-6,ufenamate,2.5,MTS004,cyclooxygenase inhibitor,"PTGS1, PTGS2",dermatology,"eczema, dermatitis",CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,Launched
BRD-K84281997-003-08-4::2.500011105::MTS004,BRD-K84281997-003-08-4,pralidoxime,2.500011105,MTS004,acetylcholinesterase inhibitor,"ACHE, BCHE",critical care,organophosphate poisoning,"C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O",Launched
BRD-K84459715-001-01-6::2.403005639::MTS004,BRD-K84459715-001-01-6,zopolrestat,2.403005639,MTS004,NA,NA,NA,NA,OC(=O)C=C1NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c2ccccc12,Phase 2
BRD-K84868168-001-01-0::2.500006364::MTS004,BRD-K84868168-001-01-0,erdafitinib,2.500006364,MTS004,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84971356-001-01-4::2.632189712::MTS004,BRD-K84971356-001-01-4,etafenone,2.632189712,MTS004,calcium channel blocker,NA,NA,NA,CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1,Launched
BRD-K85882401-323-01-5::2.500009065::MTS004,BRD-K85882401-323-01-5,avibactam,2.500009065,MTS004,beta lactamase inhibitor,NA,infectious disease,"intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis","NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O",Launched
BRD-K86171477-001-01-3::2.5::MTS004,BRD-K86171477-001-01-3,eltoprazine,2.5,MTS004,serotonin receptor agonist,"HTR1A, HTR1B",NA,NA,"C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12",Phase 2
BRD-K86358349-001-02-0::2.440473496::MTS004,BRD-K86358349-001-02-0,bromantan,2.440473496,MTS004,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",NA,neurology/psychiatry,neurasthenia,"Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1",Launched
BRD-K86410485-046-01-0::2.499987354::MTS004,BRD-K86410485-046-01-0,eliglustat,2.499987354,MTS004,Glycosyl transferase inhibitor,UGCG,hematology,"Gaucher disease, Gaucher disease","CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1",Launched
BRD-K86670086-001-02-5::2.500040519::MTS004,BRD-K86670086-001-02-5,sutezolid,2.500040519,MTS004,protein synthesis inhibitor,NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1,Phase 2
BRD-K86856088-001-06-9::2.5::MTS004,BRD-K86856088-001-06-9,UNC0638,2.5,MTS004,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1",Preclinical
BRD-K86864073-001-01-1::2.5::MTS004,BRD-K86864073-001-01-1,chloroprocaine,2.5,MTS004,sodium channel blocker,"ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3",neurology/psychiatry,local anesthetic,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,Launched
BRD-K86873305-236-14-7::2.448463554::MTS004,BRD-K86873305-236-14-7,piperacillin,2.448463554,MTS004,bacterial cell wall synthesis inhibitor,NA,infectious disease,"intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia","CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)NC(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O",Launched
BRD-K87316765-001-01-4::2.499975056::MTS004,BRD-K87316765-001-01-4,prinaberel,2.499975056,MTS004,estrogen receptor agonist,"ESR2, NCOA1",NA,NA,Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1,Phase 2
BRD-K87386013-001-01-7::2.5::MTS004,BRD-K87386013-001-01-7,diroximel-fumarate,2.5,MTS004,anti-inflammatory agent,NA,NA,NA,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,Phase 3
BRD-K87465484-001-02-7::2.5::MTS004,BRD-K87465484-001-02-7,UNC0646,2.5,MTS004,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K87573013-001-01-0::2.5::MTS004,BRD-K87573013-001-01-0,CL-225385,2.5,MTS004,NA,NA,NA,NA,O=C(CC#N)c1ccccc1,Phase 2
BRD-K87777313-001-02-2::2.5::MTS004,BRD-K87777313-001-02-2,irosustat,2.5,MTS004,steroid sulfatase inhibitor,"CA2, STS",NA,NA,NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1,Phase 2
BRD-K87948281-001-01-9::2.499985333::MTS004,BRD-K87948281-001-01-9,F-11440,2.499985333,MTS004,serotonin receptor agonist,HTR1A,NA,NA,Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O,Phase 2
BRD-K88143662-001-01-5::2.5::MTS004,BRD-K88143662-001-01-5,metharbital,2.5,MTS004,GABA receptor modulator,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,epilepsy,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Launched
BRD-K88854110-001-01-5::2.499975441::MTS004,BRD-K88854110-001-01-5,taprenepag,2.499975441,MTS004,prostaglandin receptor agonist,PTGER2,NA,NA,OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1,Phase 2
BRD-K89085489-001-23-2::2.499967871::MTS004,BRD-K89085489-001-23-2,fenretinide,2.499967871,MTS004,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89121095-001-01-7::2.499999138::MTS004,BRD-K89121095-001-01-7,tedizolid-phosphate,2.499999138,MTS004,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89272869-003-01-8::2.499996082::MTS004,BRD-K89272869-003-01-8,nalfurafine,2.499996082,MTS004,opioid receptor agonist,"OPRK1, OPRM1",nephrology,uremic pruritus,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1,Launched
BRD-K89413285-074-01-5::2.500023482::MTS004,BRD-K89413285-074-01-5,remimazolam,2.500023482,MTS004,benzodiazepine receptor agonist,GABBR1,NA,NA,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12,Phase 3
BRD-K89490285-001-08-1::2.521612095::MTS004,BRD-K89490285-001-08-1,bentazepam,2.521612095,MTS004,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89920762-001-01-4::2.500013597::MTS004,BRD-K89920762-001-01-4,paritaprevir,2.500013597,MTS004,HCV inhibitor,NA,infectious disease,hepatitis C,Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1,Launched
BRD-K90069354-001-03-7::2.5::MTS004,BRD-K90069354-001-03-7,isovaleramide,2.5,MTS004,alcohol dehydrogenase inhibitor,NA,NA,NA,"CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O",Phase 2
BRD-K90171280-001-01-4::2.328630918::MTS004,BRD-K90171280-001-01-4,LY2452473,2.328630918,MTS004,androgen receptor modulator,AR,NA,NA,CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N,Phase 2
BRD-K90563805-001-02-6::2.5::MTS004,BRD-K90563805-001-02-6,natamycin,2.5,MTS004,fungal ergosterol inhibitor,NA,"ophthalmology, infectious disease","conjunctivitis, fungal keratosis, blepharitis","C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O",Launched
BRD-K90629600-001-01-4::2.5::MTS004,BRD-K90629600-001-01-4,emorfazone,2.5,MTS004,"antiinflammatory agent, cyclooxygenase inhibitor",NA,dental,mouth inflammation,CCOc1c(cnn(C)c1=O)N1CCOCC1,Launched
BRD-K90982969-001-01-2::2.5::MTS004,BRD-K90982969-001-01-2,etilevodopa,2.5,MTS004,dopamine receptor agonist,DRD3,NA,NA,"CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1",Phase 3
BRD-K91244729-003-01-3::2.316613157::MTS004,BRD-K91244729-003-01-3,propiverine,2.316613157,MTS004,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Launched
BRD-K91405252-001-01-9::2.500076093::MTS004,BRD-K91405252-001-01-9,MK-0354,2.500076093,MTS004,niacin receptor agonist,"HCAR2, HCAR3",NA,NA,C1Cc2[nH]nc(-c3nnn[nH]3)c2C1,Phase 2
BRD-K91543828-001-02-0::2.500044381::MTS004,BRD-K91543828-001-02-0,pentostatin,2.500044381,MTS004,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91900765-001-07-6::2.500030257::MTS004,BRD-K91900765-001-07-6,VX-745,2.500030257,MTS004,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1",Phase 2
BRD-K92073408-001-15-7::2.5::MTS004,BRD-K92073408-001-15-7,norethindrone,2.5,MTS004,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92413528-001-06-9::2.5::MTS004,BRD-K92413528-001-06-9,procysteine,2.5,MTS004,glutathione synthase stimulant,NA,NA,NA,OC(=O)[C@@H]1CSC(=O)N1,Phase 3
BRD-K92426617-001-06-3::2.5::MTS004,BRD-K92426617-001-06-3,esaprazole,2.5,MTS004,NA,NA,NA,NA,"O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1",Phase 2
BRD-K92490248-001-06-6::2.500037393::MTS004,BRD-K92490248-001-06-6,anethole-trithione,2.500037393,MTS004,glutathione transferase stimulant,NA,NA,NA,"COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1",Launched
BRD-K92581468-001-01-6::2.389082227::MTS004,BRD-K92581468-001-01-6,ocinaplon,2.389082227,MTS004,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1,Phase 3
BRD-K92902018-001-01-9::2.507952536::MTS004,BRD-K92902018-001-01-9,hydroxyprogesterone-acetate,2.507952536,MTS004,progesterone receptor agonist,PGR,NA,NA,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K92908289-001-01-8::2.501017998::MTS004,BRD-K92908289-001-01-8,medica-16,2.501017998,MTS004,ATP citrase lyase inhibitor,FFAR1,NA,NA,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O,Phase 2
BRD-K93442924-001-03-4::2.5::MTS004,BRD-K93442924-001-03-4,vorapaxar,2.5,MTS004,thrombin receptor antagonist,F2R,cardiology,"myocardial infarction, peripheral artery disease (PAD)",CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1,Launched
BRD-K93900986-001-15-0::2.613957824::MTS004,BRD-K93900986-001-15-0,stetaderm,2.613957824,MTS004,NA,NA,NA,NA,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C,Launched
BRD-K94072573-001-09-9::2.5::MTS004,BRD-K94072573-001-09-9,medronic-acid,2.5,MTS004,bone resorption inhibitor,NA,radiology,skeletal imaging agent,OP(O)(=O)CP(O)(O)=O,Launched
BRD-K94146583-001-01-6::2.500085506::MTS004,BRD-K94146583-001-01-6,didox,2.500085506,MTS004,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer,ONC(=O)c1ccc(O)c(O)c1,Launched
BRD-K94830213-001-01-3::2.635005669::MTS004,BRD-K94830213-001-01-3,tofisopam,2.635005669,MTS004,"phosphodiesterase inhibitor, cytochrome P450 inhibitor","CYP3A4, PDE10A, PDE2A, PDE3A, PDE4A",neurology/psychiatry,"anxiety, abstinence from alcohol",CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12,Launched
BRD-K95362002-001-01-1::2.354783058::MTS004,BRD-K95362002-001-01-1,cipemastat,2.354783058,MTS004,metalloproteinase inhibitor,"ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9",NA,NA,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,Phase 3
BRD-K95941975-001-01-5::2.5::MTS004,BRD-K95941975-001-01-5,piperazinedione,2.5,MTS004,DNA synthesis inhibitor,NA,NA,NA,O=C1CNC(=O)CN1,Phase 2
BRD-K96206066-001-07-9::2.591957442::MTS004,BRD-K96206066-001-07-9,difenpiramide,2.591957442,MTS004,"cyclooxygenase inhibitor, prostaglandin inhibitor",NA,NA,NA,O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1,Launched
BRD-K96344439-002-02-7::2.500011072::MTS004,BRD-K96344439-002-02-7,tofogliflozin,2.500011072,MTS004,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96471533-001-09-0::2.592774962::MTS004,BRD-K96471533-001-09-0,nitazoxanide,2.592774962,MTS004,pyruvate ferredoxin oxidoreductase inhibitor,NA,gastroenterology,diarrhea,"CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O",Launched
BRD-K96669468-300-01-1::2.5::MTS004,BRD-K96669468-300-01-1,pyridoxamine,2.5,MTS004,AGE inhibitor,NA,NA,NA,Cc1ncc(CO)c(CN)c1O,Phase 3
BRD-K96691275-001-01-2::2.5::MTS004,BRD-K96691275-001-01-2,mebrofenin,2.5,MTS004,NA,NA,radiology,diagnostic agent,Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br,Launched
BRD-K96734425-304-01-7::2.500007729::MTS004,BRD-K96734425-304-01-7,ceftriaxone,2.500007729,MTS004,bacterial cell wall synthesis inhibitor,NA,"infectious disease, otolaryngology","gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K96874295-015-01-0::2.500009134::MTS004,BRD-K96874295-015-01-0,gonadorelin,2.500009134,MTS004,gonadotropin releasing factor hormone receptor agonist,"GNRHR, GNRHR2",obstetrics/gynecology,"cystic ovaries, reproductive synchrony",CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,Launched
BRD-K97939847-001-12-0::2.5::MTS004,BRD-K97939847-001-12-0,cridanimod,2.5,MTS004,progesterone receptor agonist,PGR,NA,NA,"OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12",Launched
BRD-K98054437-001-09-9::2.494413182::MTS004,BRD-K98054437-001-09-9,epalrestat,2.494413182,MTS004,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy,"CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1",Launched
BRD-K98557884-001-01-6::2.5::MTS004,BRD-K98557884-001-01-6,suritozole,2.5,MTS004,GABA receptor inverse agonist,GABBR1,NA,NA,Cn1nc(-c2cccc(F)c2)n(C)c1=S,Phase 2
BRD-K99077012-001-01-9::2.332734192::MTS004,BRD-K99077012-001-01-9,befuraline,2.332734192,MTS004,NA,NA,NA,NA,O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1,Phase 2
BRD-K99199077-001-16-1::2.603211317::MTS004,BRD-K99199077-001-16-1,hydrocortisone-butyrate,2.603211317,MTS004,glucocorticoid receptor agonist,NR3C1,dermatology,"corticosteroid-responsive dermatoses, eczema","CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO",Launched
BRD-K99431849-001-01-7::2.500018158::MTS004,BRD-K99431849-001-01-7,peretinoin,2.500018158,MTS004,retinoid receptor agonist,RXRA,NA,NA,"CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O",Phase 3
BRD-K99447003-335-04-1::2.37737659::MTS004,BRD-K99447003-335-04-1,enalaprilat,2.37737659,MTS004,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",Launched
BRD-K99506538-001-03-8::2.5::MTS004,BRD-K99506538-001-03-8,xenalipin,2.5,MTS004,NA,NA,NA,NA,OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F,Phase 2
BRD-K99616396-001-05-1::2.499991421::MTS004,BRD-K99616396-001-05-1,motesanib,2.499991421,MTS004,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99879819-001-02-1::2.5187366::MTS004,BRD-K99879819-001-02-1,lorlatinib,2.5187366,MTS004,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99919177-001-01-3::2.5::MTS004,BRD-K99919177-001-01-3,deslanoside,2.5,MTS004,Na/K-ATPase inhibitor,"ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2",cardiology,"congestive heart failure, cardiac arrythmia",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Launched
BRD-M63173034-001-03-6::2.64076472::MTS004,BRD-M63173034-001-03-6,clonixin-lysinate,2.64076472,MTS004,cyclooxygenase inhibitor,NA,neurology/psychiatry,pain relief,"NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O",Launched
BRD-A00077618-236-07-6::2.5::HTS,BRD-A00077618-236-07-6,8-bromo-cGMP,2.5,HTS,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00100033-001-08-9::2.5::HTS,BRD-A00100033-001-08-9,nifurtimox,2.5,HTS,DNA inhibitor,NA,infectious disease,"Chagas disease, African trypanosomiasis",CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O,Launched
BRD-A00147595-001-01-5::2.5::HTS,BRD-A00147595-001-01-5,balaglitazone,2.5,HTS,"insulin sensitizer, PPAR receptor partial agonist",PPARG,NA,NA,Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O,Phase 3
BRD-A00218260-001-03-4::2.5::HTS,BRD-A00218260-001-03-4,flutrimazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,mycosis,Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1,Launched
BRD-A00376169-001-01-6::2.5::HTS,BRD-A00376169-001-01-6,KBG,2.5,HTS,neprilysin inhibitor,MME,NA,NA,OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1,Phase 2
BRD-A00520476-001-07-4::2.5::HTS,BRD-A00520476-001-07-4,otenzepad,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12, CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12",Phase 3
BRD-A00546892-001-02-6::2.5::HTS,BRD-A00546892-001-02-6,biperiden,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",neurology/psychiatry,Parkinson's Disease,"OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1, OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1",Launched
BRD-A00578795-001-04-3::2.5::HTS,BRD-A00578795-001-04-3,zaltoprofen,2.5,HTS,cyclooxygenase inhibitor,NA,"endocrinology, neurology/psychiatry","fever, pain relief",CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1,Launched
BRD-A00758722-001-04-9::2.5::HTS,BRD-A00758722-001-04-9,noretynodrel,2.5,HTS,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00827783-001-24-6::2.5::HTS,BRD-A00827783-001-24-6,dyphylline,2.5,HTS,"adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B",pulmonary,"asthma, bronchitis, emphysema","Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O",Launched
BRD-A00993607-003-24-6::2.5::HTS,BRD-A00993607-003-24-6,alprenolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A",cardiology,angina pectoris,CC(C)NCC(O)COc1ccccc1CC=C,Launched
BRD-A01098288-001-02-9::2.5::HTS,BRD-A01098288-001-02-9,azelnidipine,2.5,HTS,calcium channel blocker,CACNA1C,cardiology,hypertension,"CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1",Launched
BRD-A01412266-001-01-0::2.5::HTS,BRD-A01412266-001-01-0,hydroxypropyl-beta-cyclodextrin,2.5,HTS,NA,NA,NA,NA,CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,Phase 2
BRD-A01493904-003-12-1::2.5::HTS,BRD-A01493904-003-12-1,WB-4101,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A",NA,NA,COc1cccc(OC)c1OCCNCC1COc2ccccc2O1,Preclinical
BRD-A01563671-001-02-7::2.5::HTS,BRD-A01563671-001-02-7,cleviprex,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1S",cardiology,hypertension,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,Launched
BRD-A01593789-001-03-1::2.5::HTS,BRD-A01593789-001-03-1,chlormadinone-acetate,2.5,HTS,5 alpha reductase inhibitor,PGR,endocrinology,"hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea",CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,Launched
BRD-A01636364-003-15-1::2.5::HTS,BRD-A01636364-003-15-1,bupivacaine,2.5,HTS,sodium channel blocker,"KCNA5, PTGER1, SCN10A, SCN4A",neurology/psychiatry,"peripheral nerve block, caudal epidural block, lumbar epidural block","CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C, CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A01643550-001-04-9::2.5::HTS,BRD-A01643550-001-04-9,prednisolone-acetate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01787639-003-16-9::2.5::HTS,BRD-A01787639-003-16-9,naftopidil,2.5,HTS,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH),"COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1",Launched
BRD-A01907367-001-01-7::2.5::HTS,BRD-A01907367-001-01-7,FK-33-824,2.5,HTS,opioid receptor agonist,OPRM1,NA,NA,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O,Phase 2
BRD-A02006392-001-16-4::2.5::HTS,BRD-A02006392-001-16-4,nitrendipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CACNG1, KCNN4",cardiology,hypertension,"CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC",Launched
BRD-A02180903-001-04-5::2.5::HTS,BRD-A02180903-001-04-5,betamethasone,2.5,HTS,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02710418-003-11-8::2.5::HTS,BRD-A02710418-003-11-8,meptazinol,2.5,HTS,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief,"CCC1(CCCCN(C)C1)c1cccc(O)c1, CCC1(CCCCN(C)C1)c1cccc(O)c1, CCC1(CCCCN(C)C1)c1cccc(O)c1",Launched
BRD-A02743701-001-03-6::2.5::HTS,BRD-A02743701-001-03-6,cilnidipine,2.5,HTS,calcium channel blocker,CACNA1B,cardiology,hypertension,"COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1",Launched
BRD-A02759312-003-24-5::2.5::HTS,BRD-A02759312-003-24-5,betaxolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC",Launched
BRD-A02990301-003-06-6::2.5::HTS,BRD-A02990301-003-06-6,lofexidine,2.5,HTS,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,opioid withdrawal,"CC(Oc1c(Cl)cccc1Cl)C1=NCCN1, CC(Oc1c(Cl)cccc1Cl)C1=NCCN1",Launched
BRD-A03061970-003-07-3::2.5::HTS,BRD-A03061970-003-07-3,alizapride,2.5,HTS,dopamine receptor antagonist,DRD2,gastroenterology,nausea,COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C,Launched
BRD-A03216249-003-24-3::2.5::HTS,BRD-A03216249-003-24-3,mepivacaine,2.5,HTS,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03359064-001-02-3::2.5::HTS,BRD-A03359064-001-02-3,ICI-89406,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",NA,NA,OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N,Phase 1
BRD-A03506276-001-01-5::2.5::HTS,BRD-A03506276-001-01-5,XL888,2.5,HTS,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03623303-045-09-5::2.5::HTS,BRD-A03623303-045-09-5,metoprolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03880619-001-01-0::2.5::HTS,BRD-A03880619-001-01-0,bismuth-subcitrate-potassium,2.5,HTS,NA,NA,gastroenterology,duodenal ulcer disease,"OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O, OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O",Launched
BRD-A03932035-004-04-3::2.5::HTS,BRD-A03932035-004-04-3,methscopolamine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A04203391-001-08-3::2.5::HTS,BRD-A04203391-001-08-3,piricapiron,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,NA,NA,CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O,Phase 2
BRD-A04252265-003-01-4::2.5::HTS,BRD-A04252265-003-01-4,eperisone,2.5,HTS,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,"amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury",CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1,Launched
BRD-A04322457-003-17-9::2.5::HTS,BRD-A04322457-003-17-9,isoprenaline,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, MAPK1, PIK3R1, PIK3R2, PIK3R3","cardiology, pulmonary","bradycardia, heart block, asthma","CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1",Launched
BRD-A04327189-001-15-1::2.5::HTS,BRD-A04327189-001-15-1,synephrine,2.5,HTS,adrenergic receptor agonist,ADRA1A,NA,NA,"CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1",Launched
BRD-A04327189-003-03-3::2.5::HTS,BRD-A04327189-003-03-3,synephrine,2.5,HTS,adrenergic receptor agonist,ADRA1A,NA,NA,"CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1",Launched
BRD-A04352665-001-05-3::2.5::HTS,BRD-A04352665-001-05-3,maraviroc,2.5,HTS,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1, CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1",Launched
BRD-A04497688-001-04-2::2.5::HTS,BRD-A04497688-001-04-2,trilostane,2.5,HTS,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,"ESR1, ESR2, HSD3B1, HSD3B2",endocrinology,Cushing's syndrome,"C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O",Launched
BRD-A04506385-001-01-2::2.5::HTS,BRD-A04506385-001-01-2,stepronin,2.5,HTS,mucolytic agent,NA,NA,NA,CC(SC(=O)c1cccs1)C(=O)NCC(O)=O,Launched
BRD-A04553218-050-16-2::2.5::HTS,BRD-A04553218-050-16-2,chlorphenamine,2.5,HTS,histamine receptor antagonist,"HRH1, SLC6A2, SLC6A3, SLC6A4",allergy,"allergic rhinitis, urticaria",CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,Launched
BRD-A04661934-001-02-9::2.5::HTS,BRD-A04661934-001-02-9,2-PMDQ,2.5,HTS,adrenergic receptor antagonist,ADRA1A,NA,NA,O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12,Preclinical
BRD-A05186015-003-19-8::2.5::HTS,BRD-A05186015-003-19-8,bupropion,2.5,HTS,dopamine uptake inhibitor,"CHRNA3, SLC6A2, SLC6A3",neurology/psychiatry,depression,"CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1, CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1, CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1",Launched
BRD-A05334458-001-02-8::2.5::HTS,BRD-A05334458-001-02-8,lisofylline,2.5,HTS,"interleukin receptor antagonist, STAT inhibitor",NA,NA,NA,CC(O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,Phase 2
BRD-A05457250-001-08-4::2.5::HTS,BRD-A05457250-001-08-4,BAY-K-8644-(+/-),2.5,HTS,L-type calcium channel activator,NA,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-A05515753-001-03-2::2.5::HTS,BRD-A05515753-001-03-2,erdosteine,2.5,HTS,mucolytic agent,NA,"pulmonary, infectious disease","bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections","OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O",Launched
BRD-A05523972-001-01-5::2.5::HTS,BRD-A05523972-001-01-5,telmesteine,2.5,HTS,mucolytic agent,NA,NA,NA,CCOC(=O)N1CSCC1C(O)=O,Launched
BRD-A05674712-001-06-0::2.5::HTS,BRD-A05674712-001-06-0,"mevalonic-d,-l-acid-lactone",2.5,HTS,NA,NA,NA,NA,CC1(O)CCOC(=O)C1,Preclinical
BRD-A05729358-001-02-0::2.5::HTS,BRD-A05729358-001-02-0,CPCCOEt,2.5,HTS,glutamate receptor antagonist,GRM1,NA,NA,"CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2, CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2",Preclinical
BRD-A05906449-004-01-1::2.5::HTS,BRD-A05906449-004-01-1,lappaconite,2.5,HTS,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A06352418-001-25-9::2.5::HTS,BRD-A06352418-001-25-9,terfenadine,2.5,HTS,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352508-001-03-7::2.5::HTS,BRD-A06352508-001-03-7,SB-218078,2.5,HTS,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06390036-001-04-6::2.5::HTS,BRD-A06390036-001-04-6,hydroquinidine,2.5,HTS,antiarrhythmic,NA,cardiology,cardiac arrythmia,CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Launched
BRD-A06426627-001-03-5::2.5::HTS,BRD-A06426627-001-03-5,diclazuril,2.5,HTS,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06627858-236-03-0::2.5::HTS,BRD-A06627858-236-03-0,monensin,2.5,HTS,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06771424-004-01-7::2.5::HTS,BRD-A06771424-004-01-7,anisotropine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C,Launched
BRD-A06916187-001-02-9::2.5::HTS,BRD-A06916187-001-02-9,CPI-613,2.5,HTS,pyruvate dehydrogenase inhibitor,PDHA1,NA,NA,OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,Phase 2
BRD-A06935312-001-04-3::2.5::HTS,BRD-A06935312-001-04-3,fusidic-acid,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,dermatology,acne vulgaris (AV),C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,Launched
BRD-A07000685-001-04-4::2.5::HTS,BRD-A07000685-001-04-4,hydrocortisone-hemisuccinate,2.5,HTS,NA,NA,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Phase 2/Phase 3
BRD-A07164067-001-01-2::2.5::HTS,BRD-A07164067-001-01-2,meluadrine,2.5,HTS,NA,NA,NA,NA,CC(C)(C)NCC(O)c1ccc(O)cc1Cl,Preclinical
BRD-A07207424-001-13-2::2.5::HTS,BRD-A07207424-001-13-2,Ro-20-1724,2.5,HTS,phosphodiesterase inhibitor,"PDE3A, PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,"CCCCOc1cc(CC2CNC(=O)N2)ccc1OC, CCCCOc1cc(CC2CNC(=O)N2)ccc1OC",Preclinical
BRD-A07232941-001-02-7::2.5::HTS,BRD-A07232941-001-02-7,8-M-PDOT,2.5,HTS,melatonin receptor agonist,"MTNR1A, MTNR1B",NA,NA,"CCC(=O)NC1CCc2cccc(OC)c2C1, CCC(=O)NC1CCc2cccc(OC)c2C1",Preclinical
BRD-A07395371-003-10-0::2.5::HTS,BRD-A07395371-003-10-0,esmolol,2.5,HTS,adrenergic receptor antagonist,ADRB1,cardiology,"ventricular tachycardia (VT), hypertension",COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,Launched
BRD-A07440155-003-25-4::2.5::HTS,BRD-A07440155-003-25-4,labetalol,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2",cardiology,hypertension,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O,Launched
BRD-A07563059-035-01-3::2.5::HTS,BRD-A07563059-035-01-3,bopindolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3, HTR1A, HTR1B",cardiology,"hypertension, coronary artery disease (CAD)",Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,Launched
BRD-A07600638-060-05-2::2.5::HTS,BRD-A07600638-060-05-2,meclocycline-sulfosalicylate,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A07704283-001-01-3::2.5::HTS,BRD-A07704283-001-01-3,isofloxythepin,2.5,HTS,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07780951-001-08-9::2.5::HTS,BRD-A07780951-001-08-9,metaproterenol,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, asthma, bronchitis, emphysema","CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A07780951-065-10-0::2.58::HTS,BRD-A07780951-065-10-0,metaproterenol,2.58,HTS,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, asthma, bronchitis, emphysema","CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A07815743-001-01-1::2.5::HTS,BRD-A07815743-001-01-1,kakonein,2.5,HTS,"GABA receptor antagonist, serotonin receptor antagonist",NA,NA,NA,OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,Phase 2
BRD-A07870296-001-07-4::2.5::HTS,BRD-A07870296-001-07-4,bicuculline-(+),2.5,HTS,GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1",NA,NA,"CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21",Preclinical
BRD-A07893380-213-01-7::2.5::HTS,BRD-A07893380-213-01-7,vigabatrin,2.5,HTS,GABA aminotransferase inhibitor,"ABAT, GABBR1, SLC32A1",neurology/psychiatry,"seizures, spasms",NC(CCC(O)=O)C=C,Launched
BRD-A07932845-050-15-8::2.5::HTS,BRD-A07932845-050-15-8,metitepine,2.5,HTS,anti-HCVE2,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,"CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1",Preclinical
BRD-A07947329-001-01-4::2.5::HTS,BRD-A07947329-001-01-4,buparvaquone,2.5,HTS,antiprotozoal agent,NA,NA,NA,CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1,Launched
BRD-A07986123-001-02-8::2.5::HTS,BRD-A07986123-001-02-8,galeterone,2.5,HTS,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A08079565-001-01-8::2.5::HTS,BRD-A08079565-001-01-8,CDBA,2.5,HTS,NA,NA,NA,NA,OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,Phase 3
BRD-A08187463-001-12-9::2.5::HTS,BRD-A08187463-001-12-9,racecadotril,2.5,HTS,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08255417-001-14-7::2.5::HTS,BRD-A08255417-001-14-7,famprofazone,2.5,HTS,cyclooxygenase inhibitor,NA,NA,NA,"CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C, CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C",Preclinical
BRD-A08302182-001-01-7::2.5::HTS,BRD-A08302182-001-01-7,etonogestrel,2.5,HTS,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C,Launched
BRD-A08545410-003-07-8::2.38::HTS,BRD-A08545410-003-07-8,doxycycline,2.38,HTS,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-08-6::2.5::HTS,BRD-A08545410-003-08-6,doxycycline,2.5,HTS,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-01-8::2.5::HTS,BRD-A08545410-311-01-8,doxycycline,2.5,HTS,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::2.5::HTS,BRD-A08545410-311-03-4,doxycycline,2.5,HTS,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08660406-001-05-9::2.5::HTS,BRD-A08660406-001-05-9,iodixanol,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,"CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I",Launched
BRD-A08715367-001-01-7::2.87::HTS,BRD-A08715367-001-01-7,L-Theanine,2.87,HTS,glutamate receptor antagonist,NA,NA,NA,CCNC(=O)CCC(N)C(O)=O,Launched
BRD-A08840375-001-01-3::2.5::HTS,BRD-A08840375-001-01-3,CID-5458317,2.5,HTS,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A09056319-003-07-7::2.5::HTS,BRD-A09056319-003-07-7,alfuzosin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2",urology,benign prostatic hyperplasia (BPH),"COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1",Launched
BRD-A09062839-003-10-0::2.5::HTS,BRD-A09062839-003-10-0,amyleine,2.5,HTS,local anesthetic,NA,NA,NA,CCC(C)(CN(C)C)OC(=O)c1ccccc1,Preclinical
BRD-A09094913-065-01-0::2.5::HTS,BRD-A09094913-065-01-0,strychnine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB",NA,NA,O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61,Preclinical
BRD-A09349126-001-10-7::2.5::HTS,BRD-A09349126-001-10-7,norethindrone-acetate,2.5,HTS,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09370961-001-01-0::2.5::HTS,BRD-A09370961-001-01-0,ioxilan,2.5,HTS,radiopaque medium,NA,radiology,angiography,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I,Launched
BRD-A09467419-003-22-4::2.5::HTS,BRD-A09467419-003-22-4,mebeverine,2.5,HTS,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,Launched
BRD-A09472452-015-23-4::2.5::HTS,BRD-A09472452-015-23-4,flecainide,2.5,HTS,sodium channel blocker,"KCNA5, KCNA7, SCN4A, SCN5A",cardiology,"ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias","FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1",Launched
BRD-A09533288-003-31-2::2.5::HTS,BRD-A09533288-003-31-2,verapamil,2.5,HTS,calcium channel blocker,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4",cardiology,hypertension,"COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC",Launched
BRD-A09554849-236-07-6::2.5::HTS,BRD-A09554849-236-07-6,8-bromo-cAMP,2.5,HTS,PKA activator,NA,NA,NA,Nc1ncnc2n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c(Br)nc12,Preclinical
BRD-A09722536-002-18-0::2.5::HTS,BRD-A09722536-002-18-0,cyclophosphamide,2.5,HTS,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09735281-001-02-5::2.5::HTS,BRD-A09735281-001-02-5,boceprevir,2.5,HTS,HCV inhibitor,"CMA1, CTSA, CTSF, CTSK, CTSL, CTSS",infectious disease,hepatitis C,"CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C",Launched
BRD-A09828896-004-11-0::2.5::HTS,BRD-A09828896-004-11-0,SKF-81297,2.5,HTS,dopamine receptor agonist,"DRD1, DRD5",NA,NA,"Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1",Preclinical
BRD-A09925278-003-05-6::2.5::HTS,BRD-A09925278-003-05-6,etilefrine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRB1","neurology/psychiatry, otolaryngology, endocrinology, pulmonary","headache, nasal congestion, fever, cough suppressant, common cold",CCNCC(O)c1cccc(O)c1,Launched
BRD-A10039652-001-01-2::2.5::HTS,BRD-A10039652-001-01-2,tipranavir,2.5,HTS,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10070317-003-28-3::2.5::HTS,BRD-A10070317-003-28-3,propranolol,2.5,HTS,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10111329-001-04-6::2.5::HTS,BRD-A10111329-001-04-6,adenosine-phosphate,2.5,HTS,adenosine receptor agonist,"ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4",NA,NA,Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-A10420615-001-04-4::2.5::HTS,BRD-A10420615-001-04-4,cyclopiazonic-acid,2.5,HTS,ATPase inhibitor,ATP2A1,NA,NA,"CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O, CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O",Preclinical
BRD-A10523515-001-07-9::2.5::HTS,BRD-A10523515-001-07-9,GSK429286A,2.5,HTS,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10652366-238-04-1::2.5::HTS,BRD-A10652366-238-04-1,fosfomycin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,urinary tract infections,"C[C@@H]1O[C@@H]1P(O)(O)=O, CC1OC1P(O)(O)=O",Launched
BRD-A10662413-043-11-2::2.5::HTS,BRD-A10662413-043-11-2,prenylamine,2.5,HTS,calcium channel blocker,"CALM1, MYLK2",NA,NA,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,Withdrawn
BRD-A10739734-003-10-6::2.5::HTS,BRD-A10739734-003-10-6,efaroxan,2.5,HTS,adrenergic receptor antagonist,ADORA2A,NA,NA,"CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1",Phase 2
BRD-A10903566-003-07-7::2.5::HTS,BRD-A10903566-003-07-7,imiloxan,2.5,HTS,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10967948-003-06-3::2.5::HTS,BRD-A10967948-003-06-3,granisetron,2.5,HTS,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting","CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12, CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12",Launched
BRD-A10977446-001-12-1::2.5::HTS,BRD-A10977446-001-12-1,carvedilol,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A11070335-236-02-1::2.5::HTS,BRD-A11070335-236-02-1,carbazochrome,2.5,HTS,NA,NA,hematology,hemorrhage,CN1C(CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O,Launched
BRD-A11132253-001-08-2::2.5::HTS,BRD-A11132253-001-08-2,nadide,2.5,HTS,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11551002-001-04-6::2.5::HTS,BRD-A11551002-001-04-6,dehydrocholate-acid,2.5,HTS,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11662333-001-03-3::2.5::HTS,BRD-A11662333-001-03-3,meparfylon,2.5,HTS,NA,NA,NA,NA,CCC(C)(O)C#C,Preclinical
BRD-A11731518-001-01-7::2.5::HTS,BRD-A11731518-001-01-7,BAY-85-8050,2.5,HTS,NA,NA,NA,NA,NC(CC(F)C(O)=O)C(O)=O,Phase 1
BRD-A11776908-065-01-5::2.5::HTS,BRD-A11776908-065-01-5,enilconazole,2.5,HTS,sterol demethylase inhibitor,"CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2",infectious disease,skin infections,Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1,Launched
BRD-A11813248-003-02-4::2.5::HTS,BRD-A11813248-003-02-4,AM-92016,2.5,HTS,potassium channel blocker,GRIN1,NA,NA,"CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1, CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1",Preclinical
BRD-A11815689-001-01-1::2.5::HTS,BRD-A11815689-001-01-1,proscillaridin-a,2.5,HTS,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11990600-001-03-4::2.5::HTS,BRD-A11990600-001-03-4,lorazepam,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A12077521-003-01-5::2.5::HTS,BRD-A12077521-003-01-5,cefepime,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"pneumonia, urinary tract infections, skin infections, intra-abdominal infections",CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1,Launched
BRD-A12230535-001-06-7::2.5::HTS,BRD-A12230535-001-06-7,nutlin-3,2.5,HTS,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12237696-001-04-2::2.5::HTS,BRD-A12237696-001-04-2,L-Citrulline,2.5,HTS,nitric oxide stimulant,"ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6","cardiology, urology","hypertension, erectile dysfunction",NC(CCCNC(N)=O)C(O)=O,Launched
BRD-A12417644-001-07-6::2.31::HTS,BRD-A12417644-001-07-6,usniacin-(+),2.31,HTS,MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12454076-001-01-9::2.5::HTS,BRD-A12454076-001-01-9,L-Hydroxyproline,2.5,HTS,NA,NA,NA,NA,OC1CNC(C1)C(O)=O,Launched
BRD-A12896037-001-04-3::2.5::HTS,BRD-A12896037-001-04-3,cisapride,2.5,HTS,serotonin receptor agonist,"HTR2A, HTR3A, HTR4, KCNH2",NA,NA,"COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC",Withdrawn
BRD-A12994259-001-02-1::2.5::HTS,BRD-A12994259-001-02-1,pomalidomide,2.5,HTS,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A13084692-001-17-3::2.5::HTS,BRD-A13084692-001-17-3,troglitazone,2.5,HTS,"insulin sensitizer, PPAR receptor agonist","ACSL4, ESRRA, ESRRG, PPARG, SERPINE1, SLC29A1, TRPM3",NA,NA,"Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O, Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O",Withdrawn
BRD-A13133631-001-04-0::2.5::HTS,BRD-A13133631-001-04-0,fluorometholone,2.5,HTS,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13188892-066-21-5::2.5::HTS,BRD-A13188892-066-21-5,doxazosin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1",Launched
BRD-A13323580-001-04-8::2.5::HTS,BRD-A13323580-001-04-8,perillyl-alcohol,2.5,HTS,"apoptosis stimulant, farnesyltransferase inhibitor",FNTA,NA,NA,"CC(=C)C1CCC(CO)=CC1, CC(=C)C1CCC(CO)=CC1",Phase 2
BRD-A13561534-003-02-0::2.5::HTS,BRD-A13561534-003-02-0,ornithine,2.5,HTS,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13598753-001-01-2::2.5::HTS,BRD-A13598753-001-01-2,5'-Chloro-5'-deoxy-ENBA-(+/-),2.5,HTS,adenosine receptor agonist,ADORA1,NA,NA,"O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12, O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12",Preclinical
BRD-A13946108-001-17-1::2.5::HTS,BRD-A13946108-001-17-1,sulindac,2.5,HTS,cyclooxygenase inhibitor,"AKR1B1, MAPK3, PPARD, PTGDR2, PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis, ankylosing spondylitis","CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O",Launched
BRD-A13964793-001-02-6::2.5::HTS,BRD-A13964793-001-02-6,TC1,2.5,HTS,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A14208071-004-19-8::2.5::HTS,BRD-A14208071-004-19-8,oxyphenonium,2.5,HTS,cholinergic receptor antagonist,CHRM1,gastroenterology,peptic ulcer disease (PUD),CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A14240607-003-26-1::2.5::HTS,BRD-A14240607-003-26-1,octopamine,2.5,HTS,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14262390-065-01-8::2.5::HTS,BRD-A14262390-065-01-8,guanadrel,2.5,HTS,adrenergic inhibitor,SLC6A2,cardiology,hypertension,NC(=N)NCC1COC2(CCCCC2)O1,Launched
BRD-A14316475-001-02-3::2.5::HTS,BRD-A14316475-001-02-3,SN-6,2.5,HTS,sodium/calcium exchange inhibitor,NA,NA,NA,"CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1, CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1",Preclinical
BRD-A14344385-001-03-2::2.5::HTS,BRD-A14344385-001-03-2,IDRA-21,2.5,HTS,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14395271-074-17-8::2.5::HTS,BRD-A14395271-074-17-8,mesoridazine,2.5,HTS,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14574269-051-02-2::2.5::HTS,BRD-A14574269-051-02-2,UB-165,2.5,HTS,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNB2",NA,NA,"Clc1ccc(cn1)C1=CCCC2CCC1N2, Clc1ccc(cn1)C1=CCCC2CCC1N2",Preclinical
BRD-A14886633-001-01-6::2.5::HTS,BRD-A14886633-001-01-6,norgestrel,2.5,HTS,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14941520-051-01-0::2.5::HTS,BRD-A14941520-051-01-0,dofequidar,2.5,HTS,"MRP inhibitor, P glycoprotein inhibitor",ABCB1,NA,NA,OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1,Phase 3
BRD-A14966924-003-07-7::2.5::HTS,BRD-A14966924-003-07-7,alaproclate,2.5,HTS,serotonin receptor antagonist,SLC6A4,NA,NA,CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1,Phase 2
BRD-A15035311-001-01-8::2.5::HTS,BRD-A15035311-001-01-8,diadenosine-tetraphosphate,2.5,HTS,adenosine kinase inhibitor,"P2RY13, P2RY2",NA,NA,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O,Phase 1
BRD-A15202882-003-02-7::2.5::HTS,BRD-A15202882-003-02-7,milnacipran,2.5,HTS,serotonin-norepinephrine reuptake inhibitor (SNRI),"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A4",rheumatology,fibromyalgia,"CCN(CC)C(=O)C1(CC1CN)c1ccccc1, CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1",Launched
BRD-A15297126-001-04-3::2.5::HTS,BRD-A15297126-001-04-3,fluocinolone-acetonide,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A15397381-001-02-5::2.5::HTS,BRD-A15397381-001-02-5,L-Cystine,2.5,HTS,NA,"CTNS, SLC3A1, SLC7A11, SLC7A9",NA,NA,"NC(CSSCC(N)C(O)=O)C(O)=O, NC(CSSCC(N)C(O)=O)C(O)=O, N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O",Launched
BRD-A15415227-003-02-9::2.5::HTS,BRD-A15415227-003-02-9,GW-1929,2.5,HTS,PPAR receptor agonist,PPARG,NA,NA,CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,Preclinical
BRD-A15435692-003-02-3::2.5::HTS,BRD-A15435692-003-02-3,BMY-14802,2.5,HTS,sigma receptor antagonist,HTR1A,NA,NA,OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1,Phase 2
BRD-A15530910-001-02-1::2.5::HTS,BRD-A15530910-001-02-1,SDZ-21009,2.5,HTS,"adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A, HTR1B",NA,NA,CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,Preclinical
BRD-A15909516-001-06-6::2.5::HTS,BRD-A15909516-001-06-6,rebamipide,2.5,HTS,free radical scavenger,FPR1,gastroenterology,"peptic ulcer disease (PUD), gastritis","OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1, OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1",Launched
BRD-A15931911-001-03-8::2.5::HTS,BRD-A15931911-001-03-8,bucladesine,2.5,HTS,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A16296925-001-01-3::2.5::HTS,BRD-A16296925-001-01-3,indobufen,2.5,HTS,"cyclooxygenase inhibitor, platelet aggregation inhibitor","PTGS1, PTGS2",hematology,thrombosis,CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Launched
BRD-A16347691-001-13-1::2.5::HTS,BRD-A16347691-001-13-1,thioctic-acid,2.5,HTS,reducing agent,"ACHE, LIAS, LIPT1, PTGS2, SLC5A6",NA,NA,OC(=O)CCCCC1CCSS1,Launched
BRD-A16350940-001-01-9::2.5::HTS,BRD-A16350940-001-01-9,doramectin,2.5,HTS,NA,NA,infectious disease,gastrointestinal roundworms,CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O,Launched
BRD-A16439188-001-01-1::2.5::HTS,BRD-A16439188-001-01-1,quinestrol,2.5,HTS,estrogen receptor agonist,ESR1,endocrinology,menopause,C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C,Launched
BRD-A16665823-001-02-0::2.5::HTS,BRD-A16665823-001-02-0,butoconazole,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,vulvovaginal candidiasis,"Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1, Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1",Launched
BRD-A16694057-001-06-8::2.5::HTS,BRD-A16694057-001-06-8,BADGE,2.5,HTS,PPAR receptor antagonist,PPARG,NA,NA,CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1,Preclinical
BRD-A16700644-003-04-4::2.5::HTS,BRD-A16700644-003-04-4,isoxsuprine,2.5,HTS,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16997652-001-02-3::2.5::HTS,BRD-A16997652-001-02-3,protirelin,2.5,HTS,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A17300716-001-01-5::2.5::HTS,BRD-A17300716-001-01-5,dehydroacetic-acid,2.5,HTS,NA,NA,NA,NA,CC(=O)C1C(=O)OC(C)=CC1=O,Preclinical
BRD-A17407635-001-04-0::2.5::HTS,BRD-A17407635-001-04-0,alclometasone-dipropionate,2.5,HTS,glucocorticoid receptor agonist,"CYP3A4, NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-A17411484-001-11-9::2.5::HTS,BRD-A17411484-001-11-9,carprofen,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,osteoarthritis,"CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21, CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21",Launched
BRD-A17428743-003-09-0::2.5::HTS,BRD-A17428743-003-09-0,BW-723C86,2.5,HTS,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",NA,NA,"CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12, CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12",Preclinical
BRD-A17453586-003-02-3::2.5::HTS,BRD-A17453586-003-02-3,MDL-72832,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,Preclinical
BRD-A17462676-003-11-6::2.5::HTS,BRD-A17462676-003-11-6,bambuterol,2.5,HTS,adrenergic receptor agonist,"ADRB2, BCHE",pulmonary,asthma,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,Launched
BRD-A17655518-001-24-4::2.5::HTS,BRD-A17655518-001-24-4,ibuprofen,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental","headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache","CC(C)Cc1ccc(cc1)C(C)C(O)=O, CC(C)Cc1ccc(cc1)C(C)C(O)=O",Launched
BRD-A17846016-001-13-9::2.5::HTS,BRD-A17846016-001-13-9,trolox,2.5,HTS,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17883755-001-06-1::2.5::HTS,BRD-A17883755-001-06-1,lenalidomide,2.5,HTS,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A18043272-001-09-9::2.5::HTS,BRD-A18043272-001-09-9,phensuximide,2.5,HTS,succinimide antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,CN1C(=O)CC(C1=O)c1ccccc1,Launched
BRD-A18056626-003-22-3::2.5::HTS,BRD-A18056626-003-22-3,methacholine,2.5,HTS,acetylcholine receptor agonist,"CHRM2, CHRM3, CHRM4",pulmonary,bronchial hyperresponsiveness diagnostic,CC(C[N+](C)(C)C)OC(C)=O,Launched
BRD-A18074780-003-02-0::2.5::HTS,BRD-A18074780-003-02-0,AGN-192403,2.5,HTS,imidazoline receptor ligand,NISCH,NA,NA,"CC(C)[C@@H]1C2CCC(C2)[C@H]1N, CC(C)[C@@H]1C2CCC(C2)[C@H]1N",Preclinical
BRD-A18233884-003-02-7::2.5::HTS,BRD-A18233884-003-02-7,bevantolol,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRB1, ADRB2",cardiology,"angina pectoris, hypertension",COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,Launched
BRD-A18396475-001-15-3::2.56::HTS,BRD-A18396475-001-15-3,malic-acid,2.56,HTS,NA,"CS, ME2, PKD2L1",NA,NA,"OC(CC(O)=O)C(O)=O, OC(CC(O)=O)C(O)=O",Launched
BRD-A18611368-001-01-5::2.5::HTS,BRD-A18611368-001-01-5,tazobactam,2.5,HTS,beta lactamase inhibitor,NA,infectious disease,pneumonia,C[C@]1(Cn2ccnn2)C(N2C(CC2=O)S1(=O)=O)C(O)=O,Launched
BRD-A18627414-001-04-9::2.5::HTS,BRD-A18627414-001-04-9,cyanocobalamin,2.5,HTS,"methylmalonyl CoA mutase stimulant, vitamin B","MMAA, MMACHC, MTHFR, MTR, MTRR, MUT","hematology, infectious disease, gastroenterology","anemia, fish tapeworm infestation, celiac disease","C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12",Launched
BRD-A18696154-003-22-6::2.5::HTS,BRD-A18696154-003-22-6,idazoxan,2.5,HTS,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18763547-300-05-5::2.5::HTS,BRD-A18763547-300-05-5,BAX-channel-blocker,2.5,HTS,cytochrome C release inhibitor,BAX,NA,NA,"OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12, OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12",Preclinical
BRD-A18795974-004-07-3::2.5::HTS,BRD-A18795974-004-07-3,7-hydroxy-DPAT,2.5,HTS,dopamine receptor agonist,"DRD2, DRD3",NA,NA,"CCCN(CCC)C1CCc2ccc(O)cc2C1, CCCN(CCC)C1CCc2ccc(O)cc2C1, CCCN(CCC)C1CCc2ccc(O)cc2C1",Preclinical
BRD-A19102171-066-01-4::2.5::HTS,BRD-A19102171-066-01-4,naltriben,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O",Preclinical
BRD-A19195498-050-14-1::2.5::HTS,BRD-A19195498-050-14-1,trimipramine,2.5,HTS,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR3A, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CC(CN(C)C)CN1c2ccccc2CCc2ccccc12, CC(CN(C)C)CN1c2ccccc2CCc2ccccc12",Launched
BRD-A19585813-003-03-3::2.5::HTS,BRD-A19585813-003-03-3,methylphenidate,2.5,HTS,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19633847-050-32-1::2.5::HTS,BRD-A19633847-050-32-1,perhexiline,2.5,HTS,carnitine palmitoyltransferase inhibitor,"CPT1A, CPT2",cardiology,angina pectoris,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,Launched
BRD-A19661776-003-27-6::2.5::HTS,BRD-A19661776-003-27-6,mianserin,2.5,HTS,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21",Launched
BRD-A19736161-001-06-7::2.5::HTS,BRD-A19736161-001-06-7,ondansetron,2.5,HTS,serotonin receptor antagonist,"HTR1A, HTR1B, HTR3A, HTR3B, HTR4, OPRM1",gastroenterology,"nausea, vomiting","Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C",Launched
BRD-A19795905-001-08-0::2.5::HTS,BRD-A19795905-001-08-0,atovaquone,2.5,HTS,mitochondrial electron transport inhibitor,DHODH,infectious disease,pneumonia,"Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O",Launched
BRD-A19952358-001-11-3::2.5::HTS,BRD-A19952358-001-11-3,closantel,2.5,HTS,"chitinase inhibitor, NFkB pathway inhibitor",NA,infectious disease,liver flukes,"Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O",Launched
BRD-A19958636-065-04-4::2.5::HTS,BRD-A19958636-065-04-4,tuaminoheptane,2.5,HTS,NA,NA,otolaryngology,nasal congestion,CCCCCC(C)N,Launched
BRD-A20119038-003-07-8::2.5::HTS,BRD-A20119038-003-07-8,mecamylamine,2.5,HTS,acetylcholine receptor antagonist,"CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7",cardiology,hypertension,CNC1(C)C2CCC(C2)C1(C)C,Launched
BRD-A20239487-001-24-9::2.5::HTS,BRD-A20239487-001-24-9,atenolol-(+/-),2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20348246-001-15-8::2.5::HTS,BRD-A20348246-001-15-8,chlormezanone,2.5,HTS,GABA receptor modulator,"GABRA1, TSPO",NA,NA,"CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O",Withdrawn
BRD-A20550616-001-02-9::2.5::HTS,BRD-A20550616-001-02-9,halothane,2.5,HTS,glutamate receptor antagonist,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GNG2, GRIN2A, GRIN3A, GRIN3B, KCNJ3, KCNJ6, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9, KCNMA1, KCNN4, MT-ND1, NPSR1, RHO",neurology/psychiatry,general anaesthetic,"FC(F)(F)C(Cl)Br, FC(F)(F)C(Cl)Br",Launched
BRD-A20644369-001-08-6::2.5::HTS,BRD-A20644369-001-08-6,canrenone,2.5,HTS,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20758144-001-04-5::2.5::HTS,BRD-A20758144-001-04-5,prasterone-acetate,2.5,HTS,NA,NA,NA,NA,CC(=O)O[C@H]1CC[C@]2(C)C3CC[C@@]4(C)C(CCC4=O)C3CC=C2C1,Preclinical
BRD-A20781140-001-01-7::2.5::HTS,BRD-A20781140-001-01-7,plovamer-acetate,2.5,HTS,NA,"TAT, TH, YARS, YARS2",NA,NA,"NC(Cc1ccc(O)cc1)C(O)=O, NC(Cc1ccc(O)cc1)C(O)=O",Phase 2
BRD-A20839672-003-01-5::2.5::HTS,BRD-A20839672-003-01-5,cefmenoxime,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,Launched
BRD-A21276153-001-01-1::2.5::HTS,BRD-A21276153-001-01-1,"2,6-dimethylpiperidine",2.5,HTS,NA,NA,NA,NA,CC1CCCC(C)N1,Preclinical
BRD-A21607826-003-05-1::2.5::HTS,BRD-A21607826-003-05-1,medetomidine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,sedative,"CC(c1c[nH]cn1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C",Launched
BRD-A21858158-001-23-5::2.5::HTS,BRD-A21858158-001-23-5,praziquantel,2.5,HTS,anthelmintic agent,NA,infectious disease,"gastrointestinal parasites, cystic hydatid disease, schistosomiasis","O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1, O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1",Launched
BRD-A22032524-074-06-5::2.5::HTS,BRD-A22032524-074-06-5,amlodipine,2.5,HTS,calcium channel blocker,"CA1, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1, CACNA2D3, CACNB1, CACNB2, SMPD1",cardiology,"hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)","CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC",Launched
BRD-A22081593-001-11-1::2.5::HTS,BRD-A22081593-001-11-1,sulmazole,2.5,HTS,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22106989-001-05-0::2.5::HTS,BRD-A22106989-001-05-0,phenothrin,2.5,HTS,NA,NA,infectious disease,lice,"CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C, CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C",Launched
BRD-A22143024-231-03-8::2.5::HTS,BRD-A22143024-231-03-8,estropipate,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2","orthopedics, endocrinology, obstetrics/gynecology","osteoporosis, menopause, vaginal atrophy, hypoestrogenism",C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O,Launched
BRD-A22152765-003-10-0::2.5::HTS,BRD-A22152765-003-10-0,tridihexethyl,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3","gastroenterology, ophthalmology","peptic ulcer disease (PUD), nystagmus",CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A22256192-003-22-7::2.5::HTS,BRD-A22256192-003-22-7,terazosin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1",Launched
BRD-A22267103-003-13-1::2.5::HTS,BRD-A22267103-003-13-1,drofenine,2.5,HTS,NA,NA,neurology/psychiatry,spasms,CCN(CC)CCOC(=O)C(C1CCCCC1)c1ccccc1,Launched
BRD-A22305049-003-13-6::2.5::HTS,BRD-A22305049-003-13-6,benfluorex,2.5,HTS,gluconeogenesis inhibitor,HMGCR,NA,NA,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1,Withdrawn
BRD-A22380646-236-05-8::2.51::HTS,BRD-A22380646-236-05-8,pantoprazole,2.51,HTS,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome","COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC",Launched
BRD-A22642447-001-01-9::2.5::HTS,BRD-A22642447-001-01-9,licarbazepine,2.5,HTS,voltage-gated sodium channel blocker,SCN5A,NA,NA,"NC(=O)N1c2ccccc2CC(O)c2ccccc12, NC(=O)N1c2ccccc2CC(O)c2ccccc12",Phase 3
BRD-A22707317-001-10-8::2.5::HTS,BRD-A22707317-001-10-8,SB-205384,2.5,HTS,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22769835-300-05-7::2.5::HTS,BRD-A22769835-300-05-7,homochlorcyclizine,2.5,HTS,antihistamine,HRH1,allergy,allergic rhinitis,CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-A22844106-001-26-0::2.5::HTS,BRD-A22844106-001-26-0,tenoxicam,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, orthopedics","rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O",Launched
BRD-A23067620-300-01-3::2.5::HTS,BRD-A23067620-300-01-3,itraconazole,2.5,HTS,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23072235-050-18-5::2.5::HTS,BRD-A23072235-050-18-5,pheniramine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23127772-001-02-3::2.5::HTS,BRD-A23127772-001-02-3,sclareol,2.5,HTS,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23359898-003-10-0::2.5::HTS,BRD-A23359898-003-10-0,sibutramine,2.5,HTS,serotonin-norepinephrine reuptake inhibitor (SNRI),"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A23603052-001-03-2::2.5::HTS,BRD-A23603052-001-03-2,rifampin,2.5,HTS,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-A24122750-001-03-7::2.5::HTS,BRD-A24122750-001-03-7,saclofen,2.5,HTS,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,NCC(CS(O)(=O)=O)c1ccc(Cl)cc1,Preclinical
BRD-A24191444-046-02-1::2.5::HTS,BRD-A24191444-046-02-1,ifenprodil,2.5,HTS,"adrenergic receptor antagonist, glutamate receptor antagonist","GRIN1, GRIN2B",NA,NA,"CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1",Launched
BRD-A24191444-046-03-9::2.4::HTS,BRD-A24191444-046-03-9,ifenprodil,2.4,HTS,"adrenergic receptor antagonist, glutamate receptor antagonist","GRIN1, GRIN2B",NA,NA,"CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1",Launched
BRD-A24228527-213-01-9::2.5::HTS,BRD-A24228527-213-01-9,ofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, otolaryngology, gastroenterology, endocrinology","respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections","CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24284985-001-09-9::2.5::HTS,BRD-A24284985-001-09-9,anabasine,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,C1CCC(NC1)c1cccnc1,Preclinical
BRD-A24297246-001-03-9::2.5::HTS,BRD-A24297246-001-03-9,troleandomycin,2.5,HTS,protein synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, tonsillitis, sinusitis",CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Launched
BRD-A24397426-001-10-4::2.5::HTS,BRD-A24397426-001-10-4,nadifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24514565-001-09-7::2.5::HTS,BRD-A24514565-001-09-7,warfarin,2.5,HTS,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24543851-001-05-7::2.5::HTS,BRD-A24543851-001-05-7,nornicotine,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,C1CNC(C1)c1cccnc1,Preclinical
BRD-A24560335-300-01-2::2.5::HTS,BRD-A24560335-300-01-2,efatutazone,2.5,HTS,PPAR receptor agonist,PPARG,NA,NA,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N,Phase 2
BRD-A24587114-066-22-5::2.5::HTS,BRD-A24587114-066-22-5,isoetharine,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A25004090-001-08-4::2.5::HTS,BRD-A25004090-001-08-4,erastin,2.5,HTS,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25143711-001-02-2::2.5::HTS,BRD-A25143711-001-02-2,hydrocortisone-valerate,2.5,HTS,glucocorticoid receptor agonist,NA,dermatology,corticosteroid-responsive dermatoses,CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO,Launched
BRD-A25234499-001-18-3::2.5::HTS,BRD-A25234499-001-18-3,aminoglutethimide,2.5,HTS,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25569250-001-03-3::2.5::HTS,BRD-A25569250-001-03-3,KI-16425,2.5,HTS,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25608658-001-01-1::2.5::HTS,BRD-A25608658-001-01-1,narasin,2.5,HTS,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25619068-003-03-4::2.5::HTS,BRD-A25619068-003-03-4,fadrozole,2.5,HTS,aromatase inhibitor,"CYP11B1, CYP19A1",oncology,breast cancer,N#Cc1ccc(cc1)C1CCCc2cncn12,Launched
BRD-A25687296-300-04-3::2.5::HTS,BRD-A25687296-300-04-3,emetine,2.5,HTS,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25800195-001-02-2::2.5::HTS,BRD-A25800195-001-02-2,L-Cysteinesulfinic-acid,2.5,HTS,glutamate receptor agonist,"GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2",NA,NA,N[C@@H](CS(O)=O)C(O)=O,Preclinical
BRD-A26032986-050-02-1::2.5::HTS,BRD-A26032986-050-02-1,zaldaride,2.5,HTS,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26334849-001-06-2::2.5::HTS,BRD-A26334849-001-06-2,propafenone,2.5,HTS,antiarrhythmic,"ADRB1, ADRB2, KCNA5, KCNH2, SCN5A",cardiology,"atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias","CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1, CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1",Launched
BRD-A26384407-001-25-1::2.5::HTS,BRD-A26384407-001-25-1,chlorthalidone,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA4, CA7, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure",NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12,Launched
BRD-A26387268-050-04-4::2.5::HTS,BRD-A26387268-050-04-4,ergonovine,2.5,HTS,"adrenergic receptor agonist, serotonin receptor agonist","ADRA1A, HTR1E",hematology,postpartum hemorrhage (PPH),CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,Launched
BRD-A26503646-001-16-6::2.5::HTS,BRD-A26503646-001-16-6,formestane,2.5,HTS,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26690767-066-01-9::2.5::HTS,BRD-A26690767-066-01-9,saquinavir,2.5,HTS,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1",Launched
BRD-A26711594-003-10-6::2.5::HTS,BRD-A26711594-003-10-6,nicardipine,2.5,HTS,calcium channel blocker,"ADORA3, ADRA1A, ADRA1B, ADRA1D, CACNA1C, CACNA1D, CACNA2D1, CACNB2, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, PDE1A, PDE1B",cardiology,"chronic stable angina, hypertension","COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1",Launched
BRD-A26845397-051-01-9::2.5::HTS,BRD-A26845397-051-01-9,isamoltane,2.5,HTS,adrenergic receptor antagonist,"HTR1A, HTR1B",NA,NA,CC(C)NCC(O)COc1ccccc1-n1cccc1,Phase 1
BRD-A27143604-001-02-0::2.5::HTS,BRD-A27143604-001-02-0,diarylpropionitrile,2.5,HTS,estrogen receptor agonist,ESR2,NA,NA,Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1,Preclinical
BRD-A27290375-330-01-1::2.5::HTS,BRD-A27290375-330-01-1,atropine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,"cycloplegia, mydriasis, amblyopia","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1",Launched
BRD-A27370296-001-03-0::2.5::HTS,BRD-A27370296-001-03-0,cyclandelate,2.5,HTS,calcium channel blocker,"CACNA2D1, CES1","cardiology, rheumatology","claudication, arteriosclerosis, Raynaud's disease","CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1",Launched
BRD-A27376179-001-01-3::2.5::HTS,BRD-A27376179-001-01-3,lestaurtinib,2.5,HTS,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27732521-003-08-3::2.5::HTS,BRD-A27732521-003-08-3,tolperisone,2.5,HTS,voltage-gated sodium channel blocker,"CYP2C19, CYP2D6","neurology/psychiatry, infectious disease, rheumatology, cardiology","muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease","CC(CN1CCCCC1)C(=O)c1ccc(C)cc1, CC(CN1CCCCC1)C(=O)c1ccc(C)cc1",Launched
BRD-A27883417-300-01-6::2.5::HTS,BRD-A27883417-300-01-6,alexidine,2.5,HTS,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27887842-001-04-0::2.5::HTS,BRD-A27887842-001-04-0,prednisolone,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27924917-001-03-3::2.5::HTS,BRD-A27924917-001-03-3,2-hydroxysaclofen,2.5,HTS,GABA receptor antagonist,"GABBR1, GABBR2",NA,NA,NCC(O)(CS(O)(=O)=O)c1ccc(Cl)cc1,Preclinical
BRD-A28044053-001-01-7::2.5::HTS,BRD-A28044053-001-01-7,arotinolol,2.5,HTS,adrenergic receptor antagonist,ADRB3,"cardiology, neurology/psychiatry","hypertension, tremors",CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O,Launched
BRD-A28301258-001-03-0::2.5::HTS,BRD-A28301258-001-03-0,salinomycin,2.5,HTS,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-04-8::2.5::HTS,BRD-A28301258-001-04-8,salinomycin,2.5,HTS,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28318179-003-08-5::2.5::HTS,BRD-A28318179-003-08-5,aminomethyltransferase,2.5,HTS,nitric oxide synthase inhibitor,NOS2,NA,NA,CC1CCN=C(N)S1,Preclinical
BRD-A28329383-001-02-1::2.5::HTS,BRD-A28329383-001-02-1,MTPG,2.5,HTS,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28467416-002-01-0::2.5::HTS,BRD-A28467416-002-01-0,PKI-179,2.5,HTS,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28545468-003-16-6::2.5::HTS,BRD-A28545468-003-16-6,selegiline,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,Parkinson's Disease,CC(Cc1ccccc1)N(C)CC#C,Launched
BRD-A28856712-003-26-0::2.5::HTS,BRD-A28856712-003-26-0,tetrahydrozoline,2.5,HTS,adrenergic receptor agonist,NA,ophthalmology,eye irritation,"C1CN=C(N1)C1CCCc2ccccc12, C1CN=C(N1)C1CCCc2ccccc12",Launched
BRD-A28887267-001-19-3::2.5::HTS,BRD-A28887267-001-19-3,proxyphylline,2.5,HTS,NA,NA,pulmonary,asthma,CC(O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12,Launched
BRD-A28940325-001-24-0::2.5::HTS,BRD-A28940325-001-24-0,trichlormethiazide,2.5,HTS,chloride channel blocker,"ATP1A1, CA1, CA2, CA4, SLC12A1, SLC12A3",cardiology,"hypertension, edema","NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl",Launched
BRD-A28958257-001-01-2::2.5::HTS,BRD-A28958257-001-01-2,centpropazine,2.5,HTS,inositol monophosphatase inhibitor,NA,NA,NA,"CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1, CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1",Phase 3
BRD-A28970875-300-04-9::2.5::HTS,BRD-A28970875-300-04-9,puromycin,2.5,HTS,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A29111201-001-04-8::2.5::HTS,BRD-A29111201-001-04-8,ethisterone,2.5,HTS,progestogen hormone,TYR,NA,NA,"CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-A29260609-003-26-0::2.5::HTS,BRD-A29260609-003-26-0,acebutolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, ventricular arrhythmias","CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O",Launched
BRD-A29281099-003-03-2::2.5::HTS,BRD-A29281099-003-03-2,clorprenaline,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,asthma,CC(C)NCC(O)c1ccccc1Cl,Launched
BRD-A29289453-001-04-7::2.5::HTS,BRD-A29289453-001-04-7,PCA-4248,2.5,HTS,platelet activating factor receptor antagonist,PTAFR,NA,NA,"COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1",Phase 1
BRD-A29349577-001-23-0::2.5::HTS,BRD-A29349577-001-23-0,dropropizine,2.5,HTS,antitussive,NA,pulmonary,cough suppressant,"OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1",Launched
BRD-A29426959-050-13-2::2.5::HTS,BRD-A29426959-050-13-2,carbinoxamine,2.5,HTS,histamine receptor antagonist,HRH1,"allergy, ophthalmology, otolaryngology, dermatology","allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism",CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,Launched
BRD-A29485665-001-12-8::2.5::HTS,BRD-A29485665-001-12-8,bicalutamide,2.5,HTS,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29520968-001-02-7::2.5::HTS,BRD-A29520968-001-02-7,acifran,2.5,HTS,cholesterol inhibitor,"HCAR2, HCAR3",NA,NA,"CC1(OC(=CC1=O)C(O)=O)c1ccccc1, CC1(OC(=CC1=O)C(O)=O)c1ccccc1",Phase 3
BRD-A29623586-001-01-3::2.5::HTS,BRD-A29623586-001-01-3,anisodamine,2.5,HTS,lipid peroxidase inhibitor,ADRA1A,NA,NA,CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1,Phase 3
BRD-A29644307-050-17-0::2.5::HTS,BRD-A29644307-050-17-0,nomifensine,2.5,HTS,"dopamine uptake inhibitor, noradrenaline uptake inhibitor","DRD2, MAOA, MAOB, MPO, SLC6A2, SLC6A3",NA,NA,"CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1",Withdrawn
BRD-A29700858-304-01-8::2.5::HTS,BRD-A29700858-304-01-8,carbenoxolone,2.5,HTS,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation","CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O",Launched
BRD-A29700858-304-02-6::2.5::HTS,BRD-A29700858-304-02-6,carbenoxolone,2.5,HTS,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation","CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O",Launched
BRD-A29731977-001-04-5::2.5::HTS,BRD-A29731977-001-04-5,17-hydroxyprogesterone-caproate,2.5,HTS,progesterone receptor agonist,"AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR",NA,NA,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,Launched
BRD-A29734509-011-13-6::2.5::HTS,BRD-A29734509-011-13-6,disopyramide,2.5,HTS,sodium channel blocker,"CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A",cardiology,"ventricular tachycardia (VT), ventricular arrhythmias","CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C",Launched
BRD-A29844814-300-01-5::2.5::HTS,BRD-A29844814-300-01-5,ABT-202,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,NC1CCN(C1)c1cccnc1,Phase 1
BRD-A29854054-236-12-6::2.5::HTS,BRD-A29854054-236-12-6,lorglumide,2.5,HTS,CCK receptor antagonist,"CCKAR, CCKBR",NA,NA,CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,Phase 1
BRD-A29944538-003-08-3::2.5::HTS,BRD-A29944538-003-08-3,proxodolol,2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1,Launched
BRD-A30051119-002-01-8::2.5::HTS,BRD-A30051119-002-01-8,amikacin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)C1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O",Launched
BRD-A30205217-001-11-2::2.5::HTS,BRD-A30205217-001-11-2,ethotoin,2.5,HTS,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"CCN1C(=O)NC(C1=O)c1ccccc1, CCN1C(=O)NC(C1=O)c1ccccc1",Launched
BRD-A30403214-001-03-3::0.25::HTS,BRD-A30403214-001-03-3,edelfosine,0.25,HTS,phospholipase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC",Phase 2
BRD-A30582499-003-05-1::2.5::HTS,BRD-A30582499-003-05-1,tiletamine,2.5,HTS,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30590053-003-02-9::2.5::HTS,BRD-A30590053-003-02-9,MR-16728,2.5,HTS,acetylcholine release enhancer,NA,NA,NA,O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1,Preclinical
BRD-A30655177-001-14-0::2.5::HTS,BRD-A30655177-001-14-0,LFM-A13,2.5,HTS,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,Preclinical
BRD-A30693873-003-12-8::2.5::HTS,BRD-A30693873-003-12-8,diperodon,2.5,HTS,local anesthetic,NA,NA,NA,"O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1, O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1",Preclinical
BRD-A30703952-201-01-2::2.5::HTS,BRD-A30703952-201-01-2,ganglioside-gm1,2.5,HTS,NA,NA,NA,NA,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(CC(O)C(NC(C)=O)C(O3)C(O)C(O)CO)C(O)=O)C2O)C(O)C1O)[C@H](O)\C=C\CCCCCCCCCCCCC,Phase 2
BRD-A30815329-001-10-5::2.5::HTS,BRD-A30815329-001-10-5,felodipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CALM1, CFTR, NR3C2, PDE1A, PDE1B, TNNC1, TNNC2",cardiology,hypertension,"CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC",Launched
BRD-A30886737-001-02-9::2.5::HTS,BRD-A30886737-001-02-9,florfenicol,2.5,HTS,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30984645-001-01-5::2.5::HTS,BRD-A30984645-001-01-5,GDC-0834,2.5,HTS,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,"CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1, CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1",Phase 1
BRD-A31095847-001-02-3::2.5::HTS,BRD-A31095847-001-02-3,mozavaptan,2.5,HTS,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31159102-003-30-4::2.5::HTS,BRD-A31159102-003-30-4,fluoxetine,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"ANO1, HTR2B, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder","CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1",Launched
BRD-A31454688-001-01-6::2.5::HTS,BRD-A31454688-001-01-6,monostearin,2.5,HTS,NA,NA,NA,NA,CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO,Preclinical
BRD-A31521121-001-26-4::2.5::HTS,BRD-A31521121-001-26-4,methocarbamol,2.5,HTS,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31564021-001-01-8::2.5::HTS,BRD-A31564021-001-01-8,isoflurane,2.5,HTS,inhaled anaesthetic,"ATP2C1, ATP5D, CALM1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9",neurology/psychiatry,general anaesthetic,"FC(F)OC(Cl)C(F)(F)F, FC(F)OC(Cl)C(F)(F)F",Launched
BRD-A31800922-003-25-1::2.5::HTS,BRD-A31800922-003-25-1,procyclidine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,"parkinsonism, Parkinson's Disease, akathisia, dystonia","OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1, OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1",Launched
BRD-A31811760-001-06-7::2.5::HTS,BRD-A31811760-001-06-7,miltefosine,2.5,HTS,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis,CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C,Launched
BRD-A31990649-304-02-3::2.5::HTS,BRD-A31990649-304-02-3,adenosine-triphosphate,2.5,HTS,adenosine receptor agonist,"ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7",NA,NA,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",Phase 2
BRD-A32172948-001-07-6::2.5::HTS,BRD-A32172948-001-07-6,methiopril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,NA,NA,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O,Phase 2
BRD-A32269193-001-01-5::2.5::HTS,BRD-A32269193-001-01-5,VGX-1027,2.5,HTS,tumor necrosis factor receptor antagonist,TLR4,NA,NA,OC(=O)CC1CC(=NO1)c1ccccc1,Phase 1
BRD-A32505112-001-04-4::2.5::HTS,BRD-A32505112-001-04-4,trandolapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction",CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O,Launched
BRD-A32597168-001-03-6::2.5::HTS,BRD-A32597168-001-03-6,letosteine,2.5,HTS,mucolytic agent,NA,"pulmonary, infectious disease","bronchitis, pneumonia",CCOC(=O)CSCCC1NC(CS1)C(O)=O,Launched
BRD-A32673558-003-03-9::2.5::HTS,BRD-A32673558-003-03-9,aceclidine,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,glaucoma,"CC(=O)OC1CN2CCC1CC2, CC(=O)OC1CN2CCC1CC2, CC(=O)OC1CN2CCC1CC2",Launched
BRD-A32988684-003-08-7::2.5::HTS,BRD-A32988684-003-08-7,heptaminol,2.5,HTS,vasoconstrictor,NA,cardiology,hypotension,CC(N)CCCC(C)(C)O,Launched
BRD-A33084557-001-06-6::2.5::HTS,BRD-A33084557-001-06-6,tioconazole,2.5,HTS,sterol demethylase inhibitor,CYP51A1,infectious disease,yeast infection,"Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl, Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl",Launched
BRD-A33168282-003-18-0::2.5::HTS,BRD-A33168282-003-18-0,sotalol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, KCNH2",cardiology,"atrial fibrillation (AF), ventricular arrhythmias","CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A33447119-001-10-8::2.5::HTS,BRD-A33447119-001-10-8,oxfendazole,2.5,HTS,anthelmintic agent,NA,infectious disease,"lungworms, tapeworm, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1",Launched
BRD-A33514596-003-01-2::2.5::HTS,BRD-A33514596-003-01-2,N-benzylnaltrindole,2.5,HTS,opioid receptor antagonist,NA,NA,NA,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1,Preclinical
BRD-A33692381-001-01-9::2.5::HTS,BRD-A33692381-001-01-9,zidovudine,2.5,HTS,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,"human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)","Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O",Launched
BRD-A33697453-008-02-4::2.5::HTS,BRD-A33697453-008-02-4,fenticonazole,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,vulvovaginal candidiasis,Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1,Launched
BRD-A33711280-003-03-1::2.5::HTS,BRD-A33711280-003-03-1,metixene,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",neurology/psychiatry,Parkinson's Disease,CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1,Launched
BRD-A34006693-001-15-4::2.5::HTS,BRD-A34006693-001-15-4,suprofen,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,"CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1, CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1",Withdrawn
BRD-A34205397-001-04-5::2.5::HTS,BRD-A34205397-001-04-5,suloctidil,2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,Withdrawn
BRD-A34255068-001-34-5::2.5::HTS,BRD-A34255068-001-34-5,rolipram,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,"COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1",Phase 3
BRD-A34358106-003-01-6::2.5::HTS,BRD-A34358106-003-01-6,sarpogrelate,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C","endocrinology, cardiology, rheumatology","diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease","COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1, COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1",Launched
BRD-A34716233-004-03-5::2.5::HTS,BRD-A34716233-004-03-5,AMPA-(RS),2.5,HTS,glutamate receptor agonist,GRIN1,NA,NA,"Cc1onc(O)c1CC(N)C(O)=O, Cc1onc(O)c1CC(N)C(O)=O",Preclinical
BRD-A34751532-001-06-9::2.5::HTS,BRD-A34751532-001-06-9,homosalate,2.5,HTS,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A35379661-001-04-6::2.5::HTS,BRD-A35379661-001-04-6,sphingosylphosphorylcholine,2.5,HTS,gene expression stimulant,GPR12,NA,NA,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C,Preclinical
BRD-A35588707-001-05-5::2.5::HTS,BRD-A35588707-001-05-5,teniposide,2.5,HTS,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35623999-001-05-7::2.5::HTS,BRD-A35623999-001-05-7,CGP-37157,2.5,HTS,"mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor",SLC8A1,NA,NA,"Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1, Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1",Preclinical
BRD-A35868371-005-01-6::2.5::HTS,BRD-A35868371-005-01-6,troventol,2.5,HTS,NA,NA,NA,NA,CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1,Phase 1
BRD-A35912562-001-02-8::2.5::HTS,BRD-A35912562-001-02-8,pregnenolone-succinate,2.5,HTS,GABA receptor negative allosteric modulator,NA,NA,NA,CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O,Preclinical
BRD-A35989968-001-04-2::2.5::HTS,BRD-A35989968-001-04-2,megestrol-acetate,2.5,HTS,progesterone receptor agonist,"NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O",Launched
BRD-A36010170-001-04-0::2.5::HTS,BRD-A36010170-001-04-0,amcinonide,2.5,HTS,glucocorticoid receptor agonist,"ANXA1, NR3C1",dermatology,corticosteroid-responsive dermatoses,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,Launched
BRD-A36057565-001-01-0::2.5::HTS,BRD-A36057565-001-01-0,bruceantin,2.5,HTS,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36074203-003-07-6::2.5::HTS,BRD-A36074203-003-07-6,remacemide,2.5,HTS,glutamate receptor antagonist,GRIN1,NA,NA,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Phase 3
BRD-A36217750-001-16-3::2.5::HTS,BRD-A36217750-001-16-3,sulfinpyrazone,2.5,HTS,uricosuric blocker,"ABCC1, ABCC2, FPR1, SLC22A12",rheumatology,gout,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1,Launched
BRD-A36267905-003-18-4::2.5::HTS,BRD-A36267905-003-18-4,buphenine,2.5,HTS,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36318220-001-08-8::2.5::HTS,BRD-A36318220-001-08-8,necrostatin-1,2.5,HTS,RIPK inhibitor,RIPK1,NA,NA,"CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O",Preclinical
BRD-A36331462-001-02-1::2.5::HTS,BRD-A36331462-001-02-1,oprozomib,2.5,HTS,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36456202-001-01-3::2.5::HTS,BRD-A36456202-001-01-3,colistin-b-sulfate,2.5,HTS,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A37288617-003-02-2::2.5::HTS,BRD-A37288617-003-02-2,amfepramone,2.5,HTS,adrenergic receptor agonist,"SLC6A2, SLC6A3",endocrinology,obesity,CCN(CC)C(C)C(=O)c1ccccc1,Launched
BRD-A37347161-003-02-6::2.5::HTS,BRD-A37347161-003-02-6,BRL-52537,2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl,Preclinical
BRD-A37390343-003-03-5::2.5::HTS,BRD-A37390343-003-03-5,amorolfine,2.5,HTS,membrane integrity inhibitor,NA,infectious disease,onychomycosis,"CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1, CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1",Launched
BRD-A37441042-003-04-8::2.5::HTS,BRD-A37441042-003-04-8,tulobuterol,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,asthma,CC(C)(C)NCC(O)c1ccccc1Cl,Launched
BRD-A37492983-001-10-3::2.5::HTS,BRD-A37492983-001-10-3,iocetamic-acid,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O,Launched
BRD-A37704979-001-10-7::2.5::HTS,BRD-A37704979-001-10-7,SB-203580,2.5,HTS,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF",NA,NA,"CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1",Preclinical
BRD-A38076815-003-10-3::2.5::HTS,BRD-A38076815-003-10-3,glafenine,2.5,HTS,DeltaF508-CFTR Correctors,CFTR,NA,NA,"OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12",Withdrawn
BRD-A38218502-001-01-2::2.5::HTS,BRD-A38218502-001-01-2,metenkephalin,2.5,HTS,immunostimulant,OPRD1,NA,NA,CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-A38350138-001-04-9::2.5::HTS,BRD-A38350138-001-04-9,ketoconazole,2.5,HTS,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38592941-001-02-7::2.5::HTS,BRD-A38592941-001-02-7,timonacic,2.5,HTS,antioxidant,ANXA5,NA,NA,OC(=O)C1CSCN1,Launched
BRD-A38747044-001-02-3::2.5::HTS,BRD-A38747044-001-02-3,KU14R,2.5,HTS,imidazoline receptor antagonist,NA,NA,NA,"CCC1(Cc2ccccc2O1)c1ncc[nH]1, CCC1(Cc2ccccc2O1)c1ncc[nH]1",Preclinical
BRD-A39052811-048-11-0::2.5::HTS,BRD-A39052811-048-11-0,mosapride,2.5,HTS,serotonin receptor agonist,HTR4,gastroenterology,"hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome","CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1, CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1",Launched
BRD-A39189014-003-22-7::2.5::HTS,BRD-A39189014-003-22-7,methoxamine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,"COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N",Launched
BRD-A39230911-001-10-2::2.5::HTS,BRD-A39230911-001-10-2,chlorphensin-carbamate,2.5,HTS,muscle relaxant,NA,NA,NA,NC(=O)OCC(O)COc1ccc(Cl)cc1,Preclinical
BRD-A39255369-001-03-1::2.5::HTS,BRD-A39255369-001-03-1,DCPIB,2.5,HTS,"chloride channel blocker, gap junction modulator, glutamate inhibitor",SLC1A2,NA,NA,CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1,Preclinical
BRD-A39390670-236-10-7::2.5::HTS,BRD-A39390670-236-10-7,rabeprazole,2.5,HTS,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39791822-001-05-1::2.5::HTS,BRD-A39791822-001-05-1,hydroxyprogesterone,2.5,HTS,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth,CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Launched
BRD-A39935389-001-05-9::2.5::HTS,BRD-A39935389-001-05-9,teroxirone,2.5,HTS,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A40084411-003-07-7::2.5::HTS,BRD-A40084411-003-07-7,CGP-12177,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",NA,NA,CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12,Phase 1
BRD-A40413915-003-01-2::2.5::HTS,BRD-A40413915-003-01-2,NTNCB,2.5,HTS,neuropeptide receptor antagonist,NPY5R,NA,NA,[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1,Preclinical
BRD-A40639672-234-18-0::2.5::HTS,BRD-A40639672-234-18-0,ketorolac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,"OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1",Launched
BRD-A40777960-001-04-2::2.5::HTS,BRD-A40777960-001-04-2,aminohydroxybutyric-acid,2.5,HTS,NA,NA,neurology/psychiatry,epilepsy,NCC(O)CC(O)=O,Launched
BRD-A40787240-066-04-6::2.5::HTS,BRD-A40787240-066-04-6,gemifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,"pulmonary, infectious disease","bronchitis, pneumonia",CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,Launched
BRD-A40940854-001-01-1::2.5::HTS,BRD-A40940854-001-01-1,ibuproxam,2.5,HTS,"cyclooxygenase inhibitor, prostaglandin inhibitor",ALOX5,"endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief",CC(C)Cc1ccc(cc1)C(C)C(=O)NO,Launched
BRD-A41250306-001-11-7::2.5::HTS,BRD-A41250306-001-11-7,cyclopenthiazide,2.5,HTS,thiazide diuretic,NA,cardiology,"hypertension, congestive heart failure",NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl,Launched
BRD-A41304429-001-14-8::2.5::HTS,BRD-A41304429-001-14-8,practolol,2.5,HTS,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41385909-001-01-3::2.5::HTS,BRD-A41385909-001-01-3,bornyl-acetate,2.5,HTS,NA,NA,NA,NA,"CC(=O)OC1CC2CCC1(C)C2(C)C, CC(=O)OC1CC2CCC1(C)C2(C)C",Preclinical
BRD-A41450521-075-10-8::2.5::HTS,BRD-A41450521-075-10-8,tosufloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Launched
BRD-A41451487-001-11-2::2.5::HTS,BRD-A41451487-001-11-2,PK-11195,2.5,HTS,benzodiazepine receptor antagonist,TSPO,NA,NA,"CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl, CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl",Phase 1
BRD-A41692738-001-07-6::2.5::HTS,BRD-A41692738-001-07-6,TGX-221,2.5,HTS,PI3K inhibitor,"PIK3CB, PIK3CD",NA,NA,"CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Preclinical
BRD-A41714661-001-02-0::2.5::HTS,BRD-A41714661-001-02-0,bilobalide,2.5,HTS,GABA receptor modulator,"GLRA1, GLRA2, GLRB, HTR3A, HTR3B",NA,NA,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123,Preclinical
BRD-A41774846-001-01-4::2.5::HTS,BRD-A41774846-001-01-4,algestone-acetophenide,2.5,HTS,NA,NA,endocrinology,contraceptive,CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1,Launched
BRD-A41995253-001-04-5::2.5::HTS,BRD-A41995253-001-04-5,brucine,2.5,HTS,glycine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",NA,NA,"COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC",Preclinical
BRD-A42167015-003-10-2::2.5::HTS,BRD-A42167015-003-10-2,carteolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,Launched
BRD-A42270467-001-04-4::2.5::HTS,BRD-A42270467-001-04-4,tenatoprazole,2.5,HTS,ATPase inhibitor,IDO1,NA,NA,COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C,Phase 2
BRD-A42553870-001-14-3::2.5::HTS,BRD-A42553870-001-14-3,L-152804,2.5,HTS,neuropeptide receptor antagonist,NPY5R,NA,NA,"CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1, CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1",Preclinical
BRD-A42571354-300-12-0::2.5::HTS,BRD-A42571354-300-12-0,cetirizine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1",Launched
BRD-A42628519-001-12-4::2.5::HTS,BRD-A42628519-001-12-4,iopanic-acid,2.5,HTS,thyroid hormone inhibitor,NA,NA,NA,CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O,Preclinical
BRD-A42699921-001-02-8::2.5::HTS,BRD-A42699921-001-02-8,teriflunomide,2.5,HTS,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::2.6::HTS,BRD-A42699921-001-03-6,teriflunomide,2.6,HTS,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42746051-001-02-9::2.5::HTS,BRD-A42746051-001-02-9,melengestrol-acetate,2.5,HTS,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42759514-001-20-5::2.5::HTS,BRD-A42759514-001-20-5,ornidazole,2.5,HTS,antiprotozoal agent,NA,infectious disease,protozoan infection,"Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O",Launched
BRD-A43082461-001-06-3::2.5::HTS,BRD-A43082461-001-06-3,linalool,2.5,HTS,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082555-001-01-1::2.5::HTS,BRD-A43082555-001-01-1,loxoprofen,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist",PTGS2,neurology/psychiatry,pain relief,"CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1, CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1",Launched
BRD-A43082555-001-02-9::2.5::HTS,BRD-A43082555-001-02-9,loxoprofen,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist",PTGS2,neurology/psychiatry,pain relief,"CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1, CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1",Launched
BRD-A43435802-001-02-0::2.5::HTS,BRD-A43435802-001-02-0,mercaptosuccinic-acid,2.5,HTS,NA,NA,NA,NA,"OC(=O)CC(S)C(O)=O, OC(=O)CC(S)C(O)=O",Launched
BRD-A43598550-001-09-4::2.5::HTS,BRD-A43598550-001-09-4,3-alpha-Hydroxy-5-beta-androstan-17-one,2.5,HTS,NA,NA,NA,NA,C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-A43671941-003-11-9::2.5::HTS,BRD-A43671941-003-11-9,oxprenolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43809092-003-02-1::2.5::HTS,BRD-A43809092-003-02-1,clobutinol,2.5,HTS,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43882281-001-15-5::2.5::HTS,BRD-A43882281-001-15-5,pinacidil,2.5,HTS,"ATP channel activator, potassium channel activator","ABCC8, ABCC9",cardiology,hypertension,"CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C, CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C",Launched
BRD-A43885598-001-08-1::2.5::HTS,BRD-A43885598-001-08-1,SID-7969543,2.5,HTS,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43930669-003-02-8::2.5::HTS,BRD-A43930669-003-02-8,L-368899,2.5,HTS,oxytocin receptor antagonist,"AVPR1A, AVPR2, OXTR",NA,NA,"Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C, Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C",Phase 1
BRD-A43999749-004-04-1::2.5::HTS,BRD-A43999749-004-04-1,homatropine-methylbromide,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,uveal tract inflammation,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,Launched
BRD-A44008656-036-25-8::2.5::HTS,BRD-A44008656-036-25-8,doxylamine,2.5,HTS,histamine receptor antagonist,"CHRM1, HRH1",neurology/psychiatry,sedative,"CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1",Launched
BRD-A44090213-001-25-6::2.5::HTS,BRD-A44090213-001-25-6,indoprofen,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44133049-003-07-8::2.5::HTS,BRD-A44133049-003-07-8,azasetron,2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B",infectious disease,genitial herpes,CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2,Launched
BRD-A44448661-001-04-8::2.5::HTS,BRD-A44448661-001-04-8,pentobarbital,2.5,HTS,"barbiturate antiepileptic, GABA receptor modulator","CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",NA,NA,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,Withdrawn
BRD-A44500574-001-01-8::2.5::HTS,BRD-A44500574-001-01-8,FLI-06,2.5,HTS,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44696962-001-01-4::2.5::HTS,BRD-A44696962-001-01-4,acetyl-11-keto-beta-boswellic-acid,2.5,HTS,lipoxygenase inhibitor,"HSD11B1, HSD11B2",NA,NA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C,Phase 2
BRD-A44863528-001-13-2::2.5::HTS,BRD-A44863528-001-13-2,proglumide,2.5,HTS,CCK receptor antagonist,"CCKAR, CCKBR",NA,NA,CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1,Withdrawn
BRD-A44936478-001-01-1::2.5::HTS,BRD-A44936478-001-01-1,cephalosporin-c-zn,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O,Preclinical
BRD-A45044890-236-02-3::2.5::HTS,BRD-A45044890-236-02-3,methylprednisolone-sodium-succinate,2.5,HTS,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry","hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis",C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12,Launched
BRD-A45107007-001-03-4::2.5::HTS,BRD-A45107007-001-03-4,salubrinal,2.5,HTS,eukaryotic translation initiation factor inhibitor,EIF2S1,NA,NA,"ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12",Preclinical
BRD-A45153512-001-01-0::2.5::HTS,BRD-A45153512-001-01-0,bimatoprost,2.5,HTS,prostanoid receptor agonist,"AKR1C3, PTGER1, PTGER3, PTGFR",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1,Launched
BRD-A45498368-001-07-1::2.5::HTS,BRD-A45498368-001-07-1,WYE-125132,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45543382-001-10-0::2.5::HTS,BRD-A45543382-001-10-0,metrizamide,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I,Launched
BRD-A45869167-001-10-0::2.5::HTS,BRD-A45869167-001-10-0,sal003,2.5,HTS,eukaryotic translation initiation factor inhibitor,EIF2A,NA,NA,"Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1, Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1, Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1",Preclinical
BRD-A45889380-300-07-1::2.5::HTS,BRD-A45889380-300-07-1,mepacrine,2.5,HTS,"cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator","PLA2G1B, PLA2G4A, PLA2G6, PLCL1",infectious disease,giardiasis,"CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12",Launched
BRD-A45906415-001-01-9::2.5::HTS,BRD-A45906415-001-01-9,K-MAP,2.5,HTS,NA,NA,NA,NA,OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C(O)C1O,Phase 2
BRD-A46066006-004-22-6::2.5::HTS,BRD-A46066006-004-22-6,clidinium,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM3",gastroenterology,"peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis",C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1,Launched
BRD-A46179541-311-02-0::2.5::HTS,BRD-A46179541-311-02-0,doxapram,2.5,HTS,potassium channel blocker,"KCNK3, KCNK9","pulmonary, neurology/psychiatry","respiratory depression, central nervous system depression, acute hypercapnia (AHC)","CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1, CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1",Launched
BRD-A46186775-369-02-0::2.5::HTS,BRD-A46186775-369-02-0,hydrocortisone-phosphate,2.5,HTS,NA,"ANXA1, NOS2, NR3C1","pulmonary, gastroenterology, hematologic malignancy, ophthalmology","asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis",CC12C[C@H](O)C3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O,Launched
BRD-A46393198-003-16-6::2.5::HTS,BRD-A46393198-003-16-6,tetramisole,2.5,HTS,immunostimulant,NA,infectious disease,gastrointestinal parasites,"C1CN2CC(N=C2S1)c1ccccc1, C1CN2CC(N=C2S1)c1ccccc1",Launched
BRD-A46717658-236-02-5::2.5::HTS,BRD-A46717658-236-02-5,azlocillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-A46813902-001-01-6::2.5::HTS,BRD-A46813902-001-01-6,iododexetimide,2.5,HTS,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46876182-003-02-8::2.5::HTS,BRD-A46876182-003-02-8,levobunolol-(+/-),2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12,Preclinical
BRD-A47342814-003-01-8::2.5::HTS,BRD-A47342814-003-01-8,naltrindole,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O",Preclinical
BRD-A47364545-003-02-6::2.5::HTS,BRD-A47364545-003-02-6,SK&F-10047-(+),2.5,HTS,sigma receptor agonist,SIGMAR1,NA,NA,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,Phase 1
BRD-A47449001-004-13-7::2.5::HTS,BRD-A47449001-004-13-7,ipratropium,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1",Launched
BRD-A47494775-003-11-3::2.5::HTS,BRD-A47494775-003-11-3,dipivefrine,2.5,HTS,adrenergic receptor agonist,"ACHE, ADRA1A, ADRA2A, ADRB2, BCHE",ophthalmology,"glaucoma, intraocular pressure",CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,Launched
BRD-A47598013-004-16-0::2.5::HTS,BRD-A47598013-004-16-0,citalopram,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"SLC6A2, SLC6A4",neurology/psychiatry,depression,"CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1",Launched
BRD-A47706533-001-02-6::2.5::HTS,BRD-A47706533-001-02-6,buthionine-sulfoximine,2.5,HTS,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47790386-001-03-6::2.61::HTS,BRD-A47790386-001-03-6,balofloxacin,2.61,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,gram-negative bacterial infections,"CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1, CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1",Launched
BRD-A47884604-051-01-2::2.5::HTS,BRD-A47884604-051-01-2,cyanopindolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, HTR1A, HTR1D",NA,NA,CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C#N,Phase 2
BRD-A47953250-001-01-7::2.5::HTS,BRD-A47953250-001-01-7,ecamsule-triethanolamine,2.5,HTS,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A48015106-004-08-9::2.5::HTS,BRD-A48015106-004-08-9,8-hydroxy-DPAT,2.5,HTS,serotonin receptor agonist,"CDK1, CHEK1, CHEK2, GSK3B, HTR5A, HTR7, LCK, MAPK14, MARK1, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",NA,NA,CCCN(CCC)C1CCc2cccc(O)c2C1,Preclinical
BRD-A48180038-003-24-3::2.5::HTS,BRD-A48180038-003-24-3,trihexyphenidyl,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",neurology/psychiatry,parkinsonism,OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1,Launched
BRD-A48237631-001-04-8::2.5::HTS,BRD-A48237631-001-04-8,mitomycin-c,2.5,HTS,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48261811-001-08-1::2.5::HTS,BRD-A48261811-001-08-1,argatroban,2.5,HTS,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT),"C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12",Launched
BRD-A48300215-001-04-8::2.5::HTS,BRD-A48300215-001-04-8,ajmaline,2.5,HTS,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48430263-003-17-2::2.5::HTS,BRD-A48430263-003-17-2,pioglitazone,2.5,HTS,"insulin sensitizer, PPAR receptor agonist","PPARG, TRPM3",endocrinology,diabetes mellitus,"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1",Launched
BRD-A48720949-001-04-0::2.5::HTS,BRD-A48720949-001-04-0,testosterone-propionate,2.5,HTS,androgen receptor agonist,AR,NA,NA,CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Launched
BRD-A49035384-003-28-9::2.39::HTS,BRD-A49035384-003-28-9,methacycline,2.39,HTS,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-30-5::2.5::HTS,BRD-A49035384-003-30-5,methacycline,2.5,HTS,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49046702-003-08-3::2.5::HTS,BRD-A49046702-003-08-3,SKF-89976A,2.5,HTS,GABA uptake inhibitor,SLC6A1,NA,NA,"OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1, OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1",Preclinical
BRD-A49160188-003-12-7::2.5::HTS,BRD-A49160188-003-12-7,donepezil,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, HTR2A",neurology/psychiatry,Alzheimer's disease,"COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC, COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC",Launched
BRD-A49172652-001-27-1::2.5::HTS,BRD-A49172652-001-27-1,lansoprazole,2.5,HTS,ATPase inhibitor,"ATP4A, ATP4B",gastroenterology,heartburn,"Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1",Launched
BRD-A49225603-045-10-0::2.5::HTS,BRD-A49225603-045-10-0,alimemazine,2.5,HTS,histamine receptor agonist,HRH1,neurology/psychiatry,sedative,CC(CN(C)C)CN1c2ccccc2Sc2ccccc12,Launched
BRD-A49358627-001-14-6::2.5::HTS,BRD-A49358627-001-14-6,ciprofibrate,2.5,HTS,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49399758-015-01-8::2.5::HTS,BRD-A49399758-015-01-8,desmopressin-acetate,2.5,HTS,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR","endocrinology, urology","central diabetes insipidus, nocturnal enuresis",NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O,Launched
BRD-A49447682-001-02-4::2.5::HTS,BRD-A49447682-001-02-4,desoximetasone,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,Launched
BRD-A49544621-003-02-8::2.5::HTS,BRD-A49544621-003-02-8,AC-7954-(+/-),2.5,HTS,urotensin receptor agonist,UTS2R,NA,NA,"CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1, CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1",Preclinical
BRD-A49622760-001-01-9::2.5::HTS,BRD-A49622760-001-01-9,faropenem,2.5,HTS,lactamase inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis",CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O,Launched
BRD-A49765801-001-04-1::2.5::HTS,BRD-A49765801-001-04-1,fludroxycortide,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49838158-001-01-1::2.5::HTS,BRD-A49838158-001-01-1,phenprocoumon,2.5,HTS,vitamin K antagonist,VKORC1,hematology,"thrombosis, pulmonary embolism (PE)",CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A49906757-004-09-8::2.5::HTS,BRD-A49906757-004-09-8,scopolamine-n-oxide,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI",NA,NA,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,Preclinical
BRD-A50028488-001-01-6::2.5::HTS,BRD-A50028488-001-01-6,TCS2002,2.5,HTS,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1, Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1",Preclinical
BRD-A50049929-001-01-9::2.5::HTS,BRD-A50049929-001-01-9,oxazepam,2.5,HTS,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50064262-001-04-7::2.5::HTS,BRD-A50064262-001-04-7,flumethasone-pivalate,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50157456-065-20-6::2.5::HTS,BRD-A50157456-065-20-6,terbutaline,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50311610-300-10-4::2.5::HTS,BRD-A50311610-300-10-4,meclizine,2.5,HTS,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50675702-001-07-1::2.5::HTS,BRD-A50675702-001-07-1,fipronil,2.5,HTS,"chloride channel blocker, GABA gated chloride channel blocker",NA,NA,NA,Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)S(=O)C(F)(F)F,Launched
BRD-A50684349-003-02-9::2.5::HTS,BRD-A50684349-003-02-9,fenoldopam,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD4, DRD5",cardiology,hypertension,"Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12, Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12",Launched
BRD-A50737080-001-03-0::2.5::HTS,BRD-A50737080-001-03-0,CGK-733,2.5,HTS,"ATM kinase inhibitor, ATR kinase inhibitor","ATM, ATR",NA,NA,"[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F",Preclinical
BRD-A50764878-003-02-8::2.5::HTS,BRD-A50764878-003-02-8,MDL-73005EF,2.5,HTS,serotonin receptor antagonist,HTR1A,NA,NA,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,Phase 1
BRD-A50922295-001-01-3::2.5::HTS,BRD-A50922295-001-01-3,valganciclovir,2.5,HTS,DNA synthesis inhibitor,NA,infectious disease,cytomegalovirus (CMV),"CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O",Launched
BRD-A50998626-001-02-1::2.5::HTS,BRD-A50998626-001-02-1,palomid-529,2.5,HTS,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A51078674-003-01-0::2.5::HTS,BRD-A51078674-003-01-0,diclofensine,2.5,HTS,dopamine reuptake inhibitor,"DRD1, MAOA, MAOB",NA,NA,COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1,Phase 3
BRD-A51355958-003-01-9::2.5::HTS,BRD-A51355958-003-01-9,nebracetam,2.5,HTS,acetylcholine receptor agonist,CHRM1,NA,NA,NCC1CN(Cc2ccccc2)C(=O)C1,Phase 3
BRD-A51382177-236-03-0::2.5::HTS,BRD-A51382177-236-03-0,fosinopril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure","CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C",Launched
BRD-A51407134-001-01-9::2.5::HTS,BRD-A51407134-001-01-9,2-octyldodecan-1-ol,2.5,HTS,NA,NA,NA,NA,"CCCCCCCCCCC(CO)CCCCCCCC, CCCCCCCCCCC(CO)CCCCCCCC",Preclinical
BRD-A51571244-001-01-9::2.5::HTS,BRD-A51571244-001-01-9,hypoestoxide,2.5,HTS,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51713165-003-02-6::2.5::HTS,BRD-A51713165-003-02-6,3-CPMT,2.5,HTS,dopamine reuptake inhibitor,NA,NA,NA,CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1,Preclinical
BRD-A51714012-003-13-6::2.5::HTS,BRD-A51714012-003-13-6,venlafaxine,2.5,HTS,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)","SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder","COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1, COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1, COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1",Launched
BRD-A51747092-003-03-0::2.5::HTS,BRD-A51747092-003-03-0,moprolol,2.5,HTS,adrenergic receptor antagonist,NA,"cardiology, ophthalmology, neurology/psychiatry","hypertension, glaucoma, anxiety",COc1ccccc1OCC(O)CNC(C)C,Launched
BRD-A51820102-008-28-9::2.5::HTS,BRD-A51820102-008-28-9,econazole,2.5,HTS,"lanosterol demethylase inhibitor, sterol demethylase inhibitor","CYP51A1, NPY1R, NPY2R, TRPM2, TRPV5",infectious disease,"tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis","Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A51829654-003-07-7::2.5::HTS,BRD-A51829654-003-07-7,BRL-15572,2.5,HTS,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,"OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1",Preclinical
BRD-A51831848-001-01-7::2.5::HTS,BRD-A51831848-001-01-7,enflurane,2.5,HTS,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, KCNN4",NA,NA,FC(F)OC(F)(F)C(F)Cl,Launched
BRD-A51964809-003-12-6::2.5::HTS,BRD-A51964809-003-12-6,halofantrine,2.5,HTS,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A52460047-001-01-3::2.5::HTS,BRD-A52460047-001-01-3,methylatropine-nitrate,2.5,HTS,acetylcholine receptor antagonist,CHRM1,NA,NA,C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1,Preclinical
BRD-A52588987-004-08-2::2.5::HTS,BRD-A52588987-004-08-2,SKF-83566,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD5",NA,NA,"CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1, CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1",Preclinical
BRD-A52660433-066-02-1::2.5::HTS,BRD-A52660433-066-02-1,tetrindole,2.5,HTS,monoamine oxidase inhibitor,MAOA,NA,NA,"C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1",Phase 3
BRD-A52922642-001-03-7::2.5::HTS,BRD-A52922642-001-03-7,gallopamil,2.5,HTS,L-type calcium channel blocker,ATP2A2,cardiology,"hypertension, cardiac arrythmia",COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC,Launched
BRD-A53037217-001-02-0::2.5::HTS,BRD-A53037217-001-02-0,BTZ043-racemate,2.5,HTS,DPRE1 inhibitor,NA,NA,NA,CC1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1,Preclinical
BRD-A53037300-001-01-0::2.5::HTS,BRD-A53037300-001-01-0,2-fluoro-2-deoxy-D-galactose,2.5,HTS,NA,LCT,NA,NA,OCC1OC(O)C(F)C(O)C1O,Phase 1
BRD-A53134341-001-03-2::2.5::HTS,BRD-A53134341-001-03-2,Ro-106-9920,2.5,HTS,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53151380-001-01-2::2.5::HTS,BRD-A53151380-001-01-2,prednisolone-tebutate,2.5,HTS,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53539450-004-01-7::2.5::HTS,BRD-A53539450-004-01-7,neo-gilurytmal,2.5,HTS,NA,NA,NA,NA,CCC[N+]12[C@H]3C[C@]45C(O)C3[C@@H](CC1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O,Launched
BRD-A53561827-004-23-1::2.5::HTS,BRD-A53561827-004-23-1,pipenzolate,2.5,HTS,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms,"CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1",Launched
BRD-A53566267-001-01-9::2.5::HTS,BRD-A53566267-001-01-9,anecortave-acetate,2.5,HTS,angiogenesis inhibitor,NA,ophthalmology,macular degeneration,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C,Launched
BRD-A53576514-048-14-3::2.5::HTS,BRD-A53576514-048-14-3,orphenadrine,2.5,HTS,acetylcholine receptor antagonist,"GRIN1, GRIN2D, GRIN3A, GRIN3B, HRH1, SCN10A, SLC6A2",neurology/psychiatry,muscle pain,"CN(C)CCOC(c1ccccc1)c1ccccc1C, CN(C)CCOC(c1ccccc1)c1ccccc1C",Launched
BRD-A53813595-001-01-8::2.5::HTS,BRD-A53813595-001-01-8,PGL5001,2.5,HTS,JNK inhibitor,"MAPK10, MAPK8, MAPK9",NA,NA,"N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1, N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1, N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1",Phase 2
BRD-A53951045-004-01-6::2.5::HTS,BRD-A53951045-004-01-6,butylscopolamine-bromide,2.5,HTS,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53952395-003-25-1::2.5::HTS,BRD-A53952395-003-25-1,prilocaine,2.5,HTS,local anesthetic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,anesthetic,"CCCNC(C)C(=O)Nc1ccccc1C, CCCNC(C)C(=O)Nc1ccccc1C",Launched
BRD-A54236247-003-04-3::2.5::HTS,BRD-A54236247-003-04-3,ephedrine-(racemic),2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA2A","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity",CNC(C)C(O)c1ccccc1,Launched
BRD-A54275602-001-01-0::2.5::HTS,BRD-A54275602-001-01-0,lanoconazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54490543-066-11-9::2.5::HTS,BRD-A54490543-066-11-9,pirlindole,2.5,HTS,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Cc1ccc2n3CCNC4CCCc(c34)c2c1,Launched
BRD-A54927599-001-16-9::2.5::HTS,BRD-A54927599-001-16-9,KF-38789,2.5,HTS,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A55272860-001-14-6::2.5::HTS,BRD-A55272860-001-14-6,sulpiride,2.5,HTS,dopamine receptor antagonist,NA,neurology/psychiatry,"schizophrenia, schizophrenia","CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O",Launched
BRD-A55272860-001-15-3::2.5::HTS,BRD-A55272860-001-15-3,sulpiride,2.5,HTS,dopamine receptor antagonist,NA,neurology/psychiatry,"schizophrenia, schizophrenia","CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O",Launched
BRD-A55312468-001-04-7::1.24::HTS,BRD-A55312468-001-04-7,k-strophanthidin,1.24,HTS,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55393291-001-09-9::2.5::HTS,BRD-A55393291-001-09-9,testosterone,2.5,HTS,androgen receptor agonist,AR,endocrinology,hypogonadism,C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O,Launched
BRD-A55424491-001-19-9::2.5::HTS,BRD-A55424491-001-19-9,methotrexate,2.5,HTS,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55455283-001-01-3::2.5::HTS,BRD-A55455283-001-01-3,"2-ethyl-1,3-hexanediol",2.5,HTS,NA,NA,NA,NA,"CCCC(O)C(CC)CO, CCCC(O)C(CC)CO",Preclinical
BRD-A55464252-001-01-2::2.5::HTS,BRD-A55464252-001-01-2,3-(4-methylbenzylidene)camphor,2.5,HTS,endocrine disruptor,NA,dermatology,sunscreen lotion,Cc1ccc(cc1)\C=C1\C2CCC(C)(C1=O)C2(C)C,Launched
BRD-A55469827-001-07-4::2.5::HTS,BRD-A55469827-001-07-4,mephenesin,2.5,HTS,muscle relaxant,NA,neurology/psychiatry,muscle relaxant,Cc1ccccc1OCC(O)CO,Launched
BRD-A55484088-050-02-5::2.5::HTS,BRD-A55484088-050-02-5,BNTX,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55664972-236-02-6::2.5::HTS,BRD-A55664972-236-02-6,sodium-tetradecyl-sulfate,2.5,HTS,NA,"PROC, PROS1",dermatology,"varicose veins, varicose veins","CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O, CCCCCCCCCCCCCCOS(O)(=O)=O",Launched
BRD-A55913614-316-09-6::2.5::HTS,BRD-A55913614-316-09-6,primaquine,2.5,HTS,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55962179-001-22-1::2.5::HTS,BRD-A55962179-001-22-1,omeprazole,2.5,HTS,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A56085258-001-01-8::2.5::HTS,BRD-A56085258-001-01-8,LGX818,2.5,HTS,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56152450-001-02-0::2.5::HTS,BRD-A56152450-001-02-0,dimercaprol,2.5,HTS,chelating agent,NA,neurology/psychiatry,metal toxicity,"OCC(S)CS, OCC(S)CS",Launched
BRD-A56359832-001-11-1::2.5::HTS,BRD-A56359832-001-11-1,zileuton,2.5,HTS,"leukotriene synthesis inhibitor, lipoxygenase inhibitor",ALOX5,pulmonary,asthma,"CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1",Launched
BRD-A56371469-001-03-3::2.5::HTS,BRD-A56371469-001-03-3,AGI-5198,2.5,HTS,isocitrate dehydrogenase inhibitor,IDH1,NA,NA,Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1,Preclinical
BRD-A56592690-001-04-3::2.5::HTS,BRD-A56592690-001-04-3,PX-12,2.5,HTS,thioredoxin inhibitor,"TXN, TXNRD1",NA,NA,CCC(C)SSc1ncc[nH]1,Phase 2
BRD-A56675431-001-12-3::2.5::HTS,BRD-A56675431-001-12-3,althiazide,2.5,HTS,diuretic,NA,cardiology,hypertension,NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl,Launched
BRD-A56858165-001-04-4::2.5::HTS,BRD-A56858165-001-04-4,cefadroxil,2.5,HTS,bacterial cell wall synthesis inhibitor,"SLC15A1, SLC15A2, SLC22A6, SLC22A8","infectious disease, otolaryngology","urinary tract infections, skin infections, tonsillitis, pharyngitis",CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O,Launched
BRD-A56987319-001-12-9::2.5::HTS,BRD-A56987319-001-12-9,SQ-22536,2.5,HTS,adenylyl cyclase inhibitor,ADCY1,NA,NA,"Nc1ncnc2n(cnc12)C1CCCO1, Nc1ncnc2n(cnc12)C1CCCO1",Preclinical
BRD-A57133233-003-11-0::2.5::HTS,BRD-A57133233-003-11-0,chlorcyclizine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-A57382968-001-29-0::2.5::HTS,BRD-A57382968-001-29-0,piroxicam,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57592049-001-01-6::2.5::HTS,BRD-A57592049-001-01-6,methsuximide,2.5,HTS,T-type calcium channel binder,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,CN1C(=O)CC(C)(C1=O)c1ccccc1,Launched
BRD-A57798112-001-03-7::2.5::HTS,BRD-A57798112-001-03-7,PD-318088,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798559-004-02-3::2.5::HTS,BRD-A57798559-004-02-3,bicuculline-methochloride-(-),2.5,HTS,GABA receptor antagonist,NA,NA,NA,"C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21",Preclinical
BRD-A57833392-001-01-7::2.5::HTS,BRD-A57833392-001-01-7,oxymatrine,2.5,HTS,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57886255-001-01-1::2.5::HTS,BRD-A57886255-001-01-1,golgicide-a,2.5,HTS,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57900429-003-05-8::2.5::HTS,BRD-A57900429-003-05-8,hydrastinine,2.5,HTS,haemostatic agent,NA,NA,NA,"CN1CCc2cc3OCOc3cc2C1O, CN1CCc2cc3OCOc3cc2C1O",Preclinical
BRD-A57957888-001-08-0::2.5::HTS,BRD-A57957888-001-08-0,citiolone,2.5,HTS,"lipotropic, mucolytic agent",NA,NA,NA,CC(=O)NC1CCSC1=O,Preclinical
BRD-A58048407-001-18-8::2.5::HTS,BRD-A58048407-001-18-8,nimodipine,2.5,HTS,calcium channel blocker,"AHR, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CFTR, NR3C2",hematology,hemorrhage,"COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C",Launched
BRD-A58193911-003-18-7::2.5::HTS,BRD-A58193911-003-18-7,oxyphencyclimine,2.5,HTS,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58564983-001-04-6::2.5::HTS,BRD-A58564983-001-04-6,selamectin,2.5,HTS,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58955223-001-03-8::2.5::HTS,BRD-A58955223-001-03-8,sulforaphane,2.5,HTS,"anticancer agent, aryl hydrocarbon receptor antagonist",NFE2L2,NA,NA,CS(=O)CCCCN=C=S,Phase 2
BRD-A59001851-001-02-1::2.5::HTS,BRD-A59001851-001-02-1,ginkgolide-b,2.5,HTS,platelet activating factor receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",NA,NA,"C[C@@H]1C(=O)OC2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O",Phase 3
BRD-A59174698-003-18-5::2.5::HTS,BRD-A59174698-003-18-5,ritodrine,2.5,HTS,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-A59198242-003-02-9::2.5::HTS,BRD-A59198242-003-02-9,viloxazine,2.5,HTS,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression,CCOc1ccccc1OCC1CNCCO1,Launched
BRD-A59303141-001-10-4::2.5::HTS,BRD-A59303141-001-10-4,quinethazone,2.5,HTS,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59337442-051-05-3::2.5::HTS,BRD-A59337442-051-05-3,xamoterol,2.5,HTS,adrenergic receptor agonist,ADRB1,NA,NA,"OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1",Phase 3
BRD-A59413292-001-08-2::2.5::HTS,BRD-A59413292-001-08-2,dexpanthenol,2.5,HTS,NA,NA,gastroenterology,paralytic ileus,"CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)C(O)C(=O)NCCCO",Launched
BRD-A59709458-001-01-8::2.5::HTS,BRD-A59709458-001-01-8,PHCCC,2.5,HTS,glutamate receptor agonist,"GRM1, GRM4",NA,NA,"O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1, O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1",Preclinical
BRD-A60197193-001-14-6::2.5::HTS,BRD-A60197193-001-14-6,amisulpride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60217728-001-11-2::2.5::HTS,BRD-A60217728-001-11-2,iohexol,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,Launched
BRD-A60594020-034-01-1::2.5::HTS,BRD-A60594020-034-01-1,8-hydroxy-PIPAT,2.5,HTS,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60786380-412-01-5::2.5::HTS,BRD-A60786380-412-01-5,sodium-stibogluconate,2.5,HTS,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A61154809-001-15-9::2.5::HTS,BRD-A61154809-001-15-9,gliclazide,2.5,HTS,"ATP channel blocker, insulin secretagogue","ABCC8, VEGFA",endocrinology,diabetes mellitus,"Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1",Launched
BRD-A61194565-003-27-0::2.5::HTS,BRD-A61194565-003-27-0,benserazide,2.5,HTS,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O",Launched
BRD-A61221616-001-04-3::2.5::HTS,BRD-A61221616-001-04-3,medroxyprogesterone-acetate,2.5,HTS,progesterone receptor agonist,NA,endocrinology,contraceptive,"C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12, C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12",Launched
BRD-A61392169-001-02-7::2.5::HTS,BRD-A61392169-001-02-7,eliprodil,2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2B",NA,NA,OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,Phase 3
BRD-A61676498-001-06-6::2.5::HTS,BRD-A61676498-001-06-6,climbazole,2.5,HTS,enzyme inducer,NA,dermatology,"dandruff, eczema","CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1, CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1",Launched
BRD-A61793559-001-15-6::2.5::HTS,BRD-A61793559-001-15-6,metolazone,2.5,HTS,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension","CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O",Launched
BRD-A61850409-001-10-7::2.5::HTS,BRD-A61850409-001-10-7,alpha-tochopheryl-acetate,2.5,HTS,antioxidant,NA,endocrinology,vitamin E deficiency,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1,Launched
BRD-A62021152-003-03-4::2.5::HTS,BRD-A62021152-003-03-4,WAY-161503,2.5,HTS,serotonin receptor agonist,HTR2C,NA,NA,"Clc1cc2NC(=O)C3CNCCN3c2cc1Cl, Clc1cc2NC(=O)C3CNCCN3c2cc1Cl",Preclinical
BRD-A62057054-001-03-1::2.5::HTS,BRD-A62057054-001-03-1,MDL-11939,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1, OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1",Phase 2
BRD-A62071884-001-04-6::2.5::HTS,BRD-A62071884-001-04-6,siguazodan,2.5,HTS,phosphodiesterase inhibitor,PDE3A,NA,NA,"CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C",Phase 1
BRD-A62209527-001-04-5::2.5::HTS,BRD-A62209527-001-04-5,ZM-226600,2.5,HTS,Kir6 channel (KATP) activator,NA,NA,NA,CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F,Preclinical
BRD-A62421304-004-18-9::2.5::HTS,BRD-A62421304-004-18-9,mepenzolate,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1",Launched
BRD-A62428732-300-06-3::2.5::HTS,BRD-A62428732-300-06-3,hydroxyzine,2.5,HTS,antihistamine,HRH1,"neurology/psychiatry, allergy, dermatology","anxiety, urticaria, itching, dermatosis, anxiety, urticaria, itching, dermatosis","OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1",Launched
BRD-A62731508-001-05-8::2.5::HTS,BRD-A62731508-001-05-8,cortisone,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"gastroenterology, rheumatology, dermatology","ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema",C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO,Launched
BRD-A63310107-001-04-8::2.5::HTS,BRD-A63310107-001-04-8,miglitol,2.5,HTS,glucosidase inhibitor,"GAA, GANAB, GANC, MGAM",endocrinology,diabetes mellitus,"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",Launched
BRD-A63444178-001-01-5::2.5::HTS,BRD-A63444178-001-01-5,ME0328,2.5,HTS,PARP inhibitor,PARP3,NA,NA,CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,Preclinical
BRD-A63546914-003-02-0::2.5::HTS,BRD-A63546914-003-02-0,Ro-04-5595,2.5,HTS,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63675168-001-01-6::2.5::HTS,BRD-A63675168-001-01-6,brivudine,2.5,HTS,DNA directed DNA polymerase inhibitor,NA,infectious disease,shingles,OC[C@H]1O[C@H](CC1O)n1cc(\C=C\Br)c(=O)[nH]c1=O,Launched
BRD-A63752151-001-01-2::2.5::HTS,BRD-A63752151-001-01-2,fidarestat,2.5,HTS,aldose reductase inhibitor,AKR1B1,NA,NA,NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1,Phase 3
BRD-A63780829-001-11-4::2.5::HTS,BRD-A63780829-001-11-4,hyperin,2.5,HTS,aldose reductase inhibitor,"ACE, AKR1B1",NA,NA,OCC1OC(Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)C(O)C(O)C1O,Preclinical
BRD-A64011898-001-01-0::2.5::HTS,BRD-A64011898-001-01-0,androstenone,2.5,HTS,steroid,NA,NA,NA,CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2,Preclinical
BRD-A64064900-001-02-3::2.5::HTS,BRD-A64064900-001-02-3,sangivamycin,2.5,HTS,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64092382-003-18-3::2.5::HTS,BRD-A64092382-003-18-3,mexiletine,2.5,HTS,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64125466-236-04-6::2.5::HTS,BRD-A64125466-236-04-6,dehydrocholate,2.5,HTS,NA,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O,Preclinical
BRD-A64227845-004-09-3::2.5::HTS,BRD-A64227845-004-09-3,SKF-77434,2.5,HTS,dopamine receptor agonist,DRD1,NA,NA,Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O,Preclinical
BRD-A64242993-001-05-6::2.5::HTS,BRD-A64242993-001-05-6,lanatoside-c,2.5,HTS,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64406146-001-01-2::2.5::HTS,BRD-A64406146-001-01-2,timofibrate,2.5,HTS,"cholesterol inhibitor, lipase clearing factor inhibitor",LPL,NA,NA,CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(O)=O,Phase 2
BRD-A64553394-001-04-4::2.68::HTS,BRD-A64553394-001-04-4,DPI-201106,2.68,HTS,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64610707-001-04-4::2.5::HTS,BRD-A64610707-001-04-4,pranoprofen,2.5,HTS,cyclooxygenase inhibitor,NA,neurology/psychiatry,pain relief,"CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1",Launched
BRD-A64698388-003-01-7::2.5::HTS,BRD-A64698388-003-01-7,levo-phencynonate,2.5,HTS,acetylcholine receptor antagonist,CHRM1,NA,NA,CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1,Launched
BRD-A64743628-001-01-5::2.5::HTS,BRD-A64743628-001-01-5,isometheptene-mucate,2.5,HTS,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64808605-003-02-7::2.5::HTS,BRD-A64808605-003-02-7,AH11110,2.5,HTS,adrenergic receptor ligand,ADRA1B,NA,NA,OC(COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1,Preclinical
BRD-A64977602-001-15-9::2.5::HTS,BRD-A64977602-001-15-9,mirtazapine,2.5,HTS,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD5, HRH1, HRH3, HTR2A, HTR2B, HTR2C, HTR3A, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21",Launched
BRD-A65013509-003-24-4::2.5::HTS,BRD-A65013509-003-24-4,oxybutynin,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",urology,urinary incontinence,"CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1, CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1, CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1",Launched
BRD-A65051990-001-12-9::2.5::HTS,BRD-A65051990-001-12-9,acenocoumarol,2.5,HTS,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O,Launched
BRD-A65145453-001-06-1::2.5::HTS,BRD-A65145453-001-06-1,ATPA,2.5,HTS,glutamate receptor agonist,"GRIA2, GRIK1",NA,NA,"CC(C)(C)c1onc(O)c1CC(N)C(O)=O, CC(C)(C)c1onc(O)c1CC(N)C(O)=O",Preclinical
BRD-A65248799-001-01-7::2.5::HTS,BRD-A65248799-001-01-7,EMD-53998,2.5,HTS,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65280694-003-13-7::2.5::HTS,BRD-A65280694-003-13-7,molindone,2.5,HTS,dopamine receptor antagonist,"CHRM1, DRD2, HRH1, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,Launched
BRD-A65440446-001-04-1::2.5::HTS,BRD-A65440446-001-04-1,cimaterol,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",NA,NA,CC(C)NCC(O)c1ccc(N)c(c1)C#N,Preclinical
BRD-A65449987-001-10-4::2.5::HTS,BRD-A65449987-001-10-4,flunisolide,2.5,HTS,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A65597028-003-07-3::2.5::HTS,BRD-A65597028-003-07-3,RX-821002,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",NA,NA,"COC1(COc2ccccc2O1)C1=NCCN1, COC1(COc2ccccc2O1)C1=NCCN1",Preclinical
BRD-A65615053-003-02-2::2.5::HTS,BRD-A65615053-003-02-2,zacopride,2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B, HTR4, HTR5A",NA,NA,"COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2, COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2",Phase 2
BRD-A65671304-001-07-5::2.5::HTS,BRD-A65671304-001-07-5,candesartan-cilextil,2.5,HTS,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-A65767837-001-04-4::2.5::HTS,BRD-A65767837-001-04-4,hydrocortisone-acetate,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, NR3C2",dermatology,corticosteroid-responsive dermatoses,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A65797496-048-09-3::2.5::HTS,BRD-A65797496-048-09-3,deptropine,2.5,HTS,histamine receptor antagonist,HRH1,NA,NA,CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12,Preclinical
BRD-A65818372-001-05-3::2.5::HTS,BRD-A65818372-001-05-3,ioversol,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,Launched
BRD-A66116161-001-02-3::2.5::HTS,BRD-A66116161-001-02-3,AM-1241,2.5,HTS,cannabinoid receptor agonist,"CNR1, CNR2",NA,NA,CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12,Preclinical
BRD-A66419424-001-02-4::2.5::HTS,BRD-A66419424-001-02-4,ixazomib-citrate,2.5,HTS,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66435872-332-01-8::2.5::HTS,BRD-A66435872-332-01-8,HTMT,2.5,HTS,histamine receptor agonist,HRH4,NA,NA,"CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1, CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1",Preclinical
BRD-A66869276-001-02-9::2.5::HTS,BRD-A66869276-001-02-9,diflorasone-diacetate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O,Launched
BRD-A66920069-001-01-3::2.5::HTS,BRD-A66920069-001-01-3,fenigam,2.5,HTS,benzodiazepine receptor agonist,"GABBR1, GABBR2",neurology/psychiatry,"posttraumatic stress disorder, anxiety, depression",NCC(CC(O)=O)c1ccccc1,Launched
BRD-A66966115-001-01-0::2.5::HTS,BRD-A66966115-001-01-0,NM107,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O,Phase 2
BRD-A67006024-001-04-8::2.5::HTS,BRD-A67006024-001-04-8,SNAP,2.5,HTS,nitric oxide donor,PTPN1,NA,NA,"CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-], CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-]",Phase 2
BRD-A67060370-001-02-9::2.5::HTS,BRD-A67060370-001-02-9,albendazole-oxide,2.5,HTS,anthelmintic agent,NA,infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis",CCCS(=O)c1ccc2nc(NC(=O)OC)[nH]c2c1,Launched
BRD-A67097164-001-18-7::2.5::HTS,BRD-A67097164-001-18-7,ifosfamide,2.5,HTS,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67101513-001-03-7::2.5::HTS,BRD-A67101513-001-03-7,hygromycin-b,2.5,HTS,polypeptide synthesis inhibitor,NA,NA,NA,CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O,Preclinical
BRD-A67181951-001-01-2::2.5::HTS,BRD-A67181951-001-01-2,gadobutrol,2.5,HTS,radiopaque medium,NA,radiology,MRI contrast agent,OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,Launched
BRD-A67363467-001-01-3::2.5::HTS,BRD-A67363467-001-01-3,dihydrostreptomycin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,NA,NA,CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO,Withdrawn
BRD-A67482312-001-02-6::2.5::HTS,BRD-A67482312-001-02-6,4-P-PDOT,2.5,HTS,melatonin receptor antagonist,"MTNR1A, MTNR1B",NA,NA,"CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1, CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1",Preclinical
BRD-A67514145-003-05-8::2.5::HTS,BRD-A67514145-003-05-8,furaltadone,2.5,HTS,bacterial DNA inhibitor,NA,NA,NA,"[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1",Launched
BRD-A67516570-001-02-8::2.5::HTS,BRD-A67516570-001-02-8,lafutidine,2.5,HTS,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67521319-001-01-6::2.5::HTS,BRD-A67521319-001-01-6,pimonidazole,2.5,HTS,NA,NA,NA,NA,OC(CN1CCCCC1)Cn1ccnc1[N+]([O-])=O,Phase 3
BRD-A67616246-001-07-9::2.5::HTS,BRD-A67616246-001-07-9,levomequitazine,2.5,HTS,histamine receptor antagonist,HRH1,NA,NA,C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12,Phase 2
BRD-A67748489-001-10-0::2.5::HTS,BRD-A67748489-001-10-0,K-858,2.5,HTS,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67862938-034-14-9::2.5::HTS,BRD-A67862938-034-14-9,naftidrofuryl,2.5,HTS,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67975844-001-01-8::2.5::HTS,BRD-A67975844-001-01-8,NSC-405020,2.5,HTS,matrix metalloprotease inhibitor,MMP1,NA,NA,"CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1, CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A68083442-001-01-6::2.5::HTS,BRD-A68083442-001-01-6,pranidipine,2.5,HTS,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68281735-001-18-6::0.25::HTS,BRD-A68281735-001-18-6,REV-5901,0.25,HTS,"leukotriene receptor antagonist, lipoxygenase inhibitor",ALOX5,NA,NA,CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,Phase 2
BRD-A68304895-003-02-2::2.5::HTS,BRD-A68304895-003-02-2,BTS-54505,2.5,HTS,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68464583-001-02-5::2.5::HTS,BRD-A68464583-001-02-5,mazindol,2.5,HTS,"dopamine reuptake inhibitor, selective serotonin reuptake inhibitor (SSRI)","SLC6A2, SLC6A3, SLC6A4",genetics,duchenne muscular dystrophy (DMD),OC1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1,Launched
BRD-A68493689-001-01-9::2.5::HTS,BRD-A68493689-001-01-9,simeprevir,2.5,HTS,HCV inhibitor,"CYP1A2, CYP3A4",infectious disease,hepatitis C,COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C,Launched
BRD-A68509429-003-03-9::2.5::HTS,BRD-A68509429-003-03-9,ethylnorepinephrine,2.5,HTS,bronchodilator,NA,NA,NA,CCC(N)C(O)c1ccc(O)c(O)c1,Preclinical
BRD-A68589262-001-04-3::2.5::HTS,BRD-A68589262-001-04-3,troxipide,2.5,HTS,glucosamine synthetase stimulant,NA,gastroenterology,gastroesophageal reflux disease (GERD),"COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1, COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1",Launched
BRD-A68631409-001-05-4::2.5::HTS,BRD-A68631409-001-05-4,evodiamine,2.5,HTS,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68723818-050-32-5::2.5::HTS,BRD-A68723818-050-32-5,brompheniramine,2.5,HTS,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1","allergy, otolaryngology","allergic rhinitis, common cold","CN(C)CCC(c1ccc(Br)cc1)c1ccccn1, CN(C)CCC(c1ccc(Br)cc1)c1ccccn1",Launched
BRD-A68888262-003-15-1::2.5::HTS,BRD-A68888262-003-15-1,azelastine,2.5,HTS,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O, CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O",Launched
BRD-A68942014-003-01-7::2.5::HTS,BRD-A68942014-003-01-7,amitifadine,2.5,HTS,serotonin transporter (SERT) inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,Clc1ccc(cc1Cl)C12CC1CNC2,Phase 3
BRD-A68969091-001-12-7::2.57::HTS,BRD-A68969091-001-12-7,echinomycin,2.57,HTS,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A69275535-001-01-5::2.5::HTS,BRD-A69275535-001-01-5,pinitol,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O,Phase 2
BRD-A69636825-003-04-7::2.5::HTS,BRD-A69636825-003-04-7,diltiazem,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5",cardiology,"hypertension, angina pectoris","COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)C1Sc2ccccc2N(CCN(C)C)C(=O)C1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O",Launched
BRD-A69651145-003-07-2::2.5::HTS,BRD-A69651145-003-07-2,minocycline,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69777949-001-24-2::2.5::HTS,BRD-A69777949-001-24-2,flumequine,2.5,HTS,topoisomerase inhibitor,NA,infectious disease,urinary tract infections,"CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A69815203-001-07-6::2.5::HTS,BRD-A69815203-001-07-6,cyclosporin-a,2.5,HTS,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69917777-065-02-2::2.5::HTS,BRD-A69917777-065-02-2,aminopentamide,2.5,HTS,acetylcholine receptor antagonist,CHRM1,gastroenterology,"acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea",CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,Launched
BRD-A70083328-001-23-5::2.5::HTS,BRD-A70083328-001-23-5,secnidazole,2.5,HTS,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-24-3::2.5::HTS,BRD-A70083328-001-24-3,secnidazole,2.5,HTS,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70268693-050-01-2::2.5::HTS,BRD-A70268693-050-01-2,PG-9,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,Preclinical
BRD-A70407468-001-02-0::2.5::HTS,BRD-A70407468-001-02-0,PSB-36,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3, CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3",Preclinical
BRD-A70514680-003-11-2::2.5::HTS,BRD-A70514680-003-11-2,articaine,2.5,HTS,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,Launched
BRD-A70649075-008-30-8::2.5::HTS,BRD-A70649075-008-30-8,sulconazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70858459-001-01-7::2.5::HTS,BRD-A70858459-001-01-7,estramustine,2.5,HTS,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70998768-004-01-1::2.5::HTS,BRD-A70998768-004-01-1,pinaverium,2.5,HTS,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome,COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC,Launched
BRD-A71033472-003-23-9::2.5::HTS,BRD-A71033472-003-23-9,fendiline,2.5,HTS,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71157293-003-10-0::2.5::HTS,BRD-A71157293-003-10-0,fursultiamine,2.5,HTS,vitamin B,NA,NA,NA,C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1,Launched
BRD-A71262238-001-08-4::2.5::HTS,BRD-A71262238-001-08-4,nafadotride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC,Preclinical
BRD-A71407503-001-01-8::2.5::HTS,BRD-A71407503-001-01-8,inimur,2.5,HTS,other antifungal,NA,NA,NA,"CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1, CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1",Launched
BRD-A71725768-001-01-3::2.5::HTS,BRD-A71725768-001-01-3,metoxibutropate,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71774530-001-05-9::2.5::HTS,BRD-A71774530-001-05-9,lufenuron,2.5,HTS,chitin inhibitor,NA,infectious disease,flea control,FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl,Launched
BRD-A72066420-001-04-5::2.5::HTS,BRD-A72066420-001-04-5,mifobate,2.5,HTS,PPAR receptor antagonist,PPARG,NA,NA,COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,Phase 2
BRD-A72212290-300-01-4::2.5::HTS,BRD-A72212290-300-01-4,eprazinone,2.5,HTS,mucolytic agent,NA,pulmonary,bronchospasm,"CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1, CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1",Launched
BRD-A72309220-001-04-1::2.5::HTS,BRD-A72309220-001-04-1,metergoline,2.5,HTS,"dopamine receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,"CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1CC(CNC(=O)OCc2ccccc2)C[C@@H]2C1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13",Launched
BRD-A72390365-001-15-2::2.5::HTS,BRD-A72390365-001-15-2,choline-alfoscerate,2.5,HTS,acetylcholine precursor,GM2A,NA,NA,C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO,Launched
BRD-A72483914-001-03-7::2.5::HTS,BRD-A72483914-001-03-7,spiroxatrine,2.5,HTS,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B",NA,NA,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,Preclinical
BRD-A72703248-003-04-9::2.5::HTS,BRD-A72703248-003-04-9,SKF-96365,2.5,HTS,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72711497-236-03-8::2.5::HTS,BRD-A72711497-236-03-8,lasalocid,2.5,HTS,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72716251-001-01-5::0.91::HTS,BRD-A72716251-001-01-5,peruvoside,0.91,HTS,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72767275-003-01-6::2.5::HTS,BRD-A72767275-003-01-6,nalmefene,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=C)CCC35O",Launched
BRD-A73368467-003-17-6::2.5::HTS,BRD-A73368467-003-17-6,fexofenadine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Launched
BRD-A73427433-240-01-3::2.5::HTS,BRD-A73427433-240-01-3,adaprev,2.5,HTS,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73556557-001-06-4::2.5::HTS,BRD-A73556557-001-06-4,tagatose,2.5,HTS,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73709786-001-01-3::2.5::HTS,BRD-A73709786-001-01-3,LB-100,2.5,HTS,protein phosphatase inhibitor,NA,NA,NA,"CN1CCN(CC1)C(=O)C1[C@H]2CC[C@H](O2)C1C(O)=O, CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O",Phase 1
BRD-A73871920-236-03-6::2.5::HTS,BRD-A73871920-236-03-6,nanchangmycin,2.5,HTS,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73908300-001-06-7::2.5::HTS,BRD-A73908300-001-06-7,EX-527,2.5,HTS,SIRT inhibitor,SIRT1,NA,NA,"NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21, NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21",Phase 2
BRD-A73930134-001-03-0::2.5::HTS,BRD-A73930134-001-03-0,5-hydroxytryptophan,2.5,HTS,neurotransmitter,"SLC36A1, SLC36A2",neurology/psychiatry,insomnia,"NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O, NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O",Launched
BRD-A74208568-003-01-5::2.5::HTS,BRD-A74208568-003-01-5,CGP-54626,2.5,HTS,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74387232-001-02-5::2.5::HTS,BRD-A74387232-001-02-5,PMPA,2.5,HTS,glutamate receptor antagonist,FOLH1,NA,NA,OC(=O)CCC(CP(O)(O)=O)C(O)=O,Preclinical
BRD-A74391928-051-01-3::2.5::HTS,BRD-A74391928-051-01-3,ibutilide,2.5,HTS,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-02-1::2.64::HTS,BRD-A74391928-051-02-1,ibutilide,2.64,HTS,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74667430-001-23-6::2.5::HTS,BRD-A74667430-001-23-6,etodolac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2, RXRA",rheumatology,"osteoarthritis, rheumatoid arthritis","CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12, CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12",Launched
BRD-A74765037-001-01-1::2.5::HTS,BRD-A74765037-001-01-1,estradiol-benzoate,2.5,HTS,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74914197-001-02-9::2.5::HTS,BRD-A74914197-001-02-9,pralatrexate,2.5,HTS,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74975734-004-10-7::2.5::HTS,BRD-A74975734-004-10-7,homatropine,2.5,HTS,acetylcholine receptor antagonist,"CES1, CHRM1",ophthalmology,pupil dilation,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1",Launched
BRD-A74980173-001-11-9::2.5::HTS,BRD-A74980173-001-11-9,gatifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,"COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-A75140635-003-10-9::2.5::HTS,BRD-A75140635-003-10-9,"isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,",2.5,HTS,NA,NA,NA,NA,COc1cc2CCNC(C)c2cc1OC,Preclinical
BRD-A75305484-001-01-3::2.5::HTS,BRD-A75305484-001-01-3,anidulafungin,2.5,HTS,"fungal 1,3-beta-D-glucan synthase inhibitor",NA,infectious disease,"candidemia, fungal infection, esophageal candidiasis",CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)c1ccc(O)cc1)C(C)O,Launched
BRD-A75369945-001-01-2::2.5::HTS,BRD-A75369945-001-01-2,vitamin-b12,2.5,HTS,NA,NA,hematology,megaloblastic anemia,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12,Launched
BRD-A75479906-001-02-4::2.5::HTS,BRD-A75479906-001-02-4,rimantadine,2.5,HTS,"antiviral, RNA synthesis inhibitor",NA,infectious disease,influenza A virus infection,"CC(N)C12CC3CC(CC(C3)C1)C2, CC(N)C12CC3CC(CC(C3)C1)C2",Launched
BRD-A75552914-001-15-0::2.5::HTS,BRD-A75552914-001-15-0,isoxicam,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,"CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O",Withdrawn
BRD-A75726477-003-21-3::2.5::HTS,BRD-A75726477-003-21-3,clenbuterol,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75769826-003-02-1::2.5::HTS,BRD-A75769826-003-02-1,SDM25N,2.5,HTS,opioid receptor antagonist,OPRD1,NA,NA,"CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O",Preclinical
BRD-A75817871-001-06-7::2.5::HTS,BRD-A75817871-001-06-7,blebbistatin-(+/-),2.5,HTS,ATPase inhibitor,MYH2,NA,NA,Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-A75850590-213-01-0::2.5::HTS,BRD-A75850590-213-01-0,lomefloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75919782-399-02-6::2.5::HTS,BRD-A75919782-399-02-6,leucovorin,2.5,HTS,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A76672327-003-02-0::2.5::HTS,BRD-A76672327-003-02-0,clindamycin-palmitate,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,"intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections",CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl,Launched
BRD-A77218119-001-03-5::2.5::HTS,BRD-A77218119-001-03-5,SYM-2206,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C",Preclinical
BRD-A77291778-003-22-0::2.5::HTS,BRD-A77291778-003-22-0,cyclopentolate,2.5,HTS,acetylcholine receptor antagonist,CHRM1,ophthalmology,"mydriasis, cycloplegia",CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,Launched
BRD-A77577770-003-08-9::2.5::HTS,BRD-A77577770-003-08-9,palmitoylcarnitine,2.5,HTS,protein kinase inhibitor,NA,NA,NA,CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C,Preclinical
BRD-A78093359-001-06-3::2.5::HTS,BRD-A78093359-001-06-3,MRS1845,2.5,HTS,calcium channel blocker,NA,NA,NA,CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,Preclinical
BRD-A78195072-001-06-2::2.5::HTS,BRD-A78195072-001-06-2,imexon,2.5,HTS,"apoptosis stimulant, ribonucleotide reductase inhibitor","RRM1, RRM2",NA,NA,N=C1NC(=O)N2CC12,Phase 2
BRD-A78322124-003-14-0::2.5::HTS,BRD-A78322124-003-14-0,dobutamine,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2",cardiology,congestive heart failure,"CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1",Launched
BRD-A78341343-001-01-6::2.5::HTS,BRD-A78341343-001-01-6,regadenoson,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",radiology,myocardial perfusion imaging (MPI),CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1,Launched
BRD-A78377521-001-05-5::2.5::HTS,BRD-A78377521-001-05-5,monastrol,2.5,HTS,kinesin inhibitor,KIF11,NA,NA,"CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1, CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1",Preclinical
BRD-A78391468-001-02-8::2.5::HTS,BRD-A78391468-001-02-8,prednisolone-hemisuccinate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78588743-001-03-4::2.5::HTS,BRD-A78588743-001-03-4,editol,2.5,HTS,NA,NA,NA,NA,CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O,Preclinical
BRD-A78723049-001-01-2::2.5::HTS,BRD-A78723049-001-01-2,cefotetan,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis",CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,Launched
BRD-A78877355-001-03-0::2.5::HTS,BRD-A78877355-001-03-0,nefopam,2.5,HTS,cyclooxygenase inhibitor,NA,neurology/psychiatry,pain relief,"CN1CCOC(c2ccccc2)c2ccccc2C1, CN1CCOC(c2ccccc2)c2ccccc2C1",Launched
BRD-A78952587-001-01-5::2.5::HTS,BRD-A78952587-001-01-5,A740003,2.5,HTS,purinergic receptor antagonist,P2RX7,NA,NA,"COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC, COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC",Preclinical
BRD-A79431551-001-01-1::2.5::HTS,BRD-A79431551-001-01-1,3-deazaadenosine,2.5,HTS,adenosylhomocysteinase inhibitor,AHCY,NA,NA,Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)C(O)C1O,Phase 2
BRD-A79672927-001-20-7::2.5::HTS,BRD-A79672927-001-20-7,tropicamide,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",ophthalmology,"mydriasis diagnostic, cycloplegia diagnostic","CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1",Launched
BRD-A79768653-001-12-0::2.5::HTS,BRD-A79768653-001-12-0,sirolimus,2.5,HTS,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-A79803969-003-16-1::2.5::HTS,BRD-A79803969-003-16-1,memantine,2.5,HTS,glutamate receptor antagonist,"CHRFAM7A, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A",neurology/psychiatry,"Alzheimer's disease, senile dementia","CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2",Launched
BRD-A79981887-003-16-4::2.5::HTS,BRD-A79981887-003-16-4,midodrine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A80017228-001-25-7::2.5::HTS,BRD-A80017228-001-25-7,bendroflumethiazide,2.5,HTS,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80213327-305-08-3::2.5::HTS,BRD-A80213327-305-08-3,NSC-23766,2.5,HTS,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80871782-004-06-9::2.5::HTS,BRD-A80871782-004-06-9,hydroxyamphetamine,2.5,HTS,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis,CC(N)Cc1ccc(O)cc1,Launched
BRD-A80908310-003-13-8::2.5::HTS,BRD-A80908310-003-13-8,cloperastine,2.5,HTS,antitussive,NA,pulmonary,cough suppressant,Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1,Launched
BRD-A81129465-001-03-8::2.5::HTS,BRD-A81129465-001-03-8,fenoprofen,2.5,HTS,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81233518-004-16-1::2.5::HTS,BRD-A81233518-004-16-1,glycopyrrolate,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1,Launched
BRD-A81370665-001-03-6::2.5::HTS,BRD-A81370665-001-03-6,BI-D1870,2.5,HTS,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81513827-001-03-6::2.5::HTS,BRD-A81513827-001-03-6,saxagliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81541225-001-06-8::2.5::HTS,BRD-A81541225-001-06-8,oligomycin-a,2.5,HTS,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81615860-003-01-7::2.5::HTS,BRD-A81615860-003-01-7,fenclonine-(+/-),2.5,HTS,tryptophan hydroxylase inhibitor,"PAH, TPH1, TPH2",NA,NA,NC(Cc1ccc(Cl)cc1)C(O)=O,Preclinical
BRD-A82035391-001-02-7::2.5::HTS,BRD-A82035391-001-02-7,tolvaptan,2.5,HTS,vasopressin receptor antagonist,"AVPR1A, AVPR2","endocrinology, cardiology, gastroenterology","hyponatremia, congestive heart failure, hepatic cirrhosis","Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1",Launched
BRD-A82396632-008-29-0::2.5::HTS,BRD-A82396632-008-29-0,miconazole,2.5,HTS,bacterial cell wall synthesis inhibitor,"KCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, NOS2, NOS3, TRPM2, TRPV5","infectious disease, neurology/psychiatry","yeast infection, itching","Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1",Launched
BRD-A82522119-001-01-7::2.5::HTS,BRD-A82522119-001-01-7,tibolone,2.5,HTS,"androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist",ESR1,obstetrics/gynecology,endometriosis,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)C12,Launched
BRD-A82772293-001-03-2::2.5::HTS,BRD-A82772293-001-03-2,mepazine,2.5,HTS,MALT1 inhibitor (JH),MALT1,NA,NA,CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1,Phase 2
BRD-A83029242-001-05-3::2.5::HTS,BRD-A83029242-001-05-3,prasugrel,2.5,HTS,purinergic receptor antagonist,P2RY12,cardiology,"myocardial infarction, acute coronary syndrome (ACS)","CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F",Launched
BRD-A83644949-236-01-6::2.5::HTS,BRD-A83644949-236-01-6,ardeparin,2.5,HTS,thrombin inhibitor,"SERPINC1, SERPIND1",NA,NA,CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O,Withdrawn
BRD-A83650191-004-02-8::2.5::HTS,BRD-A83650191-004-02-8,A61603,2.5,HTS,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83802939-304-04-2::2.5::HTS,BRD-A83802939-304-04-2,dexamethasone-sodium-phosphate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O, C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O",Launched
BRD-A83937277-001-10-5::2.5::HTS,BRD-A83937277-001-10-5,mephenytoin,2.5,HTS,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A84174393-236-07-1::2.5::HTS,BRD-A84174393-236-07-1,meloxicam,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84389633-001-05-7::2.5::HTS,BRD-A84389633-001-05-7,"tropanyl-3,5-dimethylbenzoate",2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B",NA,NA,CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(C)c1,Preclinical
BRD-A84481105-003-31-3::2.5::HTS,BRD-A84481105-003-31-3,thioridazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCNH2",NA,NA,"CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1",Withdrawn
BRD-A84575140-001-02-4::2.5::HTS,BRD-A84575140-001-02-4,pimobendan,2.5,HTS,"calcium sensitizer, phosphodiesterase inhibitor",PDE3A,cardiology,congestive heart failure,COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C,Launched
BRD-A84687895-001-03-2::2.5::HTS,BRD-A84687895-001-03-2,nilvadipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNA2D3, CACNB2",cardiology,"hypertension, cerebral artery occlusion","COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N, COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N",Launched
BRD-A84907376-300-03-8::2.5::HTS,BRD-A84907376-300-03-8,alcuronium,2.5,HTS,muscle relaxant,"CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7",neurology/psychiatry,muscle relaxant,OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21,Launched
BRD-A85025557-001-02-5::2.5::HTS,BRD-A85025557-001-02-5,NCS-382,2.5,HTS,GABA receptor antagonist,"GABBR1, GABBR2, SLC52A2",NA,NA,OC1c2ccccc2CCC\C1=C/C(O)=O,Preclinical
BRD-A85216385-003-02-4::2.5::HTS,BRD-A85216385-003-02-4,3-alpha-bis-(4-fluorophenyl)-methoxytropane,2.5,HTS,dopamine uptake inhibitor,"CHRM1, SLC6A2, SLC6A3, SLC6A4",NA,NA,CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,Preclinical
BRD-A85242401-001-12-3::2.5::HTS,BRD-A85242401-001-12-3,ascorbic-acid,2.5,HTS,antioxidant,"ALKBH2, ALKBH3, BBOX1, DBH, EGLN1, EGLN2, EGLN3, KDM5D, LCT, OGFOD1, OGFOD2, P3H1, P3H2, P3H3, P4HA1, P4HTM, PAM, PHYH, PLOD1, PLOD2, PLOD3, SLC23A1, SLC23A2, TMLHE",endocrinology,scurvy,"OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O",Launched
BRD-A85472596-001-02-2::2.5::HTS,BRD-A85472596-001-02-2,L-670596,2.5,HTS,prostanoid receptor antagonist,NA,NA,NA,CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1,Preclinical
BRD-A85548292-001-01-8::2.5::HTS,BRD-A85548292-001-01-8,piketoprofen,2.5,HTS,cyclooxygenase inhibitor,NA,neurology/psychiatry,pain relief,CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1,Launched
BRD-A85587465-001-03-3::2.5::HTS,BRD-A85587465-001-03-3,bemesetron,2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B",NA,NA,"CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1, CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1",Phase 3
BRD-A85651701-001-19-7::2.5::HTS,BRD-A85651701-001-19-7,clopamide,2.5,HTS,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85667082-001-12-7::2.5::HTS,BRD-A85667082-001-12-7,fulvestrant,2.5,HTS,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85876464-001-01-5::2.5::HTS,BRD-A85876464-001-01-5,nibentan,2.5,HTS,potassium channel blocker,NA,NA,NA,CCN(CC)CCCCC(NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1,Phase 2
BRD-A86044036-001-26-5::2.5::HTS,BRD-A86044036-001-26-5,flurbiprofen-(+/-),2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1, CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1",Launched
BRD-A86216746-046-02-6::2.5::HTS,BRD-A86216746-046-02-6,varenicline,2.5,HTS,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNA6, CHRNA7",neurology/psychiatry,smoking cessation,C1C2CNCC1c1cc3nccnc3cc21,Launched
BRD-A86248581-001-01-4::2.5::HTS,BRD-A86248581-001-01-4,tetrahydrouridine,2.5,HTS,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86354194-002-01-7::2.5::HTS,BRD-A86354194-002-01-7,L-(+)-Rhamnose-Monohydrate,2.5,HTS,NA,NA,NA,NA,C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O,Preclinical
BRD-A86414188-003-01-5::2.5::HTS,BRD-A86414188-003-01-5,ractopamine,2.5,HTS,adrenergic receptor agonist,NA,NA,NA,"CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1, CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1",Launched
BRD-A86415025-050-01-0::2.5::HTS,BRD-A86415025-050-01-0,"1-(1,2-Diphenylethyl)piperidine-(+/-)",2.5,HTS,glutamate receptor antagonist,NA,NA,NA,C(C(N1CCCCC1)c1ccccc1)c1ccccc1,Preclinical
BRD-A86619021-001-04-8::2.5::HTS,BRD-A86619021-001-04-8,andrographolide,2.5,HTS,tumor necrosis factor production inhibitor,NFKB1,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CCC12,Phase 2
BRD-A86871940-001-01-9::2.5::HTS,BRD-A86871940-001-01-9,nicaraven,2.5,HTS,free radical scavenger,NA,NA,NA,CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1,Phase 3
BRD-A87130939-001-07-9::2.5::HTS,BRD-A87130939-001-07-9,masoprocol,2.5,HTS,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK),CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,Launched
BRD-A87435144-001-01-6::2.5::HTS,BRD-A87435144-001-01-6,AZD7545,2.5,HTS,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1,Phase 1
BRD-A87479750-001-02-7::2.5::HTS,BRD-A87479750-001-02-7,tenidap,2.5,HTS,cyclooxygenase inhibitor,"KCNJ4, PTGS1",NA,NA,"NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12, NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12",Phase 3
BRD-A87673115-001-04-1::2.5::HTS,BRD-A87673115-001-04-1,moguisteine,2.5,HTS,ATP-sensitive potassium channel inhibitor,NA,NA,NA,CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC,Phase 2
BRD-A87715314-003-14-4::2.5::HTS,BRD-A87715314-003-14-4,pronethalol,2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,"CC(C)NCC(O)c1ccc2ccccc2c1, CC(C)NCC(O)c1ccc2ccccc2c1",Withdrawn
BRD-A87983072-001-01-1::2.5::HTS,BRD-A87983072-001-01-1,benzotript,2.5,HTS,CCK receptor antagonist,"CCKAR, CCKBR",NA,NA,OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,Phase 1
BRD-A88080608-001-04-2::2.5::HTS,BRD-A88080608-001-04-2,equilin,2.5,HTS,estrogen receptor agonist,HSD17B1,NA,NA,CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O,Preclinical
BRD-A88138582-001-04-8::2.5::HTS,BRD-A88138582-001-04-8,halcinonide,2.5,HTS,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88369366-001-01-7::2.5::HTS,BRD-A88369366-001-01-7,trelagliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O,Launched
BRD-A88548664-004-02-7::2.5::HTS,BRD-A88548664-004-02-7,SKF-38393,2.5,HTS,dopamine receptor agonist,"CALY, DRD1, DRD5",NA,NA,Oc1cc2CCNCC(c3ccccc3)c2cc1O,Preclinical
BRD-A88684804-001-04-3::2.5::HTS,BRD-A88684804-001-04-3,bucetin,2.5,HTS,analgesic agent,NA,NA,NA,CCOc1ccc(NC(=O)CC(C)O)cc1,Withdrawn
BRD-A89164055-001-03-3::2.5::HTS,BRD-A89164055-001-03-3,sorbinil,2.5,HTS,aldose reductase inhibitor,AKR1B1,NA,NA,Fc1ccc2OCCC3(NC(=O)NC3=O)c2c1,Phase 3
BRD-A89175223-051-14-8::2.5::HTS,BRD-A89175223-051-14-8,bisoprolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,hypertension,"CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1",Launched
BRD-A89196962-300-01-7::2.5::HTS,BRD-A89196962-300-01-7,dalargin,2.5,HTS,opioid receptor agonist,OPRM1,NA,NA,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O,Phase 2
BRD-A89337244-001-02-9::2.5::HTS,BRD-A89337244-001-02-9,PD-102807,2.5,HTS,acetylcholine receptor antagonist,CHRM4,NA,NA,"CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12, CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12",Preclinical
BRD-A89585551-003-16-6::2.5::HTS,BRD-A89585551-003-16-6,mefloquine,2.5,HTS,"adenosine receptor antagonist, hemoglobin antagonist","ADORA2A, HBA1",infectious disease,malaria,OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F,Launched
BRD-A89594340-003-11-5::2.5::HTS,BRD-A89594340-003-11-5,carnitine-(D/L),2.5,HTS,NA,NA,NA,NA,"C[N+](C)(C)CC(O)CC(O)=O, C[N+](C)(C)CC(O)CC(O)=O",Phase 3
BRD-A89672324-001-03-0::2.5::HTS,BRD-A89672324-001-03-0,CGP-55845,2.5,HTS,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A90272038-001-01-7::2.5::HTS,BRD-A90272038-001-01-7,CGP-37849,2.5,HTS,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90515964-001-16-5::2.5::HTS,BRD-A90515964-001-16-5,guaifenesin,2.5,HTS,expectorant,NA,pulmonary,cough suppressant,"COc1ccccc1OCC(O)CO, COc1ccccc1OCC(O)CO",Launched
BRD-A90547603-001-02-5::2.5::HTS,BRD-A90547603-001-02-5,eptifibatide,2.5,HTS,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90551241-001-10-8::2.5::HTS,BRD-A90551241-001-10-8,lornoxicam,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, neurology/psychiatry","osteoarthritis, sciata","CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O",Launched
BRD-A90625545-001-02-0::2.5::HTS,BRD-A90625545-001-02-0,clinofibrate,2.5,HTS,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia,CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O,Launched
BRD-A90695733-001-07-4::2.5::HTS,BRD-A90695733-001-07-4,manidipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-A90799790-001-19-9::2.5::HTS,BRD-A90799790-001-19-9,isradipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C",Launched
BRD-A90926615-001-01-9::2.5::HTS,BRD-A90926615-001-01-9,adrafinil,2.5,HTS,adrenergic receptor agonist,NA,neurology/psychiatry,fatigue,"ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1, ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1",Launched
BRD-A91008255-003-24-8::2.5::HTS,BRD-A91008255-003-24-8,bepridil,2.5,HTS,calcium channel blocker,"ATP1A1, CACNA1A, CACNA1H, CACNA2D2, CALM1, KCNQ1, KCNQ4, PDE1A, PDE1B, TNNC1",cardiology,angina pectoris,"CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1",Launched
BRD-A91366704-001-01-9::2.5::HTS,BRD-A91366704-001-01-9,eprinomectin,2.5,HTS,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91452556-001-04-0::2.5::HTS,BRD-A91452556-001-04-0,estradiol-cypionate,2.5,HTS,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91699651-316-10-9::2.5::HTS,BRD-A91699651-316-10-9,chloroquine,2.5,HTS,antimalarial agent,"GSTA2, MRGPRX1, TLR9, TNF",infectious disease,"malaria, amebiasis","CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12",Launched
BRD-A91733352-300-04-5::2.5::HTS,BRD-A91733352-300-04-5,camylofine-chlorhydrate,2.5,HTS,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91822151-001-05-0::2.5::HTS,BRD-A91822151-001-05-0,picrotin,2.5,HTS,GABA receptor antagonist,"GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB",NA,NA,CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C,Phase 2
BRD-A91831168-003-02-5::2.5::HTS,BRD-A91831168-003-02-5,tetrahydropapaverine,2.5,HTS,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A92096630-001-02-8::2.5::HTS,BRD-A92096630-001-02-8,shikimic-acid,2.5,HTS,NA,NA,NA,NA,O[C@@H]1CC(=CC(O)C1O)C(O)=O,Preclinical
BRD-A92439610-001-05-7::2.5::HTS,BRD-A92439610-001-05-7,triamcinolone-acetonide,2.5,HTS,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92537424-001-04-7::2.5::HTS,BRD-A92537424-001-04-7,danazol,2.5,HTS,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92630576-050-24-1::2.5::HTS,BRD-A92630576-050-24-1,trimebutine,2.5,HTS,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92670106-003-05-4::2.5::HTS,BRD-A92670106-003-05-4,tocainide,2.5,HTS,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,CC(N)C(=O)Nc1c(C)cccc1C,Launched
BRD-A92800748-001-05-5::2.5::HTS,BRD-A92800748-001-05-5,tie2-kinase-inhibitor,2.5,HTS,TIE tyrosine kinase inhibitor,"KDR, MAPK14",NA,NA,COc1ccc2cc(ccc2c1)-c1nc([nH]c1-c1ccncc1)-c1ccc(cc1)S(C)=O,Preclinical
BRD-A92826379-001-01-5::2.5::HTS,BRD-A92826379-001-01-5,lupanine,2.5,HTS,sodium channel blocker,INS,NA,NA,O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3,Phase 1
BRD-A92872453-001-01-8::2.5::HTS,BRD-A92872453-001-01-8,N-acetylmannosamine,2.5,HTS,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92933783-050-01-6::2.5::HTS,BRD-A92933783-050-01-6,SM-21,2.5,HTS,sigma receptor antagonist,PGRMC1,NA,NA,CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C,Preclinical
BRD-A93000692-001-08-1::2.5::HTS,BRD-A93000692-001-08-1,ciglitazone,2.5,HTS,PPAR receptor agonist,PPARG,NA,NA,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1,Phase 2
BRD-A93093700-001-02-9::2.5::HTS,BRD-A93093700-001-02-9,temazepam,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93236127-001-04-5::2.5::HTS,BRD-A93236127-001-04-5,digitoxin,2.5,HTS,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93255169-001-28-3::2.5::HTS,BRD-A93255169-001-28-3,thalidomide,2.5,HTS,tumor necrosis factor production inhibitor,"CRBN, FGFR2, NFKB1, ORM1, ORM2, PTGS2, TNF",NA,NA,"O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12, O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12",Launched
BRD-A93353767-008-02-2::2.5::HTS,BRD-A93353767-008-02-2,isoconazole,2.5,HTS,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections,Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Launched
BRD-A93407926-001-01-1::2.5::HTS,BRD-A93407926-001-01-1,allopurinol-riboside,2.5,HTS,anti-leishmanial agent,NA,NA,NA,OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O,Phase 2
BRD-A93477898-001-04-2::2.5::HTS,BRD-A93477898-001-04-2,PETCM,2.5,HTS,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93695607-322-02-5::2.47::HTS,BRD-A93695607-322-02-5,nicotine,2.47,HTS,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93699261-236-03-4::2.5::HTS,BRD-A93699261-236-03-4,sodium-danshensu,2.5,HTS,NA,NA,NA,NA,"OC(Cc1ccc(O)c(O)c1)C(O)=O, OC(Cc1ccc(O)c(O)c1)C(O)=O",Preclinical
BRD-A93964801-003-03-3::2.5::HTS,BRD-A93964801-003-03-3,clinafloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,"NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1",Phase 3
BRD-A94008949-001-01-9::2.5::HTS,BRD-A94008949-001-01-9,telithromycin,2.5,HTS,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7",infectious disease,pneumonia,"CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC",Launched
BRD-A94033181-001-01-4::2.5::HTS,BRD-A94033181-001-01-4,AZD6765,2.5,HTS,glutamate receptor antagonist,GRIN1,NA,NA,NC(Cc1ccccn1)c1ccccc1,Phase 2
BRD-A94276798-001-01-4::2.5::HTS,BRD-A94276798-001-01-4,talinolol,2.5,HTS,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Launched
BRD-A94323479-001-02-8::2.5::HTS,BRD-A94323479-001-02-8,ki16198,2.5,HTS,lipoprotein antagonist,LPA,NA,NA,COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl,Preclinical
BRD-A94523291-304-02-7::2.5::HTS,BRD-A94523291-304-02-7,prednisolone-sodium-phosphate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, asthma, meningitis, psoriatic arthritis, rheumatoid arthritis",C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O,Launched
BRD-A94543220-001-24-7::2.5::HTS,BRD-A94543220-001-24-7,bifonazole,2.5,HTS,sterol demethylase inhibitor,CYP2B6,infectious disease,"tinea pedis, tinea cruris","c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1, c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1",Launched
BRD-A94624445-236-17-0::2.5::HTS,BRD-A94624445-236-17-0,bucladesine,2.5,HTS,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94709349-001-08-3::2.5::HTS,BRD-A94709349-001-08-3,metaxalone,2.5,HTS,muscle relaxant,NA,neurology/psychiatry,muscle pain,Cc1cc(C)cc(OCC2CNC(=O)O2)c1,Launched
BRD-A94756469-001-04-7::2.5::HTS,BRD-A94756469-001-04-7,digoxin,2.5,HTS,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94993966-001-04-4::2.5::HTS,BRD-A94993966-001-04-4,vildagliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N",Launched
BRD-A94993966-001-05-1::2.63::HTS,BRD-A94993966-001-05-1,vildagliptin,2.63,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N",Launched
BRD-A95121829-001-08-9::2.5::HTS,BRD-A95121829-001-08-9,ginkgolide-a,2.5,HTS,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95340155-001-09-7::2.5::HTS,BRD-A95340155-001-09-7,methyclothiazide,2.5,HTS,chloride reabsorption inhibitor,"CA1, CA2, CA4, SLC12A1, SLC12A3",cardiology,"hypertension, edema",CN1C(CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O,Launched
BRD-A95602221-003-02-1::2.5::HTS,BRD-A95602221-003-02-1,celiprolol,2.5,HTS,adrenergic receptor antagonist,"ADRA2A, ADRB1, ADRB2",genetics,Ehlers-Danlos syndrome (EDS),CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O,Launched
BRD-A95696066-003-13-8::2.5::HTS,BRD-A95696066-003-13-8,nisoxetine,2.5,HTS,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95755460-001-01-3::2.5::HTS,BRD-A95755460-001-01-3,talarozole,2.5,HTS,cytochrome P450 inhibitor,CYP26A1,NA,NA,CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,Phase 2
BRD-A95869247-001-26-9::2.5::HTS,BRD-A95869247-001-26-9,indapamide,2.5,HTS,thiazide diuretic,"KCNE1, KCNQ1, SLC12A3",cardiology,"hypertension, congestive heart failure","CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O",Launched
BRD-A95886749-001-03-5::2.5::HTS,BRD-A95886749-001-03-5,colfosceril-palmitate,2.5,HTS,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95939040-001-01-2::2.5::HTS,BRD-A95939040-001-01-2,sertaconazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,tinea pedis,Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Launched
BRD-A96292436-003-16-1::2.5::HTS,BRD-A96292436-003-16-1,eflornithine,2.5,HTS,ornithine decarboxylase inhibitor,"ARG2, ODC1",dermatology,facial hair reduction,NCCCC(N)(C(F)F)C(O)=O,Launched
BRD-A96407378-001-15-1::2.5::HTS,BRD-A96407378-001-15-1,allantoin,2.5,HTS,cosmetic,NA,dermatology,skin protectant,NC(=O)NC1NC(=O)NC1=O,Launched
BRD-A96456596-001-02-2::2.5::HTS,BRD-A96456596-001-02-2,FPL-55712,2.5,HTS,leukotriene receptor antagonist,NA,NA,NA,CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O,Phase 1
BRD-A96485169-001-14-3::2.5::HTS,BRD-A96485169-001-14-3,EBPC,2.5,HTS,aldose reductase inhibitor,AKR1B1,NA,NA,CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O,Preclinical
BRD-A96529864-001-01-3::2.5::HTS,BRD-A96529864-001-01-3,isosteviol,2.5,HTS,NA,NA,NA,NA,C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)C3CC2,Phase 2
BRD-A96977263-001-03-7::2.5::HTS,BRD-A96977263-001-03-7,M-14157,2.5,HTS,ATP-sensitive potassium channel antagonist,KCNQ1,NA,NA,CCCCCC(O)CCCC(O)=O,Phase 2
BRD-A97104540-004-15-0::2.5::HTS,BRD-A97104540-004-15-0,fenoterol,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",NA,NA,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,Withdrawn
BRD-A97437073-050-14-5::2.5::HTS,BRD-A97437073-050-14-5,rosiglitazone,2.5,HTS,"insulin sensitizer, PPAR receptor agonist","ACSL4, FFAR1, PPARG, TRPC5, TRPM3",NA,NA,"CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1",Withdrawn
BRD-A97479839-003-13-3::2.5::HTS,BRD-A97479839-003-13-3,piperidolate,2.5,HTS,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms,CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1,Launched
BRD-A97674275-001-11-8::2.5::HTS,BRD-A97674275-001-11-8,ranolazine,2.5,HTS,sodium channel blocker,"SCN10A, SCN4A, SCN5A, SCN9A",cardiology,chronic stable angina,"COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1",Launched
BRD-A97701745-001-16-0::2.5::HTS,BRD-A97701745-001-16-0,pindolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97730597-003-11-5::2.5::HTS,BRD-A97730597-003-11-5,hexylcaine,2.5,HTS,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,local anesthetic,CC(CNC1CCCCC1)OC(=O)c1ccccc1,Launched
BRD-A97739905-001-26-5::2.5::HTS,BRD-A97739905-001-26-5,ketoprofen,2.5,HTS,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A98174560-001-02-1::2.5::HTS,BRD-A98174560-001-02-1,chloralose,2.5,HTS,NA,NA,NA,NA,OCC(O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl,Preclinical
BRD-A98299281-050-09-6::2.5::HTS,BRD-A98299281-050-09-6,"hydroxytacrine-maleate-(r,s)",2.5,HTS,cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98378129-001-02-2::2.5::HTS,BRD-A98378129-001-02-2,talniflumate,2.5,HTS,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief,"FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1, FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1",Launched
BRD-A98845662-036-03-7::2.5::HTS,BRD-A98845662-036-03-7,desvenlafaxine,2.5,HTS,serotonin-norepinephrine reuptake inhibitor (SNRI),"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1",Launched
BRD-A98990573-003-01-3::2.5::HTS,BRD-A98990573-003-01-3,epinastine,2.5,HTS,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A99117172-065-04-0::2.5::HTS,BRD-A99117172-065-04-0,hydroxychloroquine,2.5,HTS,antimalarial agent,"TLR7, TLR9",infectious disease,malaria,"CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12",Launched
BRD-A99388803-001-01-5::2.5::HTS,BRD-A99388803-001-01-5,metipranolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",NA,NA,CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C,Withdrawn
BRD-A99633051-001-07-0::2.5::HTS,BRD-A99633051-001-07-0,ethosuximide,2.5,HTS,succinimide antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,epilepsy,"CCC1(C)CC(=O)NC1=O, CCC1(C)CC(=O)NC1=O",Launched
BRD-A99833829-003-27-1::2.5::HTS,BRD-A99833829-003-27-1,bethanechol,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",urology,urinary retention,"CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O",Launched
BRD-A99888680-001-03-8::2.38::HTS,BRD-A99888680-001-03-8,paliperidone,2.38,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-04-6::2.5::HTS,BRD-A99888680-001-04-6,paliperidone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99939097-001-24-2::2.5::HTS,BRD-A99939097-001-24-2,carisoprodol,2.5,HTS,acetylcholine receptor antagonist,CYP2C19,neurology/psychiatry,muscle relaxant,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,Launched
BRD-K00077635-304-01-2::2.5::HTS,BRD-K00077635-304-01-2,estramustine-phosphate,2.5,HTS,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00091711-001-01-2::2.5::HTS,BRD-K00091711-001-01-2,RWJ-21757,2.5,HTS,toll-like receptor agonist,TLR7,NA,NA,"Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1, Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1, Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1",Phase 1
BRD-K00152668-001-01-5::2.5::HTS,BRD-K00152668-001-01-5,adarotene,2.5,HTS,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00259736-001-16-4::2.5::HTS,BRD-K00259736-001-16-4,colchicine,2.5,HTS,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00312224-001-09-5::2.5::HTS,BRD-K00312224-001-09-5,PPT,2.5,HTS,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00317371-001-06-1::2.4::HTS,BRD-K00317371-001-06-1,RITA,2.4,HTS,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00337317-001-06-6::2.5::HTS,BRD-K00337317-001-06-6,NU-7441,2.5,HTS,DNA dependent protein kinase inhibitor,PRKDC,NA,NA,O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1,Preclinical
BRD-K00405906-001-01-9::2.5::HTS,BRD-K00405906-001-01-9,phloroglucin,2.5,HTS,NA,NA,NA,NA,Oc1cc(O)cc(O)c1,Launched
BRD-K00486786-001-02-2::2.5::HTS,BRD-K00486786-001-02-2,Ro-08-2750,2.5,HTS,NA,NGF,NA,NA,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O,Preclinical
BRD-K00494077-066-01-9::2.5::HTS,BRD-K00494077-066-01-9,trovafloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00519864-341-03-3::2.39::HTS,BRD-K00519864-341-03-3,peramivir,2.39,HTS,neuraminidase inhibitor,NA,infectious disease,influenza A virus infection,"CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O",Launched
BRD-K00521308-019-01-9::2.5::HTS,BRD-K00521308-019-01-9,ATN-161,2.5,HTS,integrin antagonist,"ITGA5, ITGAV, ITGB1, ITGB3",NA,NA,"CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O",Phase 2
BRD-K00535541-001-05-5::2.5::HTS,BRD-K00535541-001-05-5,9-aminoacridine,2.5,HTS,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::2.5::HTS,BRD-K00535541-001-06-3,9-aminoacridine,2.5,HTS,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00573984-003-01-5::2.5::HTS,BRD-K00573984-003-01-5,delapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1,Launched
BRD-K00603606-003-24-0::2.5::HTS,BRD-K00603606-003-24-0,ticlopidine,2.5,HTS,purinergic receptor antagonist,P2RY12,"hematology, neurology/psychiatry","thrombosis, stroke","Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1",Launched
BRD-K00610438-003-02-5::2.5::HTS,BRD-K00610438-003-02-5,altanserin,2.5,HTS,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1",Phase 2
BRD-K00615600-001-12-9::2.5::HTS,BRD-K00615600-001-12-9,AG-14361,2.5,HTS,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00627859-003-03-7::2.5::HTS,BRD-K00627859-003-03-7,tubastatin-a,2.5,HTS,HDAC inhibitor,HDAC6,NA,NA,"CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO",Preclinical
BRD-K00662280-001-09-4::2.5::HTS,BRD-K00662280-001-09-4,CL-218872,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00673382-001-18-9::2.5::HTS,BRD-K00673382-001-18-9,famotidine,2.5,HTS,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00674894-001-01-4::2.5::HTS,BRD-K00674894-001-01-4,orteronel,2.5,HTS,"androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor",CYP17A1,NA,NA,CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12,Phase 3
BRD-K00911143-001-01-9::2.5::HTS,BRD-K00911143-001-01-9,brexpiprazole,2.5,HTS,dopamine receptor partial agonist,DRD2,neurology/psychiatry,"depression, schizophrenia",O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1,Launched
BRD-K00911807-003-01-2::2.5::HTS,BRD-K00911807-003-01-2,D-Phenylalanine,2.5,HTS,enkephalinase inhibitor,"CCBL1, CRH, HCAR3",NA,NA,"N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O",Preclinical
BRD-K00926464-001-01-8::2.5::HTS,BRD-K00926464-001-01-8,IMREG-1,2.5,HTS,NA,NA,NA,NA,N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O,Phase 3
BRD-K00938507-001-17-8::2.5::HTS,BRD-K00938507-001-17-8,sulfamethoxypyridazine,2.5,HTS,bacterial antifolate,NA,NA,NA,"COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1",Withdrawn
BRD-K01029106-001-01-4::2.52::HTS,BRD-K01029106-001-01-4,picolinic-acid,2.52,HTS,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01039503-001-01-2::2.5::HTS,BRD-K01039503-001-01-2,sofalcone,2.5,HTS,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD),CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1,Launched
BRD-K01095011-001-15-9::2.5::HTS,BRD-K01095011-001-15-9,finasteride,2.5,HTS,5 alpha reductase inhibitor,"AKR1D1, SRD5A1, SRD5A2",endocrinology,androgenetic alopecia,"CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K01109406-001-03-7::2.5::HTS,BRD-K01109406-001-03-7,nitisinone,2.5,HTS,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01174345-001-01-9::2.5::HTS,BRD-K01174345-001-01-9,anamorelin,2.5,HTS,growth hormone secretagogue receptor agonist,GHSR,NA,NA,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N,Phase 3
BRD-K01244426-236-12-1::2.5::HTS,BRD-K01244426-236-12-1,cloxacillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl",Launched
BRD-K01292756-001-25-0::2.5::HTS,BRD-K01292756-001-25-0,pimozide,2.5,HTS,dopamine receptor antagonist,"CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2",neurology/psychiatry,Tourette's disorder,"Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1",Launched
BRD-K01294196-001-01-5::2.5::HTS,BRD-K01294196-001-01-5,sucrose-octaacetate,2.5,HTS,NA,NA,NA,NA,CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,Preclinical
BRD-K01295354-001-02-8::2.5::HTS,BRD-K01295354-001-02-8,uric-acid,2.5,HTS,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01377300-001-01-1::2.5::HTS,BRD-K01377300-001-01-1,CZC24832,2.5,HTS,PI3K inhibitor,PIK3CG,NA,NA,"CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1",Preclinical
BRD-K01493881-001-29-4::2.5::HTS,BRD-K01493881-001-29-4,apigenin,2.5,HTS,"casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1",NA,NA,"Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1",Preclinical
BRD-K01507359-001-22-9::2.5::HTS,BRD-K01507359-001-22-9,rifampin,2.5,HTS,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01567962-001-23-0::2.5::HTS,BRD-K01567962-001-23-0,pyrazolanthrone,2.5,HTS,JNK inhibitor,"MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK",NA,NA,"O=C1c2ccccc2-c2n[nH]c3cccc1c23, O=C1c2ccccc2-c2n[nH]c3cccc1c23",Preclinical
BRD-K01577834-001-15-1::2.5::HTS,BRD-K01577834-001-15-1,adenosine,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4",cardiology,Wolff-Parkinson-White Syndrome (WPW),"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K01614093-001-02-6::2.5::HTS,BRD-K01614093-001-02-6,dihydromyricetin,2.5,HTS,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01624185-001-05-7::2.5::HTS,BRD-K01624185-001-05-7,maltobionic-acid,2.5,HTS,matrix metalloprotease inhibitor,NA,dermatology,cosmetic,OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O,Launched
BRD-K01649396-003-07-1::2.5::HTS,BRD-K01649396-003-07-1,indatraline,2.5,HTS,norepinephrine transporter inhibitor,"MAOA, MAOB",NA,NA,"CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-K01653460-001-01-1::2.5::HTS,BRD-K01653460-001-01-1,chlorindanol,2.5,HTS,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01663662-003-20-2::2.5::HTS,BRD-K01663662-003-20-2,diphenidol,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,vertigo,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,Launched
BRD-K01669786-001-02-2::2.5::HTS,BRD-K01669786-001-02-2,triapine,2.5,HTS,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01674964-300-06-3::2.5::HTS,BRD-K01674964-300-06-3,histamine,2.5,HTS,histamine receptor agonist,"HRH1, HRH2, HRH3, HRH4",allergy,allergic rhinitis,"NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1",Launched
BRD-K01683783-001-02-6::2.5::HTS,BRD-K01683783-001-02-6,TAK-901,2.5,HTS,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01767299-050-02-1::2.5::HTS,BRD-K01767299-050-02-1,ciproxifan,2.5,HTS,histamine receptor antagonist,"ADRA2A, ADRA2C, HRH3, HRH4, HTR3A",NA,NA,O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1,Preclinical
BRD-K01773560-001-02-4::2.59::HTS,BRD-K01773560-001-02-4,UNC2250,2.59,HTS,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01815685-001-15-5::2.5::HTS,BRD-K01815685-001-15-5,indole-3-carbinol,2.5,HTS,"aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor",AHR,NA,NA,OCc1c[nH]c2ccccc12,Phase 2/Phase 3
BRD-K01824921-001-18-5::2.5::HTS,BRD-K01824921-001-18-5,DPCPX,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1,Phase 1
BRD-K01868942-003-02-7::2.5::HTS,BRD-K01868942-003-02-7,RS-23597-190,2.5,HTS,serotonin receptor antagonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,Preclinical
BRD-K01902415-001-11-7::2.5::HTS,BRD-K01902415-001-11-7,pirinixic-acid,2.5,HTS,PPAR receptor agonist,PPARA,NA,NA,"Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C",Preclinical
BRD-K01942991-005-08-2::2.5::HTS,BRD-K01942991-005-08-2,oxotremorine-m,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O",Preclinical
BRD-K01950558-001-14-7::2.5::HTS,BRD-K01950558-001-14-7,succinylsulfathiazole,2.5,HTS,dihydrofolate reductase inhibitor,DHFR,NA,NA,OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,Phase 2
BRD-K01980392-003-11-6::2.5::HTS,BRD-K01980392-003-11-6,guvacine,2.5,HTS,GABA uptake inhibitor,"SLC6A1, SLC6A11, SLC6A12, SLC6A13",NA,NA,OC(=O)C1=CCCNC1,Preclinical
BRD-K01995783-001-01-6::2.5::HTS,BRD-K01995783-001-01-6,AMG-9810,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,"CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1, CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1",Preclinical
BRD-K02017404-300-06-2::2.5::HTS,BRD-K02017404-300-06-2,NVP-BSK805,2.5,HTS,JAK inhibitor,JAK2,NA,NA,"Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1",Preclinical
BRD-K02079473-001-01-3::2.5::HTS,BRD-K02079473-001-01-3,oxatomide,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,Launched
BRD-K02113016-001-15-4::2.5::HTS,BRD-K02113016-001-15-4,olaparib,2.5,HTS,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02123250-001-06-7::2.5::HTS,BRD-K02123250-001-06-7,JNJ-38877605,2.5,HTS,tyrosine kinase inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1,Phase 1
BRD-K02130563-001-11-4::2.5::HTS,BRD-K02130563-001-11-4,panobinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02241333-001-02-7::2.5::HTS,BRD-K02241333-001-02-7,CHIR-124,2.5,HTS,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02265150-001-26-5::2.5::HTS,BRD-K02265150-001-26-5,amoxapine,2.5,HTS,norepinephrine reputake inhibitor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1",Launched
BRD-K02292852-001-02-1::2.5::HTS,BRD-K02292852-001-02-1,cefoperazone,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O",Launched
BRD-K02314383-001-01-3::2.5::HTS,BRD-K02314383-001-01-3,epitiostanol,2.5,HTS,androgen receptor agonist,AR,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O,Launched
BRD-K02389548-001-02-5::2.5::HTS,BRD-K02389548-001-02-5,RG2833,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02404261-001-16-7::2.5::HTS,BRD-K02404261-001-16-7,caffeine,2.5,HTS,"adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3",neurology/psychiatry,"fatigue, drowsiness, fatigue, drowsiness",Cn1cnc2n(C)c(=O)n(C)c(=O)c12,Launched
BRD-K02407574-001-09-7::2.5::HTS,BRD-K02407574-001-09-7,parbendazole,2.5,HTS,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02464583-001-02-2::2.5::HTS,BRD-K02464583-001-02-2,ethyl-paraben,2.5,HTS,NA,NA,NA,NA,CCOC(=O)c1ccc(O)cc1,Preclinical
BRD-K02475039-001-01-0::2.5::HTS,BRD-K02475039-001-01-0,ethopabate,2.5,HTS,antiprotozoal agent,NA,infectious disease,coccidiosis,CCOc1cc(NC(C)=O)ccc1C(=O)OC,Launched
BRD-K02501528-001-01-1::2.5::HTS,BRD-K02501528-001-01-1,S18986,2.5,HTS,glutamate receptor modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,O=S1(=O)N[C@H]2CCCN2c2ccccc12,Phase 2
BRD-K02594908-001-16-4::2.5::HTS,BRD-K02594908-001-16-4,sulfanilamide,2.5,HTS,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02637541-001-18-0::2.5::HTS,BRD-K02637541-001-18-0,celecoxib,2.5,HTS,cyclooxygenase inhibitor,"CA12, PDPK1, PTGS2","rheumatology, endocrinology","osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)","Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F",Launched
BRD-K02703275-001-07-5::2.5::HTS,BRD-K02703275-001-07-5,gedunin,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1,Preclinical
BRD-K02715688-001-02-1::2.5::HTS,BRD-K02715688-001-02-1,"hydrastine-(1r,-9s)",2.5,HTS,tyrosine hydroxylase inhibitor,NA,NA,NA,COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12,Preclinical
BRD-K02733959-236-07-7::2.5::HTS,BRD-K02733959-236-07-7,cefuroxime,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1",Launched
BRD-K02764365-001-13-6::2.5::HTS,BRD-K02764365-001-13-6,methiazole,2.5,HTS,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02816415-001-01-9::2.5::HTS,BRD-K02816415-001-01-9,CRT0044876,2.5,HTS,NA,NA,NA,NA,OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1,Preclinical
BRD-K02867583-300-08-9::2.5::HTS,BRD-K02867583-300-08-9,minaprine,2.5,HTS,serotonin reuptake inhibitor,"ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4",NA,NA,Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1,Withdrawn
BRD-K02898090-001-02-7::2.5::HTS,BRD-K02898090-001-02-7,kifunensine,2.5,HTS,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02900412-001-11-3::2.5::HTS,BRD-K02900412-001-11-3,clofoctol,2.5,HTS,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02908048-003-06-4::2.5::HTS,BRD-K02908048-003-06-4,preclamol,2.5,HTS,dopamine receptor agonist,DRD2,NA,NA,CCCN1CCC[C@@H](C1)c1cccc(O)c1,Phase 2
BRD-K02943813-001-01-9::2.5::HTS,BRD-K02943813-001-01-9,dasabuvir,2.5,HTS,HCV inhibitor,NA,infectious disease,hepatitis C,COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1,Launched
BRD-K02950022-001-02-9::2.5::HTS,BRD-K02950022-001-02-9,BMS-299897,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O,Phase 1
BRD-K02953697-001-09-2::2.5::HTS,BRD-K02953697-001-09-2,naringin,2.5,HTS,cytochrome P450 inhibitor,SLCO1A2,NA,NA,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,Preclinical
BRD-K02965346-001-07-5::2.5::HTS,BRD-K02965346-001-07-5,SU-11274,2.5,HTS,"hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor",MET,NA,NA,"CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1",Preclinical
BRD-K02965577-001-03-4::0.25::HTS,BRD-K02965577-001-03-4,secalciferol,0.25,HTS,vitamin D receptor agonist,VDR,critical care,bone fracture,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,Launched
BRD-K02992638-001-11-8::2.5::HTS,BRD-K02992638-001-11-8,lamivudine,2.5,HTS,nucleoside reverse transcriptase inhibitor,NA,infectious disease,"human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B","Nc1ccn(C2CSC(CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1",Launched
BRD-K03063480-001-05-8::2.5::HTS,BRD-K03063480-001-05-8,PF-477736,2.5,HTS,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::2.42::HTS,BRD-K03063480-001-06-6,PF-477736,2.42,HTS,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03095347-001-06-1::2.5::HTS,BRD-K03095347-001-06-1,levosimendan,2.5,HTS,calcium sensitizer,"KCNJ11, KCNJ8, PDE3A, TNNC1",cardiology,congestive heart failure,"C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1",Launched
BRD-K03109492-001-02-2::2.5::HTS,BRD-K03109492-001-02-2,NSC-663284,2.5,HTS,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03155172-001-02-2::2.5::HTS,BRD-K03155172-001-02-2,GSK3787,2.5,HTS,PPAR receptor antagonist,PPARD,NA,NA,"FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1",Preclinical
BRD-K03164761-001-02-1::2.5::HTS,BRD-K03164761-001-02-1,thiazovivin,2.5,HTS,rho associated kinase inhibitor,NA,NA,NA,O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1,Preclinical
BRD-K03194791-001-04-8::2.5::HTS,BRD-K03194791-001-04-8,roflumilast,2.5,HTS,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis",FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl,Launched
BRD-K03243820-001-23-8::2.37::HTS,BRD-K03243820-001-23-8,trifluridine,2.37,HTS,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-25-3::2.5::HTS,BRD-K03243820-001-25-3,trifluridine,2.5,HTS,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03273112-001-01-8::2.5::HTS,BRD-K03273112-001-01-8,1-azakenpaullone,2.5,HTS,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03289018-001-02-7::2.5::HTS,BRD-K03289018-001-02-7,CCT137690,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289534-001-01-4::2.5::HTS,BRD-K03289534-001-01-4,lersivirine,2.5,HTS,non-nucleoside reverse transcriptase inhibitor,NA,NA,NA,CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N,Phase 2
BRD-K03294269-001-08-0::2.5::HTS,BRD-K03294269-001-08-0,NU6027,2.5,HTS,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03301001-003-02-5::2.5::HTS,BRD-K03301001-003-02-5,A-7,2.5,HTS,calmodulin antagonist,NA,NA,NA,"NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",Preclinical
BRD-K03353589-236-01-4::2.5::HTS,BRD-K03353589-236-01-4,ecabet,2.5,HTS,"gastrin inhibitor, urease inhibitor",NOXO1,ophthalmology,dry eye syndrome,CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O,Launched
BRD-K03384561-001-02-7::2.5::HTS,BRD-K03384561-001-02-7,roquinimex,2.5,HTS,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03390685-001-01-7::2.5::HTS,BRD-K03390685-001-01-7,cobimetinib,2.5,HTS,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03406345-001-27-8::2.5::HTS,BRD-K03406345-001-27-8,azacitidine,2.5,HTS,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03449891-001-08-6::2.5::HTS,BRD-K03449891-001-08-6,foretinib,2.5,HTS,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03504028-001-07-6::2.5::HTS,BRD-K03504028-001-07-6,amygdalin,2.5,HTS,caspase activator,CASP3,NA,NA,"OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K03549949-001-01-0::2.5::HTS,BRD-K03549949-001-01-0,XL388,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03564313-001-03-3::2.5::HTS,BRD-K03564313-001-03-3,DMNB,2.5,HTS,DNA dependent protein kinase inhibitor,NA,NA,NA,COc1cc(C=O)c(cc1OC)[N+]([O-])=O,Preclinical
BRD-K03601870-001-01-2::2.5::HTS,BRD-K03601870-001-01-2,ixabepilone,2.5,HTS,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03739921-001-06-8::2.5::HTS,BRD-K03739921-001-06-8,hypoxanthine,2.5,HTS,PARP inhibitor,PNP,NA,NA,O=c1[nH]cnc2nc[nH]c12,Preclinical
BRD-K04111260-001-10-0::2.5::HTS,BRD-K04111260-001-10-0,raclopride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04112579-001-07-0::2.5::HTS,BRD-K04112579-001-07-0,nepafenac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",ophthalmology,eye inflammation,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,Launched
BRD-K04176066-001-08-3::2.5::HTS,BRD-K04176066-001-08-3,bergenin,2.5,HTS,interleukin inhibitor,"IL1B, TNF",NA,NA,"COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O",Preclinical
BRD-K04185004-003-11-9::2.5::HTS,BRD-K04185004-003-11-9,oxybuprocaine,2.5,HTS,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic,"CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC",Launched
BRD-K04196797-001-24-4::2.5::HTS,BRD-K04196797-001-24-4,oxcarbazepine,2.5,HTS,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04264130-001-01-4::2.5::HTS,BRD-K04264130-001-01-4,favipiravir,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04394237-001-03-7::2.49::HTS,BRD-K04394237-001-03-7,drospirenone,2.49,HTS,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-06-0::2.5::HTS,BRD-K04394237-001-06-0,drospirenone,2.5,HTS,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04414442-001-08-3::2.5::HTS,BRD-K04414442-001-08-3,SB-222200,2.5,HTS,tachykinin antagonist,TACR3,NA,NA,"CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K04430056-001-17-7::2.5::HTS,BRD-K04430056-001-17-7,7-nitroindazole,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::2.5::HTS,BRD-K04430056-236-02-1,7-nitroindazole,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04497194-001-02-1::2.5::HTS,BRD-K04497194-001-02-1,lithocholic-acid,2.5,HTS,"FXR antagonist, vitamin D receptor agonist","GPBAR1, NR1H4, NR1I2, VDR",NA,NA,C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Preclinical
BRD-K04548931-003-16-5::2.5::HTS,BRD-K04548931-003-16-5,epirubicin,2.5,HTS,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04552268-001-02-4::5::HTS,BRD-K04552268-001-02-4,4-pyrimidinecarbonitrile,5.0,HTS,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04568635-300-01-4::2.5::HTS,BRD-K04568635-300-01-4,octenidine,2.5,HTS,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04622161-001-02-3::2.5::HTS,BRD-K04622161-001-02-3,YO-01027,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04623885-001-07-5::2.5::HTS,BRD-K04623885-001-07-5,BIBR-1532,2.5,HTS,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04657451-001-01-0::2.5::HTS,BRD-K04657451-001-01-0,D-delta-Tocopherol,2.5,HTS,NA,NA,NA,NA,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1,Launched
BRD-K04691817-001-01-8::2.5::HTS,BRD-K04691817-001-01-8,AGI-6780,2.5,HTS,isocitrate dehydrogenase inhibitor,IDH2,NA,NA,FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1,Preclinical
BRD-K04704168-003-14-3::2.5::HTS,BRD-K04704168-003-14-3,clemizole,2.5,HTS,HCV inhibitor,NA,allergy,allergic rhinitis,"Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1",Launched
BRD-K04804440-001-09-5::2.5::HTS,BRD-K04804440-001-09-5,ciprofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis,"OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K04833372-001-06-2::2.5::HTS,BRD-K04833372-001-06-2,GSK1904529A,2.5,HTS,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04851519-001-06-8::2.5::HTS,BRD-K04851519-001-06-8,aloe-emodin,2.5,HTS,anticancer agent,CASP8,NA,NA,OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,Preclinical
BRD-K04923131-001-15-4::2.5::HTS,BRD-K04923131-001-15-4,GSK-3-inhibitor-IX,2.5,HTS,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04956647-003-02-5::2.5::HTS,BRD-K04956647-003-02-5,nebivolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,hypertension,"O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1",Launched
BRD-K04993719-001-01-7::2.5::HTS,BRD-K04993719-001-01-7,LY2334737,2.5,HTS,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K05048137-001-03-9::1.57::HTS,BRD-K05048137-001-03-9,phytosphingosine,1.57,HTS,NA,NA,NA,NA,CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO,Phase 1
BRD-K05104363-001-10-0::2.5::HTS,BRD-K05104363-001-10-0,PD-184352,2.5,HTS,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05151076-001-02-6::2.5::HTS,BRD-K05151076-001-02-6,ZK-164015,2.5,HTS,estrogen receptor antagonist,"ESR1, ESR2",NA,NA,"CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1",Preclinical
BRD-K05181084-003-03-7::2.5::HTS,BRD-K05181084-003-03-7,NGB-2904,2.5,HTS,dopamine receptor antagonist,DRD3,NA,NA,"Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl",Preclinical
BRD-K05236810-001-19-0::2.5::HTS,BRD-K05236810-001-19-0,luteolin,2.5,HTS,glucosidase inhibitor,TOP1,NA,NA,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1,Phase 2
BRD-K05361803-001-03-9::2.5::HTS,BRD-K05361803-001-03-9,SC-10,2.5,HTS,protein kinase activator,PRKCA,NA,NA,CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,Preclinical
BRD-K05395900-322-05-4::2.5::HTS,BRD-K05395900-322-05-4,nicotine,2.5,HTS,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-K05434375-001-06-5::2.5::HTS,BRD-K05434375-001-06-5,HA-1004,2.5,HTS,calcium channel blocker,NA,NA,NA,NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12,Phase 2
BRD-K05444225-001-01-7::2.5::HTS,BRD-K05444225-001-01-7,E7449,2.5,HTS,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05445342-001-05-3::2.57::HTS,BRD-K05445342-001-05-3,WP1066,2.57,HTS,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05446112-001-01-8::2.5::HTS,BRD-K05446112-001-01-8,ledipasvir,2.5,HTS,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K05464208-001-05-7::2.5::HTS,BRD-K05464208-001-05-7,JX-401,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,"COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1",Preclinical
BRD-K05524748-003-04-4::2.5::HTS,BRD-K05524748-003-04-4,dronedarone,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05528470-305-02-2::2.5::HTS,BRD-K05528470-305-02-2,L-745870,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7",NA,NA,"Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1",Preclinical
BRD-K05619559-001-12-7::2.5::HTS,BRD-K05619559-001-12-7,tobramycin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,"bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections","NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O",Launched
BRD-K05638300-001-01-2::2.5::HTS,BRD-K05638300-001-01-2,sevoflurane,2.5,HTS,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05658747-001-02-9::2.5::HTS,BRD-K05658747-001-02-9,raltegravir,2.5,HTS,HIV integrase inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C",Launched
BRD-K05673000-236-12-1::2.5::HTS,BRD-K05673000-236-12-1,dicloxacillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl",Launched
BRD-K05674516-001-01-7::2.5::HTS,BRD-K05674516-001-01-7,PSI-7976,2.5,HTS,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-02-5::2.5::HTS,BRD-K05674516-001-02-5,sofosbuvir,2.5,HTS,RNA polymerase inhibitor,NA,infectious disease,hepatitis C,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Launched
BRD-K05677083-001-05-4::2.5::HTS,BRD-K05677083-001-05-4,PACOCF3,2.5,HTS,phospholipase inhibitor,PLA2G4A,NA,NA,CCCCCCCCCCCCCCCC(=O)C(F)(F)F,Preclinical
BRD-K05804044-001-06-0::2.5::HTS,BRD-K05804044-001-06-0,AZ-628,2.5,HTS,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05850076-001-01-5::2.5::HTS,BRD-K05850076-001-01-5,sotagliflozin,2.5,HTS,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",NA,NA,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1,Phase 3
BRD-K05878375-236-05-7::2.5::HTS,BRD-K05878375-236-05-7,sodium-butyrate,2.5,HTS,HDAC inhibitor,"BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8",NA,NA,"CCCC(O)=O, CCCC(O)=O",Phase 2
BRD-K05900209-001-03-4::2.47::HTS,BRD-K05900209-001-03-4,dexlansoprazole,2.47,HTS,ATPase inhibitor,"ATP4A, ATP4B",gastroenterology,"gastroesophageal reflux disease (GERD), erosive esophagitis (EE)","Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1",Launched
BRD-K05906022-001-05-1::2.5::HTS,BRD-K05906022-001-05-1,limonin,2.5,HTS,HIV protease inhibitor,NA,NA,NA,CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1,Preclinical
BRD-K05907307-001-07-1::2.5::HTS,BRD-K05907307-001-07-1,nonivamide,2.5,HTS,TRPV agonist,TRPV1,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain",CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,Launched
BRD-K05919151-001-01-6::2.5::HTS,BRD-K05919151-001-01-6,dixanthogen,2.5,HTS,NA,NA,NA,NA,CCOC(=S)SSC(=S)OCC,Preclinical
BRD-K05977355-001-19-0::2.5::HTS,BRD-K05977355-001-19-0,fluconazole,2.5,HTS,sterol demethylase inhibitor,CYP51A1,infectious disease,"esophageal candidiasis, meningitis","OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F",Launched
BRD-K06147391-300-06-8::2.5::HTS,BRD-K06147391-300-06-8,telenzepine,2.5,HTS,acetylcholine receptor antagonist,CHRM1,NA,NA,"CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1",Phase 3
BRD-K06152156-001-01-8::2.5::HTS,BRD-K06152156-001-01-8,methoxyflurane,2.5,HTS,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06181161-048-15-1::2.5::HTS,BRD-K06181161-048-15-1,carbetapentane,2.5,HTS,acetylcholine receptor antagonist,CHRM2,"otolaryngology, pulmonary","common cold, nasal congestion, bronchitis","CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1",Launched
BRD-K06208435-003-08-2::2.5::HTS,BRD-K06208435-003-08-2,YS-035,2.5,HTS,calcium channel blocker,NA,NA,NA,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,Preclinical
BRD-K06221026-001-06-8::2.5::HTS,BRD-K06221026-001-06-8,DUP-697,2.5,HTS,cyclooxygenase inhibitor,PTGS2,NA,NA,"CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1",Phase 1
BRD-K06222852-001-03-2::2.5::HTS,BRD-K06222852-001-03-2,posaconazole,2.5,HTS,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06234293-001-04-2::2.5::HTS,BRD-K06234293-001-04-2,LY364947,2.5,HTS,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06240250-001-01-6::2.5::HTS,BRD-K06240250-001-01-6,rilpivirine,2.5,HTS,non-nucleoside reverse transcriptase inhibitor,"NR1I2, SCN10A",infectious disease,human immunodeficiency virus (HIV-1),Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1,Launched
BRD-K06294530-001-01-5::2.5::HTS,BRD-K06294530-001-01-5,UK-383367,2.5,HTS,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06335600-003-20-7::2.5::HTS,BRD-K06335600-003-20-7,tizanidine,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, NISCH",neurology/psychiatry,spasms,"Clc1ccc2nsnc2c1NC1=NCCN1, Clc1ccc2nsnc2c1NC1=NCCN1, Clc1ccc2nsnc2c1NC1=NCCN1",Launched
BRD-K06388322-312-02-6::2.5::HTS,BRD-K06388322-312-02-6,pramipexole,2.5,HTS,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,Parkinson's Disease,"CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1",Launched
BRD-K06408664-001-03-5::2.5::HTS,BRD-K06408664-001-03-5,fludrocortisone-acetate,2.5,HTS,NA,"AR, NR3C1, NR3C2",endocrinology,"Addison's disease, adrenogenital syndrome","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K06426971-001-02-7::2.5::HTS,BRD-K06426971-001-02-7,ryuvidine,2.5,HTS,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06542892-001-01-9::2.5::HTS,BRD-K06542892-001-01-9,ASP3026,2.5,HTS,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",Phase 1
BRD-K06543683-066-02-1::2.5::HTS,BRD-K06543683-066-02-1,bisindolylmaleimide-ix,2.5,HTS,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06557128-001-07-0::2.5::HTS,BRD-K06557128-001-07-0,voriconazole,2.5,HTS,cytochrome P450 inhibitor,"CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1",infectious disease,"esophageal candidiasis, aspergillosis, skin infections","C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",Launched
BRD-K06593056-001-04-8::2.5::HTS,BRD-K06593056-001-04-8,LE-135,2.5,HTS,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06644925-001-03-0::2.5::HTS,BRD-K06644925-001-03-0,oleamide,2.5,HTS,cannabinoid receptor agonist,"HTR7, PLA2G2A",NA,NA,CCCCCCCC\C=C/CCCCCCCC(N)=O,Preclinical
BRD-K06674495-334-03-2::2.5::HTS,BRD-K06674495-334-03-2,nafamostat,2.5,HTS,serine protease inhibitor,"ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7",NA,NA,"NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N",Launched
BRD-K06749501-001-02-1::2.5::HTS,BRD-K06749501-001-02-1,GSK1838705A,2.5,HTS,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06753942-001-14-5::2.5::HTS,BRD-K06753942-001-14-5,nobiletin,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06762493-001-08-1::2.5::HTS,BRD-K06762493-001-08-1,isbufylline,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12,Phase 2
BRD-K06814349-304-01-9::2.5::HTS,BRD-K06814349-304-01-9,fosbretabulin,2.5,HTS,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06854232-001-19-9::2.5::HTS,BRD-K06854232-001-19-9,AM-580,2.5,HTS,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06858286-001-01-3::2.5::HTS,BRD-K06858286-001-01-3,cabazitaxel,2.5,HTS,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06878038-001-18-6::2.5::HTS,BRD-K06878038-001-18-6,deferiprone,2.5,HTS,chelating agent,UGT1A6,hematology,"transfusional hemosiderosis, thalassemia, iron overload","Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C",Launched
BRD-K06900071-001-01-2::2.5::HTS,BRD-K06900071-001-01-2,tebipenem,2.5,HTS,bacterial cell wall synthesis inhibitor,CNR1,"infectious disease, otolaryngology","pneumonia, otitis",C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C,Launched
BRD-K06902185-003-01-7::2.5::HTS,BRD-K06902185-003-01-7,minoxidil,2.5,HTS,"KATP activator, Kir6 channel (KATP) activator, vasodilator","ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1",endocrinology,androgenetic alopecia,"Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1",Launched
BRD-K06980535-003-25-9::2.5::HTS,BRD-K06980535-003-25-9,promazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12",Launched
BRD-K07106112-003-03-8::2.5::HTS,BRD-K07106112-003-03-8,BMS-599626,2.5,HTS,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07160047-001-01-3::2.5::HTS,BRD-K07160047-001-01-3,fiacitabine,2.5,HTS,DNA synthesis inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,Phase 2
BRD-K07166362-330-02-8::2.5::HTS,BRD-K07166362-330-02-8,streptomycin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,tuberculosis,"CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O, CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O",Launched
BRD-K07202345-001-19-4::2.5::HTS,BRD-K07202345-001-19-4,frentizole,2.5,HTS,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07208025-001-29-7::2.5::HTS,BRD-K07208025-001-29-7,trimethoprim,2.5,HTS,dihydrofolate reductase inhibitor,"DHFR, TYMS","infectious disease, gastroenterology","urinary tract infections, ear infections, diarrhea","COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC",Launched
BRD-K07220430-001-18-4::2.5::HTS,BRD-K07220430-001-18-4,cinnarazine,2.5,HTS,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-19-2::2.5::HTS,BRD-K07220430-001-19-2,cinnarazine,2.5,HTS,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07237224-001-19-6::2.5::HTS,BRD-K07237224-001-19-6,moclobemide,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,"depression, anxiety","Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1",Launched
BRD-K07265709-003-05-6::2.61::HTS,BRD-K07265709-003-05-6,dexrazoxane,2.61,HTS,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07283971-001-01-3::2.5::HTS,BRD-K07283971-001-01-3,oxyclozanide,2.5,HTS,NA,NA,infectious disease,fascioliasis,Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K07310275-001-02-5::2.5::HTS,BRD-K07310275-001-02-5,PF-04691502,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07359318-001-03-9::2.45::HTS,BRD-K07359318-001-03-9,benfotiamine,2.45,HTS,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07441213-001-18-9::2.5::HTS,BRD-K07441213-001-18-9,paroxypropione,2.5,HTS,gonadotropin inhibitor,NA,NA,NA,CCC(=O)c1ccc(O)cc1,Launched
BRD-K07442505-001-03-6::2.5::HTS,BRD-K07442505-001-03-6,BAM7,2.5,HTS,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07487750-001-03-3::2.5::HTS,BRD-K07487750-001-03-3,WHI-P154,2.5,HTS,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07507905-236-02-6::2.5::HTS,BRD-K07507905-236-02-6,BRL-37344,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",NA,NA,"C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1",Phase 2
BRD-K07572174-001-39-4::2.48::HTS,BRD-K07572174-001-39-4,curcumin,2.48,HTS,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07609981-001-01-7::2.5::HTS,BRD-K07609981-001-01-7,dexloxiglumide,2.5,HTS,CCK receptor antagonist,CCKAR,NA,NA,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,Phase 3
BRD-K07612980-001-05-3::2.59::HTS,BRD-K07612980-001-05-3,sparfloxacin,2.59,HTS,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-07-9::2.5::HTS,BRD-K07612980-001-07-9,sparfloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07691486-001-15-5::2.5::HTS,BRD-K07691486-001-15-5,roscovitine,2.5,HTS,CDK inhibitor,"CDK2, CDK9",NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1",Phase 2
BRD-K07736136-001-04-6::2.51::HTS,BRD-K07736136-001-04-6,VX-702,2.51,HTS,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07753030-003-17-6::2.5::HTS,BRD-K07753030-003-17-6,acecainide,2.5,HTS,polarization inhibitor,SCN5A,NA,NA,CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,Phase 3
BRD-K07762753-001-04-4::2.5::HTS,BRD-K07762753-001-04-4,aminopurvalanol-a,2.5,HTS,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07798980-001-01-9::2.5::HTS,BRD-K07798980-001-01-9,PSI-6130,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,Phase 1
BRD-K07857022-002-01-1::2.5::HTS,BRD-K07857022-002-01-1,alvimopan,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,postoperative ileus,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1,Launched
BRD-K07881437-001-03-8::2.5::HTS,BRD-K07881437-001-03-8,danusertib,2.5,HTS,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::2.41::HTS,BRD-K07881437-001-04-6,danusertib,2.41,HTS,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07940445-310-02-9::2.5::HTS,BRD-K07940445-310-02-9,quinine,2.5,HTS,hemozoin biocrystallization inhibitor,"GP9, KCNB2, KCNN4, SLC29A4",infectious disease,malaria,"COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1",Launched
BRD-K07954936-001-01-3::2.5::HTS,BRD-K07954936-001-01-3,2-iminobiotin,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2",NA,NA,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12,Phase 2
BRD-K07955840-001-02-3::2.5::HTS,BRD-K07955840-001-02-3,PF-05212384,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07972848-001-02-0::2.5::HTS,BRD-K07972848-001-02-0,GSK2126458,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K08033334-003-04-3::2.5::HTS,BRD-K08033334-003-04-3,lincomycin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,gastroenterology,enteritis,"CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O",Launched
BRD-K08037784-001-12-6::2.5::HTS,BRD-K08037784-001-12-6,arbutin,2.5,HTS,melanin inhibitor,TYR,NA,NA,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2/Phase 3
BRD-K08078237-001-19-8::2.5::HTS,BRD-K08078237-001-19-8,tetrandrine,2.5,HTS,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08109215-001-06-4::2.5::HTS,BRD-K08109215-001-06-4,I-BET-762,2.5,HTS,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109516-001-07-8::2.5::HTS,BRD-K08109516-001-07-8,L-701324,2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12",Preclinical
BRD-K08111240-001-02-8::2.5::HTS,BRD-K08111240-001-02-8,danoprevir,2.5,HTS,HCV inhibitor,NA,NA,NA,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1,Phase 2
BRD-K08111712-001-16-7::2.5::HTS,BRD-K08111712-001-16-7,chloramphenicol,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,CD55,"infectious disease, endocrinology","meningitis, fever, cholera","OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K08188887-001-02-4::2.5::HTS,BRD-K08188887-001-02-4,astragaloside-a,2.5,HTS,antiinflammatory agent,NA,NA,NA,CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C,Preclinical
BRD-K08206212-002-01-0::2.5::HTS,BRD-K08206212-002-01-0,entecavir,2.5,HTS,"DNA replication inhibitor, nucleoside reverse transcriptase inhibitor",NA,infectious disease,hepatitis B,Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1,Launched
BRD-K08223200-001-01-1::2.5::HTS,BRD-K08223200-001-01-1,WAY-200070,2.5,HTS,estrogen receptor agonist,"ERBB2, ERBB3, ERBB4, ESR2",NA,NA,"Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1",Preclinical
BRD-K08231299-001-08-1::2.5::HTS,BRD-K08231299-001-08-1,propoxur,2.5,HTS,NA,NA,NA,NA,CNC(=O)Oc1ccccc1OC(C)C,Launched
BRD-K08248804-001-01-8::2.5::HTS,BRD-K08248804-001-01-8,LCL-161,2.5,HTS,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08251020-001-01-0::2.5::HTS,BRD-K08251020-001-01-0,falecalcitriol,2.5,HTS,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,"C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K08252256-236-33-8::2.5::HTS,BRD-K08252256-236-33-8,diclofenac,2.5,HTS,cyclooxygenase inhibitor,"AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A","rheumatology, neurology/psychiatry","rheumatoid arthritis, osteoarthritis, migraine headache","OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl",Launched
BRD-K08273968-001-19-0::2.5::HTS,BRD-K08273968-001-19-0,griseofulvin,2.5,HTS,tubulin polymerization inhibitor,KRT12,infectious disease,"ringworm, tinea pedis","COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12, COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12",Launched
BRD-K08287586-001-14-3::2.5::HTS,BRD-K08287586-001-14-3,butyl-paraben,2.5,HTS,DNA synthesis inhibitor,NA,NA,NA,CCCCOC(=O)c1ccc(O)cc1,Preclinical
BRD-K08288352-001-03-6::2.5::HTS,BRD-K08288352-001-03-6,1-ethyl-2-pyrrolidone,2.5,HTS,transdermal absorption-enhancing compound,NA,NA,NA,CCN1CCCC1=O,Preclinical
BRD-K08303368-001-10-0::2.5::HTS,BRD-K08303368-001-10-0,chlorpyrifos,2.5,HTS,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08310154-001-03-8::2.5::HTS,BRD-K08310154-001-03-8,AG-1024,2.5,HTS,insulin growth factor receptor inhibitor,IGF1R,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,Preclinical
BRD-K08356259-003-24-7::2.5::HTS,BRD-K08356259-003-24-7,xylometazoline,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","otolaryngology, allergy","nasal congestion, allergic rhinitis","Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K08493205-001-04-9::2.5::HTS,BRD-K08493205-001-04-9,salicyl-alcohol,2.5,HTS,NA,NA,NA,NA,OCc1ccccc1O,Preclinical
BRD-K08525451-003-05-2::2.5::HTS,BRD-K08525451-003-05-2,sarafloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08542803-001-03-1::0.8::HTS,BRD-K08542803-001-03-1,gambogic-acid,0.8,HTS,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08547377-394-03-5::2.5::HTS,BRD-K08547377-394-03-5,irinotecan,2.5,HTS,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08586861-001-01-1::2.5::HTS,BRD-K08586861-001-01-1,ramatroban,2.5,HTS,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08619574-334-05-4::2.5::HTS,BRD-K08619574-334-05-4,thioproperazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619838-300-05-7::2.5::HTS,BRD-K08619838-300-05-7,tremorine,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08640512-003-02-3::2.5::HTS,BRD-K08640512-003-02-3,RS-100329,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,Preclinical
BRD-K08681769-323-03-7::2.5::HTS,BRD-K08681769-323-03-7,ibandronate,2.5,HTS,bone resorption inhibitor,FDPS,orthopedics,osteoporosis,"CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
BRD-K08703257-001-12-1::2.5::HTS,BRD-K08703257-001-12-1,3-amino-benzamide,2.5,HTS,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08791496-001-01-0::2.5::HTS,BRD-K08791496-001-01-0,fenaclon,2.5,HTS,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08799216-001-05-3::2.5::HTS,BRD-K08799216-001-05-3,pelitinib,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08832567-001-11-5::2.5::HTS,BRD-K08832567-001-11-5,naringenin,2.5,HTS,"aromatase inhibitor, TRPV antagonist","CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1",NA,NA,Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,Phase 1
BRD-K08837089-236-01-6::2.5::HTS,BRD-K08837089-236-01-6,actinoquinol,2.5,HTS,NA,NA,NA,NA,CCOc1ccc(c2cccnc12)S(O)(=O)=O,Preclinical
BRD-K08859203-001-01-9::2.5::HTS,BRD-K08859203-001-01-9,DU-728,2.5,HTS,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08864679-001-02-2::2.5::HTS,BRD-K08864679-001-02-2,fexaramine,2.5,HTS,FXR agonist,NR1H4,NA,NA,"COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1",Preclinical
BRD-K08893438-001-04-9::2.52::HTS,BRD-K08893438-001-04-9,CCG-50014,2.52,HTS,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08924299-003-06-1::2.5::HTS,BRD-K08924299-003-06-1,palonosetron,2.5,HTS,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting",O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2,Launched
BRD-K08953028-001-09-6::2.5::HTS,BRD-K08953028-001-09-6,U-0521,2.5,HTS,catechol O methyltransferase inhibitor,COMT,NA,NA,CC(C)C(=O)c1ccc(O)c(O)c1,Preclinical
BRD-K08976401-001-18-5::2.5::HTS,BRD-K08976401-001-18-5,azelaic-acid,2.5,HTS,tyrosinase inhibitor,"AKR1D1, SRD5A2, TYR",dermatology,rosacea,OC(=O)CCCCCCCC(O)=O,Launched
BRD-K08996725-332-01-7::2.5::HTS,BRD-K08996725-332-01-7,zolantidine,2.5,HTS,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08998509-001-02-4::2.5::HTS,BRD-K08998509-001-02-4,fananserin,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,NA,NA,"Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1",Phase 2
BRD-K08999871-213-01-5::2.5::HTS,BRD-K08999871-213-01-5,pipemidic-acid,2.5,HTS,topoisomerase inhibitor,NA,infectious disease,gram-negative bacterial infections,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1,Launched
BRD-K09090523-001-02-1::2.5::HTS,BRD-K09090523-001-02-1,firocoxib,2.5,HTS,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O,Launched
BRD-K09090949-001-01-9::2.5::HTS,BRD-K09090949-001-01-9,"CP-945,598",2.5,HTS,cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09126848-003-01-9::2.5::HTS,BRD-K09126848-003-01-9,nepicastat,2.5,HTS,dopamine beta hydroxylase inhibitor,DBH,NA,NA,"NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1",Phase 2
BRD-K09132007-001-07-5::2.5::HTS,BRD-K09132007-001-07-5,D-4476,2.5,HTS,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09255212-001-16-6::2.5::HTS,BRD-K09255212-001-16-6,clioquinol,2.5,HTS,chelating agent,OPRK1,NA,NA,Oc1c(I)cc(Cl)c2cccnc12,Withdrawn
BRD-K09295674-001-09-8::2.5::HTS,BRD-K09295674-001-09-8,carzenide,2.5,HTS,NA,"CA1, CA12, CA14, CA2, CA6, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)C(O)=O,Preclinical
BRD-K09338665-001-07-1::2.5::HTS,BRD-K09338665-001-07-1,1-octanol,2.5,HTS,NA,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1",NA,NA,"CCCCCCCCO, CCCCCCCCO",Phase 2
BRD-K09353376-001-03-9::2.5::HTS,BRD-K09353376-001-03-9,tariquidar,2.5,HTS,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC",Phase 3
BRD-K09372874-001-01-0::2.5::HTS,BRD-K09372874-001-01-0,merimepodib,2.5,HTS,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09397065-003-06-1::2.5::HTS,BRD-K09397065-003-06-1,SR-57227A,2.5,HTS,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09416995-001-39-9::2.5::HTS,BRD-K09416995-001-39-9,lovastatin,2.5,HTS,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09426783-300-01-0::2.5::HTS,BRD-K09426783-300-01-0,TAS-103,2.5,HTS,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09443272-001-03-3::2.5::HTS,BRD-K09443272-001-03-3,PHA-680632,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09471561-001-18-2::2.5::HTS,BRD-K09471561-001-18-2,levofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, otolaryngology, pulmonary, urology","pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague","C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-K09537769-001-04-0::2.5::HTS,BRD-K09537769-001-04-0,NU-7026,2.5,HTS,"DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",PRKDC,NA,NA,"O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1",Preclinical
BRD-K09549677-300-03-4::2.5::HTS,BRD-K09549677-300-03-4,mibefradil,2.5,HTS,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09602097-001-13-6::2.5::HTS,BRD-K09602097-001-13-6,forskolin,2.5,HTS,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09619322-001-03-8::2.5::HTS,BRD-K09619322-001-03-8,CD-1530,2.5,HTS,retinoid receptor agonist,RARG,NA,NA,OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2,Preclinical
BRD-K09619578-001-01-3::2.5::HTS,BRD-K09619578-001-01-3,DS2-(806622),2.5,HTS,NA,NA,NA,NA,"Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1",Preclinical
BRD-K09635314-001-03-4::2.5::HTS,BRD-K09635314-001-03-4,m-3M3FBS,2.5,HTS,NA,"PLCB2, PLCB3, PLCD1, PLCG1, PLCG2",NA,NA,"Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K09659835-003-01-4::2.5::HTS,BRD-K09659835-003-01-4,loreclezole,2.5,HTS,benzodiazepine receptor agonist,"GABRB2, GABRB3",NA,NA,Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl,Phase 2
BRD-K09711437-001-04-3::2.5::HTS,BRD-K09711437-001-04-3,varespladib,2.5,HTS,secretory phospholipase inhibitor,PLA2G2A,NA,NA,CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1,Phase 3
BRD-K09757388-065-04-0::2.5::HTS,BRD-K09757388-065-04-0,atazanavir,2.5,HTS,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Launched
BRD-K09778810-001-10-6::2.5::HTS,BRD-K09778810-001-10-6,FGIN-1-27,2.5,HTS,inositol monophosphatase inhibitor,TSPO,NA,NA,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1",Preclinical
BRD-K09785578-001-01-2::2.5::HTS,BRD-K09785578-001-01-2,bakuchiol,2.5,HTS,DNA polymerase inhibitor,HIF1A,NA,NA,"CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1",Phase 2
BRD-K09877029-001-01-2::2.5::HTS,BRD-K09877029-001-01-2,VS-4718,2.5,HTS,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09900591-001-26-7::2.5::HTS,BRD-K09900591-001-26-7,caffeic-acid,2.5,HTS,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09951645-001-06-8::2.5::HTS,BRD-K09951645-001-06-8,dabrafenib,2.5,HTS,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K10029415-005-06-9::2.5::HTS,BRD-K10029415-005-06-9,enisamium-iodide,2.5,HTS,NA,NA,NA,NA,C[n+]1ccc(cc1)C(=O)NCc1ccccc1,Launched
BRD-K10065684-001-07-4::2.5::HTS,BRD-K10065684-001-07-4,dantron,2.5,HTS,laxative,NA,NA,NA,Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12,Withdrawn
BRD-K10071630-001-01-0::2.5::HTS,BRD-K10071630-001-01-0,ertugliflozin,2.5,HTS,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,Launched
BRD-K10176267-001-03-3::2.5::HTS,BRD-K10176267-001-03-3,L-701252,2.5,HTS,glutamate receptor antagonist,GRIN1,NA,NA,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,Preclinical
BRD-K10177585-003-02-4::2.5::HTS,BRD-K10177585-003-02-4,PSB-11,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA3",NA,NA,"CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1, CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1",Preclinical
BRD-K10196357-003-02-0::2.5::HTS,BRD-K10196357-003-02-0,besifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,ophthalmology,conjunctivitis,N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1,Launched
BRD-K10314788-003-12-7::2.5::HTS,BRD-K10314788-003-12-7,meclofenoxate,2.5,HTS,nootropic agent,NA,neurology/psychiatry,"senile dementia, Alzheimer's disease",CN(C)CCOC(=O)COc1ccc(Cl)cc1,Launched
BRD-K10362825-001-03-4::2.5::HTS,BRD-K10362825-001-03-4,teniposide,2.5,HTS,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-K10575656-034-01-0::2.5::HTS,BRD-K10575656-034-01-0,MRS3777,2.5,HTS,adenosine receptor antagonist,ADORA2A,NA,NA,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12,Preclinical
BRD-K10598093-303-06-1::2.5::HTS,BRD-K10598093-303-06-1,hexamethonium,2.5,HTS,cholinergic receptor antagonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6",NA,NA,"C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C",Preclinical
BRD-K10670311-001-15-5::2.5::HTS,BRD-K10670311-001-15-5,sulfasalazine,2.5,HTS,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10671814-001-14-8::2.5::HTS,BRD-K10671814-001-14-8,sulfaphenazole,2.5,HTS,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1,Launched
BRD-K10673031-004-02-0::2.5::HTS,BRD-K10673031-004-02-0,S-Isopropylisothiourea,2.5,HTS,nitric oxide synthase inhibitor,NOS3,NA,NA,CC(C)SC(N)=N,Preclinical
BRD-K10705233-001-02-2::2.5::HTS,BRD-K10705233-001-02-2,GW-405833,2.5,HTS,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10706131-046-03-6::2.5::HTS,BRD-K10706131-046-03-6,rivastigmine,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,"Alzheimer's disease, Parkinson's Disease, senile dementia","CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C",Launched
BRD-K10759144-001-04-3::2.5::HTS,BRD-K10759144-001-04-3,xylose,2.5,HTS,NA,NA,NA,NA,"OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O",Launched
BRD-K10784860-003-02-3::2.5::HTS,BRD-K10784860-003-02-3,temocapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10799896-001-26-2::2.5::HTS,BRD-K10799896-001-26-2,clobetasol-propionate,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10836013-001-01-3::2.5::HTS,BRD-K10836013-001-01-3,sitafloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,buruli ulcer,N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F,Launched
BRD-K10843433-001-22-7::2.5::HTS,BRD-K10843433-001-22-7,phenylbutazone,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-23-5::2.58::HTS,BRD-K10843433-001-23-5,phenylbutazone,2.58,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10845183-304-01-6::2.5::HTS,BRD-K10845183-304-01-6,tiludronate,2.5,HTS,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10852020-001-04-5::2.5::HTS,BRD-K10852020-001-04-5,tolcapone,2.5,HTS,catechol O methyltransferase inhibitor,COMT,NA,NA,"Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O",Withdrawn
BRD-K10852020-001-05-2::2.57::HTS,BRD-K10852020-001-05-2,tolcapone,2.57,HTS,catechol O methyltransferase inhibitor,COMT,NA,NA,"Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O",Withdrawn
BRD-K10859802-001-01-0::2.5::HTS,BRD-K10859802-001-01-0,APD668,2.5,HTS,glucose dependent insulinotropic receptor agonist,GPR119,NA,NA,CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O,Phase 1
BRD-K10878147-001-02-2::2.5::HTS,BRD-K10878147-001-02-2,OAC1,2.5,HTS,Oct activator,NA,NA,NA,"O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1",Preclinical
BRD-K10906636-001-02-9::2.67::HTS,BRD-K10906636-001-02-9,silodosin,2.67,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),"C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F",Launched
BRD-K10961822-001-05-1::2.5::HTS,BRD-K10961822-001-05-1,latanoprost,2.5,HTS,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10974103-001-21-1::2.5::HTS,BRD-K10974103-001-21-1,diloxanide,2.5,HTS,protein synthesis inhibitor,NA,infectious disease,amebiasis,CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,Launched
BRD-K10990317-001-04-5::2.5::HTS,BRD-K10990317-001-04-5,clotiapine,2.5,HTS,NA,NA,neurology/psychiatry,psychosis,CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12,Launched
BRD-K11046126-001-02-0::2.5::HTS,BRD-K11046126-001-02-0,VUF10166,2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B",NA,NA,CN1CCN(CC1)c1nc2ccccc2nc1Cl,Preclinical
BRD-K11071038-001-01-7::2.5::HTS,BRD-K11071038-001-01-7,ICI-162846,2.5,HTS,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11073688-001-01-6::2.5::HTS,BRD-K11073688-001-01-6,CPI-1189,2.5,HTS,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11094367-001-10-1::2.5::HTS,BRD-K11094367-001-10-1,acetanilide,2.5,HTS,hydrogen peroxide decomposition inhibitor,NA,NA,NA,"CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1",Preclinical
BRD-K11099631-001-07-6::2.5::HTS,BRD-K11099631-001-07-6,gadoterate-meglumine,2.5,HTS,radiopaque medium,NA,radiology,MRI contrast agent,"OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1",Launched
BRD-K11124378-001-04-6::2.5::HTS,BRD-K11124378-001-04-6,ceftibuten,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"pulmonary, otolaryngology","bronchitis, otitis, pharyngitis, tonsillitis","Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O",Launched
BRD-K11129031-001-27-5::2.5::HTS,BRD-K11129031-001-27-5,gemfibrozil,2.5,HTS,lipoprotein lipase activator,"LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1","endocrinology, cardiology","hyperlipidemia, coronary heart disease","Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1",Launched
BRD-K11153516-001-05-5::2.5::HTS,BRD-K11153516-001-05-5,iniparib,2.5,HTS,PARP inhibitor,PARP1,NA,NA,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,Phase 3
BRD-K11196887-001-21-2::2.5::HTS,BRD-K11196887-001-21-2,norfloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::2.49::HTS,BRD-K11196887-001-22-0,norfloxacin,2.49,HTS,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11215326-001-03-7::2.31::HTS,BRD-K11215326-001-03-7,tazemetostat,2.31,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11244467-001-08-5::2.5::HTS,BRD-K11244467-001-08-5,ambazone,2.5,HTS,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11267252-001-04-4::2.5::HTS,BRD-K11267252-001-04-4,alectinib,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11292736-300-02-8::2.5::HTS,BRD-K11292736-300-02-8,ambenonium,2.5,HTS,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,Launched
BRD-K11373525-003-02-1::2.5::HTS,BRD-K11373525-003-02-1,ZD-7155,2.5,HTS,angiotensin receptor antagonist,AGTR1,NA,NA,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1,Preclinical
BRD-K11399644-003-11-3::2.5::HTS,BRD-K11399644-003-11-3,phenformin,2.5,HTS,AMPK activator,"KCNJ8, PRKAA1",NA,NA,"NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1",Withdrawn
BRD-K11411329-001-01-3::2.5::HTS,BRD-K11411329-001-01-3,NOV-002,2.5,HTS,NA,"GSR, GSTM2",NA,NA,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,Phase 3
BRD-K11433652-001-17-0::2.5::HTS,BRD-K11433652-001-17-0,aspirin,2.5,HTS,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11510141-001-01-8::2.5::HTS,BRD-K11510141-001-01-8,teprenone,2.5,HTS,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11558771-001-13-9::2.5::HTS,BRD-K11558771-001-13-9,droxinostat,2.5,HTS,HDAC inhibitor,"HDAC6, HDAC8",NA,NA,Cc1cc(Cl)ccc1OCCCC(=O)NO,Preclinical
BRD-K11590034-002-03-4::2.49::HTS,BRD-K11590034-002-03-4,morin,2.49,HTS,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11595419-001-01-4::2.5::HTS,BRD-K11595419-001-01-4,dipeptamin,2.5,HTS,NA,NA,NA,NA,"C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O",Launched
BRD-K11630072-001-13-2::2.5::HTS,BRD-K11630072-001-13-2,carmofur,2.5,HTS,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11631773-001-10-8::2.58::HTS,BRD-K11631773-001-10-8,sesamin,2.58,HTS,NFkB pathway inhibitor,NA,NA,NA,"C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1",Preclinical
BRD-K11636097-001-03-1::2.5::HTS,BRD-K11636097-001-03-1,JNJ-7706621,2.5,HTS,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11640013-001-15-8::2.5::HTS,BRD-K11640013-001-15-8,sulfamethazine,2.5,HTS,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::2.5::HTS,BRD-K11640013-236-10-1,sulfamethazine,2.5,HTS,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11663430-001-02-3::2.5::HTS,BRD-K11663430-001-02-3,pyroxamide,2.5,HTS,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11672787-001-01-5::2.5::HTS,BRD-K11672787-001-01-5,rostafuroxine,2.5,HTS,ATPase inhibitor,ATP1A1,NA,NA,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1",Phase 2
BRD-K11696279-003-02-3::2.5::HTS,BRD-K11696279-003-02-3,BU-239,2.5,HTS,"imidazoline receptor ligand, imidazoline receptor agonist",NA,NA,NA,C1CN=C(N1)c1cnc2ccccc2n1,Preclinical
BRD-K11717138-001-30-3::2.5::HTS,BRD-K11717138-001-30-3,benzbromarone,2.5,HTS,chloride channel blocker,ABCC1,rheumatology,gout,"CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1",Launched
BRD-K11742128-003-23-4::2.5::HTS,BRD-K11742128-003-23-4,triprolidine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1",Launched
BRD-K11756522-001-09-9::2.5::HTS,BRD-K11756522-001-09-9,furazolidone,2.5,HTS,bacterial DNA inhibitor,NA,"gastroenterology, infectious disease","diarrhea, enteritis, cholera",[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1,Launched
BRD-K11796549-001-04-5::2.5::HTS,BRD-K11796549-001-04-5,NBQX,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B",NA,NA,"NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O",Preclinical
BRD-K11853856-001-01-7::2.5::HTS,BRD-K11853856-001-01-7,PJ-34,2.5,HTS,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11900042-001-14-4::2.5::HTS,BRD-K11900042-001-14-4,methylthiouracil,2.5,HTS,NA,NA,endocrinology,hyperthyroidism,"Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1",Launched
BRD-K11911061-003-11-9::2.5::HTS,BRD-K11911061-003-11-9,GR-127935,2.5,HTS,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,Preclinical
BRD-K11927976-050-02-9::2.5::HTS,BRD-K11927976-050-02-9,ER-27319,2.5,HTS,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11973162-003-01-8::2.5::HTS,BRD-K11973162-003-01-8,tipiracil,2.5,HTS,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K12014493-001-02-2::2.5::HTS,BRD-K12014493-001-02-2,betaine,2.5,HTS,nitric oxide donor,NA,metabolism,homocystinuria,C[N+](C)(C)CC(O)=O,Launched
BRD-K12040459-001-06-0::2.5::HTS,BRD-K12040459-001-06-0,AT7867,2.5,HTS,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12047401-001-01-5::2.5::HTS,BRD-K12047401-001-01-5,palifosfamide,2.5,HTS,DNA alkylating agent,NA,NA,NA,"OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl",Phase 3
BRD-K12068470-001-02-5::2.36::HTS,BRD-K12068470-001-02-5,LY2608204,2.36,HTS,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-04-1::2.5::HTS,BRD-K12068470-001-04-1,LY2608204,2.5,HTS,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12079898-001-02-6::2.5::HTS,BRD-K12079898-001-02-6,PD-160170,2.5,HTS,neuropeptide receptor antagonist,NPY1R,NA,NA,"CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O",Preclinical
BRD-K12102668-001-25-5::2.5::HTS,BRD-K12102668-001-25-5,nialamide,2.5,HTS,monoamine oxidase inhibitor,"COMT, MAOA, MAOB",NA,NA,"O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1",Withdrawn
BRD-K12120659-305-02-2::2.5::HTS,BRD-K12120659-305-02-2,GR-144053,2.5,HTS,integrin antagonist,"ITGA2B, ITGB3",NA,NA,NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1,Preclinical
BRD-K12184916-001-15-4::2.5::HTS,BRD-K12184916-001-15-4,NVP-BEZ235,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12219985-001-26-1::2.5::HTS,BRD-K12219985-001-26-1,glipizide,2.5,HTS,sulfonylurea,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,"diabetes mellitus, hyperglycemia","Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
BRD-K12244279-001-05-8::2.5::HTS,BRD-K12244279-001-05-8,MEK1-2-inhibitor,2.5,HTS,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12251893-065-04-7::2.5::HTS,BRD-K12251893-065-04-7,vincristine,2.5,HTS,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12329651-001-18-8::2.5::HTS,BRD-K12329651-001-18-8,androsterone,2.5,HTS,androgen receptor agonist,NA,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K12343256-001-08-9::2.5::HTS,BRD-K12343256-001-08-9,trametinib,2.5,HTS,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12502280-001-08-0::2.5::HTS,BRD-K12502280-001-08-0,TG-101348,2.5,HTS,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12513978-001-24-1::2.5::HTS,BRD-K12513978-001-24-1,fenbufen,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,Launched
BRD-K12539416-001-01-4::2.5::HTS,BRD-K12539416-001-01-4,sulbutiamine,2.5,HTS,acetylcholine receptor antagonist,NA,neurology/psychiatry,asthenia,CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O,Launched
BRD-K12539581-001-23-7::2.5::HTS,BRD-K12539581-001-23-7,nocodazole,2.5,HTS,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12568846-001-14-6::2.5::HTS,BRD-K12568846-001-14-6,amidopyrine,2.5,HTS,analgesic agent,NA,dermatology,dermatitis herpetiformis (DH),"CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K12609457-001-03-1::2.5::HTS,BRD-K12609457-001-03-1,exalamide,2.5,HTS,membrane permeability inhibitor,NA,NA,NA,CCCCCCOc1ccccc1C(N)=O,Launched
BRD-K12614344-003-01-8::2.5::HTS,BRD-K12614344-003-01-8,CGS-21680,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,Preclinical
BRD-K12630395-001-14-9::2.5::HTS,BRD-K12630395-001-14-9,harmane,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,Cc1nccc2c3ccccc3[nH]c12,Preclinical
BRD-K12735121-001-01-4::2.5::HTS,BRD-K12735121-001-01-4,TG-100801,2.5,HTS,"src inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl,Phase 2
BRD-K12737986-001-01-4::2.5::HTS,BRD-K12737986-001-01-4,veliparib,2.5,HTS,PARP inhibitor,"PARP1, PARP2",NA,NA,C[C@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O,Phase 3
BRD-K12762134-001-06-2::2.5::HTS,BRD-K12762134-001-06-2,XAV-939,2.5,HTS,tankyrase inhibitor,"TNKS, TNKS2",NA,NA,"Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F, Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F, Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F",Preclinical
BRD-K12769093-003-01-3::2.5::HTS,BRD-K12769093-003-01-3,PNU-37883,2.5,HTS,ATP-sensitive potassium channel antagonist,NA,NA,NA,"C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2, C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K12787259-001-04-3::2.5::HTS,BRD-K12787259-001-04-3,CX-5461,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12807006-001-18-5::2.5::HTS,BRD-K12807006-001-18-5,kaempferol,2.5,HTS,"bone resorption inhibitor, estrogen-related receptor inverse agonist","AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1",NA,NA,"Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K12829205-003-02-8::2.5::HTS,BRD-K12829205-003-02-8,mechlorethamine,2.5,HTS,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12867552-001-04-7::2.5::HTS,BRD-K12867552-001-04-7,PCI-24781,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12885236-001-02-7::2.5::HTS,BRD-K12885236-001-02-7,dapivirine,2.5,HTS,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12932420-001-02-3::2.5::HTS,BRD-K12932420-001-02-3,YM-976,2.5,HTS,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12968785-001-13-3::2.5::HTS,BRD-K12968785-001-13-3,bergapten,2.5,HTS,NA,NA,NA,NA,"COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12",Preclinical
BRD-K12994359-001-18-4::2.5::HTS,BRD-K12994359-001-18-4,valdecoxib,2.5,HTS,cyclooxygenase inhibitor,"CA12, PTGS2",NA,NA,"Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1",Withdrawn
BRD-K13044802-213-20-7::2.5::HTS,BRD-K13044802-213-20-7,ciclopirox,2.5,HTS,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13049116-001-05-7::2.5::HTS,BRD-K13049116-001-05-7,BMS-754807,2.5,HTS,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13050303-001-17-3::2.5::HTS,BRD-K13050303-001-17-3,uridine,2.5,HTS,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-18-1::2.5::HTS,BRD-K13050303-001-18-1,uridine,2.5,HTS,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050541-001-01-9::2.8::HTS,BRD-K13050541-001-01-9,acivicin,2.8,HTS,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13078532-001-28-4::2.5::HTS,BRD-K13078532-001-28-4,hydrochlorothiazide,2.5,HTS,thiazide diuretic,"CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3",cardiology,"hypertension, congestive heart failure","NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl",Launched
BRD-K13087974-001-02-5::2.5::HTS,BRD-K13087974-001-02-5,CGP-52411,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13094524-001-07-5::2.63::HTS,BRD-K13094524-001-07-5,PFI-1,2.63,HTS,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13112821-001-17-4::2.5::HTS,BRD-K13112821-001-17-4,artemisinin,2.5,HTS,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13167095-001-02-9::2.5::HTS,BRD-K13167095-001-02-9,AR-42,2.5,HTS,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13169950-001-14-4::2.5::HTS,BRD-K13169950-001-14-4,NSC-3852,2.5,HTS,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13183738-317-10-2::2.5::HTS,BRD-K13183738-317-10-2,pentamidine,2.5,HTS,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13211965-003-02-8::2.5::HTS,BRD-K13211965-003-02-8,L-741742,2.5,HTS,dopamine receptor antagonist,"DRD3, DRD4, SCN1A, SCN3A",NA,NA,Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1,Preclinical
BRD-K13238168-001-02-0::2.5::HTS,BRD-K13238168-001-02-0,haloprogin,2.5,HTS,other antifungal,NA,infectious disease,tinea pedis,Clc1cc(Cl)c(OCC#CI)cc1Cl,Launched
BRD-K13238618-001-05-9::2.5::HTS,BRD-K13238618-001-05-9,carsalam,2.5,HTS,analgesic agent,NA,NA,NA,O=c1[nH]c(=O)c2ccccc2o1,Preclinical
BRD-K13249881-001-02-3::2.5::HTS,BRD-K13249881-001-02-3,piperazine,2.5,HTS,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13261168-300-01-0::2.5::HTS,BRD-K13261168-300-01-0,quinelorane,2.5,HTS,dopamine receptor agonist,"DRD2, DRD3",NA,NA,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12,Phase 3
BRD-K13296708-001-05-8::2.5::HTS,BRD-K13296708-001-05-8,rimonabant,2.5,HTS,cannabinoid receptor antagonist,"CNR1, GPR55",NA,NA,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,Withdrawn
BRD-K13302470-001-02-7::2.5::HTS,BRD-K13302470-001-02-7,KY02111,2.5,HTS,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13314656-001-01-0::2.5::HTS,BRD-K13314656-001-01-0,ebastine,2.5,HTS,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13356952-001-25-1::2.5::HTS,BRD-K13356952-001-25-1,methazolamide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"glaucoma, intraocular pressure","CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O",Launched
BRD-K13387373-004-14-5::2.5::HTS,BRD-K13387373-004-14-5,thonzonium,2.5,HTS,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13390322-001-06-3::2.5::HTS,BRD-K13390322-001-06-3,AT-7519,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13409143-001-01-9::2.5::HTS,BRD-K13409143-001-01-9,isopropyl-myristate,2.5,HTS,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13421763-001-06-2::2.5::HTS,BRD-K13421763-001-06-2,aminothiazole,2.5,HTS,cyclin D inhibitor,NOS2,NA,NA,"Nc1nccs1, Nc1nccs1, Nc1nccs1",Preclinical
BRD-K13474508-001-01-2::2.5::HTS,BRD-K13474508-001-01-2,"L-655,708",2.5,HTS,GABA receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRG2",NA,NA,"CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21",Preclinical
BRD-K13486660-001-01-0::2.5::HTS,BRD-K13486660-001-01-0,sulfacarbamide,2.5,HTS,NA,NA,NA,NA,NC(=O)NS(=O)(=O)c1ccc(N)cc1,Withdrawn
BRD-K13495773-001-11-4::2.5::HTS,BRD-K13495773-001-11-4,creatinine,2.5,HTS,NA,NA,NA,NA,"CN1CC(=O)NC1=N, CN1CC(=O)NC1=N",Preclinical
BRD-K13511380-001-01-4::2.5::HTS,BRD-K13511380-001-01-4,naringin-dihydrochalcone,2.5,HTS,cytochrome P450 inhibitor,NA,NA,NA,C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,Preclinical
BRD-K13514097-001-05-3::2.5::HTS,BRD-K13514097-001-05-3,everolimus,2.5,HTS,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13566078-001-02-3::2.5::HTS,BRD-K13566078-001-02-3,BMS-345541,2.5,HTS,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13571841-001-14-4::2.5::HTS,BRD-K13571841-001-14-4,pepstatin,2.5,HTS,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13606314-001-01-3::2.5::HTS,BRD-K13606314-001-01-3,P5091,2.5,HTS,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13619941-213-01-8::2.5::HTS,BRD-K13619941-213-01-8,aceglutamide,2.5,HTS,NA,NA,gastroenterology,peptic ulcer disease (PUD),CC(=O)N[C@@H](CCC(N)=O)C(O)=O,Launched
BRD-K13646352-001-03-8::2.5::HTS,BRD-K13646352-001-03-8,midostaurin,2.5,HTS,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13662825-001-07-5::2.5::HTS,BRD-K13662825-001-07-5,dinaciclib,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13756951-001-01-4::2.5::HTS,BRD-K13756951-001-01-4,bitopertin,2.5,HTS,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13800121-001-01-5::2.5::HTS,BRD-K13800121-001-01-5,parecoxib,2.5,HTS,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief,CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1,Launched
BRD-K13810148-311-03-2::2.5::HTS,BRD-K13810148-311-03-2,givinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13819402-003-10-2::2.4::HTS,BRD-K13819402-003-10-2,desoxypeganine,2.4,HTS,"acetylcholinesterase inhibitor, monoamine oxidase inhibitor",ACHE,NA,NA,C1CN2Cc3ccccc3N=C2C1,Phase 1
BRD-K13829090-303-02-9::2.5::HTS,BRD-K13829090-303-02-9,IEM1460,2.5,HTS,glutamate receptor antagonist,GRIA2,NA,NA,"C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K13888115-003-02-2::2.5::HTS,BRD-K13888115-003-02-2,LY2365109,2.5,HTS,Glycine transporter 1 inhibitor,SLC6A9,NA,NA,"CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O",Preclinical
BRD-K13926615-003-03-3::2.5::HTS,BRD-K13926615-003-03-3,vardenafil,2.5,HTS,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H",urology,erectile dysfunction,"CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1",Launched
BRD-K13949769-001-01-7::2.5::HTS,BRD-K13949769-001-01-7,tenovin-6,2.5,HTS,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13994703-003-15-8::2.5::HTS,BRD-K13994703-003-15-8,propranolol-(S),2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3, HTR1A, HTR1B, HTR5A, SLC10A1",NA,NA,"CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12",Preclinical
BRD-K14003026-003-09-0::2.46::HTS,BRD-K14003026-003-09-0,ritodrine,2.46,HTS,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14109347-001-03-4::2.5::HTS,BRD-K14109347-001-03-4,LY2603618,2.5,HTS,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14116214-001-09-6::2.5::HTS,BRD-K14116214-001-09-6,sulfamonomethoxine,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1,Launched
BRD-K14127446-005-22-7::2.5::HTS,BRD-K14127446-005-22-7,isopropamide-iodide,2.5,HTS,acetylcholine receptor antagonist,"CHRM3, CHRM4",gastroenterology,"peptic ulcer disease (PUD), gastrointestinal acidosis",CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,Launched
BRD-K14175878-001-01-6::2.5::HTS,BRD-K14175878-001-01-6,MK-0812,2.5,HTS,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14235254-001-01-2::2.5::HTS,BRD-K14235254-001-01-2,GTS21,2.5,HTS,cholinergic receptor agonist,CHRNA7,NA,NA,COc1ccc(\C=C2CCCN=C/2c2cccnc2)c(OC)c1,Phase 1/Phase 2
BRD-K14329163-001-03-9::2.5::HTS,BRD-K14329163-001-03-9,BAY-K-8644-(s)-(-),2.5,HTS,L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14349461-003-13-1::2.5::HTS,BRD-K14349461-003-13-1,pyridoxine,2.5,HTS,vitamin B,"DDC, PDXK",metabolism,vitamin B6 deficiency,"Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O",Launched
BRD-K14385366-001-04-4::2.59::HTS,BRD-K14385366-001-04-4,FG-4592,2.59,HTS,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14395568-001-16-3::2.5::HTS,BRD-K14395568-001-16-3,NECA,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HSP90B1",NA,NA,"CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",Launched
BRD-K14401183-001-10-7::2.5::HTS,BRD-K14401183-001-10-7,avobenzone,2.5,HTS,UV blocker,TYR,dermatology,"cosmetic, sunscreen lotion","COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C",Launched
BRD-K14496212-066-04-8::2.5::HTS,BRD-K14496212-066-04-8,bromocriptine,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7","endocrinology, neurology/psychiatry","hyperprolactinemia, Parkinson's Disease, acromegaly","CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C",Launched
BRD-K14529030-001-01-9::2.5::HTS,BRD-K14529030-001-01-9,meisoindigo,2.5,HTS,STAT inhibitor,STAT3,NA,NA,CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12,Phase 3
BRD-K14560436-001-01-4::2.5::HTS,BRD-K14560436-001-01-4,TG-02,2.5,HTS,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14618467-001-04-6::2.5::HTS,BRD-K14618467-001-04-6,IKK-16,2.5,HTS,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14619660-001-01-5::2.5::HTS,BRD-K14619660-001-01-5,altrenogest,2.5,HTS,progestogen hormone,PGR,endocrinology,estrus,"C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C",Launched
BRD-K14653796-001-01-1::2.5::HTS,BRD-K14653796-001-01-1,tasquinimod,2.5,HTS,"angiogenesis inhibitor, S100A9 inhibitor",HDAC4,NA,NA,COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12,Phase 3
BRD-K14704277-001-22-6::2.5::HTS,BRD-K14704277-001-22-6,cinoxacin,2.5,HTS,topoisomerase inhibitor,NA,infectious disease,urinary tract infections,"CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12",Launched
BRD-K14705039-001-16-4::2.5::HTS,BRD-K14705039-001-16-4,sulfathiazole,2.5,HTS,dihydropteroate synthase inhibitor,NA,NA,NA,"Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",Launched
BRD-K14711741-001-02-1::2.5::HTS,BRD-K14711741-001-02-1,PF-4708671,2.5,HTS,ribosomal protein inhibitor,RPS6KB1,NA,NA,"CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F, CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F",Preclinical
BRD-K14762862-001-01-9::2.5::HTS,BRD-K14762862-001-01-9,I-BZA,2.5,HTS,NA,NA,NA,NA,CCN(CC)CCNC(=O)c1ccc(I)cc1,Phase 2
BRD-K14763542-001-02-3::2.5::HTS,BRD-K14763542-001-02-3,flurothyl,2.5,HTS,NA,NA,NA,NA,"FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F",Preclinical
BRD-K14765469-003-12-2::2.5::HTS,BRD-K14765469-003-12-2,vesamicol,2.5,HTS,acetylcholinesterase inhibitor,SLC18A3,NA,NA,"O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1",Preclinical
BRD-K14767410-001-02-3::2.5::HTS,BRD-K14767410-001-02-3,SC-560,2.5,HTS,cyclooxygenase inhibitor,PTGS1,NA,NA,"COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",Preclinical
BRD-K14796088-003-26-8::2.5::HTS,BRD-K14796088-003-26-8,berberine,2.5,HTS,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14807180-001-02-5::2.5::HTS,BRD-K14807180-001-02-5,SB-221284,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F,Preclinical
BRD-K14870255-001-02-3::2.5::HTS,BRD-K14870255-001-02-3,R-428,2.5,HTS,AXL kinase inhibitor,AXL,NA,NA,Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1,Phase 1
BRD-K14880289-001-02-2::2.5::HTS,BRD-K14880289-001-02-2,GW-501516,2.5,HTS,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14920963-304-02-7::2.5::HTS,BRD-K14920963-304-02-7,erythrosine,2.5,HTS,coloring agent,NA,NA,NA,OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12,Preclinical
BRD-K14965640-001-12-4::2.5::HTS,BRD-K14965640-001-12-4,ibuprofen-(s),2.5,HTS,cyclooxygenase inhibitor,"ASIC1, BCL2, CFTR, FABP2, PLAT, PPARG, PTGS1, PTGS2, SLC5A8, THBD",NA,NA,"CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O",Preclinical
BRD-K14991967-001-02-6::2.5::HTS,BRD-K14991967-001-02-6,GSK650394,2.5,HTS,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14993104-001-05-9::2.5::HTS,BRD-K14993104-001-05-9,bemegride,2.5,HTS,chemoreceptor agonist,GABRA1,critical care,poison antidote,CCC1(C)CC(=O)NC(=O)C1,Launched
BRD-K15010214-364-02-7::2.5::HTS,BRD-K15010214-364-02-7,emedastine,2.5,HTS,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1",Launched
BRD-K15025317-001-15-1::2.5::HTS,BRD-K15025317-001-15-1,BAY-11-7082,2.5,HTS,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15045219-001-01-8::2.5::HTS,BRD-K15045219-001-01-8,salazodine,2.5,HTS,NA,NA,NA,NA,COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1,Phase 2
BRD-K15071410-001-01-1::2.5::HTS,BRD-K15071410-001-01-1,tiotidine,2.5,HTS,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15086322-050-01-3::2.5::HTS,BRD-K15086322-050-01-3,JNJ-10191584,2.5,HTS,histamine receptor antagonist,HRH4,NA,NA,"CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1",Preclinical
BRD-K15108141-001-06-6::2.5::HTS,BRD-K15108141-001-06-6,gemcitabine,2.5,HTS,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15164005-001-05-6::2.5::HTS,BRD-K15164005-001-05-6,apoptosis-activator-II,2.5,HTS,carboxylesterase inhibitor,"BCHE, CES1",NA,NA,"Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl",Preclinical
BRD-K15170068-001-03-2::2.89::HTS,BRD-K15170068-001-03-2,swainsonine,2.89,HTS,alpha mannosidase inhibitor,MAN2A1,NA,NA,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,Phase 2
BRD-K15179513-001-03-4::2.5::HTS,BRD-K15179513-001-03-4,NVP-ADW742,2.5,HTS,insulin growth factor receptor inhibitor,IGF1R,NA,NA,"Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1",Preclinical
BRD-K15179879-001-03-2::2.5::HTS,BRD-K15179879-001-03-2,carfilzomib,2.5,HTS,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15196155-001-02-3::2.5::HTS,BRD-K15196155-001-02-3,IBC-293,2.5,HTS,hydroxycarboxylic acid receptor agonist,HCAR3,NA,NA,CC(C)n1nnc2cc(ccc12)C(O)=O,Preclinical
BRD-K15231341-001-01-5::2.5::HTS,BRD-K15231341-001-01-5,hemomex-s,2.5,HTS,NA,PPARG,NA,NA,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C,Launched
BRD-K15318383-201-01-5::2.5::HTS,BRD-K15318383-201-01-5,ammonium-glycyrrhizinate,2.5,HTS,thrombin inhibitor,"HSD11B1, HSD11B2, SLCO1B1, SLCO1B3",dermatology,cosmetic,"C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O",Launched
BRD-K15318909-001-10-5::2.5::HTS,BRD-K15318909-001-10-5,PRIMA1,2.5,HTS,TP53 inhibitor,ACHE,NA,NA,"OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O",Preclinical
BRD-K15337272-001-01-3::2.5::HTS,BRD-K15337272-001-01-3,C-751,2.5,HTS,NA,NA,NA,NA,CCOC(=O)c1c[nH]cn1,Preclinical
BRD-K15409150-001-05-8::2.5::HTS,BRD-K15409150-001-05-8,penfluridol,2.5,HTS,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15424032-001-03-6::2.5::HTS,BRD-K15424032-001-03-6,SB-228357,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15426076-001-01-2::2.5::HTS,BRD-K15426076-001-01-2,iguratimod,2.5,HTS,"cyclooxygenase inhibitor, NFkB pathway inhibitor",PTGS2,rheumatology,rheumatoid arthritis,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,Launched
BRD-K15502390-001-20-9::2.5::HTS,BRD-K15502390-001-20-9,nevirapine,2.5,HTS,non-nucleoside reverse transcriptase inhibitor,"CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5",infectious disease,human immunodeficiency virus (HIV-1),"Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1, Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1",Launched
BRD-K15507868-001-03-7::2.5::HTS,BRD-K15507868-001-03-7,tesaglitazar,2.5,HTS,"insulin sensitizer, PPAR receptor agonist","PPARA, PPARG",NA,NA,"CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O",Phase 3
BRD-K15519488-050-01-3::2.5::HTS,BRD-K15519488-050-01-3,CS-110266,2.5,HTS,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15563106-001-18-0::2.5::HTS,BRD-K15563106-001-18-0,phloretin,2.5,HTS,sodium/glucose cotransporter inhibitor,"AQP9, CLCN3, SLC23A1",NA,NA,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1,Launched
BRD-K15567136-003-27-2::2.5::HTS,BRD-K15567136-003-27-2,papaverine,2.5,HTS,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15588452-003-02-7::2.5::HTS,BRD-K15588452-003-02-7,R-96544,2.5,HTS,serotonin receptor antagonist,HTR2A,NA,NA,"COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1",Preclinical
BRD-K15600710-066-04-1::2.5::HTS,BRD-K15600710-066-04-1,obatoclax,2.5,HTS,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15601958-001-03-9::2.5::HTS,BRD-K15601958-001-03-9,SEW-2871,2.5,HTS,lysophospholipid receptor agonist,S1PR1,NA,NA,FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F,Preclinical
BRD-K15697815-001-16-2::2.5::HTS,BRD-K15697815-001-16-2,ursodiol,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator",NR1H4,gastroenterology,gallstones,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K15766189-001-09-8::2.5::HTS,BRD-K15766189-001-09-8,cefdinir,2.5,HTS,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15791587-003-02-5::2.5::HTS,BRD-K15791587-003-02-5,L-733060,2.5,HTS,tachykinin antagonist,TACR1,NA,NA,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,Preclinical
BRD-K15834839-001-02-3::2.5::HTS,BRD-K15834839-001-02-3,lobendazole,2.5,HTS,anthelmintic agent,NA,NA,NA,CCOC(=O)Nc1nc2ccccc2[nH]1,Preclinical
BRD-K15868788-003-07-7::2.5::HTS,BRD-K15868788-003-07-7,SDZ-205-557,2.5,HTS,serotonin receptor antagonist,"HTR3A, HTR3B",NA,NA,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,Preclinical
BRD-K15891719-001-05-1::2.45::HTS,BRD-K15891719-001-05-1,tenofovir,2.45,HTS,"HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor",NA,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B","C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O",Launched
BRD-K15898725-001-01-7::2.5::HTS,BRD-K15898725-001-01-7,maytansinol-isobutyrate,2.5,HTS,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15916496-001-27-9::2.5::HTS,BRD-K15916496-001-27-9,clotrimazole,2.5,HTS,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15933101-003-06-1::2.5::HTS,BRD-K15933101-003-06-1,ropinirole,2.5,HTS,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome","CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12",Launched
BRD-K15976406-001-03-3::2.5::HTS,BRD-K15976406-001-03-3,telbivudine,2.5,HTS,DNA polymerase inhibitor,TK2,infectious disease,hepatitis B,Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O,Launched
BRD-K16037980-001-01-1::2.5::HTS,BRD-K16037980-001-01-1,Z160,2.5,HTS,N-type calcium channel blocker,CACNA2D1,NA,NA,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-K16077845-001-06-1::2.5::HTS,BRD-K16077845-001-06-1,fentiazac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1,Launched
BRD-K16136380-001-01-7::2.5::HTS,BRD-K16136380-001-01-7,pyrithione-zinc,2.5,HTS,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16189898-003-03-3::2.5::HTS,BRD-K16189898-003-03-3,CHIR-99021,2.5,HTS,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16195444-003-26-0::2.5::HTS,BRD-K16195444-003-26-0,oxymetazoline,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16277217-001-10-9::2.5::HTS,BRD-K16277217-001-10-9,piperacetazine,2.5,HTS,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16295392-003-01-3::2.5::HTS,BRD-K16295392-003-01-3,atrasentan,2.5,HTS,endothelin receptor antagonist,EDNRA,NA,NA,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1,Phase 3
BRD-K16338837-001-02-6::2.5::HTS,BRD-K16338837-001-02-6,CCMI,2.5,HTS,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16444452-001-09-1::2.5::HTS,BRD-K16444452-001-09-1,ibudilast,2.5,HTS,"leukotriene receptor antagonist, phosphodiesterase inhibitor","IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","pulmonary, neurology/psychiatry","asthma, stroke","CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C",Launched
BRD-K16474819-001-09-6::2.5::HTS,BRD-K16474819-001-09-6,metacetamol,2.5,HTS,analgesic agent,NA,NA,NA,CC(=O)Nc1cccc(O)c1,Preclinical
BRD-K16478699-001-09-2::2.5::HTS,BRD-K16478699-001-09-2,PLX-4720,2.5,HTS,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16484091-001-01-1::2.5::HTS,BRD-K16484091-001-01-1,metocurine,2.5,HTS,acetylcholine receptor antagonist,"CHRM2, CHRNA2",neurology/psychiatry,muscle relaxant,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,Launched
BRD-K16485616-001-08-9::2.5::HTS,BRD-K16485616-001-08-9,mocetinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16508793-001-05-9::2.5::HTS,BRD-K16508793-001-05-9,diazepam,2.5,HTS,benzodiazepine receptor agonist,"ADRA1A, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",neurology/psychiatry,"generalized anxiety disorder (GAD), abstinence from alcohol, hallucinosis, tremors",CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K16542329-001-13-5::2.5::HTS,BRD-K16542329-001-13-5,zaprinast,2.5,HTS,phosphodiesterase inhibitor,"GPR35, PDE1A, PDE4D, PDE5A, PDE9A",NA,NA,"CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1, CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1, CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1",Phase 2
BRD-K16551357-001-03-2::2.5::HTS,BRD-K16551357-001-03-2,evacetrapib,2.5,HTS,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551401-003-03-4::2.5::HTS,BRD-K16551401-003-03-4,PNU-22394,2.5,HTS,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C, MAOA, MAOB",NA,NA,Cn1c2CCNCCc2c2ccccc12,Phase 2
BRD-K16664969-001-03-3::2.5::HTS,BRD-K16664969-001-03-3,GTP-14564,2.5,HTS,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16730910-001-07-3::2.5::HTS,BRD-K16730910-001-07-3,regorafenib,2.5,HTS,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16732600-001-01-7::2.5::HTS,BRD-K16732600-001-01-7,MK-0893,2.5,HTS,glucagon receptor antagonist,GCGR,NA,NA,COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1,Phase 2
BRD-K16757695-050-02-5::2.5::HTS,BRD-K16757695-050-02-5,PRX-08066,2.5,HTS,serotonin receptor antagonist,HTR2B,NA,NA,Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N,Phase 2
BRD-K16758059-001-01-8::2.5::HTS,BRD-K16758059-001-01-8,perfluamine,2.5,HTS,NA,NA,NA,NA,FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F,Launched
BRD-K16761703-001-03-8::2.5::HTS,BRD-K16761703-001-03-8,sotrastaurin,2.5,HTS,PKC inhibitor,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ",NA,NA,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1,Phase 2
BRD-K16803204-001-01-6::2.5::HTS,BRD-K16803204-001-01-6,filgotinib,2.5,HTS,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16810791-001-01-0::2.5::HTS,BRD-K16810791-001-01-0,LGK-974,2.5,HTS,porcupine inhibitor,PORCN,NA,NA,Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C,Phase 2
BRD-K16898998-001-01-6::2.5::HTS,BRD-K16898998-001-01-6,bevirimat-dimeglumine,2.5,HTS,HIV capsid assembly inhibitor,NA,NA,NA,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,Phase 2
BRD-K17008822-303-02-1::2.5::HTS,BRD-K17008822-303-02-1,BD-1008,2.5,HTS,sigma receptor antagonist,NA,NA,NA,CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1,Preclinical
BRD-K17016787-001-16-7::2.5::HTS,BRD-K17016787-001-16-7,estriol,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2","endocrinology, obstetrics/gynecology, infectious disease","menopause, vaginal atrophy, urinary tract infections","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, CC12CCC3C(CCc4cc(O)ccc34)C1C[C@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O",Launched
BRD-K17026858-001-01-2::2.5::HTS,BRD-K17026858-001-01-2,pibenzimol,2.5,HTS,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17061841-001-03-5::2.5::HTS,BRD-K17061841-001-03-5,stattic,2.5,HTS,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17068645-003-04-2::2.5::HTS,BRD-K17068645-003-04-2,bendamustine,2.5,HTS,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17075857-001-17-6::2.5::HTS,BRD-K17075857-001-17-6,chloroxine,2.5,HTS,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::2.5::HTS,BRD-K17075857-001-18-4,chloroxine,2.5,HTS,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17203476-001-01-9::2.5::HTS,BRD-K17203476-001-01-9,LY2874455,2.5,HTS,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17205817-001-06-1::2.5::HTS,BRD-K17205817-001-06-1,sulfametopyrazine,2.5,HTS,PABA antagonist,NA,infectious disease,"malaria, urinary tract infections, respiratory tract infections",COc1nccnc1NS(=O)(=O)c1ccc(N)cc1,Launched
BRD-K17223896-001-10-0::2.5::HTS,BRD-K17223896-001-10-0,chloroxylenol,2.5,HTS,ATP synthase inhibitor,NA,infectious disease,skin infections,Cc1cc(O)cc(C)c1Cl,Launched
BRD-K17294426-050-12-3::2.5::HTS,BRD-K17294426-050-12-3,clebopride,2.5,HTS,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17368287-001-18-3::2.5::HTS,BRD-K17368287-001-18-3,adrenosterone,2.5,HTS,11-beta hydroxysteroid dehydrogenase inhibitor,"HSD11B1, HSD11B2",NA,NA,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K17378184-300-05-9::2.5::HTS,BRD-K17378184-300-05-9,BP-897,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B",NA,NA,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,Phase 2
BRD-K17415526-001-03-5::2.5::HTS,BRD-K17415526-001-03-5,tyrphostin-AG-835,2.5,HTS,protein tyrosine kinase inhibitor,EGFR,NA,NA,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,Preclinical
BRD-K17443395-065-02-2::2.5::HTS,BRD-K17443395-065-02-2,abacavir,2.5,HTS,nucleoside reverse transcriptase inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1",Launched
BRD-K17497770-001-03-6::2.5::HTS,BRD-K17497770-001-03-6,butein,2.5,HTS,"EGFR inhibitor, src inhibitor",ACE,NA,NA,"Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1",Preclinical
BRD-K17498618-344-02-6::2.5::HTS,BRD-K17498618-344-02-6,betaxolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC",Launched
BRD-K17500877-001-02-1::2.5::HTS,BRD-K17500877-001-02-1,bropirimine,2.5,HTS,interferon inducer,NA,NA,NA,Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1,Phase 3
BRD-K17513304-001-01-9::2.5::HTS,BRD-K17513304-001-01-9,firategrast,2.5,HTS,integrin antagonist,ITGA4,NA,NA,CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(O)=O)cc2)c(OC)c1,Phase 2
BRD-K17518951-001-03-0::2.5::HTS,BRD-K17518951-001-03-0,penicillamine-(D),2.5,HTS,chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17555800-003-01-5::2.5::HTS,BRD-K17555800-003-01-5,talmapimod,2.5,HTS,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17561142-003-32-5::2.5::HTS,BRD-K17561142-003-32-5,amiodarone,2.5,HTS,potassium channel blocker,"ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2",cardiology,ventricular arrhythmias,"CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1",Launched
BRD-K17565903-066-23-1::2.5::HTS,BRD-K17565903-066-23-1,pridinol,2.5,HTS,muscle relaxant,NA,neurology/psychiatry,muscle relaxant,"OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1",Launched
BRD-K17702546-001-03-2::2.5::HTS,BRD-K17702546-001-03-2,PD-168393,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17705806-003-04-4::2.5::HTS,BRD-K17705806-003-04-4,JTC-801,2.5,HTS,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17743125-001-08-4::2.5::HTS,BRD-K17743125-001-08-4,belinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743697-066-03-6::2.5::HTS,BRD-K17743697-066-03-6,KB-R7943,2.5,HTS,sodium/calcium exchange inhibitor,"SLC8A1, TRPC3, TRPC5, TRPC6",NA,NA,"NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1",Preclinical
BRD-K17774839-001-02-9::2.5::HTS,BRD-K17774839-001-02-9,JNJ-7777120,2.5,HTS,histamine receptor antagonist,HRH4,NA,NA,"CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1",Preclinical
BRD-K17849083-001-31-1::2.5::HTS,BRD-K17849083-001-31-1,tranilast,2.5,HTS,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::2.43::HTS,BRD-K17849083-001-32-9,tranilast,2.43,HTS,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17850764-236-11-9::2.5::HTS,BRD-K17850764-236-11-9,cloprostenol-(+/-),2.5,HTS,prostaglandin receptor agonist,"PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R",NA,NA,O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,Launched
BRD-K17868609-001-05-0::2.5::HTS,BRD-K17868609-001-05-0,BRL-54443,2.5,HTS,serotonin receptor agonist,"HTR1E, HTR1F",NA,NA,"CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12",Preclinical
BRD-K17874705-300-03-2::2.5::HTS,BRD-K17874705-300-03-2,2-pyridylethylamine,2.5,HTS,histamine receptor agonist,HRH1,NA,NA,"NCCc1ccccn1, NCCc1ccccn1",Preclinical
BRD-K17894950-001-14-3::2.5::HTS,BRD-K17894950-001-14-3,indirubin,2.5,HTS,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17953908-001-01-7::2.5::HTS,BRD-K17953908-001-01-7,LY2886721,2.5,HTS,beta-secretase inhibitor,BACE1,NA,NA,NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F,Phase 1/Phase 2
BRD-K17977438-048-02-4::2.5::HTS,BRD-K17977438-048-02-4,oxelaidin,2.5,HTS,antitussive,NA,pulmonary,cough suppressant,"CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1",Launched
BRD-K17979676-001-01-2::2.5::HTS,BRD-K17979676-001-01-2,eprobemide,2.5,HTS,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K18036262-001-02-8::2.5::HTS,BRD-K18036262-001-02-8,L-168049,2.5,HTS,glucagon receptor antagonist,GCGR,NA,NA,"CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1",Preclinical
BRD-K18059238-001-10-4::0.25::HTS,BRD-K18059238-001-10-4,gamma-linolenic-acid,0.25,HTS,"cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O",Phase 2
BRD-K18131774-001-17-6::2.5::HTS,BRD-K18131774-001-17-6,ethoxzolamide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9","ophthalmology, gastroenterology","glaucoma, duodenal ulcer disease","CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O",Launched
BRD-K18135438-001-16-7::2.5::HTS,BRD-K18135438-001-16-7,chenodeoxycholic-acid,2.5,HTS,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K18157228-001-01-7::2.5::HTS,BRD-K18157228-001-01-7,fdcyd,2.5,HTS,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18163608-001-05-6::2.48::HTS,BRD-K18163608-001-05-6,HA14-1,2.48,HTS,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18172896-001-02-5::2.5::HTS,BRD-K18172896-001-02-5,eltanolone,2.5,HTS,membrane integrity inhibitor,"GABRA1, GABRB2, GABRG2",NA,NA,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 3
BRD-K18194590-065-08-0::2.5::HTS,BRD-K18194590-065-08-0,mephentermine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3",cardiology,hypotension,CNC(C)(C)Cc1ccccc1,Launched
BRD-K18250272-003-11-0::2.5::HTS,BRD-K18250272-003-11-0,propoxycaine,2.5,HTS,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18316707-001-02-7::2.5::HTS,BRD-K18316707-001-02-7,O-1918,2.5,HTS,cannabinoid receptor antagonist,NA,NA,NA,"COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C",Preclinical
BRD-K18323388-001-01-1::2.5::HTS,BRD-K18323388-001-01-1,uridine-triacetate,2.5,HTS,NA,NA,nephrology,orotic aciduria,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O,Launched
BRD-K18324993-001-01-6::2.5::HTS,BRD-K18324993-001-01-6,budipine,2.5,HTS,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease,CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1,Launched
BRD-K18375018-376-02-3::2.5::HTS,BRD-K18375018-376-02-3,spermine,2.5,HTS,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18424115-003-01-3::2.5::HTS,BRD-K18424115-003-01-3,TG-100572,2.5,HTS,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18518344-001-15-9::2.5::HTS,BRD-K18518344-001-15-9,digitoxigenin,2.5,HTS,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18574842-236-17-7::2.5::HTS,BRD-K18574842-236-17-7,nafcillin,2.5,HTS,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-323-10-8::2.51::HTS,BRD-K18574842-323-10-8,nafcillin,2.51,HTS,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18613660-001-05-5::2.5::HTS,BRD-K18613660-001-05-5,mexeneone,2.5,HTS,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18619710-001-14-4::2.5::HTS,BRD-K18619710-001-14-4,digoxigenin,2.5,HTS,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18673820-001-15-5::2.5::HTS,BRD-K18673820-001-15-5,folic-acid,2.5,HTS,folate receptor ligand,"FOLR2, FOLR3, SLC19A1, SLC46A1",hematology,megaloblastic anemia,Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1,Launched
BRD-K18678457-003-02-8::2.5::HTS,BRD-K18678457-003-02-8,ZD-7288,2.5,HTS,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",NA,NA,"CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1, CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1",Phase 2
BRD-K18772613-303-02-4::2.5::HTS,BRD-K18772613-303-02-4,benzoquinonium-dibromide,2.5,HTS,cholinergic receptor antagonist,CHRNA1,NA,NA,CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1,Preclinical
BRD-K18779551-003-07-8::2.5::HTS,BRD-K18779551-003-07-8,bifemelane,2.5,HTS,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18787491-001-08-6::2.5::HTS,BRD-K18787491-001-08-6,U-0126,2.5,HTS,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18834913-001-01-1::2.5::HTS,BRD-K18834913-001-01-1,LB42708,2.5,HTS,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18849474-001-04-4::2.61::HTS,BRD-K18849474-001-04-4,dalcetrapib,2.61,HTS,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18850819-001-04-6::2.5::HTS,BRD-K18850819-001-04-6,MK-0752,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K18895904-001-16-1::2.5::HTS,BRD-K18895904-001-16-1,olanzapine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder","CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12",Launched
BRD-K18905250-003-02-4::2.5::HTS,BRD-K18905250-003-02-4,ST-91,2.5,HTS,adrenergic receptor agonist,NA,NA,NA,"CCc1cccc(CC)c1N=C1NCCN1, CCc1cccc(CC)c1N=C1NCCN1",Preclinical
BRD-K18910433-001-36-6::2.58::HTS,BRD-K18910433-001-36-6,estradiol,2.58,HTS,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-43-2::2.5::HTS,BRD-K18910433-001-43-2,estradiol,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18922609-004-23-1::2.5::HTS,BRD-K18922609-004-23-1,neostigmine,2.5,HTS,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,"CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C",Launched
BRD-K18948558-001-01-9::2.5::HTS,BRD-K18948558-001-01-9,clevudine,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O,Launched
BRD-K18961567-001-01-1::2.5::HTS,BRD-K18961567-001-01-1,LY2801653,2.5,HTS,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K19034817-001-01-4::2.5::HTS,BRD-K19034817-001-01-4,pacritinib,2.5,HTS,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19061412-001-02-4::2.5::HTS,BRD-K19061412-001-02-4,mubritinib,2.5,HTS,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19085898-001-01-8::2.5::HTS,BRD-K19085898-001-01-8,darapladib,2.5,HTS,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19111024-001-20-9::2.5::HTS,BRD-K19111024-001-20-9,clofibric-acid,2.5,HTS,PPAR receptor agonist,PPARA,NA,NA,"CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O",Launched
BRD-K19136521-001-08-9::2.5::HTS,BRD-K19136521-001-08-9,indirubin-3-monoxime,2.5,HTS,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B",NA,NA,O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12,Preclinical
BRD-K19171642-001-02-3::2.5::HTS,BRD-K19171642-001-02-3,CP-91149,2.5,HTS,glycogen phosphorylase inhibitor,PYGL,NA,NA,CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,Preclinical
BRD-K19180152-001-02-6::2.5::HTS,BRD-K19180152-001-02-6,meprobamate,2.5,HTS,NA,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,anxiety,CCCC(C)(COC(N)=O)COC(N)=O,Launched
BRD-K19203487-001-01-4::2.5::HTS,BRD-K19203487-001-01-4,SPP301,2.5,HTS,endothelin receptor antagonist,EDNRA,NA,NA,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,Phase 3
BRD-K19227686-001-18-6::2.5::HTS,BRD-K19227686-001-18-6,phenolphthalein,2.5,HTS,indicator dye,UGT1A9,NA,NA,Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1,Withdrawn
BRD-K19284129-001-02-6::2.5::HTS,BRD-K19284129-001-02-6,salvinorin-a,2.5,HTS,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19295594-015-14-3::2.29::HTS,BRD-K19295594-015-14-3,gossypol,2.29,HTS,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19309090-300-05-5::2.5::HTS,BRD-K19309090-300-05-5,SR-95639A,2.5,HTS,acetylcholine receptor agonist,CHRM1,NA,NA,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,Preclinical
BRD-K19318328-001-01-3::2.5::HTS,BRD-K19318328-001-01-3,FR-139317,2.5,HTS,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19333160-001-01-3::2.5::HTS,BRD-K19333160-001-01-3,RKI-1447,2.5,HTS,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19352500-070-12-4::2.5::HTS,BRD-K19352500-070-12-4,prochlorperazine,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4",gastroenterology,"nausea, vomiting","CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1",Launched
BRD-K19388745-003-01-7::2.5::HTS,BRD-K19388745-003-01-7,colforsin-daproate,2.5,HTS,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19412355-001-01-0::2.5::HTS,BRD-K19412355-001-01-0,SB-242235,2.5,HTS,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19416115-001-05-3::2.5::HTS,BRD-K19416115-001-05-3,sitagliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F",Launched
BRD-K19438463-001-05-5::2.5::HTS,BRD-K19438463-001-05-5,CNQX,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N",Phase 1
BRD-K19456237-001-27-6::2.5::HTS,BRD-K19456237-001-27-6,piracetam,2.5,HTS,acetylcholine receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",neurology/psychiatry,senile dementia,"NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O",Launched
BRD-K19462402-003-24-6::2.5::HTS,BRD-K19462402-003-24-6,buflomedil,2.5,HTS,"adrenergic receptor antagonist, calcium channel blocker",ADRA1A,cardiology,peripheral artery disease (PAD),"COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1",Launched
BRD-K19477839-001-07-6::2.5::HTS,BRD-K19477839-001-07-6,SGX523,2.5,HTS,hepatocyte growth factor receptor inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1,Phase 1
BRD-K19507340-001-22-1::2.38::HTS,BRD-K19507340-001-22-1,megestrol-acetate,2.38,HTS,progesterone receptor agonist,"NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O",Launched
BRD-K19540840-001-09-4::2.5::HTS,BRD-K19540840-001-09-4,saracatinib,2.5,HTS,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19601669-001-03-5::2.5::HTS,BRD-K19601669-001-03-5,ruxolitinib-(S),2.5,HTS,JAK inhibitor,"JAK1, JAK2",NA,NA,N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Preclinical
BRD-K19605405-001-02-7::2.5::HTS,BRD-K19605405-001-02-7,ZM-241385,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1",Preclinical
BRD-K19615002-001-02-3::2.5::HTS,BRD-K19615002-001-02-3,creatine,2.5,HTS,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19655798-001-01-9::2.5::HTS,BRD-K19655798-001-01-9,compound-401,2.5,HTS,DNA dependent protein kinase inhibitor,"MTOR, PRKDC",NA,NA,O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1,Preclinical
BRD-K19669037-001-01-1::2.5::HTS,BRD-K19669037-001-01-1,GGTI-298,2.5,HTS,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19672466-001-02-3::2.5::HTS,BRD-K19672466-001-02-3,ethimizol,2.5,HTS,NA,NA,NA,NA,CCn1cnc(C(=O)NC)c1C(=O)NC,Phase 1
BRD-K19687926-379-07-4::2.5::HTS,BRD-K19687926-379-07-4,lapatinib,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19741547-003-01-7::2.5::HTS,BRD-K19741547-003-01-7,vernakalant,2.5,HTS,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF),COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Launched
BRD-K19761926-001-02-8::2.5::HTS,BRD-K19761926-001-02-8,eplerenone,2.5,HTS,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::2.45::HTS,BRD-K19761926-001-03-6,eplerenone,2.45,HTS,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19796430-001-05-6::2.5::HTS,BRD-K19796430-001-05-6,sonidegib,2.5,HTS,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19939891-001-05-4::2.5::HTS,BRD-K19939891-001-05-4,TIC10,2.5,HTS,"AKT inhibitor, TRAIL modulator","AKT1, MAPK1",NA,NA,"Cc1ccccc1CN1CC2=C(CCN(Cc3ccccc3)C2=O)N2CCN=C12, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2",Phase 2
BRD-K19972289-001-01-4::2.5::HTS,BRD-K19972289-001-01-4,octinoxate,2.5,HTS,NA,NA,dermatology,sunscreen lotion,CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1,Launched
BRD-K20001883-001-02-7::2.5::HTS,BRD-K20001883-001-02-7,apabetalone,2.5,HTS,apolipoprotein expression enhancer,BRD3,NA,NA,COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1,Phase 3
BRD-K20008181-001-01-3::2.5::HTS,BRD-K20008181-001-01-3,LCQ908,2.5,HTS,diacylglycerol O acyltransferase inhibitor,DGAT1,NA,NA,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1,Phase 3
BRD-K20013301-001-02-6::2.5::HTS,BRD-K20013301-001-02-6,LY411575,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,Preclinical
BRD-K20075662-300-04-0::2.5::HTS,BRD-K20075662-300-04-0,betazole,2.5,HTS,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic,NCCc1cc[nH]n1,Launched
BRD-K20079257-001-09-6::2.5::HTS,BRD-K20079257-001-09-6,rufinamide,2.5,HTS,voltage-gated sodium channel blocker,"GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,Launched
BRD-K20141153-003-13-7::2.5::HTS,BRD-K20141153-003-13-7,atomoxetine,2.5,HTS,norepinephrine transporter inhibitor,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD),"CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1",Launched
BRD-K20152659-001-04-6::2.5::HTS,BRD-K20152659-001-04-6,dihomo-gamma-linolenic-acid,2.5,HTS,prostanoid receptor agonist,"PTGS1, PTGS2",NA,NA,"CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O",Phase 2
BRD-K20168442-004-06-3::2.5::HTS,BRD-K20168442-004-06-3,vecuronium,2.5,HTS,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1",Launched
BRD-K20285085-001-07-1::2.5::HTS,BRD-K20285085-001-07-1,R406,2.5,HTS,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::2.5::HTS,BRD-K20285085-074-04-5,R406,2.5,HTS,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20290250-001-01-3::2.5::HTS,BRD-K20290250-001-01-3,BIX-02188,2.5,HTS,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::2.38::HTS,BRD-K20290250-001-02-1,BIX-02188,2.38,HTS,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20313525-001-04-6::2.5::HTS,BRD-K20313525-001-04-6,rosmarinic-acid,2.5,HTS,GABA transaminase inhibitor,"MCL1, TYR",NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1,Launched
BRD-K20338176-001-17-7::2.5::HTS,BRD-K20338176-001-17-7,cefaclor,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"infectious disease, otolaryngology","pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis","N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1",Launched
BRD-K20372197-001-03-1::2.5::HTS,BRD-K20372197-001-03-1,droxidopa,2.5,HTS,norepinephrine precursor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH","cardiology, neurology/psychiatry","hypertension, Parkinson's Disease","N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K20417253-001-01-9::2.5::HTS,BRD-K20417253-001-01-9,oxiniacic-acid,2.5,HTS,NA,NA,NA,NA,"OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1",Preclinical
BRD-K20431737-001-08-1::2.5::HTS,BRD-K20431737-001-08-1,benzoylpas,2.5,HTS,NA,NA,NA,NA,"OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O",Preclinical
BRD-K20482099-001-09-4::2.5::HTS,BRD-K20482099-001-09-4,rutin,2.5,HTS,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-11-0::2.5::HTS,BRD-K20482099-001-11-0,rutin,2.5,HTS,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20545304-001-01-6::2.5::HTS,BRD-K20545304-001-01-6,bardoxolone,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20548681-001-01-3::2.5::HTS,BRD-K20548681-001-01-3,SCP-1,2.5,HTS,analgesic agent,NA,NA,NA,Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1,Phase 1
BRD-K20605374-001-05-4::2.5::HTS,BRD-K20605374-001-05-4,NSC-697923,2.5,HTS,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20655524-003-12-0::2.5::HTS,BRD-K20655524-003-12-0,mefexamide,2.5,HTS,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20714604-003-02-9::2.5::HTS,BRD-K20714604-003-02-9,RS-56812,2.5,HTS,serotonin receptor partial agonist,HTR3A,NA,NA,Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12,Preclinical
BRD-K20722021-001-02-1::2.5::HTS,BRD-K20722021-001-02-1,CEP-32496,2.5,HTS,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20738689-001-01-2::2.5::HTS,BRD-K20738689-001-01-2,dazmegrel,2.5,HTS,thromboxane synthase inhibitor,TBXAS1,NA,NA,Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O,Phase 2
BRD-K20742498-003-02-9::2.5::HTS,BRD-K20742498-003-02-9,RS-39604,2.5,HTS,serotonin receptor antagonist,HTR4,NA,NA,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,Preclinical
BRD-K20745393-003-01-0::2.5::HTS,BRD-K20745393-003-01-0,olprinone,2.5,HTS,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N,Launched
BRD-K20755323-001-05-9::2.5::HTS,BRD-K20755323-001-05-9,SKI-II,2.5,HTS,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20897876-001-10-0::2.5::HTS,BRD-K20897876-001-10-0,castanospermine,2.5,HTS,glucosidase inhibitor,"GAA, GBA",NA,NA,"O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12",Phase 2
BRD-K20920669-304-09-1::2.5::HTS,BRD-K20920669-304-09-1,cromoglicic-acid,2.5,HTS,immunosuppressant,"KCNMA1, S100P","pulmonary, ophthalmology, allergy, gastroenterology","asthma, conjunctivitis, urticaria, ulcerative colitis","OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O",Launched
BRD-K20958582-001-01-4::2.5::HTS,BRD-K20958582-001-01-4,TH-302,2.5,HTS,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20995441-001-02-5::2.5::HTS,BRD-K20995441-001-02-5,U-54494A,2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K21025364-001-04-9::2.5::HTS,BRD-K21025364-001-04-9,NVP-TAE226,2.5,HTS,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::2.44::HTS,BRD-K21025364-001-05-6,NVP-TAE226,2.44,HTS,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21071223-001-02-8::2.5::HTS,BRD-K21071223-001-02-8,VP-20629,2.5,HTS,beta amyloid antagonist,"PLA2G2E, SLC36A1",NA,NA,OC(=O)CCc1c[nH]c2ccccc12,Phase 1
BRD-K21123171-001-02-9::2.5::HTS,BRD-K21123171-001-02-9,pramiracetam,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,Launched
BRD-K21160401-065-01-0::2.5::HTS,BRD-K21160401-065-01-0,dextroamphetamine,2.5,HTS,monoamine oxidase inhibitor,"ADRA1A, ADRA1B, SLC18A2, SLC6A2, SLC6A3, TAAR1",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",C[C@H](N)Cc1ccccc1,Launched
BRD-K21164796-001-02-8::2.5::HTS,BRD-K21164796-001-02-8,beta-naphthol,2.5,HTS,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21283037-001-21-5::2.5::HTS,BRD-K21283037-001-21-5,riluzole,2.5,HTS,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21295289-001-01-6::2.5::HTS,BRD-K21295289-001-01-6,senicapoc,2.5,HTS,intermediate conductance potassium channel blocker,KCNN4,NA,NA,NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,Phase 3
BRD-K21361524-001-01-1::2.5::HTS,BRD-K21361524-001-01-1,selinexor,2.5,HTS,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21372554-003-01-7::2.5::HTS,BRD-K21372554-003-01-7,cefetamet-pivoxil,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K21396683-001-04-8::2.5::HTS,BRD-K21396683-001-04-8,marimastat,2.5,HTS,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21450440-001-14-6::2.5::HTS,BRD-K21450440-001-14-6,benzthiazide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA4, CA9, SLC12A3",cardiology,"hypertension, edema","NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O",Launched
BRD-K21452876-003-01-8::2.5::HTS,BRD-K21452876-003-01-8,chlorazanil,2.5,HTS,NA,NA,NA,NA,Nc1ncnc(Nc2ccc(Cl)cc2)n1,Preclinical
BRD-K21520694-236-02-6::2.5::HTS,BRD-K21520694-236-02-6,sulfacetamide,2.5,HTS,PABA antagonist,NA,ophthalmology,conjunctivitis,"CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1",Launched
BRD-K21528677-001-02-8::2.44::HTS,BRD-K21528677-001-02-8,desonide,2.44,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-03-6::2.5::HTS,BRD-K21528677-001-03-6,desonide,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21547160-001-01-4::2.5::HTS,BRD-K21547160-001-01-4,sufentanil,2.5,HTS,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21548250-003-19-1::2.5::HTS,BRD-K21548250-003-19-1,moracizine,2.5,HTS,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1,Launched
BRD-K21565985-001-22-5::2.5::HTS,BRD-K21565985-001-22-5,xylazine,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21615095-001-08-4::2.5::HTS,BRD-K21615095-001-08-4,acetohydroxamic-acid,2.5,HTS,urease inhibitor,MMP12,infectious disease,urinary tract infections,CC(=O)NO,Launched
BRD-K21670884-001-01-9::2.5::HTS,BRD-K21670884-001-01-9,cariporide,2.5,HTS,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21672174-001-03-0::2.5::HTS,BRD-K21672174-001-03-0,Ro-28-1675,2.5,HTS,glucokinase activator,GCK,NA,NA,CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1,Preclinical
BRD-K21673112-003-01-3::2.5::HTS,BRD-K21673112-003-01-3,BF2.649,2.5,HTS,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21680192-300-14-4::2.5::HTS,BRD-K21680192-300-14-4,mitoxantrone,2.5,HTS,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21718444-001-06-8::2.5::HTS,BRD-K21718444-001-06-8,KW-2449,2.5,HTS,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21728777-001-02-3::2.5::HTS,BRD-K21728777-001-02-3,AMG900,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21733600-001-14-1::2.5::HTS,BRD-K21733600-001-14-1,rofecoxib,2.5,HTS,cyclooxygenase inhibitor,"ELN, PTGS2",NA,NA,"CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1",Withdrawn
BRD-K21771665-304-04-2::2.5::HTS,BRD-K21771665-304-04-2,merbromin,2.5,HTS,antiseptic,NA,infectious disease,first-aid antiseptic,O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12,Launched
BRD-K21782625-001-02-4::2.5::HTS,BRD-K21782625-001-02-4,AMG458,2.5,HTS,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-03-2::2.45::HTS,BRD-K21782625-001-03-2,AMG458,2.45,HTS,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21867462-001-02-9::2.5::HTS,BRD-K21867462-001-02-9,GSK2816126,2.5,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",Phase 1
BRD-K21884483-001-03-7::2.5::HTS,BRD-K21884483-001-03-7,mizolastine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"urticaria, allergic rhinitis",CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1,Launched
BRD-K21906513-001-04-0::2.36::HTS,BRD-K21906513-001-04-0,UNC669,2.36,HTS,L3MBTL antagonist,L3MBTL1,NA,NA,"Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1",Preclinical
BRD-K21908111-001-01-8::2.5::HTS,BRD-K21908111-001-01-8,AZD1208,2.5,HTS,Pim kinase inhibitor,"PIM1, PIM2, PIM3",NA,NA,N[C@@H]1CCCN(C1)c1c(cccc1-c1ccccc1)\C=C1/SC(=O)NC1=O,Phase 1
BRD-K21910317-001-12-3::2.5::HTS,BRD-K21910317-001-12-3,"2,4-dinitrophenol",2.5,HTS,ATP synthase inhibitor,APP,NA,NA,Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O,Preclinical
BRD-K21913543-001-02-4::2.5::HTS,BRD-K21913543-001-02-4,fluorescein,2.5,HTS,NA,SLC22A6,ophthalmology,ophthalmology diagnostic,Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1,Launched
BRD-K21937671-001-09-2::2.53::HTS,BRD-K21937671-001-09-2,loxistatin-acid,2.53,HTS,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-10-0::2.5::HTS,BRD-K21937671-001-10-0,loxistatin-acid,2.5,HTS,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K22009844-001-12-5::2.5::HTS,BRD-K22009844-001-12-5,phenprobamate,2.5,HTS,muscle relaxant,NA,neurology/psychiatry,"anxiety, muscle relaxant",NC(=O)OCCCc1ccccc1,Launched
BRD-K22024824-001-03-7::2.5::HTS,BRD-K22024824-001-03-7,RG4733,2.5,HTS,gamma secretase inhibitor,PSEN1,NA,NA,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O,Phase 2
BRD-K22025381-003-01-9::2.5::HTS,BRD-K22025381-003-01-9,U-18666A,2.5,HTS,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22031190-001-23-6::2.5::HTS,BRD-K22031190-001-23-6,diflunisal,2.5,HTS,prostanoid receptor antagonist,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F,Launched
BRD-K22097830-001-01-9::2.5::HTS,BRD-K22097830-001-01-9,OCO-1112,2.5,HTS,cholesterol inhibitor,NA,NA,NA,CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O,Phase 2
BRD-K22127577-001-03-7::2.58::HTS,BRD-K22127577-001-03-7,crenolanib,2.58,HTS,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22134346-001-22-3::2.5::HTS,BRD-K22134346-001-22-3,simvastatin,2.5,HTS,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::2.42::HTS,BRD-K22134346-001-24-9,simvastatin,2.42,HTS,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22193694-001-13-6::2.5::HTS,BRD-K22193694-001-13-6,dioxybenzone,2.5,HTS,topical sunscreen agent,NA,NA,NA,COc1ccc(C(=O)c2ccccc2O)c(O)c1,Preclinical
BRD-K22261391-001-01-2::2.5::HTS,BRD-K22261391-001-01-2,pirodavir,2.5,HTS,NA,NA,NA,NA,CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1,Phase 2
BRD-K22314899-001-02-4::2.5::HTS,BRD-K22314899-001-02-4,CH223191,2.5,HTS,aryl hydrocarbon receptor antagonist,AHR,NA,NA,Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C,Preclinical
BRD-K22356203-001-01-8::2.5::HTS,BRD-K22356203-001-01-8,IDO5L,2.5,HTS,"indoleamine 2,3-dioxygenase inhibitor",IDO1,NA,NA,Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1,Preclinical
BRD-K22385716-001-02-5::2.5::HTS,BRD-K22385716-001-02-5,LY303511,2.5,HTS,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22482860-001-21-4::2.5::HTS,BRD-K22482860-001-21-4,dalfampridine,2.5,HTS,potassium channel blocker,"KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2",neurology/psychiatry,multiple sclerosis,"Nc1ccncc1, Nc1ccncc1",Launched
BRD-K22503835-001-11-0::2.5::HTS,BRD-K22503835-001-11-0,scriptaid,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22520627-001-01-7::2.5::HTS,BRD-K22520627-001-01-7,DVD-111,2.5,HTS,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22662435-001-18-3::2.5::HTS,BRD-K22662435-001-18-3,ganciclovir,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,cytomegalovirus (CMV),"Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1",Launched
BRD-K22662435-001-19-1::2.5::HTS,BRD-K22662435-001-19-1,ganciclovir,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,cytomegalovirus (CMV),"Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1",Launched
BRD-K22662557-300-01-7::2.5::HTS,BRD-K22662557-300-01-7,WIN-64338,2.5,HTS,bradykinin receptor antagonist,BDKRB2,NA,NA,"CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1",Preclinical
BRD-K22685337-001-13-4::2.5::HTS,BRD-K22685337-001-13-4,roxarsone,2.5,HTS,antiprotozoal agent,NA,endocrinology,weight-gain aid,Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O,Launched
BRD-K22745370-003-02-3::2.5::HTS,BRD-K22745370-003-02-3,2-BFI,2.5,HTS,imidazoline receptor ligand,"ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB",NA,NA,C1CN=C(N1)c1cc2ccccc2o1,Preclinical
BRD-K22749967-046-02-3::2.5::HTS,BRD-K22749967-046-02-3,ABT-239,2.5,HTS,histamine receptor antagonist,"HRH1, HRH2, HRH3",NA,NA,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,Phase 1
BRD-K22822991-001-02-3::2.5::HTS,BRD-K22822991-001-02-3,odanacatib,2.5,HTS,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22829793-001-01-0::2.5::HTS,BRD-K22829793-001-01-0,ZCL-278,2.5,HTS,CDC inhibitor,CDC42,NA,NA,"Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1",Preclinical
BRD-K22861715-001-17-4::2.5::HTS,BRD-K22861715-001-17-4,chrysin,2.5,HTS,breast cancer resistance protein inhibitor,"AKR1B1, CDK6, CYP19A1, CYP1B1",NA,NA,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,Phase 1
BRD-K22936972-003-23-6::2.5::HTS,BRD-K22936972-003-23-6,diphenylpyraline,2.5,HTS,dopamine uptake inhibitor,"HRH1, SLC6A3",allergy,allergic rhinitis,"CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1",Launched
BRD-K23067689-001-02-1::2.4::HTS,BRD-K23067689-001-02-1,zanamivir,2.4,HTS,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection,"CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O",Launched
BRD-K23082237-003-01-5::2.5::HTS,BRD-K23082237-003-01-5,butaclamol,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A",NA,NA,CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34,Phase 2
BRD-K23163214-050-15-1::2.5::HTS,BRD-K23163214-050-15-1,dizocilpine-(-),2.5,HTS,glutamate receptor antagonist,NA,NA,NA,"C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21",Phase 1
BRD-K23190681-001-01-1::2.5::HTS,BRD-K23190681-001-01-1,AV-412,2.5,HTS,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23204545-001-16-4::2.5::HTS,BRD-K23204545-001-16-4,busulfan,2.5,HTS,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23228615-001-02-8::2.5::HTS,BRD-K23228615-001-02-8,GDC-0980,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23248433-001-01-8::2.5::HTS,BRD-K23248433-001-01-8,camicinal,2.5,HTS,motilin receptor agonist,MLNR,NA,NA,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1,Phase 2
BRD-K23301018-001-11-7::2.63::HTS,BRD-K23301018-001-11-7,broxyquinoline,2.63,HTS,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23335153-300-02-5::2.5::HTS,BRD-K23335153-300-02-5,AMN-082,2.5,HTS,glutamate receptor modulator,GRM7,NA,NA,"C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1",Preclinical
BRD-K23363278-001-02-1::2.5::HTS,BRD-K23363278-001-02-1,CYT-997,2.5,HTS,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23383398-001-09-9::2.5::HTS,BRD-K23383398-001-09-9,T-0901317,2.5,HTS,LXR agonist,"NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB",NA,NA,"OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F",Preclinical
BRD-K23403298-003-01-9::2.5::HTS,BRD-K23403298-003-01-9,benzyldimethylhexadecylammonium,2.5,HTS,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23541596-300-07-2::2.5::HTS,BRD-K23541596-300-07-2,dimaprit,2.5,HTS,histamine receptor agonist,"HRH2, HRH3, HRH4",NA,NA,"CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N",Preclinical
BRD-K23566484-001-15-1::2.5::HTS,BRD-K23566484-001-15-1,nilutamide,2.5,HTS,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23586533-001-03-6::2.5::HTS,BRD-K23586533-001-03-6,clindamycin,2.5,HTS,protein synthesis inhibitor,NA,infectious disease,"respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections","CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O",Launched
BRD-K23647661-001-02-2::2.5::HTS,BRD-K23647661-001-02-2,volinanserin,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C, KCNH2",NA,NA,"COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC",Phase 3
BRD-K23672206-001-01-4::2.5::HTS,BRD-K23672206-001-01-4,BCI-540,2.5,HTS,glutamate receptor agonist,NA,NA,NA,Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C,Phase 2
BRD-K23677682-003-01-2::2.5::HTS,BRD-K23677682-003-01-2,voreloxin,2.5,HTS,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23728141-001-01-2::2.5::HTS,BRD-K23728141-001-01-2,tafamidis-meglumine,2.5,HTS,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP),OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1,Launched
BRD-K23779958-001-05-8::2.5::HTS,BRD-K23779958-001-05-8,dichlorvos,2.5,HTS,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23913458-001-20-7::2.5::HTS,BRD-K23913458-001-20-7,coumarin,2.5,HTS,vitamin K antagonist,"CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6","gastroenterology, pulmonary","ulcerative colitis, asthma, celiac disease","O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1",Launched
BRD-K23922020-075-02-9::2.5::HTS,BRD-K23922020-075-02-9,arecaidine-propargyl-ester,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"CN1CCC=C(C1)C(=O)OCC#C, CN1CCC=C(C1)C(=O)OCC#C",Preclinical
BRD-K23925186-001-01-0::2.5::HTS,BRD-K23925186-001-01-0,oridonin,2.5,HTS,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::2.51::HTS,BRD-K23925186-001-02-8,oridonin,2.51,HTS,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23952234-236-01-8::2.5::HTS,BRD-K23952234-236-01-8,BMS-986020,2.5,HTS,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23976833-001-01-0::2.5::HTS,BRD-K23976833-001-01-0,travoprost,2.5,HTS,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F,Launched
BRD-K23984367-075-15-2::2.5::HTS,BRD-K23984367-075-15-2,sorafenib,2.5,HTS,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K24048528-001-01-7::2.59::HTS,BRD-K24048528-001-01-7,abiraterone-acetate,2.59,HTS,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::2.5::HTS,BRD-K24048528-001-02-5,abiraterone-acetate,2.5,HTS,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24084088-001-11-3::2.5::HTS,BRD-K24084088-001-11-3,paraxanthine,2.5,HTS,adenosine receptor antagonist,NA,NA,NA,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,Phase 1
BRD-K24179883-001-16-7::2.5::HTS,BRD-K24179883-001-16-7,arsanilic-acid,2.5,HTS,NA,LYZ,NA,NA,Nc1ccc(cc1)[As](O)(O)=O,Phase 1
BRD-K24187789-001-01-7::2.5::HTS,BRD-K24187789-001-01-7,VU0238429,2.5,HTS,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24201553-003-11-5::2.5::HTS,BRD-K24201553-003-11-5,SB-269970,2.5,HTS,serotonin receptor antagonist,HTR7,NA,NA,"CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1",Preclinical
BRD-K24219278-001-01-6::2.5::HTS,BRD-K24219278-001-01-6,amineptine,2.5,HTS,dopamine receptor agonist,"SLC6A2, SLC6A4",NA,NA,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,Withdrawn
BRD-K24227647-364-01-5::2.5::HTS,BRD-K24227647-364-01-5,TC2559,2.5,HTS,acetylcholine receptor agonist,CHRNA4,NA,NA,"CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1",Preclinical
BRD-K24242599-001-02-8::2.5::HTS,BRD-K24242599-001-02-8,GW-2580,2.5,HTS,cFMS kinase inhibitor,CSF1R,NA,NA,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,Preclinical
BRD-K24255045-001-05-3::2.5::HTS,BRD-K24255045-001-05-3,fluoxymesterone,2.5,HTS,androgen receptor modulator,"AR, ESR1, NR3C1, PRLR",endocrinology,hypogonadism,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Launched
BRD-K24258499-001-05-8::2.5::HTS,BRD-K24258499-001-05-8,vanillin,2.5,HTS,NA,"ABAT, ALDH5A1",NA,NA,COc1cc(C=O)ccc1O,Preclinical
BRD-K24297741-001-05-2::2.5::HTS,BRD-K24297741-001-05-2,urethane,2.5,HTS,local anesthetic,NA,NA,NA,CCOC(N)=O,Preclinical
BRD-K24312986-001-01-2::2.5::HTS,BRD-K24312986-001-01-2,tecovirimat,2.5,HTS,orthopoxvirus egress inhibitor,NA,NA,NA,FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,Phase 3
BRD-K24443618-001-10-2::2.5::HTS,BRD-K24443618-001-10-2,etebenecid,2.5,HTS,uricosuric blocker,NA,NA,NA,CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O,Preclinical
BRD-K24507548-001-01-8::2.5::HTS,BRD-K24507548-001-01-8,cintriamide,2.5,HTS,NA,NA,NA,NA,COc1cc(cc(OC)c1OC)\C=C\C(N)=O,Preclinical
BRD-K24548560-342-02-1::2.5::HTS,BRD-K24548560-342-02-1,evans-blue,2.5,HTS,glutamate receptor negative allosteric modulator,"GRIA1, PTPN1",NA,NA,Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(c(C)c1)\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O,Launched
BRD-K24556098-001-16-7::2.45::HTS,BRD-K24556098-001-16-7,deoxycorticosterone-acetate,2.45,HTS,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-19-1::2.5::HTS,BRD-K24556098-001-19-1,deoxycorticosterone-acetate,2.5,HTS,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556407-001-02-3::2.5::HTS,BRD-K24556407-001-02-3,ETP-46464,2.5,HTS,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24566386-001-01-9::2.5::HTS,BRD-K24566386-001-01-9,SD-208,2.5,HTS,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1",Preclinical
BRD-K24576554-001-04-8::2.5::HTS,BRD-K24576554-001-04-8,AT-9283,2.5,HTS,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24593301-001-02-3::2.54::HTS,BRD-K24593301-001-02-3,AZD3463,2.54,HTS,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24601397-001-01-1::2.5::HTS,BRD-K24601397-001-01-1,phlorizin,2.5,HTS,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24603946-001-02-1::2.5::HTS,BRD-K24603946-001-02-1,5-hydroxymethyl-tolterodine,2.5,HTS,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24616672-003-20-1::2.5::HTS,BRD-K24616672-003-20-1,procaine,2.5,HTS,HMGCR inhibitor,"CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3",neurology/psychiatry,anesthetic,"CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1",Launched
BRD-K24689407-001-06-3::2.5::HTS,BRD-K24689407-001-06-3,3-bromo-7-nitroindazole,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2c(Br)n[nH]c12, [O-][N+](=O)c1cccc2c(Br)n[nH]c12",Preclinical
BRD-K24696047-001-02-3::2.5::HTS,BRD-K24696047-001-02-3,NVP-AEW541,2.5,HTS,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24697665-001-01-4::2.5::HTS,BRD-K24697665-001-01-4,bucillamine,2.5,HTS,immunosuppressant,NA,rheumatology,rheumatoid arthritis,"CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K24715592-406-02-1::2.53::HTS,BRD-K24715592-406-02-1,ethacridine-lactate-monohydrate,2.53,HTS,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24723746-036-02-5::2.5::HTS,BRD-K24723746-036-02-5,solifenacin-succinate,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency","O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1, O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1",Launched
BRD-K24771047-001-01-6::2.5::HTS,BRD-K24771047-001-01-6,ampalex,2.5,HTS,glutamate receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,O=C(N1CCCCC1)c1ccc2nccnc2c1,Phase 2
BRD-K24790130-001-07-1::2.5::HTS,BRD-K24790130-001-07-1,tricaprylin,2.5,HTS,NA,NA,dermatology,cosmetic,CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,Launched
BRD-K24820488-001-01-7::2.5::HTS,BRD-K24820488-001-01-7,CH-170,2.5,HTS,NA,NA,NA,NA,Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1,Phase 1
BRD-K24821794-001-01-4::2.5::HTS,BRD-K24821794-001-01-4,SGC-CBP30,2.5,HTS,bromodomain inhibitor,"CREBBP, EP300",NA,NA,"COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl",Preclinical
BRD-K24844714-001-24-5::2.5::HTS,BRD-K24844714-001-24-5,5-fluorouracil,2.5,HTS,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24869513-001-02-1::2.5::HTS,BRD-K24869513-001-02-1,CNX-2006,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24943235-001-01-3::2.5::HTS,BRD-K24943235-001-01-3,grazoprevir,2.5,HTS,HCV inhibitor,NA,NA,NA,"COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C",Launched
BRD-K24968862-001-01-0::2.5::HTS,BRD-K24968862-001-01-0,SB-683698,2.5,HTS,integrin antagonist,"ITGA4, ITGAV, ITGB1, ITGB7",NA,NA,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1,Phase 1
BRD-K25015158-001-01-2::2.5::HTS,BRD-K25015158-001-01-2,limaprost-alfadex,2.5,HTS,prostanoid receptor agonist,PTGER1,cardiology,claudication,"CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O",Launched
BRD-K25114078-003-08-1::2.5::HTS,BRD-K25114078-003-08-1,aminoguanidine,2.5,HTS,nitric oxide synthase inhibitor,NOS2,NA,NA,"NNC(N)=N, NNC(N)=N",Phase 3
BRD-K25140590-001-03-0::2.5::HTS,BRD-K25140590-001-03-0,CX-516,2.5,HTS,glutamate receptor modulator,NA,NA,NA,O=C(N1CCCCC1)c1ccc2OCOc2c1,Phase 2/Phase 3
BRD-K25186396-001-09-6::2.5::HTS,BRD-K25186396-001-09-6,tangeritin,2.5,HTS,cell cycle inhibitor,NA,NA,NA,COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K25204779-001-01-1::2.5::HTS,BRD-K25204779-001-01-1,pritelivir,2.5,HTS,helicase primase inhibitor,NA,NA,NA,CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O,Phase 2
BRD-K25224017-001-25-0::2.5::HTS,BRD-K25224017-001-25-0,pirenperone,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25244359-066-03-4::2.68::HTS,BRD-K25244359-066-03-4,apatinib,2.68,HTS,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25279140-001-01-5::2.5::HTS,BRD-K25279140-001-01-5,MK-8745,2.5,HTS,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25311561-001-10-7::2.5::HTS,BRD-K25311561-001-10-7,KU-55933,2.5,HTS,ATM kinase inhibitor,"ATM, PRKDC",NA,NA,"O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1",Preclinical
BRD-K25312248-001-01-5::2.5::HTS,BRD-K25312248-001-01-5,matrine,2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34,Phase 2
BRD-K25317177-065-01-4::2.5::HTS,BRD-K25317177-065-01-4,modaline,2.5,HTS,NA,NA,NA,NA,Cc1nccnc1N1CCCCC1,Preclinical
BRD-K25340465-001-11-1::2.58::HTS,BRD-K25340465-001-11-1,OSI-930,2.58,HTS,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25359048-001-02-6::2.5::HTS,BRD-K25359048-001-02-6,WZ811,2.5,HTS,CC chemokine receptor antagonist,CXCR4,NA,NA,C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1,Preclinical
BRD-K25394294-001-14-9::2.5::HTS,BRD-K25394294-001-14-9,oxaprozin,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1",Launched
BRD-K25412176-001-01-9::2.5::HTS,BRD-K25412176-001-01-9,GSK2110183,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25433859-003-25-4::2.5::HTS,BRD-K25433859-003-25-4,maprotiline,2.5,HTS,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25486274-300-01-0::2.5::HTS,BRD-K25486274-300-01-0,DRF053-(R),2.5,HTS,CDK inhibitor,CSNK1A1,NA,NA,"CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K25596805-001-01-8::2.5::HTS,BRD-K25596805-001-01-8,JNJ-16259685,2.5,HTS,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25630527-001-03-8::2.5::HTS,BRD-K25630527-001-03-8,LY2784544,2.5,HTS,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25649279-001-02-0::2.5::HTS,BRD-K25649279-001-02-0,2-iodomelatonin,2.5,HTS,melatonin receptor agonist,"MTNR1A, MTNR1B, NQO2",NA,NA,COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,Preclinical
BRD-K25650355-065-02-0::2.5::HTS,BRD-K25650355-065-02-0,physostigmine,2.5,HTS,cholinesterase inhibitor,"ACHE, BCHE","cardiology, neurology/psychiatry, ophthalmology, gastroenterology","hypotension, Alzheimer's disease, glaucoma, gastroparesis",CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1,Launched
BRD-K25690923-001-02-4::2.5::HTS,BRD-K25690923-001-02-4,4-iodo-6-phenylpyrimidine,2.5,HTS,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25691735-001-09-5::2.5::HTS,BRD-K25691735-001-09-5,chuanxiongzine,2.5,HTS,NA,NA,NA,NA,Cc1nc(C)c(C)nc1C,Phase 2
BRD-K25699529-003-01-1::2.5::HTS,BRD-K25699529-003-01-1,tapentadol,2.5,HTS,opioid receptor agonist,"HTR3A, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4",neurology/psychiatry,"acute pain, muscle pain","CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1, CC[C@H]([C@@H](C)CN(C)C)c1cccc(O)c1, CC[C@H]([C@@H](C)CN(C)C)c1cccc(O)c1",Launched
BRD-K25723200-001-02-7::2.5::HTS,BRD-K25723200-001-02-7,azilsartan-medoxomil,2.5,HTS,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K25835157-001-01-4::2.5::HTS,BRD-K25835157-001-01-4,PRT062070,2.5,HTS,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25837718-001-03-8::2.5::HTS,BRD-K25837718-001-03-8,josamycin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25875056-001-02-0::2.5::HTS,BRD-K25875056-001-02-0,SC-9,2.5,HTS,protein tyrosine kinase activator,PRKCA,NA,NA,"Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1",Preclinical
BRD-K25906698-303-02-7::2.5::HTS,BRD-K25906698-303-02-7,immepip,2.5,HTS,histamine receptor agonist,"HRH3, HRH4",NA,NA,C(C1CCNCC1)c1c[nH]cn1,Preclinical
BRD-K25943794-001-02-3::2.5::HTS,BRD-K25943794-001-02-3,blonanserin,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,schizophrenia,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,Launched
BRD-K25991633-001-01-9::2.5::HTS,BRD-K25991633-001-01-9,BMS-649,2.5,HTS,retinoid receptor agonist,RXRA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O",Preclinical
BRD-K26005076-001-12-8::2.5::HTS,BRD-K26005076-001-12-8,gramine,2.5,HTS,norepinephrine reputake inhibitor,NA,NA,NA,CN(C)Cc1c[nH]c2ccccc12,Preclinical
BRD-K26011976-001-01-0::2.5::HTS,BRD-K26011976-001-01-0,licochalcone-a,2.5,HTS,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26060080-065-05-6::2.5::HTS,BRD-K26060080-065-05-6,adenine,2.5,HTS,protein synthesis stimulant,"ACACB, ACP1, APRT, MTAP, PECR, SRPK2",NA,NA,"Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12",Preclinical
BRD-K26160755-003-02-6::2.5::HTS,BRD-K26160755-003-02-6,RS-45041-190,2.5,HTS,imidazoline receptor agonist,NA,NA,NA,Clc1cccc2CN(Cc12)C1=NCCN1,Preclinical
BRD-K26168087-001-09-7::2.5::HTS,BRD-K26168087-001-09-7,magnolol,2.5,HTS,PPAR receptor agonist,"GABRA1, PPARG",NA,NA,Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O,Preclinical
BRD-K26222048-001-01-7::2.5::HTS,BRD-K26222048-001-01-7,"trans-10,cis-12-Conjugated-linoleic-acid",2.5,HTS,NA,NA,NA,NA,CCCCC\C=C/C=C/CCCCCCCCC(O)=O,Launched
BRD-K26253904-001-01-5::2.5::HTS,BRD-K26253904-001-01-5,NMS-873,2.5,HTS,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26262077-238-01-5::2.5::HTS,BRD-K26262077-238-01-5,acamprosate,2.5,HTS,glutamate receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5",neurology/psychiatry,abstinence from alcohol,"CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O",Launched
BRD-K26305185-001-02-1::2.5::HTS,BRD-K26305185-001-02-1,K-Ras(G12C)-inhibitor-6,2.5,HTS,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26325692-003-01-3::2.5::HTS,BRD-K26325692-003-01-3,API-001,2.5,HTS,sigma receptor antagonist,SIGMAR1,NA,NA,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,Phase 2
BRD-K26341917-001-01-3::2.5::HTS,BRD-K26341917-001-01-3,L-ergothioneine,2.5,HTS,free radical scavenger,NA,NA,NA,C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O,Phase 2
BRD-K26349472-001-01-3::2.5::HTS,BRD-K26349472-001-01-3,OG-L002,2.5,HTS,histone lysine demethylase inhibitor,KDM1A,NA,NA,"N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1",Preclinical
BRD-K26373640-001-05-1::2.5::HTS,BRD-K26373640-001-05-1,IKK-2-inhibitor,2.5,HTS,"IKK inhibitor, SYK inhibitor",IKBKB,NA,NA,"NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1",Preclinical
BRD-K26502378-001-07-9::2.5::HTS,BRD-K26502378-001-07-9,vanitiolide,2.5,HTS,NA,NA,NA,NA,COc1cc(ccc1O)C(=S)N1CCOCC1,Preclinical
BRD-K26531771-001-01-4::2.5::HTS,BRD-K26531771-001-01-4,EPZ-5676,2.5,HTS,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::2.35::HTS,BRD-K26531771-001-02-2,EPZ-5676,2.35,HTS,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26548821-003-10-5::2.5::HTS,BRD-K26548821-003-10-5,quinpirol-(-),2.5,HTS,dopamine receptor agonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C",NA,NA,"CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12",Phase 2
BRD-K26573499-300-02-1::2.5::HTS,BRD-K26573499-300-02-1,DMAB-anabaseine,2.5,HTS,adrenergic receptor agonist,CHRNA7,NA,NA,"CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1, CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1",Preclinical
BRD-K26581543-001-01-6::2.5::HTS,BRD-K26581543-001-01-6,bifendate,2.5,HTS,NA,NA,NA,NA,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC,Launched
BRD-K26603252-003-04-9::2.5::HTS,BRD-K26603252-003-04-9,PD-153035,2.5,HTS,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26619122-001-02-1::2.5::HTS,BRD-K26619122-001-02-1,thiocolchicoside,2.5,HTS,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26634012-001-04-9::2.5::HTS,BRD-K26634012-001-04-9,tilmicosin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26657438-001-15-2::2.5::HTS,BRD-K26657438-001-15-2,imiquimod,2.5,HTS,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26667523-001-02-5::2.5::HTS,BRD-K26667523-001-02-5,TAK-733,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26701552-001-01-8::2.5::HTS,BRD-K26701552-001-01-8,tegobuvir,2.5,HTS,"HCV inhibitor, protease inhibitor",NA,NA,NA,Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1,Phase 3
BRD-K26712974-001-01-5::2.5::HTS,BRD-K26712974-001-01-5,VX-765,2.5,HTS,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26739552-003-15-4::2.5::HTS,BRD-K26739552-003-15-4,fenspiride,2.5,HTS,bronchodilator,NA,"pulmonary, otolaryngology","asthma, otitis, sinusitis, rhinopharyngitis, laryngitis","O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1",Launched
BRD-K26756394-001-02-2::2.5::HTS,BRD-K26756394-001-02-2,VE-821,2.5,HTS,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26801045-001-02-9::2.5::HTS,BRD-K26801045-001-02-9,pipamperone,2.5,HTS,dopamine receptor antagonist,"DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A",neurology/psychiatry,schizophrenia,NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1,Launched
BRD-K26807903-001-04-3::2.5::HTS,BRD-K26807903-001-04-3,aklomide,2.5,HTS,NA,NA,infectious disease,coccidiosis,NC(=O)c1ccc(cc1Cl)[N+]([O-])=O,Launched
BRD-K26818574-305-04-3::2.5::HTS,BRD-K26818574-305-04-3,BIX-01294,2.5,HTS,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26823213-001-02-9::2.5::HTS,BRD-K26823213-001-02-9,GW-842166,2.5,HTS,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26824830-001-02-0::2.5::HTS,BRD-K26824830-001-02-0,azomycin-(2-nitroimidazole),2.5,HTS,protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26833429-001-02-8::2.5::HTS,BRD-K26833429-001-02-8,costunolide,2.5,HTS,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26838195-075-04-9::2.5::HTS,BRD-K26838195-075-04-9,AST-1306,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26862302-001-05-2::2.5::HTS,BRD-K26862302-001-05-2,diosmetin,2.5,HTS,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1,Launched
BRD-K26901728-001-06-2::2.5::HTS,BRD-K26901728-001-06-2,lumiracoxib,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,"Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1",Withdrawn
BRD-K26989966-001-03-5::2.5::HTS,BRD-K26989966-001-03-5,UNC1999,2.5,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C",Preclinical
BRD-K26997899-001-02-2::2.5::HTS,BRD-K26997899-001-02-2,D-64131,2.5,HTS,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K27062708-001-23-1::2.5::HTS,BRD-K27062708-001-23-1,chlorotrianisene,2.5,HTS,estrogenic hormone,"ESR1, ESR2","endocrinology, oncology","menopause, prostate cancer",COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1,Launched
BRD-K27135764-001-08-7::2.5::HTS,BRD-K27135764-001-08-7,xanthone,2.5,HTS,antimalarial agent,NA,NA,NA,O=c1c2ccccc2oc2ccccc12,Preclinical
BRD-K27141178-003-07-3::2.5::HTS,BRD-K27141178-003-07-3,SB-203186,2.5,HTS,serotonin receptor antagonist,HTR4,NA,NA,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,Preclinical
BRD-K27168049-001-02-8::2.5::HTS,BRD-K27168049-001-02-8,SDZ-220-581,2.5,HTS,glutamate receptor antagonist,GRIN1,NA,NA,"N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O",Preclinical
BRD-K27182532-001-02-3::2.5::HTS,BRD-K27182532-001-02-3,metatinib,2.5,HTS,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27184429-300-01-3::2.5::HTS,BRD-K27184429-300-01-3,levocetirizine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27204852-001-01-9::2.5::HTS,BRD-K27204852-001-01-9,balicatib,2.5,HTS,cathepsin inhibitor,CTSK,NA,NA,"CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N",Phase 2
BRD-K27217864-001-22-3::2.5::HTS,BRD-K27217864-001-22-3,butamben,2.5,HTS,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27305650-001-16-6::2.5::HTS,BRD-K27305650-001-16-6,LY294002,2.5,HTS,"mTOR inhibitor, PI3K inhibitor, DNA dependent protein kinase inhibitor, phosphodiesterase inhibitor, PLK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1",Preclinical
BRD-K27316855-001-13-3::2.44::HTS,BRD-K27316855-001-13-3,calcitriol,2.44,HTS,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-19-0::2.5::HTS,BRD-K27316855-001-19-0,calcitriol,2.5,HTS,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27335680-001-10-0::2.5::HTS,BRD-K27335680-001-10-0,rhein,2.5,HTS,NA,HSP90AA1,NA,NA,OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,Phase 1
BRD-K27351809-001-09-5::2.5::HTS,BRD-K27351809-001-09-5,nomegestrol-acetate,2.5,HTS,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27382019-418-01-9::2.5::HTS,BRD-K27382019-418-01-9,piperaquine-phosphate,2.5,HTS,antimalarial agent,NA,infectious disease,malaria,Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1,Launched
BRD-K27393415-001-01-0::2.5::HTS,BRD-K27393415-001-01-0,xipamide,2.5,HTS,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension",Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O,Launched
BRD-K27406233-001-07-7::2.5::HTS,BRD-K27406233-001-07-7,acetyl-l-leucine,2.5,HTS,NA,NA,neurology/psychiatry,vertigo,CC(C)C[C@H](NC(C)=O)C(O)=O,Launched
BRD-K27721098-065-08-6::2.5::HTS,BRD-K27721098-065-08-6,clopidogrel,2.5,HTS,purinergic receptor antagonist,P2RY12,"cardiology, neurology/psychiatry","myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)","COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl",Launched
BRD-K27737647-300-03-0::2.5::HTS,BRD-K27737647-300-03-0,H-89,2.5,HTS,PKA inhibitor,"GSG2, PKIA, PRKACA",NA,NA,"Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1",Preclinical
BRD-K27771035-001-02-5::2.5::HTS,BRD-K27771035-001-02-5,clindamycin-phosphate,2.5,HTS,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27799744-001-02-8::2.52::HTS,BRD-K27799744-001-02-8,cyclovirobuxin-d,2.52,HTS,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27853494-003-04-7::2.5::HTS,BRD-K27853494-003-04-7,"1s,2r-phenylpropanolamine",2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRB1, ADRB2, DRD1",NA,NA,C[C@@H](N)[C@@H](O)c1ccccc1,Withdrawn
BRD-K27871792-001-01-8::2.5::HTS,BRD-K27871792-001-01-8,flucloxacillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"infectious disease, otolaryngology, dermatology, gastroenterology","gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia","Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl",Launched
BRD-K27911943-001-02-8::2.5::HTS,BRD-K27911943-001-02-8,"chromanol-293B-(-)-[3R,4S]",2.5,HTS,potassium channel blocker,NA,NA,NA,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N,Preclinical
BRD-K27938825-001-02-4::2.5::HTS,BRD-K27938825-001-02-4,ASA-404,2.5,HTS,angiogenesis inhibitor,NA,NA,NA,Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C,Phase 3
BRD-K27955832-001-02-9::2.5::HTS,BRD-K27955832-001-02-9,lomeguatrib,2.5,HTS,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,NA,NA,"Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1",Phase 2
BRD-K28007504-051-01-2::2.5::HTS,BRD-K28007504-051-01-2,Ro-60-0175,2.5,HTS,NA,"HTR2A, HTR2B, HTR2C",NA,NA,"C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12",Preclinical
BRD-K28029915-001-02-2::2.5::HTS,BRD-K28029915-001-02-2,dolasetron,2.5,HTS,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting","O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12",Launched
BRD-K28042756-001-01-9::5::HTS,BRD-K28042756-001-01-9,NA,5.0,HTS,NA,NA,NA,NA,NA,NA
BRD-K28059174-334-01-2::2.5::HTS,BRD-K28059174-334-01-2,INCB-003284,2.5,HTS,CC chemokine receptor antagonist,NA,NA,NA,COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,Phase 2
BRD-K28115081-001-02-7::2.5::HTS,BRD-K28115081-001-02-7,apafant,2.5,HTS,platelet activating factor receptor antagonist,PTAFR,NA,NA,"Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl",Phase 3
BRD-K28120222-001-08-4::2.5::HTS,BRD-K28120222-001-08-4,parthenolide-(alternate-stereo),2.5,HTS,NFkB pathway inhibitor,"IKBKB, RELA",NA,NA,C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K28121004-001-01-1::2.5::HTS,BRD-K28121004-001-01-1,N-acetylglycyl-D-glutamic-acid,2.5,HTS,glutamate receptor agonist,NA,NA,NA,"CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O",Preclinical
BRD-K28143534-001-02-2::2.5::HTS,BRD-K28143534-001-02-2,cyproheptadine,2.5,HTS,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-003-25-9::2.5::HTS,BRD-K28143534-003-25-9,cyproheptadine,2.5,HTS,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28183345-003-11-4::2.5::HTS,BRD-K28183345-003-11-4,proguanil,2.5,HTS,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Launched
BRD-K28192623-066-08-1::2.5::HTS,BRD-K28192623-066-08-1,spiradoline,2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28210218-236-08-1::2.5::HTS,BRD-K28210218-236-08-1,cephalothin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"skin infections, surgical prophylaxis",CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O,Launched
BRD-K28217197-001-01-4::2.5::HTS,BRD-K28217197-001-01-4,ganaxolone,2.5,HTS,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 3
BRD-K28307902-001-21-7::2.5::HTS,BRD-K28307902-001-21-7,flutamide,2.5,HTS,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28308851-303-01-8::2.5::HTS,BRD-K28308851-303-01-8,alpha-methylhistamine-dihydrobromide-(S)-(+),2.5,HTS,histamine receptor agonist,HRH3,NA,NA,C[C@H](N)Cc1c[nH]cn1,Preclinical
BRD-K28343777-001-01-6::2.5::HTS,BRD-K28343777-001-01-6,20-hydroxyecdysone,2.5,HTS,ecdysone receptor modulator,NA,NA,NA,CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C,Preclinical
BRD-K28352084-001-02-3::2.5::HTS,BRD-K28352084-001-02-3,CH5132799,2.5,HTS,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28360340-001-08-3::2.31::HTS,BRD-K28360340-001-08-3,TW-37,2.31,HTS,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28383148-001-01-4::2.5::HTS,BRD-K28383148-001-01-4,AP1903,2.5,HTS,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28392481-001-05-1::2.5::HTS,BRD-K28392481-001-05-1,AZD4547,2.5,HTS,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28405228-001-06-7::2.5::HTS,BRD-K28405228-001-06-7,mecarbinate,2.5,HTS,NA,NA,NA,NA,CCOC(=O)c1c(C)n(C)c2ccc(O)cc12,Preclinical
BRD-K28428262-001-04-1::2.5::HTS,BRD-K28428262-001-04-1,brivanib,2.5,HTS,"FGFR inhibitor, VEGFR inhibitor","CYP3A4, FGFR1, FLT1, KCNH2, KDR",NA,NA,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,Phase 3
BRD-K28442028-001-01-3::2.5::HTS,BRD-K28442028-001-01-3,R-1479,2.5,HTS,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1,Phase 1
BRD-K28453807-003-11-2::2.5::HTS,BRD-K28453807-003-11-2,nitrocaramiphen,2.5,HTS,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28456624-001-01-1::2.5::HTS,BRD-K28456624-001-01-1,seocalcitol,2.5,HTS,vitamin D receptor agonist,VDR,NA,NA,"CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 3
BRD-K28492574-001-01-6::2.5::HTS,BRD-K28492574-001-01-6,piconol,2.5,HTS,NA,NA,NA,NA,OCc1ccccn1,Preclinical
BRD-K28494619-001-28-2::2.5::HTS,BRD-K28494619-001-28-2,sulfamethoxazole,2.5,HTS,PABA antagonist,NA,"infectious disease, gastroenterology","pneumonia, enteritis, urinary tract infections","Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1",Launched
BRD-K28542495-003-13-5::2.5::HTS,BRD-K28542495-003-13-5,benzydamine,2.5,HTS,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28570407-001-02-0::2.5::HTS,BRD-K28570407-001-02-0,A-803467,2.5,HTS,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28578425-001-07-0::2.5::HTS,BRD-K28578425-001-07-0,cilostamide,2.5,HTS,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28595280-001-04-5::2.5::HTS,BRD-K28595280-001-04-5,meglumine,2.5,HTS,excipient,NA,NA,NA,"CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",Launched
BRD-K28667793-001-28-1::2.5::HTS,BRD-K28667793-001-28-1,pyrazinamide,2.5,HTS,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis,"NC(=O)c1cnccn1, NC(=O)c1cnccn1",Launched
BRD-K28690501-001-02-1::2.5::HTS,BRD-K28690501-001-02-1,diosgenin,2.5,HTS,steroid,NA,NA,NA,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K28761384-300-01-0::2.5::HTS,BRD-K28761384-300-01-0,zuclopenthixol,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A",neurology/psychiatry,"schizophrenia, bipolar disorder",OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,Launched
BRD-K28761891-001-10-1::2.5::HTS,BRD-K28761891-001-10-1,ramelteon,2.5,HTS,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,insomnia,"CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12",Launched
BRD-K28822270-001-01-1::2.5::HTS,BRD-K28822270-001-01-1,resminostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28824103-001-02-8::2.5::HTS,BRD-K28824103-001-02-8,genipin,2.5,HTS,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-04-4::2.5::HTS,BRD-K28824103-001-04-4,genipin,2.5,HTS,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28849549-001-13-4::2.5::HTS,BRD-K28849549-001-13-4,mesalazine,2.5,HTS,"cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2",gastroenterology,"ulcerative colitis, inflammatory bowel disease","Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O",Launched
BRD-K28861668-001-01-9::2.5::HTS,BRD-K28861668-001-01-9,A922500,2.5,HTS,diacylglycerol O acyltransferase inhibitor,DGAT1,NA,NA,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,Preclinical
BRD-K28863208-001-02-0::2.5::HTS,BRD-K28863208-001-02-0,PNU-282987,2.5,HTS,cholinergic receptor agonist,CHRNA7,NA,NA,"Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2",Preclinical
BRD-K28907958-001-04-3::2.5::HTS,BRD-K28907958-001-04-3,CD-437,2.5,HTS,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28912512-001-23-2::2.5::HTS,BRD-K28912512-001-23-2,nicotinamide,2.5,HTS,protein synthesis stimulant,"BST1, LDHA, PARP1, SIRT5",dermatology,acne vulgaris (AV),"NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1",Launched
BRD-K28936863-051-33-0::2.5::HTS,BRD-K28936863-051-33-0,ketotifen,2.5,HTS,"histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor","HRH1, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B, PGD",neurology/psychiatry,itching,"CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12",Launched
BRD-K28965160-001-01-1::2.5::HTS,BRD-K28965160-001-01-1,BVD-523,2.5,HTS,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28971625-003-01-4::2.5::HTS,BRD-K28971625-003-01-4,ZD-7114,2.5,HTS,adrenergic receptor agonist,ADRB3,NA,NA,COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,Phase 1
BRD-K28982731-001-01-6::2.5::HTS,BRD-K28982731-001-01-6,emoxipin,2.5,HTS,NA,NA,NA,NA,CCc1nc(C)ccc1O,Phase 2
BRD-K29133151-001-03-2::2.5::HTS,BRD-K29133151-001-03-2,"ICI-185,282",2.5,HTS,thromboxane receptor antagonist,NA,NA,NA,OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F,Phase 1
BRD-K29173907-001-09-2::2.5::HTS,BRD-K29173907-001-09-2,isoflupredone-acetate,2.5,HTS,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29220403-001-10-8::2.5::HTS,BRD-K29220403-001-10-8,eszopiclone,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,insomnia,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1,Launched
BRD-K29254801-001-14-7::2.5::HTS,BRD-K29254801-001-14-7,thiram,2.5,HTS,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29322660-001-01-9::2.5::HTS,BRD-K29322660-001-01-9,edoxaban,2.5,HTS,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)",CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@H](C1)NC(=O)c1nc2CCN(C)Cc2s1,Launched
BRD-K29359156-001-30-1::2.5::HTS,BRD-K29359156-001-30-1,ebselen,2.5,HTS,"cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor",ALB,NA,NA,O=c1n([se]c2ccccc12)-c1ccccc1,Phase 2/Phase 3
BRD-K29392254-001-02-2::2.5::HTS,BRD-K29392254-001-02-2,pantothenic-acid,2.5,HTS,coenzyme A precursor,NA,NA,NA,"CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O",Launched
BRD-K29395450-001-06-8::2.5::HTS,BRD-K29395450-001-06-8,PIK-93,2.5,HTS,PI3K inhibitor,"PI4KB, PIK3C3, PIK3CG",NA,NA,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO,Preclinical
BRD-K29415052-050-04-8::2.5::HTS,BRD-K29415052-050-04-8,BGT226,2.5,HTS,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29458283-001-29-9::2.5::HTS,BRD-K29458283-001-29-9,chlorambucil,2.5,HTS,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29462201-001-01-9::2.5::HTS,BRD-K29462201-001-01-9,deserpidine,2.5,HTS,angiotensin converting enzyme inhibitor,"ACE, SLC18A2",cardiology,hypertension,"CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1",Launched
BRD-K29530284-001-06-2::2.5::HTS,BRD-K29530284-001-06-2,amlexanox,2.5,HTS,histamine receptor modulator,"FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13","dental, pulmonary, ophthalmology, allergy","aphthous ulcers, asthma, conjunctivitis, allergic rhinitis","CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O",Launched
BRD-K29542628-001-03-9::2.5::HTS,BRD-K29542628-001-03-9,1-naphthyl-PP1,2.5,HTS,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29546239-001-02-3::2.5::HTS,BRD-K29546239-001-02-3,SNC-80,2.5,HTS,NA,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1",Preclinical
BRD-K29582115-066-01-2::2.5::HTS,BRD-K29582115-066-01-2,ziprasidone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582677-300-10-6::2.5::HTS,BRD-K29582677-300-10-6,flunarizine,2.5,HTS,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1","neurology/psychiatry, cardiology","migraine headache, vertigo, peripheral artery disease (PAD)","Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1",Launched
BRD-K29653726-001-13-4::2.5::HTS,BRD-K29653726-001-13-4,topiramate,2.5,HTS,"carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist","CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, migraine headache","CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1",Launched
BRD-K29656036-001-02-5::2.5::HTS,BRD-K29656036-001-02-5,MK-8245,2.5,HTS,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29668683-300-02-2::2.5::HTS,BRD-K29668683-300-02-2,BD-1063,2.5,HTS,sigma receptor antagonist,SIGMAR1,NA,NA,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,Preclinical
BRD-K29673530-001-05-4::2.5::HTS,BRD-K29673530-001-05-4,hypericin,2.5,HTS,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29713308-001-01-7::2.5::HTS,BRD-K29713308-001-01-7,mebhydrolin,2.5,HTS,antihistamine,NA,allergy,"allergic rhinitis, urticaria",CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1,Launched
BRD-K29713308-077-04-1::2.5::HTS,BRD-K29713308-077-04-1,"mebhydroline-1,5-naphtalenedisulfonate",2.5,HTS,NA,NA,NA,NA,CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1,Preclinical
BRD-K29735307-001-02-9::2.5::HTS,BRD-K29735307-001-02-9,ostarine,2.5,HTS,androgen receptor modulator,AR,NA,NA,C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,Phase 3
BRD-K29834313-001-01-4::2.5::HTS,BRD-K29834313-001-01-4,myricitrin,2.5,HTS,PKC inhibitor,"NOS1, PRKCA",NA,NA,C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O,Preclinical
BRD-K29895144-001-01-0::2.5::HTS,BRD-K29895144-001-01-0,SKLB1002,2.5,HTS,VEGFR inhibitor,KDR,NA,NA,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,Preclinical
BRD-K29905972-001-06-3::2.5::HTS,BRD-K29905972-001-06-3,axitinib,2.5,HTS,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29918010-003-04-1::2.5::HTS,BRD-K29918010-003-04-1,glucosamine,2.5,HTS,glycosylated protein precursor,"IFNG, IL1B, MMP9, NFKB2, TNF","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis, joint pain, backache",N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K29950728-048-17-4::2.5::HTS,BRD-K29950728-048-17-4,clomifene,2.5,HTS,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29968218-001-03-2::2.5::HTS,BRD-K29968218-001-03-2,KX2-391,2.5,HTS,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K30019776-003-01-5::2.5::HTS,BRD-K30019776-003-01-5,dexfosfoserine,2.5,HTS,membrane integrity inhibitor,"CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2",NA,NA,"N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O",Preclinical
BRD-K30020243-051-02-5::2.5::HTS,BRD-K30020243-051-02-5,aliskiren-hemifumarate,2.5,HTS,renin inhibitor,REN,cardiology,hypertension,"COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC",Launched
BRD-K30114692-001-15-9::2.5::HTS,BRD-K30114692-001-15-9,methenamine,2.5,HTS,bacterial DNA inhibitor,NA,infectious disease,urinary tract infections,"C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3",Launched
BRD-K30126819-304-02-7::2.5::HTS,BRD-K30126819-304-02-7,dimesna,2.5,HTS,tubulin polymerization inhibitor,NA,NA,NA,"OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O",Phase 3
BRD-K30213273-001-01-6::2.5::HTS,BRD-K30213273-001-01-6,fenofibric-acid,2.5,HTS,cytochrome P450 inhibitor,"CLCN1, PPARA",cardiology,dyslipidemia,CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O,Launched
BRD-K30237152-300-02-5::2.5::HTS,BRD-K30237152-300-02-5,1400W,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,CC(=N)NCc1cccc(CN)c1,Preclinical
BRD-K30240666-051-15-9::2.5::HTS,BRD-K30240666-051-15-9,clemastine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1",Launched
BRD-K30331124-001-01-7::2.5::HTS,BRD-K30331124-001-01-7,ASC-J9,2.5,HTS,androgen receptor enhancer,AR,NA,NA,"COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1",Phase 2
BRD-K30373883-001-02-8::2.5::HTS,BRD-K30373883-001-02-8,dutasteride,2.5,HTS,5 alpha reductase inhibitor,"SRD5A1, SRD5A2",urology,benign prostatic hyperplasia (BPH),C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F,Launched
BRD-K30374899-001-09-3::2.5::HTS,BRD-K30374899-001-09-3,mannitol-D,2.5,HTS,diuretic,NA,"neurology/psychiatry, ophthalmology, gastroenterology","intracranial pressure, intraocular pressure, constipation","OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",Launched
BRD-K30421593-050-04-9::2.5::HTS,BRD-K30421593-050-04-9,timolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"ocular hypertension, glaucoma","CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1",Launched
BRD-K30431096-004-01-3::2.5::HTS,BRD-K30431096-004-01-3,domiphen,2.5,HTS,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30466858-001-09-6::2.5::HTS,BRD-K30466858-001-09-6,ellagic-acid,2.5,HTS,"glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor","CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK",NA,NA,"Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O",Phase 2
BRD-K30480208-001-18-5::2.5::HTS,BRD-K30480208-001-18-5,torasemide,2.5,HTS,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30519779-001-03-1::2.5::HTS,BRD-K30519779-001-03-1,homoquinolinic-acid,2.5,HTS,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30550578-001-01-3::2.5::HTS,BRD-K30550578-001-01-3,PF-04620110,2.5,HTS,diacylglycerol O acyltransferase inhibitor,DGAT1,NA,NA,Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12,Phase 1
BRD-K30553453-001-13-2::2.5::HTS,BRD-K30553453-001-13-2,hesperetin,2.5,HTS,ACAT inhibitor,"DGAT1, MTTP, SOAT1, SOAT2",NA,NA,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,Launched
BRD-K30563334-001-02-9::2.5::HTS,BRD-K30563334-001-02-9,rifabutin,2.5,HTS,protein synthesis inhibitor,"HSP90AA1, HSP90B1",infectious disease,human immunodeficiency virus (HIV-1),CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21,Launched
BRD-K30572193-001-02-0::2.5::HTS,BRD-K30572193-001-02-0,CTEP,2.5,HTS,glutamate receptor antagonist,GRM5,NA,NA,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,Preclinical
BRD-K30577245-001-04-3::2.5::HTS,BRD-K30577245-001-04-3,docetaxel,2.5,HTS,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::2.5::HTS,BRD-K30577245-341-01-9,docetaxel,2.5,HTS,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30634073-046-01-0::2.5::HTS,BRD-K30634073-046-01-0,levallorphan,2.5,HTS,opioid antagonist,"CHRNA2, OPRM1",pulmonary,respiratory depression,Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1,Launched
BRD-K30649484-003-13-7::2.5::HTS,BRD-K30649484-003-13-7,mafenide,2.5,HTS,carbonic anhydrase inhibitor,"CA12, CA14, CA2, CA4, CA6, CA9",infectious disease,"first-aid antibiotic, skin infections",NCc1ccc(cc1)S(N)(=O)=O,Launched
BRD-K30652337-004-02-1::2.5::HTS,BRD-K30652337-004-02-1,eletriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,"CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12",Launched
BRD-K30685142-001-15-4::2.5::HTS,BRD-K30685142-001-15-4,levothyroxine,2.5,HTS,thyroid hormone stimulant,"THRA, THRB",endocrinology,myxedema coma,"N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O",Launched
BRD-K30707190-001-04-1::2.5::HTS,BRD-K30707190-001-04-1,PNU-74654,2.5,HTS,beta-catenin inhibitor,"CTNNB1, TCF4",NA,NA,"Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1",Preclinical
BRD-K30758549-001-01-8::2.5::HTS,BRD-K30758549-001-01-8,isopropyl-palmitate,2.5,HTS,cosmetic moisturizer,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K30867024-003-03-3::2.5::HTS,BRD-K30867024-003-03-3,SB-216641,2.5,HTS,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30933884-001-01-0::2.5::HTS,BRD-K30933884-001-01-0,UNBS-5162,2.5,HTS,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30977212-001-02-8::2.5::HTS,BRD-K30977212-001-02-8,PIK-293,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,Preclinical
BRD-K30990140-003-02-4::2.5::HTS,BRD-K30990140-003-02-4,FR-122047,2.5,HTS,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K31054881-300-04-7::2.5::HTS,BRD-K31054881-300-04-7,BMY-7378,2.5,HTS,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A",NA,NA,"COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1",Preclinical
BRD-K31086665-005-04-6::2.5::HTS,BRD-K31086665-005-04-6,NH125,2.5,HTS,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31092604-003-03-5::2.5::HTS,BRD-K31092604-003-03-5,donitriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6",NA,NA,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12,Phase 2
BRD-K31111078-001-04-2::2.5::HTS,BRD-K31111078-001-04-2,dimethyl-fumarate,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator",KEAP1,neurology/psychiatry,multiple sclerosis,"COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC",Launched
BRD-K31135544-001-07-0::2.5::HTS,BRD-K31135544-001-07-0,IB-MECA,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,Phase 3
BRD-K31283835-048-04-4::2.5::HTS,BRD-K31283835-048-04-4,tofacitinib,2.5,HTS,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",rheumatology,rheumatoid arthritis,"C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N",Launched
BRD-K31309378-001-01-5::2.5::HTS,BRD-K31309378-001-01-5,lucitanib,2.5,HTS,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31313613-003-04-2::2.5::HTS,BRD-K31313613-003-04-2,BS-181,2.5,HTS,CDK inhibitor,CDK7,NA,NA,"CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12",Preclinical
BRD-K31339321-001-03-6::2.5::HTS,BRD-K31339321-001-03-6,lirimilast,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl,Phase 2
BRD-K31385749-003-01-3::2.5::HTS,BRD-K31385749-003-01-3,ivabradine,2.5,HTS,"HCN channel antagonist, potassium channel blocker, sodium channel blocker","HCN1, HCN3, HCN4",cardiology,angina pectoris,COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC,Launched
BRD-K31468676-237-01-8::2.5::HTS,BRD-K31468676-237-01-8,oxonic-acid,2.5,HTS,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31476763-001-01-5::2.5::HTS,BRD-K31476763-001-01-5,AZD9668,2.5,HTS,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31491153-003-05-9::2.5::HTS,BRD-K31491153-003-05-9,1-phenylbiguanide,2.5,HTS,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31495718-001-01-1::2.5::HTS,BRD-K31495718-001-01-1,AZD7687,2.5,HTS,diacylglycerol O acyltransferase inhibitor,DGAT1,NA,NA,Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1,Phase 1
BRD-K31519811-001-02-2::2.5::HTS,BRD-K31519811-001-02-2,PF-02545920,2.5,HTS,phosphodiesterase inhibitor,PDE10A,NA,NA,Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1,Phase 2
BRD-K31553034-001-03-0::2.5::HTS,BRD-K31553034-001-03-0,zibotentan,2.5,HTS,endothelin receptor antagonist,EDNRA,NA,NA,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1,Phase 3
BRD-K31560319-001-01-5::2.5::HTS,BRD-K31560319-001-01-5,olvanil,2.5,HTS,TRPV agonist,"CNR1, GPR119, TRPV1",NA,NA,"CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1",Preclinical
BRD-K31627533-001-09-5::2.5::HTS,BRD-K31627533-001-09-5,rimexolone,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31633810-003-02-8::2.5::HTS,BRD-K31633810-003-02-8,DAU-5884,2.5,HTS,acetylcholine receptor antagonist,CHRM3,NA,NA,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O",Preclinical
BRD-K31682896-001-24-0::2.5::HTS,BRD-K31682896-001-24-0,sulfamethizole,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,"Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1",Launched
BRD-K31698212-001-02-9::2.5::HTS,BRD-K31698212-001-02-9,icotinib,2.5,HTS,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31731454-237-02-5::2.5::HTS,BRD-K31731454-237-02-5,pemirolast,2.5,HTS,mediator release inhibitor,HRH1,pulmonary,asthma,"Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O, Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O",Launched
BRD-K31812033-003-11-0::2.5::HTS,BRD-K31812033-003-11-0,levobunolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31841515-001-07-8::2.5::HTS,BRD-K31841515-001-07-8,oxypurinol,2.5,HTS,xanthine oxidase inhibitor,XDH,NA,NA,O=c1[nH]c2n[nH]cc2c(=O)[nH]1,Phase 2/Phase 3
BRD-K31843556-001-04-1::2.5::HTS,BRD-K31843556-001-04-1,T-0070907,2.5,HTS,PPAR receptor antagonist,PPARG,NA,NA,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1",Preclinical
BRD-K31866293-001-01-6::2.5::HTS,BRD-K31866293-001-01-6,TAK-632,2.5,HTS,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31920458-001-23-6::2.5::HTS,BRD-K31920458-001-23-6,mestranol,2.5,HTS,estrogen receptor agonist,ESR1,endocrinology,contraceptive,"COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1",Launched
BRD-K31928526-001-02-1::2.5::HTS,BRD-K31928526-001-02-1,barasertib,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K32007074-001-02-9::3.16::HTS,BRD-K32007074-001-02-9,enocitabine,3.16,HTS,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32021043-001-14-3::2.5::HTS,BRD-K32021043-001-14-3,sulfachlorpyridazine,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1,Launched
BRD-K32101625-001-01-6::2.5::HTS,BRD-K32101625-001-01-6,LX1031,2.5,HTS,tryptophan hydroxylase inhibitor,TPH1,NA,NA,COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,Phase 2
BRD-K32107296-001-16-9::2.5::HTS,BRD-K32107296-001-16-9,temozolomide,2.5,HTS,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32164935-001-30-8::2.5::HTS,BRD-K32164935-001-30-8,tolazamide,2.5,HTS,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1",Launched
BRD-K32218650-001-01-6::2.5::HTS,BRD-K32218650-001-01-6,MBX-2982,2.5,HTS,glucose dependent insulinotropic receptor agonist,GPR119,NA,NA,CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1,Phase 2
BRD-K32247306-001-29-4::2.5::HTS,BRD-K32247306-001-29-4,primidone,2.5,HTS,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1",Launched
BRD-K32273377-001-17-9::2.5::HTS,BRD-K32273377-001-17-9,sulfadiazine,2.5,HTS,bacterial antifolate,NA,"infectious disease, ophthalmology","malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid","Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1",Launched
BRD-K32285926-001-02-1::2.5::HTS,BRD-K32285926-001-02-1,AMG-208,2.5,HTS,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32289541-001-01-0::2.5::HTS,BRD-K32289541-001-01-0,EHop-016,2.5,HTS,Ras GTPase inhibitor,"RAC1, RAC3",NA,NA,CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12,Preclinical
BRD-K32292990-001-03-6::2.5::HTS,BRD-K32292990-001-03-6,CGP-53353,2.5,HTS,"EGFR inhibitor, PKC inhibitor","EGFR, PRKCB",NA,NA,"Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1",Preclinical
BRD-K32311154-001-01-0::2.5::HTS,BRD-K32311154-001-01-0,nifekalant,2.5,HTS,potassium channel blocker,NA,cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)",Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O,Launched
BRD-K32318651-001-23-7::2.5::HTS,BRD-K32318651-001-23-7,acyclovir,2.5,HTS,DNA polymerase inhibitor,PNP,infectious disease,"genitial herpes, shingles, chicken pox","Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1",Launched
BRD-K32318651-001-24-5::2.5::HTS,BRD-K32318651-001-24-5,acyclovir,2.5,HTS,DNA polymerase inhibitor,PNP,infectious disease,"genitial herpes, shingles, chicken pox","Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1",Launched
BRD-K32372024-001-01-0::2.5::HTS,BRD-K32372024-001-01-0,D-7193,2.5,HTS,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32405725-001-02-8::2.5::HTS,BRD-K32405725-001-02-8,etomoxir,2.5,HTS,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32501161-300-06-2::2.5::HTS,BRD-K32501161-300-06-2,vanoxerine,2.5,HTS,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32572029-001-04-4::2.5::HTS,BRD-K32572029-001-04-4,orotic-acid,2.5,HTS,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32681104-001-11-6::2.5::HTS,BRD-K32681104-001-11-6,2-aminobenzenesulfonamide,2.5,HTS,carbonic anhydrase inhibitor,"CA12, CA14, CA2, CA6, CA9",NA,NA,Nc1ccccc1S(N)(=O)=O,Preclinical
BRD-K32730239-001-01-0::2.5::HTS,BRD-K32730239-001-01-0,SU3327,2.5,HTS,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32744045-001-31-2::2.5::HTS,BRD-K32744045-001-31-2,disulfiram,2.5,HTS,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32768103-051-02-6::2.5::HTS,BRD-K32768103-051-02-6,vonoprazan,2.5,HTS,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD),"CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1",Launched
BRD-K32821942-001-21-3::2.5::HTS,BRD-K32821942-001-21-3,azathioprine,2.5,HTS,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32830106-001-02-6::2.5::HTS,BRD-K32830106-001-02-6,guanfacine,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl",Launched
BRD-K32830106-003-20-4::2.5::HTS,BRD-K32830106-003-20-4,guanfacine,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl",Launched
BRD-K32847234-065-04-6::2.5::HTS,BRD-K32847234-065-04-6,sparteine-sulfate,2.5,HTS,NA,NA,NA,NA,C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1,Launched
BRD-K32977963-001-05-0::2.5::HTS,BRD-K32977963-001-05-0,eugenol,2.5,HTS,androgen receptor antagonist,AR,dental,toothache,COc1cc(CC=C)ccc1O,Launched
BRD-K33082088-001-03-3::2.5::HTS,BRD-K33082088-001-03-3,retapamulin,2.5,HTS,protein synthesis inhibitor,NA,infectious disease,impetigo,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,Launched
BRD-K33127281-001-05-6::2.5::HTS,BRD-K33127281-001-05-6,adapalene,2.5,HTS,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33141550-003-05-7::2.5::HTS,BRD-K33141550-003-05-7,L-NAME,2.5,HTS,nitric oxide synthase inhibitor,NOS3,NA,NA,"COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O",Phase 2/Phase 3
BRD-K33151569-003-09-7::2.5::HTS,BRD-K33151569-003-09-7,deoxyepinephrine,2.5,HTS,"adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2",NA,NA,CNCCc1ccc(O)c(O)c1,Preclinical
BRD-K33183200-303-02-4::2.5::HTS,BRD-K33183200-303-02-4,imetit,2.5,HTS,histamine receptor agonist,"HRH3, HRH4",NA,NA,NC(=N)SCCc1c[nH]cn1,Preclinical
BRD-K33211335-004-01-7::2.5::HTS,BRD-K33211335-004-01-7,dextromethorphan,2.5,HTS,"glutamate receptor antagonist, sigma receptor agonist","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4",pulmonary,cough suppressant,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,Launched
BRD-K33219225-001-01-9::2.5::HTS,BRD-K33219225-001-01-9,allylisothiocyanate,2.5,HTS,TRPV agonist,TRPA1,NA,NA,C=CCN=C=S,Preclinical
BRD-K33226500-001-01-0::2.5::HTS,BRD-K33226500-001-01-0,indinavir,2.5,HTS,HIV protease inhibitor,"CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,Launched
BRD-K33251802-001-01-3::2.5::HTS,BRD-K33251802-001-01-3,miglustat,2.5,HTS,Glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Launched
BRD-K33277808-331-01-3::2.5::HTS,BRD-K33277808-331-01-3,ouabain,2.5,HTS,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33379087-001-07-5::2.5::HTS,BRD-K33379087-001-07-5,tivantinib,2.5,HTS,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33396764-001-08-7::0.25::HTS,BRD-K33396764-001-08-7,alpha-linolenic-acid,0.25,HTS,omega 3 fatty acid stimulant,"ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1",NA,NA,"CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O",Phase 3
BRD-K33425534-001-12-5::2.5::HTS,BRD-K33425534-001-12-5,exemestane,2.5,HTS,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33453211-003-11-5::2.5::HTS,BRD-K33453211-003-11-5,levocabastine,2.5,HTS,histamine receptor antagonist,"HRH1, NTSR2",ophthalmology,conjunctivitis,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,Launched
BRD-K33459542-001-07-4::2.5::HTS,BRD-K33459542-001-07-4,ditolylguanidine,2.5,HTS,sigma receptor agonist,"GRIN1, GRIN2A, GRIN2B, SIGMAR1",NA,NA,Cc1ccccc1NC(=N)Nc1ccccc1C,Preclinical
BRD-K33483813-001-10-0::2.5::HTS,BRD-K33483813-001-10-0,actarit,2.5,HTS,interleukin receptor agonist,NA,rheumatology,rheumatoid arthritis,CC(=O)Nc1ccc(CC(O)=O)cc1,Launched
BRD-K33510429-001-03-1::2.5::HTS,BRD-K33510429-001-03-1,vanillylacetone,2.5,HTS,NA,NA,NA,NA,"COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O",Preclinical
BRD-K33583600-001-16-1::2.5::HTS,BRD-K33583600-001-16-1,isoliquiritigenin,2.5,HTS,guanylate cyclase activator,GABBR1,NA,NA,Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O,Preclinical
BRD-K33588785-001-01-9::2.5::HTS,BRD-K33588785-001-01-9,obidoxime,2.5,HTS,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33610132-001-02-9::2.5::HTS,BRD-K33610132-001-02-9,rociletinib,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33622447-066-01-9::2.5::HTS,BRD-K33622447-066-01-9,abemaciclib,2.5,HTS,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33681278-036-01-2::2.5::HTS,BRD-K33681278-036-01-2,prucalopride,2.5,HTS,serotonin receptor agonist,HTR4,gastroenterology,constipation,"COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12",Launched
BRD-K33690734-001-01-5::2.5::HTS,BRD-K33690734-001-01-5,5-BDBD,2.5,HTS,purinergic receptor antagonist,P2RX4,NA,NA,"Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21",Preclinical
BRD-K33720171-001-01-0::2.5::HTS,BRD-K33720171-001-01-0,difluprednate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33732501-004-01-0::2.5::HTS,BRD-K33732501-004-01-0,methylnaltrexone,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,constipation,C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O,Launched
BRD-K33743361-003-02-6::2.5::HTS,BRD-K33743361-003-02-6,ML133,2.5,HTS,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33809398-001-01-8::2.5::HTS,BRD-K33809398-001-01-8,SCMC-Lys,2.5,HTS,mucolytic agent,GSTP1,NA,NA,"N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O",Launched
BRD-K33813875-003-01-8::2.5::HTS,BRD-K33813875-003-01-8,valnemulin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33814251-001-01-4::2.6::HTS,BRD-K33814251-001-01-4,lubiprostone,2.6,HTS,chloride channel activator,CLCN2,gastroenterology,"constipation, irritable bowel syndrome","CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",Launched
BRD-K33814251-001-02-2::2.5::HTS,BRD-K33814251-001-02-2,lubiprostone,2.5,HTS,chloride channel activator,CLCN2,gastroenterology,"constipation, irritable bowel syndrome","CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",Launched
BRD-K33818169-003-04-6::2.5::HTS,BRD-K33818169-003-04-6,GW-3965,2.5,HTS,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33852358-001-09-9::2.5::HTS,BRD-K33852358-001-09-9,arofylline,2.5,HTS,phosphodiesterase inhibitor,PDE4A,NA,NA,CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O,Phase 3
BRD-K33864865-001-02-5::2.5::HTS,BRD-K33864865-001-02-5,LY225910,2.5,HTS,CCK receptor antagonist,CCKBR,NA,NA,"CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O",Preclinical
BRD-K33882852-003-02-8::2.5::HTS,BRD-K33882852-003-02-8,ZK-93423,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33892651-001-02-4::2.5::HTS,BRD-K33892651-001-02-4,ML347,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"ACVR1, ACVRL1, BMPR1A",NA,NA,"COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K34022604-001-06-6::2.5::HTS,BRD-K34022604-001-06-6,clofarabine,2.5,HTS,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34032314-001-04-1::2.5::HTS,BRD-K34032314-001-04-1,betamethasone-valerate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO",Launched
BRD-K34058848-304-03-1::2.5::HTS,BRD-K34058848-304-03-1,cefonicid,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1",Launched
BRD-K34073885-001-09-3::2.54::HTS,BRD-K34073885-001-09-3,tanshinone-i,2.54,HTS,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34122555-057-11-5::2.5::HTS,BRD-K34122555-057-11-5,denatonium-benzoate,2.5,HTS,NA,NA,NA,NA,CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1,Preclinical
BRD-K34154330-003-06-4::2.5::HTS,BRD-K34154330-003-06-4,tracazolate,2.5,HTS,GABA receptor modulator,GABRA1,NA,NA,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,Phase 2
BRD-K34157611-001-16-0::2.5::HTS,BRD-K34157611-001-16-0,cimetidine,2.5,HTS,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34185671-001-02-8::2.5::HTS,BRD-K34185671-001-02-8,AMG-517,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1,Phase 1
BRD-K34313798-001-01-6::2.5::HTS,BRD-K34313798-001-01-6,LY215490,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1",NA,NA,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,Phase 1
BRD-K34321528-003-01-2::2.5::HTS,BRD-K34321528-003-01-2,CGP-71683,2.5,HTS,neuropeptide receptor antagonist,NPY5R,NA,NA,"Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12",Preclinical
BRD-K34328244-001-01-4::2.5::HTS,BRD-K34328244-001-01-4,MF-101,2.5,HTS,estrogen receptor agonist,"CYP19A1, XDH",NA,NA,Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1,Phase 3
BRD-K34332569-001-01-3::2.5::HTS,BRD-K34332569-001-01-3,imidapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34341643-001-01-4::2.5::HTS,BRD-K34341643-001-01-4,glasdegib,2.5,HTS,hedgehog pathway inhibitor,SMO,NA,NA,CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N,Phase 2
BRD-K34388247-236-08-2::2.5::HTS,BRD-K34388247-236-08-2,methicillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,"COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K34411947-001-12-5::2.5::HTS,BRD-K34411947-001-12-5,streptozotocin,2.5,HTS,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34415467-003-13-0::2.5::HTS,BRD-K34415467-003-13-0,trimethobenzamide,2.5,HTS,histamine receptor antagonist,DRD2,gastroenterology,"vomiting, nausea, gastroenteritis",COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,Launched
BRD-K34441861-003-07-0::2.47::HTS,BRD-K34441861-003-07-0,moexipril,2.47,HTS,angiotensin converting enzyme inhibitor,"ACE, ACE2",cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O",Launched
BRD-K34469523-003-03-0::2.5::HTS,BRD-K34469523-003-03-0,levalbuterol,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,Launched
BRD-K34533029-001-08-5::2.5::HTS,BRD-K34533029-001-08-5,tyrphostin-AG-494,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34568562-001-04-3::2.5::HTS,BRD-K34568562-001-04-3,tilorone,2.5,HTS,interferon inducer,NA,"infectious disease, gastroenterology, neurology/psychiatry","influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C",CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1,Launched
BRD-K34591242-001-04-3::2.5::HTS,BRD-K34591242-001-04-3,methoprene-(s),2.5,HTS,NA,NA,NA,NA,COC(C)(C)CCC[C@H](C)C\C=C\C(C)=C\C(=O)OC(C)C,Preclinical
BRD-K34608650-001-02-4::2.5::HTS,BRD-K34608650-001-02-4,GP2a,2.5,HTS,cannabinoid receptor agonist,CNR2,NA,NA,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1,Preclinical
BRD-K34663752-001-09-1::2.5::HTS,BRD-K34663752-001-09-1,6-chloromelatonin,2.5,HTS,melatonin receptor agonist,"MTNR1A, MTNR1B",NA,NA,"COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl",Preclinical
BRD-K34672903-001-01-7::2.5::HTS,BRD-K34672903-001-01-7,HEMADO,2.5,HTS,NA,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1",Preclinical
BRD-K34685430-050-12-5::2.5::HTS,BRD-K34685430-050-12-5,methylergometrine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C","hematology, neurology/psychiatry","postpartum hemorrhage (PPH), migraine headache","CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34",Launched
BRD-K34713073-001-01-3::2.5::HTS,BRD-K34713073-001-01-3,PD-123319,2.5,HTS,angiotensin antagonist,AGTR2,NA,NA,"CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C",Phase 1
BRD-K34730807-001-17-6::2.5::HTS,BRD-K34730807-001-17-6,levodopa,2.5,HTS,dopamine precursor,"DRD1, DRD2, DRD3, DRD4, DRD5, GPR143",neurology/psychiatry,Parkinson's Disease,"N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K34776109-001-16-6::2.5::HTS,BRD-K34776109-001-16-6,glimepiride,2.5,HTS,insulin secretagogue,"ABCC8, KCNJ1, KCNJ11",endocrinology,diabetes mellitus,"CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O",Launched
BRD-K34801930-001-01-9::2.5::HTS,BRD-K34801930-001-01-9,AZD5069,2.5,HTS,CC chemokine receptor antagonist,CXCR2,NA,NA,C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,Phase 2
BRD-K34851558-001-02-3::2.5::HTS,BRD-K34851558-001-02-3,parthenolide-(-),2.5,HTS,NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34870043-001-01-8::2.5::HTS,BRD-K34870043-001-01-8,adoprazine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor agonist","DRD2, HTR1A",NA,NA,Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1,Phase 2
BRD-K34888156-213-01-4::2.5::HTS,BRD-K34888156-213-01-4,theobromine,2.5,HTS,phosphodiesterase inhibitor,"ADORA1, ADORA2A, PDE4B",NA,NA,"Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12",Launched
BRD-K35007173-001-07-5::2.5::HTS,BRD-K35007173-001-07-5,enprofylline,2.5,HTS,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B",NA,NA,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,Phase 3
BRD-K35034482-001-01-8::2.5::HTS,BRD-K35034482-001-01-8,bunazosin,2.5,HTS,adrenergic receptor antagonist,ADRA1A,ophthalmology,"glaucoma, intraocular pressure",CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,Launched
BRD-K35079116-001-02-5::2.71::HTS,BRD-K35079116-001-02-5,asiatic-acid,2.71,HTS,apoptosis stimulant,PYGM,NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O",Preclinical
BRD-K35079116-001-03-3::2.5::HTS,BRD-K35079116-001-03-3,asiatic-acid,2.5,HTS,apoptosis stimulant,PYGM,NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O",Preclinical
BRD-K35169477-001-01-9::2.5::HTS,BRD-K35169477-001-01-9,taranabant,2.5,HTS,cannabinoid receptor inverse agonist,CNR1,NA,NA,C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N,Phase 3
BRD-K35170555-001-09-5::2.5::HTS,BRD-K35170555-001-09-5,caprylic-acid,2.5,HTS,NA,NA,NA,NA,"CCCCCCCC(O)=O, CCCCCCCC(O)=O",Launched
BRD-K35189033-001-26-1::2.5::HTS,BRD-K35189033-001-26-1,levonorgestrel,2.5,HTS,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35240538-001-26-2::2.5::HTS,BRD-K35240538-001-26-2,methylprednisolone,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35245662-001-01-2::2.5::HTS,BRD-K35245662-001-01-2,ciclesonide,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35329391-334-01-7::2.5::HTS,BRD-K35329391-334-01-7,GZD824,2.5,HTS,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35430135-003-02-3::2.5::HTS,BRD-K35430135-003-02-3,SR-59230A,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",NA,NA,"CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12",Preclinical
BRD-K35498378-001-06-1::2.5::HTS,BRD-K35498378-001-06-1,alrestatin,2.5,HTS,aldose reductase inhibitor,AKR1B1,NA,NA,"OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K35520305-001-17-7::2.5::HTS,BRD-K35520305-001-17-7,dacarbazine,2.5,HTS,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35559145-050-08-5::2.5::HTS,BRD-K35559145-050-08-5,levomepromazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C","neurology/psychiatry, gastroenterology","psychosis, schizophrenia, bipolar disorder, nausea, insomnia","COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1",Launched
BRD-K35586044-003-15-4::2.5::HTS,BRD-K35586044-003-15-4,yohimbine,2.5,HTS,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8",cardiology,"cardiac arrythmia, bradycardia","COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12",Launched
BRD-K35589454-003-01-1::2.5::HTS,BRD-K35589454-003-01-1,danegaptide,2.5,HTS,gap junction modulator,NA,NA,NA,NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1,Phase 2
BRD-K35601925-001-01-9::2.5::HTS,BRD-K35601925-001-01-9,CS-917,2.5,HTS,fructose biphosphate inhibitor,FBP1,NA,NA,"CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O",Phase 2
BRD-K35629949-001-02-0::2.5::HTS,BRD-K35629949-001-02-0,SR-27897,2.5,HTS,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35687421-001-02-5::2.5::HTS,BRD-K35687421-001-02-5,gimeracil,2.5,HTS,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35698076-001-01-2::2.5::HTS,BRD-K35698076-001-01-2,laurocapram,2.5,HTS,NA,NA,NA,NA,CCCCCCCCCCCCN1CCCCCC1=O,Phase 3
BRD-K35719256-001-02-6::2.5::HTS,BRD-K35719256-001-02-6,rotundine,2.5,HTS,serotonin receptor agonist,"DRD1, DRD2, DRD3, HTR1A",NA,NA,COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC,Launched
BRD-K35775715-001-03-1::2.5::HTS,BRD-K35775715-001-03-1,liranaftate,2.5,HTS,fungal squalene epoxidase inhibitor,NA,infectious disease,fungal infection,COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1,Launched
BRD-K35781423-001-01-6::2.5::HTS,BRD-K35781423-001-01-6,SANT-2,2.5,HTS,smoothened receptor antagonist,"SHH, SMO",NA,NA,"CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1",Preclinical
BRD-K35952844-236-01-6::2.5::HTS,BRD-K35952844-236-01-6,sodium-glucoheptonate,2.5,HTS,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-238-01-2::2.5::HTS,BRD-K35952844-238-01-2,calcium-gluceptate,2.5,HTS,NA,NA,NA,NA,"OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O",Launched
BRD-K35960502-001-20-0::2.5::HTS,BRD-K35960502-001-20-0,niclosamide,2.5,HTS,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K36016295-001-04-5::2.5::HTS,BRD-K36016295-001-04-5,KU-60019,2.5,HTS,ATM kinase inhibitor,ATM,NA,NA,"C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1",Preclinical
BRD-K36021395-300-02-4::2.5::HTS,BRD-K36021395-300-02-4,ABT-702,2.5,HTS,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36040345-001-01-1::2.5::HTS,BRD-K36040345-001-01-1,TXA127,2.5,HTS,angiotensin receptor agonist,NA,NA,NA,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O",Phase 2
BRD-K36055864-001-19-2::2.5::HTS,BRD-K36055864-001-19-2,cycloheximide,2.5,HTS,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36116267-001-15-3::2.5::HTS,BRD-K36116267-001-15-3,pyrithyldione,2.5,HTS,psychoactive drug,NA,NA,NA,CCC1(CC)C(=O)NC=CC1=O,Withdrawn
BRD-K36198571-001-02-0::2.5::HTS,BRD-K36198571-001-02-0,WAY-170523,2.5,HTS,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36207157-001-07-0::2.52::HTS,BRD-K36207157-001-07-0,chlorprothixene,2.52,HTS,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"schizophrenia, bipolar disorder","CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12",Launched
BRD-K36207157-001-09-6::2.5::HTS,BRD-K36207157-001-09-6,chlorprothixene,2.5,HTS,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"schizophrenia, bipolar disorder","CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12",Launched
BRD-K36222532-001-01-8::2.5::HTS,BRD-K36222532-001-01-8,broxaldine,2.5,HTS,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36234266-001-09-8::2.5::HTS,BRD-K36234266-001-09-8,carmustine,2.5,HTS,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36258877-001-03-1::2.5::HTS,BRD-K36258877-001-03-1,AZ-10417808,2.5,HTS,caspase inhibitor,CASP3,NA,NA,"[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1",Preclinical
BRD-K36262466-001-06-3::2.5::HTS,BRD-K36262466-001-06-3,aceneuramic-acid,2.5,HTS,NA,"AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1",NA,NA,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,Phase 3
BRD-K36269323-300-02-6::2.5::HTS,BRD-K36269323-300-02-6,asymmetrical-dimethylarginine,2.5,HTS,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36270037-001-01-7::2.5::HTS,BRD-K36270037-001-01-7,esculin,2.5,HTS,antioxidant,NA,NA,NA,OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O,Phase 1
BRD-K36363294-001-04-2::2.5::HTS,BRD-K36363294-001-04-2,I-BET151,2.5,HTS,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36381762-300-02-7::2.5::HTS,BRD-K36381762-300-02-7,nor-Binaltorphimine-dihydrochloride,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O",Preclinical
BRD-K36386086-001-01-1::2.5::HTS,BRD-K36386086-001-01-1,dolutegravir,2.5,HTS,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36395411-003-02-2::2.5::HTS,BRD-K36395411-003-02-2,SB-206553,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1",Preclinical
BRD-K36449075-001-01-0::2.5::HTS,BRD-K36449075-001-01-0,copper-histidine,2.5,HTS,NA,"HAL, HARS, HDC, SLC15A3, SLC15A4, SLC38A3, SLC38A5",NA,NA,N[C@H](Cc1c[nH]cn1)C(O)=O,Phase 3
BRD-K36461289-001-05-8::2.5::HTS,BRD-K36461289-001-05-8,picrotoxinin,2.5,HTS,GABA receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",NA,NA,CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,Preclinical
BRD-K36467523-001-02-8::2.5::HTS,BRD-K36467523-001-02-8,bindarit,2.5,HTS,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36529613-001-02-6::2.5::HTS,BRD-K36529613-001-02-6,PU-H71,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36627727-001-05-4::2.5::HTS,BRD-K36627727-001-05-4,tamibarotene,2.5,HTS,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36660044-001-24-2::2.5::HTS,BRD-K36660044-001-24-2,bufexamac,2.5,HTS,cyclooxygenase inhibitor,"HDAC10, HDAC6",NA,NA,"CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1",Withdrawn
BRD-K36680103-001-01-6::2.5::HTS,BRD-K36680103-001-01-6,omecamtiv-mecarbil,2.5,HTS,cardiac myosin activator,MYBPC3,NA,NA,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,Phase 2
BRD-K36711084-001-02-0::2.5::HTS,BRD-K36711084-001-02-0,cyromazine,2.5,HTS,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36732695-001-01-9::2.5::HTS,BRD-K36732695-001-01-9,setiptiline,2.5,HTS,adrenergic receptor antagonist,"HRH1, HTR2A, HTR2C",neurology/psychiatry,depression,CN1CCC2=C(C1)c1ccccc1Cc1ccccc21,Launched
BRD-K36739687-001-03-0::2.5::HTS,BRD-K36739687-001-03-0,stemregenin-1,2.5,HTS,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36740062-001-06-6::2.5::HTS,BRD-K36740062-001-06-6,GSK1070916,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36756879-003-08-7::2.5::HTS,BRD-K36756879-003-08-7,ethaverine,2.5,HTS,calcium channel blocker,NA,neurology/psychiatry,"muscle relaxant, spasms",CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,Launched
BRD-K36775483-001-01-4::2.5::HTS,BRD-K36775483-001-01-4,DMeOB,2.5,HTS,NA,GRM5,NA,NA,COc1cccc(c1)\C=N\N=C\c1cccc(OC)c1,Preclinical
BRD-K36788280-001-01-2::2.5::HTS,BRD-K36788280-001-01-2,ribociclib,2.5,HTS,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36859431-300-02-3::2.5::HTS,BRD-K36859431-300-02-3,sapropterin,2.5,HTS,phenylalanine 4-hydroxylase stimulant,"NOS3, PAH, TH, TPH1",metabolism,hyperphenylalaninemia (HPA),"C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1",Launched
BRD-K36862742-001-25-6::2.5::HTS,BRD-K36862742-001-25-6,hydroflumethiazide,2.5,HTS,sodium/potassium/chloride transporter inhibitor,"ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension",NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,Launched
BRD-K36864847-303-02-5::2.5::HTS,BRD-K36864847-303-02-5,BD-1047,2.5,HTS,adrenergic receptor antagonist,SIGMAR1,NA,NA,"CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1",Preclinical
BRD-K36889451-001-01-1::2.5::HTS,BRD-K36889451-001-01-1,tetramethylthiuram-monosulfide,2.5,HTS,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36927236-001-32-6::2.5::HTS,BRD-K36927236-001-32-6,glyburide,2.5,HTS,"ATP channel blocker, insulin secretagogue, sulfonylurea","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1",endocrinology,"diabetes mellitus, hyperglycemia","COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
BRD-K36965586-003-08-8::2.5::HTS,BRD-K36965586-003-08-8,m-Chlorophenylbiguanide,2.5,HTS,NA,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1cccc(Cl)c1,Preclinical
BRD-K36970462-001-01-6::2.5::HTS,BRD-K36970462-001-01-6,tonabersat,2.5,HTS,"gap junction modulator, nitric oxide production inhibitor",NA,NA,NA,CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1,Phase 2
BRD-K36984403-001-02-7::2.5::HTS,BRD-K36984403-001-02-7,go-6983,2.5,HTS,protein kinase inhibitor,"PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ",NA,NA,"COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1",Preclinical
BRD-K37069697-001-01-3::2.5::HTS,BRD-K37069697-001-01-3,fexinidazole,2.5,HTS,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37083340-001-02-3::2.5::HTS,BRD-K37083340-001-02-3,lycopene,2.5,HTS,free radical scavenger,NA,NA,NA,CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C,Phase 3
BRD-K37111771-300-02-6::2.5::HTS,BRD-K37111771-300-02-6,trientine,2.5,HTS,chelating agent,CA14,metabolism,Wilson's disease,NCCNCCNCCN,Launched
BRD-K37130656-001-04-6::2.5::HTS,BRD-K37130656-001-04-6,rivaroxaban,2.5,HTS,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)","Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O",Launched
BRD-K37203094-001-02-5::2.5::HTS,BRD-K37203094-001-02-5,1-hexadecanol,2.5,HTS,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO",Launched
BRD-K37237504-001-02-7::2.5::HTS,BRD-K37237504-001-02-7,CEP-33779,2.5,HTS,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37249724-001-25-7::2.5::HTS,BRD-K37249724-001-25-7,astemizole,2.5,HTS,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37270826-001-27-6::2.66::HTS,BRD-K37270826-001-27-6,mifepristone,2.66,HTS,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-31-8::2.5::HTS,BRD-K37270826-001-31-8,mifepristone,2.5,HTS,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37289225-001-36-4::2.5::HTS,BRD-K37289225-001-36-4,clozapine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7",neurology/psychiatry,schizophrenia,"CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12",Launched
BRD-K37312348-001-15-0::2.5::HTS,BRD-K37312348-001-15-0,kenpaullone,2.5,HTS,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37355418-236-01-6::2.5::HTS,BRD-K37355418-236-01-6,efaproxiral,2.5,HTS,haemoglobin oxygen release stimulant,"HBA1, HBB",NA,NA,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1,Phase 3
BRD-K37379014-001-01-2::2.5::HTS,BRD-K37379014-001-01-2,filanesib,2.5,HTS,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37385792-003-02-1::2.5::HTS,BRD-K37385792-003-02-1,conivaptan,2.5,HTS,vasopressin receptor antagonist,"AVPR1A, AVPR2",endocrinology,hyponatremia,Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc3-c2[nH]1,Launched
BRD-K37516142-001-10-5::2.5::HTS,BRD-K37516142-001-10-5,idebenone,2.5,HTS,calcium channel modulator,NA,"neurology/psychiatry, ophthalmology","Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)","COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O",Launched
BRD-K37561857-001-15-5::2.5::HTS,BRD-K37561857-001-15-5,zardaverine,2.5,HTS,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37590257-001-02-8::2.5::HTS,BRD-K37590257-001-02-8,GSK256066,2.5,HTS,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37618799-001-03-0::2.5::HTS,BRD-K37618799-001-03-0,MRS-1220,2.5,HTS,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37682401-001-09-3::2.44::HTS,BRD-K37682401-001-09-3,piromidic-acid,2.44,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,"CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1",Phase 2
BRD-K37682401-213-01-1::2.5::HTS,BRD-K37682401-213-01-1,piromidic-acid,2.5,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,"CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1",Phase 2
BRD-K37687095-001-06-9::2.5::HTS,BRD-K37687095-001-06-9,AZD8330,2.5,HTS,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687387-237-01-7::2.5::HTS,BRD-K37687387-237-01-7,RU-28318,2.5,HTS,cytochrome P450 inhibitor,NR3C2,NA,NA,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12,Phase 2
BRD-K37688416-003-13-1::2.5::HTS,BRD-K37688416-003-13-1,fipexide,2.5,HTS,psychoactive drug,NA,NA,NA,Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1,Withdrawn
BRD-K37694030-003-12-7::2.5::HTS,BRD-K37694030-003-12-7,doxepin,2.5,HTS,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HRH2, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, KCNH2, SLC6A2, SLC6A4",neurology/psychiatry,"depression, anxiety","CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12",Launched
BRD-K37714784-305-02-1::2.5::HTS,BRD-K37714784-305-02-1,ABT-724,2.5,HTS,dopamine receptor agonist,DRD4,NA,NA,C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1,Phase 2
BRD-K37720887-001-07-8::2.5::HTS,BRD-K37720887-001-07-8,SB-525334,2.5,HTS,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37723606-001-01-5::2.5::HTS,BRD-K37723606-001-01-5,dioscin,2.5,HTS,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37753391-046-03-2::2.5::HTS,BRD-K37753391-046-03-2,tylosin,2.5,HTS,protein synthesis inhibitor,NA,"infectious disease, gastroenterology","gram-positive bacterial infections, colitis","CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K37764012-001-04-1::2.5::HTS,BRD-K37764012-001-04-1,PF-03758309,2.5,HTS,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37793595-003-01-7::2.5::HTS,BRD-K37793595-003-01-7,afobazole,2.5,HTS,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37798499-001-27-2::2.5::HTS,BRD-K37798499-001-27-2,etoposide,2.5,HTS,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37814297-050-09-6::2.5::HTS,BRD-K37814297-050-09-6,acepromazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,sedative,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O,Launched
BRD-K37846922-001-09-4::0.25::HTS,BRD-K37846922-001-09-4,"3,3'-diindolylmethane",0.25,HTS,"CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor","AR, HIF1A, IFNG, PI3",NA,NA,C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12,Phase 3
BRD-K37865504-001-04-1::2.5::HTS,BRD-K37865504-001-04-1,LY2183240,2.5,HTS,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37872686-003-01-9::2.5::HTS,BRD-K37872686-003-01-9,tirofiban,2.5,HTS,"platelet aggregation inhibitor, structural glycoprotein antagonist","ITGA2B, ITGB3",cardiology,"myocardial infarction, refactory angina",CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O,Launched
BRD-K37890730-001-15-1::2.5::HTS,BRD-K37890730-001-15-1,camptothecin,2.5,HTS,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37949327-001-06-3::2.5::HTS,BRD-K37949327-001-06-3,etidronic-acid,2.5,HTS,bone resorption inhibitor,"ATP6V1A, PTPRS","endocrinology, orthopedics","Paget's disease, heterotopic ossification","CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O",Launched
BRD-K37952347-001-01-4::2.5::HTS,BRD-K37952347-001-01-4,"L-732,138",2.5,HTS,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Preclinical
BRD-K37991163-003-13-4::2.5::HTS,BRD-K37991163-003-13-4,paroxetine,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder","Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1",Launched
BRD-K38003476-001-09-1::2.5::HTS,BRD-K38003476-001-09-1,clocortolone-pivalate,2.5,HTS,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38055836-001-21-1::2.5::HTS,BRD-K38055836-001-21-1,ethamivan,2.5,HTS,respiratory stimulant,NA,NA,NA,"CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1",Preclinical
BRD-K38140108-002-01-2::2.5::HTS,BRD-K38140108-002-01-2,gadodiamide,2.5,HTS,radiopaque medium,NA,radiology,MRI contrast agent,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,Launched
BRD-K38158531-001-02-1::2.5::HTS,BRD-K38158531-001-02-1,traxoprodil,2.5,HTS,glutamate receptor antagonist,GRIN2B,NA,NA,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1,Phase 2
BRD-K38183498-001-02-0::2.5::HTS,BRD-K38183498-001-02-0,clonazepam,2.5,HTS,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38197229-001-29-9::2.5::HTS,BRD-K38197229-001-29-9,bumetanide,2.5,HTS,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38287497-001-01-2::2.5::HTS,BRD-K38287497-001-01-2,narlaprevir,2.5,HTS,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38305202-001-17-4::2.5::HTS,BRD-K38305202-001-17-4,domperidone,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38323065-001-19-9::2.5::HTS,BRD-K38323065-001-19-9,phenacetin,2.5,HTS,cyclooxygenase inhibitor,PTGS1,NA,NA,"CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1",Withdrawn
BRD-K38332599-001-01-3::2.5::HTS,BRD-K38332599-001-01-3,uprosertib,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38350380-001-01-8::2.5::HTS,BRD-K38350380-001-01-8,FK-3311,2.5,HTS,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38370968-050-01-3::2.5::HTS,BRD-K38370968-050-01-3,3-AQC,2.5,HTS,serotonin receptor agonist,HTR3A,NA,NA,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,Preclinical
BRD-K38380126-001-01-4::2.5::HTS,BRD-K38380126-001-01-4,thiamet-g,2.5,HTS,GLCNAC phosphotransferase inhibitor,MGEA5,NA,NA,"CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1",Preclinical
BRD-K38436528-003-26-1::2.5::HTS,BRD-K38436528-003-26-1,imipramine,2.5,HTS,"norepinephrine reputake inhibitor, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry, urology","depression, nocturnal enuresis","CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12",Launched
BRD-K38458514-001-01-8::2.5::HTS,BRD-K38458514-001-01-8,diazooxonorleucine,2.5,HTS,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38473998-001-02-0::2.5::HTS,BRD-K38473998-001-02-0,cilomilast,2.5,HTS,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4D",NA,NA,COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N,Phase 3
BRD-K38548312-001-01-0::2.5::HTS,BRD-K38548312-001-01-0,VER-49009,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38580127-003-15-4::2.5::HTS,BRD-K38580127-003-15-4,serotonin,2.5,HTS,growth factor receptor activator,"DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1",neurology/psychiatry,"anxiety, depression, sleeplessness","NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12",Launched
BRD-K38602774-001-03-2::2.5::HTS,BRD-K38602774-001-03-2,sulisobenzone,2.5,HTS,NA,NA,dermatology,sunscreen lotion,"COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1",Launched
BRD-K38684403-001-05-4::2.5::HTS,BRD-K38684403-001-05-4,roxithromycin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,"ABCB1, MLNR",infectious disease,"respiratory tract infections, urinary tract infections, skin infections","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K38687824-001-02-5::2.5::HTS,BRD-K38687824-001-02-5,beta-amyloid-synthesis-inhibitor,2.5,HTS,beta amyloid synthesis inhibitor,APP,NA,NA,Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,Preclinical
BRD-K38797369-003-01-1::2.46::HTS,BRD-K38797369-003-01-1,PD-128907,2.46,HTS,dopamine receptor agonist,"DRD2, DRD3",NA,NA,"CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21",Preclinical
BRD-K38852836-001-02-1::2.5::HTS,BRD-K38852836-001-02-1,ganetespib,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38860038-001-01-2::2.5::HTS,BRD-K38860038-001-01-2,JK-184,2.5,HTS,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38868394-001-01-3::2.5::HTS,BRD-K38868394-001-01-3,MK-0773,2.5,HTS,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38903228-001-13-5::2.5::HTS,BRD-K38903228-001-13-5,hesperidin,2.5,HTS,flavanone glycoside,CACNA1B,NA,NA,"COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1",Launched
BRD-K38904395-001-02-3::2.5::HTS,BRD-K38904395-001-02-3,SAR131675,2.5,HTS,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38911213-003-01-6::2.5::HTS,BRD-K38911213-003-01-6,apraclonidine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C",ophthalmology,"glaucoma, intraocular pressure",Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,Launched
BRD-K38913877-300-01-9::2.5::HTS,BRD-K38913877-300-01-9,azimilide,2.5,HTS,potassium channel blocker,"KCNA5, KCNE1, KCNH2, KCNQ1",NA,NA,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,Phase 3
BRD-K38938675-001-01-4::2.5::HTS,BRD-K38938675-001-01-4,morniflumate,2.5,HTS,anti-inflammatory agent,NA,neurology/psychiatry,pain relief,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1,Launched
BRD-K39023557-001-01-7::2.5::HTS,BRD-K39023557-001-01-7,octocrylene,2.5,HTS,NA,NA,dermatology,sunscreen lotion,CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1,Launched
BRD-K39061174-001-01-0::2.62::HTS,BRD-K39061174-001-01-0,beta-glycerophosphoric-acid,2.62,HTS,NA,NA,NA,NA,OCC(CO)OP(O)(O)=O,Preclinical
BRD-K39079086-001-07-6::2.5::HTS,BRD-K39079086-001-07-6,cinchonidine,2.5,HTS,P glycoprotein inhibitor,NA,NA,NA,"O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",Phase 1
BRD-K39120595-304-04-7::2.5::HTS,BRD-K39120595-304-04-7,bithionol,2.5,HTS,autotaxin inhibitor,"ESR1, ESR2, MCL1",NA,NA,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,Withdrawn
BRD-K39160765-003-02-9::2.5::HTS,BRD-K39160765-003-02-9,4-chlorophenylguanidine,2.5,HTS,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39166528-001-01-0::2.5::HTS,BRD-K39166528-001-01-0,ID-8,2.5,HTS,NA,NA,NA,NA,"COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12",Preclinical
BRD-K39171998-001-01-1::2.5::HTS,BRD-K39171998-001-01-1,STF-118804,2.5,HTS,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39252998-003-01-5::2.5::HTS,BRD-K39252998-003-01-5,atipamezole,2.5,HTS,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39339537-001-21-0::2.5::HTS,BRD-K39339537-001-21-0,epirizole,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,COc1cc(C)nn1-c1nc(C)cc(OC)n1,Launched
BRD-K39371216-001-01-3::2.5::HTS,BRD-K39371216-001-01-3,cyacetacide,2.5,HTS,NA,NA,NA,NA,NNC(=O)CC#N,Preclinical
BRD-K39381259-001-01-0::2.5::HTS,BRD-K39381259-001-01-0,DMH1,2.5,HTS,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39462424-050-09-8::2.5::HTS,BRD-K39462424-050-09-8,dexchlorpheniramine,2.5,HTS,histamine receptor antagonist,NA,"allergy, cardiology","allergic conjunctivitis, allergic rhinitis, urticaria, angioedema",CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K39467894-001-05-9::2.5::HTS,BRD-K39467894-001-05-9,nithiamide,2.5,HTS,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::2.5::HTS,BRD-K39467894-001-06-7,nithiamide,2.5,HTS,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39484304-001-16-5::2.5::HTS,BRD-K39484304-001-16-5,triptolide,2.5,HTS,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39495750-001-01-2::2.5::HTS,BRD-K39495750-001-01-2,chlorobutanol,2.5,HTS,NA,NA,neurology/psychiatry,"anesthetic, sedative","CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl",Launched
BRD-K39503511-001-03-9::2.5::HTS,BRD-K39503511-001-03-9,quiflapon,2.5,HTS,leukotriene synthesis inhibitor,"ALOX5, ALOX5AP",NA,NA,CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,Phase 2
BRD-K39558284-001-01-2::2.5::HTS,BRD-K39558284-001-01-2,SDZ-WAG-994,2.5,HTS,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39624409-003-02-6::2.5::HTS,BRD-K39624409-003-02-6,ADL5859,2.5,HTS,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39670393-303-02-1::2.5::HTS,BRD-K39670393-303-02-1,amthamine,2.5,HTS,histamine receptor agonist,HRH2,NA,NA,Cc1nc(N)sc1CCN,Preclinical
BRD-K39693230-001-01-2::2.5::HTS,BRD-K39693230-001-01-2,N-salicoylaminophenol,2.5,HTS,ribonucleotide reductase inhibitor,NA,NA,NA,Oc1ccc(NC(=O)c2ccccc2O)cc1,Preclinical
BRD-K39733634-001-02-6::2.5::HTS,BRD-K39733634-001-02-6,L-161982,2.5,HTS,prostanoid receptor antagonist,PTGER4,NA,NA,"CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C",Preclinical
BRD-K39805756-001-01-6::2.5::HTS,BRD-K39805756-001-01-6,TPPS4,2.5,HTS,NA,NA,NA,NA,OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2,Phase 1
BRD-K39841531-001-02-1::2.5::HTS,BRD-K39841531-001-02-1,TG-101209,2.5,HTS,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39915878-036-24-4::2.5::HTS,BRD-K39915878-036-24-4,loxapine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,schizophrenia,"CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12",Launched
BRD-K39974922-001-04-3::2.5::HTS,BRD-K39974922-001-04-3,lenvatinib,2.5,HTS,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39983086-001-06-1::2.45::HTS,BRD-K39983086-001-06-1,loteprednol,2.45,HTS,"glucocorticoid receptor agonist, phospholipase inhibitor",NR3C1,ophthalmology,conjunctivitis,"CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl",Launched
BRD-K39987650-001-24-1::2.5::HTS,BRD-K39987650-001-24-1,bisacodyl,2.5,HTS,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K40109029-001-02-9::2.5::HTS,BRD-K40109029-001-02-9,SB-505124,2.5,HTS,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40175214-001-11-6::2.5::HTS,BRD-K40175214-001-11-6,torin-1,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40227168-001-12-9::1.7::HTS,BRD-K40227168-001-12-9,vinburnine,1.7,HTS,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,stroke,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,Launched
BRD-K40255344-001-17-6::2.5::HTS,BRD-K40255344-001-17-6,tyrphostin-A9,2.5,HTS,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40269473-001-02-2::2.5::HTS,BRD-K40269473-001-02-2,cathepsin-inhibitor-1,2.5,HTS,cathepsin inhibitor,"CTSB, CTSL, CTSV",NA,NA,Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C,Preclinical
BRD-K40302533-001-02-9::2.5::HTS,BRD-K40302533-001-02-9,PF-5274857,2.5,HTS,smoothened receptor antagonist,SMO,NA,NA,"Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O",Preclinical
BRD-K40308497-001-01-2::2.54::HTS,BRD-K40308497-001-01-2,crizotinib-(S),2.54,HTS,MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-02-0::2.5::HTS,BRD-K40308497-001-02-0,crizotinib-(S),2.5,HTS,MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40331046-305-01-5::2.5::HTS,BRD-K40331046-305-01-5,CR8-(R),2.5,HTS,CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40366680-001-03-3::2.5::HTS,BRD-K40366680-001-03-3,CAY10505,2.5,HTS,PI3K inhibitor,PIK3CG,NA,NA,"Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1",Preclinical
BRD-K40438880-305-06-6::2.5::HTS,BRD-K40438880-305-06-6,spermidine,2.5,HTS,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40496271-396-01-1::2.34::HTS,BRD-K40496271-396-01-1,eltrombopag,2.34,HTS,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40530731-001-11-6::2.5::HTS,BRD-K40530731-001-11-6,hyoscyamine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40578143-001-02-6::2.5::HTS,BRD-K40578143-001-02-6,GR-79236,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A",NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,Phase 1
BRD-K40621224-001-06-7::2.5::HTS,BRD-K40621224-001-06-7,pentetic-acid,2.5,HTS,chelating agent,PGD,NA,NA,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,Phase 2
BRD-K40654626-236-01-5::2.5::HTS,BRD-K40654626-236-01-5,ditiocarb-sodium-trihydrate,2.5,HTS,immunostimulant,"CA1, CA2, CA4",NA,NA,"CCN(CC)C(S)=S, CCN(CC)C(S)=S",Phase 3
BRD-K40715924-001-01-1::2.5::HTS,BRD-K40715924-001-01-1,medorinone,2.5,HTS,NA,NA,NA,NA,Cc1nccc2[nH]c(=O)ccc12,Phase 1
BRD-K40718343-001-02-6::2.5::HTS,BRD-K40718343-001-02-6,AEE788,2.5,HTS,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40738845-001-05-0::2.5::HTS,BRD-K40738845-001-05-0,BMS-777607,2.5,HTS,"AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor","AXL, MERTK, MET, MST1R, TYRO3",NA,NA,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,Phase 1/Phase 2
BRD-K40758068-001-08-2::2.5::HTS,BRD-K40758068-001-08-2,efavirenz,2.5,HTS,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1,Launched
BRD-K40782193-003-02-9::2.5::HTS,BRD-K40782193-003-02-9,QX-222,2.5,HTS,sodium channel blocker,NA,NA,NA,Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,Preclinical
BRD-K40787673-001-02-1::2.5::HTS,BRD-K40787673-001-02-1,lacitol,2.5,HTS,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40797222-001-01-8::2.5::HTS,BRD-K40797222-001-01-8,SC-12267,2.5,HTS,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40870905-001-01-7::2.5::HTS,BRD-K40870905-001-01-7,CT-7758,2.5,HTS,integrin antagonist,ITGA4,NA,NA,OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1,Phase 2
BRD-K40887525-001-21-9::2.5::HTS,BRD-K40887525-001-21-9,ritanserin,2.5,HTS,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1",Phase 3
BRD-K40901640-003-01-6::2.5::HTS,BRD-K40901640-003-01-6,cinanserin,2.5,HTS,serotonin receptor antagonist,HTR2A,NA,NA,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,Preclinical
BRD-K40905133-001-04-9::2.5::HTS,BRD-K40905133-001-04-9,phenacemide,2.5,HTS,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, seizures",NC(=O)NC(=O)Cc1ccccc1,Launched
BRD-K40992116-001-09-7::2.5::HTS,BRD-K40992116-001-09-7,parachlorophenol,2.5,HTS,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K41024817-325-01-0::2.5::HTS,BRD-K41024817-325-01-0,4-phenolsulfonic-acid,2.5,HTS,NA,NA,NA,NA,Oc1ccc(cc1)S(O)(=O)=O,Preclinical
BRD-K41104902-001-01-3::2.5::HTS,BRD-K41104902-001-01-3,GSK2656157,2.5,HTS,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41141507-001-16-2::2.5::HTS,BRD-K41141507-001-16-2,cyproterone-acetate,2.5,HTS,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41143549-003-02-4::2.5::HTS,BRD-K41143549-003-02-4,N20C,2.5,HTS,glutamate receptor antagonist,NA,NA,NA,NC(=O)CNCCC(c1ccccc1)c1ccccc1,Preclinical
BRD-K41160163-001-06-8::2.5::HTS,BRD-K41160163-001-06-8,fenobam,2.5,HTS,glutamate receptor antagonist,GRM5,NA,NA,"CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1",Phase 2
BRD-K41170226-001-13-8::2.5::HTS,BRD-K41170226-001-13-8,deoxycholic-acid,2.5,HTS,"biliverdin reductase A activator, G protein-coupled receptor agonist","EFTUD1, FPR1, GPBAR1",endocrinology,submental fat,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,Launched
BRD-K41185545-001-02-3::2.5::HTS,BRD-K41185545-001-02-3,ambrisentan,2.5,HTS,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1,Launched
BRD-K41213548-001-02-0::2.5::HTS,BRD-K41213548-001-02-0,KW-2478,2.5,HTS,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41234004-001-03-1::0.03::HTS,BRD-K41234004-001-03-1,icomucret,0.03,HTS,mucin production enhancer,LTB4R2,NA,NA,CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O,Phase 3
BRD-K41256143-001-12-7::2.5::HTS,BRD-K41256143-001-12-7,dehydroepiandrosterone,2.5,HTS,protein synthesis stimulant,"ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1",NA,NA,"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K41260949-236-16-8::2.5::HTS,BRD-K41260949-236-16-8,valproic-acid,2.5,HTS,HDAC inhibitor,"ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O",Launched
BRD-K41278234-001-03-0::2.5::HTS,BRD-K41278234-001-03-0,CUDC-101,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41298358-395-03-4::2.46::HTS,BRD-K41298358-395-03-4,tetraethylenepentamine,2.46,HTS,superoxide dismutase inhibitor,"SOD1, SOD2",NA,NA,"NCCNCCNCCNCCN, NCCNCCNCCNCCN",Phase 2/Phase 3
BRD-K41304947-001-03-2::2.5::HTS,BRD-K41304947-001-03-2,HA-966-(S)-(-),2.5,HTS,glutamate receptor antagonist,GRIA1,NA,NA,N[C@H]1CCN(O)C1=O,Preclinical
BRD-K41312087-001-02-7::2.5::HTS,BRD-K41312087-001-02-7,GW-441756,2.5,HTS,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41337261-001-03-0::2.5::HTS,BRD-K41337261-001-03-0,ZM-306416,2.5,HTS,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41406082-001-16-2::2.5::HTS,BRD-K41406082-001-16-2,sulfapyridine,2.5,HTS,PABA antagonist,NA,NA,NA,"Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K41410256-304-02-2::2.5::HTS,BRD-K41410256-304-02-2,balsalazide,2.5,HTS,cyclooxygenase inhibitor,"ALOX5, PPARG, PTGS1, PTGS2",gastroenterology,ulcerative colitis,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O,Launched
BRD-K41434598-003-01-9::2.5::HTS,BRD-K41434598-003-01-9,org-9768,2.5,HTS,adrenergic receptor antagonist,ADRA2A,NA,NA,CC1(CN)Cc2ccccc2C1,Phase 1
BRD-K41438959-001-01-7::2.5::HTS,BRD-K41438959-001-01-7,perampanel,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",neurology/psychiatry,seizures,O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N,Launched
BRD-K41445866-001-18-8::2.5::HTS,BRD-K41445866-001-18-8,alfaxalone,2.5,HTS,"chloride channel agonist, benzodiazepine receptor agonist",GABBR1,neurology/psychiatry,general anaesthetic,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,Launched
BRD-K41524689-001-23-5::2.5::HTS,BRD-K41524689-001-23-5,paracetamol,2.5,HTS,cyclooxygenase inhibitor,"FAAH, PTGS1, PTGS2, TRPV1","neurology/psychiatry, endocrinology","pain relief, fever","CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1",Launched
BRD-K41564320-001-02-0::2.5::HTS,BRD-K41564320-001-02-0,purvalanol-b,2.5,HTS,tyrosine kinase inhibitor,"CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K41567364-001-04-6::2.5::HTS,BRD-K41567364-001-04-6,SB-334867,2.5,HTS,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,"Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1",Preclinical
BRD-K41567533-001-08-3::2.5::HTS,BRD-K41567533-001-08-3,coumophos,2.5,HTS,cholinesterase inhibitor,NA,NA,NA,CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1,Preclinical
BRD-K41599323-001-02-3::2.5::HTS,BRD-K41599323-001-02-3,lonafarnib,2.5,HTS,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41707108-001-05-6::2.5::HTS,BRD-K41707108-001-05-6,ceramide,2.5,HTS,"phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator",NA,dermatology,cosmetic,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O,Launched
BRD-K41713976-300-02-6::2.5::HTS,BRD-K41713976-300-02-6,E-4031,2.5,HTS,potassium channel blocker,"KCNH1, KCNH2",NA,NA,"Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1",Phase 1
BRD-K41731458-001-15-1::2.5::HTS,BRD-K41731458-001-15-1,triclosan,2.5,HTS,antibacterial agent,DNMT1,NA,NA,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Launched
BRD-K41772907-001-01-2::2.5::HTS,BRD-K41772907-001-01-2,tolimidone,2.5,HTS,src activator,"LYN, SRC",NA,NA,"Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1",Phase 2
BRD-K41779183-001-01-2::2.5::HTS,BRD-K41779183-001-01-2,CB-03-01,2.5,HTS,androgen receptor antagonist,AR,NA,NA,"CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO",Phase 3
BRD-K41783120-001-02-8::2.5::HTS,BRD-K41783120-001-02-8,STA-5326,2.5,HTS,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41853443-001-02-9::2.5::HTS,BRD-K41853443-001-02-9,"1,3-dipropyl-8-phenylxanthine",2.5,HTS,adenosine receptor antagonist,NA,NA,NA,CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)-c1ccccc1,Preclinical
BRD-K41859756-001-06-8::2.5::HTS,BRD-K41859756-001-06-8,NVP-AUY922,2.5,HTS,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41866823-001-01-3::2.5::HTS,BRD-K41866823-001-01-3,2-hydroxyethyl-salicylate,2.5,HTS,NA,NA,NA,NA,OCCOC(=O)c1ccccc1O,Launched
BRD-K41869275-001-02-8::2.5::HTS,BRD-K41869275-001-02-8,2-phenylmelatonin,2.5,HTS,melatonin receptor agonist,"MTNR1A, MTNR1B",NA,NA,"COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1",Preclinical
BRD-K41876534-001-13-7::2.5::HTS,BRD-K41876534-001-13-7,tioxolone,2.5,HTS,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41918892-001-05-9::2.5::HTS,BRD-K41918892-001-05-9,A-769662,2.5,HTS,AMPK activator,NA,NA,NA,"Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12",Preclinical
BRD-K42090719-001-06-5::2.43::HTS,BRD-K42090719-001-06-5,trichloroacetic-acid,2.43,HTS,NA,NA,dermatology,warts,"OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl",Launched
BRD-K42095107-001-17-1::2.5::HTS,BRD-K42095107-001-17-1,daidzein,2.5,HTS,estrogen receptor agonist,"ESRRA, ESRRB, ESRRG, TRPC5",NA,NA,"Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",Phase 2
BRD-K42098891-003-20-5::2.5::HTS,BRD-K42098891-003-20-5,protriptyline,2.5,HTS,tricyclic antidepressant,"SLC6A2, SLC6A4",neurology/psychiatry,depression,CNCCCC1c2ccccc2C=Cc2ccccc12,Launched
BRD-K42191735-001-05-3::2.5::HTS,BRD-K42191735-001-05-3,buparlisib,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42205652-001-02-7::2.5::HTS,BRD-K42205652-001-02-7,"MNS-(3,4-Methylenedioxy-nitrostyrene)",2.5,HTS,"src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42221274-003-07-7::2.5::HTS,BRD-K42221274-003-07-7,NNC-711,2.5,HTS,GABA uptake inhibitor,"SIGMAR1, SLC6A1",NA,NA,"OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1",Preclinical
BRD-K42260897-001-07-6::2.48::HTS,BRD-K42260897-001-07-6,ezetimibe,2.48,HTS,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia","OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1",Launched
BRD-K42260897-001-09-2::2.5::HTS,BRD-K42260897-001-09-2,ezetimibe,2.5,HTS,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia","OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1",Launched
BRD-K42348709-003-13-1::2.5::HTS,BRD-K42348709-003-13-1,cyclobenzaprine,2.5,HTS,"adrenergic receptor agonist, serotonin receptor agonist",HTR2A,neurology/psychiatry,spasms,CN(C)CCC=C1c2ccccc2C=Cc2ccccc12,Launched
BRD-K42352790-001-05-3::2.5::HTS,BRD-K42352790-001-05-3,anandamide,2.5,HTS,cannabinoid receptor agonist,"CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO,Phase 2
BRD-K42417338-045-01-9::2.5::HTS,BRD-K42417338-045-01-9,butorphanol-(+)-tartrate,2.5,HTS,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1","neurology/psychiatry, gastroenterology","muscle pain, headache, abdominal pain",Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1,Launched
BRD-K42436189-001-01-2::2.5::HTS,BRD-K42436189-001-01-2,AZ20,2.5,HTS,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42452249-001-02-5::2.5::HTS,BRD-K42452249-001-02-5,EO-1428,2.5,HTS,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl",Preclinical
BRD-K42495768-001-01-7::2.5::HTS,BRD-K42495768-001-01-7,tasisulam,2.5,HTS,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42497885-001-01-1::2.5::HTS,BRD-K42497885-001-01-1,satraplatin,2.5,HTS,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42500029-001-03-5::2.5::HTS,BRD-K42500029-001-03-5,CGP-57380,2.5,HTS,MAP kinase inhibitor,"AURKB, LCK, MKNK1, MKNK2, SGK1",NA,NA,"Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12",Preclinical
BRD-K42563464-001-01-9::2.5::HTS,BRD-K42563464-001-01-9,YM-58483,2.5,HTS,calcium channel blocker,"TRPC3, TRPC5, TRPM4",NA,NA,"Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F",Preclinical
BRD-K42679050-001-02-1::2.5::HTS,BRD-K42679050-001-02-1,Y-27152,2.5,HTS,potassium channel activator,KCNJ8,NA,NA,CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,Phase 1
BRD-K42748308-300-02-0::2.5::HTS,BRD-K42748308-300-02-0,XE-991,2.5,HTS,potassium channel blocker,"KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",NA,NA,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,Preclinical
BRD-K42756753-001-01-9::2.5::HTS,BRD-K42756753-001-01-9,epiandrosterone,2.5,HTS,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42805893-001-04-9::2.5::HTS,BRD-K42805893-001-04-9,osimertinib,2.5,HTS,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42828737-044-09-0::2.5::HTS,BRD-K42828737-044-09-0,sunitinib,2.5,HTS,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42859542-001-03-3::2.5::HTS,BRD-K42859542-001-03-3,CFM-2,2.5,HTS,glutamate receptor antagonist,NA,NA,NA,COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC,Preclinical
BRD-K42898655-001-01-8::2.5::HTS,BRD-K42898655-001-01-8,temsirolimus,2.5,HTS,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42938903-332-01-1::2.5::HTS,BRD-K42938903-332-01-1,acetophenazine,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42948882-305-01-1::2.5::HTS,BRD-K42948882-305-01-1,AMD11070,2.5,HTS,CC chemokine receptor antagonist,CXCR4,NA,NA,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12,Phase 1/Phase 2
BRD-K42959922-001-01-5::2.5::HTS,BRD-K42959922-001-01-5,trans-2-Undecenoic-acid,2.5,HTS,NA,NA,NA,NA,CCCCCCCC\C=C\C(O)=O,Preclinical
BRD-K42973005-001-04-0::2.5::HTS,BRD-K42973005-001-04-0,CHIR-98014,2.5,HTS,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42981054-001-01-9::2.5::HTS,BRD-K42981054-001-01-9,mibampator,2.5,HTS,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42991124-001-03-0::2.5::HTS,BRD-K42991124-001-03-0,creatinol-phosphate,2.5,HTS,NA,NA,NA,NA,"CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N",Launched
BRD-K43002771-034-01-6::2.5::HTS,BRD-K43002771-034-01-6,SR-33805,2.5,HTS,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43055376-001-01-2::2.5::HTS,BRD-K43055376-001-01-2,ADD-233089,2.5,HTS,benzodiazepine receptor agonist,NA,NA,NA,Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1,Phase 1
BRD-K43106192-320-11-8::2.5::HTS,BRD-K43106192-320-11-8,gallamine-triethiodide,2.5,HTS,acetylcholine receptor antagonist,"ACHE, CHRM2, CHRNA1, CHRNA2",neurology/psychiatry,muscle relaxant,"CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC",Launched
BRD-K43149758-001-22-7::2.5::HTS,BRD-K43149758-001-22-7,myricetin,2.5,HTS,"androgen receptor agonist, cytochrome P450 inhibitor",PIK3CG,NA,NA,"Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O",Preclinical
BRD-K43164539-001-11-5::2.5::HTS,BRD-K43164539-001-11-5,cholic-acid,2.5,HTS,bile acid,"ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B","gastroenterology, neurology/psychiatry, genetics","bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome",C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,Launched
BRD-K43187018-001-03-3::2.52::HTS,BRD-K43187018-001-03-3,GDC-0349,2.52,HTS,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187796-001-02-3::2.5::HTS,BRD-K43187796-001-02-3,3-indolebutyric-acid,2.5,HTS,NA,"B2M, HLA-A, TRAC, TRBC1",NA,NA,OC(=O)CCCc1c[nH]c2ccccc12,Preclinical
BRD-K43192255-048-03-6::2.5::HTS,BRD-K43192255-048-03-6,methyllycaconitine,2.5,HTS,acetylcholine receptor antagonist,CHRNA7,NA,NA,"CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14",Preclinical
BRD-K43236057-001-07-1::2.6::HTS,BRD-K43236057-001-07-1,polydatin,2.6,HTS,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43305603-004-02-8::2.5::HTS,BRD-K43305603-004-02-8,rocuronium,2.5,HTS,acetylcholine receptor antagonist,"CHRM2, CHRNA2, HTR3A",neurology/psychiatry,anesthetic,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1",Launched
BRD-K43363084-001-01-3::2.5::HTS,BRD-K43363084-001-01-3,atglistatin,2.5,HTS,adipose triglyceride lipase inhibitor,NA,NA,NA,"CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C",Preclinical
BRD-K43383936-001-05-2::2.5::HTS,BRD-K43383936-001-05-2,flopropione,2.5,HTS,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms,"CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O",Launched
BRD-K43389675-003-16-7::2.35::HTS,BRD-K43389675-003-16-7,daunorubicin,2.35,HTS,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::2.5::HTS,BRD-K43389675-003-20-9,daunorubicin,2.5,HTS,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389698-001-09-9::2.4::HTS,BRD-K43389698-001-09-9,BMS-387032,2.4,HTS,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43410529-001-02-3::2.5::HTS,BRD-K43410529-001-02-3,MLN2480,2.5,HTS,RAF inhibitor,NA,NA,NA,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F,Phase 1
BRD-K43449605-001-01-0::2.5::HTS,BRD-K43449605-001-01-0,oncrasin-1,2.5,HTS,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43457670-001-27-8::2.5::HTS,BRD-K43457670-001-27-8,acetazolamide,2.5,HTS,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43471985-001-03-0::2.69::HTS,BRD-K43471985-001-03-0,OTX015,2.69,HTS,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-05-5::2.5::HTS,BRD-K43471985-001-05-5,OTX015,2.5,HTS,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43578482-001-01-4::2.5::HTS,BRD-K43578482-001-01-4,defactinib,2.5,HTS,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43586850-001-02-9::2.5::HTS,BRD-K43586850-001-02-9,lacidipine,2.5,HTS,calcium channel blocker,CACNA1C,cardiology,hypertension,CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,Launched
BRD-K43621685-001-02-5::2.5::HTS,BRD-K43621685-001-02-5,CP-673451,2.5,HTS,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43644456-001-04-0::2.38::HTS,BRD-K43644456-001-04-0,WP1130,2.38,HTS,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43786866-300-02-3::2.5::HTS,BRD-K43786866-300-02-3,opipramol,2.5,HTS,sigma receptor agonist,NA,neurology/psychiatry,generalized anxiety disorder (GAD),OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1,Launched
BRD-K43797669-001-30-4::2.5::HTS,BRD-K43797669-001-30-4,genistein,2.5,HTS,tyrosine kinase inhibitor,"CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5",NA,NA,"Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",Phase 2/Phase 3
BRD-K43802723-340-01-9::2.5::HTS,BRD-K43802723-340-01-9,AMG-837,2.5,HTS,free fatty acid receptor agonist,FFAR1,NA,NA,CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1,Phase 1
BRD-K43806473-066-02-1::2.5::HTS,BRD-K43806473-066-02-1,camostat-mesilate,2.5,HTS,protease inhibitor,PRSS1,gastroenterology,pancreatitis,"CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1",Launched
BRD-K43860855-065-11-9::2.5::HTS,BRD-K43860855-065-11-9,iobenguane,2.5,HTS,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43873574-001-01-8::2.5::HTS,BRD-K43873574-001-01-8,ilepcimide,2.5,HTS,anticonvulsant,NA,NA,NA,O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1,Phase 3
BRD-K43880410-001-14-4::2.5::HTS,BRD-K43880410-001-14-4,pregnenolone,2.5,HTS,glutamate receptor modulator,"CYP17A1, SULT2B1",NA,NA,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K43887077-003-26-3::2.5::HTS,BRD-K43887077-003-26-3,dopamine,2.5,HTS,dopamine receptor agonist,"DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4","cardiology, neurology/psychiatry","ventricular arrhythmias, depression, headache, tremors","NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1",Launched
BRD-K43905307-001-01-2::2.5::HTS,BRD-K43905307-001-01-2,"L-798,106",2.5,HTS,prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43927145-001-01-2::2.5::HTS,BRD-K43927145-001-01-2,BIBN4096,2.5,HTS,calcitonin antagonist,"CALCA, CALCRL, RAMP1",NA,NA,"NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1",Phase 2
BRD-K43966364-237-04-8::2.5::HTS,BRD-K43966364-237-04-8,penicillin-v-potassium,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever",CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O,Launched
BRD-K44004064-001-07-3::2.5::HTS,BRD-K44004064-001-07-3,acefylline,2.5,HTS,adenosine receptor agonist,ADORA1,pulmonary,asthma,Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O,Launched
BRD-K44009692-001-02-3::2.5::HTS,BRD-K44009692-001-02-3,hyodeoxycholic-acid,2.5,HTS,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44067360-001-30-3::2.5::HTS,BRD-K44067360-001-30-3,flufenamic-acid,2.5,HTS,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44084986-300-08-4::2.5::HTS,BRD-K44084986-300-08-4,Y-27632,2.5,HTS,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44133266-001-10-0::2.5::HTS,BRD-K44133266-001-10-0,sulbactam,2.5,HTS,beta lactamase inhibitor,NA,infectious disease,"skin infections, intra-abdominal infections, gynecologic infections","CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)C(N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O",Launched
BRD-K44227013-001-06-4::2.5::HTS,BRD-K44227013-001-06-4,ponatinib,2.5,HTS,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44273375-001-25-0::2.5::HTS,BRD-K44273375-001-25-0,tolnaftate,2.5,HTS,fungal squalene epoxidase inhibitor,NA,infectious disease,"tinea pedis, tinea corporis","CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1",Launched
BRD-K44276885-001-07-4::2.5::HTS,BRD-K44276885-001-07-4,acarbose,2.5,HTS,glucosidase inhibitor,"AMY2A, GAA, MGAM, SI",endocrinology,diabetes mellitus,"C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O",Launched
BRD-K44309363-003-02-1::2.5::HTS,BRD-K44309363-003-02-1,dexniguldipine,2.5,HTS,calmodulin antagonist,ADORA3,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,Phase 2
BRD-K44353683-001-08-3::2.5::HTS,BRD-K44353683-001-08-3,nateglinide,2.5,HTS,insulin secretagogue,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O",Launched
BRD-K44366189-001-01-9::2.5::HTS,BRD-K44366189-001-01-9,anacetrapib,2.5,HTS,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,Phase 3
BRD-K44408410-001-17-6::2.5::HTS,BRD-K44408410-001-17-6,2-methoxyestradiol,2.5,HTS,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44442813-001-12-9::2.5::HTS,BRD-K44442813-001-12-9,pidotimod,2.5,HTS,"interferon receptor agonist, interleukin receptor agonist",NA,infectious disease,immune adjuvant,"OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1",Launched
BRD-K44590731-001-01-7::2.5::HTS,BRD-K44590731-001-01-7,TU-2100,2.5,HTS,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44665581-001-01-8::2.5::HTS,BRD-K44665581-001-01-8,bromosporine,2.5,HTS,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44771174-066-01-0::2.5::HTS,BRD-K44771174-066-01-0,ibutamoren,2.5,HTS,growth hormone secretagogue receptor agonist,"GHR, GHSR",NA,NA,"CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1",Phase 2
BRD-K44777625-001-03-5::2.5::HTS,BRD-K44777625-001-03-5,FH1,2.5,HTS,hepatocyte function enhancer,NA,NA,NA,"CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1",Preclinical
BRD-K44824027-001-02-1::2.5::HTS,BRD-K44824027-001-02-1,beclamide,2.5,HTS,anticonvulsant,NA,neurology/psychiatry,"sedative, seizures",ClCCC(=O)NCc1ccccc1,Launched
BRD-K44825564-065-01-4::2.5::HTS,BRD-K44825564-065-01-4,ZAPA,2.5,HTS,NA,NA,NA,NA,NC(=N)S\C=C/C(O)=O,Preclinical
BRD-K44827188-001-06-0::2.5::HTS,BRD-K44827188-001-06-0,vismodegib,2.5,HTS,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44844162-001-01-6::2.5::HTS,BRD-K44844162-001-01-6,taselisib,2.5,HTS,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44849676-001-10-5::2.5::HTS,BRD-K44849676-001-10-5,capsazepine,2.5,HTS,TRPV agonist,"TRPV1, TRPV4",NA,NA,"Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1",Preclinical
BRD-K44876623-001-03-7::2.5::HTS,BRD-K44876623-001-03-7,zolpidem,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3",neurology/psychiatry,insomnia,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1,Launched
BRD-K44942188-001-09-1::2.5::HTS,BRD-K44942188-001-09-1,fomocaine,2.5,HTS,voltage-gated sodium channel modulator,NA,neurology/psychiatry,local anesthetic,C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1,Launched
BRD-K44942604-346-05-4::2.5::HTS,BRD-K44942604-346-05-4,pentolinium,2.5,HTS,cholinergic receptor antagonist,"CHRNA10, CHRNA3, CHRNA4, CHRNB4",cardiology,hypertension,"C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1",Launched
BRD-K44963273-001-06-9::2.5::HTS,BRD-K44963273-001-06-9,HQK-1001,2.5,HTS,NA,NA,NA,NA,"CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O",Phase 2
BRD-K44974079-001-01-3::2.5::HTS,BRD-K44974079-001-01-3,ticagrelor,2.5,HTS,purinergic receptor antagonist,P2RY12,cardiology,"acute coronary syndrome (ACS), myocardial infarction",CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1,Launched
BRD-K44993696-001-12-3::2.5::HTS,BRD-K44993696-001-12-3,atenolol-(-),2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K45014108-003-01-8::2.5::HTS,BRD-K45014108-003-01-8,ephedrine,2.5,HTS,adrenergic receptor agonist,"ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity",CN[C@@H](C)[C@H](O)c1ccccc1,Launched
BRD-K45033733-001-12-2::2.5::HTS,BRD-K45033733-001-12-2,famciclovir,2.5,HTS,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45071273-003-25-6::2.5::HTS,BRD-K45071273-003-25-6,tetracaine,2.5,HTS,membrane integrity inhibitor,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,anesthetic,"CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C",Launched
BRD-K45086103-001-15-5::2.5::HTS,BRD-K45086103-001-15-5,sulfaguanidine,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,"NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1",Launched
BRD-K45086103-001-16-3::2.5::HTS,BRD-K45086103-001-16-3,sulfaguanidine,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,"NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1",Launched
BRD-K45114938-236-01-8::2.35::HTS,BRD-K45114938-236-01-8,mezlocillin,2.35,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O",Launched
BRD-K45117373-001-02-9::2.5::HTS,BRD-K45117373-001-02-9,Y-26763,2.5,HTS,potassium channel activator,KCNJ8,NA,NA,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,Phase 1
BRD-K45152786-001-08-4::2.5::HTS,BRD-K45152786-001-08-4,merbarone,2.5,HTS,topoisomerase inhibitor,TOP2A,NA,NA,O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O,Phase 2
BRD-K45158365-001-11-4::2.5::HTS,BRD-K45158365-001-11-4,valsartan,2.5,HTS,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O",Launched
BRD-K45163704-001-01-5::2.5::HTS,BRD-K45163704-001-01-5,midafotel,2.5,HTS,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1",Phase 3
BRD-K45168550-001-01-9::2.5::HTS,BRD-K45168550-001-01-9,SB-756050,2.5,HTS,G protein-coupled receptor agonist,GPBAR1,NA,NA,COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1,Phase 1
BRD-K45216060-001-10-0::2.5::HTS,BRD-K45216060-001-10-0,mequinol,2.5,HTS,NA,TYR,dermatology,skin depigmentation,"COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1",Launched
BRD-K45216060-001-11-8::2.5::HTS,BRD-K45216060-001-11-8,mequinol,2.5,HTS,NA,TYR,dermatology,skin depigmentation,"COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1",Launched
BRD-K45238818-001-02-6::2.5::HTS,BRD-K45238818-001-02-6,succinic-acid,2.5,HTS,NA,"ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE",NA,NA,OC(=O)CCC(O)=O,Launched
BRD-K45245728-335-01-4::2.5::HTS,BRD-K45245728-335-01-4,ursodeoxycholyltaurine,2.5,HTS,cholesterol inhibitor,NA,NA,NA,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 2
BRD-K45252063-001-13-6::2.5::HTS,BRD-K45252063-001-13-6,clofibrate,2.5,HTS,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45275534-001-01-3::2.5::HTS,BRD-K45275534-001-01-3,betrixaban,2.5,HTS,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT),COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1,Launched
BRD-K45293975-001-02-0::2.5::HTS,BRD-K45293975-001-02-0,7-hydroxystaurosporine,2.5,HTS,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45330754-001-21-7::2.5::HTS,BRD-K45330754-001-21-7,diethylstilbestrol,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2, ESRRB, ESRRG",NA,NA,"CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1, CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1",Withdrawn
BRD-K45385835-001-02-4::2.5::HTS,BRD-K45385835-001-02-4,SX-011,2.5,HTS,MAP kinase inhibitor,MAPK14,NA,NA,"CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1",Preclinical
BRD-K45401373-001-20-9::2.5::HTS,BRD-K45401373-001-20-9,betulinic-acid,2.5,HTS,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-22-5::2.5::HTS,BRD-K45401373-001-22-5,betulinic-acid,2.5,HTS,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45435259-003-11-1::2.5::HTS,BRD-K45435259-003-11-1,SCH-23390,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD5, HTR2C, KCNJ4, KCNJ6",NA,NA,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,Preclinical
BRD-K45437867-005-03-3::2.5::HTS,BRD-K45437867-005-03-3,5-methylfurmethiodide,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1",Preclinical
BRD-K45446451-001-05-0::2.5::HTS,BRD-K45446451-001-05-0,JZL-184,2.5,HTS,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45462423-001-03-7::2.5::HTS,BRD-K45462423-001-03-7,VU0361737,2.5,HTS,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45479396-050-01-5::2.5::HTS,BRD-K45479396-050-01-5,BP-554,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,"C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1",Preclinical
BRD-K45503887-001-01-1::2.5::HTS,BRD-K45503887-001-01-1,delivert,2.5,HTS,angiotensin receptor agonist,"AGTR1, AGTR2",NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O,Launched
BRD-K45519571-001-01-8::2.5::HTS,BRD-K45519571-001-01-8,RN-1747,2.5,HTS,TRPV agonist,TRPV4,NA,NA,"[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1",Preclinical
BRD-K45528773-001-06-4::2.5::HTS,BRD-K45528773-001-06-4,M-344,2.5,HTS,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::2.59::HTS,BRD-K45528773-001-07-2,M-344,2.59,HTS,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45542189-048-22-1::2.5::HTS,BRD-K45542189-048-22-1,diethylcarbamazine,2.5,HTS,lipoxygenase inhibitor,"ALOX5, PTGS1",infectious disease,filariasis,CCN(CC)C(=O)N1CCN(C)CC1,Launched
BRD-K45551181-001-02-1::2.49::HTS,BRD-K45551181-001-02-1,MPI-0479605,2.49,HTS,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45662124-050-01-5::2.5::HTS,BRD-K45662124-050-01-5,3'-fluorobenzylspiperone,2.5,HTS,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45664306-001-19-6::2.52::HTS,BRD-K45664306-001-19-6,prednisolone-acetate,2.52,HTS,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-K45724504-001-01-6::1.36::HTS,BRD-K45724504-001-01-6,anguidine,1.36,HTS,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45746021-003-01-9::2.5::HTS,BRD-K45746021-003-01-9,CC-401,2.5,HTS,JNK inhibitor,MAPK8,NA,NA,C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1ncn[nH]1,Phase 1
BRD-K45841694-001-11-7::2.65::HTS,BRD-K45841694-001-11-7,IU1,2.65,HTS,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,"Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1",Preclinical
BRD-K45861246-001-13-4::2.5::HTS,BRD-K45861246-001-13-4,azaperone,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,sedative,"Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1",Launched
BRD-K45875383-001-01-2::2.5::HTS,BRD-K45875383-001-01-2,XBD173,2.5,HTS,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45909031-001-01-5::2.5::HTS,BRD-K45909031-001-01-5,WZ4003,2.5,HTS,AMPK inhibitor,"NUAK1, NUAK2",NA,NA,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1,Preclinical
BRD-K45916615-066-02-5::2.5::HTS,BRD-K45916615-066-02-5,danofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,pulmonary,bovine respiratory disease (BRD),CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,Launched
BRD-K45924332-001-16-8::2.5::HTS,BRD-K45924332-001-16-8,amrinone,2.5,HTS,phosphodiesterase inhibitor,"PDE3A, PDE3B, PDE4B, TNF",cardiology,congestive heart failure,Nc1cc(c[nH]c1=O)-c1ccncc1,Launched
BRD-K46018455-001-27-6::2.5::HTS,BRD-K46018455-001-27-6,bezafibrate,2.5,HTS,PPAR receptor agonist,"PPARA, PPARD, PPARG",cardiology,cholesterol,"CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O",Launched
BRD-K46061689-001-01-9::2.5::HTS,BRD-K46061689-001-01-9,desogestrel,2.5,HTS,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K46133855-304-03-8::2.5::HTS,BRD-K46133855-304-03-8,NXY-059,2.5,HTS,free radical scavenger,NA,NA,NA,"CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O",Phase 3
BRD-K46142322-003-02-4::2.5::HTS,BRD-K46142322-003-02-4,RS-67333,2.5,HTS,serotonin receptor partial agonist,HTR4,NA,NA,CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,Preclinical
BRD-K46211610-003-26-7::2.5::HTS,BRD-K46211610-003-26-7,tolazoline,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2",neurology/psychiatry,reverse sedative,"C(C1=NCCN1)c1ccccc1, C(C1=NCCN1)c1ccccc1",Launched
BRD-K46254452-001-01-5::0.25::HTS,BRD-K46254452-001-01-5,GABA-linoleamide,0.25,HTS,benzodiazepine receptor agonist,NA,NA,NA,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O,Phase 2
BRD-K46290096-001-01-1::2.5::HTS,BRD-K46290096-001-01-1,preladenant,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,Phase 3
BRD-K46317332-003-17-8::2.5::HTS,BRD-K46317332-003-17-8,proadifen,2.5,HTS,nitric oxide synthase inhibitor,NOS1,NA,NA,"CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1",Preclinical
BRD-K46331928-001-05-8::2.5::HTS,BRD-K46331928-001-05-8,ethynodiol-diacetate,2.5,HTS,NA,"ESR1, PGR",endocrinology,contraceptive,"CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1",Launched
BRD-K46331928-001-06-6::2.38::HTS,BRD-K46331928-001-06-6,ethynodiol-diacetate,2.38,HTS,NA,"ESR1, PGR",endocrinology,contraceptive,"CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1",Launched
BRD-K46384212-001-02-9::2.5::HTS,BRD-K46384212-001-02-9,o-3M3FBS,2.5,HTS,phospholipase activator,NA,NA,NA,"Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F",Preclinical
BRD-K46386702-001-02-1::2.5::HTS,BRD-K46386702-001-02-1,ARRY-334543,2.5,HTS,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46392623-001-02-5::2.5::HTS,BRD-K46392623-001-02-5,TG-100713,2.5,HTS,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46424862-001-14-1::2.5::HTS,BRD-K46424862-001-14-1,hymecromone,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,"Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12",Phase 2
BRD-K46428823-001-02-5::2.5::HTS,BRD-K46428823-001-02-5,liothyronine-(isomer),2.5,HTS,NA,NA,NA,NA,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,Preclinical
BRD-K46435528-001-04-4::2.5::HTS,BRD-K46435528-001-04-4,trichloroethylene,2.5,HTS,NA,NA,NA,NA,"ClC=C(Cl)Cl, ClC=C(Cl)Cl",Preclinical
BRD-K46435977-003-11-1::2.5::HTS,BRD-K46435977-003-11-1,valaciclovir,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,"shingles, virus herpes simplex (HSV)","CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O",Launched
BRD-K46493214-001-06-7::2.5::HTS,BRD-K46493214-001-06-7,saccharin,2.5,HTS,DNA polymerase inhibitor,"CA1, CA12, CA2, CA9",NA,NA,O=C1NS(=O)(=O)c2ccccc12,Launched
BRD-K46523383-003-22-9::2.5::HTS,BRD-K46523383-003-22-9,pramoxine,2.5,HTS,topical anesthetic,NA,dermatology,corticosteroid-responsive dermatoses,"CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1",Launched
BRD-K46556543-001-01-4::2.5::HTS,BRD-K46556543-001-01-4,potassium-canrenoate,2.5,HTS,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O",Launched
BRD-K46556543-237-10-5::2.55::HTS,BRD-K46556543-237-10-5,potassium-canrenoate,2.55,HTS,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O",Launched
BRD-K46585355-001-14-3::2.5::HTS,BRD-K46585355-001-14-3,acetylsalicylsalicylic-acid,2.5,HTS,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46654563-238-01-0::2.5::HTS,BRD-K46654563-238-01-0,zofenopril-calcium,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1,Launched
BRD-K46690591-001-01-2::2.5::HTS,BRD-K46690591-001-01-2,KP-1212,2.5,HTS,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46692793-004-01-8::2.5::HTS,BRD-K46692793-004-01-8,umeclidinium,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis, emphysema",OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,Launched
BRD-K46731503-050-01-8::2.5::HTS,BRD-K46731503-050-01-8,fesoterodine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C",Launched
BRD-K46741531-001-02-4::1.58::HTS,BRD-K46741531-001-02-4,cafestol,1.58,HTS,pregnane X receptor agonist,NA,NA,NA,C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3,Launched
BRD-K46742498-003-11-0::2.5::HTS,BRD-K46742498-003-11-0,alosetron,2.5,HTS,serotonin receptor antagonist,HTR3A,NA,NA,Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C,Withdrawn
BRD-K46766488-003-02-0::2.5::HTS,BRD-K46766488-003-02-0,S-14506,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,"COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1",Preclinical
BRD-K46791647-001-01-2::2.5::HTS,BRD-K46791647-001-01-2,stanozolol,2.5,HTS,androgen receptor agonist,AR,hematology,anemia,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5[nH]ncc5C[C@]4(C)[C@H]3CC[C@]12C,Launched
BRD-K46839850-050-04-2::2.5::HTS,BRD-K46839850-050-04-2,cinepazide,2.5,HTS,calcium channel activator,NA,NA,NA,"COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1, COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1",Withdrawn
BRD-K46863940-001-06-2::2.5::HTS,BRD-K46863940-001-06-2,dibenzothiophene,2.5,HTS,NA,NA,NA,NA,"c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21",Preclinical
BRD-K46914825-300-01-0::2.5::HTS,BRD-K46914825-300-01-0,zimelidine,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"MAOA, MAOB, SLC6A4",NA,NA,CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1,Withdrawn
BRD-K46937689-001-15-0::2.5::HTS,BRD-K46937689-001-15-0,phenazone,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46970505-003-01-9::2.5::HTS,BRD-K46970505-003-01-9,cefozopran,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1,Launched
BRD-K46982791-001-09-4::2.5::HTS,BRD-K46982791-001-09-4,cloxyquin,2.5,HTS,potassium channel activator,KCNK18,NA,NA,Oc1ccc(Cl)c2cccnc12,Preclinical
BRD-K47000838-001-01-6::1.04::HTS,BRD-K47000838-001-01-6,cytochalasin-b,1.04,HTS,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47029922-003-10-9::2.5::HTS,BRD-K47029922-003-10-9,tranylcypromine,2.5,HTS,monoamine oxidase inhibitor,"KDM1A, MAOA, MAOB",neurology/psychiatry,depression,"N[C@H]1C[C@@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1, NC1C[C@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1",Launched
BRD-K47031502-001-01-6::2.5::HTS,BRD-K47031502-001-01-6,eupatilin,2.5,HTS,mucus protecting agent,NA,NA,NA,"COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1",Launched
BRD-K47049295-300-01-5::2.5::HTS,BRD-K47049295-300-01-5,BAN-ORL-24,2.5,HTS,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47079459-004-04-6::2.5::HTS,BRD-K47079459-004-04-6,cetrimonium,2.5,HTS,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47095176-001-01-6::2.5::HTS,BRD-K47095176-001-01-6,talnetant,2.5,HTS,tachykinin antagonist,"TACR2, TACR3",NA,NA,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,Phase 2
BRD-K47105409-001-14-5::2.5::HTS,BRD-K47105409-001-14-5,AG-490,2.5,HTS,"EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3",NA,NA,"Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1",Preclinical
BRD-K47114202-001-14-6::2.58::HTS,BRD-K47114202-001-14-6,chlorogenic-acid,2.58,HTS,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47150025-001-05-3::2.5::HTS,BRD-K47150025-001-05-3,KI-8751,2.5,HTS,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47177710-001-03-1::2.5::HTS,BRD-K47177710-001-03-1,DAPT,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1",Preclinical
BRD-K47192521-001-05-4::0.25::HTS,BRD-K47192521-001-05-4,icosapent,0.25,HTS,platelet aggregation inhibitor,"ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1",endocrinology,hypertriglyceridemia,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,Launched
BRD-K47195926-001-06-6::2.5::HTS,BRD-K47195926-001-06-6,acedoben,2.5,HTS,NA,NA,NA,NA,CC(=O)Nc1ccc(cc1)C(O)=O,Phase 2
BRD-K47264279-001-08-9::2.5::HTS,BRD-K47264279-001-08-9,psoralen,2.5,HTS,NA,"MAOA, MAOB",dermatology,"psoriasis, eczema, vitiligo",O=c1ccc2cc3ccoc3cc2o1,Launched
BRD-K47278471-003-26-3::2.5::HTS,BRD-K47278471-003-26-3,diphenhydramine,2.5,HTS,histamine receptor antagonist,HRH1,neurology/psychiatry,headache,"CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1",Launched
BRD-K47323024-003-24-4::2.5::HTS,BRD-K47323024-003-24-4,methapyrilene,2.5,HTS,histamine receptor antagonist,HRH1,NA,NA,"CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1",Withdrawn
BRD-K47337578-034-02-5::2.5::HTS,BRD-K47337578-034-02-5,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,2.5,HTS,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47371940-001-01-6::2.5::HTS,BRD-K47371940-001-01-6,ecabapide,2.5,HTS,NA,NA,NA,NA,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Phase 3
BRD-K47376733-001-08-1::2.5::HTS,BRD-K47376733-001-08-1,JNJ-1661010,2.5,HTS,FAAH inhibitor,FAAH,NA,NA,"O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1",Preclinical
BRD-K47407372-001-17-1::2.5::HTS,BRD-K47407372-001-17-1,nifenazone,2.5,HTS,analgesic agent,NA,neurology/psychiatry,pain relief,"Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C",Launched
BRD-K47539947-001-03-7::2.5::HTS,BRD-K47539947-001-03-7,tetradecylthioacetic-acid,2.5,HTS,lipid peroxidase inhibitor,NA,NA,NA,CCCCCCCCCCCCCCSCC(O)=O,Phase 2
BRD-K47554101-001-01-2::2.5::HTS,BRD-K47554101-001-01-2,eperezolid,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1,Phase 1
BRD-K47557313-001-02-7::2.5::HTS,BRD-K47557313-001-02-7,LY2109761,2.5,HTS,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47598052-001-15-8::2.5::HTS,BRD-K47598052-001-15-8,PP-1,2.5,HTS,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47631482-003-06-2::2.5::HTS,BRD-K47631482-003-06-2,bromhexine,2.5,HTS,mucolytic agent,NA,pulmonary,chest congestion,"CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1",Launched
BRD-K47635719-001-21-1::2.5::HTS,BRD-K47635719-001-21-1,dexamethasone-acetate,2.5,HTS,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47639036-003-06-6::2.5::HTS,BRD-K47639036-003-06-6,flavoxate,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2",urology,"urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis",Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,Launched
BRD-K47642186-001-01-3::2.5::HTS,BRD-K47642186-001-01-3,piclamilast,2.5,HTS,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",NA,NA,"COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl",Phase 2
BRD-K47659338-003-02-8::2.5::HTS,BRD-K47659338-003-02-8,EMD-386088,2.5,HTS,serotonin receptor agonist,HTR6,NA,NA,"Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1",Preclinical
BRD-K47679368-236-01-7::2.5::HTS,BRD-K47679368-236-01-7,bromfenac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1,Withdrawn
BRD-K47780086-001-07-9::2.5::HTS,BRD-K47780086-001-07-9,penciclovir,2.5,HTS,DNA directed DNA polymerase inhibitor,NA,dental,cold sore,"Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1",Launched
BRD-K47827687-001-02-2::2.5::HTS,BRD-K47827687-001-02-2,amprenavir,2.5,HTS,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Launched
BRD-K47832606-001-30-1::2.5::HTS,BRD-K47832606-001-30-1,floxuridine,2.5,HTS,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47869605-001-32-0::2.5::HTS,BRD-K47869605-001-32-0,podophyllotoxin,2.5,HTS,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47878171-086-06-0::2.5::HTS,BRD-K47878171-086-06-0,bephenium-hydroxynaphthoate,2.5,HTS,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47886988-001-21-4::2.5::HTS,BRD-K47886988-001-21-4,nalidixic-acid,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,urinary tract infections,"CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12",Launched
BRD-K47936004-003-11-4::2.5::HTS,BRD-K47936004-003-11-4,piribedil,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B",neurology/psychiatry,"Parkinson's Disease, dizziness",C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,Launched
BRD-K47949423-001-03-1::2.56::HTS,BRD-K47949423-001-03-1,mirabegron,2.56,HTS,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",urology,urinary incontinence,"Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1",Launched
BRD-K47976015-001-01-2::2.5::HTS,BRD-K47976015-001-01-2,balapiravir,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47978074-001-02-4::2.5::HTS,BRD-K47978074-001-02-4,trometamol,2.5,HTS,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K48061146-066-01-7::2.5::HTS,BRD-K48061146-066-01-7,benztropine-mesylate,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, HRH1, SLC6A3",neurology/psychiatry,"extrapyramidal symptoms (EPS), Parkinson's Disease",CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,Launched
BRD-K48068743-001-01-6::2.5::HTS,BRD-K48068743-001-01-6,teneligliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1,Launched
BRD-K48141473-001-01-7::2.5::HTS,BRD-K48141473-001-01-7,cebranopadol,2.5,HTS,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48168960-001-19-2::2.5::HTS,BRD-K48168960-001-19-2,propylthiouracil,2.5,HTS,thyroid peroxidase inhibitor,"DIO1, TPO",endocrinology,"hyperthyroidism, Grave's disease, goiter","CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1",Launched
BRD-K48173020-001-01-8::2.5::HTS,BRD-K48173020-001-01-8,ameltolide,2.5,HTS,anticonvulsant,NA,NA,NA,Cc1cccc(C)c1NC(=O)c1ccc(N)cc1,Preclinical
BRD-K48195008-001-19-9::2.5::HTS,BRD-K48195008-001-19-9,ethinyl-estradiol,2.5,HTS,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195801-001-01-6::2.5::HTS,BRD-K48195801-001-01-6,tecastemizole,2.5,HTS,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48213016-001-01-8::2.5::HTS,BRD-K48213016-001-01-8,CC-930,2.5,HTS,JNK inhibitor,NA,NA,NA,O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1,Phase 2
BRD-K48247567-001-01-9::2.5::HTS,BRD-K48247567-001-01-9,diatrizoic-acid,2.5,HTS,NA,NA,radiology,contrast agent,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I,Launched
BRD-K48300629-001-14-5::2.5::HTS,BRD-K48300629-001-14-5,zonisamide,2.5,HTS,"sodium channel blocker, T-type calcium channel blocker","CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"seizures, epilepsy","NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12",Launched
BRD-K48329353-001-01-3::2.5::HTS,BRD-K48329353-001-01-3,"6,_7-dehydro-17-acetoxy-progesterone",2.5,HTS,steroidal progestin,NA,NA,NA,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,Preclinical
BRD-K48367671-001-05-9::2.5::HTS,BRD-K48367671-001-05-9,febuxostat,2.5,HTS,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia,"CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O",Launched
BRD-K48443249-001-01-0::2.5::HTS,BRD-K48443249-001-01-0,CNX-774,2.5,HTS,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48488978-001-05-3::2.5::HTS,BRD-K48488978-001-05-3,YM-201636,2.5,HTS,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48535733-003-01-2::2.5::HTS,BRD-K48535733-003-01-2,VU0155069,2.5,HTS,phospholipase inhibitor,PLD1,NA,NA,"C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1",Preclinical
BRD-K48578705-001-16-8::2.5::HTS,BRD-K48578705-001-16-8,methyldopa,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::2.5::HTS,BRD-K48578705-001-17-6,methyldopa,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48619321-004-16-8::2.54::HTS,BRD-K48619321-004-16-8,methscopolamine,2.54,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K48684885-001-04-2::2.5::HTS,BRD-K48684885-001-04-2,BAY-11-7085,2.5,HTS,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48692744-001-02-0::2.5::HTS,BRD-K48692744-001-02-0,NU-1025,2.5,HTS,PARP inhibitor,PARP1,NA,NA,"Cc1nc2c(O)cccc2c(=O)[nH]1, Cc1nc2c(O)cccc2c(=O)[nH]1",Preclinical
BRD-K48722258-300-10-2::2.5::HTS,BRD-K48722258-300-10-2,dilazep,2.5,HTS,adenosine reuptake inhibitor,SLC29A1,NA,NA,"COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1",Launched
BRD-K48722833-001-07-6::2.5::HTS,BRD-K48722833-001-07-6,iloperidone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O,Launched
BRD-K48812570-001-02-3::2.5::HTS,BRD-K48812570-001-02-3,macitentan,2.5,HTS,endothelin receptor antagonist,"EDNRA, EDNRB",endocrinology,contraceptive,"CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",Launched
BRD-K48826825-001-01-8::2.5::HTS,BRD-K48826825-001-01-8,S26948,2.5,HTS,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48830578-001-01-9::2.5::HTS,BRD-K48830578-001-01-9,OMDM-2,2.5,HTS,FAAH inhibitor,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,Preclinical
BRD-K48888725-001-01-9::2.5::HTS,BRD-K48888725-001-01-9,CG-400549,2.5,HTS,FABI inhibitor,NA,NA,NA,"Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O",Phase 2
BRD-K48892307-001-04-1::2.5::HTS,BRD-K48892307-001-04-1,sasapyrine,2.5,HTS,NFkB pathway inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O",Launched
BRD-K48894757-001-01-8::2.5::HTS,BRD-K48894757-001-01-8,laropiprant,2.5,HTS,prostanoid receptor antagonist,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R",cardiology,cholesterol,CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12,Launched
BRD-K48988407-001-01-2::2.5::HTS,BRD-K48988407-001-01-2,cytochlor,2.5,HTS,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48996094-001-01-3::2.5::HTS,BRD-K48996094-001-01-3,pentacosanoic-acid,2.5,HTS,NA,NA,NA,NA,CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O,Preclinical
BRD-K49027941-001-01-1::2.5::HTS,BRD-K49027941-001-01-1,PSB-1115,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49049886-001-08-7::2.5::HTS,BRD-K49049886-001-08-7,CGS-15943,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49055432-001-04-2::2.5::HTS,BRD-K49055432-001-04-2,A66,2.5,HTS,PI3K inhibitor,PIK3CA,NA,NA,"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C",Preclinical
BRD-K49071277-001-04-7::2.5::HTS,BRD-K49071277-001-04-7,securinine,2.5,HTS,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49075727-001-08-5::2.5::HTS,BRD-K49075727-001-08-5,nintedanib,2.5,HTS,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49111258-003-29-7::2.5::HTS,BRD-K49111258-003-29-7,prazosin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49119234-003-02-6::2.5::HTS,BRD-K49119234-003-02-6,TMPH,2.5,HTS,NA,NA,NA,NA,"CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1",Preclinical
BRD-K49197823-001-09-8::2.5::HTS,BRD-K49197823-001-09-8,CV-1808,2.5,HTS,adenosine receptor agonist,ADORA2A,NA,NA,Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Preclinical
BRD-K49215523-001-04-2::2.5::HTS,BRD-K49215523-001-04-2,GSK2636771,2.5,HTS,PI3K inhibitor,PIK3CB,NA,NA,"Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O",Phase 2
BRD-K49236613-001-02-3::2.5::HTS,BRD-K49236613-001-02-3,6-iodo-nordihydrocapsaicin,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,Preclinical
BRD-K49294207-300-03-8::2.5::HTS,BRD-K49294207-300-03-8,BIBU-1361,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49313711-001-05-4::2.5::HTS,BRD-K49313711-001-05-4,ribitol,2.5,HTS,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49328571-001-15-0::2.5::HTS,BRD-K49328571-001-15-0,dasatinib,2.5,HTS,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49338325-001-03-4::2.5::HTS,BRD-K49338325-001-03-4,etofibrate,2.5,HTS,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia,CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,Launched
BRD-K49350383-001-13-7::2.5::HTS,BRD-K49350383-001-13-7,thioguanine,2.5,HTS,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49371609-003-03-8::2.5::HTS,BRD-K49371609-003-03-8,PIK-75,2.5,HTS,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49404994-001-10-9::2.5::HTS,BRD-K49404994-001-10-9,levetiracetam,2.5,HTS,calcium channel blocker,"CACNA1B, SCN1A, SV2A",neurology/psychiatry,seizures,"CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O",Launched
BRD-K49456274-001-01-9::2.5::HTS,BRD-K49456274-001-01-9,pilaralisib,2.5,HTS,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49460120-001-02-5::2.5::HTS,BRD-K49460120-001-02-5,10058-F4,2.5,HTS,c-Myc inhibitor,NA,NA,NA,"CCc1ccc(cc1)\C=C1\SC(=S)NC1=O, CCc1ccc(cc1)\C=C1\SC(=S)NC1=O, CCc1ccc(cc1)\C=C1\SC(=S)NC1=O",Preclinical
BRD-K49481516-004-18-3::2.5::HTS,BRD-K49481516-004-18-3,galantamine,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG",neurology/psychiatry,senile dementia,"COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24",Launched
BRD-K49504902-001-01-6::2.5::HTS,BRD-K49504902-001-01-6,SEP-227900,2.5,HTS,D-Amino Acid Oxidase Inhibitor,DAO,NA,NA,OC(=O)c1cc2occc2[nH]1,Phase 1
BRD-K49519144-001-04-6::2.5::HTS,BRD-K49519144-001-04-6,LY2140023,2.5,HTS,glutamate receptor agonist,GRM3,NA,NA,"N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",Phase 3
BRD-K49522529-001-02-9::2.53::HTS,BRD-K49522529-001-02-9,alfacalcidol,2.53,HTS,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-03-7::2.5::HTS,BRD-K49522529-001-03-7,alfacalcidol,2.5,HTS,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49545903-003-01-4::2.5::HTS,BRD-K49545903-003-01-4,"4,4-pentamethylenepiperidine",2.5,HTS,M2 channel blocker,NA,NA,NA,C1CCC2(CC1)CCNCC2,Preclinical
BRD-K49554218-001-01-0::2.5::HTS,BRD-K49554218-001-01-0,carebastine,2.5,HTS,histamine receptor antagonist,HRH1,NA,NA,CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Phase 1
BRD-K49555808-001-03-9::2.5::HTS,BRD-K49555808-001-03-9,BMS-707035,2.5,HTS,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49657628-001-14-8::2.5::HTS,BRD-K49657628-001-14-8,tyrphostin-AG-18,2.5,HTS,"EGFR inhibitor, tyrosine kinase inhibitor",EGFR,NA,NA,"Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O",Preclinical
BRD-K49668410-001-18-8::2.5::HTS,BRD-K49668410-001-18-8,clarithromycin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,CYP3A4,"otolaryngology, pulmonary, infectious disease","pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC",Launched
BRD-K49669041-001-08-4::2.5::HTS,BRD-K49669041-001-08-4,BX-912,2.5,HTS,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49671696-045-08-5::2.5::HTS,BRD-K49671696-045-08-5,ketanserin,2.5,HTS,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2",cardiology,hypertension,"Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1",Launched
BRD-K49685476-001-15-9::2.5::HTS,BRD-K49685476-001-15-9,TTNPB,2.5,HTS,retinoid receptor agonist,"RARA, RARB, RARG",NA,NA,"C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C",Phase 1
BRD-K49702221-003-01-6::2.5::HTS,BRD-K49702221-003-01-6,SNAP-94847,2.5,HTS,NA,"ADRA1A, DRD2",NA,NA,"CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1",Preclinical
BRD-K49738308-065-04-9::2.5::HTS,BRD-K49738308-065-04-9,agmatine,2.5,HTS,nitric oxide synthase inhibitor,"ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH",NA,NA,NCCCCNC(N)=N,Phase 3
BRD-K49759007-001-11-9::2.5::HTS,BRD-K49759007-001-11-9,4-hydroxy-phenazone,2.5,HTS,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49783248-303-08-4::2.5::HTS,BRD-K49783248-303-08-4,decamethonium,2.5,HTS,acetylcholine receptor agonist,"ACHE, CHRNA2",neurology/psychiatry,muscle relaxant,"C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C",Launched
BRD-K49807096-003-15-5::2.5::HTS,BRD-K49807096-003-15-5,benazepril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O",Launched
BRD-K49811169-004-06-6::2.5::HTS,BRD-K49811169-004-06-6,NSC-9965,2.5,HTS,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",NA,NA,CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,Preclinical
BRD-K49840922-001-05-1::2.5::HTS,BRD-K49840922-001-05-1,etofylline-clofibrate,2.5,HTS,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49865102-001-08-4::2.5::HTS,BRD-K49865102-001-08-4,PD-0325901,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49880111-236-09-2::2.5::HTS,BRD-K49880111-236-09-2,cephapirin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,obstetrics/gynecology,mastitis,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O",Launched
BRD-K49945136-001-10-0::2.5::HTS,BRD-K49945136-001-10-0,GR-113808,2.5,HTS,serotonin receptor antagonist,HTR4,NA,NA,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,Preclinical
BRD-K49954789-001-02-9::2.5::HTS,BRD-K49954789-001-02-9,mesna,2.5,HTS,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49962337-001-01-1::2.5::HTS,BRD-K49962337-001-01-1,baicalin,2.5,HTS,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::2.56::HTS,BRD-K49962337-001-02-9,baicalin,2.56,HTS,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K50000283-001-04-4::2.5::HTS,BRD-K50000283-001-04-4,PHA-767491,2.5,HTS,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50018155-003-02-1::2.5::HTS,BRD-K50018155-003-02-1,RS-67506,2.5,HTS,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50031829-001-01-6::2.5::HTS,BRD-K50031829-001-01-6,PF-04447943,2.5,HTS,phosphodiesterase inhibitor,PDE9A,NA,NA,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1,Phase 2
BRD-K50050533-001-02-1::2.5::HTS,BRD-K50050533-001-02-1,docosanol,2.5,HTS,lipase clearing factor inhibitor,TLR7,dental,cold sore,"CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO",Launched
BRD-K50071428-001-03-3::2.5::HTS,BRD-K50071428-001-03-3,abiraterone,2.5,HTS,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50133271-001-18-7::2.5::HTS,BRD-K50133271-001-18-7,tolfenamic-acid,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist",NA,neurology/psychiatry,migraine headache,"Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O",Launched
BRD-K50135270-300-02-3::2.5::HTS,BRD-K50135270-300-02-3,GBR-12935,2.5,HTS,dopamine uptake inhibitor,"AGTR1, SLC6A3",NA,NA,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,Preclinical
BRD-K50140147-001-10-1::2.5::HTS,BRD-K50140147-001-10-1,NVP-TAE684,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50163129-001-01-4::2.5::HTS,BRD-K50163129-001-01-4,acrivastine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,Launched
BRD-K50168500-001-07-9::2.5::HTS,BRD-K50168500-001-07-9,canertinib,2.5,HTS,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50293352-300-02-1::2.5::HTS,BRD-K50293352-300-02-1,MM77,2.5,HTS,serotonin receptor antagonist,HTR1A,NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,Preclinical
BRD-K50325075-001-02-1::2.5::HTS,BRD-K50325075-001-02-1,UCL-2077,2.5,HTS,slow afterhyperpolarization channel blocker,NA,NA,NA,"C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1",Preclinical
BRD-K50388907-001-30-4::2.5::HTS,BRD-K50388907-001-30-4,fenofibrate,2.5,HTS,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50398167-236-22-7::2.5::HTS,BRD-K50398167-236-22-7,meclofenamic-acid,2.5,HTS,"cyclooxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2","rheumatology, neurology/psychiatry, endocrinology","joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)",Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,Launched
BRD-K50406511-001-26-0::2.5::HTS,BRD-K50406511-001-26-0,hycanthone,2.5,HTS,RNA synthesis inhibitor,NA,infectious disease,schistosomiasis,CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12,Launched
BRD-K50417881-003-17-4::2.5::HTS,BRD-K50417881-003-17-4,eticlopride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, DRD4",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,Preclinical
BRD-K50422030-001-05-3::2.5::HTS,BRD-K50422030-001-05-3,clomethiazole,2.5,HTS,"GABA receptor antagonist, GABA receptor modulator",GABRA1,neurology/psychiatry,"Parkinson's Disease, sedative, muscle relaxant","Cc1ncsc1CCCl, Cc1ncsc1CCCl",Launched
BRD-K50495309-001-02-0::2.5::HTS,BRD-K50495309-001-02-0,SRC-kinase-inhibitor-I,2.5,HTS,src inhibitor,"CSK, LCK, RIPK2",NA,NA,"COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC",Preclinical
BRD-K50498985-001-03-3::2.5::HTS,BRD-K50498985-001-03-3,taladegib,2.5,HTS,smoothened receptor antagonist,"DHH, IHH, SMO",NA,NA,CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F,Phase 2
BRD-K50564936-001-01-6::2.5::HTS,BRD-K50564936-001-01-6,E-2012,2.5,HTS,gamma secretase modulator,"APH1A, APH1B, PSENEN",NA,NA,"COc1cc(ccc1-n1cnc(C)c1)\C=C1/CCCN([C@@H](C)c2ccc(F)cc2)C1=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC",Phase 1
BRD-K50590187-001-19-9::2.5::HTS,BRD-K50590187-001-19-9,capsaicin,2.5,HTS,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50631926-001-02-3::2.5::HTS,BRD-K50631926-001-02-3,PIK-294,2.5,HTS,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O,Preclinical
BRD-K50677762-001-01-5::2.5::HTS,BRD-K50677762-001-01-5,oxiracetam,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50785021-001-02-1::2.5::HTS,BRD-K50785021-001-02-1,cyclamic-acid,2.5,HTS,NA,NA,NA,NA,"OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1",Preclinical
BRD-K50817623-303-05-7::2.5::HTS,BRD-K50817623-303-05-7,pancuronium,2.5,HTS,acetylcholine receptor antagonist,"CHRM2, CHRM3, CHRNA1, CHRNA2","critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1",Launched
BRD-K50836978-001-02-5::2.5::HTS,BRD-K50836978-001-02-5,purvalanol-a,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K50850824-237-04-8::2.5::HTS,BRD-K50850824-237-04-8,acesulfame-potassium,2.5,HTS,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50853363-001-02-3::2.5::HTS,BRD-K50853363-001-02-3,dienogest,2.5,HTS,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50859149-001-19-5::2.5::HTS,BRD-K50859149-001-19-5,sulfafurazole,2.5,HTS,bacterial antifolate,NA,infectious disease,urinary tract infections,"Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C",Launched
BRD-K50866992-003-09-5::2.5::HTS,BRD-K50866992-003-09-5,tropisetron,2.5,HTS,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::2.5::HTS,BRD-K50866992-003-10-3,tropisetron,2.5,HTS,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50891186-001-04-4::2.5::HTS,BRD-K50891186-001-04-4,GR-103691,2.5,HTS,dopamine receptor antagonist,DRD3,NA,NA,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,Preclinical
BRD-K50938287-036-13-8::2.5::HTS,BRD-K50938287-036-13-8,sumatriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7",neurology/psychiatry,migraine headache,"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1",Launched
BRD-K50938786-003-11-8::2.5::HTS,BRD-K50938786-003-11-8,ropivacaine,2.5,HTS,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Launched
BRD-K51033547-003-02-6::2.5::HTS,BRD-K51033547-003-02-6,tramadol,2.5,HTS,"norepinephrine reputake inhibitor, opioid receptor agonist, serotonin reuptake inhibitor","CHRFAM7A, CHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4",neurology/psychiatry,"acute pain, chronic pain",COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C,Launched
BRD-K51040301-001-02-1::2.5::HTS,BRD-K51040301-001-02-1,cobicistat,2.5,HTS,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51087630-001-01-6::2.5::HTS,BRD-K51087630-001-01-6,tirasemtiv,2.5,HTS,troponin activator,NA,NA,NA,CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C,Phase 2
BRD-K51143828-003-03-1::2.5::HTS,BRD-K51143828-003-03-1,lurasidone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51199656-003-01-4::2.5::HTS,BRD-K51199656-003-01-4,fluoromethylcholine,2.5,HTS,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51207550-001-23-0::2.5::HTS,BRD-K51207550-001-23-0,ethionamide,2.5,HTS,mycolic synthesis inhibitor,NA,infectious disease,tuberculosis,"CCc1cc(ccn1)C(S)=N, CCc1cc(ccn1)C(S)=N",Launched
BRD-K51247865-001-01-2::2.5::HTS,BRD-K51247865-001-01-2,ipragliflozin-l-proline,2.5,HTS,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1,Launched
BRD-K51263939-001-08-6::2.5::HTS,BRD-K51263939-001-08-6,sarcosine,2.5,HTS,Glycine transporter 1 inhibitor,SLC6A9,NA,NA,CNCC(O)=O,Phase 2
BRD-K51313569-003-03-3::2.5::HTS,BRD-K51313569-003-03-3,palbociclib,2.5,HTS,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51318897-001-15-3::2.5::HTS,BRD-K51318897-001-15-3,fenbendazole,2.5,HTS,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51324732-001-01-0::2.5::HTS,BRD-K51324732-001-01-0,meglitinide,2.5,HTS,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51333959-003-01-3::2.5::HTS,BRD-K51333959-003-01-3,siramesine,2.5,HTS,sigma receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",NA,NA,Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12,Phase 2
BRD-K51350053-048-16-5::2.5::HTS,BRD-K51350053-048-16-5,toremifene,2.5,HTS,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51431759-001-02-9::2.5::HTS,BRD-K51431759-001-02-9,dextrose,2.5,HTS,NA,NA,endocrinology,hypoglycemia,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O,Launched
BRD-K51471001-303-04-7::2.5::HTS,BRD-K51471001-303-04-7,demecarium,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51474575-001-10-4::2.5::HTS,BRD-K51474575-001-10-4,taurine,2.5,HTS,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51485625-001-08-4::2.5::HTS,BRD-K51485625-001-08-4,ritonavir,2.5,HTS,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,Launched
BRD-K51486818-003-02-8::2.5::HTS,BRD-K51486818-003-02-8,lazabemide,2.5,HTS,monoamine oxidase inhibitor,MAOB,NA,NA,"NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1",Phase 3
BRD-K51541829-050-01-0::2.5::HTS,BRD-K51541829-050-01-0,Ro-25-6981,2.5,HTS,NA,GRIN2B,NA,NA,"C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1",Preclinical
BRD-K51544265-001-04-2::2.5::HTS,BRD-K51544265-001-04-2,cabozantinib,2.5,HTS,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51575138-001-13-2::2.5::HTS,BRD-K51575138-001-13-2,TPCA-1,2.5,HTS,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51579475-003-02-4::2.5::HTS,BRD-K51579475-003-02-4,dapoxetine,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"HTR1A, HTR1B, HTR2C, SLC6A4",urology,premature ejaculation (PE),CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,Launched
BRD-K51662849-001-05-4::2.5::HTS,BRD-K51662849-001-05-4,ilomastat,2.5,HTS,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::2.61::HTS,BRD-K51662849-001-08-8,ilomastat,2.61,HTS,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51671335-001-10-6::2.5::HTS,BRD-K51671335-001-10-6,levosulpiride,2.5,HTS,dopamine receptor antagonist,"CA1, CA12, CA7, DRD2, DRD3","neurology/psychiatry, gastroenterology, urology","schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)","CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O",Launched
BRD-K51677086-001-12-0::2.5::HTS,BRD-K51677086-001-12-0,erythromycin-ethylsuccinate,2.5,HTS,"cytochrome P450 inhibitor, protein synthesis inhibitor","ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1",infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C",Launched
BRD-K51747290-001-12-3::2.5::HTS,BRD-K51747290-001-12-3,hydroxyurea,2.5,HTS,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::2.5::HTS,BRD-K51747290-001-13-1,hydroxyurea,2.5,HTS,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51751936-001-09-1::2.5::HTS,BRD-K51751936-001-09-1,alfadolone-acetate,2.5,HTS,benzodiazepine receptor agonist,NA,NA,NA,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,Phase 2
BRD-K51770398-001-01-9::2.5::HTS,BRD-K51770398-001-01-9,JNJ-17203212,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,"FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1",Preclinical
BRD-K51791723-003-01-7::2.5::HTS,BRD-K51791723-003-01-7,P276-00,2.5,HTS,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51885093-001-11-2::2.5::HTS,BRD-K51885093-001-11-2,quinolinic-acid,2.5,HTS,glutamate receptor agonist,NA,NA,NA,OC(=O)c1cccnc1C(O)=O,Preclinical
BRD-K51911221-001-01-2::2.5::HTS,BRD-K51911221-001-01-2,nemorubicin,2.5,HTS,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51918615-303-02-9::2.5::HTS,BRD-K51918615-303-02-9,iodophenpropit,2.5,HTS,histamine receptor antagonist,"HRH3, HRH4",NA,NA,Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1,Preclinical
BRD-K51937257-001-01-4::2.5::HTS,BRD-K51937257-001-01-4,bilastine,2.5,HTS,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1,Launched
BRD-K51967704-001-03-6::2.5::HTS,BRD-K51967704-001-03-6,BIIB021,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K52020312-001-26-8::2.5::HTS,BRD-K52020312-001-26-8,metronidazole,2.5,HTS,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52075040-001-09-7::5.6::HTS,BRD-K52075040-001-09-7,cerulenin,5.6,HTS,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,Launched
BRD-K52075715-001-06-7::2.5::HTS,BRD-K52075715-001-06-7,oxibendazole,2.5,HTS,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52080565-001-09-2::2.5::HTS,BRD-K52080565-001-09-2,nandrolone,2.5,HTS,imidazoline receptor agonist,"AR, CYP19A1, MAOA, MAOB",hematology,anemia,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O",Launched
BRD-K52113681-003-02-1::2.5::HTS,BRD-K52113681-003-02-1,CP-339818,2.5,HTS,potassium channel blocker,KCNA3,NA,NA,CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12,Preclinical
BRD-K52172416-001-11-4::2.5::HTS,BRD-K52172416-001-11-4,anastrozole,2.5,HTS,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52219182-001-02-4::2.5::HTS,BRD-K52219182-001-02-4,ICI-63197,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,"CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O",Preclinical
BRD-K52233191-001-02-4::2.5::HTS,BRD-K52233191-001-02-4,R547,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52256627-300-06-6::2.5::HTS,BRD-K52256627-300-06-6,chlorhexidine,2.5,HTS,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52284881-236-02-4::2.5::HTS,BRD-K52284881-236-02-4,chiniofon,2.5,HTS,antiprotozoal agent,NA,infectious disease,amebiasis,Oc1c(I)cc(c2cccnc12)S(O)(=O)=O,Launched
BRD-K52313696-001-12-3::2.5::HTS,BRD-K52313696-001-12-3,tacedinaline,2.5,HTS,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52394958-001-02-7::2.5::HTS,BRD-K52394958-001-02-7,GR-159897,2.5,HTS,tachykinin antagonist,"TAC1, TACR2",NA,NA,"COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1",Preclinical
BRD-K52396582-001-06-7::2.5::HTS,BRD-K52396582-001-06-7,CF102,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12,Phase 2
BRD-K52397688-003-06-4::2.5::HTS,BRD-K52397688-003-06-4,amperozide,2.5,HTS,dopamine receptor antagonist,"FAAH, HTR2A",neurology/psychiatry,psychosis,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Launched
BRD-K52408781-001-02-8::2.5::HTS,BRD-K52408781-001-02-8,clobazam,2.5,HTS,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,seizures,CN1c2ccc(Cl)cc2N(c2ccccc2)C(=O)CC1=O,Launched
BRD-K52459018-001-09-1::2.5::HTS,BRD-K52459018-001-09-1,kainic-acid,2.5,HTS,kainate receptor agonist,"GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5",NA,NA,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O,Preclinical
BRD-K52459643-001-17-7::2.5::HTS,BRD-K52459643-001-17-7,alprostadil,2.5,HTS,prostanoid receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR",cardiology,congenital heart defects,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",Launched
BRD-K52487250-003-01-2::2.5::HTS,BRD-K52487250-003-01-2,"ICI-215,001",2.5,HTS,adrenergic receptor agonist,ADRB3,NA,NA,O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,Preclinical
BRD-K52512893-001-08-9::2.5::HTS,BRD-K52512893-001-08-9,SC-19220,2.5,HTS,prostanoid receptor antagonist,PTGER1,NA,NA,"CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12",Preclinical
BRD-K52523550-001-01-5::2.5::HTS,BRD-K52523550-001-01-5,N-acetylcarnosine,2.5,HTS,NA,NA,NA,NA,CC(=O)NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O,Phase 2
BRD-K52559566-001-02-9::2.5::HTS,BRD-K52559566-001-02-9,monosodium-alpha-luminol,2.5,HTS,NA,NA,NA,NA,"Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O",Launched
BRD-K52618540-001-09-9::2.5::HTS,BRD-K52618540-001-09-9,inositol,2.5,HTS,insulin sensitizer,"CDIPT, GBA",NA,NA,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,Launched
BRD-K52662033-003-21-2::2.5::HTS,BRD-K52662033-003-21-2,lidocaine,2.5,HTS,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52670952-003-01-4::2.5::HTS,BRD-K52670952-003-01-4,cis-urocanic-acid,2.5,HTS,serotonin receptor agonist,HTR2A,NA,NA,"OC(=O)\C=C\c1c[nH]cn1, OC(=O)\C=C\c1c[nH]cn1",Phase 2
BRD-K52751261-001-06-1::2.5::HTS,BRD-K52751261-001-06-1,TAK-715,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52756523-001-24-7::2.5::HTS,BRD-K52756523-001-24-7,dirithromycin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52762805-001-01-2::2.5::HTS,BRD-K52762805-001-01-2,epothilone-d,2.5,HTS,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52818472-001-02-2::2.5::HTS,BRD-K52818472-001-02-2,ivacaftor,2.5,HTS,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis,CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C,Launched
BRD-K52911425-001-09-8::2.5::HTS,BRD-K52911425-001-09-8,GDC-0941,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52959329-238-01-9::2.5::HTS,BRD-K52959329-238-01-9,mitiglinide,2.5,HTS,insulin secretagogue,"ABCC8, KCNJ10, PPARG",endocrinology,diabetes mellitus,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Launched
BRD-K52989797-003-26-4::2.5::HTS,BRD-K52989797-003-26-4,clomipramine,2.5,HTS,serotonin transporter (SERT) inhibitor,"GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,obsessive compulsive disorder (OCD),"CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12",Launched
BRD-K53061490-003-13-9::2.5::HTS,BRD-K53061490-003-13-9,ozagrel,2.5,HTS,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke,"OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1",Launched
BRD-K53083666-001-01-0::2.5::HTS,BRD-K53083666-001-01-0,"1,5-dicaffeoylquinic-acid",2.5,HTS,NA,NA,NA,NA,O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O,Phase 1
BRD-K53097745-001-01-5::2.5::HTS,BRD-K53097745-001-01-5,pterostilbene,2.5,HTS,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53123955-001-10-5::2.5::HTS,BRD-K53123955-001-10-5,niridazole,2.5,HTS,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53124401-001-03-8::0.03::HTS,BRD-K53124401-001-03-8,LTB4,0.03,HTS,leukocyte activator,"LTB4R, LTB4R2",NA,NA,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,Phase 2
BRD-K53153417-001-10-4::2.5::HTS,BRD-K53153417-001-10-4,butylated-hydroxytoluene,2.5,HTS,carbonic anhydrase inhibitor,CA2,NA,NA,Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,Phase 1
BRD-K53205568-001-02-6::2.5::HTS,BRD-K53205568-001-02-6,afalanine,2.5,HTS,dopamine receptor agonist,DRD2,NA,NA,CC(=O)N[C@@H](Cc1ccccc1)C(O)=O,Phase 3
BRD-K53220666-001-02-6::2.5::HTS,BRD-K53220666-001-02-6,trimetozine,2.5,HTS,sedative,NA,neurology/psychiatry,sedative,COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1,Launched
BRD-K53234107-001-01-6::2.5::HTS,BRD-K53234107-001-01-6,IWP-L6,2.5,HTS,porcupine inhibitor,PORCN,NA,NA,O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1,Preclinical
BRD-K53263234-001-05-2::2.5::HTS,BRD-K53263234-001-05-2,CITCO,2.5,HTS,constitutive androstane receptor (CAR) agonist,NR1I3,NA,NA,"Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1",Preclinical
BRD-K53318339-001-24-9::2.5::HTS,BRD-K53318339-001-24-9,vinpocetine,2.5,HTS,"phosphodiesterase inhibitor, sodium channel blocker","PDE1A, PDE1C",NA,NA,"CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41",Launched
BRD-K53397409-001-12-3::2.5::HTS,BRD-K53397409-001-12-3,benzoic-acid,2.5,HTS,food preservative,"DAO, HRSP12, PRDX5, RAB9A",infectious disease,tinea pedis,"OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1",Launched
BRD-K53414658-001-08-2::2.5::HTS,BRD-K53414658-001-08-2,tivozanib,2.5,HTS,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53417444-003-03-1::2.5::HTS,BRD-K53417444-003-03-1,OTS167,2.5,HTS,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53448858-001-07-0::2.5::HTS,BRD-K53448858-001-07-0,acadesine,2.5,HTS,AMPK activator,NA,NA,NA,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N",Phase 3
BRD-K53508936-001-01-0::2.5::HTS,BRD-K53508936-001-01-0,CTS-1027,2.5,HTS,metalloproteinase inhibitor,"MMP1, MMP13, MMP2, MMP3, MMP9",NA,NA,"ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1",Phase 2
BRD-K53517854-051-01-4::2.5::HTS,BRD-K53517854-051-01-4,fluvoxamine,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),"COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN",Launched
BRD-K53523901-001-04-4::2.5::HTS,BRD-K53523901-001-04-4,arctigenin,2.5,HTS,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53532120-003-09-5::2.5::HTS,BRD-K53532120-003-09-5,U-50488-(-),2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,"CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",Preclinical
BRD-K53532120-003-11-1::2.5::HTS,BRD-K53532120-003-11-1,U-50488-(-),2.5,HTS,opioid receptor agonist,OPRK1,NA,NA,"CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",Preclinical
BRD-K53561341-001-07-5::2.5::HTS,BRD-K53561341-001-07-5,aurora-a-inhibitor-i,2.5,HTS,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53581288-001-02-9::2.5::HTS,BRD-K53581288-001-02-9,baricitinib,2.5,HTS,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53665955-001-03-0::2.5::HTS,BRD-K53665955-001-03-0,MK-5108,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53720352-001-03-2::2.5::HTS,BRD-K53720352-001-03-2,cinalukast,2.5,HTS,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53734668-003-02-0::2.66::HTS,BRD-K53734668-003-02-0,PRT062607,2.66,HTS,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-04-6::2.5::HTS,BRD-K53734668-003-04-6,PRT062607,2.5,HTS,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53737926-003-27-8::2.5::HTS,BRD-K53737926-003-27-8,amitriptyline,2.5,HTS,"norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin-norepinephrine reuptake inhibitor (SNRI)","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,"CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12",Launched
BRD-K53765467-001-02-1::2.5::HTS,BRD-K53765467-001-02-1,empagliflozin,2.5,HTS,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1,Launched
BRD-K53814070-310-01-3::2.5::HTS,BRD-K53814070-310-01-3,ripasudil,2.5,HTS,rho associated kinase inhibitor,"ROCK1, ROCK2",ophthalmology,"glaucoma, ocular hypertension",C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,Launched
BRD-K53852914-001-01-8::2.5::HTS,BRD-K53852914-001-01-8,menbutone,2.5,HTS,NA,NA,gastroenterology,bile stimulation,COc1ccc(C(=O)CCC(O)=O)c2ccccc12,Launched
BRD-K53857191-001-22-7::2.5::HTS,BRD-K53857191-001-22-7,risperidone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder, irritability","Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-K53913732-001-05-9::2.5::HTS,BRD-K53913732-001-05-9,SB-408124,2.5,HTS,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,"CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1",Preclinical
BRD-K53963539-004-02-0::2.5::HTS,BRD-K53963539-004-02-0,vortioxetine,2.5,HTS,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4",neurology/psychiatry,depression,"Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1",Launched
BRD-K53972329-001-07-0::2.5::HTS,BRD-K53972329-001-07-0,ruxolitinib,2.5,HTS,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53979406-003-02-8::2.5::HTS,BRD-K53979406-003-02-8,ALX-5407,2.5,HTS,Glycine transporter 1 inhibitor,SLC6A9,NA,NA,"CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O",Phase 1
BRD-K54006094-051-01-7::2.5::HTS,BRD-K54006094-051-01-7,formoterol,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,"asthma, chronic obstructive pulmonary disease (COPD), bronchospasm","COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1",Launched
BRD-K54028654-001-02-6::2.5::HTS,BRD-K54028654-001-02-6,cabaletta,2.5,HTS,pharmacological chaperone,NA,NA,NA,OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K54057105-001-01-2::2.5::HTS,BRD-K54057105-001-01-2,isobutyramide,2.5,HTS,gene expression stimulant,"HBE1, HBG1",NA,NA,CC(C)C(N)=O,Phase 2
BRD-K54094468-003-11-1::2.5::HTS,BRD-K54094468-003-11-1,remoxipride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54095730-001-03-1::2.5::HTS,BRD-K54095730-001-03-1,CMPD-1,2.5,HTS,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54142781-003-11-8::2.5::HTS,BRD-K54142781-003-11-8,cirazoline,2.5,HTS,adrenergic receptor agonist,ADRA1A,NA,NA,"C(Oc1ccccc1C1CC1)C1=NCCN1, C(Oc1ccccc1C1CC1)C1=NCCN1",Preclinical
BRD-K54187111-001-08-4::2.51::HTS,BRD-K54187111-001-08-4,dichlorisone-acetate,2.51,HTS,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::2.5::HTS,BRD-K54187111-001-09-2,dichlorisone-acetate,2.5,HTS,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54247840-004-01-3::2.5::HTS,BRD-K54247840-004-01-3,halofuginone,2.5,HTS,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54256913-001-08-7::2.5::HTS,BRD-K54256913-001-08-7,MK-1775,2.5,HTS,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54262262-001-09-0::2.5::HTS,BRD-K54262262-001-09-0,monobenzone,2.5,HTS,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54314721-001-10-2::2.5::HTS,BRD-K54314721-001-10-2,zolmitriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54316499-046-04-5::2.5::HTS,BRD-K54316499-046-04-5,tolterodine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency","CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C",Launched
BRD-K54330070-001-15-4::2.5::HTS,BRD-K54330070-001-15-4,SB-202190,2.5,HTS,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",NA,NA,"Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1",Preclinical
BRD-K54395039-001-01-7::2.5::HTS,BRD-K54395039-001-01-7,PR-619,2.5,HTS,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54416256-001-19-9::2.5::HTS,BRD-K54416256-001-19-9,methimazole,2.5,HTS,antithyroid agent,TPO,endocrinology,hyperthyroidism,"Cn1cc[nH]c1=S, Cn1cc[nH]c1=S",Launched
BRD-K54472332-001-03-4::2.5::HTS,BRD-K54472332-001-03-4,elvitegravir,2.5,HTS,HIV integrase inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C,Launched
BRD-K54496168-003-01-2::2.5::HTS,BRD-K54496168-003-01-2,propacetamol,2.5,HTS,cyclooxygenase inhibitor,PTGS2,"endocrinology, neurology/psychiatry","fever, pain relief",CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,Launched
BRD-K54520417-001-01-2::2.5::HTS,BRD-K54520417-001-01-2,LXR-623,2.5,HTS,LXR agonist,"AR, NR1H2, NR1H3, NR1I2, NR3C1",NA,NA,Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F,Phase 1
BRD-K54521836-001-02-1::2.5::HTS,BRD-K54521836-001-02-1,thiodiglycol,2.5,HTS,NA,NA,NA,NA,OCCSCCO,Preclinical
BRD-K54529596-001-26-3::2.5::HTS,BRD-K54529596-001-26-3,captopril,2.5,HTS,angiotensin converting enzyme inhibitor,"ACE, LTA4H, MMP2, MMP9","cardiology, endocrinology, nephrology","hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy","C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O",Launched
BRD-K54606188-001-13-1::2.5::HTS,BRD-K54606188-001-13-1,JQ1-(+),2.5,HTS,bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54634444-001-05-9::2.5::HTS,BRD-K54634444-001-05-9,artesunate,2.5,HTS,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54640016-001-04-7::2.5::HTS,BRD-K54640016-001-04-7,WAY-362450,2.5,HTS,FXR agonist,NR1H4,NA,NA,CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1,Phase 1
BRD-K54665485-001-07-9::2.5::HTS,BRD-K54665485-001-07-9,R-59022,2.5,HTS,"diacylglycerol kinase inhibitor, protein kinase inhibitor",DGKA,NA,NA,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1",Preclinical
BRD-K54708045-001-02-1::2.5::HTS,BRD-K54708045-001-02-1,nTZDpa,2.5,HTS,PPAR receptor agonist,PPARG,NA,NA,"OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1, OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1",Preclinical
BRD-K54759182-003-08-0::2.5::HTS,BRD-K54759182-003-08-0,dosulepin,2.5,HTS,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4",neurology/psychiatry,depression,CN(C)CC\C=C1/c2ccccc2CSc2ccccc12,Launched
BRD-K54770957-001-04-3::2.5::HTS,BRD-K54770957-001-04-3,etoricoxib,2.5,HTS,cyclooxygenase inhibitor,PTGS2,rheumatology,"rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis",Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O,Launched
BRD-K54790157-001-15-5::2.5::HTS,BRD-K54790157-001-15-5,trioxsalen,2.5,HTS,DNA synthesis inhibitor,NA,dermatology,"vitiligo, eczema",Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,Launched
BRD-K54824716-001-04-0::2.5::HTS,BRD-K54824716-001-04-0,procodazole,2.5,HTS,immunostimulant,NA,NA,NA,"OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1",Preclinical
BRD-K54838207-001-02-0::2.5::HTS,BRD-K54838207-001-02-0,fudosteine,2.5,HTS,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::2.5::HTS,BRD-K54838207-001-03-8,fudosteine,2.5,HTS,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54847683-001-03-2::2.5::HTS,BRD-K54847683-001-03-2,equol,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::2.5::HTS,BRD-K54847683-001-04-0,equol,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54936858-001-01-6::2.5::HTS,BRD-K54936858-001-01-6,DMP-777,2.5,HTS,elastase inhibitor,MPO,NA,NA,CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1,Phase 2
BRD-K54997624-001-06-0::2.5::HTS,BRD-K54997624-001-06-0,alpelisib,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K55013654-003-02-3::2.5::HTS,BRD-K55013654-003-02-3,lorcaserin,2.5,HTS,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",endocrinology,obesity,C[C@H]1CNCCc2ccc(Cl)cc12,Launched
BRD-K55034111-066-17-1::2.5::HTS,BRD-K55034111-066-17-1,pefloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","gastrointestinal infections, urethritis, gonorrhea, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1",Launched
BRD-K55044200-001-14-6::2.5::HTS,BRD-K55044200-001-14-6,amoxicillin,2.5,HTS,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::2.5::HTS,BRD-K55044200-001-15-3,amoxicillin,2.5,HTS,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55055802-001-10-2::2.5::HTS,BRD-K55055802-001-10-2,etomidate,2.5,HTS,GABA receptor modulator,"ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,general anaesthetic,"CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1",Launched
BRD-K55127134-300-11-2::2.5::HTS,BRD-K55127134-300-11-2,fluphenazine,2.5,HTS,dopamine receptor antagonist,"CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,Launched
BRD-K55160477-001-04-7::2.5::HTS,BRD-K55160477-001-04-7,benzo[d]thiazole-2(3h)-thione,2.5,HTS,NA,NA,NA,NA,Sc1nc2ccccc2s1,Phase 1
BRD-K55166090-001-09-0::2.5::HTS,BRD-K55166090-001-09-0,efloxate,2.5,HTS,vasodilator,NA,NA,NA,CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1,Preclinical
BRD-K55187425-236-05-2::2.5::HTS,BRD-K55187425-236-05-2,rigosertib,2.5,HTS,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55191674-237-18-3::2.5::HTS,BRD-K55191674-237-18-3,benzylpenicillin,2.5,HTS,penicillin binding protein inhibitor,NA,infectious disease,"celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia","CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55250441-001-13-0::2.5::HTS,BRD-K55250441-001-13-0,sulfadoxine,2.5,HTS,dihydropteroate synthase inhibitor,NA,infectious disease,malaria,"COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC",Launched
BRD-K55305701-001-01-2::2.5::HTS,BRD-K55305701-001-01-2,SC-144,2.5,HTS,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55344148-003-02-6::2.5::HTS,BRD-K55344148-003-02-6,BU-224,2.5,HTS,imidazoline receptor ligand,"MAOA, MAOB",NA,NA,C1CN=C(N1)c1ccc2ccccc2n1,Preclinical
BRD-K55424922-003-02-8::2.5::HTS,BRD-K55424922-003-02-8,anpirtoline,2.5,HTS,serotonin receptor agonist,HTR1B,NA,NA,"Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1",Phase 1
BRD-K55462201-001-07-3::2.5::HTS,BRD-K55462201-001-07-3,AM-404,2.5,HTS,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55468218-001-26-1::2.5::HTS,BRD-K55468218-001-26-1,spiperone,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7",neurology/psychiatry,schizophrenia,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1",Launched
BRD-K55512740-001-01-6::2.5::HTS,BRD-K55512740-001-01-6,MK-8033,2.5,HTS,c-Met inhibitor,MET,NA,NA,Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1,Phase 1
BRD-K55567017-001-12-3::2.5::HTS,BRD-K55567017-001-12-3,formononetin,2.5,HTS,alcohol dehydrogenase inhibitor,"ADH1C, SLC5A2",NA,NA,COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,Preclinical
BRD-K55675242-001-03-0::2.5::HTS,BRD-K55675242-001-03-0,torcetrapib,2.5,HTS,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55677650-003-02-9::2.5::HTS,BRD-K55677650-003-02-9,CO-101244,2.5,HTS,glutamate receptor antagonist,GRIN2B,NA,NA,"Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1",Preclinical
BRD-K55703048-001-07-7::2.5::HTS,BRD-K55703048-001-07-7,latrepirdine,2.5,HTS,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55705469-065-01-0::2.5::HTS,BRD-K55705469-065-01-0,penbutolol,2.5,HTS,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B",cardiology,hypertension,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,Launched
BRD-K55748775-001-02-2::2.5::HTS,BRD-K55748775-001-02-2,SCH-28080,2.5,HTS,ATPase inhibitor,ATP4A,NA,NA,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,Phase 1
BRD-K55773932-001-02-0::2.5::HTS,BRD-K55773932-001-02-0,BMS-806,2.5,HTS,HIV attachment inhibitor,NA,NA,NA,"COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12",Phase 1
BRD-K55781385-001-01-7::2.5::HTS,BRD-K55781385-001-01-7,BMS-927711,2.5,HTS,calcitonin antagonist,CALCA,NA,NA,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F,Phase 2
BRD-K55847762-304-01-7::2.5::HTS,BRD-K55847762-304-01-7,lobenzarit,2.5,HTS,immunosuppressant,NA,rheumatology,rheumatoid arthritis,OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O,Launched
BRD-K55892330-001-01-8::2.5::HTS,BRD-K55892330-001-01-8,sorbic-acid,2.5,HTS,NA,NA,NA,NA,CC=CC=CC(O)=O,Preclinical
BRD-K55930204-236-24-3::2.5::HTS,BRD-K55930204-236-24-3,phenytoin,2.5,HTS,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1",Launched
BRD-K55966568-001-05-4::2.5::HTS,BRD-K55966568-001-05-4,orantinib,2.5,HTS,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K56032964-001-02-1::2.5::HTS,BRD-K56032964-001-02-1,AP26113,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56033645-001-07-5::2.5::HTS,BRD-K56033645-001-07-5,5-methylhydantoin-(L),2.5,HTS,NA,NA,NA,NA,C[C@@H]1NC(=O)NC1=O,Preclinical
BRD-K56047318-001-06-3::2.5::HTS,BRD-K56047318-001-06-3,RHC-80267,2.5,HTS,triacylglycerol lipase inhibitor,"DAGLA, DAGLB",NA,NA,"O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1",Preclinical
BRD-K56077740-001-09-2::2.5::HTS,BRD-K56077740-001-09-2,MMPX,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1,Preclinical
BRD-K56104152-008-04-1::2.5::HTS,BRD-K56104152-008-04-1,oxiconazole,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Launched
BRD-K56115039-003-02-1::2.5::HTS,BRD-K56115039-003-02-1,BU226,2.5,HTS,imidazoline receptor ligand,NA,NA,NA,C1CN=C(N1)c1cc2ccccc2cn1,Preclinical
BRD-K56156805-001-09-6::2.5::HTS,BRD-K56156805-001-09-6,benznidazole,2.5,HTS,DNA synthesis inhibitor,NA,infectious disease,Chagas disease,[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1,Launched
BRD-K56195681-001-01-0::2.5::HTS,BRD-K56195681-001-01-0,losmapimod,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1,Phase 3
BRD-K56277358-001-07-5::2.5::HTS,BRD-K56277358-001-07-5,MGCD-265,2.5,HTS,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56291712-001-01-0::2.5::HTS,BRD-K56291712-001-01-0,voxtalisib,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56301217-001-07-4::2.5::HTS,BRD-K56301217-001-07-4,ABT-737,2.5,HTS,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56334280-001-05-1::2.5::HTS,BRD-K56334280-001-05-1,amonafide,2.5,HTS,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56343971-001-10-6::2.5::HTS,BRD-K56343971-001-10-6,vemurafenib,2.5,HTS,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56405753-001-02-4::2.5::HTS,BRD-K56405753-001-02-4,MK-2461,2.5,HTS,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56483981-342-06-4::2.5::HTS,BRD-K56483981-342-06-4,chicago-sky-blue-6b,2.5,HTS,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56515112-001-21-6::2.5::HTS,BRD-K56515112-001-21-6,medrysone,2.5,HTS,glucocorticoid receptor agonist,NR3C1,ophthalmology,"conjunctivitis, episcleritis","C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12",Launched
BRD-K56542719-065-01-4::2.5::HTS,BRD-K56542719-065-01-4,cefpirome,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1,Launched
BRD-K56543881-001-02-7::2.5::HTS,BRD-K56543881-001-02-7,ADX-47273,2.5,HTS,glutamate receptor modulator,GRM5,NA,NA,Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1,Preclinical
BRD-K56558538-003-11-9::2.5::HTS,BRD-K56558538-003-11-9,ambroxol,2.5,HTS,sodium channel blocker,CYP3A4,pulmonary,bronchitis,"Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1",Launched
BRD-K56596464-004-10-7::2.5::HTS,BRD-K56596464-004-10-7,QX-314,2.5,HTS,sodium channel blocker,"MAPK14, TGFBR1",NA,NA,"CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C",Preclinical
BRD-K56614220-001-19-0::2.5::HTS,BRD-K56614220-001-19-0,clofazimine,2.5,HTS,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56691760-001-01-2::2.5::HTS,BRD-K56691760-001-01-2,pikamilone,2.5,HTS,NA,NA,NA,NA,OC(=O)CCCNC(=O)c1cccnc1,Phase 1
BRD-K56707426-001-02-0::2.5::HTS,BRD-K56707426-001-02-0,nitarsone,2.5,HTS,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56735750-001-06-8::2.5::HTS,BRD-K56735750-001-06-8,carbadox,2.5,HTS,other antibiotic,NA,"infectious disease, gastroenterology","dysentry, enteritis","COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]",Launched
BRD-K56751279-300-01-4::2.5::HTS,BRD-K56751279-300-01-4,Y-39983,2.5,HTS,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56810756-001-03-0::2.5::HTS,BRD-K56810756-001-03-0,fomepizole,2.5,HTS,alcohol dehydrogenase inhibitor,"ADH1A, ADH1B, ADH1C, AKR1A1, CAT",critical care,poison antidote,"Cc1cn[nH]c1, Cc1cn[nH]c1",Launched
BRD-K56851771-001-06-8::2.5::HTS,BRD-K56851771-001-06-8,enzalutamide,2.5,HTS,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56908511-001-01-2::2.5::HTS,BRD-K56908511-001-01-2,fluroxene,2.5,HTS,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56940463-001-13-8::2.5::HTS,BRD-K56940463-001-13-8,oxethazaine,2.5,HTS,local anesthetic,NA,neurology/psychiatry,local anesthetic,"CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1",Launched
BRD-K56940914-001-04-2::2.5::HTS,BRD-K56940914-001-04-2,cresol,2.5,HTS,NA,NA,NA,NA,Cc1ccc(O)cc1,Launched
BRD-K56957086-001-06-3::2.5::HTS,BRD-K56957086-001-06-3,dacinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K57033106-003-19-7::2.5::HTS,BRD-K57033106-003-19-7,tripelennamine,2.5,HTS,histamine receptor antagonist,HRH1,"pulmonary, allergy","asthma, allergic rhinitis, urticaria","CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1",Launched
BRD-K57041787-001-02-6::2.5::HTS,BRD-K57041787-001-02-6,dabigatran-etexilate,2.5,HTS,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1",Launched
BRD-K57080016-001-15-9::2.5::HTS,BRD-K57080016-001-15-9,selumetinib,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57136142-001-02-4::2.5::HTS,BRD-K57136142-001-02-4,CCT129202,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57169635-001-04-5::2.5::HTS,BRD-K57169635-001-04-5,dacomitinib,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57179821-001-15-4::2.5::HTS,BRD-K57179821-001-15-4,crotamiton,2.5,HTS,antipruritic,NA,infectious disease,scabies,CCN(C(=O)\C=C\C)c1ccccc1C,Launched
BRD-K57222227-001-30-1::2.5::HTS,BRD-K57222227-001-30-1,indomethacin,2.5,HTS,cyclooxygenase inhibitor,"GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1","rheumatology, orthopedics","rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1",Launched
BRD-K57252450-001-02-5::2.5::HTS,BRD-K57252450-001-02-5,cilengitide,2.5,HTS,integrin antagonist,"ITGAV, ITGB3",NA,NA,CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,Phase 3
BRD-K57275767-001-02-4::2.61::HTS,BRD-K57275767-001-02-4,geniposide,2.61,HTS,GLP receptor agonist,GLP1R,NA,NA,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K57275767-001-03-2::2.5::HTS,BRD-K57275767-001-03-2,geniposide,2.5,HTS,GLP receptor agonist,GLP1R,NA,NA,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K57284066-001-01-6::2.5::HTS,BRD-K57284066-001-01-6,Ro-9187,2.5,HTS,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57291914-003-09-4::2.5::HTS,BRD-K57291914-003-09-4,moroxydine,2.5,HTS,antiviral,NA,infectious disease,influenza A virus infection,"NC(=N)NC(=N)N1CCOCC1, NC(=N)NC(=N)N1CCOCC1",Launched
BRD-K57304726-003-06-9::2.5::HTS,BRD-K57304726-003-06-9,PRE-084,2.5,HTS,sigma receptor agonist,SIGMAR1,NA,NA,"O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1",Preclinical
BRD-K57313110-001-06-8::2.5::HTS,BRD-K57313110-001-06-8,pidolic-acid,2.5,HTS,NA,"ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA",dermatology,xerosis cutis,OC(=O)[C@@H]1CCC(=O)N1,Launched
BRD-K57371763-001-01-7::2.5::HTS,BRD-K57371763-001-01-7,fidaxomicin,2.5,HTS,RNA polymerase inhibitor,NA,gastroenterology,diarrhea,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O,Launched
BRD-K57432881-003-21-8::2.5::HTS,BRD-K57432881-003-21-8,tiapride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,"dyskinesia, abstinence from alcohol, psychosis",CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O,Launched
BRD-K57545991-050-23-1::2.5::HTS,BRD-K57545991-050-23-1,enalapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O",Launched
BRD-K57569181-001-27-5::2.5::HTS,BRD-K57569181-001-27-5,pentoxifylline,2.5,HTS,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF",cardiology,claudication,"CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O",Launched
BRD-K57597776-001-01-2::2.5::HTS,BRD-K57597776-001-01-2,org-27569,2.5,HTS,cannabinoid receptor modulator,CNR1,NA,NA,CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1,Preclinical
BRD-K57631554-003-06-2::2.5::HTS,BRD-K57631554-003-06-2,5-aminolevulinic-acid,2.5,HTS,oxidizing agent,ALAD,NA,NA,"NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O",Launched
BRD-K57718010-001-11-9::2.5::HTS,BRD-K57718010-001-11-9,pentylenetetrazol,2.5,HTS,GABA receptor antagonist,NA,NA,NA,"C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1",Withdrawn
BRD-K57754230-001-02-7::2.5::HTS,BRD-K57754230-001-02-7,EPZ005687,2.5,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,Preclinical
BRD-K57764956-001-02-8::2.5::HTS,BRD-K57764956-001-02-8,cariprazine,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,schizophrenia,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1,Launched
BRD-K57853941-304-02-5::2.5::HTS,BRD-K57853941-304-02-5,olsalazine,2.5,HTS,cyclooxygenase inhibitor,"IFNG, TPMT",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O",Launched
BRD-K57927309-001-01-7::2.5::HTS,BRD-K57927309-001-01-7,BW-180C,2.5,HTS,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K58010567-003-02-2::2.5::HTS,BRD-K58010567-003-02-2,vilazodone,2.5,HTS,serotonin reuptake inhibitor,"DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4",neurology/psychiatry,depression,"NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1",Launched
BRD-K58046914-001-03-8::2.5::HTS,BRD-K58046914-001-03-8,HA-966-(R)-(+),2.5,HTS,glutamate receptor agonist,GRIA1,NA,NA,N[C@@H]1CCN(O)C1=O,Preclinical
BRD-K58049875-001-04-7::2.5::HTS,BRD-K58049875-001-04-7,thiostrepton,2.5,HTS,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58114536-001-01-6::2.5::HTS,BRD-K58114536-001-01-6,rasagiline,2.5,HTS,monoamine oxidase inhibitor,"BCL2, MAOB",neurology/psychiatry,Parkinson's Disease,"C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12",Launched
BRD-K58122457-001-02-2::2.5::HTS,BRD-K58122457-001-02-2,hesperadin,2.5,HTS,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58148589-001-03-6::2.5::HTS,BRD-K58148589-001-03-6,betamethasone-dipropionate,2.5,HTS,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58160573-001-05-4::2.5::HTS,BRD-K58160573-001-05-4,dapagliflozin,2.5,HTS,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,"CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1",Launched
BRD-K58262659-001-09-7::2.5::HTS,BRD-K58262659-001-09-7,doxifluridine,2.5,HTS,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58265391-001-12-7::2.5::HTS,BRD-K58265391-001-12-7,meticrane,2.5,HTS,diuretic,NA,cardiology,edema,"Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O",Launched
BRD-K58299615-001-03-5::2.5::HTS,BRD-K58299615-001-03-5,Ro-90-7501,2.5,HTS,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58343622-001-01-6::2.5::HTS,BRD-K58343622-001-01-6,DY131,2.5,HTS,estrogen-related receptor agonist,"ESRRB, ESRRG",NA,NA,"CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1, CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1",Preclinical
BRD-K58435339-001-03-0::2.5::HTS,BRD-K58435339-001-03-0,AT13387,2.5,HTS,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58466253-003-14-0::2.5::HTS,BRD-K58466253-003-14-0,palmatine-chloride,2.5,HTS,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58486055-001-02-7::2.5::HTS,BRD-K58486055-001-02-7,reparixin,2.5,HTS,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O,Phase 3
BRD-K58497451-237-10-7::2.5::HTS,BRD-K58497451-237-10-7,potassium-p-aminobenzoate,2.5,HTS,NA,NA,"rheumatology, urology","scleroderma, dermatomyositis, Peyronie's disease",Nc1ccc(cc1)C(O)=O,Launched
BRD-K58501140-002-01-0::2.5::HTS,BRD-K58501140-002-01-0,TAK-875,2.5,HTS,insulin secretagogue,FFAR1,NA,NA,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1,Phase 3
BRD-K58513245-304-02-7::2.5::HTS,BRD-K58513245-304-02-7,pamidronate,2.5,HTS,bone resorption inhibitor,FDPS,"endocrinology, oncology, hematologic malignancy","hypercalcemia, Paget's disease, breast cancer, multiple myeloma","NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
BRD-K58550667-001-08-7::2.5::HTS,BRD-K58550667-001-08-7,FK-866,2.5,HTS,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58568447-001-01-1::2.5::HTS,BRD-K58568447-001-01-1,K02288,2.5,HTS,bone morphogenic protein inhibitor,BMP1,NA,NA,"COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1",Preclinical
BRD-K58626373-003-07-8::2.5::HTS,BRD-K58626373-003-07-8,dexfenfluramine,2.5,HTS,serotonin receptor agonist,"HTR2C, SLC6A4",NA,NA,CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F,Withdrawn
BRD-K58648841-001-04-7::2.5::HTS,BRD-K58648841-001-04-7,cresopirine,2.5,HTS,NA,NA,NA,NA,CC(=O)Oc1c(C)cccc1C(O)=O,Preclinical
BRD-K58685305-001-20-4::2.5::HTS,BRD-K58685305-001-20-4,emodin,2.5,HTS,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,NA,NA,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,Preclinical
BRD-K58736316-001-09-5::2.5::HTS,BRD-K58736316-001-09-5,cianidanol,2.5,HTS,fatty acid synthase inhibitor,PTGS1,NA,NA,O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1,Withdrawn
BRD-K58770988-001-01-8::2.5::HTS,BRD-K58770988-001-01-8,NMS-E973,2.5,HTS,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58772419-001-07-0::2.5::HTS,BRD-K58772419-001-07-0,AZD6482,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58794715-001-01-8::2.5::HTS,BRD-K58794715-001-01-8,bentiromide,2.5,HTS,NA,HPN,gastroenterology,pancreas diagnostic agent,"OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1",Launched
BRD-K58819470-001-05-9::2.5::HTS,BRD-K58819470-001-05-9,2-thiouracil,2.5,HTS,NA,NA,NA,NA,"Oc1ccnc(S)n1, Oc1ccnc(S)n1",Preclinical
BRD-K58930050-050-15-8::2.5::HTS,BRD-K58930050-050-15-8,dizocilpine-(+),2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21",Preclinical
BRD-K58937086-001-01-4::2.5::HTS,BRD-K58937086-001-01-4,glutathione-monoisopropyl-ester,2.5,HTS,lipid peroxidase inhibitor,NA,NA,NA,"CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O",Phase 2
BRD-K58968598-001-03-6::2.5::HTS,BRD-K58968598-001-03-6,sucralose,2.5,HTS,NA,NA,NA,NA,"OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl",Launched
BRD-K59013864-001-01-1::2.5::HTS,BRD-K59013864-001-01-1,AM-24,2.5,HTS,lipoxygenase inhibitor,ALOX5,NA,NA,Oc1c(I)cc(I)cc1I,Phase 2
BRD-K59036917-001-16-7::2.5::HTS,BRD-K59036917-001-16-7,ML161,2.5,HTS,protease-activated receptor inhibitor,NA,NA,NA,"CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1",Preclinical
BRD-K59037100-001-14-7::2.5::HTS,BRD-K59037100-001-14-7,oxybenzone,2.5,HTS,lipase inhibitor,LIPE,dermatology,sunscreen lotion,COc1ccc(C(=O)c2ccccc2)c(O)c1,Launched
BRD-K59045783-001-01-1::2.5::HTS,BRD-K59045783-001-01-1,faropenem-medoxomil,2.5,HTS,lactamase inhibitor,NA,"otolaryngology, infectious disease, pulmonary","sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections","C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C",Launched
BRD-K59058747-001-18-3::2.5::HTS,BRD-K59058747-001-18-3,acetylcysteine,2.5,HTS,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-20-9::2.5::HTS,BRD-K59058747-001-20-9,acetylcysteine,2.5,HTS,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59110290-238-01-7::2.5::HTS,BRD-K59110290-238-01-7,fosamprenavir,2.5,HTS,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Launched
BRD-K59146805-001-03-7::2.5::HTS,BRD-K59146805-001-03-7,AZ3146,2.5,HTS,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59184148-001-21-6::2.5::HTS,BRD-K59184148-001-21-6,SB-216763,2.5,HTS,glycogen synthase kinase inhibitor,"CCNA2, CDK2, GSK3A, GSK3B",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12",Preclinical
BRD-K59197931-001-04-5::2.5::HTS,BRD-K59197931-001-04-5,naproxen,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59204667-001-03-1::2.5::HTS,BRD-K59204667-001-03-1,DBeQ,2.5,HTS,ATPase inhibitor,CASP3,NA,NA,"C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1",Preclinical
BRD-K59227464-334-02-4::2.5::HTS,BRD-K59227464-334-02-4,LY2228820,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,"CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C",Phase 2
BRD-K59273480-001-10-6::2.5::HTS,BRD-K59273480-001-10-6,propentofylline,2.5,HTS,"adenosine reuptake inhibitor, phosphodiesterase inhibitor",PDE1A,neurology/psychiatry,stroke,CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12,Launched
BRD-K59284035-001-07-9::2.5::HTS,BRD-K59284035-001-07-9,chrysophanic-acid,2.5,HTS,EGFR inhibitor,"EGFR, MTOR",NA,NA,Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,Preclinical
BRD-K59317601-001-05-5::2.5::HTS,BRD-K59317601-001-05-5,MLN0128,2.5,HTS,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59325863-001-02-8::2.5::HTS,BRD-K59325863-001-02-8,delanzomib,2.5,HTS,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-03-6::2.46::HTS,BRD-K59325863-001-03-6,delanzomib,2.46,HTS,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59332007-300-02-7::2.5::HTS,BRD-K59332007-300-02-7,linopirdine,2.5,HTS,potassium channel blocker,"KCNQ2, KCNQ3, KCNQ4, KCNQ5",NA,NA,"O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1",Phase 3
BRD-K59333713-003-02-0::2.5::HTS,BRD-K59333713-003-02-0,niguldipine-(S)-(+),2.5,HTS,adrenergic receptor antagonist,ADRA1A,NA,NA,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1",Preclinical
BRD-K59339270-001-02-6::2.5::HTS,BRD-K59339270-001-02-6,AH6809,2.5,HTS,prostanoid receptor antagonist,"PTGDR, PTGER1, PTGER2, PTGER3",NA,NA,"CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O",Preclinical
BRD-K59369769-001-20-3::2.5::HTS,BRD-K59369769-001-20-3,tozasertib,2.5,HTS,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59390331-045-01-5::2.5::HTS,BRD-K59390331-045-01-5,tarafenacin,2.5,HTS,acetylcholine receptor antagonist,CHRM3,NA,NA,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2,Phase 2
BRD-K59419204-001-02-7::2.5::HTS,BRD-K59419204-001-02-7,AM-281,2.5,HTS,cannabinoid receptor antagonist,"CNR1, CNR2, GPR55",NA,NA,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1,Preclinical
BRD-K59424860-001-01-4::2.5::HTS,BRD-K59424860-001-01-4,val,2.5,HTS,NA,"BCAT1, PCCB, VARS",NA,NA,CC(C)[C@@H](N)C(O)=O,Phase 2
BRD-K59433843-001-01-7::2.5::HTS,BRD-K59433843-001-01-7,ICI-192605,2.5,HTS,thromboxane receptor antagonist,TBXA2R,NA,NA,"OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl",Phase 2
BRD-K59436580-001-01-7::2.5::HTS,BRD-K59436580-001-01-7,tedizolid,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59456551-001-22-6::2.51::HTS,BRD-K59456551-001-22-6,methotrexate,2.51,HTS,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-K59469039-001-08-0::2.5::HTS,BRD-K59469039-001-08-0,tyrphostin-AG-879,2.5,HTS,tyrosine kinase inhibitor,"ERBB2, KDR, NTRK1",NA,NA,"CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S, CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S",Preclinical
BRD-K59506194-015-04-9::2.5::HTS,BRD-K59506194-015-04-9,targinine,2.5,HTS,nitric oxide synthase inhibitor,NOS3,NA,NA,CNC(=N)NCCC[C@H](N)C(O)=O,Phase 3
BRD-K59522102-001-14-6::2.5::HTS,BRD-K59522102-001-14-6,piperine,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-15-3::2.46::HTS,BRD-K59522102-001-15-3,piperine,2.46,HTS,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59524082-001-01-3::2.5::HTS,BRD-K59524082-001-01-3,maribavir,2.5,HTS,"cytomegalovirus inhibitor, protein kinase inhibitor",PYGM,NA,NA,CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,Phase 3
BRD-K59527975-236-01-8::2.5::HTS,BRD-K59527975-236-01-8,S-Sulfo-L-cysteine-sodium-salt,2.5,HTS,glutamate receptor agonist,NA,NA,NA,N[C@@H](CSS(O)(=O)=O)C(O)=O,Preclinical
BRD-K59574735-001-11-8::2.5::HTS,BRD-K59574735-001-11-8,ubenimex,2.5,HTS,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59597909-001-17-6::2.5::HTS,BRD-K59597909-001-17-6,phenothiazine,2.5,HTS,dopamine receptor antagonist,NA,NA,NA,"N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12",Preclinical
BRD-K59632282-052-03-1::2.5::HTS,BRD-K59632282-052-03-1,quinidine,2.5,HTS,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59647213-001-10-5::2.5::HTS,BRD-K59647213-001-10-5,levocarnitine,2.5,HTS,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59715032-362-01-4::2.5::HTS,BRD-K59715032-362-01-4,pasireotide,2.5,HTS,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5",endocrinology,"Cushing's syndrome, acromegaly",NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1,Launched
BRD-K59745944-001-02-0::2.5::HTS,BRD-K59745944-001-02-0,PHT-427,2.5,HTS,"AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1",NA,NA,"CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1",Preclinical
BRD-K59831625-001-01-6::2.5::HTS,BRD-K59831625-001-01-6,LDN-212854,2.5,HTS,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59875992-001-01-8::2.5::HTS,BRD-K59875992-001-01-8,FPL-62064,2.5,HTS,"cyclooxygenase inhibitor, lipoxygenase inhibitor",NA,NA,NA,COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1,Phase 2
BRD-K59929863-001-01-9::2.5::HTS,BRD-K59929863-001-01-9,CB-10-277,2.5,HTS,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59983611-001-21-9::2.5::HTS,BRD-K59983611-001-21-9,sulfabenzamide,2.5,HTS,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59998349-003-01-4::2.5::HTS,BRD-K59998349-003-01-4,aminolevulinic-acid-benzyl-ester,2.5,HTS,NA,NA,NA,NA,NCC(=O)CCC(=O)OCc1ccccc1,Phase 1
BRD-K60005752-001-01-9::2.5::HTS,BRD-K60005752-001-01-9,S-111,2.5,HTS,PARP inhibitor,PARP1,NA,NA,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,Phase 2
BRD-K60025295-003-06-6::2.5::HTS,BRD-K60025295-003-06-6,crystal-violet,2.5,HTS,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60036103-003-01-6::2.5::HTS,BRD-K60036103-003-01-6,L-NIL,2.5,HTS,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,CC(=N)NCCCC[C@H](N)C(O)=O,Preclinical
BRD-K60038276-001-09-0::2.5::HTS,BRD-K60038276-001-09-0,irbesartan,2.5,HTS,angiotensin receptor antagonist,"AGTR1, JUN, SLC10A1","cardiology, nephrology","hypertension, diabetic nephropathy","CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K60060639-005-02-2::2.5::HTS,BRD-K60060639-005-02-2,N-methyllidocaine-iodide,2.5,HTS,antiarrhythmic medication,NA,NA,NA,CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,Preclinical
BRD-K60102752-001-02-2::2.5::HTS,BRD-K60102752-001-02-2,alibendol,2.5,HTS,antispasmodic,NA,gastroenterology,bile stimulation,COc1cc(CC=C)cc(C(=O)NCCO)c1O,Launched
BRD-K60150510-001-15-6::2.5::HTS,BRD-K60150510-001-15-6,N6-cyclopentyladenosine,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1",NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,Preclinical
BRD-K60160658-003-11-2::2.5::HTS,BRD-K60160658-003-11-2,tiagabine,2.5,HTS,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60184833-001-05-6::2.5::HTS,BRD-K60184833-001-05-6,tyrphostin-AG-99,2.5,HTS,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60212747-236-01-1::2.5::HTS,BRD-K60212747-236-01-1,neridronic-acid,2.5,HTS,bone resorption inhibitor,FDPS,endocrinology,"brittle bone disease, Paget's disease",NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,Launched
BRD-K60230970-001-17-5::2.4::HTS,BRD-K60230970-001-17-5,MG-132,2.4,HTS,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60237333-001-27-1::2.5::HTS,BRD-K60237333-001-27-1,niacin,2.5,HTS,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60240222-001-01-4::2.5::HTS,BRD-K60240222-001-01-4,carglumic-acid,2.5,HTS,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,Launched
BRD-K60287130-001-05-7::2.5::HTS,BRD-K60287130-001-05-7,"5,7-dichlorokynurenic-acid",2.5,HTS,glutamate receptor antagonist,"GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1, OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1",Preclinical
BRD-K60341624-001-02-2::2.5::HTS,BRD-K60341624-001-02-2,GSK1292263,2.5,HTS,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60348325-065-09-9::2.5::HTS,BRD-K60348325-065-09-9,brilliant-green,2.5,HTS,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60369935-001-18-3::2.5::HTS,BRD-K60369935-001-18-3,ribavirin,2.5,HTS,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60441002-001-04-8::2.5::HTS,BRD-K60441002-001-04-8,muscimol,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",NA,NA,NCc1cc(O)no1,Phase 1
BRD-K60443845-001-08-6::2.5::HTS,BRD-K60443845-001-08-6,chlormidazole,2.5,HTS,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60446698-001-01-2::2.5::HTS,BRD-K60446698-001-01-2,ONX-0914,2.5,HTS,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60511616-236-08-9::2.5::HTS,BRD-K60511616-236-08-9,pravastatin,2.5,HTS,HMGCR inhibitor,"HMGCR, SLCO1B1","endocrinology, cardiology","hypercholesterolemia, myocardial infarction, hyperlipidemia","CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12",Launched
BRD-K60567437-001-10-2::2.5::HTS,BRD-K60567437-001-10-2,dimpylate,2.5,HTS,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C,Launched
BRD-K60585088-001-01-5::2.5::HTS,BRD-K60585088-001-01-5,paricalcitol,2.5,HTS,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60640630-001-11-0::2.5::HTS,BRD-K60640630-001-11-0,mometasone-furoate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl",Launched
BRD-K60690191-001-03-3::2.5::HTS,BRD-K60690191-001-03-3,MPEP,2.5,HTS,glutamate receptor antagonist,"GRM1, GRM4, GRM5",NA,NA,"Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1",Preclinical
BRD-K60770992-066-25-0::2.47::HTS,BRD-K60770992-066-25-0,pergolide,2.47,HTS,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,"CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",Withdrawn
BRD-K60866521-001-07-1::2.5::HTS,BRD-K60866521-001-07-1,idelalisib,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60907894-003-23-5::2.5::HTS,BRD-K60907894-003-23-5,adiphenine,2.5,HTS,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms,"CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1",Launched
BRD-K60914966-001-01-4::2.5::HTS,BRD-K60914966-001-01-4,etosalamide,2.5,HTS,anti-inflammatory agent,NA,NA,NA,CCOCCOc1ccccc1C(N)=O,Preclinical
BRD-K60918217-001-03-8::2.56::HTS,BRD-K60918217-001-03-8,laquinimod,2.56,HTS,immunosuppressant,CXCL2,NA,NA,"CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1",Phase 3
BRD-K60984070-001-01-0::2.5::HTS,BRD-K60984070-001-01-0,PD-166793,2.5,HTS,"collagenase inhibitor, metalloproteinase inhibitor","MMP13, MMP2, MMP3",NA,NA,"CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O",Preclinical
BRD-K60997853-001-02-3::2.5::HTS,BRD-K60997853-001-02-3,PHA-848125,2.5,HTS,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K61032563-001-02-9::2.5::HTS,BRD-K61032563-001-02-9,neohesperidin-dihydrochalcone,2.5,HTS,NA,NA,NA,NA,COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O,Preclinical
BRD-K61036791-001-01-6::2.5::HTS,BRD-K61036791-001-01-6,rucinol,2.5,HTS,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61097567-001-08-5::2.5::HTS,BRD-K61097567-001-08-5,SB-218795,2.5,HTS,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61128465-001-09-9::2.5::HTS,BRD-K61128465-001-09-9,mdivi-1,2.5,HTS,dynamin inhibitor,DNM1,NA,NA,"COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O",Preclinical
BRD-K61177364-003-02-9::2.5::HTS,BRD-K61177364-003-02-9,NBI-27914,2.5,HTS,corticosteroid releasing factor receptor antagonist,CRHR1,NA,NA,"CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl",Preclinical
BRD-K61192372-001-05-5::2.54::HTS,BRD-K61192372-001-05-5,capecitabine,2.54,HTS,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::2.5::HTS,BRD-K61192372-001-08-9,capecitabine,2.5,HTS,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61195623-001-01-4::2.5::HTS,BRD-K61195623-001-01-4,combretastatin-A-4,2.5,HTS,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61228301-001-01-2::2.5::HTS,BRD-K61228301-001-01-2,SGI-1027,2.5,HTS,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61236135-001-08-2::2.5::HTS,BRD-K61236135-001-08-2,tiratricol,2.5,HTS,thyroid hormone stimulant,"THRA, THRB",endocrinology,Refetoff syndrome,"OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1",Launched
BRD-K61237927-001-01-7::2.5::HTS,BRD-K61237927-001-01-7,eslicarbazepine-acetate,2.5,HTS,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12,Launched
BRD-K61250484-001-02-3::2.5::HTS,BRD-K61250484-001-02-3,FPH1-(BRD-6125),2.5,HTS,hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250553-003-32-2::2.5::HTS,BRD-K61250553-003-32-2,loperamide,2.5,HTS,opioid receptor agonist,"CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC",gastroenterology,diarrhea,"CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1",Launched
BRD-K61269089-001-05-5::2.5::HTS,BRD-K61269089-001-05-5,daphnetin,2.5,HTS,protein kinase inhibitor,NA,NA,NA,Oc1ccc2ccc(=O)oc2c1O,Preclinical
BRD-K61279411-001-02-0::2.5::HTS,BRD-K61279411-001-02-0,oxaloacetate,2.5,HTS,glutamate release inhibitor,"CS, SPR",NA,NA,"OC(=O)CC(=O)C(O)=O, OC(=O)CC(=O)C(O)=O",Phase 2/Phase 3
BRD-K61295575-001-03-6::2.5::HTS,BRD-K61295575-001-03-6,blebbistatin-(-),2.5,HTS,ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61314889-001-04-4::2.5::HTS,BRD-K61314889-001-04-4,endo-IWR-1,2.5,HTS,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-05-1::2.5::HTS,BRD-K61314889-001-05-1,endo-IWR-1,2.5,HTS,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61323504-001-04-0::2.5::HTS,BRD-K61323504-001-04-0,SB-225002,2.5,HTS,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61337602-003-02-1::2.5::HTS,BRD-K61337602-003-02-1,naratriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1",Launched
BRD-K61397605-001-03-4::2.5::HTS,BRD-K61397605-001-03-4,romidepsin,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61443506-239-01-6::2.5::HTS,BRD-K61443506-239-01-6,esomeprazole,2.5,HTS,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)","COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-K61443650-236-13-1::2.5::HTS,BRD-K61443650-236-13-1,thiomersal,2.5,HTS,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61452026-001-04-6::2.5::HTS,BRD-K61452026-001-04-6,emtricitabine,2.5,HTS,nucleoside reverse transcriptase inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1,Launched
BRD-K61496577-001-20-2::2.5::HTS,BRD-K61496577-001-20-2,flumethasone,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61536336-001-01-7::2.5::HTS,BRD-K61536336-001-01-7,SB-366791,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61567297-001-01-9::2.5::HTS,BRD-K61567297-001-01-9,resatorvid,2.5,HTS,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61585876-001-01-0::2.5::HTS,BRD-K61585876-001-01-0,3-carboxy-4-hydroxyphenylglycine-(S),2.5,HTS,glutamate receptor antagonist,"GRM1, GRM5",NA,NA,N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,Preclinical
BRD-K61642990-001-01-0::2.5::HTS,BRD-K61642990-001-01-0,FERb-033,2.5,HTS,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61665160-001-01-5::2.5::HTS,BRD-K61665160-001-01-5,BYK-204165,2.5,HTS,PARP inhibitor,PARP1,NA,NA,"Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12",Preclinical
BRD-K61688984-001-02-9::2.5::HTS,BRD-K61688984-001-02-9,RGFP966,2.5,HTS,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61691541-001-01-1::2.5::HTS,BRD-K61691541-001-01-1,PF-03084014,2.5,HTS,gamma secretase inhibitor,NA,NA,NA,CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C,Phase 2
BRD-K61693562-300-01-7::2.5::HTS,BRD-K61693562-300-01-7,pyrazinoylguanidine,2.5,HTS,diuretic,NA,NA,NA,NC(=N)NC(=O)c1cnccn1,Phase 1
BRD-K61717546-001-04-3::2.5::HTS,BRD-K61717546-001-04-3,fleroxacin,2.5,HTS,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::2.47::HTS,BRD-K61717546-001-05-0,fleroxacin,2.47,HTS,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61734568-003-02-1::2.5::HTS,BRD-K61734568-003-02-1,"2,3-DCPE",2.5,HTS,Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61802864-001-08-8::2.5::HTS,BRD-K61802864-001-08-8,chlorindione,2.5,HTS,NA,NA,NA,NA,Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O,Preclinical
BRD-K61868322-050-01-7::2.5::HTS,BRD-K61868322-050-01-7,tenofovir-disoproxil,2.5,HTS,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B","CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C",Launched
BRD-K61936403-001-01-7::2.5::HTS,BRD-K61936403-001-01-7,AS-1949490,2.5,HTS,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61937613-001-01-1::2.5::HTS,BRD-K61937613-001-01-1,doconexent-ethyl-ester,2.5,HTS,omega 3 fatty acid stimulant,NA,NA,NA,CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,Launched
BRD-K61951118-001-07-9::2.5::HTS,BRD-K61951118-001-07-9,FG-7142,2.5,HTS,GABA benzodiazepine site receptor inverse agonist,NA,NA,NA,"CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21",Preclinical
BRD-K61988078-001-01-2::2.5::HTS,BRD-K61988078-001-01-2,moxidectin,2.5,HTS,chloride channel antagonist,NA,infectious disease,gastrointestinal parasites,CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C,Launched
BRD-K62008436-001-22-1::2.5::HTS,BRD-K62008436-001-22-1,paclitaxel,2.5,HTS,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62012036-001-14-4::2.44::HTS,BRD-K62012036-001-14-4,acitretin,2.44,HTS,retinoid receptor agonist,"RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3",dermatology,psoriasis,"COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C",Launched
BRD-K62056274-332-01-8::2.5::HTS,BRD-K62056274-332-01-8,N-methylquipazine,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4",NA,NA,CN1CCN(CC1)c1ccc2ccccc2n1,Preclinical
BRD-K62186992-334-02-8::2.5::HTS,BRD-K62186992-334-02-8,hydroxystilbamidine,2.5,HTS,NA,NA,NA,NA,NC(=N)c1ccc(cc1)\C=C\c1ccc(cc1O)C(N)=N,Launched
BRD-K62196610-001-01-6::2.5::HTS,BRD-K62196610-001-01-6,AVN-944,2.5,HTS,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62200014-003-10-5::2.5::HTS,BRD-K62200014-003-10-5,anagrelide,2.5,HTS,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62213621-001-01-6::2.5::HTS,BRD-K62213621-001-01-6,dihydroartemisinin,2.5,HTS,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62277907-001-01-6::1.2::HTS,BRD-K62277907-001-01-6,PYM50028,1.2,HTS,neurotrophic agent,NA,NA,NA,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1,Phase 2
BRD-K62304154-001-04-2::2.5::HTS,BRD-K62304154-001-04-2,deforolimus,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62310379-001-10-5::2.5::HTS,BRD-K62310379-001-10-5,fluticasone-propionate,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62326629-001-19-0::2.5::HTS,BRD-K62326629-001-19-0,dichlorophen,2.5,HTS,anticestodal agent,NA,NA,NA,"Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O",Launched
BRD-K62353271-001-04-7::2.5::HTS,BRD-K62353271-001-04-7,baclofen-(R),2.5,HTS,benzodiazepine receptor agonist,"GABBR1, GABBR2",NA,NA,"NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1",Preclinical
BRD-K62363391-001-24-9::2.5::HTS,BRD-K62363391-001-24-9,dapsone,2.5,HTS,bacterial antifolate,DHFR,"dermatology, infectious disease","dermatitis herpetiformis (DH), leprosy",Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1,Launched
BRD-K62374253-001-07-8::2.5::HTS,BRD-K62374253-001-07-8,rufloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,gram-negative bacterial infections,CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O,Launched
BRD-K62387885-001-01-9::2.5::HTS,BRD-K62387885-001-01-9,basimglurant,2.5,HTS,glutamate receptor antagonist,GRM5,NA,NA,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,Phase 2
BRD-K62391742-001-03-0::2.5::HTS,BRD-K62391742-001-03-0,venetoclax,2.5,HTS,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62398570-300-01-2::2.5::HTS,BRD-K62398570-300-01-2,lerisetron,2.5,HTS,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62412084-001-07-1::2.5::HTS,BRD-K62412084-001-07-1,para-toluenesulfonamide,2.5,HTS,NA,"CA12, CA2, CA6, CA9",NA,NA,Cc1ccc(cc1)S(N)(=O)=O,Phase 3
BRD-K62414032-001-12-0::2.5::HTS,BRD-K62414032-001-12-0,NMDA,2.5,HTS,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O",Preclinical
BRD-K62427771-001-01-0::2.5::HTS,BRD-K62427771-001-01-0,AS-77,2.5,HTS,potassium channel blocker,"KCNA3, KCNA5, KCNN4",NA,NA,O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,Preclinical
BRD-K62456038-003-07-1::2.5::HTS,BRD-K62456038-003-07-1,PD-128907,2.5,HTS,dopamine receptor agonist,"DRD2, DRD3",NA,NA,"CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21",Preclinical
BRD-K62537556-001-02-5::2.5::HTS,BRD-K62537556-001-02-5,4-IBP,2.5,HTS,sigma receptor agonist,SIGMAR1,NA,NA,Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1,Preclinical
BRD-K62562723-003-02-7::2.5::HTS,BRD-K62562723-003-02-7,SR-2640,2.5,HTS,leukotriene receptor antagonist,CYSLTR1,NA,NA,"OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1",Phase 2
BRD-K62581435-001-03-8::2.5::HTS,BRD-K62581435-001-03-8,3-MPPI,2.5,HTS,adrenergic receptor ligand,ADRA1A,NA,NA,COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1,Preclinical
BRD-K62594868-082-08-6::2.5::HTS,BRD-K62594868-082-08-6,GR125487,2.5,HTS,serotonin receptor antagonist,HTR4,NA,NA,COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K62607865-001-09-7::2.62::HTS,BRD-K62607865-001-09-7,aztreonam,2.62,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62621335-001-01-7::2.5::HTS,BRD-K62621335-001-01-7,SRPIN340,2.5,HTS,serine arginine protein kinase inhibitor,"SRPK1, SRPK2",NA,NA,"FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1",Preclinical
BRD-K62627508-001-01-5::2.5::HTS,BRD-K62627508-001-01-5,idasanutlin,2.5,HTS,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62676709-065-05-5::2.5::HTS,BRD-K62676709-065-05-5,guanethidine,2.5,HTS,adrenergic inhibitor,SLC6A2,cardiology,hypertension,"NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1",Launched
BRD-K62685538-001-01-7::2.5::HTS,BRD-K62685538-001-01-7,triptorelin,2.5,HTS,gonadotropin releasing factor hormone receptor agonist,GNRHR,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria",CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,Launched
BRD-K62696033-001-01-4::2.5::HTS,BRD-K62696033-001-01-4,G-1,2.5,HTS,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62734952-001-01-0::2.5::HTS,BRD-K62734952-001-01-0,arglabin,2.5,HTS,farnesyltransferase inhibitor,"FNTA, NFKB1",NA,NA,CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13,Launched
BRD-K62736196-015-11-0::2.41::HTS,BRD-K62736196-015-11-0,guanaben-acetate,2.41,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl",Launched
BRD-K62736196-015-13-6::2.5::HTS,BRD-K62736196-015-13-6,guanaben-acetate,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl",Launched
BRD-K62737565-003-02-6::2.5::HTS,BRD-K62737565-003-02-6,gabapentin,2.5,HTS,calcium channel blocker,"ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","infectious disease, neurology/psychiatry","virus herpes simplex (HSV), shingles, seizures, restless leg syndrome","NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1",Launched
BRD-K62762455-001-01-3::2.5::HTS,BRD-K62762455-001-01-3,RU-58841,2.5,HTS,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62779383-001-05-5::2.38::HTS,BRD-K62779383-001-05-5,cholecalciferol,2.38,HTS,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62782754-337-02-5::2.5::HTS,BRD-K62782754-337-02-5,tiotropium,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis, emphysema",C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,Launched
BRD-K62810658-001-12-2::2.5::HTS,BRD-K62810658-001-12-2,PD-98059,2.5,HTS,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62814476-001-03-3::2.5::HTS,BRD-K62814476-001-03-3,BMS-265246,2.5,HTS,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62858456-001-01-8::2.5::HTS,BRD-K62858456-001-01-8,lomerizine,2.5,HTS,calcium channel blocker,"CACNA1B, SCN5A",neurology/psychiatry,migraine headache,"COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC",Launched
BRD-K62929068-001-16-5::2.5::HTS,BRD-K62929068-001-16-5,6-benzylaminopurine,2.5,HTS,purinergic receptor activator,NA,NA,NA,N(Cc1ccccc1)c1ncnc2nc[nH]c12,Preclinical
BRD-K62965247-001-04-9::2.5::HTS,BRD-K62965247-001-04-9,tipifarnib,2.5,HTS,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62996583-001-10-3::2.5::HTS,BRD-K62996583-001-10-3,lidoflazine,2.5,HTS,calcium channel blocker,"SCN1A, SCN3A, SLC29A1",NA,NA,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Launched
BRD-K63001556-001-08-8::2.5::HTS,BRD-K63001556-001-08-8,orbifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,urinary tract infections,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Launched
BRD-K63001556-001-09-6::2.57::HTS,BRD-K63001556-001-09-6,orbifloxacin,2.57,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,urinary tract infections,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Launched
BRD-K63068307-001-08-9::2.5::HTS,BRD-K63068307-001-08-9,ZSTK-474,2.5,HTS,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63123526-001-01-2::2.5::HTS,BRD-K63123526-001-01-2,S-methylcysteine,2.5,HTS,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63126190-003-01-6::2.5::HTS,BRD-K63126190-003-01-6,epinephrine,2.5,HTS,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63150726-001-02-1::2.5::HTS,BRD-K63150726-001-02-1,JTE-907,2.5,HTS,cannabinoid receptor inverse agonist,CNR2,NA,NA,"CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12",Phase 1
BRD-K63151507-001-02-4::2.5::HTS,BRD-K63151507-001-02-4,MNITMT,2.5,HTS,lymphocyte inhibitor,NA,NA,NA,Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O,Preclinical
BRD-K63165456-001-10-8::2.5::HTS,BRD-K63165456-001-10-8,norcyclobenzaprine,2.5,HTS,"adrenergic receptor agonist, serotonin receptor antagonist",NA,NA,NA,CNCCC=C1c2ccccc2C=Cc2ccccc12,Preclinical
BRD-K63169195-001-01-5::2.5::HTS,BRD-K63169195-001-01-5,U-0124,2.5,HTS,MEK inhibitor,NA,NA,NA,CS\C(N)=C(C#N)\C(C#N)=C(/N)SC,Preclinical
BRD-K63178091-001-01-1::2.5::HTS,BRD-K63178091-001-01-1,telotristat,2.5,HTS,tryptophan hydroxylase inhibitor,TPH1,NA,NA,Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,Launched
BRD-K63343048-001-12-2::2.5::HTS,BRD-K63343048-001-12-2,orlistat,2.5,HTS,lipase inhibitor,"CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP",endocrinology,weight-loss aid,"CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O",Launched
BRD-K63430059-001-17-2::2.5::HTS,BRD-K63430059-001-17-2,methoxsalen,2.5,HTS,DNA synthesis inhibitor,"CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4",dermatology,psoriasis,"COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12",Launched
BRD-K63504947-001-15-4::2.5::HTS,BRD-K63504947-001-15-4,semaxanib,2.5,HTS,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63516691-003-02-0::2.5::HTS,BRD-K63516691-003-02-0,T-0156,2.5,HTS,phosphodiesterase inhibitor,PDE5A,NA,NA,"COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1",Preclinical
BRD-K63533170-001-02-9::2.5::HTS,BRD-K63533170-001-02-9,AM-630,2.5,HTS,cannabinoid receptor antagonist,"CNR1, CNR2",NA,NA,"COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12",Preclinical
BRD-K63550407-001-12-7::2.5::HTS,BRD-K63550407-001-12-7,erythromycin,2.5,HTS,NFkB pathway inhibitor,MLNR,infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K63550407-001-13-5::2.5::HTS,BRD-K63550407-001-13-5,erythromycin,2.5,HTS,NFkB pathway inhibitor,MLNR,infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K63630713-001-25-8::2.5::HTS,BRD-K63630713-001-25-8,etacrynic-acid,2.5,HTS,sodium/potassium/chloride transporter inhibitor,"ATP1A1, SLC12A1","cardiology, gastroenterology, nephrology, rheumatology","hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome",CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl,Launched
BRD-K63675182-003-23-6::2.5::HTS,BRD-K63675182-003-23-6,triflupromazine,2.5,HTS,dopamine receptor antagonist,"CHRM1, CHRM2, DRD1, DRD2, HTR2B","neurology/psychiatry, gastroenterology","psychosis, nausea, vomiting","CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F",Launched
BRD-K63712959-001-01-8::2.5::HTS,BRD-K63712959-001-01-8,temoporfin,2.5,HTS,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63736853-001-04-8::2.5::HTS,BRD-K63736853-001-04-8,acipimox,2.5,HTS,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63750851-001-20-7::2.5::HTS,BRD-K63750851-001-20-7,mycophenolic-acid,2.5,HTS,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63784565-001-06-2::2.51::HTS,BRD-K63784565-001-06-2,10-hydroxycamptothecin,2.51,HTS,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63792901-075-02-1::2.5::HTS,BRD-K63792901-075-02-1,arecaidine-but-2-ynyl-ester,2.5,HTS,acetylcholine receptor agonist,CHRM2,NA,NA,CC#CCOC(=O)C1=CCCN(C)C1,Preclinical
BRD-K63806092-236-02-6::2.5::HTS,BRD-K63806092-236-02-6,sitaxentan,2.5,HTS,endothelin receptor antagonist,EDNRA,NA,NA,"Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl",Withdrawn
BRD-K63828191-003-32-1::2.5::HTS,BRD-K63828191-003-32-1,raloxifene,2.5,HTS,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63861289-001-19-6::2.5::HTS,BRD-K63861289-001-19-6,molsidomine,2.5,HTS,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD),CCOC(=O)Nc1c[n+](no1)N1CCOCC1,Launched
BRD-K63874012-001-02-9::2.5::HTS,BRD-K63874012-001-02-9,thioperamide,2.5,HTS,histamine receptor antagonist,"HRH3, HRH4",NA,NA,"S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1, S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1",Preclinical
BRD-K63915849-001-03-7::2.5::HTS,BRD-K63915849-001-03-7,AS-604850,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O,Preclinical
BRD-K63919159-003-07-0::2.5::HTS,BRD-K63919159-003-07-0,aptiganel,2.5,HTS,glutamate receptor antagonist,GRIN1,NA,NA,"CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12",Phase 3
BRD-K63923597-001-10-0::2.5::HTS,BRD-K63923597-001-10-0,barasertib-HQPA,2.5,HTS,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63932022-001-01-5::2.5::HTS,BRD-K63932022-001-01-5,2'-MeCCPA,2.5,HTS,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K64052750-001-17-5::2.5::HTS,BRD-K64052750-001-17-5,gefitinib,2.5,HTS,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64054020-001-03-5::0.25::HTS,BRD-K64054020-001-03-5,epoprostenol,0.25,HTS,prostacyclin analog,"P2RY12, PTGER1, PTGER4, PTGIR, PTGIS",cardiology,hypertension,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O,Launched
BRD-K64137799-003-02-5::2.5::HTS,BRD-K64137799-003-02-5,2-methyl-5-hydroxytryptamine,2.5,HTS,serotonin receptor agonist,"HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6",NA,NA,"Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN",Preclinical
BRD-K64157027-003-02-7::2.5::HTS,BRD-K64157027-003-02-7,ZD-2079,2.5,HTS,adrenergic receptor agonist,ADRB3,NA,NA,O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1,Phase 2
BRD-K64178227-001-09-0::2.5::HTS,BRD-K64178227-001-09-0,BTS,2.5,HTS,NA,NA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1",Preclinical
BRD-K64191834-001-03-1::2.5::HTS,BRD-K64191834-001-03-1,"CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide",2.5,HTS,NA,NA,NA,NA,C1CCC(CC1)NSc1nc2ccccc2s1,Preclinical
BRD-K64338723-001-01-6::2.5::HTS,BRD-K64338723-001-01-6,milacemide,2.5,HTS,monoamine oxidase inhibitor,MAOB,NA,NA,CCCCCNCC(N)=O,Phase 3
BRD-K64341947-003-02-4::2.5::HTS,BRD-K64341947-003-02-4,CFM-1571,2.5,HTS,guanylate cyclase activator,NA,NA,NA,"COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1",Preclinical
BRD-K64381438-001-03-8::2.5::HTS,BRD-K64381438-001-03-8,ulipristal,2.5,HTS,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64400208-001-08-3::2.5::HTS,BRD-K64400208-001-08-3,DNQX,2.5,HTS,glutamate receptor antagonist,"GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B",NA,NA,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O",Preclinical
BRD-K64422603-300-02-7::2.5::HTS,BRD-K64422603-300-02-7,N-alpha-Methylhistamine-dihydrochloride,2.5,HTS,histamine receptor agonist,HRH4,NA,NA,CNCCc1cnc[nH]1,Phase 3
BRD-K64514229-001-05-2::2.5::HTS,BRD-K64514229-001-05-2,toltrazuril,2.5,HTS,antiprotozoal agent,NA,infectious disease,coccidiosis,"Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O",Launched
BRD-K64538373-001-01-4::2.5::HTS,BRD-K64538373-001-01-4,Ro-4987655,2.5,HTS,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64557645-001-02-4::2.5::HTS,BRD-K64557645-001-02-4,zotepine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4",neurology/psychiatry,schizophrenia,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12,Launched
BRD-K64614248-001-12-3::2.5::HTS,BRD-K64614248-001-12-3,salicin,2.5,HTS,anti-inflammatory agent,NA,NA,NA,"OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O",Phase 1
BRD-K64636206-001-02-7::2.5::HTS,BRD-K64636206-001-02-7,D-alpha-tocopheryl-succinate,2.5,HTS,NA,NA,NA,NA,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1,Launched
BRD-K64659768-001-12-8::2.5::HTS,BRD-K64659768-001-12-8,phthalylsulfathiazole,2.5,HTS,dihydropteroate synthetase inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis","OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",Launched
BRD-K64716392-001-01-3::2.5::HTS,BRD-K64716392-001-01-3,nedocromil,2.5,HTS,histamine receptor antagonist,"CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR","neurology/psychiatry, ophthalmology","itching, conjunctivitis","CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O",Launched
BRD-K64755930-003-03-2::2.5::HTS,BRD-K64755930-003-03-2,etazolate,2.5,HTS,phosphodiesterase inhibitor,"GABRB3, PDE4A",NA,NA,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,Phase 2
BRD-K64785675-001-04-0::2.5::HTS,BRD-K64785675-001-04-0,TG100-115,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64800655-001-07-4::2.5::HTS,BRD-K64800655-001-07-4,PHA-793887,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64835161-001-02-8::2.5::HTS,BRD-K64835161-001-02-8,ML167,2.5,HTS,"CLK inhibitor, DYRK inhibitor","CLK4, DYRK1B",NA,NA,Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1,Preclinical
BRD-K64838454-001-01-0::2.5::HTS,BRD-K64838454-001-01-0,dipraglurant,2.5,HTS,glutamate receptor negative allosteric modulator,GRM5,NA,NA,Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,Phase 2
BRD-K64866502-001-03-9::2.5::HTS,BRD-K64866502-001-03-9,CYC116,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64874225-001-04-7::1.13::HTS,BRD-K64874225-001-04-7,NSC-4644,1.13,HTS,"ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor",PYGM,NA,NA,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,Phase 2
BRD-K64881305-001-03-7::2.5::HTS,BRD-K64881305-001-03-7,ispinesib,2.5,HTS,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64888243-001-03-7::2.5::HTS,BRD-K64888243-001-03-7,AZ960,2.5,HTS,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64890080-001-13-8::2.5::HTS,BRD-K64890080-001-13-8,BI-2536,2.5,HTS,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64925568-001-01-8::2.5::HTS,BRD-K64925568-001-01-8,AMG-232,2.5,HTS,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64931368-003-01-4::2.5::HTS,BRD-K64931368-003-01-4,aminocaproic-acid,2.5,HTS,plasminogen activator inhibitor,"LPA, PLAT, PLG",hematology,fibrinolytic bleeding,"NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O",Launched
BRD-K64990126-004-01-1::2.5::HTS,BRD-K64990126-004-01-1,scopolamine,2.5,HTS,acetylcholine receptor antagonist,NA,"neurology/psychiatry, gastroenterology","motion sickness, vomiting, nausea","CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K64990520-001-08-4::2.5::HTS,BRD-K64990520-001-08-4,apocynin,2.5,HTS,NADPH oxidase inhibitor,NOX4,NA,NA,COc1cc(ccc1O)C(C)=O,Phase 1
BRD-K64994968-001-32-5::2.5::HTS,BRD-K64994968-001-32-5,progesterone,2.5,HTS,progesterone receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5","obstetrics/gynecology, endocrinology","infertility, amenorrhea","CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
BRD-K65146499-001-27-9::2.5::HTS,BRD-K65146499-001-27-9,nabumetone,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1",Launched
BRD-K65170927-001-01-6::2.5::HTS,BRD-K65170927-001-01-6,aprepitant,2.5,HTS,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,Launched
BRD-K65275554-001-04-7::2.5::HTS,BRD-K65275554-001-04-7,NPC-15199,2.5,HTS,ICAM1 antagonist,PPARG,NA,NA,CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,Phase 2
BRD-K65285700-001-02-3::2.5::HTS,BRD-K65285700-001-02-3,GP1a,2.5,HTS,cannabinoid receptor agonist,CNR2,NA,NA,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,Preclinical
BRD-K65359424-001-01-3::2.5::HTS,BRD-K65359424-001-01-3,eglumetad,2.5,HTS,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM8",NA,NA,"N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",Phase 2
BRD-K65377893-001-07-4::2.58::HTS,BRD-K65377893-001-07-4,7-aminocephalosporanic-acid,2.58,HTS,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65417056-003-10-1::2.5::HTS,BRD-K65417056-003-10-1,meprylcaine,2.5,HTS,local anesthetic,NA,NA,NA,CCCNC(C)(C)COC(=O)c1ccccc1,Preclinical
BRD-K65428967-001-08-4::2.5::HTS,BRD-K65428967-001-08-4,cordycepin,2.5,HTS,DNA inhibitor,NA,NA,NA,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O",Phase 1/Phase 2
BRD-K65503129-001-06-3::2.5::HTS,BRD-K65503129-001-06-3,CCT018159,2.5,HTS,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O",Preclinical
BRD-K65518078-002-01-1::2.5::HTS,BRD-K65518078-002-01-1,cilazapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O,Launched
BRD-K65544384-001-15-8::2.5::HTS,BRD-K65544384-001-15-8,4-aminohippuric-acid,2.5,HTS,NA,SLC22A6,NA,NA,"Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O",Launched
BRD-K65639003-001-09-0::2.5::HTS,BRD-K65639003-001-09-0,icariin,2.5,HTS,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",Phase 3
BRD-K65667145-001-14-0::2.5::HTS,BRD-K65667145-001-14-0,kinetin,2.5,HTS,cell division inducer,NA,dermatology,sunburn,C(Nc1ncnc2[nH]cnc12)c1ccco1,Launched
BRD-K65678996-001-05-5::2.5::HTS,BRD-K65678996-001-05-5,nefiracetam,2.5,HTS,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65716359-001-02-1::2.5::HTS,BRD-K65716359-001-02-1,exifone,2.5,HTS,nootropic agent,TYR,NA,NA,"Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O",Withdrawn
BRD-K65781196-001-03-0::2.5::HTS,BRD-K65781196-001-03-0,avanafil,2.5,HTS,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65786282-001-07-5::2.5::HTS,BRD-K65786282-001-07-5,CGP-7930,2.5,HTS,GABA receptor modulator,GABBR1,NA,NA,"CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Preclinical
BRD-K65814004-003-02-9::2.5::HTS,BRD-K65814004-003-02-9,diphenyleneiodonium,2.5,HTS,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65820248-001-01-8::2.5::HTS,BRD-K65820248-001-01-8,SDZ-NKT-343,2.5,HTS,tachykinin antagonist,TACR1,NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O",Phase 1
BRD-K65856711-001-04-4::2.5::HTS,BRD-K65856711-001-04-4,rolipram-S(+),2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,"COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1",Preclinical
BRD-K65877271-001-01-8::2.5::HTS,BRD-K65877271-001-01-8,halobetasol-propionate,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65890018-236-01-1::2.5::HTS,BRD-K65890018-236-01-1,SSR128129E,2.5,HTS,NA,NA,NA,NA,COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12,Preclinical
BRD-K65904673-001-01-4::2.5::HTS,BRD-K65904673-001-01-4,tandospirone,2.5,HTS,serotonin receptor agonist,HTR1A,neurology/psychiatry,"generalized anxiety disorder (GAD), dysthymic disorder","O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1",Launched
BRD-K65924316-001-03-1::2.5::HTS,BRD-K65924316-001-03-1,serdemetan,2.5,HTS,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65928735-001-04-3::2.5::HTS,BRD-K65928735-001-04-3,AZD1480,2.5,HTS,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65991129-001-02-9::2.5::HTS,BRD-K65991129-001-02-9,SB-705498,2.5,HTS,TRPV antagonist,TRPV1,NA,NA,FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br,Phase 2
BRD-K65992024-001-01-5::2.5::HTS,BRD-K65992024-001-01-5,pirenoxine,2.5,HTS,AGE inhibitor,NA,ophthalmology,cataracts,OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1,Launched
BRD-K66030860-001-03-6::2.5::HTS,BRD-K66030860-001-03-6,salidroside,2.5,HTS,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66035042-001-10-1::2.5::HTS,BRD-K66035042-001-10-1,sorbitol,2.5,HTS,mucolytic agent,NA,NA,NA,"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO",Launched
BRD-K66093087-001-03-1::2.5::HTS,BRD-K66093087-001-03-1,FGIN-1-43,2.5,HTS,benzodiazepine receptor agonist,TSPO,NA,NA,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1",Preclinical
BRD-K66094457-001-01-5::2.5::HTS,BRD-K66094457-001-01-5,CPP,2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66097663-001-01-8::2.5::HTS,BRD-K66097663-001-01-8,TMC-353121,2.5,HTS,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66175015-001-09-0::2.5::HTS,BRD-K66175015-001-09-0,afatinib,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66241279-001-01-8::2.5::HTS,BRD-K66241279-001-01-8,cinromide,2.5,HTS,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66296774-236-11-3::2.63::HTS,BRD-K66296774-236-11-3,fluvastatin,2.63,HTS,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66353228-001-14-6::2.5::HTS,BRD-K66353228-001-14-6,zoxazolamine,2.5,HTS,myorelaxant,NA,NA,NA,"Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1",Phase 2
BRD-K66404838-310-01-1::2.5::HTS,BRD-K66404838-310-01-1,nalbuphine,2.5,HTS,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1",neurology/psychiatry,pain relief,"O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45",Launched
BRD-K66412701-066-01-6::2.5::HTS,BRD-K66412701-066-01-6,pazufloxacin,2.5,HTS,topoisomerase inhibitor,NA,infectious disease,"pneumonia, peritonitis, bacterial septicemia",C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1,Launched
BRD-K66465025-001-05-1::2.5::HTS,BRD-K66465025-001-05-1,ACPC,2.5,HTS,glutamate receptor antagonist,NA,NA,NA,NC1(CC1)C(O)=O,Phase 1
BRD-K66480997-003-10-0::2.5::HTS,BRD-K66480997-003-10-0,isoguvacine,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",NA,NA,OC(=O)C1=CCNCC1,Preclinical
BRD-K66527818-001-02-6::2.5::HTS,BRD-K66527818-001-02-6,VU0364770,2.5,HTS,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66538826-001-07-2::2.5::HTS,BRD-K66538826-001-07-2,amuvatinib,2.5,HTS,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor","KIT, MET",NA,NA,S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12,Phase 2
BRD-K66615216-003-14-8::2.5::HTS,BRD-K66615216-003-14-8,moxifloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,TOP2A,"otolaryngology, pulmonary, infectious disease","sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections","COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1",Launched
BRD-K66664625-001-01-2::2.5::HTS,BRD-K66664625-001-01-2,4-iodo-L-phenylalanine,2.5,HTS,NA,DPP4,NA,NA,N[C@H](Cc1ccc(I)cc1)C(O)=O,Preclinical
BRD-K66715657-050-01-0::2.5::HTS,BRD-K66715657-050-01-0,UH-232-(+),2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66766661-001-19-2::2.5::HTS,BRD-K66766661-001-19-2,estradiol-valerate,2.5,HTS,estrogen receptor agonist,ESR1,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, hypoestrogenism, menopause, vaginal atrophy","CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C",Launched
BRD-K66788707-001-14-3::2.5::HTS,BRD-K66788707-001-14-3,fludarabine,2.5,HTS,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66808046-065-03-7::2.5::HTS,BRD-K66808046-065-03-7,oxyquinoline,2.5,HTS,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66850609-001-07-4::2.5::HTS,BRD-K66850609-001-07-4,voglibose,2.5,HTS,glucosidase inhibitor,MGAM,endocrinology,"diabetes mellitus, hyperglycemia","OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O",Launched
BRD-K66876909-001-12-6::2.5::HTS,BRD-K66876909-001-12-6,linezolid,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,"MAOA, MAOB",infectious disease,"pneumonia, skin infections","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1",Launched
BRD-K66896231-001-08-1::2.5::HTS,BRD-K66896231-001-08-1,ipidacrine,2.5,HTS,acetylcholinesterase inhibitor,ACHE,NA,NA,Nc1c2CCCc2nc2CCCCc12,Phase 3
BRD-K66911501-003-01-2::2.5::HTS,BRD-K66911501-003-01-2,MK-3207,2.5,HTS,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66937583-001-01-2::2.5::HTS,BRD-K66937583-001-01-2,lodoxamide,2.5,HTS,histamine receptor antagonist,NA,ophthalmology,vernal keratoconjunctivitis (VKC),OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N,Launched
BRD-K66956375-001-11-3::2.5::HTS,BRD-K66956375-001-11-3,oleoylethanolamide,2.5,HTS,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K67017579-001-28-1::2.5::HTS,BRD-K67017579-001-28-1,cilostazol,2.5,HTS,phosphodiesterase inhibitor,"PDE3A, PDE3B",cardiology,claudication,"O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1",Launched
BRD-K67043667-001-26-4::2.5::HTS,BRD-K67043667-001-26-4,altretamine,2.5,HTS,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67068943-001-01-0::2.5::HTS,BRD-K67068943-001-01-0,ORE1001,2.5,HTS,angiotensin converting enzyme inhibitor,ACE2,NA,NA,CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O,Phase 1/Phase 2
BRD-K67080878-001-15-4::2.5::HTS,BRD-K67080878-001-15-4,milrinone,2.5,HTS,phosphodiesterase inhibitor,"PDE2A, PDE3A, PDE3B, PDE5A",cardiology,congestive heart failure,"Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N",Launched
BRD-K67100011-003-06-3::2.5::HTS,BRD-K67100011-003-06-3,pivmecillinam,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, gram-negative bacterial infections","CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O",Launched
BRD-K67102207-236-07-7::2.5::HTS,BRD-K67102207-236-07-7,phenylbutyrate,2.5,HTS,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders,"OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1",Launched
BRD-K67121414-001-03-3::2.5::HTS,BRD-K67121414-001-03-3,apixaban,2.5,HTS,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)","COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O",Launched
BRD-K67173685-001-06-9::2.39::HTS,BRD-K67173685-001-06-9,4E1RCat,2.39,HTS,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67217586-001-08-0::2.5::HTS,BRD-K67217586-001-08-0,fenthion,2.5,HTS,cholinesterase inhibitor,NA,NA,NA,COP(=S)(OC)Oc1ccc(SC)c(C)c1,Launched
BRD-K67261995-001-11-7::2.5::HTS,BRD-K67261995-001-11-7,iodipamide,2.5,HTS,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67277431-002-10-5::2.5::HTS,BRD-K67277431-002-10-5,picotamide,2.5,HTS,"thromboxane receptor antagonist, thromboxane synthase inhibitor",TBXA2R,hematology,thrombosis,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,Launched
BRD-K67298865-001-09-0::2.5::HTS,BRD-K67298865-001-09-0,SB-431542,2.5,HTS,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67304264-001-08-5::2.5::HTS,BRD-K67304264-001-08-5,SKA-31,2.5,HTS,potassium channel activator,KCNN4,NA,NA,"Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1",Preclinical
BRD-K67511046-001-02-3::2.5::HTS,BRD-K67511046-001-02-3,naloxone,2.5,HTS,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67525671-001-02-5::2.5::HTS,BRD-K67525671-001-02-5,ZK-200775,2.5,HTS,kainate receptor antagonist,NA,NA,NA,"OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F",Phase 2
BRD-K67536197-003-11-4::2.5::HTS,BRD-K67536197-003-11-4,cyclocytidine,2.5,HTS,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67537649-001-04-5::2.5::HTS,BRD-K67537649-001-04-5,PQ-401,2.5,HTS,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67563174-001-17-6::2.5::HTS,BRD-K67563174-001-17-6,acemetacin,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,osteoarthritis,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1",Launched
BRD-K67566344-001-07-5::2.5::HTS,BRD-K67566344-001-07-5,ku-0063794,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67578145-001-09-7::2.38::HTS,BRD-K67578145-001-09-7,GDC-0879,2.38,HTS,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-12-1::2.5::HTS,BRD-K67578145-001-12-1,GDC-0879,2.5,HTS,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67601717-037-02-4::2.5::HTS,BRD-K67601717-037-02-4,almotriptan,2.5,HTS,serotonin receptor agonist,"HTR1B, HTR1D",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12",Launched
BRD-K67637637-003-12-6::2.5::HTS,BRD-K67637637-003-12-6,olopatadine,2.5,HTS,histamine receptor antagonist,"HRH1, S100A1, S100A12, S100A13, S100A2, S100B",ophthalmology,conjunctivitis,"CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12",Launched
BRD-K67680372-003-02-6::2.5::HTS,BRD-K67680372-003-02-6,CI-966,2.5,HTS,GAT inhibitor,SLC6A1,NA,NA,"OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1",Phase 1
BRD-K67772619-001-05-1::2.5::HTS,BRD-K67772619-001-05-1,rheochrysidin,2.5,HTS,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67783091-001-26-1::2.5::HTS,BRD-K67783091-001-26-1,haloperidol,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1",neurology/psychiatry,"schizophrenia, Tourette's disorder","OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1",Launched
BRD-K67789209-001-01-0::2.5::HTS,BRD-K67789209-001-01-0,adatanserin,2.5,HTS,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR2A",NA,NA,O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2,Phase 2
BRD-K67831364-003-03-3::2.5::HTS,BRD-K67831364-003-03-3,ZM-323881,2.5,HTS,VEGFR inhibitor,KDR,NA,NA,"Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O",Preclinical
BRD-K67844266-003-01-9::2.5::HTS,BRD-K67844266-003-01-9,pevonedistat,2.5,HTS,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67860401-001-05-6::2.5::HTS,BRD-K67860401-001-05-6,AR-A014418,2.5,HTS,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1",Preclinical
BRD-K67868012-001-07-6::2.5::HTS,BRD-K67868012-001-07-6,PI-103,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67901620-001-02-0::2.5::HTS,BRD-K67901620-001-02-0,avasimibe,2.5,HTS,ACAT inhibitor,CES1,NA,NA,"CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C",Phase 3
BRD-K67943528-050-01-4::2.5::HTS,BRD-K67943528-050-01-4,lisuride,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6",neurology/psychiatry,Parkinson's Disease,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,Launched
BRD-K67966701-001-11-6::2.5::HTS,BRD-K67966701-001-11-6,lisinopril,2.5,HTS,angiotensin converting enzyme inhibitor,"ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus","NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",Launched
BRD-K67966701-001-12-4::2.5::HTS,BRD-K67966701-001-12-4,lisinopril,2.5,HTS,angiotensin converting enzyme inhibitor,"ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus","NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",Launched
BRD-K67977190-066-02-3::2.5::HTS,BRD-K67977190-066-02-3,eprosartan,2.5,HTS,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K68065987-300-09-1::2.5::HTS,BRD-K68065987-300-09-1,MK-2206,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68095457-001-10-1::2.5::HTS,BRD-K68095457-001-10-1,palmitoylethanolamide,2.5,HTS,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68103045-001-02-9::2.5::HTS,BRD-K68103045-001-02-9,CGS-20625,2.5,HTS,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68132782-003-13-8::2.5::HTS,BRD-K68132782-003-13-8,terbinafine,2.5,HTS,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12",Launched
BRD-K68164687-001-01-6::2.5::HTS,BRD-K68164687-001-01-6,epothilone-b,2.5,HTS,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68174511-001-06-6::2.5::HTS,BRD-K68174511-001-06-6,torin-2,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68185022-001-14-8::2.5::HTS,BRD-K68185022-001-14-8,ursolic-acid,2.5,HTS,"ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor","HSD11B1, PLA2G1B, PTPN1, PYGM",NA,NA,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O",Phase 1
BRD-K68188368-001-09-4::2.5::HTS,BRD-K68188368-001-09-4,nifuroxazide,2.5,HTS,bacterial DNA inhibitor,NA,gastroenterology,"colitis, diarrhea","Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O",Launched
BRD-K68202742-001-16-5::2.63::HTS,BRD-K68202742-001-16-5,trichostatin-a,2.63,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68232413-001-01-2::2.5::HTS,BRD-K68232413-001-01-2,etizolam,2.5,HTS,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,"insomnia, anxiety",CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Launched
BRD-K68232650-001-02-2::2.5::HTS,BRD-K68232650-001-02-2,lacosamide,2.5,HTS,"collapsin response mediator protein inhibitor, collapsin response mediator protein stimulant, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,Launched
BRD-K68264559-045-02-4::2.5::HTS,BRD-K68264559-045-02-4,brimonidine,2.5,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12",Launched
BRD-K68264559-045-04-0::2.58::HTS,BRD-K68264559-045-04-0,brimonidine,2.58,HTS,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12",Launched
BRD-K68336408-001-10-9::2.5::HTS,BRD-K68336408-001-10-9,tyrphostin-AG-1478,2.5,HTS,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68346641-001-01-4::2.5::HTS,BRD-K68346641-001-01-4,amsacrine,2.5,HTS,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-02-2::2.5::HTS,BRD-K68346641-001-02-2,amsacrine,2.5,HTS,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68392338-003-02-0::2.5::HTS,BRD-K68392338-003-02-0,ZK-93426,2.5,HTS,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68395654-001-03-1::2.5::HTS,BRD-K68395654-001-03-1,EVP4593,2.5,HTS,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68402494-003-03-5::2.5::HTS,BRD-K68402494-003-03-5,ML-9,2.5,HTS,myosin light chain kinase inhibitor,TRPC6,NA,NA,"Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1",Preclinical
BRD-K68405354-001-06-4::2.5::HTS,BRD-K68405354-001-06-4,spaglumic-acid,2.5,HTS,glutamate receptor antagonist,GRM3,allergy,"allergic conjunctivitis, allergic rhinitis","CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K68405354-001-07-2::2.5::HTS,BRD-K68405354-001-07-2,spaglumic-acid,2.5,HTS,glutamate receptor antagonist,GRM3,allergy,"allergic conjunctivitis, allergic rhinitis","CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K68408467-065-01-8::2.5::HTS,BRD-K68408467-065-01-8,proflavine-hemisulfate,2.5,HTS,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68474068-001-01-8::2.5::HTS,BRD-K68474068-001-01-8,MM-102,2.5,HTS,WDR5/MLL interaction inhibitor,NA,NA,NA,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1,Preclinical
BRD-K68488863-001-04-9::2.5::HTS,BRD-K68488863-001-04-9,ENMD-2076,2.5,HTS,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68502831-001-01-2::2.5::HTS,BRD-K68502831-001-01-2,dianhydrogalactitol,2.5,HTS,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68507560-003-24-6::2.5::HTS,BRD-K68507560-003-24-6,dicycloverine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68532323-003-02-8::2.5::HTS,BRD-K68532323-003-02-8,SB-743921,2.5,HTS,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68538666-001-12-3::2.5::HTS,BRD-K68538666-001-12-3,aceclofenac,2.5,HTS,prostanoid receptor antagonist,PTGS2,rheumatology,"rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia",OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Launched
BRD-K68552125-001-05-3::2.03::HTS,BRD-K68552125-001-05-3,12-O-tetradecanoylphorbol-13-acetate,2.03,HTS,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68553471-003-12-3::2.5::HTS,BRD-K68553471-003-12-3,todralazine,2.5,HTS,antihypertensive agent,NA,NA,NA,CCOC(=O)NNc1nncc2ccccc12,Launched
BRD-K68558722-001-04-0::2.5::HTS,BRD-K68558722-001-04-0,deracoxib,2.5,HTS,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,Launched
BRD-K68567222-001-01-2::2.5::HTS,BRD-K68567222-001-01-2,BVT-948,2.5,HTS,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68620903-001-11-4::2.5::HTS,BRD-K68620903-001-11-4,dydrogesterone,2.5,HTS,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C",Launched
BRD-K68633617-003-02-9::2.5::HTS,BRD-K68633617-003-02-9,ACDPP,2.5,HTS,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68653965-001-01-1::2.5::HTS,BRD-K68653965-001-01-1,picolamine,2.5,HTS,NA,NA,NA,NA,NCc1cccnc1,Preclinical
BRD-K68693535-001-03-4::2.5::HTS,BRD-K68693535-001-03-4,lidamidine,2.5,HTS,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68747584-001-02-0::2.5::HTS,BRD-K68747584-001-02-0,PF-03814735,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68756823-001-07-1::2.5::HTS,BRD-K68756823-001-07-1,FR-180204,2.5,HTS,MAP kinase inhibitor,"MAPK1, MAPK3",NA,NA,"Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1",Preclinical
BRD-K68770713-001-01-8::2.5::HTS,BRD-K68770713-001-01-8,azosemide,2.5,HTS,electrolyte reabsorption inhibitor,"SLC12A1, SLC12A2",cardiology,edema,NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl,Launched
BRD-K68805147-001-01-8::2.5::HTS,BRD-K68805147-001-01-8,pafuramidine,2.5,HTS,DNA synthesis inhibitor,NA,NA,NA,CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC,Phase 3
BRD-K68810443-001-01-9::2.5::HTS,BRD-K68810443-001-01-9,adiporon,2.5,HTS,adiponectin receptor agonist,"ADIPOR1, ADIPOR2",NA,NA,"O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1",Preclinical
BRD-K68867920-051-11-5::2.5::HTS,BRD-K68867920-051-11-5,quetiapine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2",neurology/psychiatry,"schizophrenia, bipolar disorder","OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12",Launched
BRD-K68870568-066-01-5::2.5::HTS,BRD-K68870568-066-01-5,flumatinib,2.5,HTS,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68904758-001-03-5::2.5::HTS,BRD-K68904758-001-03-5,cephalomannine,2.5,HTS,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68938568-001-01-7::2.5::HTS,BRD-K68938568-001-01-7,GDC-0152,2.5,HTS,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68997413-001-05-1::2.5::HTS,BRD-K68997413-001-05-1,PF-3845,2.5,HTS,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K69001009-001-02-8::2.5::HTS,BRD-K69001009-001-02-8,golvatinib,2.5,HTS,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69035426-001-01-3::2.5::HTS,BRD-K69035426-001-01-3,omeprazole-sulfide,2.5,HTS,ATPase inhibitor,NA,NA,NA,COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1,Phase 1
BRD-K69070623-003-01-7::2.5::HTS,BRD-K69070623-003-01-7,EPZ004777,2.5,HTS,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12",Preclinical
BRD-K69116396-001-04-1::2.5::HTS,BRD-K69116396-001-04-1,sertindole,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69122748-001-10-1::2.5::HTS,BRD-K69122748-001-10-1,diacerein,2.5,HTS,interleukin inhibitor,IL1B,rheumatology,osteoarthritis,"CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O",Launched
BRD-K69172251-001-08-9::2.5::HTS,BRD-K69172251-001-08-9,cisplatin,2.5,HTS,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69195780-004-08-4::2.5::HTS,BRD-K69195780-004-08-4,NAN-190,2.5,HTS,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69216798-001-01-9::2.5::HTS,BRD-K69216798-001-01-9,iodoantipyrine,2.5,HTS,NA,NA,NA,NA,Cc1c(I)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K69231085-003-05-7::2.86::HTS,BRD-K69231085-003-05-7,trigonelline,2.86,HTS,NA,NA,NA,NA,C[n+]1cccc(c1)C(O)=O,Phase 1
BRD-K69236721-001-02-7::2.5::HTS,BRD-K69236721-001-02-7,lumacaftor,2.5,HTS,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis,Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O,Launched
BRD-K69247067-001-01-8::2.5::HTS,BRD-K69247067-001-01-8,afloqualone,2.5,HTS,acetylcholine receptor antagonist,NA,neurology/psychiatry,sedative,Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O,Launched
BRD-K69253806-001-02-0::2.5::HTS,BRD-K69253806-001-02-0,hexestrol,2.5,HTS,synthetic estrogen,"AKR1C1, ESR1, ESR2",NA,NA,"CCC(C(CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1",Launched
BRD-K69280563-001-01-8::2.5::HTS,BRD-K69280563-001-01-8,vinorelbine,2.5,HTS,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69346723-001-04-8::2.5::HTS,BRD-K69346723-001-04-8,glutathione,2.5,HTS,antioxidant,"ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12",NA,NA,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,Phase 3
BRD-K69469734-003-02-5::2.5::HTS,BRD-K69469734-003-02-5,trospium,2.5,HTS,acetylcholine receptor antagonist,CHRM1,urology,"urinary incontinence, urinary frequency",OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1,Launched
BRD-K69470111-236-08-9::2.5::HTS,BRD-K69470111-236-08-9,montelukast,2.5,HTS,leukotriene receptor antagonist,"ALOX5, CYSLTR1","pulmonary, allergy","asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)","CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1",Launched
BRD-K69577666-001-01-3::2.5::HTS,BRD-K69577666-001-01-3,SGC-0946,2.5,HTS,histone lysine methyltransferase inhibitor,NA,NA,NA,"CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12",Preclinical
BRD-K69600043-328-05-5::2.5::HTS,BRD-K69600043-328-05-5,thiethylperazine,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, DRD4",gastroenterology,nausea,CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K69608737-001-10-2::2.5::HTS,BRD-K69608737-001-10-2,tacrolimus,2.5,HTS,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69650333-003-13-2::2.48::HTS,BRD-K69650333-003-13-2,idarubicin,2.48,HTS,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::2.5::HTS,BRD-K69650333-003-14-0,idarubicin,2.5,HTS,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69688083-004-23-1::2.5::HTS,BRD-K69688083-004-23-1,mestinon,2.5,HTS,cholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,"CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1",Launched
BRD-K69694239-001-02-2::2.5::HTS,BRD-K69694239-001-02-2,bardoxolone-methyl,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69726342-238-02-4::2.5::HTS,BRD-K69726342-238-02-4,atorvastatin,2.5,HTS,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726595-001-01-2::2.5::HTS,BRD-K69726595-001-01-2,mericitabine,2.5,HTS,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69776681-001-03-8::2.5::HTS,BRD-K69776681-001-03-8,volasertib,2.5,HTS,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69812556-305-02-0::2.5::HTS,BRD-K69812556-305-02-0,WAY-100635,2.5,HTS,serotonin receptor antagonist,HTR1A,NA,NA,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,Phase 1
BRD-K69837166-003-02-0::2.5::HTS,BRD-K69837166-003-02-0,trap-101,2.5,HTS,"nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist",OPRL1,NA,NA,"CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O",Preclinical
BRD-K69907333-001-10-6::2.5::HTS,BRD-K69907333-001-10-6,flurbiprofen-(S)-(+),2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1",Launched
BRD-K69932463-001-10-6::2.5::HTS,BRD-K69932463-001-10-6,AZD8055,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K70053378-001-01-1::2.5::HTS,BRD-K70053378-001-01-1,SM-108,2.5,HTS,NA,NA,NA,NA,"NC(=O)c1[nH]cnc1O, NC(=O)c1[nH]cnc1O",Phase 2
BRD-K70088346-001-01-6::2.5::HTS,BRD-K70088346-001-01-6,2-chloro-N6-cyclopentyladenosine,2.5,HTS,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K70159787-001-01-1::2.5::HTS,BRD-K70159787-001-01-1,SMI-4a,2.5,HTS,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70163715-300-05-7::2.42::HTS,BRD-K70163715-300-05-7,vatalanib,2.42,HTS,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70177501-003-01-4::2.5::HTS,BRD-K70177501-003-01-4,INH1,2.5,HTS,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70246307-001-04-1::2.5::HTS,BRD-K70246307-001-04-1,riboflavin,2.5,HTS,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70281171-050-08-9::2.5::HTS,BRD-K70281171-050-08-9,U-99194,2.5,HTS,dopamine receptor antagonist,DRD3,NA,NA,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,Preclinical
BRD-K70301465-001-02-6::2.5::HTS,BRD-K70301465-001-02-6,ibrutinib,2.5,HTS,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301876-034-13-7::2.5::HTS,BRD-K70301876-034-13-7,escitalopram,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD)","CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1",Launched
BRD-K70327167-348-13-4::2.5::HTS,BRD-K70327167-348-13-4,suramin,2.5,HTS,DNA synthesis inhibitor,"F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5",infectious disease,"African trypanosomiasis, onchocerciasis","Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O",Launched
BRD-K70327191-001-02-2::2.5::HTS,BRD-K70327191-001-02-2,benzoxiquine,2.5,HTS,antiinfective drug,NA,NA,NA,O=C(Oc1cccc2cccnc12)c1ccccc1,Preclinical
BRD-K70330367-003-07-9::2.5::HTS,BRD-K70330367-003-07-9,amantadine,2.5,HTS,glutamate receptor antagonist,"DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A","infectious disease, neurology/psychiatry","influenza A virus infection, Parkinson's Disease","NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2",Launched
BRD-K70358946-001-15-7::2.5::HTS,BRD-K70358946-001-15-7,aripiprazole,2.5,HTS,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70401845-003-09-6::2.5::HTS,BRD-K70401845-003-09-6,erlotinib,2.5,HTS,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70402238-001-02-8::2.5::HTS,BRD-K70402238-001-02-8,nexturastat-a,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70463136-001-01-5::2.5::HTS,BRD-K70463136-001-01-5,BAY-87-2243,2.5,HTS,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70487031-001-02-8::2.5::HTS,BRD-K70487031-001-02-8,flupentixol,2.5,HTS,dopamine receptor antagonist,"ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A",neurology/psychiatry,"schizophrenia, depression",OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,Launched
BRD-K70490179-300-01-2::2.5::HTS,BRD-K70490179-300-01-2,rimcazole,2.5,HTS,sigma receptor antagonist,SIGMAR1,NA,NA,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,Phase 1
BRD-K70505054-003-12-4::2.5::HTS,BRD-K70505054-003-12-4,ranitidine,2.5,HTS,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70507123-001-09-7::2.5::HTS,BRD-K70507123-001-09-7,doxofylline,2.5,HTS,adenosine receptor antagonist,"ADORA1, PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,asthma,"Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O",Launched
BRD-K70511574-001-06-9::2.5::HTS,BRD-K70511574-001-06-9,HMN-214,2.5,HTS,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70557564-305-03-6::2.5::HTS,BRD-K70557564-305-03-6,zosuquidar,2.5,HTS,P glycoprotein inhibitor,"ABCB1, ABCB4",NA,NA,"O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F",Phase 3
BRD-K70586315-001-02-4::2.5::HTS,BRD-K70586315-001-02-4,1-EBIO,2.5,HTS,potassium channel activator,"KCNN1, KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O",Preclinical
BRD-K70592483-001-01-0::2.5::HTS,BRD-K70592483-001-01-0,phenylacetylglutamine,2.5,HTS,"DNA methylase inhibitor, protein synthesis inhibitor",NA,NA,NA,NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O,Phase 2
BRD-K70610771-001-02-9::2.5::HTS,BRD-K70610771-001-02-9,VX-222,2.5,HTS,HCV inhibitor,NA,NA,NA,C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C,Phase 2
BRD-K70778732-003-26-7::2.5::HTS,BRD-K70778732-003-26-7,trazodone,2.5,HTS,"adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4",neurology/psychiatry,depression,"Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1",Launched
BRD-K70792160-003-04-6::2.5::HTS,BRD-K70792160-003-04-6,10-DEBC,2.5,HTS,AKT inhibitor,PIM1,NA,NA,"CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12",Preclinical
BRD-K70821460-300-02-4::2.5::HTS,BRD-K70821460-300-02-4,4-methylhistamine,2.5,HTS,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70898774-001-03-5::2.5::HTS,BRD-K70898774-001-03-5,naloxone-benzoylhydrazone,2.5,HTS,opioid receptor antagonist,"OPRK1, OPRM1",NA,NA,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1",Preclinical
BRD-K70912147-001-01-8::2.5::HTS,BRD-K70912147-001-01-8,co-102862,2.5,HTS,NA,"SCN4A, SCN9A",NA,NA,NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1,Phase 1
BRD-K70914287-300-02-8::2.5::HTS,BRD-K70914287-300-02-8,BIBX-1382,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70924353-001-01-2::2.5::HTS,BRD-K70924353-001-01-2,amtolmetin-guacil,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis",COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,Launched
BRD-K71035033-001-07-1::2.5::HTS,BRD-K71035033-001-07-1,masitinib,2.5,HTS,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71055333-224-05-8::2.5::HTS,BRD-K71055333-224-05-8,etamsylate,2.5,HTS,haemostatic agent,NA,hematology,hemorrhage,"Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O",Launched
BRD-K71058253-001-01-9::2.5::HTS,BRD-K71058253-001-01-9,luliconazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis",Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1,Launched
BRD-K71059170-001-11-6::2.5::HTS,BRD-K71059170-001-11-6,cefixime,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"infectious disease, otolaryngology, pulmonary","urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis","Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K71075609-003-01-0::2.5::HTS,BRD-K71075609-003-01-0,dorzolamide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71103788-003-12-0::2.5::HTS,BRD-K71103788-003-12-0,duloxetine,2.5,HTS,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)","HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy","CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1",Launched
BRD-K71106091-001-06-1::2.5::HTS,BRD-K71106091-001-06-1,fludarabine-phosphate,2.5,HTS,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71125014-001-27-1::2.5::HTS,BRD-K71125014-001-27-1,sulphadimethoxine,2.5,HTS,dihydropteroate synthetase inhibitor,NA,NA,NA,"COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1",Launched
BRD-K71164191-001-01-0::2.5::HTS,BRD-K71164191-001-01-0,KD-023,2.5,HTS,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71221037-001-01-6::2.5::HTS,BRD-K71221037-001-01-6,birinapant,2.5,HTS,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71266197-236-02-7::2.5::HTS,BRD-K71266197-236-02-7,PSB-06126,2.5,HTS,NTPDase inhibitor,ENTPD3,NA,NA,Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O,Preclinical
BRD-K71281111-001-04-3::2.5::HTS,BRD-K71281111-001-04-3,SNX-2112,2.5,HTS,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71289571-001-11-4::2.5::HTS,BRD-K71289571-001-11-4,zafirlukast,2.5,HTS,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2",pulmonary,asthma,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,Launched
BRD-K71350836-001-02-4::2.5::HTS,BRD-K71350836-001-02-4,butalbital,2.5,HTS,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,"headache, muscle relaxant",CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,Launched
BRD-K71430621-303-02-3::2.5::HTS,BRD-K71430621-303-02-3,clobenpropit,2.5,HTS,histamine receptor antagonist,"HRH1, HRH2, HRH3, HRH4",NA,NA,Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,Preclinical
BRD-K71467466-001-02-3::2.5::HTS,BRD-K71467466-001-02-3,KPT-185,2.5,HTS,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71480163-001-01-4::2.5::HTS,BRD-K71480163-001-01-4,GDC-0068,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71499074-001-12-9::2.5::HTS,BRD-K71499074-001-12-9,diclofenamide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA4, CA7","ophthalmology, neurology/psychiatry","glaucoma, epilepsy",NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,Launched
BRD-K71512533-066-02-8::2.5::HTS,BRD-K71512533-066-02-8,SNS-314,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71534238-001-10-0::2.5::HTS,BRD-K71534238-001-10-0,GW-9508,2.5,HTS,"free fatty acid receptor agonist, G protein-coupled receptor agonist","FFAR1, FFAR4",NA,NA,"OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1",Preclinical
BRD-K71603915-003-01-8::2.5::HTS,BRD-K71603915-003-01-8,EVP-6124,2.5,HTS,acetylcholine receptor agonist,CHRNA7,NA,NA,Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2,Phase 3
BRD-K71698503-003-01-6::2.5::HTS,BRD-K71698503-003-01-6,I-BZA2,2.5,HTS,NA,NA,NA,NA,CCN(CC)CCNC(=O)c1ccccc1I,Phase 3
BRD-K71731651-001-04-3::2.5::HTS,BRD-K71731651-001-04-3,PNU-120596,2.5,HTS,acetylcholine receptor agonist,CHRNA7,NA,NA,"COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl",Preclinical
BRD-K71799949-001-36-4::2.5::HTS,BRD-K71799949-001-36-4,carbamazepine,2.5,HTS,carboxamide antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2C=Cc2ccccc12, NC(=O)N1c2ccccc2C=Cc2ccccc12, NC(=O)N1c2ccccc2C=Cc2ccccc12",Launched
BRD-K71822263-001-03-2::2.5::HTS,BRD-K71822263-001-03-2,D-Serine,2.5,HTS,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71823332-001-03-7::2.5::HTS,BRD-K71823332-001-03-7,epothilone-a,2.5,HTS,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71847383-001-12-5::2.5::HTS,BRD-K71847383-001-12-5,cytarabine,2.5,HTS,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71926323-001-13-8::2.5::HTS,BRD-K71926323-001-13-8,marbofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,gram-negative bacterial infections,"CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O",Launched
BRD-K71926323-001-14-6::2.52::HTS,BRD-K71926323-001-14-6,marbofloxacin,2.52,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,gram-negative bacterial infections,"CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O",Launched
BRD-K72004355-001-01-9::2.5::HTS,BRD-K72004355-001-01-9,CFTRinh-172,2.5,HTS,chloride channel blocker,CFTR,NA,NA,"OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F, OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F, OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F",Preclinical
BRD-K72005722-001-01-2::2.5::HTS,BRD-K72005722-001-01-2,VT-464,2.5,HTS,cytochrome P450 inhibitor,CYP17A1,NA,NA,CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1,Phase 2
BRD-K72029282-001-22-0::2.5::HTS,BRD-K72029282-001-22-0,probucol,2.5,HTS,atherogenesis inhibitor,"ABCA1, ABCB11, CES1",cardiology,coronary artery disease (CAD),"CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Launched
BRD-K72093121-001-16-3::2.5::HTS,BRD-K72093121-001-16-3,vidarabine,2.5,HTS,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093555-001-01-0::2.5::HTS,BRD-K72093555-001-01-0,procyanidin-b-2,2.5,HTS,NA,NA,NA,NA,"O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1",Phase 2
BRD-K72106461-001-02-1::2.5::HTS,BRD-K72106461-001-02-1,SYM-2081,2.5,HTS,kainate receptor antagonist,"GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2",NA,NA,C[C@H](C[C@H](N)C(O)=O)C(O)=O,Preclinical
BRD-K72166146-066-05-4::2.5::HTS,BRD-K72166146-066-05-4,dihydroergotamine,2.5,HTS,serotonin receptor agonist,"ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,"CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K72167406-001-02-1::2.5::HTS,BRD-K72167406-001-02-1,cefditoren-pivoxil,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-03-9::2.5::HTS,BRD-K72167406-001-03-9,cefditoren-pivoxil,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72215350-001-06-5::2.5::HTS,BRD-K72215350-001-06-5,acexamic-acid,2.5,HTS,5 alpha reductase inhibitor,GAST,dermatology,wound healing,CC(=O)NCCCCCC(O)=O,Launched
BRD-K72222507-003-16-8::2.5::HTS,BRD-K72222507-003-16-8,quinapril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, angioedema","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O",Launched
BRD-K72231366-001-02-3::2.5::HTS,BRD-K72231366-001-02-3,TAME,2.5,HTS,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72327355-001-14-7::2.5::HTS,BRD-K72327355-001-14-7,baicalein,2.5,HTS,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72339976-065-02-1::2.5::HTS,BRD-K72339976-065-02-1,cefoselis,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K72339976-065-03-9::2.5::HTS,BRD-K72339976-065-03-9,cefoselis,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K72339976-065-04-7::2.5::HTS,BRD-K72339976-065-04-7,cefoselis,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K72369578-001-04-1::2.5::HTS,BRD-K72369578-001-04-1,AZD4282,2.5,HTS,glutamate receptor antagonist,"AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9",NA,NA,NCC(O)=O,Phase 1
BRD-K72384124-001-08-0::2.5::HTS,BRD-K72384124-001-08-0,sulbentine,2.5,HTS,other antifungal,NA,NA,NA,S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,Preclinical
BRD-K72414522-001-06-7::2.5::HTS,BRD-K72414522-001-06-7,AZD5438,2.5,HTS,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72420232-001-12-3::2.5::HTS,BRD-K72420232-001-12-3,WZ-4002,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72462751-001-02-7::2.5::HTS,BRD-K72462751-001-02-7,C-1,2.5,HTS,protein kinase inhibitor,PRKCA,NA,NA,"O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12",Preclinical
BRD-K72542090-304-02-4::2.5::HTS,BRD-K72542090-304-02-4,clodronic-acid,2.5,HTS,bone resorption inhibitor,"SLC25A4, SLC25A5, SLC25A6","orthopedics, endocrinology, hematologic malignancy","osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma","OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O",Launched
BRD-K72687424-001-02-6::2.5::HTS,BRD-K72687424-001-02-6,VU0364439,2.5,HTS,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl",Preclinical
BRD-K72703948-001-10-1::2.5::HTS,BRD-K72703948-001-10-1,ZM-447439,2.5,HTS,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72723676-003-17-8::2.5::HTS,BRD-K72723676-003-17-8,benzethonium,2.5,HTS,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72726508-001-02-1::2.5::HTS,BRD-K72726508-001-02-1,arcyriaflavin-a,2.5,HTS,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72728560-001-01-4::2.5::HTS,BRD-K72728560-001-01-4,dimetridazole,2.5,HTS,bacterial DNA inhibitor,NA,NA,NA,Cc1ncc(n1C)[N+]([O-])=O,Launched
BRD-K72815923-034-01-2::2.5::HTS,BRD-K72815923-034-01-2,xanomeline,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72827473-001-01-0::2.5::HTS,BRD-K72827473-001-01-0,CEP-37440,2.5,HTS,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72904818-001-01-1::2.5::HTS,BRD-K72904818-001-01-1,NNC-63-0532,2.5,HTS,opioid receptor agonist,OPRL1,NA,NA,"COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O",Preclinical
BRD-K72912098-001-02-3::2.5::HTS,BRD-K72912098-001-02-3,telaprevir,2.5,HTS,HCV inhibitor,"CTSA, PGR",infectious disease,hepatitis C,"CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1",Launched
BRD-K72915123-001-18-1::2.5::HTS,BRD-K72915123-001-18-1,cinchophen,2.5,HTS,analgesic agent,NA,rheumatology,gout,"OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1",Launched
BRD-K72925150-001-11-1::2.5::HTS,BRD-K72925150-001-11-1,sclareolide,2.5,HTS,other antifungal,NA,NA,NA,"C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2",Launched
BRD-K72951360-001-01-4::2.5::HTS,BRD-K72951360-001-01-4,valrubicin,2.5,HTS,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K73073971-001-01-7::2.5::HTS,BRD-K73073971-001-01-7,ZLN005,2.5,HTS,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73107279-003-12-5::2.5::HTS,BRD-K73107279-003-12-5,levamisole,2.5,HTS,acetylcholine receptor agonist,"ALPL, ALPPL2, CHRNA3",NA,NA,"C1CN2C[C@@H](N=C2S1)c1ccccc1, C1CN2C[C@@H](N=C2S1)c1ccccc1",Withdrawn
BRD-K73109821-001-20-1::2.5::HTS,BRD-K73109821-001-20-1,diazoxide,2.5,HTS,potassium channel activator,"ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3",endocrinology,hypoglycemia,"CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1",Launched
BRD-K73157543-001-04-1::2.5::HTS,BRD-K73157543-001-04-1,phenyl-aminosalicylate,2.5,HTS,NA,NA,infectious disease,tuberculosis,Nc1ccc(C(=O)Oc2ccccc2)c(O)c1,Launched
BRD-K73191876-001-11-2::2.5::HTS,BRD-K73191876-001-11-2,alizarin,2.5,HTS,NA,NA,NA,NA,"Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O",Preclinical
BRD-K73196317-003-14-8::2.5::HTS,BRD-K73196317-003-14-8,urapidil,2.5,HTS,adrenergic receptor antagonist,HTR1A,cardiology,hypertension,"COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1",Launched
BRD-K73197500-001-02-2::2.5::HTS,BRD-K73197500-001-02-2,SNX-5422,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73234506-235-02-1::2.5::HTS,BRD-K73234506-235-02-1,lithium-acetoacetate,2.5,HTS,NA,NA,NA,NA,CC(=O)CC(O)=O,Preclinical
BRD-K73237276-001-01-0::2.5::HTS,BRD-K73237276-001-01-0,tacalcitol,2.5,HTS,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73251053-003-22-2::2.5::HTS,BRD-K73251053-003-22-2,clorgiline,2.5,HTS,monoamine oxidase inhibitor,MAOA,NA,NA,"CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C",Phase 2
BRD-K73290745-003-02-6::2.5::HTS,BRD-K73290745-003-02-6,ICI-199441,2.5,HTS,opioid receptor agonist,"CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R",NA,NA,"CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1",Preclinical
BRD-K73293050-001-03-1::2.5::HTS,BRD-K73293050-001-03-1,WZ-3146,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73303757-001-21-6::2.5::HTS,BRD-K73303757-001-21-6,4-methylgenistein,2.5,HTS,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73309154-003-02-8::2.5::HTS,BRD-K73309154-003-02-8,OSI-420,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73319509-001-08-0::2.5::HTS,BRD-K73319509-001-08-0,PF-04217903,2.5,HTS,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73323637-003-10-9::2.5::HTS,BRD-K73323637-003-10-9,levobunolol-(+),2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12,Preclinical
BRD-K73368362-001-07-5::2.5::HTS,BRD-K73368362-001-07-5,BIX-02189,2.5,HTS,MEK inhibitor,"MAP2K5, MAPK7",NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1",Preclinical
BRD-K73381198-001-01-1::2.5::HTS,BRD-K73381198-001-01-1,5-fluoro-3-pyridyl-methanol,2.5,HTS,NA,NA,NA,NA,OCc1cncc(F)c1,Preclinical
BRD-K73381542-003-23-4::2.5::HTS,BRD-K73381542-003-23-4,phenylephrine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D","otolaryngology, gastroenterology, cardiology","nasal congestion, hemorrhoids, hypotension","CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1",Launched
BRD-K73383190-001-02-3::2.56::HTS,BRD-K73383190-001-02-3,C646,2.56,HTS,histone acetyltransferase inhibitor,EP300,NA,NA,"CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O",Preclinical
BRD-K73383190-001-03-1::2.5::HTS,BRD-K73383190-001-03-1,C646,2.5,HTS,histone acetyltransferase inhibitor,EP300,NA,NA,"CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O",Preclinical
BRD-K73391359-003-10-2::2.5::HTS,BRD-K73391359-003-10-2,dimethisoquin,2.5,HTS,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73394555-237-01-1::2.5::HTS,BRD-K73394555-237-01-1,oxolinic-acid,2.5,HTS,bacterial DNA gyrase inhibitor,NA,NA,NA,CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12,Preclinical
BRD-K73397362-001-06-6::2.5::HTS,BRD-K73397362-001-06-6,purmorphamine,2.5,HTS,smoothened receptor agonist,SMO,NA,NA,"C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12",Preclinical
BRD-K73425385-065-04-8::2.5::HTS,BRD-K73425385-065-04-8,bekanamycin,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73440166-001-01-3::2.5::HTS,BRD-K73440166-001-01-3,cinaciguat,2.5,HTS,guanylate cyclase activator,"GUCY1A3, GUCY1B3",NA,NA,OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O,Phase 2
BRD-K73469236-001-01-8::2.5::HTS,BRD-K73469236-001-01-8,nedaplatin,2.5,HTS,DNA inhibitor,NA,NA,NA,"N[Pt++]1(N)OCC(=O)O1, N[Pt]1(N)OCC(=O)O1",Launched
BRD-K73477617-001-08-5::2.5::HTS,BRD-K73477617-001-08-5,dibutyl-phthalate,2.5,HTS,NA,TRPA1,NA,NA,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Preclinical
BRD-K73524797-001-01-1::2.5::HTS,BRD-K73524797-001-01-1,ST-1859,2.5,HTS,antiamyloidogenic agent,NA,NA,NA,Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12,Phase 1
BRD-K73529671-001-02-9::2.5::HTS,BRD-K73529671-001-02-9,troxerutin,2.5,HTS,antioxidant,NA,NA,NA,"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K73529671-001-04-5::2.5::HTS,BRD-K73529671-001-04-5,troxerutin,2.5,HTS,antioxidant,NA,NA,NA,"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K73541271-001-03-6::2.5::HTS,BRD-K73541271-001-03-6,etofenamate,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,Launched
BRD-K73589401-001-23-6::2.5::HTS,BRD-K73589401-001-23-6,corticosterone,2.5,HTS,mineralocorticoid receptor agonist,"HSD11B1, NCOA1, NR3C2",NA,NA,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO",Preclinical
BRD-K73589491-001-11-2::2.5::HTS,BRD-K73589491-001-11-2,nizatidine,2.5,HTS,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73642618-001-13-3::2.5::HTS,BRD-K73642618-001-13-3,bromopride,2.5,HTS,dopamine receptor antagonist,DRD2,gastroenterology,"nausea, vomiting, gastroesophageal reflux disease (GERD)",CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,Launched
BRD-K73700643-001-11-2::2.5::HTS,BRD-K73700643-001-11-2,N-acetyltryptamine,2.5,HTS,melatonin receptor agonist,NA,NA,NA,"CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12",Preclinical
BRD-K73771095-001-02-5::2.44::HTS,BRD-K73771095-001-02-5,geniposidic-acid,2.44,HTS,cyclooxygenase inhibitor,NA,NA,NA,"OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K73771095-001-03-3::2.5::HTS,BRD-K73771095-001-03-3,geniposidic-acid,2.5,HTS,cyclooxygenase inhibitor,NA,NA,NA,"OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K73789395-001-10-7::2.5::HTS,BRD-K73789395-001-10-7,ZM-336372,2.5,HTS,RAF inhibitor,"BRAF, LCK, MAPK14, RAF1",NA,NA,"CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1",Preclinical
BRD-K73815512-001-02-5::2.5::HTS,BRD-K73815512-001-02-5,HC-030031,2.5,HTS,TRPA1 channel blocker,TRPA1,NA,NA,CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1,Phase 1
BRD-K73838513-003-05-5::2.5::HTS,BRD-K73838513-003-05-5,cinacalcet,2.5,HTS,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73923631-003-02-9::2.5::HTS,BRD-K73923631-003-02-9,difloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,"skin infections, urinary tract infections","CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1",Launched
BRD-K73982490-001-02-9::2.5::HTS,BRD-K73982490-001-02-9,BI-78D3,2.5,HTS,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73999723-001-11-3::2.5::HTS,BRD-K73999723-001-11-3,telmisartan,2.5,HTS,angiotensin receptor antagonist,"AGTR1, PPARG",cardiology,hypertension,"CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C",Launched
BRD-K74057757-001-01-9::2.5::HTS,BRD-K74057757-001-01-9,indibulin,2.5,HTS,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74065929-001-07-2::2.5::HTS,BRD-K74065929-001-07-2,doramapimod,2.5,HTS,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK13, MAPK14",NA,NA,"Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C",Phase 2
BRD-K74117820-066-10-8::2.5::HTS,BRD-K74117820-066-10-8,nelfinavir,2.5,HTS,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Launched
BRD-K74141488-003-11-2::2.5::HTS,BRD-K74141488-003-11-2,naftifine,2.5,HTS,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74186897-001-12-4::2.5::HTS,BRD-K74186897-001-12-4,cytisine,2.5,HTS,acetylcholine receptor agonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4",neurology/psychiatry,nicotinism,"O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12",Launched
BRD-K74186897-001-13-2::2.5::HTS,BRD-K74186897-001-13-2,cytisine,2.5,HTS,acetylcholine receptor agonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4",neurology/psychiatry,nicotinism,"O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12",Launched
BRD-K74190368-001-04-3::2.5::HTS,BRD-K74190368-001-04-3,resorcinol,2.5,HTS,phosphodiesterase inhibitor,"CA12, CA14, CA2, PTGS1",dermatology,"acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis",Oc1cccc(O)c1,Launched
BRD-K74193284-001-04-8::2.5::HTS,BRD-K74193284-001-04-8,phenylmercuric-acetate,2.5,HTS,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74195153-050-12-1::2.5::HTS,BRD-K74195153-050-12-1,irsogladine,2.5,HTS,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD),"Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl",Launched
BRD-K74227499-001-01-1::2.5::HTS,BRD-K74227499-001-01-1,se-methylselenocysteine,2.5,HTS,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74236708-001-01-9::2.5::HTS,BRD-K74236708-001-01-9,acitazanolast,2.5,HTS,mediator release inhibitor,NA,allergy,allergic rhinitis,"OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1, OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1",Launched
BRD-K74305673-001-06-2::2.5::HTS,BRD-K74305673-001-06-2,IKK-2-inhibitor-V,2.5,HTS,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74339692-001-01-9::2.5::HTS,BRD-K74339692-001-01-9,tamsulosin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),"CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O",Launched
BRD-K74363950-004-01-0::2.5::HTS,BRD-K74363950-004-01-0,aclidinium,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)",OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1,Launched
BRD-K74371986-001-01-7::2.5::HTS,BRD-K74371986-001-01-7,NSI-189,2.5,HTS,neurotrophic agent,NA,NA,NA,CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1,Phase 2
BRD-K74501079-001-18-1::2.5::HTS,BRD-K74501079-001-18-1,azithromycin,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74514084-001-03-9::2.5::HTS,BRD-K74514084-001-03-9,pazopanib,2.5,HTS,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74603273-003-01-1::2.5::HTS,BRD-K74603273-003-01-1,"ICI-118,551",2.5,HTS,adrenergic receptor antagonist,"ADRB2, ADRB3",NA,NA,CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12,Phase 2
BRD-K74664543-213-01-2::2.5::HTS,BRD-K74664543-213-01-2,selenomethionine,2.5,HTS,NA,NA,NA,NA,"C[Se]CCC(N)C(O)=O, C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O",Launched
BRD-K74717603-001-02-2::2.5::HTS,BRD-K74717603-001-02-2,etravirine,2.5,HTS,non-nucleoside reverse transcriptase inhibitor,"CYP2C19, CYP2C9, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N,Launched
BRD-K74763371-002-04-0::2.5::HTS,BRD-K74763371-002-04-0,bosentan,2.5,HTS,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74765201-001-16-7::0.25::HTS,BRD-K74765201-001-16-7,tomelukast,0.25,HTS,leukotriene receptor antagonist,CYSLTR1,NA,NA,CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O,Phase 3
BRD-K74913225-001-12-4::2.5::HTS,BRD-K74913225-001-12-4,brinzolamide,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA5A, CA7",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O",Launched
BRD-K74990253-001-02-8::2.5::HTS,BRD-K74990253-001-02-8,BW-373U86,2.5,HTS,opioid receptor agonist,OPRD1,NA,NA,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1,Preclinical
BRD-K75009076-001-02-1::2.43::HTS,BRD-K75009076-001-02-1,SCH-900776,2.43,HTS,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75024268-001-01-0::2.5::HTS,BRD-K75024268-001-01-0,lesinurad,2.5,HTS,uric acid diuretic,SLC22A12,rheumatology,gout,OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,Launched
BRD-K75037734-003-13-9::2.5::HTS,BRD-K75037734-003-13-9,carbachol,2.5,HTS,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75080769-001-01-6::2.5::HTS,BRD-K75080769-001-01-6,"trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",2.5,HTS,NA,NA,NA,NA,OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1,Preclinical
BRD-K75089421-003-24-5::2.5::HTS,BRD-K75089421-003-24-5,procainamide,2.5,HTS,sodium channel blocker,"DNMT1, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)",CCN(CC)CCNC(=O)c1ccc(N)cc1,Launched
BRD-K75250001-001-01-3::2.5::HTS,BRD-K75250001-001-01-3,tiracizine,2.5,HTS,sodium channel blocker,SCN5A,NA,NA,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1,Withdrawn
BRD-K75282704-001-02-4::2.5::HTS,BRD-K75282704-001-02-4,BL-5583,2.5,HTS,hypercalcaemic agent,NA,NA,NA,OC(=O)c1cc2ccccc2s1,Preclinical
BRD-K75295174-001-05-0::2.5::HTS,BRD-K75295174-001-05-0,alisertib,2.5,HTS,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75308783-001-07-0::2.5::HTS,BRD-K75308783-001-07-0,SAR-245409,2.5,HTS,PI3K inhibitor,"MTOR, PIK3CG",NA,NA,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,Phase 1/Phase 2
BRD-K75352575-001-01-3::2.5::HTS,BRD-K75352575-001-01-3,KPT-276,2.5,HTS,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75360161-001-18-0::2.5::HTS,BRD-K75360161-001-18-0,protionamide,2.5,HTS,NA,NA,infectious disease,tuberculosis,"CCCc1cc(ccn1)C(S)=N, CCCc1cc(ccn1)C(S)=N",Launched
BRD-K75466013-001-14-4::2.5::HTS,BRD-K75466013-001-14-4,benzocaine,2.5,HTS,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75478907-001-02-3::2.5::HTS,BRD-K75478907-001-02-3,GS-39783,2.5,HTS,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75506300-001-01-6::2.5::HTS,BRD-K75506300-001-01-6,NPS-2143,2.5,HTS,calcium receptor antagonist,CASR,NA,NA,"CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N",Preclinical
BRD-K75516118-001-03-3::2.5::HTS,BRD-K75516118-001-03-3,rolipram-R(-),2.5,HTS,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D, PDE5A",NA,NA,"COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1",Preclinical
BRD-K75527158-360-04-9::2.5::HTS,BRD-K75527158-360-04-9,alendronate,2.5,HTS,bone resorption inhibitor,"ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS",orthopedics,osteoporosis,"NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
BRD-K75608666-001-08-3::2.5::HTS,BRD-K75608666-001-08-3,hydroxytoluic-acid,2.5,HTS,NA,NA,NA,NA,Cc1cccc(C(O)=O)c1O,Preclinical
BRD-K75615183-300-03-9::2.5::HTS,BRD-K75615183-300-03-9,talipexole,2.5,HTS,"adrenergic receptor agonist, dopamine receptor agonist","ADRA2A, DRD2, HTR3A",infectious disease,genitial herpes,"Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1",Launched
BRD-K75641298-003-25-0::2.5::HTS,BRD-K75641298-003-25-0,metoclopramide,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","CHRM1, DRD2, HTR3A, HTR3B, HTR4",gastroenterology,"gastroparesis, nausea, vomiting",CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Launched
BRD-K75649340-001-13-1::2.5::HTS,BRD-K75649340-001-13-1,tioguanine,2.5,HTS,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75699339-057-08-1::2.5::HTS,BRD-K75699339-057-08-1,rizatriptan,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12",Launched
BRD-K75844781-003-08-0::2.5::HTS,BRD-K75844781-003-08-0,mCPP,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6",NA,NA,Clc1cccc(c1)N1CCNCC1,Phase 2
BRD-K75855670-001-14-2::2.5::HTS,BRD-K75855670-001-14-2,iodoquinol,2.5,HTS,antiseptic,NA,infectious disease,amebiasis,Oc1c(I)cc(I)c2cccnc12,Launched
BRD-K75868704-001-05-3::2.5::HTS,BRD-K75868704-001-05-3,iopamidol,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,Launched
BRD-K75911534-001-01-6::2.5::HTS,BRD-K75911534-001-01-6,SU014813,2.5,HTS,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75923785-003-02-1::2.5::HTS,BRD-K75923785-003-02-1,scopine,2.5,HTS,NA,NA,NA,NA,"CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21",Launched
BRD-K75956464-237-01-5::2.5::HTS,BRD-K75956464-237-01-5,VCH-916,2.5,HTS,HCV inhibitor,NA,NA,NA,CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1,Phase 1
BRD-K75958195-037-09-4::2.5::HTS,BRD-K75958195-037-09-4,pizotifen,2.5,HTS,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C",neurology/psychiatry,migraine headache,"CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12",Launched
BRD-K75958547-238-01-0::2.5::HTS,BRD-K75958547-238-01-0,pitavastatin,2.5,HTS,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K76011241-001-01-8::2.5::HTS,BRD-K76011241-001-01-8,oseltamivir-phosphate,2.5,HTS,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76022557-003-02-7::2.5::HTS,BRD-K76022557-003-02-7,r(-)-apomorphine,2.5,HTS,dopamine receptor agonist,"DRD2, HTR5A",neurology/psychiatry,Parkinson's Disease,"CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31",Launched
BRD-K76037122-001-02-5::2.5::HTS,BRD-K76037122-001-02-5,guanidine,2.5,HTS,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76064317-001-07-3::2.5::HTS,BRD-K76064317-001-07-3,tyrphostin-AG-1296,2.5,HTS,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76180386-001-01-6::2.5::HTS,BRD-K76180386-001-01-6,JIB04,2.5,HTS,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76205745-237-16-5::2.5::HTS,BRD-K76205745-237-16-5,losartan,2.5,HTS,angiotensin receptor antagonist,AGTR1,"cardiology, nephrology","hypertension, diabetic nephropathy","CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K76210423-001-01-6::2.5::HTS,BRD-K76210423-001-01-6,resiquimod,2.5,HTS,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76239644-001-01-8::2.5::HTS,BRD-K76239644-001-01-8,BMS-690514,2.5,HTS,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76304753-003-20-3::2.5::HTS,BRD-K76304753-003-20-3,phenazopyridine,2.5,HTS,local anesthetic,SCN1A,infectious disease,urinary tract infections,"Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1",Launched
BRD-K76304753-003-21-1::2.5::HTS,BRD-K76304753-003-21-1,phenazopyridine,2.5,HTS,local anesthetic,SCN1A,infectious disease,urinary tract infections,"Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1",Launched
BRD-K76381435-001-08-6::2.5::HTS,BRD-K76381435-001-08-6,nitromide,2.5,HTS,NA,NA,NA,NA,NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O,Launched
BRD-K76406695-001-02-9::2.5::HTS,BRD-K76406695-001-02-9,CCT128930,2.5,HTS,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76452401-001-03-6::2.5::HTS,BRD-K76452401-001-03-6,piperonyl-butoxide,2.5,HTS,cytochrome P450 inhibitor,NA,infectious disease,lice,CCCCOCCOCCOCc1cc2OCOc2cc1CCC,Launched
BRD-K76534306-001-22-7::2.5::HTS,BRD-K76534306-001-22-7,enrofloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,infectious disease,"gram-negative bacterial infections, gram-negative bacterial infections","CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1",Launched
BRD-K76568384-001-02-2::2.5::HTS,BRD-K76568384-001-02-2,PHTPP,2.5,HTS,estrogen receptor antagonist,ESR2,NA,NA,"Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1",Preclinical
BRD-K76592088-001-02-1::2.5::HTS,BRD-K76592088-001-02-1,3-carboxy-4-hydroxyphenylglycine-(R),2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",NA,NA,N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,Preclinical
BRD-K76600340-045-04-9::2.5::HTS,BRD-K76600340-045-04-9,nicotinyl-alcohol-tartrate,2.5,HTS,NA,NA,NA,NA,OCc1cccnc1,Launched
BRD-K76606751-001-01-7::2.5::HTS,BRD-K76606751-001-01-7,mebicar,2.5,HTS,anxiolytic,NA,neurology/psychiatry,anxiety,CN1C2C(N(C)C1=O)N(C)C(=O)N2C,Launched
BRD-K76609936-001-08-4::2.5::HTS,BRD-K76609936-001-08-4,imidacloprid,2.5,HTS,acetylcholine receptor antagonist,CHRFAM7A,NA,NA,[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1,Launched
BRD-K76617868-003-11-9::2.5::HTS,BRD-K76617868-003-11-9,fasudil,2.5,HTS,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1, ROCK2",neurology/psychiatry,cerebral vasospasm,"O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12",Launched
BRD-K76634210-001-14-7::2.5::HTS,BRD-K76634210-001-14-7,idoxuridine,2.5,HTS,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76674262-001-03-3::2.5::HTS,BRD-K76674262-001-03-3,homoharringtonine,2.5,HTS,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76677554-003-02-1::2.5::HTS,BRD-K76677554-003-02-1,AJ76-(+),2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, DRD4",NA,NA,CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K76703230-004-03-3::2.5::HTS,BRD-K76703230-004-03-3,YM-155,2.5,HTS,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::2.5::HTS,BRD-K76703230-004-04-1,YM-155,2.5,HTS,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76775527-001-30-2::2.5::HTS,BRD-K76775527-001-30-2,nimesulide,2.5,HTS,cyclooxygenase inhibitor,"LTF, PLA2G2E, PTGS1, PTGS2","rheumatology, obstetrics/gynecology","osteoarthritis, menstrual pain","CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O",Launched
BRD-K76805682-001-15-9::2.5::HTS,BRD-K76805682-001-15-9,SB-415286,2.5,HTS,glycogen synthase kinase inhibitor,"GSK3A, GSK3B, RPS6KB1",NA,NA,"Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl",Preclinical
BRD-K76810206-001-07-3::2.5::HTS,BRD-K76810206-001-07-3,nicergoline,2.5,HTS,adrenergic receptor antagonist,ADRA1A,"rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis","CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13",Launched
BRD-K76810206-001-08-1::2.5::HTS,BRD-K76810206-001-08-1,nicergoline,2.5,HTS,adrenergic receptor antagonist,ADRA1A,"rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis","CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13",Launched
BRD-K76811153-003-01-3::2.5::HTS,BRD-K76811153-003-01-3,L-Arginine,2.5,HTS,nitric oxide precursor,"ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4","cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology","congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold",N[C@H](CCCNC(N)=N)C(O)=O,Launched
BRD-K76812510-236-14-8::2.5::HTS,BRD-K76812510-236-14-8,metamizole,2.5,HTS,"cyclooxygenase inhibitor, opioid receptor agonist",PTGS1,NA,NA,CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O,Withdrawn
BRD-K76840893-003-02-5::2.5::HTS,BRD-K76840893-003-02-5,RS-17053,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76841105-001-04-7::2.5::HTS,BRD-K76841105-001-04-7,tazarotene,2.5,HTS,retinoid receptor agonist,"RARA, RARB, RARG, RXRB",dermatology,"cosmetic, sunscreen lotion",CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1,Launched
BRD-K76845197-001-05-4::2.5::HTS,BRD-K76845197-001-05-4,sulfanitran,2.5,HTS,NA,NA,NA,NA,CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O,Launched
BRD-K76890464-001-02-3::2.5::HTS,BRD-K76890464-001-02-3,triazolam,2.5,HTS,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12,Withdrawn
BRD-K76908866-001-07-6::2.5::HTS,BRD-K76908866-001-07-6,CP-724714,2.5,HTS,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76953762-001-08-5::2.5::HTS,BRD-K76953762-001-08-5,indoramin,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension",O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Launched
BRD-K76973696-001-12-6::2.01::HTS,BRD-K76973696-001-12-6,tryptanthrin,2.01,HTS,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K77008974-001-03-2::2.5::HTS,BRD-K77008974-001-03-2,WYE-354,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77012840-300-01-6::2.5::HTS,BRD-K77012840-300-01-6,AY-9944,2.5,HTS,hedgehog pathway modulator,NA,NA,NA,Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1,Preclinical
BRD-K77060810-001-01-5::2.5::HTS,BRD-K77060810-001-01-5,AZD1283,2.5,HTS,purinergic receptor antagonist,P2RY12,NA,NA,CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1,Preclinical
BRD-K77115421-001-02-6::2.5::HTS,BRD-K77115421-001-02-6,phthalylsulfacetamide,2.5,HTS,NA,NA,NA,NA,"CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1",Preclinical
BRD-K77171813-034-01-8::2.5::HTS,BRD-K77171813-034-01-8,proxyfan,2.5,HTS,histamine receptor modulator,HRH3,NA,NA,"C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1",Preclinical
BRD-K77245796-003-01-6::2.5::HTS,BRD-K77245796-003-01-6,gamma-aminobutyric-acid,2.5,HTS,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77251551-304-02-9::2.5::HTS,BRD-K77251551-304-02-9,sodium-picosulfate,2.5,HTS,NA,NA,gastroenterology,constipation,OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1,Launched
BRD-K77258318-001-04-6::2.5::HTS,BRD-K77258318-001-04-6,lactulose,2.5,HTS,laxative,NA,gastroenterology,portal-systemic encephalopathy (PSE),OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,Launched
BRD-K77300776-001-02-5::2.5::HTS,BRD-K77300776-001-02-5,choline,2.5,HTS,acetylcholine precursor,"ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2",NA,NA,"C[N+](C)(C)CCO, C[N+](C)(C)CCO",Phase 3
BRD-K77345217-001-05-0::2.5::HTS,BRD-K77345217-001-05-0,gallic-acid,2.5,HTS,"beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP",NA,NA,OC(=O)c1cc(O)c(O)c(O)c1,Preclinical
BRD-K77396579-300-01-0::2.5::HTS,BRD-K77396579-300-01-0,NVP-DPP728,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,NA,NA,O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N,Phase 2
BRD-K77484724-001-02-0::2.5::HTS,BRD-K77484724-001-02-0,adefovir,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12",Launched
BRD-K77552740-004-01-0::2.5::HTS,BRD-K77552740-004-01-0,tiquizium,2.5,HTS,acetylcholine receptor antagonist,NA,neurology/psychiatry,spasms,C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1,Launched
BRD-K77554836-001-11-6::2.57::HTS,BRD-K77554836-001-11-6,triamcinolone,2.57,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-14-0::2.5::HTS,BRD-K77554836-001-14-0,triamcinolone,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77561571-001-01-1::2.5::HTS,BRD-K77561571-001-01-1,topiroxostat,2.5,HTS,xanthine oxidase inhibitor,XDH,"rheumatology, nephrology","gout, hyperuricemia",N#Cc1cc(ccn1)-c1n[nH]c(n1)-c1ccncc1,Launched
BRD-K77597856-003-02-5::2.5::HTS,BRD-K77597856-003-02-5,detomidine,2.5,HTS,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative,Cc1cccc(Cc2c[nH]cn2)c1C,Launched
BRD-K77625799-001-07-7::2.5::HTS,BRD-K77625799-001-07-7,vandetanib,2.5,HTS,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77627880-001-04-0::2.5::HTS,BRD-K77627880-001-04-0,A205804,2.5,HTS,ICAM1 expression inhibitor,"ICAM1, SELE",NA,NA,"Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1",Preclinical
BRD-K77634909-001-03-5::2.5::HTS,BRD-K77634909-001-03-5,AEG3482,2.5,HTS,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77638923-001-02-0::2.5::HTS,BRD-K77638923-001-02-0,CUDC-907,2.5,HTS,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77641333-003-27-1::2.5::HTS,BRD-K77641333-003-27-1,naphazoline,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA2A",ophthalmology,eye irritation,"C(C1=NCCN1)c1cccc2ccccc12, C(C1=NCCN1)c1cccc2ccccc12",Launched
BRD-K77677632-003-02-6::2.5::HTS,BRD-K77677632-003-02-6,SB-200646,2.5,HTS,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77685957-300-09-1::2.5::HTS,BRD-K77685957-300-09-1,dequalinium,2.5,HTS,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77695569-001-30-0::2.5::HTS,BRD-K77695569-001-30-0,tiabendazole,2.5,HTS,angiogenesis inhibitor,NA,infectious disease,"gastrointestinal roundworms, hookworm","c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1",Launched
BRD-K77771411-003-10-7::2.5::HTS,BRD-K77771411-003-10-7,moxonidine,2.5,HTS,imidazoline receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"COc1nc(C)nc(Cl)c1NC1=NCCN1, COc1nc(C)nc(Cl)c1NC1=NCCN1, COc1nc(C)nc(Cl)c1NC1=NCCN1",Launched
BRD-K77791657-001-01-1::2.5::HTS,BRD-K77791657-001-01-1,3-deazaneplanocin-A,2.5,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::2.67::HTS,BRD-K77791657-003-01-7,3-deazaneplanocin-A,2.67,HTS,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77793136-003-03-0::2.5::HTS,BRD-K77793136-003-03-0,hydroxyfasudil,2.5,HTS,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1",NA,NA,Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1,Preclinical
BRD-K77821588-364-01-2::2.5::HTS,BRD-K77821588-364-01-2,azatadine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12",Launched
BRD-K77841042-001-14-1::2.5::HTS,BRD-K77841042-001-14-1,brefeldin-a,2.5,HTS,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77867004-001-02-7::2.5::HTS,BRD-K77867004-001-02-7,U-104,2.5,HTS,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA9",NA,NA,"NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1",Preclinical
BRD-K77908580-001-09-6::2.5::HTS,BRD-K77908580-001-09-6,entinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77925998-050-14-3::2.5::HTS,BRD-K77925998-050-14-3,quipazine,2.5,HTS,serotonin receptor agonist,NA,NA,NA,"C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1",Preclinical
BRD-K77943374-001-02-8::2.5::HTS,BRD-K77943374-001-02-8,NVP-BVU972,2.5,HTS,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77947974-001-16-3::2.5::HTS,BRD-K77947974-001-16-3,fluspirilene,2.5,HTS,dopamine receptor antagonist,"CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A",neurology/psychiatry,schizophrenia,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,Launched
BRD-K77950083-001-03-3::2.5::HTS,BRD-K77950083-001-03-3,UPF-1069,2.5,HTS,PARP inhibitor,PARP2,NA,NA,"O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1",Preclinical
BRD-K77987382-001-13-2::2.5::HTS,BRD-K77987382-001-13-2,mebendazole,2.5,HTS,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K78010432-001-21-5::2.5::HTS,BRD-K78010432-001-21-5,furosemide,2.5,HTS,diuretic,"CA2, GPR35, SLC12A1, SLC12A2","cardiology, rheumatology","edema, hypertension, congestive heart failure, nephrotic syndrome","NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl",Launched
BRD-K78055238-001-01-8::2.5::HTS,BRD-K78055238-001-01-8,LY2090314,2.5,HTS,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78061844-050-01-9::2.5::HTS,BRD-K78061844-050-01-9,4-PPBP,2.5,HTS,sigma receptor ligand,SIGMAR1,NA,NA,"C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1",Preclinical
BRD-K78086729-001-02-7::2.5::HTS,BRD-K78086729-001-02-7,GW-788388,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78096648-001-05-7::2.5::HTS,BRD-K78096648-001-05-7,oxiperomide,2.5,HTS,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78113049-001-16-2::2.5::HTS,BRD-K78113049-001-16-2,enoxacin,2.5,HTS,topoisomerase inhibitor,TOP2A,infectious disease,"urinary tract infections, gonorrhea","CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1",Launched
BRD-K78118466-001-03-3::2.5::HTS,BRD-K78118466-001-03-3,LY2157299,2.5,HTS,TGF beta receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O,Phase 2/Phase 3
BRD-K78122587-300-02-7::2.5::HTS,BRD-K78122587-300-02-7,NNC-55-0396,2.5,HTS,T-type calcium channel blocker,"CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1",Preclinical
BRD-K78126613-001-28-5::2.5::HTS,BRD-K78126613-001-28-5,menadione,2.5,HTS,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78177893-001-02-4::2.5::HTS,BRD-K78177893-001-02-4,A-674563,2.5,HTS,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78294846-001-12-4::2.5::HTS,BRD-K78294846-001-12-4,osthol,2.5,HTS,calcium channel blocker,NA,NA,NA,COc1ccc2ccc(=O)oc2c1CC=C(C)C,Preclinical
BRD-K78299798-001-02-2::2.5::HTS,BRD-K78299798-001-02-2,mepiroxol,2.5,HTS,NA,NA,NA,NA,"OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1",Preclinical
BRD-K78303961-001-02-3::2.5::HTS,BRD-K78303961-001-02-3,glycitein,2.5,HTS,tumor necrosis factor release inhibitor,TNF,NA,NA,COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O,Phase 3
BRD-K78318619-001-02-7::2.5::HTS,BRD-K78318619-001-02-7,PF-4981517,2.5,HTS,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78342372-001-02-4::2.5::HTS,BRD-K78342372-001-02-4,hematoxylin,2.5,HTS,NA,NA,NA,NA,"Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O, Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O",Preclinical
BRD-K78431006-001-10-2::2.5::HTS,BRD-K78431006-001-10-2,crizotinib,2.5,HTS,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78455053-001-01-2::2.5::HTS,BRD-K78455053-001-01-2,wnt-c59,2.5,HTS,porcupine inhibitor,PORCN,NA,NA,"Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1",Preclinical
BRD-K78485176-001-07-8::2.5::HTS,BRD-K78485176-001-07-8,olmesartan-medoxomil,2.5,HTS,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Launched
BRD-K78496197-001-03-9::2.5::HTS,BRD-K78496197-001-03-9,SCS,2.5,HTS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78513633-001-15-7::2.5::HTS,BRD-K78513633-001-15-7,lonidamine,2.5,HTS,glucokinase inhibitor,GCK,NA,NA,"OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12",Launched
BRD-K78567475-001-01-4::2.5::HTS,BRD-K78567475-001-01-4,dolastatin-10,2.5,HTS,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78633253-001-10-3::2.5::HTS,BRD-K78633253-001-10-3,EXO-1,2.5,HTS,ARF inhibitor,NA,NA,NA,"COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1",Preclinical
BRD-K78637815-001-02-2::2.5::HTS,BRD-K78637815-001-02-2,LY320135,2.5,HTS,cannabinoid receptor antagonist,CNR1,NA,NA,COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N,Preclinical
BRD-K78643075-001-11-6::2.5::HTS,BRD-K78643075-001-11-6,bromperidol,2.5,HTS,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,Launched
BRD-K78659596-001-03-9::2.5::HTS,BRD-K78659596-001-03-9,ixazomib,2.5,HTS,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78666826-003-01-6::2.5::HTS,BRD-K78666826-003-01-6,procaterol,2.5,HTS,adrenergic receptor agonist,ADRB2,pulmonary,asthma,"CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12",Launched
BRD-K78692225-001-24-5::2.5::HTS,BRD-K78692225-001-24-5,leflunomide,2.5,HTS,"dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor","AHR, DHODH, PTK2B",rheumatology,rheumatoid arthritis,"Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-K78720403-001-01-6::2.5::HTS,BRD-K78720403-001-01-6,SB-328437,2.5,HTS,CCR antagonist,NA,NA,NA,"COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12",Preclinical
BRD-K78781788-003-01-9::2.5::HTS,BRD-K78781788-003-01-9,barnidipine,2.5,HTS,calcium channel blocker,NA,cardiology,hypertension,COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1,Launched
BRD-K78789465-001-01-6::2.5::HTS,BRD-K78789465-001-01-6,pentagastrin,2.5,HTS,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-02-4::2.5::HTS,BRD-K78789465-001-02-4,pentagastrin,2.5,HTS,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78809024-001-05-7::2.5::HTS,BRD-K78809024-001-05-7,SB-590885,2.5,HTS,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78815826-001-14-6::2.5::HTS,BRD-K78815826-001-14-6,suxibuzone,2.5,HTS,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78844995-001-02-6::2.5::HTS,BRD-K78844995-001-02-6,N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide,2.5,HTS,sigma receptor ligand,NA,NA,NA,Ic1ccc(cc1)C(=O)NCCN1CCCCC1,Preclinical
BRD-K78941306-001-02-4::2.5::HTS,BRD-K78941306-001-02-4,SB-742457,2.5,HTS,serotonin receptor antagonist,HTR6,NA,NA,"O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1",Phase 3
BRD-K78959463-001-13-2::2.5::HTS,BRD-K78959463-001-13-2,FPL-64176,2.5,HTS,calcium channel activator,"CACNA1C, CACNA1S",NA,NA,"COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1",Preclinical
BRD-K78960041-001-03-2::2.5::HTS,BRD-K78960041-001-03-2,oxaliplatin,2.5,HTS,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::2.54::HTS,BRD-K78960041-001-05-7,oxaliplatin,2.54,HTS,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K79092138-001-11-0::2.5::HTS,BRD-K79092138-001-11-0,nitrofurazone,2.5,HTS,bacterial DNA inhibitor,NA,infectious disease,first-aid antibiotic,"NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O",Launched
BRD-K79095980-001-09-6::2.5::HTS,BRD-K79095980-001-09-6,broxuridine,2.5,HTS,antimetabolite,NA,NA,NA,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O,Phase 2
BRD-K79102359-003-01-6::2.5::HTS,BRD-K79102359-003-01-6,idalopirdine,2.5,HTS,serotonin receptor antagonist,HTR6,NA,NA,FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1,Phase 3
BRD-K79116891-003-15-1::2.5::HTS,BRD-K79116891-003-15-1,proxymetacaine,2.5,HTS,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,anesthetic,"CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC",Launched
BRD-K79124250-001-08-9::2.5::HTS,BRD-K79124250-001-08-9,ioxaglic-acid,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I,Launched
BRD-K79131256-001-17-9::2.5::HTS,BRD-K79131256-001-17-9,albendazole,2.5,HTS,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79132813-001-09-0::2.5::HTS,BRD-K79132813-001-09-0,pibenzimol,2.5,HTS,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K79145628-001-05-5::2.5::HTS,BRD-K79145628-001-05-5,nimorazole,2.5,HTS,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145749-003-02-2::2.5::HTS,BRD-K79145749-003-02-2,dibenzepine,2.5,HTS,norepinephrine reputake inhibitor,NA,NA,NA,CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O,Preclinical
BRD-K79239947-001-06-8::2.5::HTS,BRD-K79239947-001-06-8,PF-573228,2.5,HTS,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79254416-001-22-6::2.5::HTS,BRD-K79254416-001-22-6,decitabine,2.5,HTS,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79259477-001-04-9::2.5::HTS,BRD-K79259477-001-04-9,NVP-BHG712,2.5,HTS,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79277568-003-04-7::2.5::HTS,BRD-K79277568-003-04-7,methoxyamine,2.5,HTS,DNA repair enzyme inhibitor,APEX1,NA,NA,CON,Phase 2
BRD-K79315489-001-07-8::2.5::HTS,BRD-K79315489-001-07-8,erythritol,2.5,HTS,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79404599-001-09-3::2.5::HTS,BRD-K79404599-001-09-3,enzastaurin,2.5,HTS,PKC inhibitor,"AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG",NA,NA,Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12,Phase 3
BRD-K79425933-001-09-3::2.5::HTS,BRD-K79425933-001-09-3,benperidol,2.5,HTS,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,Launched
BRD-K79437791-001-05-7::2.5::HTS,BRD-K79437791-001-05-7,acetyl-farnesyl-cysteine,2.5,HTS,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV),"CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O, CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O",Launched
BRD-K79501723-001-04-6::2.5::HTS,BRD-K79501723-001-04-6,cyclizine,2.5,HTS,histamine receptor modulator,"HRH1, SULT1E1","gastroenterology, neurology/psychiatry","nausea, vomiting, vertigo, motion sickness","CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K79555887-001-01-0::2.5::HTS,BRD-K79555887-001-01-0,RI-1,2.5,HTS,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79584249-001-01-3::2.5::HTS,BRD-K79584249-001-01-3,CGM097,2.5,HTS,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79595931-312-01-3::2.5::HTS,BRD-K79595931-312-01-3,bavisant,2.5,HTS,histamine receptor antagonist,HRH3,NA,NA,O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1,Phase 2
BRD-K79602928-003-19-9::2.5::HTS,BRD-K79602928-003-19-9,metformin,2.5,HTS,insulin sensitizer,"ACACB, PRKAB1",endocrinology,diabetes mellitus,"CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N",Launched
BRD-K79612754-001-19-1::2.62::HTS,BRD-K79612754-001-19-1,inosine,2.62,HTS,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-21-7::2.5::HTS,BRD-K79612754-001-21-7,inosine,2.5,HTS,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79633074-001-01-8::2.5::HTS,BRD-K79633074-001-01-8,xilobam,2.5,HTS,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79684402-300-02-8::2.5::HTS,BRD-K79684402-300-02-8,Ro-10-5824,2.5,HTS,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79711234-001-18-3::2.5::HTS,BRD-K79711234-001-18-3,thiamphenicol,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,pelvic inflammatory disease,"CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl",Launched
BRD-K79753741-001-01-7::2.5::HTS,BRD-K79753741-001-01-7,UBP-302,2.5,HTS,glutamate receptor antagonist,GRIK1,NA,NA,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O",Preclinical
BRD-K79759585-048-04-8::2.5::HTS,BRD-K79759585-048-04-8,sildenafil,2.5,HTS,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3",cardiology,hypertension,"CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1",Launched
BRD-K79884267-001-01-4::2.5::HTS,BRD-K79884267-001-01-4,retinaldehyde,2.5,HTS,NA,NA,dermatology,cosmetic,CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O,Launched
BRD-K79892937-001-02-5::2.5::HTS,BRD-K79892937-001-02-5,phenolsulfonphthalein,2.5,HTS,NA,NA,NA,NA,Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1,Launched
BRD-K79905821-004-03-6::2.5::HTS,BRD-K79905821-004-03-6,gabazine,2.5,HTS,GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2",NA,NA,"COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1",Preclinical
BRD-K79930101-300-03-7::2.5::HTS,BRD-K79930101-300-03-7,GW-583340,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79966802-034-01-2::2.5::HTS,BRD-K79966802-034-01-2,rivanicline,2.5,HTS,acetylcholine receptor agonist,"CHRNA4, CHRNB2, CXCL8",NA,NA,CNCC\C=C\c1cccnc1,Phase 2
BRD-K79989959-001-01-4::2.5::HTS,BRD-K79989959-001-01-4,nesbuvir,2.5,HTS,RNA polymerase inhibitor,NA,NA,NA,CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1,Phase 2
BRD-K80025777-001-01-4::2.5::HTS,BRD-K80025777-001-01-4,"cis-9,trans-11-Conjugated-linoleic-acid",2.5,HTS,NA,NA,NA,NA,CCCCCC\C=C\C=C/CCCCCCCC(O)=O,Launched
BRD-K80028314-303-02-6::2.5::HTS,BRD-K80028314-303-02-6,alpha-methylhistamine-dihydrobromide-(R)-(-),2.5,HTS,histamine receptor agonist,HRH3,NA,NA,C[C@@H](N)Cc1c[nH]cn1,Preclinical
BRD-K80036624-001-04-0::2.5::HTS,BRD-K80036624-001-04-0,clopidol,2.5,HTS,NA,NA,infectious disease,coccidiosis,Cc1nc(C)c(Cl)c(O)c1Cl,Launched
BRD-K80043866-236-01-1::2.5::HTS,BRD-K80043866-236-01-1,sodium-gualenate,2.5,HTS,antacid,NA,NA,NA,CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O,Launched
BRD-K80060353-303-03-9::2.46::HTS,BRD-K80060353-303-03-9,IEM1754,2.46,HTS,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80082640-001-01-0::2.5::HTS,BRD-K80082640-001-01-0,otamixaban,2.5,HTS,coagulation factor inhibitor,F10,NA,NA,COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1,Phase 3
BRD-K80129304-001-08-1::2.5::HTS,BRD-K80129304-001-08-1,uracil,2.5,HTS,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80262108-001-07-0::2.5::HTS,BRD-K80262108-001-07-0,amifampridine,2.5,HTS,potassium channel blocker,NA,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),Nc1ccncc1N,Launched
BRD-K80267133-001-17-7::2.5::HTS,BRD-K80267133-001-17-7,aminosalicylate,2.5,HTS,cyclooxygenase inhibitor,"ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2",gastroenterology,"inflammatory bowel disease, ulcerative colitis","Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1",Launched
BRD-K80267133-001-19-3::2.5::HTS,BRD-K80267133-001-19-3,aminosalicylate,2.5,HTS,cyclooxygenase inhibitor,"ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2",gastroenterology,"inflammatory bowel disease, ulcerative colitis","Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1",Launched
BRD-K80315159-051-02-0::2.5::HTS,BRD-K80315159-051-02-0,DPPE,2.5,HTS,histamine receptor antagonist,"ABCB1, HRH1",NA,NA,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,Phase 3
BRD-K80343549-001-02-6::2.5::HTS,BRD-K80343549-001-02-6,TAK-285,2.5,HTS,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80353138-001-12-1::2.5::HTS,BRD-K80353138-001-12-1,silibinin,2.5,HTS,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis,"COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O",Launched
BRD-K80396088-001-12-0::2.5::HTS,BRD-K80396088-001-12-0,gliquidone,2.5,HTS,sulfonylurea,"ABCC8, KCNJ10, KCNJ8",endocrinology,diabetes mellitus,COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C,Launched
BRD-K80431395-001-07-3::2.49::HTS,BRD-K80431395-001-07-3,triciribine,2.49,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-09-9::2.5::HTS,BRD-K80431395-001-09-9,triciribine,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80451230-051-02-6::2.5::HTS,BRD-K80451230-051-02-6,zamifenacin,2.5,HTS,acetylcholine receptor antagonist,CHRM3,NA,NA,"C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1",Phase 3
BRD-K80480517-001-02-4::2.5::HTS,BRD-K80480517-001-02-4,repsox,2.5,HTS,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80608265-001-01-6::2.5::HTS,BRD-K80608265-001-01-6,erteberel,2.5,HTS,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80639402-003-02-9::2.5::HTS,BRD-K80639402-003-02-9,SB-258585,2.5,HTS,serotonin receptor antagonist,HTR6,NA,NA,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,Preclinical
BRD-K80653534-001-01-7::2.5::HTS,BRD-K80653534-001-01-7,N-acetyl-D-glucosamine,2.5,HTS,NA,"B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP",NA,NA,CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,Phase 2/Phase 3
BRD-K80700417-001-04-2::2.5::HTS,BRD-K80700417-001-04-2,SGI-1776,2.5,HTS,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80725821-300-02-9::2.5::HTS,BRD-K80725821-300-02-9,RS-16566,2.5,HTS,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80778372-001-02-5::2.5::HTS,BRD-K80778372-001-02-5,Ro-19-4605,2.5,HTS,NA,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C",Preclinical
BRD-K80935598-001-01-1::2.5::HTS,BRD-K80935598-001-01-1,AZ191,2.5,HTS,DYRK inhibitor,DYRK1B,NA,NA,"COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1",Preclinical
BRD-K81016934-001-02-0::2.5::HTS,BRD-K81016934-001-02-0,INC-280,2.5,HTS,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81062487-001-05-8::2.5::HTS,BRD-K81062487-001-05-8,taurocholate,2.5,HTS,G protein-coupled receptor agonist,"CEL, FABP6, SLCO1C1",NA,NA,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,Phase 1
BRD-K81074237-001-02-3::2.5::HTS,BRD-K81074237-001-02-3,azilsartan,2.5,HTS,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81092066-311-01-6::2.5::HTS,BRD-K81092066-311-01-6,phenacaine,2.5,HTS,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1,Launched
BRD-K81101512-234-01-9::2.5::HTS,BRD-K81101512-234-01-9,fosfomycin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,urinary tract infections,"C[C@@H]1O[C@@H]1P(O)(O)=O, CC1OC1P(O)(O)=O",Launched
BRD-K81128206-003-24-4::2.5::HTS,BRD-K81128206-003-24-4,edrophonium,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,CC[N+](C)(C)c1cccc(O)c1,Launched
BRD-K81130846-001-17-4::2.5::HTS,BRD-K81130846-001-17-4,salicylamide,2.5,HTS,analgesic agent,NA,"neurology/psychiatry, endocrinology","pain relief, fever",NC(=O)c1ccccc1O,Launched
BRD-K81136890-003-01-6::2.5::HTS,BRD-K81136890-003-01-6,leucylleucine-methyl-ester,2.5,HTS,NA,NA,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C,Phase 2
BRD-K81144366-003-19-7::2.5::HTS,BRD-K81144366-003-19-7,moxisylyte,2.5,HTS,adrenergic receptor antagonist,NA,NA,NA,CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C,Withdrawn
BRD-K81197548-003-01-4::2.5::HTS,BRD-K81197548-003-01-4,NSC-632839,2.5,HTS,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81225797-001-02-3::2.5::HTS,BRD-K81225797-001-02-3,SCH-58261,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81272440-236-13-5::2.5::HTS,BRD-K81272440-236-13-5,dantrolene,2.5,HTS,calcium channel blocker,"RYR1, RYR3","neurology/psychiatry, endocrinology","spasms, malignant hyperthermia (MH)","[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1",Launched
BRD-K81316007-001-01-8::2.5::HTS,BRD-K81316007-001-01-8,4-mu-8C,2.5,HTS,IRE1 inhibitor,ERN1,NA,NA,Cc1cc(=O)oc2c(C=O)c(O)ccc12,Preclinical
BRD-K81326768-001-04-0::2.5::HTS,BRD-K81326768-001-04-0,zomepirac,2.5,HTS,prostaglandin synthesis inhibitor,PTGDR2,NA,NA,"Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1",Withdrawn
BRD-K81330143-001-04-8::2.38::HTS,BRD-K81330143-001-04-8,tideglusib,2.38,HTS,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81332461-001-01-4::2.5::HTS,BRD-K81332461-001-01-4,maxacalcitol,2.5,HTS,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81376179-001-04-8::2.5::HTS,BRD-K81376179-001-04-8,TCS-359,2.5,HTS,FLT3 inhibitor,FLT3,NA,NA,"COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O",Preclinical
BRD-K81418486-001-47-5::2.5::HTS,BRD-K81418486-001-47-5,vorinostat,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81447180-003-21-4::2.58::HTS,BRD-K81447180-003-21-4,lincomycin,2.58,HTS,bacterial 30S ribosomal subunit inhibitor,NA,gastroenterology,enteritis,"CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O",Launched
BRD-K81458380-001-04-9::2.5::HTS,BRD-K81458380-001-04-9,CX-4945,2.5,HTS,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81473043-001-14-6::2.5::HTS,BRD-K81473043-001-14-6,tanespimycin,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473089-003-26-1::2.5::HTS,BRD-K81473089-003-26-1,tacrine,2.5,HTS,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,Alzheimer's disease,"Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12",Launched
BRD-K81528515-001-13-8::2.5::HTS,BRD-K81528515-001-13-8,nilotinib,2.5,HTS,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81548480-001-01-2::2.5::HTS,BRD-K81548480-001-01-2,AC-264613,2.5,HTS,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81572616-001-01-9::2.5::HTS,BRD-K81572616-001-01-9,CK-636,2.5,HTS,actin related protein inhibitor,"ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5",NA,NA,"Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1",Preclinical
BRD-K81613478-001-01-8::2.5::HTS,BRD-K81613478-001-01-8,gastrodin,2.5,HTS,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81623406-004-08-3::2.5::HTS,BRD-K81623406-004-08-3,EIT-hydrobromide,2.5,HTS,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CCSC(N)=N,Preclinical
BRD-K81645297-236-01-1::2.5::HTS,BRD-K81645297-236-01-1,NKP-1339,2.5,HTS,HSP inhibitor,NA,NA,NA,"Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",Phase 1
BRD-K81645907-001-01-1::2.5::HTS,BRD-K81645907-001-01-1,captamine,2.5,HTS,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81647657-001-04-3::2.5::HTS,BRD-K81647657-001-04-3,3-methyladenine,2.5,HTS,PI3K inhibitor,PI3,NA,NA,"Cn1cnc(=N)c2nc[nH]c12, Cn1cnc(=N)c2nc[nH]c12",Preclinical
BRD-K81672972-001-03-1::2.5::HTS,BRD-K81672972-001-03-1,dinoprost,2.5,HTS,prostacyclin analog,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R",obstetrics/gynecology,labor induction,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,Launched
BRD-K81694556-003-01-9::2.5::HTS,BRD-K81694556-003-01-9,VTP-27999,2.5,HTS,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81728688-001-04-4::2.5::HTS,BRD-K81728688-001-04-4,WZ8040,2.5,HTS,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81729199-001-02-8::2.5::HTS,BRD-K81729199-001-02-8,AQ-RA741,2.5,HTS,acetylcholine receptor antagonist,CHRM2,NA,NA,"CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1",Preclinical
BRD-K81795818-019-01-4::2.5::HTS,BRD-K81795818-019-01-4,exherin,2.5,HTS,cadherin antagonist,CDH2,NA,NA,CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O,Phase 2
BRD-K81801188-001-02-8::2.5::HTS,BRD-K81801188-001-02-8,PP-121,2.5,HTS,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81807412-001-10-6::2.5::HTS,BRD-K81807412-001-10-6,N6-methyladenosine,2.5,HTS,NA,NA,NA,NA,CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Preclinical
BRD-K81839095-001-25-1::2.6::HTS,BRD-K81839095-001-25-1,estrone,2.6,HTS,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::2.5::HTS,BRD-K81839095-001-30-1,estrone,2.5,HTS,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81855038-003-13-9::2.5::HTS,BRD-K81855038-003-13-9,roxatidine-acetate,2.5,HTS,histamine receptor antagonist,HRH2,gastroenterology,"Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis","CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1",Launched
BRD-K81876028-300-02-0::2.5::HTS,BRD-K81876028-300-02-0,CP-93129,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,Preclinical
BRD-K81916719-001-13-9::2.5::HTS,BRD-K81916719-001-13-9,triclabendazole,2.5,HTS,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81957469-001-01-0::2.5::HTS,BRD-K81957469-001-01-0,semagacestat,2.5,HTS,gamma secretase inhibitor,PSEN1,NA,NA,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O,Phase 3
BRD-K82002057-001-01-2::2.5::HTS,BRD-K82002057-001-01-2,DFB,2.5,HTS,glutamate receptor agonist,GRM5,NA,NA,Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1,Preclinical
BRD-K82027074-001-07-5::2.5::HTS,BRD-K82027074-001-07-5,2-hydroxyflutamide,2.5,HTS,androgen receptor antagonist,AR,NA,NA,"CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Phase 1/Phase 2
BRD-K82028950-300-02-9::2.5::HTS,BRD-K82028950-300-02-9,CGH2466,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1",Preclinical
BRD-K82036761-003-20-3::2.5::HTS,BRD-K82036761-003-20-3,sertraline,2.5,HTS,selective serotonin reuptake inhibitor (SSRI),"SLC6A3, SLC6A4","neurology/psychiatry, obstetrics/gynecology","depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder","CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12",Launched
BRD-K82091397-001-03-0::2.5::HTS,BRD-K82091397-001-03-0,SB-239063,2.5,HTS,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82104468-001-05-0::2.5::HTS,BRD-K82104468-001-05-0,ethyl-vanillin,2.5,HTS,NA,NA,NA,NA,CCOc1cc(C=O)ccc1O,Preclinical
BRD-K82122102-323-01-1::2.5::HTS,BRD-K82122102-323-01-1,amfenac,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82135108-001-04-3::2.5::HTS,BRD-K82135108-001-04-3,elesclomol,2.5,HTS,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82142815-001-19-1::2.5::HTS,BRD-K82142815-001-19-1,betamipron,2.5,HTS,panipenem uptake inhibitor,NA,nephrology,renal toxicity,"OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1",Launched
BRD-K82143716-001-19-9::2.5::HTS,BRD-K82143716-001-19-9,flucytosine,2.5,HTS,other antifungal,DNMT1,infectious disease,"bacterial septicemia, endocarditis, urinary tract infections, meningitis","Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F",Launched
BRD-K82164249-001-03-5::2.5::HTS,BRD-K82164249-001-03-5,andarine,2.5,HTS,androgen receptor modulator,AR,NA,NA,CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1,Phase 1
BRD-K82166906-236-02-8::2.5::HTS,BRD-K82166906-236-02-8,sodium-oxybate,2.5,HTS,benzodiazepine receptor agonist,"GABRB1, HCAR1, SLC52A2",neurology/psychiatry,narcolepsy,OCCCC(O)=O,Launched
BRD-K82181219-001-04-3::2.5::HTS,BRD-K82181219-001-04-3,pyritinol,2.5,HTS,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82225283-001-03-1::2.5::HTS,BRD-K82225283-001-03-1,isosorbide-mononitrate,2.5,HTS,nitric oxide stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,"angina pectoris, coronary artery disease (CAD)",O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O,Launched
BRD-K82234479-001-09-4::2.5::HTS,BRD-K82234479-001-09-4,tramiprosate,2.5,HTS,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,NCCCS(O)(=O)=O,Phase 3
BRD-K82236108-001-04-9::2.5::HTS,BRD-K82236108-001-04-9,"N-methyl-(-)ephedrine-[1r,2s]",2.5,HTS,NA,NA,NA,NA,C[C@@H]([C@H](O)c1ccccc1)N(C)C,Preclinical
BRD-K82236179-213-01-0::2.5::HTS,BRD-K82236179-213-01-0,dicoumarol,2.5,HTS,NADPH inhibitor,"CRYZ, NQO1, VKORC1",hematology,deep vein thrombosis (DVT),Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12,Launched
BRD-K82244583-001-01-3::2.5::HTS,BRD-K82244583-001-01-3,MEK162,2.5,HTS,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82255054-001-15-9::2.5::HTS,BRD-K82255054-001-15-9,propofol,2.5,HTS,benzodiazepine receptor agonist,"FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A",neurology/psychiatry,anesthetic,"CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O",Launched
BRD-K82343404-003-02-4::2.5::HTS,BRD-K82343404-003-02-4,adrenalone,2.5,HTS,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage,"CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1",Launched
BRD-K82357231-001-17-5::2.5::HTS,BRD-K82357231-001-17-5,desloratadine,2.5,HTS,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1",Launched
BRD-K82381502-003-23-1::2.5::HTS,BRD-K82381502-003-23-1,acetylcholine,2.5,HTS,acetylcholine receptor agonist,"ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","neurology/psychiatry, gastroenterology, pulmonary","drowsiness, fatigue, headache, indigestion, chest congestion","CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C",Launched
BRD-K82421491-001-02-6::2.5::HTS,BRD-K82421491-001-02-6,IPAG,2.5,HTS,NA,NA,NA,NA,Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1,Preclinical
BRD-K82467063-001-02-7::2.5::HTS,BRD-K82467063-001-02-7,SB-271046,2.5,HTS,serotonin receptor antagonist,HTR6,NA,NA,"COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1",Phase 1
BRD-K82484965-003-03-5::2.5::HTS,BRD-K82484965-003-03-5,carmoxirole,2.5,HTS,dopamine receptor agonist,DRD2,NA,NA,"OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1",Phase 2
BRD-K82522873-001-01-1::2.5::HTS,BRD-K82522873-001-01-1,N6022,2.5,HTS,alcohol dehydrogenase inhibitor,ADH5,NA,NA,Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O,Phase 1/Phase 2
BRD-K82562631-236-04-6::2.5::HTS,BRD-K82562631-236-04-6,tolmetin,2.5,HTS,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C",Launched
BRD-K82603084-408-01-1::2.5::HTS,BRD-K82603084-408-01-1,ethylenediaminetetraacetic-acid,2.5,HTS,PKC inhibitor,NA,neurology/psychiatry,metal toxicity,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,Launched
BRD-K82677201-001-01-6::2.5::HTS,BRD-K82677201-001-01-6,almitrine,2.5,HTS,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD),Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1,Launched
BRD-K82731415-001-07-0::2.5::HTS,BRD-K82731415-001-07-0,olomoucine,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK5, MAPK1",NA,NA,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,Preclinical
BRD-K82746043-001-15-1::2.5::HTS,BRD-K82746043-001-15-1,navitoclax,2.5,HTS,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82767007-001-01-1::2.5::HTS,BRD-K82767007-001-01-1,dazoxiben,2.5,HTS,thromboxane synthase inhibitor,TBXAS1,NA,NA,OC(=O)c1ccc(OCCn2ccnc2)cc1,Phase 2
BRD-K82795137-001-26-2::2.5::HTS,BRD-K82795137-001-26-2,loratadine,2.5,HTS,histamine receptor antagonist,HRH1,"allergy, neurology/psychiatry","allergic rhinitis, itching","CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12",Launched
BRD-K82800842-001-01-9::2.5::HTS,BRD-K82800842-001-01-9,inositol-hexanicotinate,2.5,HTS,NA,NA,"dermatology, cardiology, rheumatology, neurology/psychiatry","statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)",O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1,Launched
BRD-K82818427-001-02-2::2.39::HTS,BRD-K82818427-001-02-2,batimastat,2.39,HTS,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::2.5::HTS,BRD-K82818427-001-04-8,batimastat,2.5,HTS,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82823076-001-02-6::2.5::HTS,BRD-K82823076-001-02-6,Ro-15-4513,2.5,HTS,NA,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",NA,NA,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-],Preclinical
BRD-K82823804-001-04-1::2.5::HTS,BRD-K82823804-001-04-1,PD-407824,2.5,HTS,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82846253-001-15-4::2.5::HTS,BRD-K82846253-001-15-4,repaglinide,2.5,HTS,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82850175-001-01-1::2.5::HTS,BRD-K82850175-001-01-1,navarixin,2.5,HTS,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82861010-001-02-5::2.5::HTS,BRD-K82861010-001-02-5,daclatasvir,2.5,HTS,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82903013-001-01-4::2.5::HTS,BRD-K82903013-001-01-4,"3,3'-dichlorobenzaldazine",2.5,HTS,glutamate receptor allosteric ligand,GRM5,NA,NA,Clc1cccc(c1)\C=N\N=C\c1cccc(Cl)c1,Preclinical
BRD-K82928847-001-04-7::2.5::HTS,BRD-K82928847-001-04-7,ACY-1215,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928892-001-02-5::2.46::HTS,BRD-K82928892-001-02-5,doxercalciferol,2.46,HTS,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82941592-238-04-5::2.5::HTS,BRD-K82941592-238-04-5,rosuvastatin,2.5,HTS,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis","CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O",Launched
BRD-K82960980-003-01-9::2.5::HTS,BRD-K82960980-003-01-9,ceftiofur,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"pneumonia, respiratory tract infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K82960980-003-02-7::2.36::HTS,BRD-K82960980-003-02-7,ceftiofur,2.36,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"pneumonia, respiratory tract infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1",Launched
BRD-K82967685-300-01-2::2.5::HTS,BRD-K82967685-300-01-2,mirodenafil,2.5,HTS,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,Launched
BRD-K82983861-001-04-3::2.5::HTS,BRD-K82983861-001-04-3,GW-0742,2.5,HTS,PPAR receptor agonist,PPARD,NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F",Preclinical
BRD-K83003151-057-02-4::2.35::HTS,BRD-K83003151-057-02-4,alogliptin,2.35,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83022601-001-01-0::2.5::HTS,BRD-K83022601-001-01-0,CI-844,2.5,HTS,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83023055-001-02-7::2.5::HTS,BRD-K83023055-001-02-7,GR-135531,2.5,HTS,melatonin receptor agonist,NA,NA,NA,COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1,Preclinical
BRD-K83036479-001-09-2::2.5::HTS,BRD-K83036479-001-09-2,salicylanilide,2.5,HTS,other antibiotic,NA,NA,NA,"Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1",Preclinical
BRD-K83063356-003-02-5::2.5::HTS,BRD-K83063356-003-02-5,RS-102895,2.5,HTS,CCR antagonist,CCR2,NA,NA,"FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1",Preclinical
BRD-K83064458-001-23-0::2.5::HTS,BRD-K83064458-001-23-0,etofylline,2.5,HTS,adenosine receptor antagonist,ADORA1,pulmonary,"asthma, bronchitis",Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,Launched
BRD-K83186168-001-01-8::2.5::HTS,BRD-K83186168-001-01-8,AZD1981,2.5,HTS,CRTH receptor antagonist,PTGDR2,NA,NA,CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12,Phase 2
BRD-K83189926-001-03-1::2.5::HTS,BRD-K83189926-001-03-1,UNC1215,2.5,HTS,L3MBTL antagonist,L3MBTL3,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1",Preclinical
BRD-K83192048-050-02-7::2.5::HTS,BRD-K83192048-050-02-7,dimethindene-(S)-(+),2.5,HTS,acetylcholine receptor antagonist,HRH1,NA,NA,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1",Preclinical
BRD-K83245588-001-01-4::2.5::HTS,BRD-K83245588-001-01-4,pilsicainide,2.5,HTS,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Launched
BRD-K83257731-003-23-5::2.5::HTS,BRD-K83257731-003-23-5,chloropyramine,2.5,HTS,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83322645-050-01-9::2.5::HTS,BRD-K83322645-050-01-9,L-693403,2.5,HTS,"sigma receptor agonist, sigma receptor antagonist","DRD2, SIGMAR1",NA,NA,C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1,Preclinical
BRD-K83335125-001-07-0::2.5::HTS,BRD-K83335125-001-07-0,chloroxoquinoline,2.5,HTS,NA,NA,NA,NA,Oc1ccnc2cc(Cl)ccc12,Launched
BRD-K83359602-001-02-3::2.5::HTS,BRD-K83359602-001-02-3,barbital,2.5,HTS,sedative,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2",neurology/psychiatry,"sedative, seizures",CCC1(CC)C(=O)NC(=O)NC1=O,Launched
BRD-K83405785-001-01-5::2.5::HTS,BRD-K83405785-001-01-5,pimavanserin,2.5,HTS,serotonin receptor inverse agonist,"DRD2, HTR2A",NA,NA,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,Launched
BRD-K83459933-001-05-4::2.5::HTS,BRD-K83459933-001-05-4,sinomenine,2.5,HTS,angiogenesis inhibitor,NA,NA,NA,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,Preclinical
BRD-K83508485-001-02-7::2.5::HTS,BRD-K83508485-001-02-7,FK-888,2.5,HTS,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83551379-001-01-8::2.5::HTS,BRD-K83551379-001-01-8,levodropropizine,2.5,HTS,antitussive,NA,pulmonary,cough suppressant,"OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1",Launched
BRD-K83551379-001-02-6::2.5::HTS,BRD-K83551379-001-02-6,levodropropizine,2.5,HTS,antitussive,NA,pulmonary,cough suppressant,"OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1",Launched
BRD-K83597974-003-22-2::2.5::HTS,BRD-K83597974-003-22-2,pargyline,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",cardiology,hypertension,CN(CC#C)Cc1ccccc1,Launched
BRD-K83607951-001-02-2::2.5::HTS,BRD-K83607951-001-02-2,skepinone-l,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83636919-001-04-8::2.5::HTS,BRD-K83636919-001-04-8,entacapone,2.5,HTS,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease,"CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O",Launched
BRD-K83699324-001-01-1::2.5::HTS,BRD-K83699324-001-01-1,NMS-1286937,2.5,HTS,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83720053-001-03-8::2.5::HTS,BRD-K83720053-001-03-8,avagacestat,2.5,HTS,gamma secretase inhibitor,PSEN1,NA,NA,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,Phase 2
BRD-K83766205-001-03-8::2.5::HTS,BRD-K83766205-001-03-8,metirosine,2.5,HTS,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension,C[C@](N)(Cc1ccc(O)cc1)C(O)=O,Launched
BRD-K83794243-001-01-8::2.5::HTS,BRD-K83794243-001-01-8,palovarotene,2.5,HTS,retinoid receptor agonist,RARG,NA,NA,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,Phase 2
BRD-K83834509-001-01-1::2.5::HTS,BRD-K83834509-001-01-1,PTC-209,2.5,HTS,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83837640-001-04-8::2.5::HTS,BRD-K83837640-001-04-8,JNJ-26481585,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83896451-001-06-7::2.5::HTS,BRD-K83896451-001-06-7,glutamine-(l),2.5,HTS,NA,"CTPS1, GLUL, GPRC6A, PPAT","gastroenterology, dental, neurology/psychiatry, rheumatology","diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia","N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O",Launched
BRD-K83963101-001-06-9::2.5::HTS,BRD-K83963101-001-06-9,MLN-8054,2.5,HTS,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83988098-001-02-0::2.5::HTS,BRD-K83988098-001-02-0,alvespimycin,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::2.5::HTS,BRD-K83988098-003-03-4,alvespimycin,2.5,HTS,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K84011460-051-01-7::2.5::HTS,BRD-K84011460-051-01-7,nizofenone,2.5,HTS,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84075000-001-05-5::2.5::HTS,BRD-K84075000-001-05-5,2-Chloropyrazine,2.5,HTS,NA,NA,NA,NA,Clc1cnccn1,Preclinical
BRD-K84091759-001-07-1::2.5::HTS,BRD-K84091759-001-07-1,candesartan,2.5,HTS,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84163249-001-01-9::2.5::HTS,BRD-K84163249-001-01-9,ercalcitriol,2.5,HTS,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84214706-001-05-7::2.5::HTS,BRD-K84214706-001-05-7,7-chlorokynurenic-acid,2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",NA,NA,"OC(=O)c1cc(O)c2ccc(Cl)cc2n1, OC(=O)c1cc(O)c2ccc(Cl)cc2n1",Preclinical
BRD-K84266862-001-03-2::2.5::HTS,BRD-K84266862-001-03-2,BRL-50481,2.5,HTS,phosphodiesterase inhibitor,"PDE7A, PDE7B",NA,NA,"CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",Preclinical
BRD-K84466663-001-05-4::2.5::HTS,BRD-K84466663-001-05-4,nelarabine,2.5,HTS,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84544951-236-01-0::2.5::HTS,BRD-K84544951-236-01-0,sodium-tetradecyl-sulfate,2.5,HTS,NA,"PROC, PROS1",dermatology,"varicose veins, varicose veins","CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O, CCCCCCCCCCCCCCOS(O)(=O)=O",Launched
BRD-K84564571-001-02-4::2.5::HTS,BRD-K84564571-001-02-4,telatinib,2.5,HTS,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84663978-003-02-9::2.5::HTS,BRD-K84663978-003-02-9,trequinsin,2.5,HTS,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84683831-001-01-0::2.5::HTS,BRD-K84683831-001-01-0,radezolid,2.5,HTS,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84698278-001-03-4::2.5::HTS,BRD-K84698278-001-03-4,agomelatine,2.5,HTS,"melatonin receptor agonist, serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B",neurology/psychiatry,depression,COc1ccc2cccc(CCNC(C)=O)c2c1,Launched
BRD-K84748119-050-01-1::2.5::HTS,BRD-K84748119-050-01-1,vicriviroc,2.5,HTS,CC chemokine receptor antagonist,CCR5,NA,NA,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,Phase 3
BRD-K84783599-001-01-0::2.5::HTS,BRD-K84783599-001-01-0,riociguat,2.5,HTS,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84794093-001-07-5::2.5::HTS,BRD-K84794093-001-07-5,dideoxyadenosine,2.5,HTS,nucleoside reverse transcriptase inhibitor,NA,NA,NA,Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1,Phase 1
BRD-K84798689-236-02-9::2.5::HTS,BRD-K84798689-236-02-9,sodium-tanshinone-ii-a-sulfonate,2.5,HTS,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84810405-003-01-1::2.5::HTS,BRD-K84810405-003-01-1,almorexant,2.5,HTS,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84892605-001-01-1::2.5::HTS,BRD-K84892605-001-01-1,IOWH032,2.5,HTS,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84895041-001-02-4::2.5::HTS,BRD-K84895041-001-02-4,BMY-45778,2.5,HTS,IP1 prostacyclin receptor agonist,PTGIR,NA,NA,OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1,Preclinical
BRD-K84925803-001-01-9::2.5::HTS,BRD-K84925803-001-01-9,T-5224,2.5,HTS,AP inhibitor,JUN,NA,NA,OC(=O)CCc1cc(ccc1OCc1ccc2c(O)noc2c1)C(=O)c1ccc(OC2CCCC2)cc1O,Phase 2
BRD-K84937637-001-09-9::2.5::HTS,BRD-K84937637-001-09-9,sirolimus,2.5,HTS,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84986517-001-01-8::2.5::HTS,BRD-K84986517-001-01-8,darunavir,2.5,HTS,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,Launched
BRD-K84996356-001-01-1::2.5::HTS,BRD-K84996356-001-01-1,AZD3514,2.5,HTS,androgen receptor modulator,AR,NA,NA,CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1,Phase 1
BRD-K85014146-001-02-5::2.5::HTS,BRD-K85014146-001-02-5,AZD2461,2.5,HTS,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85015012-003-02-9::2.5::HTS,BRD-K85015012-003-02-9,NNC-05-2090,2.5,HTS,"GABA uptake inhibitor, GAT inhibitor",SLC6A12,NA,NA,"COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1",Preclinical
BRD-K85046107-003-01-2::2.5::HTS,BRD-K85046107-003-01-2,ramosetron,2.5,HTS,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting, irritable bowel syndrome",Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12,Launched
BRD-K85066592-001-01-6::2.5::HTS,BRD-K85066592-001-01-6,gly-gln,2.5,HTS,NA,NA,NA,NA,NCC(=O)N[C@@H](CCC(N)=O)C(O)=O,Phase 2
BRD-K85090592-008-22-7::2.5::HTS,BRD-K85090592-008-22-7,pilocarpine,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85119730-001-28-9::2.5::HTS,BRD-K85119730-001-28-9,tolbutamide,2.5,HTS,ATP channel blocker,"ABCC8, KCNJ1, KCNJ11, KCNJ8",endocrinology,diabetes mellitus,"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1",Launched
BRD-K85140930-001-12-7::2.5::HTS,BRD-K85140930-001-12-7,aphidicolin,2.5,HTS,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85146014-314-05-4::2.5::HTS,BRD-K85146014-314-05-4,foscarnet,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85178109-001-02-3::2.5::HTS,BRD-K85178109-001-02-3,fostamatinib,2.5,HTS,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC",Launched
BRD-K85307935-236-09-5::2.5::HTS,BRD-K85307935-236-09-5,novobiocin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-10-3::2.5::HTS,BRD-K85307935-236-10-3,novobiocin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85333151-003-13-4::2.5::HTS,BRD-K85333151-003-13-4,ramifenazone,2.5,HTS,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85337334-004-02-6::2.5::HTS,BRD-K85337334-004-02-6,otilonium,2.5,HTS,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,Launched
BRD-K85402309-001-06-6::2.5::HTS,BRD-K85402309-001-06-6,dovitinib,2.5,HTS,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-389-03-2::2.5::HTS,BRD-K85402309-389-03-2,dovitinib,2.5,HTS,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85406984-001-01-0::2.5::HTS,BRD-K85406984-001-01-0,sobetirome,2.5,HTS,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85479953-001-11-3::2.5::HTS,BRD-K85479953-001-11-3,STF-62247,2.5,HTS,autophagy inducer,NA,NA,NA,"Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K85503079-001-02-8::2.5::HTS,BRD-K85503079-001-02-8,perospirone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, DRD3, DRD4",neurology/psychiatry,"schizophrenia, bipolar disorder","O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K85554912-001-06-3::2.5::HTS,BRD-K85554912-001-06-3,ivermectin,2.5,HTS,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-08-9::2.5::HTS,BRD-K85554912-001-08-9,ivermectin,2.5,HTS,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85606544-001-09-1::2.5::HTS,BRD-K85606544-001-09-1,neratinib,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85751432-001-03-3::2.5::HTS,BRD-K85751432-001-03-3,refametinib,2.5,HTS,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85757157-001-01-7::2.5::HTS,BRD-K85757157-001-01-7,nifursol,2.5,HTS,bacterial DNA inhibitor,NA,NA,NA,Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,Launched
BRD-K85849709-001-01-5::2.5::HTS,BRD-K85849709-001-01-5,AZD2858,2.5,HTS,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85872723-001-15-9::2.5::HTS,BRD-K85872723-001-15-9,kynurenic-acid,2.5,HTS,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85883481-001-25-7::2.5::HTS,BRD-K85883481-001-25-7,prednisone,2.5,HTS,glucocorticoid receptor agonist,"HSD11B1, NR3C1","endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry","congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis","C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K85920262-001-02-1::2.5::HTS,BRD-K85920262-001-02-1,WAY-600,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85925969-001-17-4::2.5::HTS,BRD-K85925969-001-17-4,zalcitabine,2.5,HTS,nucleoside reverse transcriptase inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1",Launched
BRD-K86003836-001-10-5::2.5::HTS,BRD-K86003836-001-10-5,flubendazole,2.5,HTS,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86109159-001-02-6::2.5::HTS,BRD-K86109159-001-02-6,VU0357121,2.5,HTS,glutamate receptor positive allosteric modulator,GRM5,NA,NA,CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F,Preclinical
BRD-K86118762-001-01-8::2.5::HTS,BRD-K86118762-001-01-8,linsitinib,2.5,HTS,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86161929-001-11-7::2.52::HTS,BRD-K86161929-001-11-7,cortisone-acetate,2.52,HTS,glucocorticoid receptor agonist,NR3C1,"pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C",Launched
BRD-K86161929-001-13-3::2.5::HTS,BRD-K86161929-001-13-3,cortisone-acetate,2.5,HTS,glucocorticoid receptor agonist,NR3C1,"pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C",Launched
BRD-K86204871-001-16-2::2.5::HTS,BRD-K86204871-001-16-2,terconazole,2.5,HTS,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86294588-001-01-9::2.5::HTS,BRD-K86294588-001-01-9,schisandrin-b,2.5,HTS,antioxidant,ATR,NA,NA,COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC,Preclinical
BRD-K86301799-001-34-8::2.5::HTS,BRD-K86301799-001-34-8,dipyridamole,2.5,HTS,phosphodiesterase inhibitor,"ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1",cardiology,"coronary artery disease (CAD), peripheral artery disease (PAD), hypertension","OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO",Launched
BRD-K86307448-001-17-5::2.5::HTS,BRD-K86307448-001-17-5,allopurinol,2.5,HTS,xanthine oxidase inhibitor,XDH,"rheumatology, urology","gout, kidney stones","O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12",Launched
BRD-K86307448-001-19-1::2.5::HTS,BRD-K86307448-001-19-1,allopurinol,2.5,HTS,xanthine oxidase inhibitor,XDH,"rheumatology, urology","gout, kidney stones","O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12",Launched
BRD-K86344238-003-04-6::2.5::HTS,BRD-K86344238-003-04-6,linsidomine,2.5,HTS,nitric oxide donor,NA,urology,erectile dysfunction,"Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1",Launched
BRD-K86435560-001-01-0::2.5::HTS,BRD-K86435560-001-01-0,perchlozone,2.5,HTS,NA,NA,infectious disease,tuberculosis,NC(=S)NN=Cc1ccncc1,Launched
BRD-K86436199-003-01-3::2.5::HTS,BRD-K86436199-003-01-3,landiolol,2.5,HTS,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia,CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,Launched
BRD-K86525559-001-04-5::2.5::HTS,BRD-K86525559-001-04-5,AZD7762,2.5,HTS,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::2.52::HTS,BRD-K86525559-001-07-8,AZD7762,2.52,HTS,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86600316-003-02-0::2.5::HTS,BRD-K86600316-003-02-0,RS-79948,2.5,HTS,adrenergic receptor antagonist,ADRA2A,NA,NA,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,Preclinical
BRD-K86687746-001-01-3::2.5::HTS,BRD-K86687746-001-01-3,R306465,2.5,HTS,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86727142-001-12-4::2.5::HTS,BRD-K86727142-001-12-4,embelin,2.5,HTS,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86797399-001-04-4::2.5::HTS,BRD-K86797399-001-04-4,SB-939,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::2.55::HTS,BRD-K86797399-001-05-1,SB-939,2.55,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86799112-001-02-0::2.5::HTS,BRD-K86799112-001-02-0,5-HMF,2.5,HTS,NA,NA,NA,NA,"OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1",Phase 2
BRD-K86816506-001-01-8::2.5::HTS,BRD-K86816506-001-01-8,PF-04457845,2.5,HTS,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86882815-001-03-2::2.5::HTS,BRD-K86882815-001-03-2,cabergoline,2.5,HTS,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7",endocrinology,hyperprolactinemia,"CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1",Launched
BRD-K86887724-001-10-6::2.59::HTS,BRD-K86887724-001-10-6,dofetilide,2.59,HTS,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86892782-001-17-0::2.5::HTS,BRD-K86892782-001-17-0,edoxudine,2.5,HTS,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O,Launched
BRD-K86930074-001-05-0::2.5::HTS,BRD-K86930074-001-05-0,cediranib,2.5,HTS,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86972824-001-01-4::2.5::HTS,BRD-K86972824-001-01-4,oltipraz,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-02-2::2.5::HTS,BRD-K86972824-001-02-2,oltipraz,2.5,HTS,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K87024524-065-17-7::2.5::HTS,BRD-K87024524-065-17-7,phenelzine,2.5,HTS,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87028197-001-01-3::2.5::HTS,BRD-K87028197-001-01-3,asunaprevir,2.5,HTS,HCV inhibitor,NA,NA,NA,COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12,Phase 3
BRD-K87036601-001-01-6::2.5::HTS,BRD-K87036601-001-01-6,azodicarbonamide,2.5,HTS,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87048468-003-02-7::2.5::HTS,BRD-K87048468-003-02-7,RS-102221,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O",Preclinical
BRD-K87112191-001-04-5::2.5::HTS,BRD-K87112191-001-04-5,PP242,2.5,HTS,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87124298-001-03-4::2.5::HTS,BRD-K87124298-001-03-4,OSI-027,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87156652-001-12-7::2.5::HTS,BRD-K87156652-001-12-7,carbimazole,2.5,HTS,antithyroid agent,TPO,endocrinology,hyperthyroidism,"CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S",Launched
BRD-K87158025-001-01-6::2.5::HTS,BRD-K87158025-001-01-6,benzamil,2.5,HTS,sodium channel blocker,"ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1",NA,NA,"NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N",Phase 2
BRD-K87202646-001-32-6::2.5::HTS,BRD-K87202646-001-32-6,isoniazid,2.5,HTS,FABI inhibitor,"CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4",infectious disease,tuberculosis,"NNC(=O)c1ccncc1, NNC(=O)c1ccncc1",Launched
BRD-K87202646-061-04-9::2.5::HTS,BRD-K87202646-061-04-9,pasiniazid,2.5,HTS,cyclooxygenase inhibitor,NA,infectious disease,tuberculosis,"NNC(=O)c1ccncc1, NNC(=O)c1ccncc1",Launched
BRD-K87278688-001-01-0::2.5::HTS,BRD-K87278688-001-01-0,armodafinil,2.5,HTS,adrenergic receptor agonist,SLC6A3,"pulmonary, neurology/psychiatry","obstructive sleep apnea, narcolepsy, shift work disorder (SWD)",NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,Launched
BRD-K87349602-001-03-8::2.5::HTS,BRD-K87349602-001-03-8,beta-CCB,2.5,HTS,benzodiazepine receptor ligand,"GABRA1, GABRG2",NA,NA,CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,Launched
BRD-K87349682-347-03-8::2.36::HTS,BRD-K87349682-347-03-8,norepinephrine,2.36,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87492696-001-16-5::2.5::HTS,BRD-K87492696-001-16-5,sulfameter,2.5,HTS,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections,"COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1",Launched
BRD-K87510569-001-02-8::2.5::HTS,BRD-K87510569-001-02-8,RS-504393,2.5,HTS,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87512222-019-01-7::2.5::HTS,BRD-K87512222-019-01-7,taltobulin,2.5,HTS,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87535339-001-01-6::2.53::HTS,BRD-K87535339-001-01-6,"5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",2.53,HTS,NA,NA,NA,NA,Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)sc2c(=O)[nH]1,Preclinical
BRD-K87696786-003-04-4::2.5::HTS,BRD-K87696786-003-04-4,LY456236,2.5,HTS,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87700323-003-05-1::2.5::HTS,BRD-K87700323-003-05-1,cetylpyridinium,2.5,HTS,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87737963-001-06-0::2.5::HTS,BRD-K87737963-001-06-0,cyt387,2.5,HTS,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87774949-001-03-9::2.5::HTS,BRD-K87774949-001-03-9,istradefylline,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87782578-001-01-4::2.5::HTS,BRD-K87782578-001-01-4,AVL-292,2.5,HTS,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87827419-001-16-8::2.5::HTS,BRD-K87827419-001-16-8,melphalan,2.5,HTS,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87909389-003-03-4::2.5::HTS,BRD-K87909389-003-03-4,alvocidib,2.5,HTS,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87932577-001-02-4::2.5::HTS,BRD-K87932577-001-02-4,CDK1-5-inhibitor,2.5,HTS,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3B",NA,NA,Nc1n[nH]c2nc3ccccc3nc12,Preclinical
BRD-K87990216-001-10-2::2.5::HTS,BRD-K87990216-001-10-2,piretanide,2.5,HTS,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K88025533-003-03-3::2.5::HTS,BRD-K88025533-003-03-3,fingolimod,2.5,HTS,"immunosuppressant, sphingosine phosphate receptor agonist","S1PR1, S1PR5",neurology/psychiatry,multiple sclerosis,"CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1",Launched
BRD-K88052444-001-08-8::2.5::HTS,BRD-K88052444-001-08-8,urea,2.5,HTS,hydroxy radical formation stimulant,"ARG1, CA2, CTNNB1",dermatology,"psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis",NC(N)=O,Launched
BRD-K88061624-001-21-4::2.5::HTS,BRD-K88061624-001-21-4,mizoribine,2.5,HTS,"immunosuppressant, inosine monophosphate dehydrogenase inhibitor",IMPDH1,NA,NA,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O",Launched
BRD-K88090157-050-10-8::2.5::HTS,BRD-K88090157-050-10-8,pimethixene,2.5,HTS,antihistamine,NA,"neurology/psychiatry, allergy","attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis",CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12,Launched
BRD-K88172511-003-20-3::2.42::HTS,BRD-K88172511-003-20-3,naltrexone,2.42,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-21-1::2.5::HTS,BRD-K88172511-003-21-1,naltrexone,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88186167-001-04-8::2.5::HTS,BRD-K88186167-001-04-8,GW-4064,2.5,HTS,FXR agonist,NR1H4,NA,NA,"CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl",Preclinical
BRD-K88219015-001-10-8::2.5::HTS,BRD-K88219015-001-10-8,asaraldehyde,2.5,HTS,cyclooxygenase inhibitor,PTGS2,NA,NA,COc1cc(OC)c(C=O)cc1OC,Preclinical
BRD-K88308881-001-06-8::2.5::HTS,BRD-K88308881-001-06-8,ethenzamide,2.5,HTS,analgesic agent,NA,"neurology/psychiatry, endocrinology, otolaryngology","headache, fever, common cold",CCOc1ccccc1C(N)=O,Launched
BRD-K88358234-003-04-8::2.5::HTS,BRD-K88358234-003-04-8,xaliproden,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,"FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1",Phase 3
BRD-K88366685-300-06-0::2.5::HTS,BRD-K88366685-300-06-0,trimetazidine,2.5,HTS,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris,COc1ccc(CN2CCNCC2)c(OC)c1OC,Launched
BRD-K88405679-003-03-1::2.5::HTS,BRD-K88405679-003-03-1,thonzylamine,2.5,HTS,antihistamine,NA,neurology/psychiatry,itching,COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,Launched
BRD-K88429204-001-35-1::2.5::HTS,BRD-K88429204-001-35-1,pyrimethamine,2.5,HTS,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88506063-001-01-8::2.5::HTS,BRD-K88506063-001-01-8,KD025,2.5,HTS,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88510285-001-11-1::2.5::HTS,BRD-K88510285-001-11-1,bortezomib,2.5,HTS,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88544581-001-06-1::2.5::HTS,BRD-K88544581-001-06-1,CI-976,2.5,HTS,ACAT inhibitor,"ACAT1, CES1",NA,NA,"CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC",Phase 1
BRD-K88553858-001-02-7::2.5::HTS,BRD-K88553858-001-02-7,benurestat,2.5,HTS,urease inhibitor,NA,NA,NA,ONC(=O)CNC(=O)c1ccc(Cl)cc1,Phase 1
BRD-K88560311-011-06-3::2.5::HTS,BRD-K88560311-011-06-3,rucaparib,2.5,HTS,PARP inhibitor,"PARP1, PARP2",NA,NA,"CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23",Phase 3
BRD-K88568253-011-19-9::2.5::HTS,BRD-K88568253-011-19-9,iproniazid,2.5,HTS,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88611939-001-22-4::2.5::HTS,BRD-K88611939-001-22-4,aniracetam,2.5,HTS,glutamate receptor agonist,"DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A",NA,NA,"COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O",Launched
BRD-K88625236-001-04-2::2.5::HTS,BRD-K88625236-001-04-2,nonoxynol-9,2.5,HTS,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88646909-004-16-2::2.5::HTS,BRD-K88646909-004-16-2,arecoline,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,"COC(=O)C1=CCCN(C)C1, COC(=O)C1=CCCN(C)C1",Phase 1
BRD-K88677950-001-03-9::2.5::HTS,BRD-K88677950-001-03-9,PD-198306,2.5,HTS,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88682005-001-15-8::2.5::HTS,BRD-K88682005-001-15-8,chlorothiazide,2.5,HTS,diuretic,"CA1, CA2, CA4, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O",Launched
BRD-K88701661-001-02-9::2.5::HTS,BRD-K88701661-001-02-9,dimercaptosuccinic-acid,2.5,HTS,chelating agent,DNMT1,neurology/psychiatry,metal toxicity,"OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O",Launched
BRD-K88742110-001-07-9::2.5::HTS,BRD-K88742110-001-07-9,PCI-34051,2.5,HTS,HDAC inhibitor,"HDAC1, HDAC10, HDAC6, HDAC8",NA,NA,"COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1",Preclinical
BRD-K88759641-003-02-8::2.5::HTS,BRD-K88759641-003-02-8,EMD-66684,2.5,HTS,angiotensin receptor antagonist,AGTR1,NA,NA,"CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Preclinical
BRD-K88789588-001-14-9::2.5::HTS,BRD-K88789588-001-14-9,letrozole,2.5,HTS,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88807631-001-01-3::2.5::HTS,BRD-K88807631-001-01-3,elacridar,2.5,HTS,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88956297-003-01-9::2.5::HTS,BRD-K88956297-003-01-9,"1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",2.5,HTS,NA,NA,NA,NA,Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2,Preclinical
BRD-K89014967-001-04-3::2.5::HTS,BRD-K89014967-001-04-3,AS-703026,2.5,HTS,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89015388-001-01-7::2.5::HTS,BRD-K89015388-001-01-7,GSK923295,2.5,HTS,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89048337-001-06-9::2.5::HTS,BRD-K89048337-001-06-9,puerarin,2.5,HTS,serotonin receptor antagonist,NA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,Phase 2
BRD-K89053832-001-01-0::2.5::HTS,BRD-K89053832-001-01-0,VLX600,2.5,HTS,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89055274-048-22-7::2.5::HTS,BRD-K89055274-048-22-7,alverine,2.5,HTS,muscle relaxant,HTR1A,gastroenterology,"irritable bowel syndrome, diverticular disease","CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1",Launched
BRD-K89056082-001-07-7::2.5::HTS,BRD-K89056082-001-07-7,chlorocresol,2.5,HTS,ryanodine receptor activator,NA,infectious disease,first-aid antiseptic,"Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl",Launched
BRD-K89071957-001-01-1::0.25::HTS,BRD-K89071957-001-01-1,CTS21166,0.25,HTS,beta-secretase inhibitor,BACE1,NA,NA,CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,Phase 1
BRD-K89072800-001-01-8::2.5::HTS,BRD-K89072800-001-01-8,2-TEDC,2.5,HTS,lipoxygenase inhibitor,ALOX12,NA,NA,Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O,Preclinical
BRD-K89104321-003-14-8::2.5::HTS,BRD-K89104321-003-14-8,gaboxadol,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3",NA,NA,"Oc1noc2CNCCc12, Oc1noc2CNCCc12, Oc1noc2CNCCc12",Phase 3
BRD-K89125793-001-26-0::2.5::HTS,BRD-K89125793-001-26-0,tinidazole,2.5,HTS,antiprotozoal agent,NA,"infectious disease, obstetrics/gynecology","giardiasis, amebiasis, bacterial vaginosis, trichomoniasis","CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O",Launched
BRD-K89152108-236-07-6::2.5::HTS,BRD-K89152108-236-07-6,liothyronine,2.5,HTS,thyroid hormone stimulant,"THRA, THRB",endocrinology,"hypothyroidism, myxedema coma","N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O",Launched
BRD-K89162000-001-06-4::2.5::HTS,BRD-K89162000-001-06-4,tandutinib,2.5,HTS,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89208535-051-01-5::2.5::HTS,BRD-K89208535-051-01-5,indacaterol,2.5,HTS,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,chronic obstructive pulmonary disease (COPD),CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Launched
BRD-K89210380-001-13-7::2.5::HTS,BRD-K89210380-001-13-7,biotin,2.5,HTS,vitamin B,"ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6",NA,NA,"OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12",Launched
BRD-K89272762-001-12-7::2.5::HTS,BRD-K89272762-001-12-7,NPPB,2.5,HTS,chloride channel blocker,"ANO1, CLCN2, CLCN7, TRPA1",NA,NA,"OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O",Preclinical
BRD-K89274813-001-02-3::2.5::HTS,BRD-K89274813-001-02-3,DMP-543,2.5,HTS,acetylcholine release enhancer,NA,NA,NA,"Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1",Phase 2
BRD-K89299012-001-06-0::2.5::HTS,BRD-K89299012-001-06-0,DCEBIO,2.5,HTS,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89306950-001-12-5::2.5::HTS,BRD-K89306950-001-12-5,ML130,2.5,HTS,NOD1 inhibitor,NA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12",Preclinical
BRD-K89348303-001-14-7::2.5::HTS,BRD-K89348303-001-14-7,ramipril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O",Launched
BRD-K89375097-300-08-8::2.5::HTS,BRD-K89375097-300-08-8,pirenzepine,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,Launched
BRD-K89391146-001-08-0::2.5::HTS,BRD-K89391146-001-08-0,RG108,2.5,HTS,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89402695-001-02-3::2.5::HTS,BRD-K89402695-001-02-3,L-655240,2.5,HTS,thromboxane receptor antagonist,PTGES,NA,NA,"Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12",Phase 1
BRD-K89561498-001-01-7::2.5::HTS,BRD-K89561498-001-01-7,SN-38,2.5,HTS,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89588135-001-01-9::2.5::HTS,BRD-K89588135-001-01-9,tagatose,2.5,HTS,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-K89634775-001-09-9::2.5::HTS,BRD-K89634775-001-09-9,allylthiourea,2.5,HTS,nitrification inhibitor,NA,NA,NA,"NC(S)=NCC=C, NC(S)=NCC=C",Preclinical
BRD-K89657519-001-01-8::2.5::HTS,BRD-K89657519-001-01-8,testosterone-enanthate,2.5,HTS,androgen receptor agonist,AR,endocrinology,hypogonadism,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Launched
BRD-K89665618-003-02-5::2.5::HTS,BRD-K89665618-003-02-5,1-deoxymannojirimycin,2.5,HTS,alpha mannosidase inhibitor,MAN2A1,NA,NA,OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K89704198-001-12-3::2.5::HTS,BRD-K89704198-001-12-3,vincamine,2.5,HTS,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89712525-001-02-1::2.57::HTS,BRD-K89712525-001-02-1,2-oxoglutaric-acid,2.57,HTS,NA,OXGR1,NA,NA,OC(=O)CCC(=O)C(O)=O,Preclinical
BRD-K89714990-001-01-5::2.5::HTS,BRD-K89714990-001-01-5,tepoxalin,2.5,HTS,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89732114-300-14-7::2.5::HTS,BRD-K89732114-300-14-7,trifluoperazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1",neurology/psychiatry,schizophrenia,"CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1",Launched
BRD-K89839824-001-05-3::2.5::HTS,BRD-K89839824-001-05-3,raltitrexed,2.5,HTS,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89917372-001-01-2::2.5::HTS,BRD-K89917372-001-01-2,retigabine,2.5,HTS,potassium channel activator,"KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",neurology/psychiatry,epilepsy,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Launched
BRD-K89997465-003-43-0::2.5::HTS,BRD-K89997465-003-43-0,chlorpromazine,2.5,HTS,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5","neurology/psychiatry, gastroenterology, hematology, infectious disease","schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus","CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12",Launched
BRD-K90027121-003-01-7::2.5::HTS,BRD-K90027121-003-01-7,amprolium,2.5,HTS,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027355-001-13-3::2.44::HTS,BRD-K90027355-001-13-3,spironolactone,2.44,HTS,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-19-0::2.5::HTS,BRD-K90027355-001-19-0,spironolactone,2.5,HTS,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90065682-300-02-6::2.5::HTS,BRD-K90065682-300-02-6,5-iodo-A-85380,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,"Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1",Phase 2
BRD-K90168339-001-08-6::2.5::HTS,BRD-K90168339-001-08-6,thiophanate,2.5,HTS,NA,NA,NA,NA,"COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC",Preclinical
BRD-K90195324-003-02-5::2.5::HTS,BRD-K90195324-003-02-5,bazedoxifene,2.5,HTS,selective estrogen receptor modulator (SERM),"ESR1, ESR2","orthopedics, endocrinology","osteoporosis, menopause","Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12",Launched
BRD-K90239174-001-01-8::2.5::HTS,BRD-K90239174-001-01-8,AMG-487,2.5,HTS,CC chemokine receptor antagonist,NA,NA,NA,CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,Phase 2
BRD-K90333595-003-21-4::2.5::HTS,BRD-K90333595-003-21-4,phentolamine,2.5,HTS,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","endocrinology, cardiology","pheochromocytoma, hypertension","Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1",Launched
BRD-K90374350-001-09-2::2.5::HTS,BRD-K90374350-001-09-2,chlorquinaldol,2.5,HTS,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90382497-001-10-7::2.5::HTS,BRD-K90382497-001-10-7,GW-843682X,2.5,HTS,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90497590-001-04-2::2.5::HTS,BRD-K90497590-001-04-2,AR-12,2.5,HTS,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90524085-001-07-8::2.5::HTS,BRD-K90524085-001-07-8,MY-5445,2.5,HTS,"phosphodiesterase inhibitor, platelet aggregation inhibitor",PDE5A,NA,NA,"Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1",Preclinical
BRD-K90574421-001-03-5::2.5::HTS,BRD-K90574421-001-03-5,ipsapirone,2.5,HTS,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90630139-003-05-9::2.5::HTS,BRD-K90630139-003-05-9,butenafine,2.5,HTS,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis",CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12,Launched
BRD-K90647725-001-06-5::2.5::HTS,BRD-K90647725-001-06-5,oleanolic-acid,2.5,HTS,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::2.5::HTS,BRD-K90647725-001-07-3,oleanolic-acid,2.5,HTS,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90777969-300-01-2::2.5::HTS,BRD-K90777969-300-01-2,cutamesine,2.5,HTS,sigma receptor agonist,SIGMAR1,NA,NA,"COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC",Phase 2
BRD-K90789829-001-07-8::2.5::HTS,BRD-K90789829-001-07-8,nefazodone,2.5,HTS,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4",NA,NA,"CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1",Withdrawn
BRD-K90817094-001-02-6::2.5::HTS,BRD-K90817094-001-02-6,bedaquiline,2.5,HTS,ATPase inhibitor,NA,infectious disease,tuberculosis,"COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12",Launched
BRD-K90825648-001-02-0::2.5::HTS,BRD-K90825648-001-02-0,RS-127445,2.5,HTS,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,Phase 1
BRD-K90868879-001-03-8::2.5::HTS,BRD-K90868879-001-03-8,canagliflozin,2.5,HTS,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,"Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",Launched
BRD-K90885812-004-24-2::2.5::HTS,BRD-K90885812-004-24-2,propantheline,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,peptic ulcer disease (PUD),CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C,Launched
BRD-K90947825-001-02-7::2.5::HTS,BRD-K90947825-001-02-7,carboplatin,2.5,HTS,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90948141-001-01-4::2.5::HTS,BRD-K90948141-001-01-4,indiplon,2.5,HTS,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90993449-001-02-7::2.5::HTS,BRD-K90993449-001-02-7,KRN-633,2.5,HTS,VEGFR inhibitor,"FLT1, FLT4, KDR",NA,NA,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,Preclinical
BRD-K91065602-003-05-5::2.5::HTS,BRD-K91065602-003-05-5,vancomycin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,endocarditis,"CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2",Launched
BRD-K91111634-001-01-2::2.5::HTS,BRD-K91111634-001-01-2,rotigotine,2.5,HTS,dopamine receptor agonist,"ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome","CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1",Launched
BRD-K91147684-001-01-5::2.5::HTS,BRD-K91147684-001-01-5,m-THP,2.5,HTS,NA,NA,NA,NA,Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Phase 1
BRD-K91159026-001-01-7::2.5::HTS,BRD-K91159026-001-01-7,telcagepant,2.5,HTS,calcitonin antagonist,"CALCRL, RAMP1",NA,NA,Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F,Phase 3
BRD-K91188791-001-18-3::2.5::HTS,BRD-K91188791-001-18-3,aloxistatin,2.5,HTS,protease inhibitor,CTSG,NA,NA,"CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C",Phase 3
BRD-K91263825-003-21-4::2.5::HTS,BRD-K91263825-003-21-4,nortriptyline,2.5,HTS,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,CNCCC=C1c2ccccc2CCc2ccccc12,Launched
BRD-K91290917-300-01-8::2.5::HTS,BRD-K91290917-300-01-8,amodiaquine,2.5,HTS,histamine receptor agonist,HNMT,infectious disease,malaria,"CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O",Launched
BRD-K91301684-003-05-5::2.5::HTS,BRD-K91301684-003-05-5,noscapine,2.5,HTS,"bradykinin receptor antagonist, tubulin polymerization inhibitor",SIGMAR1,pulmonary,cough suppressant,"COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12",Launched
BRD-K91308639-001-02-7::2.5::HTS,BRD-K91308639-001-02-7,apalutamide,2.5,HTS,androgen receptor antagonist,NA,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F,Launched
BRD-K91315211-300-05-7::2.5::HTS,BRD-K91315211-300-05-7,betahistine,2.5,HTS,"histamine receptor agonist, histamine receptor antagonist","HRH1, HRH3",neurology/psychiatry,Meniere's disease,"CNCCc1ccccn1, CNCCc1ccccn1",Launched
BRD-K91336023-003-01-0::2.5::HTS,BRD-K91336023-003-01-0,mesulergine,2.5,HTS,dopamine receptor agonist,"HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7",NA,NA,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,Phase 2
BRD-K91370081-001-25-1::2.5::HTS,BRD-K91370081-001-25-1,anisomycin,2.5,HTS,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91422571-001-01-8::2.5::HTS,BRD-K91422571-001-01-8,tromaril,2.5,HTS,prostanoid receptor antagonist,NA,NA,NA,OC(=O)c1ccccc1NCCc1ccccc1,Launched
BRD-K91456750-238-01-7::2.5::HTS,BRD-K91456750-238-01-7,sacubitril,2.5,HTS,neprilysin inhibitor,MME,cardiology,congestive heart failure,"CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O",Launched
BRD-K91495480-001-02-2::2.5::HTS,BRD-K91495480-001-02-2,AGP-103,2.5,HTS,membrane permeability inhibitor,NA,NA,NA,CCCCCCCCCCCCCCCCCCCCCC(O)=O,Launched
BRD-K91509126-001-23-6::2.5::HTS,BRD-K91509126-001-23-6,piceatannol,2.5,HTS,SYK inhibitor,"ATP5A1, ATP5B, ATP5C1, IRF3",NA,NA,"Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K91544578-001-03-8::2.5::HTS,BRD-K91544578-001-03-8,nikethamide,2.5,HTS,immunostimulant,NA,NA,NA,CCN(CC)C(=O)c1cccnc1,Withdrawn
BRD-K91601245-001-12-0::2.5::HTS,BRD-K91601245-001-12-0,mercaptopurine,2.5,HTS,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91614056-001-02-2::2.5::HTS,BRD-K91614056-001-02-2,trans-4-Hydroxycrotonic-acid,2.5,HTS,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91623615-001-05-0::2.46::HTS,BRD-K91623615-001-05-0,ABT-751,2.46,HTS,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91699951-001-10-2::2.5::HTS,BRD-K91699951-001-10-2,benzonatate,2.5,HTS,local anesthetic,SCN5A,pulmonary,cough suppressant,CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,Launched
BRD-K91701654-001-03-1::2.38::HTS,BRD-K91701654-001-03-1,U-0126,2.38,HTS,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91740057-001-19-8::2.5::HTS,BRD-K91740057-001-19-8,felbinac,2.5,HTS,cyclooxygenase inhibitor,CTSL,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain",OC(=O)Cc1ccc(cc1)-c1ccccc1,Launched
BRD-K91758890-001-10-0::2.5::HTS,BRD-K91758890-001-10-0,4-HQN,2.5,HTS,PARP inhibitor,PARP1,NA,NA,Oc1ncnc2ccccc12,Preclinical
BRD-K91822704-003-07-2::2.5::HTS,BRD-K91822704-003-07-2,torcitabine,2.5,HTS,DNA polymerase inhibitor,"DCK, TK2",NA,NA,Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Phase 2
BRD-K91825936-001-01-2::2.5::HTS,BRD-K91825936-001-01-2,ZK811752,2.5,HTS,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91868854-001-03-6::2.5::HTS,BRD-K91868854-001-03-6,2-[1-(4-piperonyl)piperazinyl]benzothiazole,2.5,HTS,serotonin receptor agonist,HTR4,NA,NA,C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1,Preclinical
BRD-K91904471-001-02-4::2.5::HTS,BRD-K91904471-001-02-4,SD-169,2.5,HTS,p38 MAPK inhibitor,MAPK14,NA,NA,NC(=O)c1ccc2[nH]ccc2c1,Preclinical
BRD-K92000912-001-12-6::2.5::HTS,BRD-K92000912-001-12-6,AM-251,2.5,HTS,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92015269-300-01-2::2.5::HTS,BRD-K92015269-300-01-2,GBR-12783,2.5,HTS,dopamine uptake inhibitor,NA,NA,NA,C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1,Preclinical
BRD-K92041145-001-09-5::2.5::HTS,BRD-K92041145-001-09-5,O6-Benzylguanine,2.5,HTS,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,NA,NA,Nc1nc(OCc2ccccc2)c2[nH]cnc2n1,Phase 3
BRD-K92049597-001-20-8::2.5::HTS,BRD-K92049597-001-20-8,triamterene,2.5,HTS,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92073408-001-16-5::2.5::HTS,BRD-K92073408-001-16-5,norethindrone,2.5,HTS,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92093830-003-30-8::2.5::HTS,BRD-K92093830-003-30-8,doxorubicin,2.5,HTS,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92107055-001-01-9::2.5::HTS,BRD-K92107055-001-01-9,pimecrolimus,2.5,HTS,calcineurin inhibitor,"FKBP1A, MTOR",dermatology,eczema,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC,Launched
BRD-K92116564-001-01-4::2.5::HTS,BRD-K92116564-001-01-4,isoxepac,2.5,HTS,anti-inflammatory agent,NA,NA,NA,OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1,Phase 2
BRD-K92150287-066-01-2::2.5::HTS,BRD-K92150287-066-01-2,exatecan-mesylate,2.5,HTS,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92213669-001-01-3::2.5::HTS,BRD-K92213669-001-01-3,lomitapide,2.5,HTS,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92241597-001-06-0::2.5::HTS,BRD-K92241597-001-06-0,tosedostat,2.5,HTS,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92301463-001-05-5::0.25::HTS,BRD-K92301463-001-05-5,"16,16-dimethylprostaglandin-e2",0.25,HTS,prostanoid receptor agonist,HPGD,NA,NA,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,Phase 2
BRD-K92303087-001-01-6::2.5::HTS,BRD-K92303087-001-01-6,oglemilast,2.5,HTS,phosphodiesterase inhibitor,NA,NA,NA,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,Phase 2
BRD-K92382976-050-01-1::2.5::HTS,BRD-K92382976-050-01-1,5-carboxamidotryptamine,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",NA,NA,NCCc1c[nH]c2ccc(cc12)C(N)=O,Preclinical
BRD-K92404805-001-07-0::2.5::HTS,BRD-K92404805-001-07-0,L-Quisqualic-acid,2.5,HTS,glutamate receptor agonist,"FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8",NA,NA,N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O,Preclinical
BRD-K92428153-001-04-4::2.5::HTS,BRD-K92428153-001-04-4,mycophenolate-mofetil,2.5,HTS,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428232-001-10-6::2.5::HTS,BRD-K92428232-001-10-6,GSK461364,2.5,HTS,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92441787-001-04-1::2.5::HTS,BRD-K92441787-001-04-1,bexarotene,2.5,HTS,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92446736-003-02-2::2.5::HTS,BRD-K92446736-003-02-2,zatebradine,2.5,HTS,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",NA,NA,"COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC",Phase 3
BRD-K92467929-001-01-1::2.5::HTS,BRD-K92467929-001-01-1,oxandrolone,2.5,HTS,androgen receptor agonist,AR,endocrinology,weight-gain aid,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C,Launched
BRD-K92492521-001-02-9::2.5::HTS,BRD-K92492521-001-02-9,LY255283,2.5,HTS,leukotriene receptor antagonist,"LTB4R, LTB4R2",NA,NA,"CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1",Preclinical
BRD-K92493880-001-03-0::2.5::HTS,BRD-K92493880-001-03-0,AMPA-(S),2.5,HTS,glutamate receptor agonist,GRIN1,NA,NA,Cc1onc(O)c1C[C@H](N)C(O)=O,Preclinical
BRD-K92577649-300-01-2::2.5::HTS,BRD-K92577649-300-01-2,GBR-13069,2.5,HTS,dopamine uptake inhibitor,SLC6A3,NA,NA,Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,Preclinical
BRD-K92588747-051-02-7::2.5::HTS,BRD-K92588747-051-02-7,2-CMDO,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD4",NA,NA,CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12,Preclinical
BRD-K92613113-066-02-7::2.5::HTS,BRD-K92613113-066-02-7,safinamide,2.5,HTS,"dopamine uptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",MAOB,neurology/psychiatry,Parkinson's Disease,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,Launched
BRD-K92657060-001-05-7::2.5::HTS,BRD-K92657060-001-05-7,zaleplon,2.5,HTS,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92723993-001-06-7::2.5::HTS,BRD-K92723993-001-06-7,imatinib,2.5,HTS,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92731339-227-04-9::2.5::HTS,BRD-K92731339-227-04-9,perindopril,2.5,HTS,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction, coronary artery disease (CAD)","CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC",Launched
BRD-K92758126-001-18-8::1.44::HTS,BRD-K92758126-001-18-8,MD-920,1.44,HTS,NFkB pathway inhibitor,AADACL2,NA,NA,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O,Phase 1
BRD-K92760278-001-07-3::2.43::HTS,BRD-K92760278-001-07-3,riboflavin,2.43,HTS,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K92778217-001-32-7::2.5::HTS,BRD-K92778217-001-32-7,mefenamic-acid,2.5,HTS,cyclooxygenase inhibitor,"KCNQ1, PTGS1, PTGS2, TRPM3",endocrinology,primary dysmenorrhea (PD),"Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C",Launched
BRD-K92830582-003-10-5::2.5::HTS,BRD-K92830582-003-10-5,propranolol-(R),2.5,HTS,adrenergic receptor antagonist,"ADRB2, ADRB3",NA,NA,CC(C)NC[C@@H](O)COc1cccc2ccccc12,Preclinical
BRD-K92838188-001-01-9::2.5::HTS,BRD-K92838188-001-01-9,rifaximin,2.5,HTS,RNA synthesis inhibitor,NR1I2,gastroenterology,"diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)","CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K92844263-001-09-8::2.5::HTS,BRD-K92844263-001-09-8,triacetin,2.5,HTS,NA,NA,NA,NA,CC(=O)OCC(COC(C)=O)OC(C)=O,Launched
BRD-K92848252-001-01-9::2.5::HTS,BRD-K92848252-001-01-9,diminazene-aceturate,2.5,HTS,angiotensin converting enzyme activator,"AOC1, PRDX5, PRSS1",NA,NA,"NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1",Phase 3
BRD-K92872987-001-02-9::2.5::HTS,BRD-K92872987-001-02-9,cefpiramide,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92968657-001-01-6::2.5::HTS,BRD-K92968657-001-01-6,tirapazamine,2.5,HTS,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92976206-001-01-5::2.5::HTS,BRD-K92976206-001-01-5,guanosine,2.5,HTS,NA,PNP,NA,NA,Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H]1O,Preclinical
BRD-K92980438-001-03-3::2.5::HTS,BRD-K92980438-001-03-3,3-bromopyruvate,2.5,HTS,hexokinase inhibitor,HK2,NA,NA,"OC(=O)C(=O)CBr, OC(=O)C(=O)CBr, OC(=O)C(=O)CBr",Preclinical
BRD-K92984783-003-05-7::2.5::HTS,BRD-K92984783-003-05-7,melperone,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,psychosis,"CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1",Launched
BRD-K92988025-001-01-9::2.5::HTS,BRD-K92988025-001-01-9,perflubron,2.5,HTS,contrast agent,NA,radiology,contrast agent,"FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br",Launched
BRD-K92991072-001-04-9::2.5::HTS,BRD-K92991072-001-04-9,PAC-1,2.5,HTS,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K93034159-001-25-8::2.5::HTS,BRD-K93034159-001-25-8,cladribine,2.5,HTS,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93035859-001-07-6::2.5::HTS,BRD-K93035859-001-07-6,butylated-hydroxyanisole,2.5,HTS,antioxidant,NA,NA,NA,COc1ccc(O)c(c1)C(C)(C)C,Preclinical
BRD-K93045741-001-01-0::2.5::HTS,BRD-K93045741-001-01-0,tozadenant,2.5,HTS,adenosine receptor antagonist,ADORA2A,NA,NA,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,Phase 3
BRD-K93123848-001-04-1::2.5::HTS,BRD-K93123848-001-04-1,RAF265,2.5,HTS,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93176058-001-03-6::2.5::HTS,BRD-K93176058-001-03-6,AC-55649,2.5,HTS,retinoid receptor agonist,"RARA, RARB",NA,NA,"CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O",Preclinical
BRD-K93188295-300-02-2::2.5::HTS,BRD-K93188295-300-02-2,ARC-239,2.5,HTS,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C",NA,NA,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,Preclinical
BRD-K93208532-001-02-5::2.5::HTS,BRD-K93208532-001-02-5,apremilast,2.5,HTS,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D","dermatology, rheumatology","psoriasis, psoriatic arthritis",CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O,Launched
BRD-K93231391-300-05-6::2.5::HTS,BRD-K93231391-300-05-6,ethambutol,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,tuberculosis,"CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO",Launched
BRD-K93240442-001-08-4::2.5::HTS,BRD-K93240442-001-08-4,dinitolmide,2.5,HTS,NA,NA,infectious disease,coccidiosis,Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O,Launched
BRD-K93255255-001-02-1::2.5::HTS,BRD-K93255255-001-02-1,indoximod,2.5,HTS,"indoleamine 2,3-dioxygenase inhibitor",IDO1,NA,NA,Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12,Phase 2
BRD-K93258693-001-17-3::2.5::HTS,BRD-K93258693-001-17-3,GW-9662,2.5,HTS,PPAR receptor antagonist,"NCOA2, PPARG, RXRA",NA,NA,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1",Preclinical
BRD-K93441486-067-12-8::2.5::HTS,BRD-K93441486-067-12-8,diphemanil,2.5,HTS,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93460210-001-23-7::2.5::HTS,BRD-K93460210-001-23-7,lamotrigine,2.5,HTS,"serotonin receptor antagonist, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, bipolar disorder","Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl",Launched
BRD-K93461745-003-25-0::2.5::HTS,BRD-K93461745-003-25-0,buspirone,2.5,HTS,serotonin receptor agonist,"DRD2, HTR1A",neurology/psychiatry,generalized anxiety disorder (GAD),"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1",Launched
BRD-K93468883-001-02-0::2.5::HTS,BRD-K93468883-001-02-0,IPI-145,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,Phase 3
BRD-K93502141-001-01-6::2.5::HTS,BRD-K93502141-001-01-6,amylene-hydrate,2.5,HTS,local anesthetic,NA,NA,NA,"CCC(C)(C)O, CCC(C)(C)O",Preclinical
BRD-K93524252-001-24-7::2.5::HTS,BRD-K93524252-001-24-7,sulfamerazine,2.5,HTS,bacterial antifolate,NA,infectious disease,"coccidiosis, cholera","Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K93568044-001-32-0::2.5::HTS,BRD-K93568044-001-32-0,hydrocortisone,2.5,HTS,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93611241-001-02-2::2.5::HTS,BRD-K93611241-001-02-2,diacetamate,2.5,HTS,NA,NA,NA,NA,CC(=O)Nc1ccc(OC(C)=O)cc1,Preclinical
BRD-K93618743-001-21-0::2.5::HTS,BRD-K93618743-001-21-0,ipriflavone,2.5,HTS,bone resorption inhibitor,NA,orthopedics,osteoporosis,"CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O",Launched
BRD-K93631643-001-02-4::2.5::HTS,BRD-K93631643-001-02-4,hordenine,2.5,HTS,NA,NA,NA,NA,"CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1",Preclinical
BRD-K93632104-001-17-2::2.5::HTS,BRD-K93632104-001-17-2,salicylic-acid,2.5,HTS,cyclooxygenase inhibitor,"AKR1C1, PTGS1, PTGS2",dermatology,acne vulgaris (AV),OC(=O)c1ccccc1O,Launched
BRD-K93632104-001-18-0::2.5::HTS,BRD-K93632104-001-18-0,sodium-salicylate,2.5,HTS,prostanoid receptor antagonist,"ASIC3, PTGS1, PTGS2","endocrinology, neurology/psychiatry","fever, pain relief","OC(=O)c1ccccc1O, OC(=O)c1ccccc1O",Launched
BRD-K93645900-001-11-3::2.5::HTS,BRD-K93645900-001-11-3,tadalafil,2.5,HTS,phosphodiesterase inhibitor,"PDE11A, PDE5A",cardiology,hypertension,"CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O",Launched
BRD-K93754473-048-20-2::2.5::HTS,BRD-K93754473-048-20-2,tamoxifen,2.5,HTS,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93767137-001-01-1::2.5::HTS,BRD-K93767137-001-01-1,oseltamivir-carboxylate,2.5,HTS,neuraminidase inhibitor,NA,infectious disease,influenza A virus infection,CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O,Launched
BRD-K93779381-001-01-9::2.5::HTS,BRD-K93779381-001-01-9,ingenol-mebutate,2.5,HTS,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93806173-003-01-8::2.5::HTS,BRD-K93806173-003-01-8,N-MPPP,2.5,HTS,opioid receptor agonist,NA,NA,NA,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1,Preclinical
BRD-K93869735-001-01-1::2.5::HTS,BRD-K93869735-001-01-1,taltirelin,2.5,HTS,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93880783-001-26-6::2.5::HTS,BRD-K93880783-001-26-6,stavudine,2.5,HTS,"DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor",NA,infectious disease,human immunodeficiency virus (HIV-1),"Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O",Launched
BRD-K93918653-001-08-9::2.5::HTS,BRD-K93918653-001-08-9,quizartinib,2.5,HTS,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93944989-001-08-0::0.25::HTS,BRD-K93944989-001-08-0,safingol,0.25,HTS,PKC inhibitor,TRPM3,NA,NA,CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO,Phase 1
BRD-K94080537-001-09-7::2.5::HTS,BRD-K94080537-001-09-7,diethyltoluamide,2.5,HTS,ionotropic receptor IR40a activator,NA,dermatology,sunscreen lotion,CCN(CC)C(=O)c1cccc(C)c1,Launched
BRD-K94144010-001-13-9::2.5::HTS,BRD-K94144010-001-13-9,cotinine,2.5,HTS,nicotine metabolite,NA,NA,NA,CN1[C@@H](CCC1=O)c1cccnc1,Phase 2
BRD-K94176593-001-09-4::2.5::HTS,BRD-K94176593-001-09-4,TWS-119,2.5,HTS,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94239562-001-05-5::2.5::HTS,BRD-K94239562-001-05-5,paeonol,2.5,HTS,anti-inflammatory agent,NA,NA,NA,COc1ccc(C(C)=O)c(O)c1,Preclinical
BRD-K94266545-001-24-1::2.5::HTS,BRD-K94266545-001-24-1,ronidazole,2.5,HTS,antiprotozoal agent,NA,infectious disease,"histomoniasis, dysentry","Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O",Launched
BRD-K94288301-001-01-7::2.5::HTS,BRD-K94288301-001-01-7,letermovir,2.5,HTS,CMV terminase inhibitor,NA,NA,NA,COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F,Phase 3
BRD-K94293891-001-01-3::2.5::HTS,BRD-K94293891-001-01-3,suvorexant,2.5,HTS,orexin receptor antagonist,"HCRTR1, HCRTR2",neurology/psychiatry,insomnia,C[C@@H]1CCN(CCN1C(=O)c1cc(C)ccc1-n1nccn1)c1nc2cc(Cl)ccc2o1,Launched
BRD-K94353609-001-21-6::2.5::HTS,BRD-K94353609-001-21-6,fluocinolone-acetonide,2.5,HTS,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94358652-001-02-1::2.5::HTS,BRD-K94358652-001-02-1,daptomycin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,"skin infections, endocarditis","CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O, CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O",Launched
BRD-K94379058-001-06-8::2.5::HTS,BRD-K94379058-001-06-8,BML-190,2.5,HTS,cannabinoid receptor inverse agonist,CNR2,NA,NA,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1",Preclinical
BRD-K94420399-001-01-9::2.5::HTS,BRD-K94420399-001-01-9,PF-04136309,2.5,HTS,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94436377-001-10-2::2.5::HTS,BRD-K94436377-001-10-2,diosmin,2.5,HTS,"aryl hydrocarbon receptor agonist, capillary stabilizing agent",AHR,"cardiology, hematology, dermatology","chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome","COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1",Launched
BRD-K94441233-001-13-0::2.6::HTS,BRD-K94441233-001-13-0,mevastatin,2.6,HTS,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-17-1::2.5::HTS,BRD-K94441233-001-17-1,mevastatin,2.5,HTS,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94455792-001-01-8::2.5::HTS,BRD-K94455792-001-01-8,ICG-001,2.5,HTS,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94485812-001-02-9::2.55::HTS,BRD-K94485812-001-02-9,LDN-57444,2.55,HTS,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94534639-001-02-5::2.5::HTS,BRD-K94534639-001-02-5,LY2811376,2.5,HTS,beta-secretase inhibitor,BACE1,NA,NA,C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1,Phase 1
BRD-K94559059-091-01-6::2.5::HTS,BRD-K94559059-091-01-6,telotristat-ethyl,2.5,HTS,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94649603-001-10-6::2.5::HTS,BRD-K94649603-001-10-6,taxifolin,2.5,HTS,opioid receptor antagonist,ADIPOR2,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1",Phase 2
BRD-K94689771-001-09-0::1.95::HTS,BRD-K94689771-001-09-0,pinocembrin,1.95,HTS,cytochrome P450 inhibitor,CYP1B1,NA,NA,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,Phase 2
BRD-K94720315-001-10-4::2.5::HTS,BRD-K94720315-001-10-4,chromocarb,2.5,HTS,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94723713-001-10-6::2.5::HTS,BRD-K94723713-001-10-6,rutaecarpine,2.5,HTS,cyclooxygenase inhibitor,PTGS2,NA,NA,O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12,Preclinical
BRD-K94780074-001-06-7::2.5::HTS,BRD-K94780074-001-06-7,S-Nitrosoglutathione,2.5,HTS,nitric oxide stimulant,PTPN1,NA,NA,"N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O",Phase 1
BRD-K94830329-001-03-0::2.5::HTS,BRD-K94830329-001-03-0,ataluren,2.5,HTS,"CFTR channel agonist, dystrophin stimulant",DMD,"genetics, pulmonary","duchenne muscular dystrophy (DMD), cystic fibrosis",OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F,Launched
BRD-K94832621-001-02-3::2.5::HTS,BRD-K94832621-001-02-3,Y-134,2.5,HTS,estrogen receptor antagonist,"ESR1, ESR2",NA,NA,"CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1",Preclinical
BRD-K95015809-001-02-8::5::HTS,BRD-K95015809-001-02-8,2-cyanopyrimidine,5.0,HTS,cathepsin inhibitor,NA,NA,NA,N#Cc1ncccn1,Preclinical
BRD-K95053546-001-01-9::2.5::HTS,BRD-K95053546-001-01-9,tempol,2.5,HTS,free radical scavenger,NA,NA,NA,"CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O",Phase 2
BRD-K95053546-001-02-7::2.5::HTS,BRD-K95053546-001-02-7,tempol,2.5,HTS,free radical scavenger,NA,NA,NA,"CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O",Phase 2
BRD-K95053546-001-03-5::2.5::HTS,BRD-K95053546-001-03-5,tempol,2.5,HTS,free radical scavenger,NA,NA,NA,"CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O",Phase 2
BRD-K95110148-003-01-5::2.5::HTS,BRD-K95110148-003-01-5,beta-funaltrexamine,2.5,HTS,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45",Preclinical
BRD-K95142244-001-01-5::2.5::HTS,BRD-K95142244-001-01-5,talazoparib,2.5,HTS,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95161686-001-02-8::2.5::HTS,BRD-K95161686-001-02-8,octisalate,2.5,HTS,NA,NA,dermatology,sunscreen lotion,CCCC[C@@H](CC)COC(=O)c1ccccc1O,Launched
BRD-K95237249-001-26-5::2.5::HTS,BRD-K95237249-001-26-5,probenecid,2.5,HTS,uricosuric blocker,"PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1","nephrology, rheumatology","hyperuricemia, gout","CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O",Launched
BRD-K95260951-050-03-1::2.5::HTS,BRD-K95260951-050-03-1,asenapine,2.5,HTS,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, HRH1, HRH2, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder","CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21, CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21.CN1C[C@@H]2[C@@H](C1)c1cc(Cl)ccc1Oc1ccccc21, CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21",Launched
BRD-K95292280-001-01-3::2.5::HTS,BRD-K95292280-001-01-3,SB-657510,2.5,HTS,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95309561-001-24-7::2.5::HTS,BRD-K95309561-001-24-7,dienestrol,2.5,HTS,estrogen receptor agonist,ESR1,endocrinology,menopause,C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C,Launched
BRD-K95412502-003-01-5::2.5::HTS,BRD-K95412502-003-01-5,istaroxime,2.5,HTS,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,Phase 2
BRD-K95435023-001-08-5::2.5::HTS,BRD-K95435023-001-08-5,PHA-665752,2.5,HTS,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-10-1::2.5::HTS,BRD-K95435023-001-10-1,PHA-665752,2.5,HTS,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95523387-001-09-6::2.5::HTS,BRD-K95523387-001-09-6,OLDA,2.5,HTS,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95573441-001-01-2::2.5::HTS,BRD-K95573441-001-01-2,PFK-015,2.5,HTS,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95581532-001-01-5::2.5::HTS,BRD-K95581532-001-01-5,RN-1734,2.5,HTS,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95600043-001-01-5::2.5::HTS,BRD-K95600043-001-01-5,NPY-5RA972,2.5,HTS,neuropeptide receptor antagonist,NPY5R,NA,NA,"CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12",Preclinical
BRD-K95609758-001-03-7::2.5::HTS,BRD-K95609758-001-03-7,BMS-191011,2.5,HTS,potassium channel activator,KCNMA1,NA,NA,"Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F",Preclinical
BRD-K95739795-001-03-7::2.5::HTS,BRD-K95739795-001-03-7,tetrabenazine,2.5,HTS,vesicular monoamine transporter inhibitor,"DRD2, SLC18A1, SLC18A2","infectious disease, neurology/psychiatry","cholera, Huntington's disease","COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC",Launched
BRD-K95763993-001-19-3::2.5::HTS,BRD-K95763993-001-19-3,trapidil,2.5,HTS,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95773607-004-03-8::2.5::HTS,BRD-K95773607-004-03-8,darifenacin,2.5,HTS,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95785345-300-14-8::2.5::HTS,BRD-K95785345-300-14-8,thiamine,2.5,HTS,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785537-001-23-1::2.5::HTS,BRD-K95785537-001-23-1,PP-2,2.5,HTS,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95828359-001-01-0::2.5::HTS,BRD-K95828359-001-01-0,MK-3697,2.5,HTS,orexin receptor antagonist,HCRTR2,NA,NA,COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC,Phase 2
BRD-K95837862-300-01-7::2.5::HTS,BRD-K95837862-300-01-7,JDTic,2.5,HTS,opioid receptor antagonist,OPRK1,NA,NA,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,Phase 1
BRD-K95851186-001-07-8::2.5::HTS,BRD-K95851186-001-07-8,CGP-13501,2.5,HTS,GABA receptor modulator,GABBR1,NA,NA,CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O,Preclinical
BRD-K95880107-001-02-4::2.5::HTS,BRD-K95880107-001-02-4,PH-797804,2.5,HTS,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O,Phase 2
BRD-K95899059-003-02-8::2.5::HTS,BRD-K95899059-003-02-8,LY344864,2.5,HTS,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7",NA,NA,"CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1",Preclinical
BRD-K95901403-001-04-5::2.5::HTS,BRD-K95901403-001-04-5,XL-147,2.5,HTS,PI3K inhibitor,"PIK3CA, PIK3CD, PIK3CG",NA,NA,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1,Phase 2
BRD-K95921201-001-14-6::2.5::HTS,BRD-K95921201-001-14-6,reserpine,2.5,HTS,vesicular monoamine transporter inhibitor,"SLC18A1, SLC18A2",cardiology,hypertension,"CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1",Launched
BRD-K95926480-003-03-6::2.5::HTS,BRD-K95926480-003-03-6,SRT1720,2.5,HTS,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95957366-001-02-6::2.5::HTS,BRD-K95957366-001-02-6,isaxonine,2.5,HTS,nerve growth factor agonist,NA,NA,NA,CC(C)Nc1ncccn1,Withdrawn
BRD-K96006502-001-02-6::2.5::HTS,BRD-K96006502-001-02-6,deflazacort,2.5,HTS,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96029467-003-01-9::2.5::HTS,BRD-K96029467-003-01-9,alagebrium,2.5,HTS,glycosylation inhibitor,NA,NA,NA,Cc1sc[n+](CC(=O)c2ccccc2)c1C,Phase 2/Phase 3
BRD-K96042922-001-09-8::2.5::HTS,BRD-K96042922-001-09-8,etanidazole,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,NA,NA,OCCNC(=O)Cn1ccnc1[N+]([O-])=O,Phase 3
BRD-K96055017-003-02-7::2.5::HTS,BRD-K96055017-003-02-7,1-acetyl-4-methylpiperazine,2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,CN1CCN(CC1)C(C)=O,Preclinical
BRD-K96104201-001-01-5::2.5::HTS,BRD-K96104201-001-01-5,azalomycin-b,2.5,HTS,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96123349-236-02-8::2.5::HTS,BRD-K96123349-236-02-8,brequinar,2.5,HTS,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96137854-001-17-1::2.5::HTS,BRD-K96137854-001-17-1,enoxolone,2.5,HTS,gap junction modulator,HSD11B1,"gastroenterology, otolaryngology","peptic ulcer disease (PUD), common cold","C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O",Launched
BRD-K96153583-001-05-1::2.52::HTS,BRD-K96153583-001-05-1,cidofovir,2.52,HTS,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96159438-001-06-3::2.5::HTS,BRD-K96159438-001-06-3,adefovir-dipivoxil,2.5,HTS,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96188950-001-16-9::2.5::HTS,BRD-K96188950-001-16-9,caffeic-acid-phenethyl-ester,2.5,HTS,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96194081-001-10-2::2.5::HTS,BRD-K96194081-001-10-2,cepharanthine,2.5,HTS,NFkB pathway inhibitor,NA,NA,NA,"COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34",Phase 2
BRD-K96233303-001-01-9::2.5::HTS,BRD-K96233303-001-01-9,TMS,2.5,HTS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96253961-046-03-1::2.5::HTS,BRD-K96253961-046-03-1,metaraminol,2.5,HTS,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96259238-001-01-4::2.5::HTS,BRD-K96259238-001-01-4,Y-320,2.5,HTS,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96263742-001-14-8::2.5::HTS,BRD-K96263742-001-14-8,GW-7647,2.5,HTS,PPAR receptor agonist,PPARA,NA,NA,"CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O",Preclinical
BRD-K96299080-001-02-7::2.5::HTS,BRD-K96299080-001-02-7,neohesperidin,2.5,HTS,NA,NA,NA,NA,COc1cc(O)cc(c1)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O1,Preclinical
BRD-K96319534-003-03-9::2.5::HTS,BRD-K96319534-003-03-9,phentermine,2.5,HTS,"dopamine uptake inhibitor, serotonin reuptake inhibitor","MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",endocrinology,weight-loss aid,CC(C)(N)Cc1ccccc1,Launched
BRD-K96358241-001-01-9::0.94::HTS,BRD-K96358241-001-01-9,harringtonine,0.94,HTS,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96391852-001-02-8::2.5::HTS,BRD-K96391852-001-02-8,aloperine,2.5,HTS,NA,NA,NA,NA,C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1,Preclinical
BRD-K96424892-001-02-9::2.5::HTS,BRD-K96424892-001-02-9,chloramphenicol-palmitate,2.5,HTS,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96436774-001-01-8::2.5::HTS,BRD-K96436774-001-01-8,pelanserin,2.5,HTS,serotonin receptor antagonist,HTR2A,NA,NA,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,Phase 2
BRD-K96550715-001-02-6::2.5::HTS,BRD-K96550715-001-02-6,linagliptin,2.5,HTS,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1",Launched
BRD-K96615647-001-01-2::2.5::HTS,BRD-K96615647-001-01-2,AV-608,2.5,HTS,tachykinin antagonist,TACR1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12,Phase 2
BRD-K96631475-001-02-4::2.43::HTS,BRD-K96631475-001-02-4,10-deacetylbaccatin,2.43,HTS,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-04-0::2.5::HTS,BRD-K96631475-001-04-0,10-deacetylbaccatin,2.5,HTS,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96671969-001-03-1::2.5::HTS,BRD-K96671969-001-03-1,PA-824,2.5,HTS,nitric oxide donor,FASN,NA,NA,[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1,Phase 3
BRD-K96714749-001-01-0::2.5::HTS,BRD-K96714749-001-01-0,isobutamben,2.5,HTS,local anesthetic,NA,NA,NA,CC(C)COC(=O)c1ccc(N)cc1,Preclinical
BRD-K96720755-001-02-6::2.5::HTS,BRD-K96720755-001-02-6,relcovaptan,2.5,HTS,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2, OXTR",NA,NA,"COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl",Phase 2
BRD-K96740444-001-02-1::2.5::HTS,BRD-K96740444-001-02-1,itopride,2.5,HTS,dopamine receptor antagonist,"CHRM3, DRD2","gastroenterology, neurology/psychiatry","dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia",COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,Launched
BRD-K96758128-001-01-8::2.5::HTS,BRD-K96758128-001-01-8,WAY-213613,2.5,HTS,glutamate inhibitor,SLC1A2,NA,NA,"N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O",Preclinical
BRD-K96786677-236-02-4::2.5::HTS,BRD-K96786677-236-02-4,oxacillin,2.5,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,staphylococcal infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1",Launched
BRD-K96786677-323-02-0::2.58::HTS,BRD-K96786677-323-02-0,oxacillin,2.58,HTS,bacterial cell wall synthesis inhibitor,NA,infectious disease,staphylococcal infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1",Launched
BRD-K96799727-001-06-6::2.5::HTS,BRD-K96799727-001-06-6,pifithrin-mu,2.5,HTS,HSP inhibitor,"HSPA1A, TP53",NA,NA,"NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1",Preclinical
BRD-K96809896-300-02-3::2.5::HTS,BRD-K96809896-300-02-3,SKF-86002,2.5,HTS,p38 MAPK inhibitor,"ALOX5, MAPK14",NA,NA,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,Preclinical
BRD-K96862998-001-15-5::2.5::HTS,BRD-K96862998-001-15-5,pirfenidone,2.5,HTS,TGF beta receptor inhibitor,"FURIN, TNF",pulmonary,idiopathic pulmonary fibrosis (IPF),"Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1",Launched
BRD-K96936751-001-01-4::2.5::HTS,BRD-K96936751-001-01-4,bretazenil,2.5,HTS,GABA benzodiazepine site receptor partial agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21",Phase 2
BRD-K97009491-238-03-8::2.58::HTS,BRD-K97009491-238-03-8,calcium-levofolinate,2.58,HTS,NA,NA,NA,NA,"Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-K97010173-001-04-1::2.5::HTS,BRD-K97010173-001-04-1,deferasirox,2.5,HTS,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97019106-005-02-9::2.5::HTS,BRD-K97019106-005-02-9,"4-acetyl-1,1-dimethylpiperazinium",2.5,HTS,acetylcholine receptor agonist,NA,NA,NA,CC(=O)N1CC[N+](C)(C)CC1,Preclinical
BRD-K97025174-001-01-4::2.5::HTS,BRD-K97025174-001-01-4,capadenoson,2.5,HTS,adenosine receptor agonist,ADORA1,NA,NA,Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N,Phase 2
BRD-K97028990-001-04-4::2.5::HTS,BRD-K97028990-001-04-4,quinine-ethyl-carbonate,2.5,HTS,NA,NA,infectious disease,malaria,CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12,Launched
BRD-K97045029-001-02-7::2.5::HTS,BRD-K97045029-001-02-7,pranlukast,2.5,HTS,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF",pulmonary,"bronchospasm, asthma, bronchospasm, asthma","O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1",Launched
BRD-K97045029-001-04-3::2.5::HTS,BRD-K97045029-001-04-3,pranlukast,2.5,HTS,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF",pulmonary,"bronchospasm, asthma, bronchospasm, asthma","O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1",Launched
BRD-K97056771-001-13-1::2.5::HTS,BRD-K97056771-001-13-1,GNF-2,2.5,HTS,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,"NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",Preclinical
BRD-K97061094-001-21-4::2.63::HTS,BRD-K97061094-001-21-4,azacyclonol,2.63,HTS,histamine receptor antagonist,HRH1,NA,NA,"OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1",Preclinical
BRD-K97072811-001-11-4::2.5::HTS,BRD-K97072811-001-11-4,TG-003,2.5,HTS,CLK inhibitor,"CLK1, CLK4, DYRK1A, DYRK1B",NA,NA,CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O,Preclinical
BRD-K97101532-001-02-8::2.5::HTS,BRD-K97101532-001-02-8,tezacaftor,2.5,HTS,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97118047-001-03-8::2.5::HTS,BRD-K97118047-001-03-8,"4,5,6,7-tetrabromobenzotriazole",2.5,HTS,casein kinase inhibitor,"AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",NA,NA,"Brc1c(Br)c(Br)c2[nH]nnc2c1Br, Brc1c(Br)c(Br)c2[nH]nnc2c1Br",Preclinical
BRD-K97158071-001-18-1::2.5::HTS,BRD-K97158071-001-18-1,droperidol,2.5,HTS,dopamine receptor antagonist,"ADRA1A, DRD2, DRD3, DRD4, HTR2A",gastroenterology,"nausea, vomiting","Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O",Launched
BRD-K97163964-001-03-3::2.5::HTS,BRD-K97163964-001-03-3,L-Aspartic-Acid,2.5,HTS,metallic radical formation stimulant,"ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13",NA,NA,"N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O",Launched
BRD-K97181089-003-24-7::2.5::HTS,BRD-K97181089-003-24-7,amiloride,2.5,HTS,sodium channel blocker,"AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2",cardiology,"hypertension, congestive heart failure","NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N",Launched
BRD-K97181463-003-01-1::2.5::HTS,BRD-K97181463-003-01-1,benidipine,2.5,HTS,calcium channel blocker,"CACNA1C, CACNA1G",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1",Launched
BRD-K97197005-001-03-2::2.5::HTS,BRD-K97197005-001-03-2,gestodene,2.5,HTS,contraceptive agent,NA,endocrinology,contraceptive,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,Launched
BRD-K97233161-003-01-5::2.5::HTS,BRD-K97233161-003-01-5,ABT-491,2.5,HTS,platelet activating factor receptor antagonist,PTAFR,NA,NA,CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C,Phase 1
BRD-K97309399-001-09-4::2.5::HTS,BRD-K97309399-001-09-4,thiothixene,2.5,HTS,dopamine receptor antagonist,"DRD1, DRD2, HRH1, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1,Launched
BRD-K97365803-001-02-1::2.5::HTS,BRD-K97365803-001-02-1,PI-828,2.5,HTS,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97399794-001-15-3::2.5::HTS,BRD-K97399794-001-15-3,quercetin,2.5,HTS,polar auxin transport inhibitor,"ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1","neurology/psychiatry, allergy","fatigue, allergic rhinitis, drowsiness","Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O",Launched
BRD-K97417064-001-02-4::2.5::HTS,BRD-K97417064-001-02-4,acedapsone,2.5,HTS,NA,NA,infectious disease,leprosy,CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1,Launched
BRD-K97428065-001-01-2::2.5::HTS,BRD-K97428065-001-01-2,netupitant,2.5,HTS,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,Launched
BRD-K97440753-066-18-1::2.5::HTS,BRD-K97440753-066-18-1,dihydroergocristine,2.5,HTS,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97464279-001-03-5::2.5::HTS,BRD-K97464279-001-03-5,diaveridine,2.5,HTS,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97472745-001-01-8::2.5::HTS,BRD-K97472745-001-01-8,gestrinone,2.5,HTS,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97521363-001-16-1::2.5::HTS,BRD-K97521363-001-16-1,clorsulon,2.5,HTS,glycolysis inhibitor,NA,infectious disease,"gastrointestinal roundworms, lungworms, liver flukes, lice, mites","Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O",Launched
BRD-K97530723-001-20-9::2.5::HTS,BRD-K97530723-001-20-9,melatonin,2.5,HTS,"melatonin receptor agonist, nitric oxide synthase inhibitor","ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB",neurology/psychiatry,sleep cycle support,"COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1",Launched
BRD-K97564742-050-32-7::2.5::HTS,BRD-K97564742-050-32-7,mepyramine,2.5,HTS,histamine receptor antagonist,HRH1,"otolaryngology, obstetrics/gynecology","common cold, menstrual pain","COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1",Launched
BRD-K97643133-003-09-3::2.5::HTS,BRD-K97643133-003-09-3,amiprilose,2.5,HTS,CD antagonist,NA,NA,NA,CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO,Phase 3
BRD-K97714174-001-01-3::2.5::HTS,BRD-K97714174-001-01-3,P22077,2.5,HTS,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97746869-001-27-0::2.5::HTS,BRD-K97746869-001-27-0,chlorpropamide,2.5,HTS,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97752965-001-16-4::2.5::HTS,BRD-K97752965-001-16-4,nicorandil,2.5,HTS,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97764662-001-17-3::2.5::HTS,BRD-K97764662-001-17-3,PD-173074,2.5,HTS,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97799481-001-16-0::2.5::HTS,BRD-K97799481-001-16-0,theophylline,2.5,HTS,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-230-01-7::2.5::HTS,BRD-K97799481-230-01-7,aminophylline,2.5,HTS,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,"asthma, bronchitis, emphysema","Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O",Launched
BRD-K97808269-001-02-7::2.5::HTS,BRD-K97808269-001-02-7,2-deoxyglucose,2.5,HTS,glycolysis inhibitor,"SLC2A1, SLC2A2, SLC2A3, SLC2A4",NA,NA,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,Phase 2
BRD-K97810537-001-12-8::2.54::HTS,BRD-K97810537-001-12-8,beclomethasone-dipropionate,2.54,HTS,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::2.5::HTS,BRD-K97810537-001-13-6,beclomethasone-dipropionate,2.5,HTS,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97883416-001-01-4::2.5::HTS,BRD-K97883416-001-01-4,BMS-626529,2.5,HTS,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97884852-001-05-4::2.5::HTS,BRD-K97884852-001-05-4,malotilate,2.5,HTS,protein synthesis stimulant,NA,gastroenterology,hepatic cirrhosis,CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1,Launched
BRD-K97963946-001-01-3::2.5::HTS,BRD-K97963946-001-01-3,EMD-1214063,2.5,HTS,hepatocyte growth factor receptor inhibitor,MET,NA,NA,CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1,Phase 1
BRD-K98004573-051-02-8::2.5::HTS,BRD-K98004573-051-02-8,rupatadine,2.5,HTS,"histamine receptor antagonist, platelet activating factor receptor antagonist","HRH1, PTAFR",allergy,"allergic rhinitis, urticaria",Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1,Launched
BRD-K98143539-001-02-2::2.5::HTS,BRD-K98143539-001-02-2,compound-w,2.5,HTS,beta-secretase inhibitor,BACE1,NA,NA,OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1,Preclinical
BRD-K98155362-001-07-7::2.5::HTS,BRD-K98155362-001-07-7,GR46611,2.5,HTS,serotonin receptor agonist,HTR1D,NA,NA,"COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1",Preclinical
BRD-K98157055-001-10-9::2.5::HTS,BRD-K98157055-001-10-9,SIB-1757,2.5,HTS,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98174813-001-18-0::2.5::HTS,BRD-K98174813-001-18-0,chlorzoxazone,2.5,HTS,bacterial 30S ribosomal subunit inhibitor,"KCNMA1, KCNN4",neurology/psychiatry,muscle relaxant,"Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1",Launched
BRD-K98203492-003-04-1::2.5::HTS,BRD-K98203492-003-04-1,GSK-J4,2.5,HTS,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98251413-001-04-0::2.5::HTS,BRD-K98251413-001-04-0,IOX2,2.5,HTS,hypoxia inducible factor inhibitor,"EGLN1, KDM2A, KDM5C",NA,NA,"OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O",Preclinical
BRD-K98357249-001-02-9::2.5::HTS,BRD-K98357249-001-02-9,IRL-2500,2.5,HTS,endothelin receptor antagonist,EDNRB,NA,NA,CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1,Preclinical
BRD-K98372770-001-08-2::2.5::HTS,BRD-K98372770-001-08-2,L-165041,2.5,HTS,PPAR receptor agonist,PPARD,NA,NA,"CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O, CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O",Preclinical
BRD-K98384930-003-01-5::2.5::HTS,BRD-K98384930-003-01-5,finafloxacin,2.5,HTS,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98453471-001-01-7::2.5::HTS,BRD-K98453471-001-01-7,salirasib,2.5,HTS,mTOR inhibitor,TRPA1,NA,NA,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O,Phase 2
BRD-K98493452-001-14-9::2.5::HTS,BRD-K98493452-001-14-9,honokiol,2.5,HTS,AKT inhibitor,"ALOX5, PTGS1, PTGS2",NA,NA,Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O,Phase 3
BRD-K98521173-001-19-4::2.5::HTS,BRD-K98521173-001-19-4,desoxycortone,2.5,HTS,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98530306-003-18-3::2.5::HTS,BRD-K98530306-003-18-3,clonidine,2.5,HTS,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, neurology/psychiatry","hypertension, attention-deficit/hyperactivity disorder (ADHD)","Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1",Launched
BRD-K98548675-001-05-9::2.5::HTS,BRD-K98548675-001-05-9,parthenolide,2.5,HTS,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98572433-001-02-9::2.5::HTS,BRD-K98572433-001-02-9,AZD8931,2.5,HTS,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98624455-074-02-8::2.5::HTS,BRD-K98624455-074-02-8,bepotastine,2.5,HTS,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K98684188-001-02-9::2.5::HTS,BRD-K98684188-001-02-9,GSK-0660,2.5,HTS,PPAR receptor antagonist,PPARD,NA,NA,"COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC",Preclinical
BRD-K98763141-001-30-8::2.5::HTS,BRD-K98763141-001-30-8,niflumic-acid,2.5,HTS,cyclooxygenase inhibitor,"ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9","rheumatology, neurology/psychiatry","joint pain, muscle pain","OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F",Launched
BRD-K98769987-001-23-7::2.5::HTS,BRD-K98769987-001-23-7,flumazenil,2.5,HTS,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,sedative,"CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21",Launched
BRD-K98795921-001-01-7::2.5::HTS,BRD-K98795921-001-01-7,SB-2343,2.5,HTS,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98963219-001-01-2::2.5::HTS,BRD-K98963219-001-01-2,ezatiostat,2.5,HTS,glutathione transferase inhibitor,GSTP1,NA,NA,"CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1",Phase 2
BRD-K99023089-001-03-7::2.5::HTS,BRD-K99023089-001-03-7,AZD5363,2.5,HTS,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99048103-001-18-4::2.5::HTS,BRD-K99048103-001-18-4,acetarsol,2.5,HTS,NA,NA,gastroenterology,diarrhea,"CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O",Launched
BRD-K99063460-001-13-1::2.5::HTS,BRD-K99063460-001-13-1,didanosine,2.5,HTS,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1),"OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12, OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12",Launched
BRD-K99092662-001-01-1::2.5::HTS,BRD-K99092662-001-01-1,PS178990,2.5,HTS,androgen receptor modulator,AR,NA,NA,Cc1c(ccc(C#N)c1Cl)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O,Phase 1
BRD-K99107520-001-24-1::2.5::HTS,BRD-K99107520-001-24-1,felbamate,2.5,HTS,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99113996-001-02-0::2.5::HTS,BRD-K99113996-001-02-0,AZD2014,2.5,HTS,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99121711-003-19-7::2.5::HTS,BRD-K99121711-003-19-7,cinchocaine,2.5,HTS,sodium channel blocker,"CALM1, SCN10A, SCN5A",neurology/psychiatry,local anesthetic,"CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1",Launched
BRD-K99149715-001-01-6::2.5::HTS,BRD-K99149715-001-01-6,plurisin-#1,2.5,HTS,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,"O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1",Preclinical
BRD-K99170882-001-04-3::2.5::HTS,BRD-K99170882-001-04-3,NSC-319726,2.5,HTS,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99174507-003-02-0::2.5::HTS,BRD-K99174507-003-02-0,cardiogenol-c,2.5,HTS,cardiomyogenesis inducer,NA,NA,NA,"COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1",Preclinical
BRD-K99241550-001-03-5::2.5::HTS,BRD-K99241550-001-03-5,metrizoic-acid,2.5,HTS,radiopaque medium,NA,radiology,contrast agent,"CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I",Launched
BRD-K99300445-003-21-6::2.5::HTS,BRD-K99300445-003-21-6,antazoline,2.5,HTS,antihistamine,HRH1,"ophthalmology, otolaryngology","conjunctivitis, nasal congestion","C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1",Launched
BRD-K99308954-304-02-4::2.5::HTS,BRD-K99308954-304-02-4,sodium-monofluorophosphate,2.5,HTS,NA,PYGM,dental,cavities,"OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O",Launched
BRD-K99383816-001-02-7::2.5::HTS,BRD-K99383816-001-02-7,ftorafur,2.5,HTS,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::2.5::HTS,BRD-K99383816-001-03-5,ftorafur,2.5,HTS,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99451608-001-07-3::2.5::HTS,BRD-K99451608-001-07-3,lopinavir,2.5,HTS,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1,Launched
BRD-K99475619-001-01-2::2.5::HTS,BRD-K99475619-001-01-2,genz-644282,2.5,HTS,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99498722-001-02-6::2.5::HTS,BRD-K99498722-001-02-6,plinabulin,2.5,HTS,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99504665-001-01-2::2.5::HTS,BRD-K99504665-001-01-2,goserelin-acetate,2.5,HTS,gonadotropin releasing factor hormone receptor agonist,"GNRHR, LHCGR","oncology, obstetrics/gynecology","prostate cancer, breast cancer, endometriosis",CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,Launched
BRD-K99545815-001-06-3::2.5::HTS,BRD-K99545815-001-06-3,PF-562271,2.5,HTS,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99604664-001-01-1::2.5::HTS,BRD-K99604664-001-01-1,tanaproget,2.5,HTS,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99615199-001-18-5::2.5::HTS,BRD-K99615199-001-18-5,medroxyprogesterone,2.5,HTS,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12,Launched
BRD-K99621550-300-01-8::2.5::HTS,BRD-K99621550-300-01-8,tubocurarine,2.5,HTS,acetylcholine receptor antagonist,"ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN",neurology/psychiatry,anesthetic,COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4,Launched
BRD-K99622919-001-23-0::2.5::HTS,BRD-K99622919-001-23-0,butacaine,2.5,HTS,local anesthetic,NA,neurology/psychiatry,local anesthetic,"CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1",Launched
BRD-K99741577-001-01-7::2.5::HTS,BRD-K99741577-001-01-7,SANT-1,2.5,HTS,smoothened receptor antagonist,"SHH, SMO",NA,NA,"Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1",Preclinical
BRD-K99749624-001-07-0::2.5::HTS,BRD-K99749624-001-07-0,linifanib,2.5,HTS,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99792991-001-34-9::2.5::HTS,BRD-K99792991-001-34-9,hexachlorophene,2.5,HTS,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99922388-001-02-0::2.5::HTS,BRD-K99922388-001-02-0,DPO-1,2.5,HTS,potassium channel blocker,KCNA5,NA,NA,CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1,Preclinical
BRD-K99946902-001-07-5::2.5::HTS,BRD-K99946902-001-07-5,hexylresorcinol,2.5,HTS,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99964838-001-11-9::2.5::HTS,BRD-K99964838-001-11-9,bosutinib,2.5,HTS,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99984802-100-13-5::2.5::HTS,BRD-K99984802-100-13-5,flunixin-meglumin,2.5,HTS,prostanoid receptor antagonist,NA,NA,NA,"Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F",Launched
BRD-M02075109-001-01-1::2.5::HTS,BRD-M02075109-001-01-1,chromanol-(+/-),2.5,HTS,potassium channel blocker,NA,NA,NA,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,Preclinical
BRD-M02179497-001-01-1::2.5::HTS,BRD-M02179497-001-01-1,bismuth-oxalate,2.5,HTS,NA,NA,NA,NA,[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O,Preclinical
BRD-M08274809-001-01-7::2.5::HTS,BRD-M08274809-001-01-7,indium(iii)-isopropoxide,2.5,HTS,NA,NA,NA,NA,[In].CC(C)O.CC(C)O.CC(C)O,Preclinical
BRD-M17926088-001-01-3::2.5::HTS,BRD-M17926088-001-01-3,FPA-124,2.5,HTS,AKT inhibitor,NA,NA,NA,"Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O, Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O",Preclinical
BRD-M29182745-001-01-4::2.5::HTS,BRD-M29182745-001-01-4,ammonium-lactate,2.5,HTS,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29936662-001-02-0::2.5::HTS,BRD-M29936662-001-02-0,cis-ACPD,2.5,HTS,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM7, GRM8",NA,NA,N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O,Preclinical
BRD-M30288325-001-01-4::2.5::HTS,BRD-M30288325-001-01-4,G-15,2.5,HTS,estrogen receptor antagonist,GPER1,NA,NA,Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12.Brc1cc2OCOc2cc1[C@@H]1Nc2ccccc2[C@@H]2C=CC[C@H]12,Preclinical
BRD-M39350793-334-01-1::2.5::HTS,BRD-M39350793-334-01-1,reboxetine,2.5,HTS,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression,"CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1, CCOc1ccccc1OC(C1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1",Launched
BRD-M41245765-001-04-2::2.5::HTS,BRD-M41245765-001-04-2,lithium-citrate,2.5,HTS,NA,NA,neurology/psychiatry,"bipolar disorder, depression","[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O",Launched
BRD-M54096567-001-01-9::2.5::HTS,BRD-M54096567-001-01-9,sodium-gluconate,2.5,HTS,NA,NA,NA,NA,"OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O",Launched
BRD-M56276249-001-01-1::2.5::HTS,BRD-M56276249-001-01-1,bismuth(iii)-trifluoromethanesulfonate,2.5,HTS,direct substitution catalyst,NA,NA,NA,[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F,Preclinical
BRD-M77041484-001-01-8::2.5::HTS,BRD-M77041484-001-01-8,TBOA-(DL),2.5,HTS,excitatory amino acid transporter inhibitor,"SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7",NA,NA,"N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O",Preclinical
BRD-M80207679-001-01-5::2.5::HTS,BRD-M80207679-001-01-5,nemonapride,2.5,HTS,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M89827113-001-01-5::2.5::HTS,BRD-M89827113-001-01-5,cromakalim,2.5,HTS,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M92352362-002-02-3::2.5::HTS,BRD-M92352362-002-02-3,talc,2.5,HTS,NA,NA,NA,NA,"O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O, O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O",Launched
BRD-M92675308-003-07-1::2.5::HTS,BRD-M92675308-003-07-1,efonidipine-monoethanolate,2.5,HTS,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M97302542-001-03-6::2.5::HTS,BRD-M97302542-001-03-6,dichloroacetate,2.5,HTS,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M98279124-300-01-1::2.5::HTS,BRD-M98279124-300-01-1,cevimeline,2.5,HTS,acetylcholine receptor agonist,"CHRM1, CHRM3",rheumatology,sjogren's syndrome,C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,Launched
BRD-U08520523-000-01-0::2.5::HTS,BRD-U08520523-000-01-0,colesevalam,2.5,HTS,NA,NA,NA,NA,NA,Preclinical
BRD-U25960968-000-01-9::2.5::HTS,BRD-U25960968-000-01-9,tyloxapol,2.5,HTS,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U45393375-000-01-6::2.5::HTS,BRD-U45393375-000-01-6,sevelamer,2.5,HTS,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U48018661-000-01-9::2.5::HTS,BRD-U48018661-000-01-9,tyloxapol,2.5,HTS,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U51753822-000-01-1::2.5::HTS,BRD-U51753822-000-01-1,phosphatidylcholine,2.5,HTS,NA,PCTP,"infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology","hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome",", CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC",Launched
